FN Thomson Reuters Web of Science™ VR 1.0 PT J AU Patel, D Martin, J Josephson, K Alessi, C AF Patel, D. Martin, J. Josephson, K. Alessi, C. TI Earlier morning rise time predicts better functional outcomes of post-acute rehabilitation for orthopedic patients. SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Meeting of the American-Geriatrics-Society CY APR 29-MAY 02, 2009 CL Chicago, IL SP Amer Geriatr Soc C1 [Patel, D.] Western Univ, Pomona, CA USA. [Martin, J.; Alessi, C.] Univ Calif Los Angeles, Los Angeles, CA USA. [Martin, J.; Josephson, K.; Alessi, C.] VA Greater Los Angeles, North Hills, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD MAR PY 2009 VL 57 BP S110 EP S110 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 425BL UT WOS:000264611900312 ER PT J AU Steinman, MA Patil, S Kamat, P Knight, S AF Steinman, M. A. Patil, S. Kamat, P. Knight, S. TI A Taxonomy of Reasons for Not Prescribing Guideline-Recommended Medications: Results from Physician Focus Groups. SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Meeting of the American-Geriatrics-Society CY APR 29-MAY 02, 2009 CL Chicago, IL SP Amer Geriatr Soc C1 [Steinman, M. A.; Patil, S.; Kamat, P.; Knight, S.] San Francisco VA Med Ctr, San Francisco, CA USA. [Steinman, M. A.; Knight, S.] Univ Calif San Francisco, San Francisco, CA 94143 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD MAR PY 2009 VL 57 BP S49 EP S49 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 425BL UT WOS:000264611900138 ER PT J AU Wilton, N Hammond, D Tio-Matos, I AF Wilton, N. Hammond, D. Tio-Matos, I. TI Rapidly Progressive Dementia- a Diagnostic Conundrum. SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Meeting of the American-Geriatrics-Society CY APR 29-MAY 02, 2009 CL Chicago, IL SP Amer Geriatr Soc C1 [Wilton, N.; Hammond, D.; Tio-Matos, I.] VA Puget Sound, Tacoma, WA USA. [Wilton, N.; Tio-Matos, I.] Madigan Army Med Ctr, Tacoma, WA 98431 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD MAR PY 2009 VL 57 BP S23 EP S24 PG 2 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 425BL UT WOS:000264611900064 ER PT J AU Yung, VY Walling, AM Min, LC Wenger, NS Ganz, DA AF Yung, V. Y. Walling, A. M. Min, L. C. Wenger, N. S. Ganz, D. A. TI Advance Care Planning and End-of-life Care Preferences in Community-dwelling Elders SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Meeting of the American-Geriatrics-Society CY APR 29-MAY 02, 2009 CL Chicago, IL SP Amer Geriatr Soc C1 [Yung, V. Y.; Walling, A. M.; Min, L. C.; Wenger, N. S.; Ganz, D. A.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Walling, A. M.; Wenger, N. S.] Univ Calif Los Angeles, Hlth Syst Eth Ctr, Los Angeles, CA 90095 USA. [Ganz, D. A.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD MAR PY 2009 VL 57 BP S97 EP S97 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 425BL UT WOS:000264611900275 ER PT J AU Odden, MC Shlipak, MG Tager, IB AF Odden, Michelle C. Shlipak, Michael G. Tager, Ira B. TI Serum Creatinine and Functional Limitation in Elderly Persons SO JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES LA English DT Article DE Aging; Creatinine; Kidney disease; Mobility limiation ID CHRONIC KIDNEY-DISEASE; BODY-COMPOSITION; CYSTATIN-C; EXERCISE CAPACITY; RENAL-FUNCTION; OLDER-PEOPLE; ADULTS; HEALTH; RISK; ASSOCIATION AB Creatinine is a commonly used measure of kidney function, but serum levels are also influenced by muscle mass. We hypothesized that higher serum creatinine would be associated with self-reported functional limitation in community-dwelling elderly. Subjects (n = 1,553) were participants in the Study of Physical Performance and Age-Related Changes in Sonomans, a cohort to study aging and physical function. We explored three strategies to account for the effects of muscle mass on serum creatinine. We observed a J-shaped association of creatinine with functional limitation. Above the study-specific mean creatinine (0.97 mg/dL in women and 1.15 mg/dL in men), the unadjusted odds ratio of functional limitation per standard deviation (0.20 mg/dL in women and 0.23 mg/dL in men) higher creatinine was 2.27 (95% confidence interval [CI] 1.75-2.94, p < .001) in women and 1.42 (95% CI 1.12-1.80, p = .003) in men. This association was inverted in persons with creatinine levels below the mean. Adjustment for muscle mass did not have an important effect on the association between creatinine and functional limitation. These associations remained after multivariable adjustment for demographics and health conditions but were statistically significant only in women. In elderly adults, higher creatinine levels are associated with functional limitation, consistent with prior literature that has demonstrated reduced physical performance in persons with kidney disease. However, the association of low creatinine levels with functional limitation suggests that creatinine levels are influenced by factors other than kidney function and muscle mass in the elderly. C1 [Odden, Michelle C.; Shlipak, Michael G.] San Francisco VA Med Ctr, Dept Gen Internal Med, San Francisco, CA 94121 USA. [Odden, Michelle C.; Tager, Ira B.] Univ Calif Berkeley, Sch Publ Hlth, Dept Epidemiol, Berkeley, CA 94720 USA. [Shlipak, Michael G.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Shlipak, Michael G.] Univ Calif San Francisco, Dept Epidemiol, San Francisco, CA 94143 USA. [Shlipak, Michael G.] Univ Calif San Francisco, Dept Biostat, San Francisco, CA 94143 USA. RP Odden, MC (reprint author), San Francisco VA Med Ctr, Dept Gen Internal Med, 4150 Clement St 111Al, San Francisco, CA 94121 USA. EM michelleodden@berkeley.edu FU National Institute on Aging [R01-AG09389, R01-AG027002] FX This study was supported by grant R01-AG09389 from the National Institute on Aging. Dr M. G. S. is supported by grant R01-AG027002 from the National Institute on Aging. NR 29 TC 24 Z9 24 U1 0 U2 1 PU GERONTOLOGICAL SOC AMER PI WASHINGTON PA 1030 15TH ST NW, STE 250, WASHINGTON, DC 20005202-842 USA SN 1079-5006 J9 J GERONTOL A-BIOL JI J. Gerontol. Ser. A-Biol. Sci. Med. Sci. PD MAR PY 2009 VL 64 IS 3 BP 370 EP 376 DI 10.1093/gerona/gln037 PG 7 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 419AC UT WOS:000264190500006 PM 19181716 ER PT J AU Neuwelt, EA Hamilton, BE Varallyay, CG Rooney, WR Edelman, RD Jacobs, PM Watnick, SG AF Neuwelt, Edward A. Hamilton, Bronwyn E. Varallyay, Csanad G. Rooney, William R. Edelman, Robert D. Jacobs, Paula M. Watnick, Suzanne G. TI Ultrasmall superparamagnetic iron oxides (USPIOs): a future alternative magnetic resonance (MR) contrast agent for patients at risk for nephrogenic systemic fibrosis (NSF)? SO KIDNEY INTERNATIONAL LA English DT Article DE nephrogenic systemic fibrosis; magnetic resonance imaging; ferumoxytol; i.v. iron ID CENTRAL-NERVOUS-SYSTEM; BRAIN-TUMORS; IN-VITRO; GADOLINIUM; FERUMOXTRAN-10; FERUMOXYTOL; ANGIOGRAPHY; NANOPARTICLES; FERUMOXIDES; PARTICLES AB Gadolinium (Gd) based contrast agents (GBCAs) in magnetic resonance imaging (MRI) are used in daily clinical practice and appear safe in most patients; however, nephrogenic systemic fibrosis (NSF) is a recently recognized severe complication associated with GBCAs. It affects primarily patients with renal disease, such as stage 4 or 5 chronic kidney disease (CKD; glomerular filtration rate < 30 ml/min per 1.73 m(2)), acute kidney injury, or kidney and liver transplant recipients with kidney dysfunction. Contrast-enhanced MRI and computed tomography (CT) scans provide important clinical information and influence patient management. An alternative contrast agent is needed to obtain adequate imaging results while avoiding the risk of NSF in this vulnerable patient group. One potential alternative is ultrasmall superparamagnetic iron oxide (USPIO) nanoparticles, which provide enhancement characteristics similar to GBCAs. We review our experience in approximately 150 patients on the potential benefits of the USPIOs ferumoxtran-10 and ferumoxytol. We focus on central nervous system (CNS) MRI but also review imaging of other vascular beds. Safety studies, including USPIO administration (ferumoxytol) as iron supplement therapy in CKD patients on and not on dialysis, suggest that decreased kidney function does not alter the safety profile. We conclude that for both CNS MR imaging and MR angiography, USPIO agents like ferumoxytol are a viable option for patients at risk for NSF. C1 [Neuwelt, Edward A.] Oregon Hlth & Sci Univ, Dept Neurol & Neurosurg, Portland, OR 97239 USA. [Neuwelt, Edward A.; Watnick, Suzanne G.] Portland VA Med Ctr, Portland, OR USA. [Hamilton, Bronwyn E.] Oregon Hlth & Sci Univ, Dept Radiol, Portland, OR 97239 USA. [Varallyay, Csanad G.] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97239 USA. [Rooney, William R.] Oregon Hlth & Sci Univ, Adv Imaging Res Ctr, Portland, OR 97239 USA. [Edelman, Robert D.] Northwestern Univ, Dept Radiol, Chicago, IL 60611 USA. [Jacobs, Paula M.] NCI Frederick, SAIC Frederick Inc, Natl Canc Inst, Canc Imaging Program, Frederick, MD USA. [Watnick, Suzanne G.] Oregon Hlth & Sci Univ, Dept Med, Portland, OR 97239 USA. RP Neuwelt, EA (reprint author), Oregon Hlth & Sci Univ, Dept Neurol & Neurosurg, 3181 SW Sam Jackson Pk Rd,Mailcode L603, Portland, OR 97239 USA. EM neuwelte@ohsu.edu FU NIH [NS33618, NS34608, NS44687]; National Institute of Neurological Disorders and Stroke [NIB1B EB007258] FX This research was supported by a Veteran's Administration Merit Review Grant and NIH grants NS33618, NS34608, and NS44687 from the National Institute of Neurological Disorders and Stroke to EAN and NIB1B EB007258 to WDR. AMAG Pharmaceuticals Inc. donated ferumoxtran-10 and ferumoxytol. NR 28 TC 111 Z9 115 U1 2 U2 15 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0085-2538 J9 KIDNEY INT JI Kidney Int. PD MAR PY 2009 VL 75 IS 5 BP 465 EP 474 DI 10.1038/ki.2008.496 PG 10 WC Urology & Nephrology SC Urology & Nephrology GA 406UJ UT WOS:000263320100010 PM 18843256 ER PT J AU Fried, LF AF Fried, Linda F. TI Creatinine and cystatin C: what are the values? SO KIDNEY INTERNATIONAL LA English DT Editorial Material AB Recent studies indicate that serum cystatin C is a better marker of glomerular filtration rate (GFR) and is a stronger predictor of cardiovascular disease and mortality than serum creatinine. Before cystatin C can gain wide acceptance, information about factors that affect generation, elimination, and analysis is needed. Stevens et al. analyze non-GFR-related factors associated with cystatin C and creatinine levels. The results will be useful in interpreting cystatin C levels in research and clinical practice. C1 [Fried, Linda F.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA 15240 USA. [Fried, Linda F.] Univ Pittsburgh, Dept Med, Pittsburgh, PA USA. [Fried, Linda F.] Univ Pittsburgh, Dept Epidemiol, Pittsburgh, PA USA. RP Fried, LF (reprint author), VA Pittsburgh Healthcare Syst, Univ Dr,Mailstop 111F-U, Pittsburgh, PA 15240 USA. EM Linda.Fried@va.gov NR 9 TC 8 Z9 8 U1 0 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0085-2538 J9 KIDNEY INT JI Kidney Int. PD MAR PY 2009 VL 75 IS 6 BP 578 EP 580 DI 10.1038/ki.2008.688 PG 4 WC Urology & Nephrology SC Urology & Nephrology GA 412KH UT WOS:000263723200003 PM 19247381 ER PT J AU Roodman, GD AF Roodman, G. D. TI Pathogenesis of myeloma bone disease SO LEUKEMIA LA English DT Review DE multiple myeloma; osteoclast; osteoblast; bone disease ID KAPPA-B LIGAND; OSTEOCLAST DIFFERENTIATION FACTOR; ADVANCED MULTIPLE-MYELOMA; TUMOR-NECROSIS-FACTOR; RECEPTOR ACTIVATOR; IN-VIVO; INHIBITS OSTEOCLASTOGENESIS; OSTEOBLAST DIFFERENTIATION; MARROW MICROENVIRONMENT; OSTEOPROTEGERIN LIGAND AB Bone disease in multiple myeloma (MM) is characterized by lytic bone lesions, which can cause severe bone pain, pathologic fractures and hypercalcemia. However, the lytic bone disease in MM differs from that in other cancer patients who have lytic bone metastases. Although increased osteoclastic bone destruction is involved in MM and other tumors involving bone, in contrast to other tumors, once the MM tumor burden exceeds 50% in a local area, osteoblast activity is either suppressed or absent. 1 The basis for this severe imbalance between increased osteoclastic bone resorption and decreased bone formation has been a topic of intensive investigation over the last several years and will be reviewed in this article. C1 Univ Pittsburgh, Vet Affairs Pittsburgh Healthcare Syst, Dept Med Hematol Oncol, Sch Med, Pittsburgh, PA 15240 USA. RP Roodman, GD (reprint author), Univ Pittsburgh, Vet Affairs Pittsburgh Healthcare Syst, Dept Med Hematol Oncol, Sch Med, Res & Dev 151-U,Univ Dr C,Room 2E113, Pittsburgh, PA 15240 USA. EM roodmangd@upmc.edu FU Multiple Myeloma Research Foundation; Department of Veteran's Affairs FX Preparation of this article was made possible by research funds from the Multiple Myeloma Research Foundation and from the Department of Veteran's Affairs (VA Merit Review Award). The materials are the result of work supported with resources and the use of facilities at the VA Pittsburgh Healthcare System, Research and Development. NR 75 TC 137 Z9 146 U1 2 U2 6 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0887-6924 J9 LEUKEMIA JI Leukemia PD MAR PY 2009 VL 23 IS 3 BP 435 EP 441 DI 10.1038/leu.2008.336 PG 7 WC Oncology; Hematology SC Oncology; Hematology GA 416VC UT WOS:000264032600002 PM 19039321 ER PT J AU Hysong, SJ AF Hysong, Sylvia J. TI Meta-Analysis Audit and Feedback Features Impact Effectiveness on Care Quality SO MEDICAL CARE LA English DT Article; Proceedings Paper CT Annual Research Meeting of the Academy-Health CT Academy Health Annual Research Meeting CY JUN 09-10, 2008 CY JUN 08-10, 2008 CL Washington, DC CL Washington, DC SP Acad Hlth SP Acad Hlth DE audit and feedback; feedback intervention theory; meta-analysis; quality of health care; health services research ID RANDOMIZED CONTROLLED-TRIAL; CLINICAL-PRACTICE; PERFORMANCE; INTERVENTIONS; IMPROVE AB Background: Audit and feedback (A&F) has long been used to improve quality of care, albeit with variable results. This meta-analytic study tested whether Feedback Intervention Theory, a framework from industrial/organizational psychology, explains the observed variability in health care A&F research. Method: Data source: studies cited by Jamtvedt's 2006 Cochrane systematic review of A&F, followed by database searches using the Cochrane review's search strategy to identify more recent studies. Inclusion criteria: Cochrane review criteria, plus: presence of a treatment group receiving only A & F; a control group receiving no intervention; a quantitatively measurable outcome; minimum n of 10 per arm; sufficient statistics for effect size calculations. Moderators: presence of discouragement and praise; correct solution, attainment level, velocity, frequency, and non-native information; feedback format (verbal, textual, graphic, public, computerized, group vs. individual); goal setting activity. Procedure: meta-analytic procedures using the Hedges-Olkin method. Results: Of 519 studies initially identified, 19 met all inclusion criteria. Studies were most often excluded due to the lack of a feedback-only ann. A&F has a modest, though significant positive effect on quality outcomes (d = 0.40, 95% confidence interval +/- 0.20); providing specific Suggestions for improvement, written, and more frequent feedback strengthened this effect, whereas graphical and verbal feedback attenuated this effect. Conclusions: A&F effectiveness is improved when feedback is delivered with specific suggestions for improvement, in writing, and frequently. Other feedback characteristics Could also potentially improve effectiveness; however, research with stricter experimental controls is needed to identify the specific feedback characteristics that maximize its effectiveness. C1 [Hysong, Sylvia J.] Baylor Coll Med, Dept Med, Houston, TX 77030 USA. [Hysong, Sylvia J.] Dept Vet Affairs Med Ctr, Hlth Serv, Res & Dev Serv, Houston VA HSR&D Ctr Excellence, Houston, TX USA. RP Hysong, SJ (reprint author), Baylor Coll Med, Dept Med, 2002 Holcombe Blvd 152, Houston, TX 77030 USA. EM hysong@bcm.tmc.edu RI Hysong, Sylvia/B-8420-2008 OI Hysong, Sylvia/0000-0002-9063-5207 FU NHLBI NIH HHS [R01 HL079173, 1R01HL079173] NR 29 TC 114 Z9 116 U1 1 U2 11 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0025-7079 EI 1537-1948 J9 MED CARE JI Med. Care PD MAR PY 2009 VL 47 IS 3 BP 356 EP 363 PG 8 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA 412VT UT WOS:000263753000013 PM 19194332 ER PT J AU Wolf, MS Shekelle, P Choudhry, NK Agnew-Blais, J Parker, RM Shrank, WH AF Wolf, Michael S. Shekelle, Paul Choudhry, Niteesh K. Agnew-Blais, Jessica Parker, Ruth M. Shrank, William H. TI Variability in Pharmacy Interpretations of Physician Prescriptions SO MEDICAL CARE LA English DT Article DE pharmacy; physician; prescription; sig; instruction; medication; variability; health literacy ID DRUG WARNING LABELS; LOW-LITERACY; MEDICATIONS AB Background: The clarity of prescription drug instructions is a health literacy and medication safety concern. Objective: To assess the variability of pharmacy interpretations of physician prescriptions. Design: Identically written prescriptions for 4 common medications (atorvastatin, alendronate, trimethoprim/sulfamethoxazole, ibuprofen) were filled in 6 pharmacies (2 largest chains, 2 grocery stores, 2 independents) in 4 cities (Boston, Chicago, Los Angeles, Austin). Measurement: Components of the instruction were coded as dose, frequency, administration route, timing, indication, and auxiliary instructions. Results: In all, 85 labels were evaluated. Dose frequency was omitted on 6% of instructions ("take 1 tablet for cholesterol"). Timing was explicitly stated on 2% of instructions ("in the morning"). All prescriptions included indications; pharmacies transcribed these onto 38% of labels. The prescription for alendronate stated not to lie down for at least 30 minutes after taking; this was transcribed with 50% of instructions. Reading difficulty was above recommended levels for 46% of instructions; with 14% greater than a high school level. Conclusions: Efforts are needed to ensure patients receive clear, consistent information supporting safe medication use. C1 [Wolf, Michael S.] Northwestern Univ, Inst Healthcare Studies, Ctr Commun Healthcare, Hlth Literacy & Learning Program,Feinberg Sch Med, Chicago, IL 60611 USA. [Wolf, Michael S.] Northwestern Univ, Feinberg Sch Med, Div Gen Internal Med, Chicago, IL 60611 USA. [Choudhry, Niteesh K.; Agnew-Blais, Jessica; Shrank, William H.] Brigham & Womens Hosp, Div Pharmacoepidemiol & Pharmacoecon, Boston, MA 02115 USA. [Choudhry, Niteesh K.; Agnew-Blais, Jessica; Shrank, William H.] Harvard Univ, Sch Med, Boston, MA USA. [Parker, Ruth M.] Emory Univ, Sch Med, Atlanta, GA USA. [Shekelle, Paul] Greater Los Angeles Vet Affairs Healthcare Syst, Div Gen Internal Med, Los Angeles, CA USA. RP Wolf, MS (reprint author), 750 N Lake Shore Dr,10th Floor, Chicago, IL 60611 USA. EM mswolf@northwestern.edu RI Agnew-Blais, Jessica/L-9236-2015 OI Agnew-Blais, Jessica/0000-0002-0755-6867 FU American College of Physicians Foundation; Disease Control and Prevention Career Development Award [K01 EF1000067-01] FX Supported by grants from the Prescription Drug Labeling Project funded by the American College of Physicians Foundation, and by a Centers for Disease Control and Prevention Career Development Award K01 EF1000067-01 (to M.S.W.) NR 18 TC 31 Z9 32 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0025-7079 J9 MED CARE JI Med. Care PD MAR PY 2009 VL 47 IS 3 BP 370 EP 373 PG 4 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA 412VT UT WOS:000263753000015 PM 19194338 ER PT J AU Schauer, IE Reusch, JEB AF Schauer, Irene E. Reusch, Jane E. -B. TI Nonesterified fatty acid exposure activates protective and mitogenic pathways in vascular smooth muscle cells by alternate signaling pathways SO METABOLISM-CLINICAL AND EXPERIMENTAL LA English DT Article ID ELEMENT-BINDING PROTEIN; GROWTH-FACTOR-I; KINASE-C-DELTA; MEDIATED DOWN-REGULATION; OLEIC-ACID; ANGIOTENSIN-II; CARDIOVASCULAR-DISEASE; DOCOSAHEXAENOIC ACID; INSULIN SENSITIVITY; ENDOTHELIAL-CELLS AB Vascular smooth muscle cells (VSMC) are dynamic cells exposed to fluctuating concentrations of nutrients on a daily basis. Nonesterified fatty acids (NEFA) have been indicted as potential mediators of atherosclerosis and exaggerated VSMC remodeling observed in diabetes, and in vitro data support a model of VSMC activation by NEFA. However, recent observations suggest that metabolic stressors such as oxidants and NEFA may also simultaneously induce cytoprotective events as pail of a homeostatic "off switch." Our group has established that the transcription factor cyclic adenosine monophosphate response element binding protein (CREB) is important for maintenance of VSMC quiescence, differentiation, and survival. We therefore examined whether acute physiologic NEFA exposure would regulate CREB in primary cultures of bovine aortic VSMC and explored the relationship between signaling to the cytoprotective CREB and the activating mitogen-activated protein kinase pathways. In vitro exposure of VSMC to 3 classes of unsaturated NEFA leads to significant acute, transient, dose-dependent, and repeatedly inducible CREB activation. As expected, extracellular signal regulated kinase, P38 mitogen-activated protein kinase, Akt, Jun N-terminal kinase, and protein kinase C (PKC) pathways are also activated by NEFA. Using a battery of pharmacologic inhibitors and antioxidants, we demonstrate that CREB activation is mediated by a novel PKC isoform and is reactive oxygen species independent, whereas extracellular signal-regulated kinase activation, in contrast, is mediated by reactive oxygen species and is PKC independent. These data suggest parallel and mechanistically distinct stimulation of separate stabilizing and activating pathways in VSMC response to acute NEFA-mediated stress. Furthermore, the down-regulation of CRFB in models of chronic metabolic stress reported in the literature would be expected to disrupt this homeostasis and shift the balance toward VSMC activation, consistent with emerging models of atherosclerosis. (C) 2009 Elsevier Inc. All rights reserved. C1 [Schauer, Irene E.] Denver VA Med Ctr, Denver Res Inst, Denver, CO 80220 USA. Univ Colorado, Dept Med, Div Endocrinol Diabet & Metab, Aurora, CO 80045 USA. RP Schauer, IE (reprint author), Denver VA Med Ctr, Denver Res Inst, Denver, CO 80220 USA. FU National Institutes of Health [R01-DK064741-01]; Department of Veterans Affairs (VA Merit); American Heart Association FX This research was supported by grants from the National Institutes of Health (NIH T32 and NIH R01-DK064741-01), the Department of Veterans Affairs (VA Merit), an NIH P01 vascular core grant, and the American Heart Association. We appreciate the technical assistance of Jody Gunter, Dr Peter Watson, and Matthew Hockin, as well as the careful reading and advice of Dr Boris Draznin. NR 50 TC 7 Z9 8 U1 0 U2 0 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0026-0495 J9 METABOLISM JI Metab.-Clin. Exp. PD MAR PY 2009 VL 58 IS 3 BP 319 EP 327 DI 10.1016/j.metabol.2008.10.003 PG 9 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 414RH UT WOS:000263882400009 PM 19217446 ER PT J AU Karaoglu, A Aydin, S Dagli, AF Cummings, DE Ozercan, IH Canatan, H Ozkan, Y AF Karaoglu, Aziz Aydin, Suleyman Dagli, Adile F. Cummings, David E. Ozercan, Ibrahim H. Canatan, Halit Ozkan, Yusuf TI Expression of obestatin and ghrelin in papillary thyroid carcinoma SO MOLECULAR AND CELLULAR BIOCHEMISTRY LA English DT Article DE Papillary thyroid carcinoma; Obestatin; Ghrelin ID HASHIMOTOS THYROIDITIS; FOOD-INTAKE; HORMONE; PEPTIDE; GROWTH; TUMORS; ADENOCARCINOMA; DISCOVERY AB Ghrelin and obestatin are two peptide hormones with opposing roles in the control of appetite: orexigenic and anorexigenic, respectively. Loss of appetite is a common, serious complication of many forms of malignancy. The goals of this study were to investigate: (i) whether there are differences in ghrelin and obestatin peptide expression in thyroid tissues from a series of papillary carcinoma cases and normal controls, and (ii) whether there are correlations between tissue ghrelin and obestatin levels in series of papillary carcinoma cases and normal controls. Immunohistochemical analysis showed that in sections of benign human thyroid tissue, anti-ghrelin antibody reacted with intense staining in colloid-filled follicles. In benign thyroid tissues, colloids displayed plentiful dispersion in comparison with papillary microcarcinomas, whereas colloids in malignant thyroid tissues were uncommon. We found markedly lower tissue ghrelin levels in thyroid tissue of patients with papillary carcinomas, compared with normal thyroid tissues (P = 0.001). Immunohistochemical analysis also showed that obestatin in papillary carcinoma stained positively to various degrees. Obestatin tissue levels in papillary carcinomas tended to be slightly higher than those in normal thyroid tissue, but this was not statistically significant (P = 0.29). We also report that thyroid tissue of patients with Hashimoto's thyroiditis produced ghrelin and obestatin at similar levels as in normal thyroid tissue, even though colloid in Hashimoto's disease is scarce. We conclude that depressed expression of ghrelin, but not obestatin, is specific to papillary carcinoma, and this difference might constitute a diagnostic tool to differentiate papillary carcinoma from normal thyroid tissue. We currently do not know how these peptides are regulated and what factors are involved in papillary carcinoma, which inhibit the expression of ghrelin but not obestatin. This issue warrants further studies. C1 [Aydin, Suleyman] Firat Univ, Firat Univ Hosp, Sch Med, Dept Med Biochem & Clin Biochem, TR-23119 Elazig, Turkey. [Karaoglu, Aziz] Firat Univ, Sch Med, Dept Med Oncol, TR-23119 Elazig, Turkey. [Dagli, Adile F.; Ozercan, Ibrahim H.] Firat Univ, Sch Med, Dept Pathol, TR-23119 Elazig, Turkey. [Cummings, David E.] Univ Washington, Vet Affairs Puget Sound Hlth Care Syst, Dept Med, Div Metab Endocrinol & Nutr, Seattle, WA 98108 USA. [Canatan, Halit] Kuwait Univ, Hlth Sci Ctr, Fac Med, Dept Pharmacol & Toxicol, Safat 13110, Kuwait. [Ozkan, Yusuf] Firat Univ, Sch Med, Dept Endocrinol & Metab, TR-23119 Elazig, Turkey. RP Aydin, S (reprint author), Firat Univ, Firat Univ Hosp, Sch Med, Dept Med Biochem & Clin Biochem, TR-23119 Elazig, Turkey. EM saydin1@hotmail.com NR 25 TC 16 Z9 16 U1 0 U2 0 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0300-8177 J9 MOL CELL BIOCHEM JI Mol. Cell. Biochem. PD MAR PY 2009 VL 323 IS 1-2 BP 113 EP 118 DI 10.1007/s11010-008-9969-0 PG 6 WC Cell Biology SC Cell Biology GA 403XU UT WOS:000263116100012 PM 19039650 ER PT J AU Punathil, T Katiyar, SK AF Punathil, Thejass Katiyar, Santosh K. TI Inhibition of Non-small Cell Lung Cancer Cell Migration by Grape Seed Proanthocyanidins Is Mediated Through the Inhibition of Nitric Oxide, Guanylate Cyclase, and ERK1/2 SO MOLECULAR CARCINOGENESIS LA English DT Article DE nitric oxide; mitogen-activated protein kinase; grape seed proanthocyanidins; guanylate cyclase; tumor cell migration; lung cancer cells ID HUMAN HEPATOCELLULAR-CARCINOMA; ACTIVATED PROTEIN-KINASES; SKH-1 HAIRLESS MICE; TUMOR PROGRESSION; SYNTHASE ACTIVITY; OXIDATIVE STRESS; BREAST-CANCER; EXPRESSION; GROWTH; ADENOCARCINOMA AB Tumor cell migration is considered as a major event in the metastatic cascade. Here we examined the effect of grape seed proanthocyanidins (GSPs) on migration capacity and signaling mechanisms using nonsmall cell human lung cancer cells. Using in vitro migration assay, we found that treatment of A549 and H 1299 cells with GSPs resulted in concentration-dependent inhibition of migration of these cells. The migration capacity of cells was reduced in presence of N(G)-nitro-L-arginine methyl ester (L-NAME), an inhibitor of nitric oxide synthase. GSPs suppressed the elevated levels of endogenous NO/NOS in A549 and H1299 cells and blocked the migration promoting capacity of L-arginine. Treatment with guanylate cyclase (GC) inhibitor 1-H-[1,2,4]oxadiaxolo[4,3-a]quinoialin-1-one (ODQ) reduced the migration of A549 cells whereas additional presence of 8-bromoguanosine 3'5'-cyclic monophosphate (8-Br-cGMP, cGMP analogue) restored the migration of these cells, suggesting a role for GC in migration of A549 cells. GSPs reduced the elevated levels of cGMP in cancer cells and also blocked the migration restoring activity of 8-Br-cGMP. The mitogen-activated protein kinase kinase (MAPKK) inhibitor, UO126, inhibited the migration of A549 cells, indicating a role for MAPKK in the migration. Additionally, UO126 and ODQ inhibited the migration restoring effects Of L-arginine in L-NAME-treated cells, suggesting the involvement of cGMP and MAPK pathways in NO-mediated migration. GSPs inhibited L-arginine and 8-Br-cGMP-induced activation of ERK1/2 in A549 cells. Together, these results indicate sequential inhibition of NOMOS, GC, and MAPK pathways by GSPs in mediating the inhibitory signals for cell migration, an essential step in invasion and metastasis. (C) 2008 Wiley-Liss, Inc. C1 [Punathil, Thejass; Katiyar, Santosh K.] Univ Alabama, Dept Dermatol, Birmingham, AL 35294 USA. [Katiyar, Santosh K.] Univ Alabama, Res Ctr, Dept Clin Nutr, Birmingham, AL 35294 USA. [Katiyar, Santosh K.] Univ Alabama, Dept Comprehens Canc Ctr, Birmingham, AL 35294 USA. [Katiyar, Santosh K.] Birmingham VA Med Ctr, Birmingham, AL USA. RP Katiyar, SK (reprint author), Univ Alabama, Dept Dermatol, 1670 Univ Blvd,Volker Hall 557,POB 202, Birmingham, AL 35294 USA. NR 36 TC 24 Z9 25 U1 1 U2 6 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0899-1987 J9 MOL CARCINOGEN JI Mol. Carcinog. PD MAR PY 2009 VL 48 IS 3 BP 232 EP 242 DI 10.1002/mc.20473 PG 11 WC Biochemistry & Molecular Biology; Oncology SC Biochemistry & Molecular Biology; Oncology GA 415OI UT WOS:000263943000007 PM 18680102 ER PT J AU Rani, CSS Elango, N Wang, SS Kobayashi, K Strong, R AF Rani, C. S. Sheela Elango, Narayanasamy Wang, Shou-shu Kobayashi, Kazuto Strong, Randy TI Identification of an Activator Protein-1-Like Sequence as the Glucocorticoid Response Element in the Rat Tyrosine Hydroxylase Gene SO MOLECULAR PHARMACOLOGY LA English DT Article ID CYCLIC-AMP; RECEPTOR-BINDING; PHORBOL ESTER; TRANSCRIPTION FACTORS; PROMOTER REGION; AP-1 COMPLEX; DNA-SEQUENCE; C-FOS; EXPRESSION; CELLS AB Glucocorticoids (GCs) generally stimulate gene transcription via consensus glucocorticoid response elements (GREs) located in the promoter region. To identify the GRE in the rat tyrosine hydroxylase (TH) gene promoter, we transiently transfected PC12 cells with a 9-kilobase (kb) TH promoter-luciferase (Luc) construct. Dexamethasone (Dex) stimulated Luc activity, which was abolished by mifepristone (RU486). Serial deletion mutations revealed a Dex-responsive 7-base pair (bp) sequence, TGACTAA, located at -5734 to -5728. Deletion of just these seven nucleotides from the 9-kb promoter completely abolished the Dex response and partially reduced the response to phorbol ester but not to forskolin. The Dex response was fully retained in a construct in which most of the 9-kb promoter was deleted, except for 100 bp around the -5.7-kb region, clearly identifying this 7-bp sequence as solely responsible for GC responsiveness. Conversely, deletion of the proximal cAMPresponse element (-45/-38) or activator protein-1 (AP-1) (-207/-201) sites in the 9-kb promoter did not affect Dex and phorbol ester responses. A radiolabeled 25-bp promoter fragment bearing the 7-bp TH-GRE/AP-1 showed specific binding to PC12 nuclear proteins. Using antibodies against the glucocorticoid receptors and AP-1 family of proteins and primers for the TH-GRE/AP-1 region, we detected a specific DNA amplicon in a chromatin immunoprecipitation assay. This 7-bp TH-GRE/AP-1 sequence (TGACTAA) does not bear similarity to any known GRE but closely resembles the consensus AP-1 binding site, TGACTCA. Our studies describe for the first time a novel GRE/AP-1 site present in the TH gene promoter that is critical for glucocorticoid regulation of the TH gene. C1 [Rani, C. S. Sheela; Wang, Shou-shu; Strong, Randy] Univ Texas Hlth Sci Ctr San Antonio, Dept Pharmacol, San Antonio, TX 78229 USA. [Rani, C. S. Sheela; Wang, Shou-shu; Strong, Randy] Univ Texas Hlth Sci Ctr San Antonio, Barshop Inst Longev & Aging Studies, San Antonio, TX 78229 USA. [Elango, Narayanasamy; Strong, Randy] S Texas Vet Hlth Care Syst, Audie L Murphy Div, San Antonio, TX USA. [Kobayashi, Kazuto] Fukushima Med Univ, Sch Med, Dept Mol Genet, Fukushima, Japan. RP Rani, CSS (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Pharmacol, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM kadapakkam@uthscsa.edu FU NIA NIH HHS [AG022307, U01 AG022307] NR 41 TC 15 Z9 18 U1 0 U2 2 PU AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3995 USA SN 0026-895X J9 MOL PHARMACOL JI Mol. Pharmacol. PD MAR PY 2009 VL 75 IS 3 BP 589 EP 598 DI 10.1124/mol.108.051219 PG 10 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 410EE UT WOS:000263559500016 PM 19060113 ER PT J AU Elder, GA Cristian, A AF Elder, Gregory A. Cristian, Adrian TI Blast-Related Mild Traumatic Brain Injury: Mechanisms of Injury and Impact on Clinical Care SO MOUNT SINAI JOURNAL OF MEDICINE LA English DT Article DE animal models; blast overpressure wave; blast-related brain injury; improvised explosive device; mild traumatic brain injury; Operation Enduring Freedom; Operation Iraqi Freedom; pathophysiology; postconcussion syndrome; posttraumatic stress disorder; shell shock ID POSTTRAUMATIC-STRESS-DISORDER; INDUCED NEUROTRAUMA; SHELL SHOCK; RAT-BRAIN; EXPOSURE; IRAQ; WAVE AB Mild traumatic brain injury has been called the signature injury of the wars in Iraq and Afghanistan. In both theaters of operation, traumatic brain injury has been a significant cause of mortality and morbidity, with blast-related injury the most common cause. Improvised explosive devices have been the major cause of blast injuries. It is estimated that 10% to 20% of veterans returning from these operations have suffered a traumatic brain injury, and there is concern that blast-related injury may produce adverse long-term health affects and affect the resilience and in-theater performance of troops. Blast-related injury occurs through several mechanisms related to the nature of the blast overpressure wave itself as well as secondary and tertiary injuries. Animal studies clearly show that blast overpressure waves are transmitted to the brain and can cause changes that neuropathologically are most similar to diffuse axonal injury. One striking feature of the mild traumatic brain injury cases being seen in veterans of the wars in Iraq and Afghanistan is the high association of mild traumatic brain injury with posttraumatic stress disorder. The overlap in symptoms between the disorders has made distinguishing them clinically challenging. The high rates of mild trumatic brain injury and posttraumatic stress disorder in the current operations are of significant concern for the long-term health of Us veterans with associated economic implications. Mt Sinai J Med 76.111-118, 2009 (C) 2009 Mount Sinai School of Medicine C1 [Elder, Gregory A.; Cristian, Adrian] Vet Affairs Med Ctr, James J Peters Dept, Rehabil Med Serv, Bronx, NY USA. RP Elder, GA (reprint author), Vet Affairs Med Ctr, James J Peters Dept, Rehabil Med Serv, Bronx, NY USA. EM gregory.elder@va.gov NR 26 TC 113 Z9 117 U1 1 U2 26 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0027-2507 J9 MT SINAI J MED JI Mt. Sinai J. Med. PD MAR-APR PY 2009 VL 76 IS 2 BP 111 EP 118 DI 10.1002/msj.20098 PG 8 WC Medicine, General & Internal SC General & Internal Medicine GA 427OE UT WOS:000264787800004 PM 19306373 ER PT J AU Julian, LJ Vella, L Frankel, D Minden, SL Oksenberg, JR Mohr, DC AF Julian, L. J. Vella, L. Frankel, D. Minden, S. L. Oksenberg, J. R. Mohr, D. C. TI ApoE alleles, depression and positive affect in multiple sclerosis SO MULTIPLE SCLEROSIS LA English DT Article DE genetics; multiple sclerosis; quality of life ID WHITE-MATTER HYPERINTENSITIES; APOLIPOPROTEIN-E POLYMORPHISM; DISABILITY STATUS SCALE; LATE-LIFE DEPRESSION; COGNITIVE IMPAIRMENT; EPSILON-4 ALLELE; DISEASE SEVERITY; NEGATIVE AFFECT; E GENOTYPE; ASSOCIATION AB Background The role of apolipoprotein E ( ApoE) alleles has received recent attention in depressive disorders, the ApoE epsilon 4 conferring greater risk for poorer outcomes, and the ApoE epsilon 2 allele providing some protective effects. Depression is common in multiple sclerosis (MS) and the role of ApoE alleles is unknown. Aims To evaluate ApoE alleles in relation to symptoms of depression in a cohort of patients with MS participating in the Sonya Slifka Longitudinal Multiple Sclerosis Study (Slifka Study). To examine risk and protection, depressed mood and positive affect were each investigated with respect to the ApoE epsilon 4 and ApoE epsilon 2 alleles, respectively. Results Of the total 101 participants, 22.8% were ApoE epsilon 2 carriers and 21.8% were ApoE epsilon 4 carriers. Hierarchical linear regression analyses suggested that after controlling for demographics, disease duration, and disability, ApoE epsilon 2 significantly predicted increased positive affect (R(2)Delta = 0.05, F(1,94) = 5.44, P = 0.02) and was associated with decreased severity of depressive symptoms, although this did not reach statistical significance (R(2)Delta = 0.03, F(1,94) = 3.44, P = 0.06). ApoE epsilon 4 did not significantly predict depression status. Conclusion The presence of the ApoE epsilon 2 allele in this study is suggested to be protective against depressive symptoms in our subsample of patients recruited from the Slifka Study. These findings are consistent with reports in psychiatric populations linking ApoE epsilon 2 with decreased incidence of depressive disorders. Further investigation would be warranted to understand the role of ApoE genotypes and risk for depressive symptoms. Multiple Sclerosis 2009; 15: 311-315. http://msj.sagepub.com C1 [Julian, L. J.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA. [Vella, L.] San Francisco VA Med Ctr, San Francisco, CA USA. [Frankel, D.; Minden, S. L.] Abt & Associates Inc, Cambridge, MA USA. [Minden, S. L.] Brigham & Womens Hosp, Boston, MA 02115 USA. [Minden, S. L.] ABT Associates Inc, Cambridge, MA USA. [Oksenberg, J. R.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA. [Mohr, D. C.] Northwestern Univ, Hines VA Med Ctr, Dept Prevent Med, Chicago, IL 60611 USA. RP Julian, LJ (reprint author), Univ Calif San Francisco, Dept Med, 3333 Calif St,Suite 270, San Francisco, CA 94143 USA. EM laura.julian@ucsf.edu FU NCRR NIH HHS [UL1 RR025741]; NICHD NIH HHS [R01 HD043323, R01 HD043323-03]; NIMH NIH HHS [K08 MH 07272401A2] NR 37 TC 12 Z9 13 U1 2 U2 4 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 1352-4585 J9 MULT SCLER JI Mult. Scler. PD MAR PY 2009 VL 15 IS 3 BP 311 EP 315 DI 10.1177/1352458508099478 PG 5 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 423AF UT WOS:000264468100006 PM 19244396 ER PT J AU Oh, SJ Morgan, MB Lu, L Hatanaka, Y Hemmi, S Young, A Claussen, GC AF Oh, Shin J. Morgan, Marla B. Lu, Liang Hatanaka, Yuki Hemmi, Shoji Young, Angela Claussen, Gwendolyn C. TI RACIAL DIFFERENCES IN MYASTHENIA GRAVIS IN ALABAMA SO MUSCLE & NERVE LA English DT Article DE MuSK antibody; myasthenia gravis; racial differences ID ACETYLCHOLINE-RECEPTOR ANTIBODY; ONSET AB Demographic, clinical, and laboratory features were compared in 235 white and African-American (AA) patients with myasthenia gravis (MG) at the University of Alabama at Birmingham Neuromuscular Disease Clinic from May 2003 to January 2008. Seventy nine percent of patients were white. Acetylcholine receptor antibody was positive in 71% of white patients and in 59% of AA. In patients with seronegative generalized MG, the rate of positive muscle-specific tyrosine kinase antibody (MuSK-Ab) was significantly higher in AA than it was in whites (50% in AA vs. 17% in whites). Ocular MG was seronegative in 75% of AA patients. In AA, MG occurred earlier and more frequently in females, whereas, in whites, disease onset was later and more common in males. Another significant difference was a higher percentage of abnormality on repetitive nerve stimulation in AA. There was also a tendency for more severe forms of MG in AA. There are racial differences in MG between whites and AA in Alabama. These racial differences highlight the need to study biological factors in the pathogenesis of MG and to assess different approaches in diagnosis and treatment. Muscle Nerve 39: 328-332, 2009 C1 [Oh, Shin J.; Morgan, Marla B.; Lu, Liang; Hatanaka, Yuki; Hemmi, Shoji; Young, Angela; Claussen, Gwendolyn C.] Univ Alabama, Birmingham Vet Affairs Med Ctr, Dept Neurol, Birmingham, AL 35294 USA. RP Oh, SJ (reprint author), Univ Alabama, Birmingham Vet Affairs Med Ctr, Dept Neurol, Univ Stn, Birmingham, AL 35294 USA. EM shinjoh@uab.edu FU NINDS NIH HHS [K08 NS057664-01A2, K08 NS057664-02, K08 NS057664] NR 21 TC 13 Z9 13 U1 0 U2 0 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0148-639X J9 MUSCLE NERVE JI Muscle Nerve PD MAR PY 2009 VL 39 IS 3 BP 328 EP 332 DI 10.1002/mus.21191 PG 5 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 411NR UT WOS:000263656800007 PM 19127534 ER PT J AU Fotuhi, M Mohassel, P Yaffe, K AF Fotuhi, Majid Mohassel, Payam Yaffe, Kristine TI Fish consumption, long-chain omega-3 fatty acids and risk of cognitive decline or Alzheimer disease: a complex association SO NATURE CLINICAL PRACTICE NEUROLOGY LA English DT Review DE Alzheimer disease; cognitive decline; dementia; fish consumption; long-chain omega-3 fatty acids ID N-3 FATTY-ACIDS; TUMOR-NECROSIS-FACTOR; CEREBRAL-BLOOD-FLOW; DOCOSAHEXAENOIC ACID; CARDIOVASCULAR-DISEASE; DIETARY SUPPLEMENTATION; SECONDARY-PREVENTION; VASCULAR DEMENTIA; BRAIN-DEVELOPMENT; PROSTAGLANDIN-E AB Long-chain omega-3 fatty acids could have neuroprotective properties against dementia, which is becoming a major global public health issue. We conducted a systematic review of the literature to establish the association between eating fish (a source of long-chain omega-3 fatty acids) or taking long-chain omega-3 fatty acid supplements and the risk of cognitive decline or Alzheimer disease (AD). We identified eleven observational studies and four clinical trials. All three observational studies that used cognitive decline as an outcome reported significant benefits, whereas only four of eight observational studies that used incidence of AD or dementia as an outcome reported positive findings. None of four small clinical trials provided convincing evidence for the use of this approach in the prevention or treatment of any form of dementia. In summary, the existing data favor a role for long-chain omega-3 fatty acids in slowing cognitive decline in elderly individuals without dementia, but not for the prevention or treatment of dementia (including AD). This apparent dichotomy might reflect differences in study designs with regard to participants, dosages, the ratio of long-chain omega-3 to omega-6 fatty acids, or the choice of outcome measurements. Large clinical trials of extended duration should help to provide definitive answers. C1 [Fotuhi, Majid] Sinai Hosp Baltimore, LifeBridge Hlth Brain & Spine Inst, Ctr Memory & Brain Hlth, Baltimore, MD 21209 USA. [Fotuhi, Majid; Mohassel, Payam] Johns Hopkins Univ, Sch Med, Baltimore, MD USA. [Yaffe, Kristine] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Yaffe, Kristine] San Francisco VA Med Ctr, Memory Disorders Clin, San Francisco, CA USA. RP Fotuhi, M (reprint author), Sinai Hosp Baltimore, LifeBridge Hlth Brain & Spine Inst, Ctr Memory & Brain Hlth, 5051 Greenspring Ave, Baltimore, MD 21209 USA. EM mfotuhi@lifebridgehealth.org OI Fotuhi, Majid/0000-0002-0980-1176 FU NIA NIH HHS [AG 031155] NR 77 TC 144 Z9 148 U1 6 U2 66 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1745-834X J9 NAT CLIN PRACT NEURO JI Nat. Clin. Pract. Neurol. PD MAR PY 2009 VL 5 IS 3 BP 140 EP 152 DI 10.1038/ncpneuro1044 PG 13 WC Clinical Neurology SC Neurosciences & Neurology GA 414VE UT WOS:000263892500009 PM 19262590 ER PT J AU Asselbergs, FW Mozaffarian, D Katz, R Kestenbaum, B Fried, LF Gottdiener, JS Shlipak, MG Siscovick, DS AF Asselbergs, Folkert W. Mozaffarian, Dariush Katz, Ronit Kestenbaum, Bryan Fried, Linda F. Gottdiener, John S. Shlipak, Michael G. Siscovick, David S. TI Association of renal function with cardiac calcifications in older adults: the cardiovascular health study SO NEPHROLOGY DIALYSIS TRANSPLANTATION LA English DT Article DE chronic kidney disease; cohort; creatinine; cystatin C; elderly ID MITRAL ANNULAR CALCIFICATION; GLOMERULAR-FILTRATION-RATE; CHRONIC KIDNEY-DISEASE; PERITONEAL-DIALYSIS PATIENTS; SERUM CYSTATIN-C; VALVE CALCIFICATION; HEMODIALYSIS-PATIENTS; ELDERLY PERSONS; ALL-CAUSE; CREATININE AB Background. Aortic valve sclerosis (AVS) and mitral annulus calcification (MAC) are highly prevalent in patients with end-stage renal disease. It is less well established whether milder kidney disease is associated with cardiac calcifications. We evaluated the relationships between renal function and MAC, aortic annular calcification (AAC) and AVS in the elderly. Methods. From the Cardiovascular Health Study, a community-based cohort of ambulatory adults >= age 65, a total of 3929 individuals (mean +/- SD age 74 +/- 5 years, 60% women) were evaluated with two-dimensional echocardiography. Renal function was assessed by means of creatinine-based estimated glomerular filtration rate (eGFR) and cystatin C. Results. The prevalences of MAC and AAC were significantly higher in individuals with an eGFR < 45 mL/ min/1.73 m(2) (P < 0.01 for each), and cystatin C levels were significantly higher in individuals with MAC or AAC compared to individuals without these cardiac calcifications (P < 0.001 for each). After multivariate-adjustment, an eGFR < 45 mL/min/1.73 m(2) was significantly associated with MAC [odds ratio 1.54 (95% CI 1.16-2.06), P = 0.003] and not associated with AAC [1.30 (0.97-1.74), P = 0.085] and AVS [1.15 (0.86-1.53), P = 0.355]. In addition, cystatin C levels were independently associated with MAC [odds ratio per SD 1.12 (1.05-1.21), P = 0.001] and not associated with AAC [1.07 (1.00-1.15), P = 0.054] and AVS [0.99 (0.93-1.06), P = 0.82]. Furthermore, the prevalence of multiple cardiac calcifications was higher in subjects with an eGFR < 45 mL/ min/1.73 m(2) and increased per quartile of cystatin C (P-values < 0.001). In addition, a significant trend was observed between an eGFR < 45 mL/min/1.73 m(2), increasing levels of cystatin C and the number of cardiac calcifications (P < 0.05). Conclusions. In a community-based cohort of the elderly, moderate kidney disease as defined by an eGFR < 45 mL/min/1.73m(2) and elevated levels of cystatin C was associated with prevalent MAC. In addition, a significant trend was observed between an eGFR < 45 mL/min/1.73m(2), increasing levels of cystatin C and the number of cardiac calcifications. No associations were found between renal function and AAC or AVS. C1 [Asselbergs, Folkert W.] Univ Groningen, Dept Cardiol, Univ Med Ctr Groningen, NL-9713 GZ Groningen, Netherlands. [Mozaffarian, Dariush] Harvard Univ, Sch Med, Dept Med, Boston, MA USA. [Mozaffarian, Dariush] Harvard Univ, Sch Med, Dept Epidemiol, Boston, MA USA. [Mozaffarian, Dariush] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA. [Katz, Ronit] Univ Washington, Coordinating Ctr, Seattle, WA 98195 USA. [Kestenbaum, Bryan] Univ Washington, Div Nephrol, Seattle, WA 98195 USA. [Fried, Linda F.] VA Pittsburgh Healthcare Syst, Med Serv, Renal Sect, Pittsburgh, PA USA. [Gottdiener, John S.] Univ Maryland Hosp, Div Cardiol, Baltimore, MD 21201 USA. [Shlipak, Michael G.] Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, Gen Internal Med Sect, San Francisco, CA 94143 USA. [Siscovick, David S.] Univ Washington, Dept Med, Seattle, WA 98195 USA. [Siscovick, David S.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. RP Asselbergs, FW (reprint author), Univ Groningen, Dept Cardiol, Univ Med Ctr Groningen, Hanzepl 1, NL-9713 GZ Groningen, Netherlands. EM fwasselbergs@hotmail.com RI Mozaffarian, Dariush/B-2276-2008 FU Netherlands Heart Foundation [2003T010]; Dutch Inter University Cardiology Institute Netherlands; American Federation for Aging Research and National Institute on Aging; Robert Wood Johnson Foundation [R01 DK066488]; National Heart, Lung and Blood Institute (NHLBI) [N01-HC-85079, N01-HC-85086, N01-HC-35129, N01-HC-15103]; [R01 HL073208-01]; [R01 AG027002] FX Dr F. W. Asselbergs is a research fellow of the Netherlands Heart Foundation (2003T010) and the Dutch Inter University Cardiology Institute Netherlands. Drs Shlipak, Fried and Katz are funded by R01 HL073208-01. Dr Shlipak is also supported by the American Federation for Aging Research and National Institute on Aging (Paul Beeson Scholars Program), by the Robert Wood Johnson Foundation (Generalist Faculty Scholars Program) and by R01 DK066488. Drs Fried, Shlipak and Siscovick are also supported by R01 AG027002. The Cardiovascular Health Study (CHS) is supported by contracts N01-HC-85079 through N01-HC-85086, N01-HC-35129 and N01-HC-15103 from the National Heart, Lung and Blood Institute ( NHLBI). A full list of participating CHS investigators and institutions can be found at www.chs-nhlbi.org. NR 28 TC 15 Z9 19 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0931-0509 J9 NEPHROL DIAL TRANSPL JI Nephrol. Dial. Transplant. PD MAR PY 2009 VL 24 IS 3 BP 834 EP 840 DI 10.1093/ndt/gfn544 PG 7 WC Transplantation; Urology & Nephrology SC Transplantation; Urology & Nephrology GA 410UY UT WOS:000263605000024 PM 18840892 ER PT J AU McLaren, DG Kosmatka, KJ Oakes, TR Kroenke, CD Kohama, SG Matochik, JA Ingram, DK Johnson, SC AF McLaren, Donald G. Kosmatka, Kristopher J. Oakes, Terrance R. Kroenke, Christopher D. Kohama, Steven G. Matochik, John A. Ingram, Don K. Johnson, Sterling C. TI A population-average MRI-based atlas collection of the rhesus macaque SO NEUROIMAGE LA English DT Article DE Rhesus macaque; MRI; Atlas; Macaca mulatta; Priors; Brain mapping; Probabilistic ID AUTOMATED IMAGE REGISTRATION; HUMAN PARIETAL OPERCULUM; PRIMATE CEREBRAL-CORTEX; SURFACE-BASED ATLASES; NONHUMAN PRIMATE; TEMPLATE IMAGES; HUMAN BRAIN; PROBABILISTIC ATLAS; MONKEY BRAIN; BABOON AB Magnetic resonance imaging (MRI) studies of non-human primates are becoming increasingly common; however, the well-developed voxel-based methodologies used in human studies are not readily applied to non-human primates. In the present study, we create a population-average MRI-based atlas collection for the rhesus macaque (Macaca mulatta) that can be used with common brain mapping packages such as SPM or FSL. In addition to creating a publicly available T1-weighted atlas (http://www.brainmap.wisc.edu/monkey. html), probabilistic tissue classification maps and T2-weighted atlases were also created. Theses atlases are aligned to the MRI volume from the Saleem, K. S. and Logothetis, N. K. (2006) atlas providing an explicit link to histological sections. Additionally, we have created a transform to integrate these atlases with the F99 surface-based atlas in CARET. It is anticipated that these tools will help facilitate voxel-based imaging methodologies in non-human primate species, which in turn may increase our understanding of brain function, development, and evolution. Published by Elsevier Inc. C1 [McLaren, Donald G.; Kosmatka, Kristopher J.; Johnson, Sterling C.] William S Middleton Mem Vet Adm Med Ctr, Geriatr Res Educ & Clin Ctr, Madison, WI 53705 USA. [McLaren, Donald G.] Univ Wisconsin, Neurosci Training Program, Madison, WI 53706 USA. [McLaren, Donald G.; Kosmatka, Kristopher J.; Johnson, Sterling C.] Univ Wisconsin, Dept Med, Madison, WI 53705 USA. [Kroenke, Christopher D.] Oregon Hlth & Sci Univ, Adv Imaging Res Ctr, Portland, OR 97239 USA. [Kroenke, Christopher D.; Kohama, Steven G.] Oregon Hlth & Sci Univ, Oregon Natl Primate Res Ctr, Div Neurosci, Beaverton, OR 97006 USA. [Matochik, John A.] Natl Inst Drug Abuse, Intramural Res Program, Neuroimaging Res Branch, Baltimore, MD 21224 USA. [Ingram, Don K.] Louisiana State Univ Syst, Pennington Biomed Res Ctr, Nutr Neurosci & Aging Lab, Baton Rouge, LA 70808 USA. [Oakes, Terrance R.] Univ Wisconsin, Waisman Ctr Brain Imaging Lab, Madison, WI 53705 USA. RP Johnson, SC (reprint author), William S Middleton Mem Vet Adm Med Ctr, Geriatr Res Educ & Clin Ctr, 2500 Overlook Terrace 11G, Madison, WI 53705 USA. EM scj@medicine.wisc.edu RI McLaren, Donald/G-9906-2011 OI Johnson, Sterling/0000-0002-8501-545X FU National Institutes of Health [RR000167, AG11915, AG20013, GM007507, RR00163, AG029612]; National Institute on Aging FX This study was supported in part by the National Institutes of Health RR000167 (UW), AG11915 (UW), AG20013 (UW), GM007507 (UW), RR00163 (ONPRC), AG029612 (OHSU) and the Intramural Research Program of the National Institute on Aging. This study was also supported with resources and use of facilities at the William S. Middleton Memorial Veterans Hospital, Madison, WI, USA. John Matochik is now at the National Institute on Alcohol Abuse and Alcoholism. The assistance of Erik K. Kastman, Brent W. Thiel, Michele E. Fitzgerald, Ron Fisher, Scott T. Baum, Josh Smith, Ricki J. Colman, Ph. D., Andy. A. Alexander, Ph. D., Barbara B. Bendlin, Ph. D. and the Waisman Center for Brain Imaging was greatly appreciated. We would especially like to thank Drs. Kadharbatcha S. Saleem and Nikos K. Logothetis for providing a digital copy of the D99-SL atlas. GRECC Manuscript Number: 2008-31. NR 66 TC 103 Z9 105 U1 4 U2 15 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1053-8119 J9 NEUROIMAGE JI Neuroimage PD MAR PY 2009 VL 45 IS 1 BP 52 EP 59 DI 10.1016/j.neuroimage.2008.10.058 PG 8 WC Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging SC Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging GA 414KR UT WOS:000263862900007 PM 19059346 ER PT J AU Sani, S Shimamoto, S Turner, RS Levesque, N Starr, PA AF Sani, Sepehr Shimamoto, Shoichi Turner, Robert S. Levesque, Nadia Starr, Philip A. TI MICROELECTRODE RECORDING IN THE POSTERIOR HYPOTHALAMIC REGION IN HUMANS SO NEUROSURGERY LA English DT Article DE Cluster headache; Electrophysiology; Hypothalamus; Microelectrode; Periventricular gray; Single-unit recording microelectrode ID DEEP-BRAIN-STIMULATION; CHRONIC CLUSTER HEADACHE; TRIGEMINAL AUTONOMIC CEPHALALGIAS; OCCIPITAL NERVE-STIMULATION; NEURONAL-ACTIVITY; HYPOCRETIN-RECEPTOR-2 GENE; G1246A POLYMORPHISM; FOLLOW-UP; AREA; EXPERIENCE AB INTRODUCTION: Deep brain stimulation of the posterior hypothalamic region (PHR) is an emerging technique for the treatment of medically intractable Cluster headache. Few reports have analyzed single unit neuronal recordings in the human PHR. We report properties of spontaneous neuronal discharge in PHR for 6 patients who underwent DBS for cluster headaches. METHODS: Initial target coordinates, determined by magnetic resonance imaging stereotactic localization, were 2 mm lateral, 3 mm posterior, and 5 mm inferior to the midpoint of the anterior commissure-posterior commissure plane. A single microelectrode penetration was performed beginning 10 mm above the anatomic target, without systemic sedation. Single units were discriminated off-line by cluster Cutting in principal components space. Discharge rates, interspike intervals, and oscillatory activity were analyzed and compared between ventromedial thalamic and hypothalamic units. RESULTS: Six patients and 24 units were evaluated, Units in the PHR had a slow, regular spontaneous discharge with wide, low-amplitude action potentials. The mean discharge rate of hypothalamic neurons was significantly lower (mean +/- standard deviation, 13.2 +/- 12,2) than that of medial thalamic units (28.0 +/- 8.2). Oscillatory activity was not detected. Microelectrode recording in this region caused no morbidity. CONCLUSION: The single-unit discharge rate of neurons in the PHR of awake humans was 13.2 Hz and was significantly lower than medial thalamic neurons recorded dorsal to the tat-get. The findings will he of use for microelectrode localization of the cluster headache target and for comparison with animal studies. C1 [Sani, Sepehr; Shimamoto, Shoichi; Turner, Robert S.; Levesque, Nadia; Starr, Philip A.] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94112 USA. [Sani, Sepehr; Turner, Robert S.; Starr, Philip A.] San Francisco VA Med Ctr, Ctr Clin, San Francisco, CA USA. RP Sani, S (reprint author), Univ Calif San Francisco, Dept Neurol Surg, 505 Parnassus Ave,Room M-779, San Francisco, CA 94112 USA. EM sepehr.sani@ucsf.edu NR 47 TC 2 Z9 2 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0148-396X J9 NEUROSURGERY JI Neurosurgery PD MAR PY 2009 VL 64 IS 3 BP S161 EP S169 DI 10.1227/01.NEU.0000334051.91501.E3 PG 9 WC Clinical Neurology; Surgery SC Neurosciences & Neurology; Surgery GA 411MN UT WOS:000263653800020 ER PT J AU Wu, YN Johnson, SW AF Wu, Yan-Na Johnson, Steven W. TI Rotenone reduces Mg2+-dependent block of NMDA currents in substantia nigra dopamine neurons SO NEUROTOXICOLOGY LA English DT Article DE Dopamine; Magnesium; Voltage-dependent; N-methyl-D-aspartate; Brain slice; Tyrosine kinase ID METHYL-D-ASPARTATE; RECEPTOR CHANNELS; PARKINSONS-DISEASE; CORTICAL-NEURONS; TYROSINE KINASE; MG2+ BLOCK; CELL-DEATH; COMPLEX-I; RAT; INHIBITION AB Rotenone is a pesticide that has been successfully used to produce a rodent model of Parkinson's disease. We reported previously that rotenone potently augmented N-methyl-D-aspartate (NMDA)-evoked currents in rat dopamine neurons via a tyrosine kinase-dependent mechanism. In this study, we investigated the effect of rotenone on the current-voltage relationship of NMIDA-induced currents in substantia nigra zona compacta neurons recorded with whole-cell patch pipettes in slices of rat brain. In a physiologic concentration of extracellular Mg2+ (1.2 mM), a 30 min perfusion with rotenone (100 nM) produced a marked increase in current evoked by bath application of NMIDA (30 mu M), especially when measured at relatively hyperpolarized currents. In the presence of rotenone, NMDA currents lost the characteristic region of negative-slope conductance that is normally produced by voltage-dependent block by Mg2+. The voltage-dependent effect of rotenone on NMDA currents was mimicked by a low extracellular concentration of Mg2+ (0.2 mM) and was antagonized by a high level of Mg2+ (6.0 mM). Moreover, we report that the tyrosine kinase inhibitor genistein blocked the ability of rotenone to augment NMDA receptor currents. These results suggest that rotenone potentiates NMDA currents by a tyrosine kinase-dependent process that attenuates voltage-dependent Mg2+ block of NMDA-gated channels. These results support the hypothesis that an excitotoxic mechanism might participate in rotenone-induced toxicity of midbrain dopamine neurons. Published by Elsevier Inc. C1 [Wu, Yan-Na; Johnson, Steven W.] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97239 USA. [Johnson, Steven W.] Portland VA Med Ctr, Portland, OR 97207 USA. RP Johnson, SW (reprint author), Oregon Hlth & Sci Univ, Dept Neurol, 3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA. EM johnsost@ohsu.edu FU Veterans Affairs Merit Review Grant; Portland VA Parkinson's Disease Research, Education, and Clinical Center; American Parkinson Disease Association FX This work was supported by a Veterans Affairs Merit Review Grant, the Portland VA Parkinson's Disease Research, Education, and Clinical Center, and a grant from the American Parkinson Disease Association. NR 40 TC 15 Z9 15 U1 0 U2 4 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0161-813X J9 NEUROTOXICOLOGY JI Neurotoxicology PD MAR PY 2009 VL 30 IS 2 BP 320 EP 325 DI 10.1016/j.neuro.2009.01.002 PG 6 WC Neurosciences; Pharmacology & Pharmacy; Toxicology SC Neurosciences & Neurology; Pharmacology & Pharmacy; Toxicology GA 429HY UT WOS:000264912700020 PM 19428506 ER PT J AU Levin, M Naseri, A Stewart, JM AF Levin, Marc Naseri, Aynan Stewart, Jay M. TI Resident-Performed Prophylactic Retinopexy and the Risk of Retinal Detachment SO OPHTHALMIC SURGERY LASERS & IMAGING LA English DT Article ID POSTERIOR VITREOUS DETACHMENT; ARGON-LASER PHOTOCOAGULATION; FELLOW EYES; BREAKS; DEGENERATIONS AB BACKGROUND AND OBJECTIVE: To examine the natural history of retinopexies performed by ophthalmology residents at universiry-affiliated clinics and to determine the rate of progression to rhegmatogenous retinal detachment. PATIENTS AND METHODS: Charts of patients receiving prophylactic thermal coagulation between 1997 and 2006 were reviewed retrospectively. Outcome measures included subsequent rhegmatogenous retinal detachment and additional prophylactic treatments. RESULTS: Review of the medical records identified 166 eyes with peripheral retinal lesions treated by residents, with an average follow-up of 2.4 +/- 0.2 years. At presentation, only 43.4% of patients were symptomatic. Two (1.2%) eyes developed rhegmatogenous retinal detachment during follow-up, with each arising in a previously healthy area of retina in a patient with a history of detachment of the fellow retina. Twenty-five eyes (15%) received at least one additional prophylactic procedure. CONCLUSION: The rate of rhegmatogenous retinal detachment following prophylactic retinopexy performed by residents at hospital-based clinics is low, supporting this standard practice. [Ophthalmic Surg Lasers Imaging 2009;40:120-126.] C1 [Levin, Marc; Naseri, Aynan; Stewart, Jay M.] Univ Calif San Francisco, Dept Ophthalmol, San Francisco, CA 94143 USA. [Naseri, Aynan] San Francisco VA Med Ctr, San Francisco, CA USA. [Stewart, Jay M.] San Francisco Gen Hosp, San Francisco, CA 94110 USA. RP Stewart, JM (reprint author), Univ Calif San Francisco, Dept Ophthalmol, 10 Koret Way,Room K301,Box 0730, San Francisco, CA 94143 USA. FU Thai Man May See, Inc., San Francisco, California; Research to Prevent Blindness, Inc., New York, New York FX Supported by Thai Man May See, Inc., San Francisco, California, and an unrestricted grant from Research to Prevent Blindness, Inc., New York, New York. NR 18 TC 7 Z9 7 U1 0 U2 0 PU SLACK INC PI THOROFARE PA 6900 GROVE RD, THOROFARE, NJ 08086 USA SN 1542-8877 J9 OPHTHAL SURG LAS IM JI Ophthalmic Surg. Lasers Imaging PD MAR-APR PY 2009 VL 40 IS 2 BP 120 EP 126 PG 7 WC Ophthalmology; Surgery SC Ophthalmology; Surgery GA 418SU UT WOS:000264170000006 PM 19320300 ER PT J AU Rutar, T Porco, TC Naseri, A AF Rutar, Tina Porco, Travis C. Naseri, Ayman TI Risk Factors for Intraoperative Complications in Resident-Performed Phacoemulsification Surgery SO OPHTHALMOLOGY LA English DT Article ID VITREOUS LOSS; CATARACT-EXTRACTION; TOPICAL ANESTHESIA; VISUAL OUTCOMES; EXPERIENCE AB Purpose: To determine the risk factors for intraoperative complications in resident-performed phacoemulsification surgery and the effect of complications on postoperative visual acuity. Design: Retrospective case series. Participants: A total of 320 consecutive eyes of predominantly male (96.6%) and elderly patients (mean age 1 standard deviation = 73.1 +/- 10.0 years) undergoing phacoemulsification surgery by ophthalmology residents at a Veterans Administration Hospital between January 2006 and 2007. There were no exclusion criteria for type of cataract undergoing phacoemulsification surgery. Methods: Data were collected by review of patients' electronic medical records. Collected data included the patient demographics, ocular comorbidities, cataract features, resident, resident experience, attending, right or left eye, anesthesia type, wound type, phacoemulsification technique, preoperative and postoperative visual acuities, and presence of any intraoperative complication. Multivariate models were constructed to determine potential risk factors for intraoperative complications. Main Outcome Measures: Major intraoperative complication rate, risk factors for major intraoperative complications, and best-corrected postoperative visual acuity. Results: The major intraoperative complication rate was 4.7%, which included 3.1% of cases with vitreous loss. The strongest association with a major complication was the presence of a case identified as challenging preoperatively, which had an odds ratio of 6.0 (95% confidence interval [CI], 1.5-24.1, P = 0.01). The challenging features most strongly associated with major complications were mature 4+ nuclear sclerotic cataracts and zonular pathology (antecedent trauma and pseudoexfoliation), which had odds ratios of 18.9 (95% CI, 3.1-117, P = 0.002) and 26.2 (95% CI, 4.3-159, P = 0.003), respectively. A major complication decreased the likelihood of achieving 20/40 or better visual acuity within 90 days of surgery (95% of uncomplicated eyes vs. 71% of complicated eyes; P = 0.009). Conclusions: Residents performing phacoemulsification surgery achieved a low overall rate of major complications. However, specific features of cataracts, such as mature nuclei and zonular pathology, carried increased intraoperative risk. Anticipating risk may help to decrease surgical complications further and to counsel patients appropriately. Financial Disclosure(s): The author(s) have no proprietary or commercial interest in any materials discussed in this article. Ophthalmology 2009;116:431-436 (C) 2009 by the American Academy of Ophthalmology. C1 [Naseri, Ayman] San Francisco Vet Adm Med Ctr, Dept Ophthalmol, San Francisco, CA 94121 USA. [Rutar, Tina; Naseri, Ayman] Univ Calif San Francisco, Dept Ophthalmol, San Francisco, CA 94143 USA. [Porco, Travis C.] Univ Calif San Francisco, Dept Epidemiol & Biostat, Div Prevent Med & Publ Hlth, Francis I Proctor Fdn Res Ophthalmol, San Francisco, CA 94143 USA. [Naseri, Ayman] Univ Calif San Francisco, Dept Ophthalmol Proctor Fdn, San Francisco, CA 94143 USA. RP Naseri, A (reprint author), San Francisco Vet Adm Med Ctr, Dept Ophthalmol, 4150 Clement St, San Francisco, CA 94121 USA. EM ayman.naseri@va.gov FU Man May See, a nonprofit organization; University of California Institutional Core Grant For Vision Research [NIH P30] FX Supported in part by an unrestricted grant from That Man May See, a nonprofit organization, and by the University of California Institutional Core Grant For Vision Research (NIH P30). NR 16 TC 51 Z9 52 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0161-6420 J9 OPHTHALMOLOGY JI Ophthalmology PD MAR PY 2009 VL 116 IS 3 BP 431 EP 436 DI 10.1016/j.ophtha.2008.10.028 PG 6 WC Ophthalmology SC Ophthalmology GA 416KQ UT WOS:000264005400011 PM 19167084 ER PT J AU Grady, D Cauley, J Stock, J Cox, D Mitlak, B Song, J Cummings, S AF Grady, D. Cauley, J. Stock, J. Cox, D. Mitlak, B. Song, J. Cummings, S. TI EFFECT OF RALOXIFENE ON ALL-CAUSE MORTALITY ACROSS CLINICAL TRIALS SO OSTEOPOROSIS INTERNATIONAL LA English DT Meeting Abstract CT 9th European Congress on Clinical an dEconomic Aspects of Osteoporosis and Osteoarthritis CY MAR 19-21, 2009 CL Athens, GREECE C1 [Grady, D.; Cummings, S.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Grady, D.] San Francisco VA Med Ctr, San Francisco, CA USA. [Cauley, J.] Univ Pittsburgh, Pittsburgh, PA USA. [Stock, J.; Cox, D.; Mitlak, B.; Song, J.] Lilly Res Labs, Indianapolis, IN USA. [Cummings, S.] Calif Pacific Med Res Inst, San Francisco Coordinating Ctr, San Francisco, CA USA. RI Cauley, Jane/N-4836-2015 OI Cauley, Jane/0000-0003-0752-4408 NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER LONDON LTD PI ARTINGTON PA ASHBOURNE HOUSE, THE GUILDWAY, OLD PORTSMOUTH ROAD, ARTINGTON GU3 1LP, GUILDFORD, ENGLAND SN 0937-941X J9 OSTEOPOROSIS INT JI Osteoporosis Int. PD MAR PY 2009 VL 20 SU 1 BP 13 EP 13 PG 1 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 536AE UT WOS:000273012800027 ER PT J AU Bradfield, J Warner, A Bersohn, MM AF Bradfield, Jason Warner, Alberta Bersohn, Malcolm M. TI Low Referral Rate for Prophylactic Implantation of Cardioverter-Defibrillators in a Tertiary Care Medical Center SO PACE-PACING AND CLINICAL ELECTROPHYSIOLOGY LA English DT Article DE implantable cardioverter-defibrillator; sudden death; sudden death prevention; left ventricular dysfunction ID SUDDEN CARDIAC DEATH; PREVENTION AB Background: Implantable cardioverter-defibrillators (ICDs) for primary prevention became standard of care after the publication of the second Multicenter Automatic Defibrillator Implantation Trial (MADIT-II) and Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). Objective: To determine the percentage of patients in a Veterans Affairs medical center appropriately referred for primary prophylaxis ICD and to further categorize the reasons patients are not being referred. Methods: Echocardiograms obtained since the release of MADIT-II in 2002 were searched for a left ventricular ejection fraction (LVEF) <= 35% and <= 30%. We randomly selected 120 patients per year from 2002 to 2006, for a total of 600 patients in each group. Data were reviewed to determine the number of ICD recipients and the reasons patients were not referred. Results: In the LVEF <= 35% group an ICD was implanted in 28% of 392 eligible patients. Nonreferral (58%) was the most common reason that eligible patients did not receive an ICD. Patients were not referred for ICD because of appropriate contraindications in 26% of cases. Overall mortality was 29% (15% with and 31% without ICD). In the LVEF <= 30% group an ICD was implanted in 33% of 388 eligible patients. Nonreferral (51%) was the most common reason that eligible patients did not receive an ICD. Patients were not referred for ICD because of appropriate contraindications in 24% of cases. Overall mortality was 28% (18% with and 32% without ICD). Conclusions: After the publication of MADIT-II and SCD-HeFT, only 42% of eligible patients with LVEF <= 35% and 49% of patients with LVEF <= 30% were offered a potentially life-saving ICD between 2002 and 2006 in our medical center, sometimes with considerable delay. (PACE 2009; 32:S194-S197) C1 Univ Calif Los Angeles, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. RP Bersohn, MM (reprint author), Cardiol 111E,11201 Wilshire Blvd, Los Angeles, CA 90073 USA. EM mbersohn@ucla.edu NR 8 TC 18 Z9 18 U1 0 U2 0 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0147-8389 J9 PACE JI PACE-Pacing Clin. Electrophysiol. PD MAR PY 2009 VL 32 BP S194 EP S197 PG 4 WC Cardiac & Cardiovascular Systems; Engineering, Biomedical SC Cardiovascular System & Cardiology; Engineering GA 452TA UT WOS:000266562900045 PM 19250092 ER PT J AU Hanlon, JT Weiner, DK AF Hanlon, Joseph T. Weiner, Debra K. TI Methadone for Chronic Pain in Older Adults: Blast from the Past But Are We Ready for It to Return to Prime Time? SO PAIN MEDICINE LA English DT Editorial Material ID ANALGESICS C1 [Hanlon, Joseph T.] VA Pittsburgh Healthcare Syst, Dept Med Geriatr Med, Dept Pharm & Therapeut, Sch Pharm,CHERP, Pittsburgh, PA USA. [Hanlon, Joseph T.] VA Pittsburgh Healthcare Syst, Dept Med Geriatr Med, Dept Pharm & Therapeut, Sch Pharm,Geriatr Res Educ & Clin Ctr, Pittsburgh, PA USA. [Weiner, Debra K.] Univ Pittsburgh, Dept Med Geriatr Med, Dept Anesthesiol, Pittsburgh, PA 15260 USA. [Weiner, Debra K.] Univ Pittsburgh, Dept Med Geriatr Med, Dept Psychiat, Pittsburgh, PA 15260 USA. [Weiner, Debra K.] VA Pittsburgh Healthcare Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA USA. RP Hanlon, JT (reprint author), VA Pittsburgh Healthcare Syst, Dept Med Geriatr Med, Dept Pharm & Therapeut, Sch Pharm,CHERP, Pittsburgh, PA USA. FU NIA NIH HHS [R01 AG027017] NR 8 TC 2 Z9 2 U1 0 U2 1 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1526-2375 J9 PAIN MED JI Pain Med. PD MAR PY 2009 VL 10 IS 2 BP 287 EP 288 DI 10.1111/j.1526-4637.2009.00560.x PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA 415CC UT WOS:000263910900002 PM 19284485 ER PT J AU Boros, LG Deng, Q Pandol, SJ Tsukamoto, H Go, VLW Lee, WNP AF Boros, Laszlo G. Deng, Qinggao Pandol, Stephen J. Tsukamoto, Hidekazu Go, Vay Liang W. Lee, Wai-Nang Paul TI Ethanol Diversely Alters Palmitate, Stearate, and Oleate Metabolism in the Liver and Pancreas of Rats Using the Deuterium Oxide Single Tracer SO PANCREAS LA English DT Article DE palmitic acid; stearic acid; oleic acid; fatty acid ratios; deuterium ID INTRAGASTRIC INFUSION; METABOLOMICS; ALCOHOL; LIPOGENESIS; FIBROSIS; FAT AB Objective: To determine tissue-specific effects of alcohol on fatty acid synthesis and distribution as related to functional changes in triglyceride transport and membrane formation. Methods: Tissue fatty acid profile and de novo lipogenesis were determined in adult male Wistar rats after 5 weeks of ethanol feeding using deuterated water and gas chromatography/mass spectrometry. Liver and pancreas fatty acid profiles and new synthesis fractions were compared with those from control rats on an isocaloric diet. Results: Fatty acid ratios in the liver indicated that there was a more than 2-fold accumulation of stearate to that of palmitate, with an apparent decrease in oleate content. On the other hand, in the pancreas, there was a 17% decrease in the stearate-to-palmitate ratio, whereas the oleate-to-palmitate ratio was increased by 30%. The fractions of deuterium-labeled palmitate and stearate were substantially reduced in the liver and pancreas of the alcohol-treated animals. Deuterium labeling of oleate was reduced in the liver but not in the pancreas, consistent with the oleate/stearate ratios in these tissues. Conclusions: Long-term alcohol exposure results in opposite effects on the desaturase activity in the liver and pancreas, limiting fatty acid transport in the liver but promoting the exocrine function of the pancreas. C1 [Boros, Laszlo G.; Lee, Wai-Nang Paul] Harbor UCLA Med Ctr, Dept Pediat Endocrinol & Metab, Torrance, CA 90502 USA. [Deng, Qinggao; Pandol, Stephen J.; Tsukamoto, Hidekazu] Univ So Calif, So Calif Res Ctr ALPD & Cirrhosis, Los Angeles, CA 90089 USA. [Pandol, Stephen J.; Tsukamoto, Hidekazu] Vet Affairs Greater Los Angeles Healthcare Syst, Dept Internal Med, Los Angeles, CA USA. [Go, Vay Liang W.; Lee, Wai-Nang Paul] Univ Calif Los Angeles, David Geffen Sch Med, UCLA Ctr Excellence Pancreat Dis, Los Angeles, CA 90095 USA. RP Boros, LG (reprint author), Harbor UCLA Med Ctr, Dept Pediat Endocrinol & Metab, 1124 W Carson St,RB1, Torrance, CA 90502 USA. EM boros@labiomed.org FU NCCIH NIH HHS [P01 AT003960, P01 AT003960-01A1]; NCI NIH HHS [P30 CA042710, P01-CA42710, P01 CA042710]; NCRR NIH HHS [M01-RR00425, M01 RR000425]; NIAAA NIH HHS [P50AA11999, P50 AA011999] NR 30 TC 5 Z9 5 U1 2 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0885-3177 J9 PANCREAS JI Pancreas PD MAR PY 2009 VL 38 IS 2 BP E47 EP E52 PG 6 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 415AC UT WOS:000263905700031 PM 19248221 ER PT J AU Mamikonyan, E Moberg, PJ Siderowf, A Duda, JE Ten Have, T Hurtig, HI Stern, MB Weintraub, D AF Mamikonyan, Eugenia Moberg, Paul J. Siderowf, Andrew Duda, John E. Ten Have, Tom Hurtig, Howard I. Stern, Matthew B. Weintraub, Daniel TI Mild cognitive impairment is common in Parkinson's disease patients with normal Mini-Mental State Examination (MMSE) scores SO PARKINSONISM & RELATED DISORDERS LA English DT Article DE Mild cognitive impairment; Parkinson's disease; Mini-Mental State Examination; Neuropsychology ID DAYTIME SLEEPINESS; DEMENTIA; DYSFUNCTION; POPULATION; PROFILE; COHORT; SCALE; AGE AB Purpose: Cognitive impairment occurs in the majority of Parkinson's disease (PD) patients, but little is known about detection of mild cognitive impairment (MCI) in this population. We report on the frequency and characteristics of cognitive deficits in PD, patients with intact global cognition based on Mini-Mental State Examination (MMSE) performance. Methods: One hundred and six PD patients with normal age- and education-adjusted MMSE scores (mean [SD] score = 29.1 [1.1]) were administered standardized neuropsychological tests assessing memory, executive function, and attention. Impairment on a cognitive domain was a low score (i.e., >= 1.5 SD below the published normative mean) on at least two measures or tests (for memory and executive abilities) or a single measure (for attention). Results: Mild cognitive impairment was found in 29.2% of PD patients, with 17.9% demonstrating single domain and 11.3% multiple domain impairment. Memory and attention impairment were most common (15.1% and 17.0% , respectively), followed by executive impairment (8.5%). Depending on the measure of disease severity chosen, increasing age and disease severity, anti-anxiety medication use, and a suggestion for increasing severity of daytime sleepiness were independent predictors of cognitive impairment. Conclusions: Cognitive deficits are common in PD patients with "normal" cognition based on MMSE performance, suggesting that MCI is under-recognized in clinical practice due to routine use of insensitive screening instruments. In contrast with some previous reports, early memory impairment may be as common as either executive or attentional deficits in PD. In addition, psychiatric medication use and daytime sleepiness may be reversible or treatable contributors to cognitive impairment. (C) 2008 Elsevier Ltd. All rights reserved. C1 [Mamikonyan, Eugenia; Moberg, Paul J.; Weintraub, Daniel] Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA. [Siderowf, Andrew; Duda, John E.; Hurtig, Howard I.; Stern, Matthew B.; Weintraub, Daniel] Univ Penn, Dept Neurol, Philadelphia, PA 19104 USA. [Duda, John E.; Stern, Matthew B.; Weintraub, Daniel] Philadelphia Vet Affairs Med Center, PADRECC, Philadelphia, PA USA. [Ten Have, Tom] Univ Penn, Ctr Clin & Epidemiol Biostat, Philadelphia, PA 19104 USA. [Weintraub, Daniel] Philadelphia Vet Affairs Med Center, MIRECC, Philadelphia, PA USA. RP Weintraub, D (reprint author), 3615 Chestnut St,Room 330, Philadelphia, PA 19104 USA. EM weintrau@mail.med.upenn.edu FU NIMH [067894] FX Funded in part by NIMH grant #067894. NR 43 TC 88 Z9 94 U1 2 U2 16 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1353-8020 J9 PARKINSONISM RELAT D JI Parkinsonism Relat. Disord. PD MAR PY 2009 VL 15 IS 3 BP 226 EP 231 DI 10.1016/j.parkreldis.2008.05.006 PG 6 WC Clinical Neurology SC Neurosciences & Neurology GA 424RJ UT WOS:000264584700009 PM 18595765 ER PT J AU Aragaki, DR Nasmyth, MC Schultz, SC Nguyen, GM Yentes, JM Kao, K Perell, K Fang, MA AF Aragaki, Dixie R. Nasmyth, Mary C. Schultz, Scott C. Nguyen, Gretchen M. Yentes, Jennifer M. Kao, Kaly Perell, Karen Fang, Meika A. TI Immediate Effects of Contralateral and Ipsilateral Cane Use On Normal Adult Gait SO PM&R LA English DT Article AB Objective: To determine the effects of ipsilateral and contralateral cane use on gait kinematics and peak vertical force in young healthy adults. Design: Prospective observational study. Setting: Veterans Affairs Healthcare Center. Participants: Fifteen healthy adults of aged 26 to 52 years (mean age 31 years) with no gait impairment and minimal experience using single-point canes. Methods: The Pedar-X Mobile System plantar pressure measurement system was used to collect kinematic data from subjects walking in 3 different conditions (relative to a randomly "assigned" limb): contralateral cane (C), ipsilateral cane (I), and no cane (N). Main Outcome Measures: Peak vertical force, cadence, percentage swing phase and double limb support, and regional plantar pressure ratios. Results: Peak vertical force (normalized for body weight) was reduced during both cane use conditions on the randomly assigned limb when compared to walking unaided (P<.001). The peak vertical force was 7% to 11% lower for the assigned limb than the opposite limb when a cane was used on either side (P<.016). Mean cadence was higher when participants ambulated without a cane (113 steps/min) than with a cane used on either the contralateral (98 steps/min) or ipsilateral (98 steps/min) side (P<.0001). Mean cadence did not significantly differ between the cane use conditions (P=.93). Regional plantar pressure ratios did not significantly change on either limb in any of the tested conditions. Double limb support slightly increased with cane use (P<.016). Conclusion: Both ipsilateral and contralateral cane use reduced cadence and mean peak vertical plantar force on the limb advanced with the cane in healthy young adults. Double limb support increased with cane use likely due to the reduced cadence and initial unfamiliarity with using an assistive device. A clinical implication of these findings is that prescription of canes for either ipsilateral or contralateral use effectively offloads a designated lower limb. C1 [Aragaki, Dixie R.; Nasmyth, Mary C.; Schultz, Scott C.; Nguyen, Gretchen M.] VA Greater Los Angeles Healthcare Syst, Dept Phys Med & Rehabil, Los Angeles, CA 90073 USA. [Aragaki, Dixie R.; Nasmyth, Mary C.; Schultz, Scott C.; Nguyen, Gretchen M.; Kao, Kaly; Fang, Meika A.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Fang, Meika A.] VA Greater Los Angeles Healthcare Syst, Rheumatol Sect, Los Angeles, CA 90073 USA. [Perell, Karen] Calif State Univ Fullerton, Fullerton, CA 92634 USA. [Yentes, Jennifer M.] VA Greater Los Angeles Healthcare Syst, Res Serv, Los Angeles, CA 90073 USA. RP Aragaki, DR (reprint author), VA Greater Los Angeles Healthcare Syst, Dept Phys Med & Rehabil, 11301 Wilshire Blvd,Mailcode 117, Los Angeles, CA 90073 USA. EM Dixie.Aragaki@va.gov OI Yentes, Jennifer/0000-0001-6550-7759 FU Office of Research and Development, Rehabilitation Research and Development Service, Department of Veterans Affairs [F3873R] FX This work was supported by the Office of Research and Development, Rehabilitation Research and Development Service, Department of Veterans Affairs (Grant F3873R). NR 27 TC 6 Z9 6 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1934-1482 J9 PM&R JI PM&R PD MAR PY 2009 VL 1 IS 3 BP 208 EP 213 DI 10.1016/j.pmrj.2008.10.002 PG 6 WC Rehabilitation; Sport Sciences SC Rehabilitation; Sport Sciences GA V24LF UT WOS:000208411200002 PM 19627896 ER PT J AU Koepsell, TD Forsberg, CW Littman, AJ AF Koepsell, Thomas D. Forsberg, Christopher W. Littman, Alyson J. TI Obesity, overweight, and weight control practices in US veterans SO PREVENTIVE MEDICINE LA English DT Article DE Obesity; Overweight; Veterans health; Weight control ID RISK-FACTORS; PREVALENCE; HEALTH; CONSEQUENCES; FACILITIES; BURDEN; ADULTS AB Objectives. We assessed the burden of obesity and overweight, as well as trends in weight control practices, among U.S. veterans and users of Department of Veterans Affairs (VA) health care in a large national survey. Methods. Data were combined from the 2003 and 2004 Behavioral Risk Factor Surveillance System surveys of U.S. adults (n = 558,426), a large telephone survey conducted in all states. Results. Some 24% of veterans were obese (Body Mass Index [BMI] >= 30 kg/m(2)), and 48% were overweight (BMI 25-29.9 kg/m(2)). After adjustment for age and gender, obesity prevalence was similar between veterans and non-veterans, but overweight was about 3.8 percentage points more frequent in veterans. Among veterans, obesity was more common among users of VA care, especially those who received all health care through the VA. Obese and overweight VA users were significantly more likely than non-users to report advice from a health care provider to lose weight, but no more likely to report that they were actually trying to lose weight. Conclusions. Obesity and overweight pose special burdens on veterans who use VA care. These results strengthen the case for system-wide interventions aimed at weight control. (C) 2009 Elsevier Inc. All rights reserved. C1 [Koepsell, Thomas D.; Littman, Alyson J.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. [Koepsell, Thomas D.] Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA. [Koepsell, Thomas D.; Forsberg, Christopher W.; Littman, Alyson J.] Seattle Epidemiol Res & Informat Ctr, VA Puget Sound Hlth Care Syst, Seattle, WA 98101 USA. RP Koepsell, TD (reprint author), Seattle Epidemiol Res & Informat Ctr, VA Puget Sound Hlth Care Syst 152E, 1100 Olive Way,Suite 1400, Seattle, WA 98101 USA. EM koepsell@u.washington.edu FU Office of Research and Development; Cooperative Studies Program; Department of Veterans Affairs FX This material is based upon work supported by the Office of Research and Development, Cooperative Studies Program, Department of Veterans Affairs. NR 27 TC 29 Z9 29 U1 0 U2 4 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0091-7435 J9 PREV MED JI Prev. Med. PD MAR PY 2009 VL 48 IS 3 BP 267 EP 271 DI 10.1016/j.ypmed.2009.01.008 PG 5 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA 426WL UT WOS:000264738900013 PM 19297689 ER PT J AU Glynn, SM Randolph, ET Garrick, T Lui, A AF Glynn, Shirley M. Randolph, Eugenia T. Garrick, Thomas Lui, Anna TI A Proof of Concept Trial of an Online Psychoeducational Program for Relatives of Both Veterans and Civilians Living with Schizophrenia SO PSYCHIATRIC REHABILITATION JOURNAL LA English DT Article DE clinical trials; family services; schizophrenia; mental health education programs ID COGNITIVE-BEHAVIOR THERAPY; MULTIPLE-FAMILY GROUPS; RANDOMIZED CONTROLLED-TRIAL; ATTITUDE SCALE; INTERNET; INTERVENTION; METAANALYSIS; DISORDERS; SUPPORT; TELEHEALTH AB Objectives: Family psychoeducation has been found to reduce relapse in schizophrenia but penetration rates are low. In this study, we evaluate the feasibility of an online multifamily group program for relatives of persons with schizophrenia that can be accessed from participants' homes. Methods: We explored participation rates and evaluations of a 12-month multimodal website intervention. Using a quasi-experimental design, we compared illness outcomes (factors on the Brief Psychiatric Rating Scale, hospitalizations) of persons with diagnosed schizophrenia, and relative distress outcomes (somatic concerns and anxiety/depression subscales on the Brief Symptom Inventory) from relatives participating in the intervention (n = 26) to archival data we had from comparable dyads who received customary care (n =16). Results: The majority of participants in the program attended more than half the core online support sessions, expressed high levels of satisfaction, and found the technology easy to access. There appeared to be little impact of online participation on clinical status of persons with schizophrenia or relatives' distress, although there was a trend for fewer hospitalizations in the online group. Small sample size is a factor in interpreting results. Conclusions: Online interventions for relatives of persons with schizophrenia, while feasible, present unique challenges. These include 1) assuring access to the intervention in populations who do not own a computer; 2) addressing privacy concerns; 3) overcoming the special challenges of conducting groups in real time; 4) managing emergent situations adequately; and 5) questions about efficacy. C1 [Glynn, Shirley M.; Randolph, Eugenia T.; Garrick, Thomas] Univ Calif Los Angeles, Semel Inst Neurosci & Biobehav, VA Greater Los Angeles Healthcare Syst W Los Ange, Los Angeles, CA 90024 USA. RP Glynn, SM (reprint author), VA GLA W Los Angeles, B151J,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM sglynn@ucla.edu FU NIMH NIH HHS [R21 MH62135] NR 34 TC 19 Z9 19 U1 1 U2 15 PU CENTER PSYCHIATRIC REHABILITATION PI BOSTON PA BOSTON UNIV, 930 COMMONWEALTH AVE, BOSTON, MA 02215 USA SN 1095-158X J9 PSYCHIATR REHABIL J JI Psychiatr. Rehabil. J. PD SPR PY 2009 VL 33 IS 4 SI SI BP 278 EP 287 DI 10.2975/33.4.2010.278.287 PG 10 WC Psychiatry; Rehabilitation SC Psychiatry; Rehabilitation GA 586RM UT WOS:000276929700006 PM 20374986 ER PT J AU Salzer, MS Katz, J Kidwell, B Federici, M Ward-Colasante, C AF Salzer, Mark S. Katz, Jason Kidwell, Betsy Federici, Matthew Ward-Colasante, Carol TI Pennsylvania Certified Peer Specialist Initiative: Training, Employment and Work Satisfaction Outcomes SO PSYCHIATRIC REHABILITATION JOURNAL LA English DT Article DE peer specialists; knowledge gain; employment outcomes; job satisfaction AB Objective: Certified Peer Specialist training initiatives leading to paid peer support positions are increasing nationally. This longitudinal study examines a comprehensive set of outcomes associated with such an initiative undertaken in Pennsylvania beginning in 2004. Methods: Certified Peer Specialist Training participants in three regions of Pennsylvania responded to a 60-item, multiple choice knowledge test based on the Certified Peer Specialist training curriculum. Additionally, these individuals were asked to provide permission to be contacted up to one year after completing the program to obtain employment information related to their experience as a certified peer specialist. Results: Ninety-seven percent of the trainees successfully completed the program with a 22% increase in knowledge. Eighty-two percent were working one year later. Peer specialists were very satisfied with their employment; felt accepted by co-workers and reported receiving good, but infrequent supervision. Conclusions: The results suggest that these initiatives can be successfully implemented, although greater attention is needed to ensure that new jobs are being created for trainees and that they are being property supervised like all other employees. C1 [Salzer, Mark S.] Univ Penn, Dept Psychiat, CMHPSR, Philadelphia, PA 19104 USA. [Salzer, Mark S.] Philadelphia VA Med Ctr, VISN Mental Illness Res Educ & Clin Ctr 4, Philadelphia, PA USA. [Katz, Jason] Univ S Carolina, Columbia, SC 29208 USA. [Kidwell, Betsy; Federici, Matthew] Mental Hlth Assoc SE PA, Inst Recovery & Community Integrat, Philadelphia, PA USA. [Ward-Colasante, Carol] PA Dept Publ Welf, Ofc Mental Hlth & Subst Abuse Serv, Harrisburg, PA USA. [Salzer, Mark S.] UPENN Collaborat Community Integrat, Philadelphia, PA USA. [Ward-Colasante, Carol] Penn Off Mental Hlth & Subst Abuse Serv, Philadelphia, PA USA. RP Salzer, MS (reprint author), Univ Penn, Dept Psychiat, CMHPSR, 3535 Market St,3rd Floor, Philadelphia, PA 19104 USA. EM Mark.Salzer@uphs.upenn.edu NR 4 TC 10 Z9 11 U1 1 U2 2 PU CENTER PSYCHIATRIC REHABILITATION PI BOSTON PA BOSTON UNIV, 930 COMMONWEALTH AVE, BOSTON, MA 02215 USA SN 1095-158X J9 PSYCHIATR REHABIL J JI Psychiatr. Rehabil. J. PD SPR PY 2009 VL 32 IS 4 BP 301 EP 305 DI 10.2975/32.4.2009.301.305 PG 5 WC Psychiatry; Rehabilitation SC Psychiatry; Rehabilitation GA 435LU UT WOS:000265346200009 PM 19346209 ER PT J AU Kamat, A Cox, LA McDonald, TJ Nathanielsz, PW Li, C AF Kamat, Amrita Cox, Laura A. McDonald, Thomas J. Nathanielsz, Peter W. Li, Cun TI Maternal 30% Global Nutrient Restriction (MNR) Increases Fetal Baboon Liver beta 2-Adrenergic Receptor (beta 2-AR) Immunoreactivity (IR) at 0.5 Gestation (G) but Normalization Occurs by 0.9 (G) Despite Continuing MNR. SO REPRODUCTIVE SCIENCES LA English DT Meeting Abstract CT 56th Annual Meeting of the Society-for-Gynecologic-Investigation CY MAR 17-21, 2009 CL Glasgow, SCOTLAND SP Soc Gynecol Invest C1 [Kamat, Amrita] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA. [Kamat, Amrita] Audie Murphy Hosp, S Texas Vet Hlth Care Syst, San Antonio, TX USA. [Cox, Laura A.] SW Fdn Biomed Res, SW Natl Reg Primate Ctr, Dept Genet, San Antonio, TX 78284 USA. [McDonald, Thomas J.; Nathanielsz, Peter W.; Li, Cun] Univ Texas Hlth Sci Ctr San Antonio, Dept OB GYN, Ctr Pregnancy & Newborn Res, San Antonio, TX 78229 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1933-7191 J9 REPROD SCI JI Reprod. Sci. PD MAR PY 2009 VL 16 IS 3 MA 239 BP 138A EP 138A PG 1 WC Obstetrics & Gynecology; Reproductive Biology SC Obstetrics & Gynecology; Reproductive Biology GA 410WU UT WOS:000263609800240 ER PT J AU Marder, SR Cohen, AN Hamilton, A Saks, E Glynn, S Hollan, D Brekke, J AF Marder, Stephen R. Cohen, A. N. Hamilton, A. Saks, E. Glynn, S. Hollan, D. Brekke, J. TI CHARACTERISTICS OF HIGH FUNCTIONING INDIVIDUALS WITH SCHIZOPHRENIA SO SCHIZOPHRENIA BULLETIN LA English DT Meeting Abstract CT 12th International Congress on Schizophrenia Research CY MAR 28-APR 01, 2009 CL San Diego, CA C1 [Marder, Stephen R.; Cohen, A. N.; Hamilton, A.; Glynn, S.] Univ Calif Los Angeles, Semel Inst, Los Angeles, CA USA. [Marder, Stephen R.; Cohen, A. N.; Glynn, S.] Mental Illness Res Educ & Clin Ctr, VA Greater Los Angeles, Los Angeles, CA USA. [Hamilton, A.; Hollan, D.] Univ Calif Los Angeles, Dept Anthropol, Los Angeles, CA 90024 USA. [Brekke, J.] Univ So Calif, Sch Social Work, Los Angeles, CA 90089 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0586-7614 J9 SCHIZOPHRENIA BULL JI Schizophr. Bull. PD MAR PY 2009 VL 35 BP 11 EP 11 PG 1 WC Psychiatry SC Psychiatry GA 415VP UT WOS:000263964700036 ER PT J AU Copeland, LA Zeber, JE Parchman, ML Lawrence, VA Hosek, BJ Miller, AL AF Copeland, Laurel A. Zeber, J. E. Parchman, M. L. Lawrence, V. A. Hosek, B. J. Miller, A. L. TI PRE-DIABETES AND DIABETES ASSESSMENT IN VETERANS WITH SCHIZOPHRENIA SO SCHIZOPHRENIA BULLETIN LA English DT Meeting Abstract CT 12th International Congress on Schizophrenia Research CY MAR 28-APR 01, 2009 CL San Diego, CA C1 [Copeland, Laurel A.; Zeber, J. E.; Parchman, M. L.; Lawrence, V. A.; Hosek, B. J.] S Texas Vet Hlth Care Syst, VERDICT HSRD, San Antonio, TX USA. [Copeland, Laurel A.; Zeber, J. E.; Miller, A. L.] Univ Texas Hlth Sci Ctr San Antonio, Dept Psychiat, San Antonio, TX 78229 USA. [Lawrence, V. A.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA. [Parchman, M. L.] Univ Texas Hlth Sci Ctr San Antonio, Dept Family & Community Med, San Antonio, TX 78229 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0586-7614 J9 SCHIZOPHRENIA BULL JI Schizophr. Bull. PD MAR PY 2009 VL 35 BP 36 EP 36 PG 1 WC Psychiatry SC Psychiatry GA 415VP UT WOS:000263964700109 ER PT J AU Wirshing, DA Rosen, J Pierre, JM Erickson, ZD Guzik, LH Mena, SJ AF Wirshing, Donna A. Rosen, J. Pierre, J. M. Erickson, Z. D. Guzik, L. H. Mena, S. J. TI SUBJECTIVE EXPERIENCE MEASUREMENT IN PATIENTS WITH SCHIZOPHRENIA/SCHIZOAFFECTIVE DISORDER USING THE NOVEL ANTIPSYCHOTIC MEDICATION EXPERIENCE SCALE (NAMES) SO SCHIZOPHRENIA BULLETIN LA English DT Meeting Abstract CT 12th International Congress on Schizophrenia Research CY MAR 28-APR 01, 2009 CL San Diego, CA C1 [Wirshing, Donna A.; Rosen, J.; Pierre, J. M.; Erickson, Z. D.; Guzik, L. H.; Mena, S. J.] VA Greater Angeles Healthcare Syst, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0586-7614 J9 SCHIZOPHRENIA BULL JI Schizophr. Bull. PD MAR PY 2009 VL 35 BP 36 EP 36 PG 1 WC Psychiatry SC Psychiatry GA 415VP UT WOS:000263964700108 ER PT J AU Horan, WP Wynn, JK Kring, AM Simons, RF Crosby, SM Nori, P Mancini, L Tripp, C Green, MF AF Horan, William Powers Wynn, J. K. Kring, A. M. Simons, R. F. Crosby, S. M. Nori, P. Mancini, L. Tripp, C. Green, M. F. TI ELECTROPHYSIOLOGICAL CORRELATES OF EMOTIONAL EXPERIENCE IN SCHIZOPHRENIA SO SCHIZOPHRENIA BULLETIN LA English DT Meeting Abstract CT 12th International Congress on Schizophrenia Research CY MAR 28-APR 01, 2009 CL San Diego, CA C1 [Horan, William Powers; Wynn, J. K.; Crosby, S. M.; Nori, P.; Mancini, L.; Tripp, C.; Green, M. F.] Univ Calif Los Angeles, Los Angeles, CA USA. [Kring, A. M.] UC Berkeley, Berkeley, CA USA. [Simons, R. F.] Univ Delaware, Newark, DE USA. [Horan, William Powers; Wynn, J. K.; Crosby, S. M.; Nori, P.; Mancini, L.; Tripp, C.; Green, M. F.] VA Greater Angeles Healthcare Syst, Los Angeles, CA USA. RI Wynn, Jonathan/H-3749-2014 OI Wynn, Jonathan/0000-0002-1763-8540 NR 0 TC 0 Z9 0 U1 0 U2 1 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0586-7614 J9 SCHIZOPHRENIA BULL JI Schizophr. Bull. PD MAR PY 2009 VL 35 BP 45 EP 45 PG 1 WC Psychiatry SC Psychiatry GA 415VP UT WOS:000263964700135 ER PT J AU Wynn, JK Horan, WP Simons, R Kring, A Nori, P Mancini, L Crosby, S Tripp, C Green, MF AF Wynn, Jonathan K. Horan, W. P. Simons, R. Kring, A. Nori, P. Mancini, L. Crosby, S. Tripp, C. Green, M. F. TI ELECTROPHYSIOLOGICAL CORRELATES OF EMOTION ANTICIPATION IN SCHIZOPHRENIA SO SCHIZOPHRENIA BULLETIN LA English DT Meeting Abstract CT 12th International Congress on Schizophrenia Research CY MAR 28-APR 01, 2009 CL San Diego, CA C1 [Wynn, Jonathan K.; Horan, W. P.] VA Greater Angeles Healthcare Syst, MIRECC, Los Angeles, CA USA. [Wynn, Jonathan K.; Horan, W. P.; Nori, P.; Mancini, L.; Crosby, S.; Tripp, C.; Green, M. F.] Univ Calif Los Angeles, Los Angeles, CA USA. [Kring, A.] Univ Calif Berkeley, Berkeley, CA 94720 USA. [Simons, R.] Univ Delaware, Newark, DE USA. RI Wynn, Jonathan/H-3749-2014 OI Wynn, Jonathan/0000-0002-1763-8540 NR 0 TC 0 Z9 0 U1 0 U2 1 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0586-7614 J9 SCHIZOPHRENIA BULL JI Schizophr. Bull. PD MAR PY 2009 VL 35 BP 45 EP 45 PG 1 WC Psychiatry SC Psychiatry GA 415VP UT WOS:000263964700136 ER PT J AU Mathalon, DH Roach, BJ Ford, JM AF Mathalon, Daniel H. Roach, B. J. Ford, J. M. TI ELECTROPHYSIOLOGICAL EVIDENCE OF ABNORMAL AUTOMATIC ACTIVATION OF SEMANTIC NETWORKS IN SCHIZOPHRENIA SO SCHIZOPHRENIA BULLETIN LA English DT Meeting Abstract CT 12th International Congress on Schizophrenia Research CY MAR 28-APR 01, 2009 CL San Diego, CA C1 [Mathalon, Daniel H.; Ford, J. M.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Mathalon, Daniel H.; Roach, B. J.; Ford, J. M.] San Francisco VA Med Ctr, Psychiat Serv 116d, San Francisco, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0586-7614 J9 SCHIZOPHRENIA BULL JI Schizophr. Bull. PD MAR PY 2009 VL 35 BP 50 EP 51 PG 2 WC Psychiatry SC Psychiatry GA 415VP UT WOS:000263964700152 ER PT J AU Condray, R Steinhauer, SR Siegle, GJ Keshavan, MS Montrose, DM Chakraborty, B AF Condray, Ruth Steinhauer, S. R. Siegle, G. J. Keshavan, M. S. Montrose, D. M. Chakraborty, B. TI EFFECTS OF WORD FREQUENCY ON SEMANTIC MEMORY IN SCHIZOPHRENIA SO SCHIZOPHRENIA BULLETIN LA English DT Meeting Abstract CT 12th International Congress on Schizophrenia Research CY MAR 28-APR 01, 2009 CL San Diego, CA C1 [Condray, Ruth; Steinhauer, S. R.; Siegle, G. J.; Keshavan, M. S.; Montrose, D. M.] Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA USA. [Condray, Ruth; Steinhauer, S. R.; Siegle, G. J.; Chakraborty, B.] VA Pittsburgh Healthcare Syst, Med Res Serv, Pittsburgh, PA USA. [Keshavan, M. S.] Wayne State Univ, Dept Psychiat, Detroit, MI USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0586-7614 J9 SCHIZOPHRENIA BULL JI Schizophr. Bull. PD MAR PY 2009 VL 35 BP 57 EP 57 PG 1 WC Psychiatry SC Psychiatry GA 415VP UT WOS:000263964700173 ER PT J AU Greenwood, TA Light, GA Swerdlow, NR Geyer, MA Radant, AD Braff, DL AF Greenwood, Tiffany A. Light, G. A. Swerdlow, N. R. Geyer, M. A. Radant, A. D. Braff, D. L. TI LARGE-SCALE CANDIDATE GENE ANALYSIS OF ENDOPHENOTYPES FOR SCHIZOPHRENIA SO SCHIZOPHRENIA BULLETIN LA English DT Meeting Abstract CT 12th International Congress on Schizophrenia Research CY MAR 28-APR 01, 2009 CL San Diego, CA C1 [Greenwood, Tiffany A.; Light, G. A.; Swerdlow, N. R.; Geyer, M. A.; Braff, D. L.] Univ Calif San Diego, Dept Psychiat, La Jolla, CA 92093 USA. [Greenwood, Tiffany A.; Geyer, M. A.] San Diego VA Healthcare Syst, San Diego, CA USA. [Radant, A. D.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Radant, A. D.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0586-7614 J9 SCHIZOPHRENIA BULL JI Schizophr. Bull. PD MAR PY 2009 VL 35 BP 122 EP 122 PG 1 WC Psychiatry SC Psychiatry GA 415VP UT WOS:000263964700356 ER PT J AU Miller, AL Velligan, DI Maples, N Li, X Copeland, L Dassori, A Moore, T Mintz, J Zeber, J Boone, C Evans, L Rodriguez, J AF Miller, Alexander L. Velligan, D. I. Maples, N. Li, X. Copeland, L. Dassori, A. Moore, T. Mintz, J. Zeber, J. Boone, C. Evans, L. Rodriguez, J. TI CONTINUITY OF CARE AFTER PSYCHIATRIC HOSPITALIZATION SO SCHIZOPHRENIA BULLETIN LA English DT Meeting Abstract CT 12th International Congress on Schizophrenia Research CY MAR 28-APR 01, 2009 CL San Diego, CA C1 [Miller, Alexander L.; Velligan, D. I.; Maples, N.; Li, X.; Copeland, L.; Dassori, A.; Moore, T.; Mintz, J.; Zeber, J.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Copeland, L.; Dassori, A.; Zeber, J.] S Texas Vet Hlth Care Syst, VERDICT Hlth Serv Res, San Antonio, TX USA. [Boone, C.; Evans, L.] Ctr Hlth Care Serv, San Antonio, TX USA. RI Mintz, Jim/N-7385-2014 OI Mintz, Jim/0000-0002-8299-5851 NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0586-7614 J9 SCHIZOPHRENIA BULL JI Schizophr. Bull. PD MAR PY 2009 VL 35 BP 131 EP 132 PG 2 WC Psychiatry SC Psychiatry GA 415VP UT WOS:000263964700381 ER PT J AU Yao, J Condray, R Reddy, RD Keshavan, MS Montrose, DM Matson, WR McEvoy, J Kaddurah-Daouk, R AF Yao, Jeffrey Condray, R. Reddy, R. D. Keshavan, M. S. Montrose, D. M. Matson, W. R. McEvoy, J. Kaddurah-Daouk, R. TI 3-HYDROXYKYNURENINE AND COGNITIVE IMPAIRMENT IN FIRST-EPISODE NEUROLEPTIC-NAIVE PATIENTS WITH SCHIZOPHRENIA SO SCHIZOPHRENIA BULLETIN LA English DT Meeting Abstract CT 12th International Congress on Schizophrenia Research CY MAR 28-APR 01, 2009 CL San Diego, CA C1 [Yao, Jeffrey; Condray, R.; Reddy, R. D.] VA Pittsburgh Healthcare Syst, Med Res Serv, Pittsburgh, PA USA. [Yao, Jeffrey; Condray, R.; Reddy, R. D.; Keshavan, M. S.; Montrose, D. M.] Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA USA. [Keshavan, M. S.] Wayne State Univ, Dept Psychiat, Detroit, MI USA. [Matson, W. R.] Bedford VA Med Ctr, Med Res Serv, Bedford, MA USA. [McEvoy, J.; Kaddurah-Daouk, R.] Duke Univ, Med Ctr, Dept Psychiat, Durham, NC 27710 USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0586-7614 J9 SCHIZOPHRENIA BULL JI Schizophr. Bull. PD MAR PY 2009 VL 35 BP 151 EP 151 PG 1 WC Psychiatry SC Psychiatry GA 415VP UT WOS:000263964700437 ER PT J AU Schooler, NR Green, MF Kern, RS Deng, BH AF Schooler, Nina. R. Green, M. F. Kern, R. S. Deng, B. H. TI FUNCTIONAL CAPACITY AND INTERVIEW-BASED MEASURES: RAND PANEL JUDGMENTS SO SCHIZOPHRENIA BULLETIN LA English DT Meeting Abstract CT 12th International Congress on Schizophrenia Research CY MAR 28-APR 01, 2009 CL San Diego, CA C1 [Schooler, Nina. R.] Suny Downstate Med Ctr, Dept Psychiat & Behav Sci, Brooklyn, NY 11203 USA. [Schooler, Nina. R.] Washington DC VA Med Ctr, VISN MIRECC 5, Washington, DC USA. [Green, M. F.; Kern, R. S.] Univ Calif Los Angeles, Semel Inst Neurosci & Human Behav, Los Angeles, CA USA. [Green, M. F.; Kern, R. S.] VA Greater Los Angeles Healthcare Syst, VISN MIRECC 22, Los Angeles, CA USA. [Deng, B. H.] Claremont Grad Univ, Dept Psychol, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0586-7614 J9 SCHIZOPHRENIA BULL JI Schizophr. Bull. PD MAR PY 2009 VL 35 BP 305 EP 306 PG 2 WC Psychiatry SC Psychiatry GA 415VP UT WOS:000263964700888 ER PT J AU Muller, AM Wirshing, DA Guzik, LH Erickson, ZD Mena, SJ AF Muller, Anna Mia Wirshing, D. A. Guzik, L. H. Erickson, Z. D. Mena, S. J. TI IMPACT OF A SHORT-TERM SKILLS-BASED INTERVENTION PROGRAM ON LEVEL OF INSIGHT AND ENGAGEMENT IN FOLLOW-UP PSYCHIATRIC CARE SO SCHIZOPHRENIA BULLETIN LA English DT Meeting Abstract CT 12th International Congress on Schizophrenia Research CY MAR 28-APR 01, 2009 CL San Diego, CA C1 [Muller, Anna Mia; Wirshing, D. A.; Guzik, L. H.; Erickson, Z. D.; Mena, S. J.] W Los Angeles VA Med Ctr, Schizophrenia Res Clin, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0586-7614 J9 SCHIZOPHRENIA BULL JI Schizophr. Bull. PD MAR PY 2009 VL 35 BP 310 EP 310 PG 1 WC Psychiatry SC Psychiatry GA 415VP UT WOS:000263964700901 ER PT J AU Rassovsky, Y Lee, J Sergi, M Nori, P Crosby, S Green, MF AF Rassovsky, Yuri Lee, J. Sergi, M. Nori, P. Crosby, S. Green, M. F. TI MEDIATORS AND MODERATORS BETWEEN NEUROCOGNITION AND FUNCTIONAL STATUS IN SCHIZOPHRENIA SO SCHIZOPHRENIA BULLETIN LA English DT Meeting Abstract CT 12th International Congress on Schizophrenia Research CY MAR 28-APR 01, 2009 CL San Diego, CA C1 [Rassovsky, Yuri; Lee, J.; Sergi, M.; Nori, P.; Crosby, S.; Green, M. F.] Univ Calif Los Angeles, Semel Inst, Los Angeles, CA USA. [Lee, J.; Nori, P.; Crosby, S.; Green, M. F.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Sergi, M.] Calif State Univ Northridge, Northridge, CA 91330 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0586-7614 J9 SCHIZOPHRENIA BULL JI Schizophr. Bull. PD MAR PY 2009 VL 35 BP 312 EP 313 PG 2 WC Psychiatry SC Psychiatry GA 415VP UT WOS:000263964700908 ER PT J AU Caponigro, J Valenti, LM Molz, AR Luther, J Paldino, DM Haas, GL AF Caponigro, Janelle Valenti, L. M. Molz, A. R. Luther, J. Paldino, D. M. Haas, G. L. TI RELIABILITY AND VALIDITY OF A BEHAVIORAL MEASURE OF SOCIAL COGNITION IN AN INTERPERSONAL SETTING SO SCHIZOPHRENIA BULLETIN LA English DT Meeting Abstract CT 12th International Congress on Schizophrenia Research CY MAR 28-APR 01, 2009 CL San Diego, CA C1 [Caponigro, Janelle; Haas, G. L.] Univ Pittsburgh, Med Ctr, Western Psychiat Inst & Clin, Pittsburgh, PA USA. [Valenti, L. M.; Molz, A. R.; Luther, J.; Paldino, D. M.; Haas, G. L.] Mental Illness Res Educ & Clin Ctr, VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Caponigro, Janelle] Univ Calif Berkeley, Berkeley, CA 94720 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0586-7614 J9 SCHIZOPHRENIA BULL JI Schizophr. Bull. PD MAR PY 2009 VL 35 BP 317 EP 318 PG 2 WC Psychiatry SC Psychiatry GA 415VP UT WOS:000263964700923 ER PT J AU Haas, GL Valenti, L Caponigro, J Molz, A Goldstein, G Luther, J AF Haas, Gretchen L. Valenti, L. Caponigro, J. Molz, A. Goldstein, G. Luther, J. TI DISSECTING SOCIAL INFORMATION PROCESSING DEFICITS IN SCHIZOPHRENIA: CONTRIBUTION OF AFFECTIVE AND NON-AFFECTIVE COGNITIVE COMPONENTS SO SCHIZOPHRENIA BULLETIN LA English DT Meeting Abstract CT 12th International Congress on Schizophrenia Research CY MAR 28-APR 01, 2009 CL San Diego, CA C1 [Haas, Gretchen L.; Luther, J.] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA. [Haas, Gretchen L.; Valenti, L.; Caponigro, J.; Molz, A.; Goldstein, G.; Luther, J.] VA Pittsburgh Healthcare Syst, MIRECC, Pittsburgh, PA USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0586-7614 J9 SCHIZOPHRENIA BULL JI Schizophr. Bull. PD MAR PY 2009 VL 35 BP 331 EP 332 PG 2 WC Psychiatry SC Psychiatry GA 415VP UT WOS:000263964700965 ER PT J AU Wood, AE Kennedy, A Martin, LM Kilzieh, N Sellars, VS Tapp, A AF Wood, Amanda Ernst Kennedy, A. Martin, L. M. Kilzieh, N. Sellars, V. S. Tapp, A. TI PILOT PROGRAM FOR MEDICATION OPTIMIZATION: SOMETIMES LESS IS MORE SO SCHIZOPHRENIA BULLETIN LA English DT Meeting Abstract CT 12th International Congress on Schizophrenia Research CY MAR 28-APR 01, 2009 CL San Diego, CA C1 [Wood, Amanda Ernst; Kennedy, A.; Martin, L. M.; Kilzieh, N.; Sellars, V. S.; Tapp, A.] VA Puget Hlth Care Syst, Tacoma, WA USA. [Wood, Amanda Ernst; Martin, L. M.; Kilzieh, N.; Tapp, A.] Univ Washington, Seattle, WA 98195 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0586-7614 J9 SCHIZOPHRENIA BULL JI Schizophr. Bull. PD MAR PY 2009 VL 35 BP 349 EP 349 PG 1 WC Psychiatry SC Psychiatry GA 415VP UT WOS:000263964701013 ER PT J AU Green, MF Horan, WP Shokat-Fadai, K Sergi, MJ Waldon, C Ofek, A Kern, RS AF Green, Michael F. Horan, W. P. Shokat-Fadai, K. Sergi, M. J. Waldon, C. Ofek, A. Kern, R. S. TI INITIAL EFFICACY DATA ON A SOCIAL COGNITIVE SKILLS TRAINING PROGRAM SO SCHIZOPHRENIA BULLETIN LA English DT Meeting Abstract CT 12th International Congress on Schizophrenia Research CY MAR 28-APR 01, 2009 CL San Diego, CA C1 [Green, Michael F.; Horan, W. P.; Sergi, M. J.; Waldon, C.; Ofek, A.; Kern, R. S.] Univ Calif Los Angeles, Los Angeles, CA USA. [Green, Michael F.; Horan, W. P.; Waldon, C.; Ofek, A.; Kern, R. S.] VA Greater Angeles Healthcare Syst, MIRECC, Los Angeles, CA USA. [Shokat-Fadai, K.; Sergi, M. J.] Cal State Univ Northridge, Northridge, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0586-7614 J9 SCHIZOPHRENIA BULL JI Schizophr. Bull. PD MAR PY 2009 VL 35 BP 350 EP 350 PG 1 WC Psychiatry SC Psychiatry GA 415VP UT WOS:000263964701017 ER PT J AU Nuechterlein, KH Green, MF Kern, RS AF Nuechterlein, Keith H. Green, M. F. Kern, R. S. TI TRANSLATION AND CULTURAL ADAPTATION OF THE MATRICS CONSENSUS COGNITIVE BATTERY SO SCHIZOPHRENIA BULLETIN LA English DT Meeting Abstract CT 12th International Congress on Schizophrenia Research CY MAR 28-APR 01, 2009 CL San Diego, CA C1 [Nuechterlein, Keith H.; Green, M. F.; Kern, R. S.] Univ Calif Los Angeles, Los Angeles, CA USA. [Green, M. F.; Kern, R. S.] VA Greater Angeles Healthcare Syst, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0586-7614 J9 SCHIZOPHRENIA BULL JI Schizophr. Bull. PD MAR PY 2009 VL 35 BP 372 EP 372 PG 1 WC Psychiatry SC Psychiatry GA 415VP UT WOS:000263964701079 ER PT J AU Kasckow, J Gurklis, J Thompson, R Crofutt, R Murray, T Richmond, I Haas, G AF Kasckow, John Gurklis, J. Thompson, R. Crofutt, R. Murray, T. Richmond, I. Haas, G. TI TELEHEALTH MONITORING OF PATIENTS WITH SCHIZOPHRENIA AND SUICIDAL BEHAVIOR SO SCHIZOPHRENIA BULLETIN LA English DT Meeting Abstract CT 12th International Congress on Schizophrenia Research CY MAR 28-APR 01, 2009 CL San Diego, CA C1 [Kasckow, John; Gurklis, J.; Thompson, R.; Crofutt, R.; Murray, T.; Richmond, I.; Haas, G.] VA Pittsburgh Hlth Care Syst, MIRECC & Behav Hlth, Pittsburgh, PA USA. [Kasckow, John; Haas, G.] Univ Pittsburgh, Med Ctr, Western Psychiat Inst & Clin, Pittsburgh, PA USA. [Crofutt, R.; Murray, T.; Richmond, I.] VA Pittsburgh Hlth Care Syst, Nursing Serv, Pittsburgh, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0586-7614 J9 SCHIZOPHRENIA BULL JI Schizophr. Bull. PD MAR PY 2009 VL 35 BP 374 EP 374 PG 1 WC Psychiatry SC Psychiatry GA 415VP UT WOS:000263964701084 ER PT J AU Antoun, TA Palevsky, PM AF Antoun, Tania Abi Palevsky, Paul M. TI Selection of Modality of Renal Replacement Therapy SO SEMINARS IN DIALYSIS LA English DT Article ID CRITICALLY-ILL PATIENTS; ACUTE KIDNEY INJURY; INTENSIVE-CARE-UNIT; CONTINUOUS ARTERIOVENOUS HEMOFILTRATION; CONTINUOUS VENOVENOUS HEMODIAFILTRATION; RANDOMIZED CLINICAL-TRIAL; INTERMITTENT HEMODIALYSIS; CYTOKINE REMOVAL; FAILURE; MULTICENTER AB The proliferation of new technologies has led to the availability of a broad range of options for the management of renal replacement therapy (RRT) in patients with acute kidney injury. We provide a review of the published literature comparing the continuous RRTs (CRRT) with other modalities of renal support, including intermittent hemodialysis and the more recently described "hybrid" therapies such as sustained, low efficiency dialysis as well as compare arteriovenous and venovenous and convective and diffusive modalities of CRRT. While there is clear evidence that venovenous therapies are superior to arteriovenous therapies, current evidence does not support superiority of convective when compared with diffusive therapies or greater survival or recovery of kidney function with any individual modality of RRT. Selection of modality of RRT should therefore rely on the resources and expertise available. C1 [Palevsky, Paul M.] VA Pittsburgh Healthcare Syst, Renal Sect, Pittsburgh, PA 15240 USA. [Antoun, Tania Abi; Palevsky, Paul M.] Univ Pittsburgh, Sch Med, Renal Electrolyte Div, Pittsburgh, PA 15260 USA. RP Palevsky, PM (reprint author), VA Pittsburgh Healthcare Syst, Renal Sect, Room 7E123 111F-U,Univ Dr, Pittsburgh, PA 15240 USA. EM palevsky@pitt.edu OI Palevsky, Paul/0000-0002-7334-5400 NR 53 TC 2 Z9 2 U1 0 U2 0 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0894-0959 J9 SEMIN DIALYSIS JI Semin. Dial. PD MAR-APR PY 2009 VL 22 IS 2 BP 108 EP 113 DI 10.1111/j.1525-139X.2008.00540.x PG 6 WC Urology & Nephrology SC Urology & Nephrology GA 435XX UT WOS:000265377700002 ER PT J AU Palevsky, PM AF Palevsky, Paul M. TI Intensity of Continuous Renal Replacement Therapy in Acute Kidney Injury SO SEMINARS IN DIALYSIS LA English DT Article ID CONTINUOUS VENOVENOUS HEMOFILTRATION; ULTRAFILTRATION FLOW-RATES; SOLUTE CLEARANCES; RANDOMIZED-TRIAL; SEPTIC SHOCK; FAILURE; HEMODIALYSIS; SURVIVAL AB The intensity of continuous renal replacement therapy (CRRT) is generally assessed on the basis of small solute clearance with dosing usually expressed in terms of total effluent volume per unit time (e.g., ml/kg/hour). Although several clinical trials have suggested an improvement in survival with higher doses of CRRT, results have not been consistent across all studies. The results of recent trials of intensity of CRRT are reviewed. The largest and most recent trials suggest that there is no additional benefit to using effluent flow rates in excess of 20 ml/kg/hour, although earlier studies suggested improved survival with doses of 35 to 45 ml/kg/hour. C1 [Palevsky, Paul M.] VA Pittsburgh Healthcare Syst, Univ Drive Div, Renal Sect, Pittsburgh, PA 15240 USA. [Palevsky, Paul M.] Univ Pittsburgh, Sch Med, Dept Med, Renal Electrolyte Div, Pittsburgh, PA USA. RP Palevsky, PM (reprint author), VA Pittsburgh Healthcare Syst, Univ Drive Div, Renal Sect, Room 7E123 111F-U, Pittsburgh, PA 15240 USA. EM palevsky@pitt.edu OI Palevsky, Paul/0000-0002-7334-5400 NR 16 TC 4 Z9 8 U1 0 U2 3 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0894-0959 J9 SEMIN DIALYSIS JI Semin. Dial. PD MAR-APR PY 2009 VL 22 IS 2 BP 151 EP 154 DI 10.1111/j.1525-139X.2008.00543.x PG 4 WC Urology & Nephrology SC Urology & Nephrology GA 435XX UT WOS:000265377700009 PM 19426419 ER PT J AU Krogh, K Perkash, I Stiens, SA Biering-Sorensen, F AF Krogh, K. Perkash, I. Stiens, S. A. Biering-Sorensen, F. TI International bowel function basic spinal cord injury data set SO SPINAL CORD LA English DT Article DE spinal cord injury; spinal cord lesion; constipation; fecal incontinence; colon; rectum ID FECAL INCONTINENCE; COLONIC TRANSIT; DYSFUNCTION; LESIONS; POPULATION; MANAGEMENT AB Study design: International expert working group. Objective: To develop an International Bowel Function Basic Spinal Cord Injury (SCI) Data Set presenting a standardized format for the collection and reporting of a minimal amount of information on bowel function in daily practice or in research. Setting: Working group consisting of members appointed by the American Spinal Injury Association (ASIA) and the International Spinal Cord Society (ISCoS). Methods: A draft prepared by the working group was reviewed by Executive Committee of the International SCI Standards and Data Sets, and later by ISCoS Scientific Committee and the ASIA Board. Relevant and interested scientific and professional (international) organizations and societies (approximately 40) were also invited to review the data set and it was posted on the ISCoS and ASIA websites for 3 months to allow comments and suggestions. The ISCoS Scientific Committee, Council and ASIA Board received the data set for final review and approval. Results: The International Bowel Function Basic SCI Data Set includes the following 12 items: date of data collection, gastrointestinal or anal sphincter dysfunction unrelated to SCI, surgical procedures on the gastrointestinal tract, awareness of the need to defecate, defecation method and bowel care procedures, average time required for defecation, frequency of defecation, frequency of fecal incontinence, need to wear pad or plug, medication affecting bowel function/constipating agents, oral laxatives and perianal problems. Conclusion: An International Bowel Function Basic SCI Data Set has been developed. C1 [Krogh, K.] Aarhus Univ Hosp, Dept Hepatol & Gastroenterol 5, Neurogastroenterol Unit, DK-8000 Aarhus, Denmark. [Krogh, K.] Aarhus Univ Hosp, Dept Surg P, DK-8000 Aarhus, Denmark. [Perkash, I.] Stanford Univ, Palo Alto, CA 94304 USA. [Perkash, I.] VA Palo Alto Hlth Care Syst, Palo Alto, CA USA. [Stiens, S. A.] VA Puget Sound Hlth Care Syst, Spinal Cord Injury Serv, Seattle, WA USA. [Biering-Sorensen, F.] Copenhagen Univ Hosp, Rigshosp, Ctr Neurosci, Clin Spinal Cord Injuries, Copenhagen, Denmark. RP Krogh, K (reprint author), Aarhus Univ Hosp, Dept Hepatol & Gastroenterol 5, Neurogastroenterol Unit, Norrebrogade 44, DK-8000 Aarhus, Denmark. EM krogh@as.aaa.dk FU Coloplast A/S, Denmark FX Coloplast A/S, Denmark has supported this study with this data set with an unconditional grant. We are thankful for comments and suggestions received from Susan Charlifue, Lawrence Vogel, Dan Lammertse, William Donovan, Inge Eriks Hoogland, Karen Smith and Peter Christensen. NR 20 TC 35 Z9 37 U1 0 U2 1 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 1362-4393 J9 SPINAL CORD JI Spinal Cord PD MAR PY 2009 VL 47 IS 3 BP 230 EP 234 DI 10.1038/sc.2008.102 PG 5 WC Clinical Neurology; Rehabilitation SC Neurosciences & Neurology; Rehabilitation GA 415AG UT WOS:000263906100008 PM 18725887 ER PT J AU Krogh, K Perkash, I Stiens, SA Biering-Sorensen, F AF Krogh, K. Perkash, I. Stiens, S. A. Biering-Sorensen, F. TI International bowel function extended spinal cord injury data set SO SPINAL CORD LA English DT Article DE spinal cord injury; spinal cord lesion; constipation; fecal incontinence; colon; rectum ID FECAL INCONTINENCE; ANORECTAL FUNCTION; COLONIC TRANSIT; ABDOMINAL-PAIN; DYSFUNCTION; LESIONS; POPULATION; MANAGEMENT; PHYSIOLOGY; DISORDERS AB Study design: International expert working group. Objective: To develop an International Bowel Function Extended Spinal Cord Injury (SCI) Data Set presenting a standardized format for the collection and reporting of an extended amount of information on bowel function. Setting: Working group consisting of members appointed by the American Spinal Injury Association (ASIA) and the International Spinal Cord Society (ISCoS). Methods: A draft prepared by the working group was reviewed by Executive Committee of the International SCI Standards and Data Sets and later by the ISCoS Scientific Committee and the ASIA Board. Relevant and interested scientific and professional organizations and societies (around 40) were also invited to review the data set and it was posted on the ISCoS and ASIA websites for 3 months to allow comments and suggestions. The ISCoS Scientific Committee, ISCoS Council and ASIA Board received the data set for final review and approval. Results: The International Bowel Function Basic SCI Data Set includes 26 items providing a thorough description of bowel- related symptoms as well as clinical assessment of anal sphincter function and description of total gastrointestinal or segmental colorectal transit times. Conclusion: An International Bowel Function Extended SCI Data Set has been developed. This Data Set is mainly for research purposes and it should be used in combination with the information obtained from the International SCI Core Data Set and the International Bowel Function Basic SCI Data Set. C1 [Krogh, K.] Aarhus Univ Hosp, Dept Hepatol & Gastroenterol 5, Neurogastroenterol Unit, DK-8000 Aarhus, Denmark. [Krogh, K.] Aarhus Univ Hosp, Dept Surg P, DK-8000 Aarhus, Denmark. [Perkash, I.] Stanford Univ, Palo Alto, CA 94304 USA. [Perkash, I.] Va Palo Alto Hlth Care Syst, Palo Alto, CA USA. [Stiens, S. A.] VA Puget Sound Hlth Care Syst, Spinal Cord Injury Serv, Seattle, WA USA. [Biering-Sorensen, F.] Copenhagen Univ Hosp, Rigshosp, Ctr Neurosci, Clin Spinal Cord Injuries, Copenhagen, Denmark. RP Krogh, K (reprint author), Aarhus Univ Hosp, Dept Hepatol & Gastroenterol 5, Neurogastroenterol Unit, Norrebrogade 44, DK-8000 Aarhus, Denmark. EM krogh@as.aaa.dk FU Coloplast A/S (Denmark) FX Coloplast A/S (Denmark) has supported the work with this Data Set with an unconditional grant. We are thankful for all comments and suggestions received. We thank Susan Charlifue, Lawrence Vogel, Dan Lammertse, William Donovan, Inge Eriks Hoogland, Karen Smith and Peter Christensen. NR 31 TC 22 Z9 24 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 1362-4393 J9 SPINAL CORD JI Spinal Cord PD MAR PY 2009 VL 47 IS 3 BP 235 EP 241 DI 10.1038/sc.2008.103 PG 7 WC Clinical Neurology; Rehabilitation SC Neurosciences & Neurology; Rehabilitation GA 415AG UT WOS:000263906100009 PM 18725886 ER PT J AU Vosler, PS Chen, J AF Vosler, Peter S. Chen, Jun TI Potential Molecular Targets for Translational Stroke Research SO STROKE LA English DT Editorial Material DE molecular targets; neuroprotection; translational stroke research ID ISCHEMIC-STROKE C1 [Chen, Jun] Univ Pittsburgh, Sch Med, Dept Neurol, BST, Pittsburgh, PA 15213 USA. [Chen, Jun] Vet Affairs Pittsburgh Hlth Care Syst, Ctr Geriatr Res Educ & Clin, Pittsburgh, PA USA. RP Chen, J (reprint author), Univ Pittsburgh, Sch Med, Dept Neurol, BST, S-507, Pittsburgh, PA 15213 USA. EM chenj2@upmc.edu FU NINDS NIH HHS [R01 NS043802-05, R01 NS045048, R01 NS056118, R01 NS044178-05, R01 NS043802, NS44178, R01 NS045048-05, NS56118, R01 NS036736, NS43802, R01 NS044178, R01 NS056118-03, R01 NS036736-11, NS45048, NS36736] NR 8 TC 17 Z9 20 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0039-2499 J9 STROKE JI Stroke PD MAR PY 2009 VL 40 IS 3 BP S119 EP S120 DI 10.1161/STROKEAHA.108.533109 PG 2 WC Clinical Neurology; Peripheral Vascular Disease SC Neurosciences & Neurology; Cardiovascular System & Cardiology GA 410QW UT WOS:000263594200039 PM 19064800 ER PT J AU Keil, DE McGuinn, WD Dudley, AC EuDaly, JG Gilkeson, GS Peden-Adams, MM AF Keil, Deborah E. McGuinn, W. David Dudley, Andrew C. EuDaly, Jackie G. Gilkeson, Gary S. Peden-Adams, Margie M. TI N,N,-Diethyl-m-Toluamide (DEET) Suppresses Humoral Immunological Function in B6C3F1 Mice SO TOXICOLOGICAL SCIENCES LA English DT Article DE DEET; immune function; Gulf War Illness; PFC response; T-cell subpopulations ID LISTERIA-MONOCYTOGENES INFECTION; REPELLENT N,N-DIETHYL-M-TOLUAMIDE DEET; NATURAL-KILLER-CELLS; GULF-WAR SYNDROME; PYRIDOSTIGMINE BROMIDE; INSECT REPELLENT; HOST-RESISTANCE; TOXIC ENCEPHALOPATHY; MOSQUITO REPELLENTS; RISK-ASSESSMENT AB N,N-diethyl-meta-toluamide (DEET) is a particularly effective broad-spectrum insect repellent used commonly in recreational, occupational and military environments. Due to its widespread use and suggested link to Gulf War Illness, this study examined the immunotoxicity of DEET. Adult female B6C3F1 mice were injected sc for 14 days with DEET at 0, 7.7, 15.5, 31, or 62 mg/kg/day. Due to differences in the dermal absorption of DEET between mice and humans, this study eliminated this confounding factor by utilizing sc injection and measured circulating blood levels of DEET to assess bioavailability from sc administration. Effects on lymphocyte proliferation, natural killer cell activity, thymus and spleen weight and cellularity, the antibody plaque-forming cell (PFC) response, and thymic and splenic CD4/CD8 lymphocyte subpopulations were assessed 24 h after the last dose. No effect was observed in lymphocyte proliferation, natural killer cell activity, thymic weight, splenic weight, thymic cellularity, or splenic cellularity. Significant decreases were observed in the percentage of splenic CD4-/CD8- and CD4+/CD8- lymphocytes but only at the 62 mg DEET/kg/day treatment level and not in absolute numbers of these cells types. Additionally, significant decreases in the antibody PFC response were observed following treatment with 15.5, 31, or 62 mg DEET/kg/day. Pharmacokinetic (PK) data from the current study indicate 95% bioavailability of the administered dose. Therefore, it is likely that DEET exposure ranges applied in this study are comparable to currently reported occupational usage. Together, the evidence for immunosuppression and available PK data suggest a potential human health risk associated with DEET in the occupational or military environments assuming similar sensitivity between human and rodent responses. C1 [Keil, Deborah E.] Univ Nevada, Clin Sci Lab, Las Vegas, NV 89154 USA. US FDA, Silver Spring, MD 20993 USA. [EuDaly, Jackie G.; Peden-Adams, Margie M.] Med Univ S Carolina, Dept Pediat, Charleston, SC 29412 USA. [McGuinn, W. David; EuDaly, Jackie G.; Gilkeson, Gary S.; Peden-Adams, Margie M.] Med Univ S Carolina, Dept Med, Div Rheumatol & Immunol, Charleston, SC 29412 USA. [Dudley, Andrew C.; EuDaly, Jackie G.; Peden-Adams, Margie M.] Med Univ S Carolina, Marine Biomed & Environm Sci Ctr, Charleston, SC 29412 USA. [Gilkeson, Gary S.] Ralph Johnson VAMC, Med Res Serv, Charleston, SC 29425 USA. RP Keil, DE (reprint author), Univ Nevada, Clin Sci Lab, 4505 Maryland Pkwy,Box 453021, Las Vegas, NV 89154 USA. EM deborah.keil@unlv.edu OI Keil, Deborah/0000-0002-5787-8514 FU U. S. Department of Defense [DAMD17-99-1-9013] FX U. S. Department of Defense (grant # DAMD17-99-1-9013) to D. E. K.; the Veterans Administration Medical Research Service to G. S. G.; and internal support from UNLV. NR 74 TC 7 Z9 8 U1 1 U2 6 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 1096-6080 J9 TOXICOL SCI JI Toxicol. Sci. PD MAR PY 2009 VL 108 IS 1 BP 110 EP 123 DI 10.1093/toxsci/kfp001 PG 14 WC Toxicology SC Toxicology GA 410VO UT WOS:000263606600012 PM 19141786 ER PT J AU Wu, JD Lin, DW Page, ST Lundgren, AD True, LD Plymate, SR AF Wu, Jennifer D. Lin, Daniel W. Page, Stephanie T. Lundgren, Ashley D. True, Lawrence D. Plymate, Stephen R. TI Oxidative DNA damage in the prostate may predispose men to a higher risk of prostate cancer SO TRANSLATIONAL ONCOLOGY LA English DT Article ID DOUBLE-STRAND BREAKS; ATM ACTIVATION; T-CELLS; ANTICANCER BARRIER; MEDICAL CASTRATION; NKG2D RECEPTOR; NK CELLS; EXPRESSION; LIGANDS; STRESS AB DNA damage has been associated with prostate cancer risk. Men who were referred for initial prostate biopsy for elevated prostate-specific antigen or abnormal digital rectal examination are often found with no cancer but have a higher risk of developing prostate cancer than the general population of men in their lifetime In this study, we investigated whether DNA damage is one of the factors that predispose these men referred for prostate biopsies to a higher risk of prostate cancer. We found significantly elevated levels of 8-oxo-2-deoxyguanosine immunoreactivity in the prostates of the referred men (n = 50) in comparison to the control prostates of men (n = 32) with no indication for referral for prostate biopsy. Twelve of these control men were healthy middle-aged men and 20 of them were older men whose conditions were diagnosed with bladder cancer but with normal serum prostate-specific antigen and digital rectal examination and no evidence of prostate disease. In all the 8-oxo-2-deoxyguanosine-positive prostates, we detected phosphorylation of the ataxia telangiectasia mutated kinase and expression of the immune-stimulatory molecule MIC in the prostate epithelium These data suggest that 1) oxidative DNA damage has occurred in the "referred" but pathologically normal prostates, indicating that these prostates may be subjected to genomic instability and eventually neoplastic transformation; 2) in response to DNA damage, two surveillance pathways, represented by ataxia telangiectasia mutated phosphorylation and induction of the NKG2D ligand MIC, were activated to prevent tumorigenesis. C1 [Wu, Jennifer D.; Page, Stephanie T.; Lundgren, Ashley D.; Plymate, Stephen R.] Univ Washington, Dept Med, Seattle, WA USA. [Lin, Daniel W.] Univ Washington, Dept Urol, Seattle, WA 98195 USA. [True, Lawrence D.] Univ Washington, Dept Pathol, Seattle, WA 98195 USA. [Plymate, Stephen R.] Vet Affairs Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA USA. RP Wu, JD (reprint author), Box 359755,325 9th Ave, Seattle, WA 98104 USA. FU Department of Defense New Invastigator's [W81XWH-04-1-0577]; National Institutes of Health Temin [1 K01 CA 116002]; Pacific Northwest Prostate Cancer SPORE Pilot [P50-CA97186]; National Institutes of Health [K23DK65083, CA 085859]; Veterans Affairs Research Service FX Supported by Department of Defense New Invastigator's Award (W81XWH-04-1-0577), National Institutes of Health Temin Award (1 K01 CA 116002), the Pacific Northwest Prostate Cancer SPORE Pilot Award (P50-CA97186) to J Wu and S.R. Plymate; National Institutes of Health Award (K23DK65083) to D Lin, and Veterans Affairs Research Service and National Institutes of Health awards (CA 085859) to S.R. Plymate NR 37 TC 8 Z9 8 U1 0 U2 4 PU NEOPLASIA PRESS PI ANN ARBOR PA 1150 W MEDICAL CENTER DR, MSRB III, RM 9303, ANN ARBOR, MI 48109-0648 USA SN 1936-5233 J9 TRANSL ONCOL JI Transl. Oncol. PD MAR PY 2009 VL 2 IS 1 BP 39 EP 45 DI 10.1593/tlo.08217 PG 7 WC Oncology SC Oncology GA 529WW UT WOS:000272550900005 PM 19252750 ER PT J AU Kramer, BJ Jouldjian, S Washington, DL Harker, JO Saliba, D Yano, EM AF Kramer, B. Josea Jouldjian, Stella Washington, Donna L. Harker, Judith O. Saliba, Debra Yano, Elizabeth M. TI HEALTH CARE FOR AMERICAN INDIAN AND ALASKA NATIVE WOMEN The Roles of the Veterans Health Administration and The Indian Health Service SO WOMENS HEALTH ISSUES LA English DT Article ID POSTTRAUMATIC-STRESS-DISORDER; AMBULATORY-CARE; PREVALENCE; AFFAIRS; VA; AVAILABILITY; DISPARITIES; COMMUNITY; TRAUMA; ACCESS AB Background. Many American Indian and Alaska Native (AIAN) women serve in the military and are eligible for healthcare from both the Veterans Health Administration (VHA) and the Indian Health Service (IHS). Little was known about these women's patterns of health care utilization when VHA and IHS executed a resource-sharing agreement in 2003 to improve access and health outcomes. Objective. We sought to describe women's healthcare utilization in VHA and IHS. Methods. We conducted a descriptive secondary data analysis of linked IHS and VHA administrative records from fiscal years 2002 and 2003 for women among all IHS beneficiaries who were veterans or used VHA for health care (n = 64,746). Results. Among these IHS beneficiaries, 4,338 (6.7%) were female veterans and 1,518 (2.8%) were female nonveterans. Comparing IHS services to VHA, the VHA provided the majority of outpatient specialty care to veterans, providing 89.9% of diagnostic and imaging services, 84.4% of mental health care, and 78.1%, of physical medicine and rehabilitation. Conversely, the IHS provided the majority of ambulatory and inpatient care for obstetrics and gynecology to these veterans. Dual users received primary care from both organizations. Nonveterans generally accessed VHA under sharing agreements and their use of health care was generally limited to outpatient diagnostic and imaging. Conclusions. The VHA seems to supplement healthcare provided by the IHS for female AIAN veterans, as well as for a small proportion of nonveterans. The VHA and the IHS have developed specialized and complementary expertise, which might be aligned to serve the needs of female AIAN veterans. C1 [Kramer, B. Josea; Saliba, Debra] VA Greater Los Angeles Healthcare Syst, Geriatr Res Educ Clin Ctr, Sepulveda, CA 91343 USA. [Kramer, B. Josea; Saliba, Debra] Univ Calif Los Angeles, David Geffen Sch Med, Div Geriatr Med, Los Angeles, CA 90095 USA. [Jouldjian, Stella; Washington, Donna L.; Harker, Judith O.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Saliba, Debra; Yano, Elizabeth M.] VA Greater Los Angeles Healthcare Syst, Hlth Serv Res Ctr Excellence, Sepulveda, CA USA. [Saliba, Debra] RAND Corp, Santa Monica, CA USA. RP Kramer, BJ (reprint author), VA Greater Los Angeles Healthcare Syst, Geriatr Res Educ Clin Ctr, 16111 Plummer St 11E, Sepulveda, CA 91343 USA. EM Josea.Kramer@va.gov NR 38 TC 3 Z9 3 U1 2 U2 6 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1049-3867 J9 WOMEN HEALTH ISS JI Womens Health Iss. PD MAR-APR PY 2009 VL 19 IS 2 BP 135 EP 143 DI 10.1016/j.whi.2008.11.002 PG 9 WC Public, Environmental & Occupational Health; Women's Studies SC Public, Environmental & Occupational Health; Women's Studies GA 423CA UT WOS:000264472800007 PM 19272564 ER PT J AU Bates-Jensen, B Guihan, M Chin, A AF Bates-Jensen, Barbara Guihan, Marylou Chin, Amy TI ASSESSING A BIOPHYSICAL DEVICE TO PREDICT PRESSURE ULCERS IN SPINAL CORD INJURY SO WOUND REPAIR AND REGENERATION LA English DT Meeting Abstract C1 [Bates-Jensen, Barbara] Univ Calif Los Angeles, Sch Nursing & Med, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Guihan, Marylou; Chin, Amy] Northwestern Univ, Ctr Management Complex Chron Care, Edward Hines Jr VA Hosp, Inst Healthcare Studies, Chicago, IL 60611 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1067-1927 J9 WOUND REPAIR REGEN JI Wound Repair Regen. PD MAR-APR PY 2009 VL 17 IS 2 BP A45 EP A45 PG 1 WC Cell Biology; Dermatology; Medicine, Research & Experimental; Surgery SC Cell Biology; Dermatology; Research & Experimental Medicine; Surgery GA 418ZJ UT WOS:000264188600158 ER PT J AU Raugi, G Reiber, G AF Raugi, Gregory Reiber, Gayle TI REDUCTION IN TIME TO HEALING AND AMPUTATIONS IN RURAL CARE SETTINGS SO WOUND REPAIR AND REGENERATION LA English DT Meeting Abstract C1 [Raugi, Gregory; Reiber, Gayle] VA Puget Sound, Seattle, WA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1067-1927 J9 WOUND REPAIR REGEN JI Wound Repair Regen. PD MAR-APR PY 2009 VL 17 IS 2 BP A20 EP A20 PG 1 WC Cell Biology; Dermatology; Medicine, Research & Experimental; Surgery SC Cell Biology; Dermatology; Research & Experimental Medicine; Surgery GA 418ZJ UT WOS:000264188600056 ER PT J AU Craig, TJ Petzel, R AF Craig, Thomas J. Petzel, Robert TI Management perspectives on research contributions to practice through collaboration in the U. S. Veterans Health Administration: QUERI Series SO IMPLEMENTATION SCIENCE LA English DT Article ID QUALITY-OF-CARE AB The Quality Enhancement Research Initiative (QUERI) is a unique quality improvement program designed to connect health services researchers to Veterans Health Administration (VHA) management and operations, as well as to provide the science and initiative for making change. Through this process, QUERI stakeholders have learned that success and impact in improving healthcare quality and outcomes largely depends on coordination and collaboration among numerous VHA programs and organizations working to develop and implement evidence-based clinical policies, practices, and quality improvement strategies. This Commentary discusses some of these collaborative efforts and perceived successes in achieving common goals from the viewpoints of two closely involved VHA Operations/Support stakeholders. The Commentary is part of a Series of articles documenting implementation science frameworks and tools developed by the U. S. Department of Veterans Affairs Quality Enhancement Research Initiative (QUERI). C1 [Petzel, Robert] US Dept Vet Affairs Midwest Hlth Care Network, Minneapolis, MN USA. [Craig, Thomas J.] US Dept Vet Affairs, Vet Hlth Adm, Off Qual & Performance, Washington, DC USA. RP Petzel, R (reprint author), US Dept Vet Affairs Midwest Hlth Care Network, Minneapolis, MN USA. EM tlc1963@earthlink.net; Robert.Petzel@va.gov NR 10 TC 5 Z9 5 U1 1 U2 3 PU BIOMED CENTRAL LTD PI LONDON PA CURRENT SCIENCE GROUP, MIDDLESEX HOUSE, 34-42 CLEVELAND ST, LONDON W1T 4LB, ENGLAND SN 1748-5908 J9 IMPLEMENT SCI JI Implement. Sci. PD FEB 26 PY 2009 VL 4 AR 8 DI 10.1186/1748-5908-4-8 PG 5 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA 433KK UT WOS:000265202500001 PM 19245708 ER PT J AU Baldys, A Gooz, M Morinelli, TA Lee, MH Raymond, JR Luttrell, LM Raymond, JR AF Baldys, Aleksander Goeoz, Monika Morinelli, Thomas A. Lee, Mi-Hye Raymond, John R., Jr. Luttrell, Louis M. Raymond, John R., Sr. TI Essential Role of c-Cbl in Amphiregulin-Induced Recycling and Signaling of the Endogenous Epidermal Growth Factor Receptor SO BIOCHEMISTRY LA English DT Article ID CLATHRIN-COATED PITS; EGF RECEPTOR; TYROSINE PHOSPHORYLATION; DOWN-REGULATION; RING FINGER; MEDIATED UBIQUITINYLATION; ENDOCYTIC SYSTEM; EPITHELIAL-CELLS; EARLY ENDOSOMES; UBIQUITINATION AB The intracellular processing of the epidermal growth factor receptor (EGFR) induced by epidermal growth factor (EGF) and transforming growth factor-alpha (TGF-alpha) has been studied meticulously, with the former resulting in EGFR degradation and the latter in EGFR recycling to the plasma membrane. However, little is known about how other EGF family growth factors affect the trafficking of the EGFR. Additionally, although both EGF and TGF-alpha have been shown to effectively induce initial c-Cbl (ubiquitin ligase)-mediated ubiquitination of the EGFR, limited information is available regarding the role of c-Cbl in the trafficking and signaling of recycling EGFR. Thus, in this study, we investigated the roles of c-Cbl in endogenous EGFR trafficking and signaling after stimulation with amphiregulin (AR). We demonstrated that a physiological concentration of AR induced recycling of the endogenous EGFR to the plasma membrane, which correlated closely with transient association of the EGFR with c-Cbl and transient EGFR ubiquitination. Most importantly, we used c-Cbl small interfering RNA (siRNA) duplexes and a c-Cbl dominant negative mutant to show that c-Cbl is critical for the efficient transition of the EGFR from early endosomes to a recycling pathway and that c-Cbl regulates the duration of extracellular signal-regulated kinase 1/2 mitogen-activated protein kinase (ERK1/2 MAPK) phosphorylation. These data support novel functions of c-Cbl in mediating recycling of EGF receptors to the plasma membrane, as well as in mediating the duration of activation (transient vs sustained) of ERK1/2 MAPK phosphorylation. C1 [Baldys, Aleksander; Goeoz, Monika; Morinelli, Thomas A.; Raymond, John R., Jr.; Raymond, John R., Sr.] Med Univ S Carolina, Dept Med, Div Nephrol, Charleston, SC 29425 USA. [Lee, Mi-Hye; Luttrell, Louis M.] Med Univ S Carolina, Dept Med, Div Endocrinol, Charleston, SC 29425 USA. [Baldys, Aleksander; Goeoz, Monika; Morinelli, Thomas A.; Lee, Mi-Hye; Luttrell, Louis M.; Raymond, John R., Sr.] Ralph H Johnson Vet Affairs Med Ctr, Med & Res Serv, Charleston, SC 29425 USA. RP Raymond, JR (reprint author), Room 213,Colcock Hall,179 Ashley Ave, Charleston, SC 29425 USA. EM raymondj@musc.edu; raymondj@musc.edu FU Department of Veterans Affairs Merit; Research Enhancement Award Program; National Institutes of Health [DK052448, GM063909]; American Heart Association; Medical University of South Carolina, Division of Nephrology, and Dialysis Clinics, Inc FX This work was supported by Department of Veterans Affairs Merit and Research Enhancement Award Program grants (to J. R. Raymond, Sr.), by National Institutes of Health Grants DK052448 and GM063909, by an American Heart Association (Mid-Atlantic) fellowship (to A.B.), and by a laboratory endowment jointly supported by the Medical University of South Carolina, Division of Nephrology, and Dialysis Clinics, Inc. (to J. R. Raymond Sr.). NR 50 TC 30 Z9 31 U1 2 U2 5 PU AMER CHEMICAL SOC PI WASHINGTON PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA SN 0006-2960 J9 BIOCHEMISTRY-US JI Biochemistry PD FEB 24 PY 2009 VL 48 IS 7 BP 1462 EP 1473 DI 10.1021/bi801771g PG 12 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 408JK UT WOS:000263431100005 PM 19173594 ER PT J AU Collins, P Mosca, L Geiger, MJ Grady, D Kornitzer, M Amewou-Atisso, MG Effron, MB Dowsett, SA Barrett-Connor, E Wenger, NK AF Collins, Peter Mosca, Lori Geiger, Mary Jane Grady, Deborah Kornitzer, Marcel Amewou-Atisso, Messan G. Effron, Mark B. Dowsett, Sherie A. Barrett-Connor, Elizabeth Wenger, Nanette K. TI Effects of the Selective Estrogen Receptor Modulator Raloxifene on Coronary Outcomes in The Raloxifene Use for the Heart Trial Results of Subgroup Analyses by Age and Other Factors SO CIRCULATION LA English DT Article DE coronary disease; hormones; raloxifene; randomized controlled trial; risk factors; women ID HEALTHY POSTMENOPAUSAL WOMEN; RANDOMIZED CONTROLLED-TRIAL; HORMONE REPLACEMENT THERAPY; BREAST-CANCER; PLUS PROGESTIN; CARDIOVASCULAR-DISEASE; CLINICAL-TRIAL; RISK; INITIATION; MENOPAUSE AB Background-The Raloxifene Use for The Heart (RUTH) trial showed that raloxifene, a selective estrogen receptor modulator, had no overall effect on the incidence of coronary events in women with established coronary heart disease or coronary heart disease risk factors. We provide detailed results of the effect of raloxifene on coronary outcomes over time and for 24 subgroups (17 predefined, 7 post hoc). Methods and Results-Postmenopausal women (n = 10 101; mean age, 67 years) were randomized to raloxifene 60 mg/d or placebo for a median of 5.6 years. Coronary outcomes were assessed by treatment group in women with coronary heart disease risk factors and those with established coronary heart disease. Raloxifene had no effect on the incidence of coronary events in any subgroup except in the case of a post hoc age subgroup analysis using age categories defined in the Women's Health Initiative randomized trials. The effect of raloxifene on the incidence of coronary events differed significantly by age ( interaction P = 0.0118). The incidence of coronary events in women < 60 years of age was significantly lower in those assigned raloxifene ( 50 events) compared with placebo ( 84 events; hazard ratio, 0.59; 95% confidence interval, 0.41 to 0.83; P=0.003; absolute risk reduction, 36 per 1000 women treated for 1 year). No difference was found between treatment groups in the incidence of coronary events in women >= 60 and < 70 or >= 70 years of age. Conclusions-In postmenopausal women at increased risk of coronary events, the overall lack of benefit of raloxifene was similar across the prespecified subgroups. (Circulation. 2009; 119: 922-930.) C1 [Collins, Peter] Univ London Imperial Coll Sci Technol & Med, Royal Brompton Hosp, London SW3 6NP, England. [Collins, Peter] Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, London SW3 6NP, England. [Mosca, Lori] Columbia Univ Coll Phys & Surg, Dept Med, New York, NY 10032 USA. [Geiger, Mary Jane; Amewou-Atisso, Messan G.; Effron, Mark B.; Dowsett, Sherie A.] Eli Lilly & Co, Lilly Res Labs, Indianapolis, IN 46285 USA. [Grady, Deborah] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Grady, Deborah] San Francisco VA Med Ctr, San Francisco, CA USA. [Kornitzer, Marcel] Free Univ Brussels, Sch Publ Hlth, Dept Epidemiol & Hlth Promot, Brussels, Belgium. [Barrett-Connor, Elizabeth] Univ Calif San Diego, Dept Family & Prevent Med, La Jolla, CA 92093 USA. [Barrett-Connor, Elizabeth] Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA. [Wenger, Nanette K.] Emory Univ, Sch Med, Atlanta, GA USA. RP Collins, P (reprint author), Univ London Imperial Coll Sci Technol & Med, Royal Brompton & Harefield NHS Trust, Dept Cardiol, Sydney St, London SW3 6NP, England. EM peter.collins@imperial.ac.uk RI Effron, Mark/P-9300-2015 FU Eli Lilly and Co, Indianapolis, Ind FX This study was sponsored by Eli Lilly and Co, Indianapolis, Ind. NR 31 TC 66 Z9 69 U1 0 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD FEB 24 PY 2009 VL 119 IS 7 BP 922 EP 930 DI 10.1161/CIRCULATIONAHA.108.817577 PG 9 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 410RT UT WOS:000263596500004 PM 19204301 ER PT J AU Casarett, DJ Fishman, JM Lu, HL O'Dwyer, PJ Barg, FK Naylor, MD Asch, DA AF Casarett, David J. Fishman, Jessica M. Lu, Hien L. O'Dwyer, Peter J. Barg, Frances K. Naylor, Mary D. Asch, David A. TI The Terrible Choice: Re-Evaluating Hospice Eligibility Criteria for Cancer SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Article ID CONJOINT-ANALYSIS; PATIENT PREFERENCES; PALLIATIVE CARE; NURSING-HOMES; HEALTH-CARE; FAMILIES; SERVICES; LIFE; MANAGEMENT; ENROLLMENT AB Purpose To be eligible for the Medicare Hospice Benefit, cancer patients with a life expectancy of 6 months or less must give up curative treatment. Our goal was to determine whether willingness to make this choice identifies patients with greater need for hospice services. Patients and Methods Three hundred patients with cancer and 171 family members were recruited from six oncology practices. Respondents completed conjoint interviews in which their perceived need for five hospice services was calculated from the choices they made among combinations of services. Patients' preferences for treatment were measured, and patients were followed for 6 months or until death. Results Thirty-eight patients (13%) said they would not want cancer treatment even if it offered an almost 100% chance of 6-month survival. These patients, who would have been eligible for hospice, did not have greater perceived need for hospice services compared with other patients (n = 262; mean, 1.75 v 1.98; Wilcoxon rank sum test, P = .46), nor did their family members (mean, 1.95 v 2.04; Wilcoxon rank sum test, P = .80). Instead, independent predictors of patients' perceived need for hospice services included African American ethnicity, less social support, worse functional status, and a greater burden of psychological symptoms. For families, predictors included caregiver burden, worse self-reported health, working outside the home, and caring for a patient with worse functional status. Conclusion The requirement that patients forgo life-sustaining treatment does not identify patients with greater perceived need for hospice services. Other characteristics offer a better way to identify the patients who are most likely to benefit from hospice. C1 [Casarett, David J.] Univ Penn, Sch Med, Philadelphia, PA 19104 USA. Univ Penn, Sch Nursing, Philadelphia, PA 19104 USA. Philadelphia Vet Affairs Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA. Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA. RP Casarett, DJ (reprint author), Univ Penn, Sch Med, 3615 Chestnut St, Philadelphia, PA 19104 USA. EM casarett@mail.med.upenn.edu OI Asch, David/0000-0002-7970-286X FU Paul Beeson Physician Faculty Scholars Award [R01CA109540]; Presidential Early Career Award for Scientists and Engineers FX Supported by Grant No. R01CA109540, the Paul Beeson Physician Faculty Scholars Award, and the Presidential Early Career Award for Scientists and Engineers (D.J.C.). NR 39 TC 32 Z9 32 U1 4 U2 6 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X J9 J CLIN ONCOL JI J. Clin. Oncol. PD FEB 20 PY 2009 VL 27 IS 6 BP 953 EP 959 DI 10.1200/JCO.2008.17.8079 PG 7 WC Oncology SC Oncology GA 409NR UT WOS:000263513000019 PM 19114698 ER PT J AU Grande, D Asch, DA AF Grande, David Asch, David A. TI Commercial versus Social Goals of Tracking What Doctors Do SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Editorial Material C1 [Grande, David] Univ Penn, Sch Med, Philadelphia, PA 19104 USA. [Asch, David A.] Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA. [Asch, David A.] Philadelphia Vet Affairs Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA. RP Grande, D (reprint author), Univ Penn, Sch Med, Philadelphia, PA 19104 USA. NR 2 TC 6 Z9 6 U1 0 U2 1 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 J9 NEW ENGL J MED JI N. Engl. J. Med. PD FEB 19 PY 2009 VL 360 IS 8 BP 747 EP 749 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA 408CN UT WOS:000263411300002 PM 19228616 ER PT J AU Qaseem, A Shekelle, P Owens, DK AF Qaseem, Amir Shekelle, Paul Owens, Douglas K. TI Is Too Much Intervention Recommended in the ACP Osteoporosis Treatment Guidelines? RESPONSE SO ANNALS OF INTERNAL MEDICINE LA English DT Letter ID BONE-MINERAL DENSITY C1 [Qaseem, Amir] Amer Coll Physicians, Philadelphia, PA 19106 USA. [Shekelle, Paul] Vet Affairs Greater Los Angeles Healthcare Syst, Santa Monica, CA 90401 USA. [Shekelle, Paul] RAND Corp, Santa Monica, CA 90401 USA. [Owens, Douglas K.] Stanford Univ, Stanford, CA 94305 USA. RP Qaseem, A (reprint author), Amer Coll Physicians, Philadelphia, PA 19106 USA. NR 2 TC 0 Z9 0 U1 0 U2 0 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 J9 ANN INTERN MED JI Ann. Intern. Med. PD FEB 17 PY 2009 VL 150 IS 4 BP 286 EP 287 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA 410FI UT WOS:000263562500018 ER PT J AU Qaseem, A Shekelle, P Owens, DK AF Qaseem, Amir Shekelle, Paul Owens, Douglas K. TI Agranulocytosis After Consumption of Cocaine Adulterated With Levamisole SO ANNALS OF INTERNAL MEDICINE LA English DT Letter C1 [Qaseem, Amir] Amer Coll Physicians, Philadelphia, PA 19106 USA. [Shekelle, Paul] Vet Affairs Greater Los Angeles Healthcare Syst, Santa Monica, CA 90401 USA. [Shekelle, Paul] RAND Corp, Santa Monica, CA 90401 USA. [Owens, Douglas K.] Stanford Univ, Stanford, CA 94305 USA. RP Qaseem, A (reprint author), Amer Coll Physicians, Philadelphia, PA 19106 USA. NR 9 TC 15 Z9 16 U1 0 U2 3 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 EI 1539-3704 J9 ANN INTERN MED JI Ann. Intern. Med. PD FEB 17 PY 2009 VL 150 IS 4 BP 287 EP 289 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA 410FI UT WOS:000263562500019 PM 19153405 ER PT J AU Ross, JS Gross, CP AF Ross, Joseph S. Gross, Cary P. TI Policy Research Using Evidence to Improve Healthcare Delivery Systems SO CIRCULATION LA English DT Editorial Material DE health policy; delivery of health care; policy ID ACUTE MYOCARDIAL-INFARCTION; COOPERATIVE CARDIOVASCULAR PROJECT; BYPASS GRAFT-SURGERY; ELDERLY MEDICARE BENEFICIARIES; RANDOMIZED CONTROLLED-TRIAL; 30-DAY MORTALITY-RATES; AGE-BASED DISPARITIES; SHORT-TERM MORTALITY; CONFLICT-OF-INTEREST; TO-BALLOON TIMES C1 [Ross, Joseph S.] Mt Sinai Sch Med, Dept Geriatr & Adult Dev, New York, NY 10029 USA. [Ross, Joseph S.] Mt Sinai Sch Med, Dept Med, New York, NY 10029 USA. [Ross, Joseph S.] James J Peters VA Med Ctr, HSR& Res Enhancement Award Program, Bronx, NY USA. [Ross, Joseph S.] James J Peters VA Med Ctr, Geriatr Res Educ & Clin Ctr, Bronx, NY USA. [Gross, Cary P.] Yale Univ, Sch Med, Robert Wood Johnson Clin Scholars Program, New Haven, CT USA. [Gross, Cary P.] Yale Univ, Sch Med, Gen Internal Med Sect, Dept Internal Med, New Haven, CT USA. RP Ross, JS (reprint author), Mt Sinai Sch Med, Dept Geriatr & Adult Dev, 1 Gustave L Levy Pl,Box 1070, New York, NY 10029 USA. EM joseph.ross@mssm.edu NR 92 TC 3 Z9 3 U1 2 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD FEB 17 PY 2009 VL 119 IS 6 BP 891 EP 898 DI 10.1161/CIRCULATIONAHA.107.729855 PG 8 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 408JZ UT WOS:000263432600018 PM 19221232 ER PT J AU Mendez, E Houck, JR Doody, DR Fan, WH Lohavanichbutr, P Rue, TC Yueh, B Futran, ND Upton, MP Farwell, DG Heagerty, PJ Zhao, LP Schwartz, SM Chen, C AF Mendez, Eduardo Houck, John R. Doody, David R. Fan, Wenhong Lohavanichbutr, Pawadee Rue, Tessa C. Yueh, Bevan Futran, Neal D. Upton, Melissa P. Farwell, D. Gregory Heagerty, Patrick J. Zhao, Lue Ping Schwartz, Stephen M. Chen, Chu TI A Genetic Expression Profile Associated with Oral Cancer Identifies a Group of Patients at High Risk of Poor Survival SO CLINICAL CANCER RESEARCH LA English DT Article ID SQUAMOUS-CELL CARCINOMA; PLASMINOGEN-ACTIVATOR INHIBITOR; ADVANCED LARYNGEAL-CANCER; GROWTH-FACTOR-BETA; NECK-CANCER; DIAGNOSTIC MARKER; INVASIVE FRONT; HEAD; RECEPTOR; LAMININ-5 AB Purpose: To determine if gene expression signature of invasive oral squamous cell carcinoma (OSCC) can subclassify OSCC based on survival. Experimental Design: We analyzed the expression of 131 genes in 119 OSCC 35 normal, and 17 dysplastic mucosa to identify cluster-defined subgroups. Multivariate Cox regression was used to estimate the association between gene expression and survival. By stepwise Cox regression, the top predictive models of OSCC-specific survival were determined and compared by receiver operating characteristic analysis. Results: The 3-year overall mean +/- SE survival for a cluster of 45 OSCC patients was 38.7 +/- 0.09% compared with 69.1 +/- 0.08% for the remaining patients. Multivariate analysis adjusted for age, sex, and stage showed that the 45 OSCC patient cluster had worse overall and OSCC-specific survival (hazard ratio, 3.31; 95% confidence interval, 1.66-6.58 and hazard ratio, 5.43; 95% confidence interval, 2.32-12.73, respectively). Stepwise Cox regression on the 131 probe sets revealed that a model with a term for LAMC2 (laminin gamma(2)) gene expression best identified patients with worst OSCC-specific survival. We fit a Cox model with a term for a principal component analysis-derived risk score marker and two other models that combined stage with either LAMC2 or PCA. The area under the curve for models combining stage with either LAMC2 or PCA was 0.80 or 0.82, respectively, compared with 0.70 for stage alone (P = 0.013 and 0.008, respectively). Conclusions: Gene expression and stage combined predict survival of OSCC patients better than stage alone. C1 [Mendez, Eduardo; Houck, John R.; Doody, David R.; Lohavanichbutr, Pawadee; Schwartz, Stephen M.; Chen, Chu] Fred Hutchinson Canc Res Ctr, Program Epidemiol, Seattle, WA 98109 USA. [Mendez, Eduardo; Futran, Neal D.; Chen, Chu] Univ Washington, Dept Otolaryngol Head & Neck Surg, Seattle, WA 98195 USA. [Rue, Tessa C.; Heagerty, Patrick J.; Zhao, Lue Ping] Univ Washington, Dept Biostat, Seattle, WA 98195 USA. [Upton, Melissa P.] Univ Washington, Dept Pathol, Seattle, WA 98195 USA. [Schwartz, Stephen M.; Chen, Chu] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. [Mendez, Eduardo] VA Puget Sound Hlth Care Syst, Surg & Perioperat Care Serv, Seattle, WA USA. [Fan, Wenhong; Zhao, Lue Ping] Fred Hutchinson Canc Res Ctr, Program Biostat & Biomath, Seattle, WA 98109 USA. [Yueh, Bevan] Univ Minnesota, Dept Otolaryngol Head & Neck Surg, Minneapolis, MN USA. [Farwell, D. Gregory] Univ Calif Davis, Dept Otolaryngol Head & Neck Surg, Sacramento, CA 95817 USA. RP Chen, C (reprint author), Fred Hutchinson Canc Res Ctr, Program Epidemiol, 1100 Fairview Ave N,M5-C800,POB 19024, Seattle, WA 98109 USA. EM cchen@fhcrc.org OI Yueh, Bevan/0000-0003-1380-1053 FU National Cancer Institute; NIH [R01CA095419]; National Center for Research Resources [1KL2RR025015-01]; Fred Hutchinson Cancer Research Center FX National Cancer Institute, NIH grant R01CA095419 (E. Mendez, J. R. Houck, D. R. Doody, W. Fan, P. Lohavanichbutr, B. Yueh, N. D. Futran, M. P. Upton, D.G. Farwell, L.P. Zhao, S.M. Schwartz, and C. Chen), National Center for Research Resources grant 1KL2RR025015-01 (E. Mendez, T.C. Rue, and P.J. Heagerty), and Fred Hutchinson Cancer Research Center institutional funds (C. Chen). NR 36 TC 31 Z9 31 U1 0 U2 3 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1078-0432 J9 CLIN CANCER RES JI Clin. Cancer Res. PD FEB 15 PY 2009 VL 15 IS 4 BP 1353 EP 1361 DI 10.1158/1078-0432.CCR-08-1816 PG 9 WC Oncology SC Oncology GA 410QI UT WOS:000263592600028 PM 19228736 ER PT J AU Fulop, T Pawelec, G Castle, S Loeb, M AF Fulop, Tamas Pawelec, Graham Castle, Steven Loeb, Mark TI Immunosenescence and Vaccination in Nursing Home Residents SO CLINICAL INFECTIOUS DISEASES LA English DT Article ID LONG-TERM-CARE; RANDOMIZED CONTROLLED-TRIAL; T-CELL DIFFERENTIATION; INFLUENZA VACCINATION; ELDERLY-PEOPLE; CYTOMEGALOVIRUS-INFECTION; SIGNAL-TRANSDUCTION; LIPID RAFTS; AGE; MORTALITY AB The elderly population continues to increase in most countries. Concomitantly, the number of individuals who are institutionalized is also increasing, unfortunately, with more and more individuals being institutionalized at greater ages. These elderly individuals are very different from healthy, community-dwelling elderly individuals, in that many are considered to be frail and have various chronic diseases. It is apparent that the immune response diminishes even in healthy elderly people and that the pathologies that occur in nursing home patients, together with malnutrition, further impair immunity required for an effective vaccine response. Therefore, it is important to take secondary age-related effects, attributable to factors such as chronic diseases, inflammation, frailty, nutrition, functional status, and stress, into account when assessing vaccination strategies. Despite these alterations that can affect immune function and their potential interaction with vaccination, vaccination is still worthwhile and is recommended for elderly nursing home residents. Research efforts should continue attempts to elucidate the immunological basis of impaired immunity in nursing home residents to design improved prevention strategies for this vulnerable group. C1 [Loeb, Mark] McMaster Univ, Dept Pathol & Mol Med, Hamilton, ON L8N 3Z5, Canada. [Fulop, Tamas] Univ Sherbrooke, Fac Med, Div Geriatr, Program Immunol,Res Ctr, Quebec City, PQ, Canada. [Loeb, Mark] McMaster Univ, Dept Clin Epidemiol & Biostat, Hamilton, ON L8N 3Z5, Canada. [Pawelec, Graham] Univ Tubingen, Sch Med, Med Res Ctr, Tubingen Ageing & Tumour Immunol Grp, Tubingen, Germany. [Castle, Steven] Univ Calif Los Angeles, Sch Med, Vet Affairs Greater Los Angeles Healthcare Syst, Ctr Geriatr Res Educ & Clin, Los Angeles, CA USA. RP Loeb, M (reprint author), McMaster Univ, Dept Pathol & Mol Med, MDCL 3200,1200 Main St W, Hamilton, ON L8N 3Z5, Canada. EM loebm@mcmaster.ca OI Pawelec, Graham/0000-0002-3600-0163 NR 52 TC 29 Z9 29 U1 1 U2 5 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD FEB 15 PY 2009 VL 48 IS 4 BP 443 EP 448 DI 10.1086/596475 PG 6 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 396IP UT WOS:000262585700013 PM 19140756 ER PT J AU Musher, DM Logan, N Bressler, AM Johnson, DP Rossignol, JF AF Musher, Daniel M. Logan, Nancy Bressler, Adam M. Johnson, David P. Rossignol, Jean-Francois TI Nitazoxanide versus Vancomycin in Clostridium difficile Infection: A Randomized, Double-Blind Study SO CLINICAL INFECTIOUS DISEASES LA English DT Article ID COLITIS; METRONIDAZOLE; DIARRHEA; DISEASE; OUTBREAK; THERAPY AB Background. Vancomycin is the only US Food and Drug Administration-approved drug for treatment of Clostridium difficile infection (CDI). Metronidazole has been widely used for this purpose but may be inferior to vancomycin, especially for hospitalized patients with severe disease. We report a prospective, double-blind, randomized controlled trial comparing nitazoxanide with vancomycin for treatment of CDI. Methods. Fifty patients with CDI were randomized to receive vancomycin or nitazoxanide for 10 days. An initial response was considered to be the absence of all CDI symptoms between days 11 and 13, and a final response was considered to be lack of symptom recurrence by day 31. Results. One patient fulfilled an exclusion criterion and was removed from the study. Twenty-seven patients received vancomycin, and 23 received nitazoxanide; 23 and 18 patients, respectively, completed the full course of treatment. Initial responses occurred in 20 (74%) of 27 patients treated with vancomycin and in 17 (77%) of 22 patients treated with nitazoxanide (95% confidence interval, -24% to +28%). In those who completed therapy, response rates were 87% ( 20 of 23 patients) in the vancomycin group and 94% ( 17 of 18 patients) in the nitazoxanide group ( 95% confidence interval, -18% to +30%). Times to complete resolution of symptoms were similar in the 2 groups (). Two patients in the vancomycin group and 1 patient in the nitazoxanide group experienced Pp. 55 relapse within 31 days after beginning treatment. Sustained response rates were 78% ( 18 of 23 patients) for the vancomycin group, and 89% ( 16 of 18 patients) for the nitazoxanide group ( 95% confidence interval, -18% to +35%). Conclusions. The small sample precludes conclusions about noninferiority of nitazoxanide to vancomycin. Nevertheless, this is the first recent randomized controlled trial to compare any antimicrobial agent other than metronidazole with vancomycin. Results suggest that nitazoxanide may be as effective as vancomycin in treating CDI. C1 [Musher, Daniel M.; Logan, Nancy] Michael E DeBakey Vet Affairs Med Ctr, Infect Dis Sect, Houston, TX 77030 USA. [Musher, Daniel M.] Baylor Coll Med, Dept Med, Houston, TX 77030 USA. [Musher, Daniel M.] Baylor Coll Med, Dept Mol Virol & Microbiol, Houston, TX 77030 USA. [Bressler, Adam M.] Dekalb Med Ctr, Infect Dis Specialists Atlanta, Atlanta, GA USA. [Bressler, Adam M.] Dekalb Med Ctr, Clin Microbiol Lab, Atlanta, GA USA. [Johnson, David P.] Bay Pines Vet Affairs Med Ctr, Div Infect Dis, Bay Pines, FL USA. [Rossignol, Jean-Francois] Romark Inst Med Res, Tampa, FL USA. [Rossignol, Jean-Francois] Stanford Univ, Sch Med, Dept Med, Div Gastroenterol & Hepatol, Palo Alto, CA 94304 USA. RP Musher, DM (reprint author), Michael E DeBakey Vet Affairs Med Ctr, Infect Dis Sect, Rm 4B-370,2002 Holcombe Blvd, Houston, TX 77030 USA. EM daniel.musher@med.va.gov FU Department of Veterans Affairs through Merit Review Funding; Romark Laboratories; Infectious Disease Section at Baylor College of Medicine FX Potential conflicts of interest. The academic departments of affiliation for D. M. M., N.L., A. M. B., and D. P. J. received funding from Romark Laboratories for studies of nitazoxanide. The Infectious Disease Section at Baylor College of Medicine has received funds in D. M. M.'s name from Salix for studies of rifaximin; from Genzyme for studies of tolevamer; and from Merck for studies of pneumococcal vaccine. J.-F.R. is an employee and owner of equity interests in Romark Laboratories. NR 19 TC 84 Z9 88 U1 0 U2 3 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD FEB 15 PY 2009 VL 48 IS 4 BP E41 EP E46 DI 10.1086/596552 PG 6 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 396IP UT WOS:000262585700027 PM 19133801 ER PT J AU Samuvel, DJ Sundararaj, KP Nareika, A Lopes-Virella, MF Huang, Y AF Samuvel, Devadoss J. Sundararaj, Kamala P. Nareika, Alena Lopes-Virella, Maria F. Huang, Yan TI Lactate Boosts TLR4 Signaling and NF-kappa B Pathway-Mediated Gene Transcription in Macrophages via Monocarboxylate Transporters and MD-2 Up-Regulation SO JOURNAL OF IMMUNOLOGY LA English DT Article ID INDUCED INSULIN-RESISTANCE; DIET-INDUCED OBESITY; SKELETAL-MUSCLE; ADIPOSE-TISSUE; MESSENGER-RNA; EXPRESSION; ACTIVATION; TOLL-LIKE-RECEPTOR-4; INFLAMMATION; HYPERLACTATEMIA AB It has been shown that lactate induces insulin resistance. However, the underlying mechanisms have not been well understood. Based on our observation that lactate augments LPS-stimulated inflammatory gene expression, we proposed that lactate may enhance TLR4 signaling in macrophages, which has been shown to play an important role in insulin resistance in adipocytes. In this study, we demonstrated that lactate stimulated NTD-2, a coreceptor for TLR4 signaling activation, NF-kappa B transcriptional activity, and the expression of inflammatory genes in human U937 histiocytes; (resident macrophages). Similar enhancement of the inflammatory gene expression by lactate was also observed in human monocyte-derived macrophages. The essential role of MD-2 in lactate-augmented TLR4 signaling was confirmed by observation that the suppression of MD-2 expression by small interfering RNA led to significant inhibition of inflammatory gene expression. To further elucidate how lactate treatment enhances TLR4 activation, we showed that the augmentation of inflammatory gene expression by lactate was abrogated by antioxidant treatment, suggesting a critical role of reactive oxygen species in the enhancement of TLR4 activation by lactate. Finally, we showed that alpha-cyano-4-hydroxycinnamic acid, a classic inhibitor for monocarboxylate transporters, blocked lactate-augmented inflammatory gene expression and nuclear NF-kappa B activity, indicating that lactate transport through monocarboxylate transporters is required for lactate-enhanced TLR4 activation. Collectively, this study documents that lactate boosts TLR4 activation and NF-kappa B-dependent inflammatory gene expression via monocarboxylate transporters and MD-2 up-regulation. The Journal of Immunology,2009,182:2476-2484. C1 [Lopes-Virella, Maria F.; Huang, Yan] Ralph H Johnson Vet Affairs Med Center, Charleston, SC 29401 USA. [Samuvel, Devadoss J.; Sundararaj, Kamala P.; Nareika, Alena; Lopes-Virella, Maria F.; Huang, Yan] Med Univ S Carolina, Dept Med, Div Endocrinol Diabet & Med Genet, Charleston, SC 29425 USA. RP Huang, Y (reprint author), Med Univ S Carolina, Ralph H Johnson Vet Affairs Med Center, 114 Doughty St, Charleston, SC 29403 USA. EM huangyan@musc.edu FU National Institutes of Health [DE16353]; Department of Veterans Affairs FX This work was supported by National Institutes of Health Grant DE16353 and a Merit Review Grant from the Department of Veterans Affairs (to Y.H.). NR 49 TC 58 Z9 61 U1 0 U2 6 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-1767 J9 J IMMUNOL JI J. Immunol. PD FEB 15 PY 2009 VL 182 IS 4 BP 2476 EP 2484 DI 10.4049/jimmunol.0802059 PG 9 WC Immunology SC Immunology GA 404BS UT WOS:000263126300078 PM 19201903 ER PT J AU Lane, R He, YS Morris, C Leverenz, JB Emre, M Ballard, C AF Lane, Roger He, Yunsheng Morris, Christopher Leverenz, James B. Emre, Murat Ballard, Clive TI BuChE-K and APOE epsilon 4 Allele Frequencies in Lewy Body Dementias, and Influence of Genotype and Hyperhomocysteinemia on Cognitive Decline SO MOVEMENT DISORDERS LA English DT Article DE Parkinson's disease dementia; dementia with Lewy bodies; apolipoprotein E; butyrylcholinesterase ID ALZHEIMERS-DISEASE; PARKINSONS-DISEASE; APOLIPOPROTEIN-E; HOMOCYSTEINE; RIVASTIGMINE; PROGRESSION; DEFICIENCY; DEPOSITION; NEURONS; PLACEBO AB Apolipoprotein E (APOE) epsilon 4 and butyrylcholinesterase-K (BuChE-K) are associated with an increased risk for Alzheimer's disease. The primary objective was to evaluate frequencies of these alleles in dementia with Lewy bodies (DLB) and Parkinson's disease dementia (PDD). A secondary objective was to evaluate influences on rate of cognitive decline. This analysis used data from participants consenting to pharmacogenetic testing in placebo-controlled rivastigmine studies. Allele frequencies in DLB and PDD were compared using logistic regression. Within the PDD placebo sample. associations with cognitive decline were evaluated (the DLB sample was too small for these evaluations). Fifty-seven DLB and 323 PDD subjects provided APOE and BuChE data. Allelic frequencies were higher in DLB, relative to PDD subjects, for BuChE-K (P = 0.06), APOE epsilon 4 (P < 0.001), or both alleles together (P < 0.001). More rapid cognitive decline was seen in PDD patients carrying both alleles, compared with other enotypes. Subjects with hyperhomo-cysteinemia were associated with more rapid decline in the presence of BuChE-K, with or without APOE epsilon 4. These results suggest that genetic and biochemical risk factors for AD and PDD pathology may be important in dementia onset and progression in these Lewy body disorders. (C) 2008 Movement Disorder Society C1 [Lane, Roger] Nova Pharmaceut Corp, E Hanover, NJ 07936 USA. [He, Yunsheng] Nova Pharmaceut Corp, Cambridge, MA USA. [Morris, Christopher] Newcastle Gen Hosp, Newcastle Upon Tyne NE4 6BE, Tyne & Wear, England. [Leverenz, James B.] PADRECC, MIRECC, VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Leverenz, James B.] Univ Washington, Seattle, WA 98195 USA. [Emre, Murat] Istanbul Univ, Istanbul Fac Med, Istanbul, Turkey. [Ballard, Clive] Kings Coll London, Wolfson Ctr Age Related Dis, London WC2R 2LS, England. RP Lane, R (reprint author), Nova Pharmaceut Corp, 59 Route 10, E Hanover, NJ 07936 USA. EM roger.lane@novartis.com FU Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA; Novartis FX This study was funded by Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA. Novartis sponsored Alpha-Plus Medical Communications Ltd (UK) to provide editorial assistance with the manuscript. NR 22 TC 22 Z9 22 U1 0 U2 4 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0885-3185 J9 MOVEMENT DISORD JI Mov. Disord. PD FEB 15 PY 2009 VL 24 IS 3 BP 392 EP 400 DI 10.1002/mds.22357 PG 9 WC Clinical Neurology SC Neurosciences & Neurology GA 412TN UT WOS:000263747200011 PM 19006190 ER PT J AU Handforth, A Martin, FC Kang, GA Vanek, Z AF Handforth, Adrian Martin, Fredricka C. Kang, Gail A. Vanek, Zeba TI Zonisamide for Essential Tremor: An Evaluator-Blinded Study SO MOVEMENT DISORDERS LA English DT Article DE essential tremor; zonisamide; clinical trial ID PLACEBO-CONTROLLED TRIAL AB In this evaluator-blinded open-treatment trial, subjects with moderate/severe upper limb essential tremor were titrated to 300 mg/day zonisamide, or adjusted to a lesser (lose if symptoms warranted, as monotherapy or as adjunct to stable antitremor medication, followed by a 12-week extension phase. The primary efficacy outcome variables were blinded rater videotaped/drawing tremor score changes at the Treatment and Extension visits compared to Baseline, based on Fahn-Tolosa-Marin and Postural Tremor Scales. Subjects also rated Functional Disabilities. Primary outcomes showed reduced tremor scores at the Treatment (P < 0.00001, n = 25) and Extension (n = 16) visits, at mean doses of 252 and 225 mg/day, respectively. Subject ratings indicated 200 mg/day was superior to 100 mg/day, whereas 300 mg/day produced no additional benefit, but instead was associated with more adverse symptoms, most commonly somnolence, poor energy, imbalance, and altered taste. Future double-blind placebo-controlled trials are warranted. (C) 2008 Movement Disorder Society C1 [Handforth, Adrian] Vet Affairs Greater Los Angeles Healthcare Syst, Dept Neurol, Los Angeles, CA USA. [Martin, Fredricka C.] Vet Affairs Greater Los Angeles Healthcare Syst, Res Serv, Los Angeles, CA USA. [Kang, Gail A.] Vet Affairs San Francisco Med Ctr, Parkinsons Dis Res Educ Clin Ctr, San Francisco, CA USA. [Vanek, Zeba] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA. RP Handforth, A (reprint author), VA Greater Los Angeles, Neurol Serv W127, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM charles.handforth@med.va.gov FU Veterans Affairs; Ralph M. Parsons Foundation, Los Angeles FX A.H., F.C.M.. G.A.K. were supported by Veterans Affairs and A.H. by the Ralph M. Parsons Foundation, Los Angeles. The statistical analysis was performed by Jeffrey Gornbein, DrPH, UCLA SBCC/Department of Biomathematics, UCLA David Geffen School of Medicine, Los Angeles. NR 10 TC 23 Z9 23 U1 0 U2 1 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0885-3185 J9 MOVEMENT DISORD JI Mov. Disord. PD FEB 15 PY 2009 VL 24 IS 3 BP 437 EP 440 DI 10.1002/mds.22418 PG 4 WC Clinical Neurology SC Neurosciences & Neurology GA 412TN UT WOS:000263747200019 PM 19117357 ER PT J AU Volpp, KG Troxel, AB Pauly, MV Glick, HA Puig, A Asch, DA Galvin, R Zhu, JS Wan, F DeGuzman, J Corbett, E Weiner, J Audrain-McGovern, J AF Volpp, Kevin G. Troxel, Andrea B. Pauly, Mark V. Glick, Henry A. Puig, Andrea Asch, David A. Galvin, Robert Zhu, Jingsan Wan, Fei DeGuzman, Jill Corbett, Elizabeth Weiner, Janet Audrain-McGovern, Janet TI A Randomized, Controlled Trial of Financial Incentives for Smoking Cessation SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Article ID LONG-TERM ABSTINENCE; PREGNANT SMOKERS; TOBACCO USE; HEALTH; PERFORMANCE; PROGRAMS AB Background Smoking is the leading preventable cause of premature death in the United States. Previous studies of financial incentives for smoking cessation in work settings have not shown that such incentives have significant effects on cessation rates, but these studies have had limited power, and the incentives used may have been insufficient. Methods We randomly assigned 878 employees of a multinational company based in the United States to receive information about smoking- cessation programs ( 442 employees) or to receive information about programs plus financial incentives ( 436 employees). The financial incentives were $ 100 for completion of a smoking- cessation program, $ 250 for cessation of smoking within 6 months after study enrollment, as confirmed by a biochemical test, and $ 400 for abstinence for an additional 6 months after the initial cessation, as confirmed by a biochemical test. Individual participants were stratified according to work site, heavy or nonheavy smoking, and income. The primary end point was smoking cessation 9 or 12 months after enrollment, depending on whether initial cessation was reported at 3 or 6 months. Secondary end points were smoking cessation within the first 6 months after enrollment and rates of participation in and completion of smoking- cessation programs. Results The incentive group had significantly higher rates of smoking cessation than did the information- only group 9 or 12 months after enrollment (14.7% vs. 5.0%, P< 0.001) and 15 or 18 months after enrollment (9.4% vs. 3.6%, P< 0.001). Incentive- group participants also had significantly higher rates of enrollment in a smoking- cessation program (15.4% vs. 5.4%, P< 0.001), completion of a smoking- cessation program (10.8% vs. 2.5%, P< 0.001), and smoking cessation within the first 6 months after enrollment (20.9% vs. 11.8%, P< 0.001). Conclusions In this study of employees of one large company, financial incentives for smoking cessation significantly increased the rates of smoking cessation. (ClinicalTrials. gov number, NCT00128375.). C1 [Volpp, Kevin G.; Pauly, Mark V.; Glick, Henry A.; Puig, Andrea; Asch, David A.] Univ Penn, Sch Med, Dept Hlth Care Management, Philadelphia, PA 19104 USA. [Volpp, Kevin G.; Pauly, Mark V.; Glick, Henry A.; Puig, Andrea; Asch, David A.] Univ Penn, Wharton Sch, Philadelphia, PA 19104 USA. [Troxel, Andrea B.; Wan, Fei] Univ Penn, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA. [Troxel, Andrea B.; Wan, Fei] Univ Penn, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA. [Volpp, Kevin G.; Asch, David A.] Univ Penn, Ctr Hlth Equ Res & Promot, Philadelphia Vet Affairs Med Ctr, Philadelphia, PA 19104 USA. [Volpp, Kevin G.; Troxel, Andrea B.; Pauly, Mark V.; Glick, Henry A.; Asch, David A.; Zhu, Jingsan; DeGuzman, Jill; Weiner, Janet] Univ Penn, Ctr Hlth Incent, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA. [Volpp, Kevin G.; Glick, Henry A.; Asch, David A.; Zhu, Jingsan; DeGuzman, Jill; Corbett, Elizabeth] Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA. [Audrain-McGovern, Janet] Univ Penn, Sch Med, Transdisciplinary Tobacco Use Res Ctr, Dept Psychiat, Philadelphia, PA 19104 USA. [Galvin, Robert] Gen Elect, Fairfield, CT USA. [Galvin, Robert] Yale Univ, Sch Med, New Haven, CT USA. RP Volpp, KG (reprint author), Univ Penn, Sch Med, Div Gen Internal Med, 1232 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA. EM volpp70@wharton.upenn.edu OI Weiner, Janet/0000-0001-5810-5807; Corbett, Elizabeth/0000-0002-3552-3181 FU Centers for Disease Control and Prevention [RO1 DP000100-01, RO1 DP001168-01]; Pennsylvania Department of Health; Aetna; Pfizer; General Electric; America's Health Insurance Plans; Merck; MedStar FX Supported by grants from the Centers for Disease Control and Prevention (RO1 DP000100-01 and RO1 DP001168-01) and from the Pennsylvania Department of Health, which specifically disclaims responsibility for any analyses, interpretations, or conclusions.; Dr. Volpp reports receiving lecture fees from Aetna and grant support from Aetna and Pfizer and owning equity in General Electric; Dr. Pauly, being a board member of Independent Health, owning equity in General Electric, receiving lecture fees from America's Health Insurance Plans, and receiving grant support from Merck and MedStar; Dr. Glick, owning equity in General Electric; and Dr. Galvin, owning equity in General Electric. No other potential conflict of interest relevant to this article was reported.; We thank Quincy Greene for his contributions to the analyses for this article and Donna Tomlinson, M. D., for assistance in implementing this study. NR 27 TC 264 Z9 265 U1 2 U2 41 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 EI 1533-4406 J9 NEW ENGL J MED JI N. Engl. J. Med. PD FEB 12 PY 2009 VL 360 IS 7 BP 699 EP 709 DI 10.1056/NEJMsa0806819 PG 11 WC Medicine, General & Internal SC General & Internal Medicine GA 405YQ UT WOS:000263260500007 PM 19213683 ER PT J AU Varkey, AB Manwell, LB Williams, ES Ibrahim, SA Brown, RL Bobula, JA Horner-Ibler, BA Schwartz, MD Konrad, TR Wiltshire, JC Linzer, M AF Varkey, Anita B. Manwell, Linda Baier Williams, Eric S. Ibrahim, Said A. Brown, Roger L. Bobula, James A. Horner-Ibler, Barbara A. Schwartz, Mark D. Konrad, Thomas R. Wiltshire, Jacqueline C. Linzer, Mark CA Memo Investigators TI Separate and Unequal Clinics Where Minority and Nonminority Patients Receive Primary Care SO ARCHIVES OF INTERNAL MEDICINE LA English DT Article; Proceedings Paper CT 29th Annual Meeting of the Society-of-General-Internal-Medicine CY APR 27-29, 2006 CL Los Angeles, CA SP Soc Gen Internal Med ID PHYSICIANS; HEALTH; SATISFACTION; VALIDITY; MODELS AB Background: Few studies have examined the influence of physician workplace conditions on health care disparities. We compared 96 primary care clinics in New York, New York, and in the upper Midwest serving various proportions of minority patients to determine differences in workplace organizational characteristics. Methods: Cross-sectional data are from surveys of 96 clinic managers, 388 primary care physicians, and 1701 of their adult patients with hypertension, diabetes mellitus, or congestive heart failure participating in the Minimizing Error, Maximizing Outcome (MEMO) study. Data from 27 clinics with at least 30% minority patients were contrasted with data from 69 clinics with less than 30% minority patients. Results: Compared with clinics serving less than 30% minority patients, clinics serving at least 30% minority patients have less access to medical supplies (2.7 vs 3.4, P < .001), referral specialists (3.0 vs 3.5, P < .005) on a scale of 1 (none) to 4 (great), and examination rooms per physician (2.2 vs 2.7, P = .002). Their patients are more frequently depressed (22.8% vs 12.1%), are more often covered by Medicaid (30.2% vs 11.4%), and report lower health literacy (3.7 vs 4.4) on a scale of 1 (low) to 5 (high) (P < .001 for all). Physicians from clinics serving higher proportions of minority populations perceive their patients as frequently speaking little or no English (27.1% vs 3.4%, P = .004), having more chronic pain (24.1% vs 12.9%, P < .001) and substance abuse problems (15.1% vs 10.1%, P = .005), and being more medically complex (53.1% vs 39.9%) and psychosocially complex (44.9% vs 28.2%) (P < .001 for both). In regression analyses, clinics with at least 30% minority patients are more likely to have chaotic work environments (odds ratio, 4.0; P = .003) and to have fewer physicians reporting high work control (0.2; P = .003) or high job satisfaction (0.4; P = .01). Conclusion: Clinics serving higher proportions of minority patients have more challenging workplace and organizational characteristics. C1 [Varkey, Anita B.] John H Stroger Jr Hosp Cook Cty, Dept Med, Chicago, IL USA. [Varkey, Anita B.] Rush Univ, Med Ctr, Chicago, IL 60612 USA. [Varkey, Anita B.] Loyola Univ, Med Ctr, Chicago, IL 60611 USA. [Manwell, Linda Baier; Bobula, James A.] Univ Wisconsin, Dept Family Med, Madison, WI USA. [Linzer, Mark] Univ Wisconsin, Dept Med, Madison, WI USA. [Wiltshire, Jacqueline C.] Univ Wisconsin, Ctr Womens Hlth Res, Madison, WI USA. [Brown, Roger L.] Univ Wisconsin, Sch Med & Publ Hlth, Madison, WI USA. [Brown, Roger L.] Univ Wisconsin, Sch Nursing, Madison, WI USA. [Horner-Ibler, Barbara A.] Med Coll Wisconsin, Dept Med, Milwaukee, WI 53226 USA. [Williams, Eric S.] Univ Alabama, Culverhouse Coll Commerce & Business Adm, Dept Management & Mkt, Tuscaloosa, AL USA. [Ibrahim, Said A.] Univ Pittsburgh, Vet Affairs Pittsburgh Hlth Care Syst, Pittsburgh, PA USA. [Ibrahim, Said A.] Univ Pittsburgh, Dept Med, Pittsburgh, PA USA. [Schwartz, Mark D.] NYU, Sch Med, Dept Med, New York, NY USA. [Schwartz, Mark D.] Vet Affairs New York Harbor Hlth Care Syst, New York, NY USA. [Konrad, Thomas R.] Univ N Carolina, Cecil G Sheps Ctr Hlth Serv Res, Chapel Hill, NC USA. RP Varkey, AB (reprint author), Loyola Univ, Med Ctr, Dept Med, 2160 S 1st Ave, Maywood, IL 60153 USA. EM avarkey@lumc.edu OI Konrad, Thomas R/0000-0002-5269-0440 FU AHRQ HHS [5R01 HS 011955] NR 25 TC 53 Z9 53 U1 3 U2 4 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA SN 0003-9926 J9 ARCH INTERN MED JI Arch. Intern. Med. PD FEB 9 PY 2009 VL 169 IS 3 BP 243 EP 250 PG 8 WC Medicine, General & Internal SC General & Internal Medicine GA 405DK UT WOS:000263202600006 PM 19204215 ER PT J AU Jung-Hynes, B Nihal, M Zhong, WX Ahmad, N AF Jung-Hynes, Brittney Nihal, Minakshi Zhong, Weixiong Ahmad, Nihal TI Role of Sirtuin Histone Deacetylase SIRT1 in Prostate Cancer A TARGET FOR PROSTATE CANCER MANAGEMENT VIA ITS INHIBITION? SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article ID FORKHEAD TRANSCRIPTION FACTOR; PROMOTES CELL-SURVIVAL; ANDROGEN RECEPTOR; LIFE-SPAN; FOXO; EXPRESSION; GROWTH; P53; LONGEVITY; DISEASE AB Prostate cancer (PCa) is a major age-related malignancy, and according to estimates from the American Cancer Society, a man's chance of developing this cancer significantly increases with increasing age, from 1 in 10,149 by age 39 to 1 in 38 by age 59 to 1 in 7 by age 70. Therefore, it is important to identify the causal connection between mechanisms of aging and PCa. Employing in vitro and in vivo approaches, in this study, we tested the hypothesis that SIRT1, which belongs to the Sir2 (silent information regulator 2) family of sirtuin class III histone deacetylases, is overexpressed in PCa, and its inhibition will have antiproliferative effects in human PCa cells. Our data demonstrated that SIRT1 was significantly overexpressed in human PCa cells (DU145, LNCaP, 22Rv1, and PC3) compared with normal prostate epithelial cells (PrEC) at protein, mRNA, and enzymatic activity levels. SIRT1 was also found to be overexpressed in human PCa tissues compared with adjacent normal prostate tissue. Interestingly, our data demonstrated that SIRT1 inhibition via nicotinamide and sirtinol (at the activity level) as well as via short hairpin RNA-mediated RNA interference (at the genetic level) resulted in a significant inhibition in the growth and viability of human PCa cells while having no effect on normal prostate epithelial cells. Further, we found that inhibition of SIRT1 caused an increase in FOXO1 acetylation and transcriptional activation in PCa cells. Our data suggested that SIRT1, via inhibiting FOXO1 activation, could contribute to the development of PCa. We suggest that SIRT1 could serve as a target toward developing novel strategies for PCa management. C1 [Ahmad, Nihal] Univ Wisconsin, Med Sci Ctr, Dept Dermatol, Madison, WI 53706 USA. [Jung-Hynes, Brittney; Ahmad, Nihal] Univ Wisconsin, Mol & Environm Toxicol Ctr, Madison, WI 53706 USA. [Nihal, Minakshi; Zhong, Weixiong] Univ Wisconsin, William S Middleton Mem Vet Hosp, Madison, WI 53706 USA. [Zhong, Weixiong] Univ Wisconsin, Dept Pathol & Lab Med, Madison, WI 53706 USA. [Zhong, Weixiong; Ahmad, Nihal] Univ Wisconsin, Ctr Comprehens Canc, Madison, WI 53706 USA. RP Ahmad, N (reprint author), Univ Wisconsin, Med Sci Ctr, Dept Dermatol, 1300 Univ Ave, Madison, WI 53706 USA. EM nahmad@wisc.edu FU National Institutes of Health; NIEHS; Molecular and Environmental Toxicology Center Training [T32ES007015] FX This work was supported, in whole or in part, by National Institutes of Health, NIEHS, Molecular and Environmental Toxicology Center Training Grant T32ES007015 (predoctoral traineeship to B.J.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. NR 62 TC 91 Z9 97 U1 0 U2 12 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 J9 J BIOL CHEM JI J. Biol. Chem. PD FEB 6 PY 2009 VL 284 IS 6 BP 3823 EP 3832 DI 10.1074/jbc.M807869200 PG 10 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 400MO UT WOS:000262872500051 PM 19075016 ER PT J AU Offner, H Vandenbark, AA Hurn, PD AF Offner, H. Vandenbark, A. A. Hurn, P. D. TI EFFECT OF EXPERIMENTAL STROKE ON PERIPHERAL IMMUNITY: CNS ISCHEMIA INDUCES PROFOUND IMMUNOSUPPRESSION SO NEUROSCIENCE LA English DT Review DE stroke; spleen; Treg cells; macrophages; immunosuppression ID REGULATORY T-CELLS; FOCAL CEREBRAL-ISCHEMIA; CENTRAL-NERVOUS-SYSTEM; MONOCYTE CHEMOATTRACTANT PROTEIN-1; INTERFERON-INDUCIBLE PROTEIN-10; CHEMOKINE RECEPTOR ANTAGONIST; MESSENGER-RNA EXPRESSION; INDUCED IMMUNODEPRESSION; TRANSCRIPTION FACTOR; LYMPHOCYTE SUBSETS AB The profound damage to the CNS caused by ischemic lesions has been well documented. Yet, relatively little is known about the contribution to and effects on the immune system during stroke. We have focused on both early and late events in the peripheral immune system during stroke in mice and have observed an early activation of splenocytes that conceivably could result in immune-mediated damage in the developing CNS lesion, followed by global immunosuppression that affects the spleen, thymus, lymph nodes and circulation. While this second immunosuppressive phase may not directly enhance infarction size, it without doubt leads to an inability to respond to antigenic challenges, thereby enhancing the risk for crippling systemic infection and septicemia in stroke survivors. These novel findings advocate the need to develop or effectively utilize agents that can block early neural splenic activation and modulate immune cells specific for brain antigens as a means to prevent mobilization of T and B cells carrying a cytokine death warrant to the brain. Equally important for the recovering stroke patient are approaches that can derail the second phase of immune dysfunction and restore the ability to mount a defense against systemic infectious insults. (C) 2009 IBRO. Published by Elsevier Ltd. All rights reserved. C1 [Offner, H.; Vandenbark, A. A.] Portland VA Med Ctr, Portland, OR 97239 USA. [Offner, H.; Vandenbark, A. A.] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97239 USA. [Offner, H.; Hurn, P. D.] Oregon Hlth & Sci Univ, Dept Anesthesiol & Perioperat Med, Portland, OR 97239 USA. [Vandenbark, A. A.] Oregon Hlth & Sci Univ, Dept Mol Microbiol & Immunol, Portland, OR 97239 USA. RP Offner, H (reprint author), Portland VA Med Ctr, 3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM offnerva@ohsu.edu FU US Public Health Service NIH [NS33668, NR03521, NS49210, RR00163]; Biomedical Laboratoty R&D Service, Department of Veterans Affairs FX The authors wish to thank Ms. Eva Niehaus for assistance in preparing and submitting the manuscript and Dr. Wenri Zhang and Ms. Susan Parker for the preparation of cerebral blood flow autoradiography in the SCID mice. This work was supported by US Public Health Service NIH grants NS33668, NR03521, NS49210, RR00163, and the Biomedical Laboratoty R&D Service, Department of Veterans Affairs. NR 62 TC 104 Z9 113 U1 1 U2 10 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0306-4522 J9 NEUROSCIENCE JI Neuroscience PD FEB 6 PY 2009 VL 158 IS 3 BP 1098 EP 1111 DI 10.1016/j.neuroscience.2008.05.033 PG 14 WC Neurosciences SC Neurosciences & Neurology GA 409TW UT WOS:000263529700013 PM 18597949 ER PT J AU Yang, JJ Cohen, A Hersh, W AF Yang, Jianji Cohen, Aaron Hersh, William TI Evaluation of a gene information summarization system by users during the analysis process of microarray datasets SO BMC BIOINFORMATICS LA English DT Article CT 1st Summit on Translational Bioinformatics CY MAR 10-12, 2008 CL San Francisco, CA SP Amer Med Informat Assoc, Int Soc Computat Biol ID BIOMEDICAL LITERATURE AB Background: Summarization of gene information in the literature has the potential to help genomics researchers translate basic research into clinical benefits. Gene expression microarrays have been used to study biomarkers for disease and discover novel types of therapeutics and the task of finding information in journal articles on sets of genes is common for translational researchers working with microarray data. However, manually searching and scanning the literature references returned from PubMed is a time-consuming task for scientists. We built and evaluated an automatic summarizer of information on genes studied in microarray experiments. The Gene Information Clustering and Summarization System (GICSS) is a system that integrates two related steps of the microarray data analysis process: functional gene clustering and gene information gathering. The system evaluation was conducted during the process of genomic researchers analyzing their own experimental microarray datasets. Results: The clusters generated by GICSS were validated by scientists during their microarray analysis process. In addition, presenting sentences in the abstract provided significantly more important information to the users than just showing the title in the default PubMed format. Conclusion: The evaluation results suggest that GICSS can be useful for researchers in genomic area. In addition, the hybrid evaluation method, partway between intrinsic and extrinsic system evaluation, may enable researchers to gauge the true usefulness of the tool for the scientists in their natural analysis workflow and also elicit suggestions for future enhancements. Availability: GICSS can be accessed online at: http://ir.ohsu.edu/jianji/index.html C1 [Yang, Jianji; Cohen, Aaron; Hersh, William] Oregon Hlth & Sci Univ, Dept Med Informat & Clin Epidemiol, Portland, OR 97239 USA. [Yang, Jianji] Portland VA Med Ctr, Portland Ctr Evaluat Clin Serv, Portland, OR 97239 USA. RP Yang, JJ (reprint author), Oregon Hlth & Sci Univ, Dept Med Informat & Clin Epidemiol, Portland, OR 97239 USA. EM jianji.yang2@va.gov; cohenaa@ohsu.edu; hersh@ohsu.edu OI Hersh, William/0000-0002-4114-5148 FU NLM NIH HHS [1T15 LM009461] NR 17 TC 3 Z9 3 U1 0 U2 0 PU BIOMED CENTRAL LTD PI LONDON PA CURRENT SCIENCE GROUP, MIDDLESEX HOUSE, 34-42 CLEVELAND ST, LONDON W1T 4LB, ENGLAND SN 1471-2105 J9 BMC BIOINFORMATICS JI BMC Bioinformatics PD FEB 5 PY 2009 VL 10 AR S5 DI 10.1186/1471-2105-10-S2-S5 PG 8 WC Biochemical Research Methods; Biotechnology & Applied Microbiology; Mathematical & Computational Biology SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology; Mathematical & Computational Biology GA 439BS UT WOS:000265602500006 PM 19208193 ER PT J AU Landrigan, CP Volpp, KG AF Landrigan, Christopher P. Volpp, Kevin G. TI Evidence-Based Evaluation of Physician Work Hour Regulations Reply SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Letter ID INTERNS; MORTALITY; REFORM; RISK C1 [Landrigan, Christopher P.] Brigham & Womens Hosp, Sleep & Patient Safety Program, Boston, MA 02115 USA. [Volpp, Kevin G.] Vet Adm Hosp, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA. RP Landrigan, CP (reprint author), Brigham & Womens Hosp, Sleep & Patient Safety Program, 75 Francis St, Boston, MA 02115 USA. EM volpp70@mail.med.upenn.edu NR 6 TC 0 Z9 0 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA SN 0098-7484 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD FEB 4 PY 2009 VL 301 IS 5 BP 484 EP 485 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA 402CS UT WOS:000262992400012 ER PT J AU Higgs, MH Spain, WJ AF Higgs, Matthew H. Spain, William J. TI Conditional Bursting Enhances Resonant Firing in Neocortical Layer 2-3 Pyramidal Neurons SO JOURNAL OF NEUROSCIENCE LA English DT Article DE burst; resonance; oscillator; frequency; cortex; pyramidal cell ID HIGH-FREQUENCY OSCILLATIONS; CAT SENSORIMOTOR CORTEX; WHITE-NOISE ANALYSIS; IN-VITRO; CORTICAL-NEURONS; SUBTHRESHOLD OSCILLATIONS; SYNAPTIC-TRANSMISSION; COINCIDENCE DETECTION; EXCITATORY NETWORKS; DYNAMIC PROPERTIES AB The frequency response properties of neurons are critical for signal transmission and control of network oscillations. At subthreshold membrane potential, some neurons show resonance caused by voltage-gated channels. During action potential firing, resonance of the spike output may arise from subthreshold mechanisms and/or spike-dependent currents that cause afterhyperpolarizations (AHPs) and afterdepolarizations (ADPs). Layer 2-3 pyramidal neurons (L2-3 PNs) have a fast ADP that can trigger bursts. The present study investigated what stimuli elicit bursting in these cells and whether bursts transmit specific frequency components of the synaptic input, leading to resonance at particular frequencies. We found that two-spike bursts are triggered by step onsets, sine waves in two frequency bands, and noise. Using noise adjusted to elicit firing at similar to 10 Hz, we measured the gain for modulation of the time-varying firing rate as a function of stimulus frequency, finding a primary peak (7-16 Hz) and a high-frequency resonance (250-450 Hz). Gain was also measured separately for single and burst spikes. For a given spike rate, bursts provided higher gain at the primary peak and lower gain at intermediate frequencies, sharpening the high-frequency resonance. Suppression of bursting using automated current feedback weakened the primary and high-frequency resonances. The primary resonance was also influenced by the SK channel-mediated medium AHP (mAHP), because the SK blocker apamin reduced the sharpness of the primary peak. Our results suggest that resonance in L2-3 PNs depends on burst firing and the mAHP. Bursting enhances resonance in two distinct frequency bands. C1 [Higgs, Matthew H.; Spain, William J.] Vet Affairs Puget Sound Hlth Care Syst, Neurol Sect, Seattle, WA 98018 USA. [Higgs, Matthew H.; Spain, William J.] Univ Washington, Dept Physiol & Biophys, Seattle, WA 98195 USA. [Spain, William J.] Univ Washington, Dept Neurol, Seattle, WA 98195 USA. RP Spain, WJ (reprint author), Vet Affairs Puget Sound Hlth Care Syst, Neurol Sect, Mail Stop 127,1660 S Columbian Way, Seattle, WA 98018 USA. EM spain@u.washington.edu FU BLRD VA [I01 BX000386] NR 82 TC 39 Z9 40 U1 0 U2 2 PU SOC NEUROSCIENCE PI WASHINGTON PA 11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA SN 0270-6474 J9 J NEUROSCI JI J. Neurosci. PD FEB 4 PY 2009 VL 29 IS 5 BP 1285 EP 1299 DI 10.1523/JNEUROSCI.3728-08.2009 PG 15 WC Neurosciences SC Neurosciences & Neurology GA 403GZ UT WOS:000263072400005 PM 19193876 ER PT J AU Krumholz, HM Ross, JS AF Krumholz, Harlan M. Ross, Joseph S. TI Relationships with the drug industry: More regulation, greater transparency SO BRITISH MEDICAL JOURNAL LA English DT Editorial Material C1 [Krumholz, Harlan M.] Yale Univ, Sch Med, Sect Cardiovasc Med, New Haven, CT 06520 USA. [Krumholz, Harlan M.] Yale Univ, Sch Med, Robert Wood Johnson Clin Scholars Program, Dept Med,Sect Hlth Policy & Adm,Sch Publ Hlth, New Haven, CT 06520 USA. [Krumholz, Harlan M.] Yale New Haven Med Ctr, Ctr Outcomes Res & Evaluat, New Haven, CT 06504 USA. [Ross, Joseph S.] Mt Sinai Sch Med, Dept Geriatr & Adult Dev, New York, NY USA. [Ross, Joseph S.] James J Peters VA Med Ctr, Bronx, NY USA. RP Krumholz, HM (reprint author), Yale Univ, Sch Med, Sect Cardiovasc Med, POB 208088, New Haven, CT 06520 USA. EM harlan.krumholz@yale.edu NR 7 TC 5 Z9 5 U1 1 U2 2 PU B M J PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 0959-8146 J9 BRIT MED J JI Br. Med. J. PD FEB 3 PY 2009 VL 338 AR b211 DI 10.1136/bmj.b211 PG 4 WC Medicine, General & Internal SC General & Internal Medicine GA 414OX UT WOS:000263876200004 PM 19193612 ER PT J AU Machida, K Tsukamoto, H Mkrtchyan, H Duan, L Dynnyk, A Liu, HM Asahina, K Govindarajan, S Raye, R Ou, JJ Seki, E Deshaies, R Miyake, K Lai, MMC AF Machida, Keigo Tsukamoto, Hidekazu Mkrtchyan, Hasmik Duan, Lewei Dynnyk, Alla Liu, Helene Minyi Asahina, Kinji Govindarajan, Sugantha Raye, Ratna Ou, Jing-hsiung James Seki, Ekihiro Deshaies, Raymond Miyake, Kensuke Lai, Michael M. -C. TI Toll-like receptor 4 mediates synergism between alcohol and HCV in hepatic oncogenesis involving stem cell marker Nanog SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA LA English DT Article ID VIRUS CORE PROTEIN; NONSTRUCTURAL 5A PROTEIN; C VIRUS; HEPATOCELLULAR-CARCINOMA; OXIDATIVE STRESS; VIRAL-HEPATITIS; TRANSGENIC MICE; UP-REGULATION; LIVER; ACTIVATION AB Alcohol synergistically enhances the progression of liver disease and the risk for liver cancer caused by hepatitis C virus (HCV). However, the molecular mechanism of this synergy remains unclear. Here, we provide the first evidence that Toll-like receptor 4 (TLR4) is induced by hepatocyte-specific transgenic (Tg) expression of the HCV nonstructural protein NS5A, and this induction mediates synergistic liver damage and tumor formation by alcohol-induced endotoxemia. We also identify Nanog, the stem/progenitor cell marker, as a novel downstream gene up-regulated by TLR4 activation and the presence of CD133/Nanog-positive cells in liver tumors of alcohol-fed NS5A Tg mice. Transplantation of p53-deficient hepatic progenitor cells transduced with TLR4 results in liver tumor development in mice following repetitive LPS injection, but concomitant transduction of Nanog short-hairpin RNA abrogates this outcome. Taken together, our study demonstrates a TLR4-dependent mechanism of synergistic liver disease by HCV and alcohol and an obligatory role for Nanog, a TLR4 downstream gene, in HCV-induced liver oncogenesis enhanced by alcohol. C1 [Machida, Keigo; Tsukamoto, Hidekazu; Mkrtchyan, Hasmik; Dynnyk, Alla; Asahina, Kinji; Govindarajan, Sugantha; Ou, Jing-hsiung James] Univ So Calif, Keck Sch Med, So Calif Res Ctr Alcohol Liver & Pancreat Dis & C, Los Angeles, CA 90033 USA. [Machida, Keigo; Duan, Lewei; Liu, Helene Minyi; Ou, Jing-hsiung James; Lai, Michael M. -C.] Univ So Calif, Keck Sch Med, Dept Mol Microbiol & Immunol, Los Angeles, CA 90033 USA. [Tsukamoto, Hidekazu; Govindarajan, Sugantha] Univ So Calif, Keck Sch Med, Dept Pathol, Los Angeles, CA 90033 USA. [Tsukamoto, Hidekazu] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90033 USA. [Raye, Ratna] St Louis Univ, Dept Pathol, St Louis, MO 63103 USA. [Seki, Ekihiro] Univ Calif San Diego, La Jolla, CA 92093 USA. [Deshaies, Raymond] CALTECH, Howard Hughes Med Inst, Pasadena, CA 91125 USA. [Deshaies, Raymond] CALTECH, Div Biol, Pasadena, CA 91125 USA. [Miyake, Kensuke] Univ Tokyo, Inst Med Sci, Tokyo 1088639, Japan. [Lai, Michael M. -C.] Natl Cheng Kung Univ, Dept Microbiol Immunol, Tainan 701, Taiwan. RP Machida, K (reprint author), Univ So Calif, Keck Sch Med, So Calif Res Ctr Alcohol Liver & Pancreat Dis & C, 2011 Zonal Ave, Los Angeles, CA 90033 USA. EM kmachida@usc.edu RI Lai, Michael Ming-Chao/I-7001-2012; Deshaies, Raymond/B-8354-2014; Seki, Ekihiro/K-2481-2016 OI Deshaies, Raymond/0000-0002-3671-9354; LIU, HELENE MINYI/0000-0003-4837-5373 FU pilot project; National Institute on Alcohol Abuse and Alcoholism/National Institutes of Health (NIAAA/NIH) [P50 AA011999, AI 40038, CA123328, CA108302]; Medical Research Service of the Veterans Administration FX We thank Qing-gao Deng, Jiaohong Wang, Sean Vorah, and Jeffrey Huang (University of Southern California) for mouse experiments; Michael Karin (University of California at San Diego) for discussions; Paul Robson (Genome Institute of Singapore, Immunos, Singapore) for Nanog-promoter luciferase construct; Steven Weinman (University of Texas) for suggestions; and Moli Chen and Alex Trana for histological service. The study was supported by pilot project funding; the Animal and Morphology Cores of the Southern California Research Center for ALPD & Cirrhosis (P50 AA011999) funded by the National Institute on Alcohol Abuse and Alcoholism/National Institutes of Health (NIAAA/NIH); NIH Grants AI 40038, CA123328, and CA108302; and the Medical Research Service of the Veterans Administration. NR 34 TC 117 Z9 129 U1 0 U2 7 PU NATL ACAD SCIENCES PI WASHINGTON PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA SN 0027-8424 J9 P NATL ACAD SCI USA JI Proc. Natl. Acad. Sci. U. S. A. PD FEB 3 PY 2009 VL 106 IS 5 BP 1548 EP 1553 DI 10.1073/pnas.0807390106 PG 6 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 403HV UT WOS:000263074600048 PM 19171902 ER PT J AU Perez, VI Van Remmen, H Bokov, A Epstein, CJ Vijg, J Richardson, A AF Perez, Viviana I. Van Remmen, Holly Bokov, Alex Epstein, Charles J. Vijg, Jan Richardson, Arlan TI The overexpression of major antioxidant enzymes does not extend the lifespan of mice SO AGING CELL LA English DT Editorial Material DE aging; antioxidant enzymes; transgenic and knockout mice ID MANGANESE SUPEROXIDE-DISMUTASE; ADULT DROSOPHILA-MELANOGASTER; UBIQUITOUS OVEREXPRESSION; TRANSGENIC MICE; EXPRESSION; CATALASE AB We evaluated the effect of overexpressing antioxidant enzymes on the lifespans of transgenic mice that overexpress copper zinc superoxide dismutase (CuZnSOD), catalase, or combinations of either CuZnSOD and catalase or CuZnSOD and manganese superoxide dismutase (MnSOD). Our results show that the overexpression of these major antioxidant enzymes, which are known to scavenge superoxide and hydrogen peroxide in the cytosolic and mitochondrial compartments, is insufficient to extend lifespan in mice. C1 [Perez, Viviana I.; Van Remmen, Holly; Bokov, Alex; Richardson, Arlan] Univ Texas Hlth Sci Ctr San Antonio, Barshop Inst Longev & Aging Studies, San Antonio, TX 78229 USA. [Perez, Viviana I.; Van Remmen, Holly; Richardson, Arlan] Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA. [Van Remmen, Holly; Bokov, Alex] Univ Texas Hlth Sci Ctr San Antonio, Dept Physiol, San Antonio, TX 78229 USA. [Van Remmen, Holly; Richardson, Arlan] S Texas Vet Hlth Care Syst, Ctr Geriatr Res Educ & Clin, San Antonio, TX 78229 USA. [Epstein, Charles J.] Univ Calif San Francisco, Inst Human Genet, Sch Med, San Francisco, CA 94143 USA. [Epstein, Charles J.] Univ Calif San Francisco, Dept Pediat, Sch Med, San Francisco, CA 94143 USA. [Vijg, Jan] Albert Einstein Coll Med, Dept Genet, Bronx, NY 10461 USA. RP Richardson, A (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Barshop Inst Longev & Aging Studies, Texas Res Pk Campus,15355 Lambda Dr, San Antonio, TX 78245 USA. EM richardsona@uthscsa.edu FU NIA NIH HHS [1P30-AG-13319, P01 AG019316, P01-AG-19316, P30 AG013319, R37 AG026557, R37-AG026557] NR 18 TC 145 Z9 145 U1 1 U2 13 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1474-9718 J9 AGING CELL JI Aging Cell PD FEB PY 2009 VL 8 IS 1 BP 73 EP 75 DI 10.1111/j.1474-9726.2008.00449.x PG 3 WC Cell Biology; Geriatrics & Gerontology SC Cell Biology; Geriatrics & Gerontology GA 400ON UT WOS:000262877900008 PM 19077044 ER PT J AU Simpson, TL Saxon, AJ Meredith, CW Malte, CA McBride, B Ferguson, LC Gross, CA Hart, KL Raskind, M AF Simpson, Tracy L. Saxon, Andrew J. Meredith, Charles W. Malte, Carol A. McBride, Brittney Ferguson, Laura C. Gross, Christopher A. Hart, Kim L. Raskind, Murray TI A Pilot Trial of the Alpha-1 Adrenergic Antagonist, Prazosin, for Alcohol Dependence SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH LA English DT Article DE Noradrenergic; Prazosin; Alcohol Dependence; Human Clinical Trial ID RANDOMIZED CONTROLLED-TRIAL; POSTTRAUMATIC-STRESS-DISORDER; PLACEBO-CONTROLLED TRIAL; DISULFIRAM TREATMENT; DOUBLE-BLIND; GENDER-DIFFERENCES; DRINKING; ETHANOL; NOREPINEPHRINE; ABSTINENCE AB Current medications for alcohol dependence (AD) show only modest efficacy. None target brain noradrenergic pathways. Theory and preclinical evidence suggest that noradrenergic circuits may be involved in alcohol reinforcement and relapse. We therefore tested the alpha-1 adrenergic receptor antagonist, prazosin, as a pharmacotherapy for AD. We randomized 24 participants with AD but without posttraumatic stress disorder to receive either prazosin or placebo in a 6-week, double-blind pilot study. Medication was titrated to a target dose of 4 mg QAM, 4 mg QPM, and 8 mg QHS by the end of week 2. Participants received 5 medical management treatment sessions. Participants were reminded 3 times each day via a text pager to take medications and to call a telephone monitoring system once daily to provide self-reports of alcohol consumption and craving, the primary outcome measures. Results were analyzed using mixed linear regression adjusted for drinking days per week at baseline and week number. Twenty of the 24 (83%) subjects completed. Among the completers, the prazosin group reported fewer drinking days per week than the placebo group during the final 3 weeks of the study. Since only 1 woman was randomized to placebo and only three women completed the trial, the following results focus on the 17 male completers. The prazosin group reported fewer drinking days per week and fewer drinks per week during the final 3 weeks of the study; average total number of drinking days for the placebo group 5.7 (SEM 1.9) versus 0.9 (SEM 0.5) for the prazosin group, and average total number of drinks 20.8 (SEM 6.5) for the placebo group versus 2.6 (SEM 1.3) for the prazosin group. Rates of adverse events were equivalent across conditions. Prazosin holds promise as a pharmacologic treatment for AD and deserves further evaluation in a larger controlled trial. C1 [Simpson, Tracy L.; Saxon, Andrew J.; Malte, Carol A.; McBride, Brittney] Univ Washington, Ctr Excellence Substance Abuse Treatment Educ, Seattle, WA 98195 USA. [Simpson, Tracy L.; Meredith, Charles W.; Ferguson, Laura C.; Gross, Christopher A.; Hart, Kim L.; Raskind, Murray] Univ Washington, Mental Illness Res Educ & Clin Ctr, Seattle, WA 98195 USA. Univ Washington, VA Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. [Simpson, Tracy L.; Saxon, Andrew J.; Meredith, Charles W.; Ferguson, Laura C.; Gross, Christopher A.; Raskind, Murray] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. RP Simpson, TL (reprint author), 1660 S Columbian Way,116-ATC-S, Seattle, WA 98108 USA. EM Tracy.Simpson@va.gov FU University of Washington's Alcohol and Drug Abuse Institute FX The funding for this study was provided by the VA Puget Sound Health Care System, Seattle, Washington Center of Excellence in Substance Abuse Treatment and Education and by a grant from the University of Washington's Alcohol and Drug Abuse Institute. The authors wish to thank the following individuals for the invaluable assistance with this project: Lynne Hyerle, M.A., Norah Sullivan, ARNP, David Hoff, PA, Craig Jaffe, MD, and Kathleen Ang Lee, MD. NR 63 TC 72 Z9 73 U1 1 U2 6 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0145-6008 J9 ALCOHOL CLIN EXP RES JI Alcoholism (NY) PD FEB PY 2009 VL 33 IS 2 BP 255 EP 263 DI 10.1111/j.1530-0277.2008.00807.x PG 9 WC Substance Abuse SC Substance Abuse GA 397KS UT WOS:000262662200007 PM 18945226 ER PT J AU Suhrie, EM Hanlon, JT Jaffe, EJ Sevick, MA Ruby, CM Aspinall, SL AF Suhrie, Erin M. Hanlon, Joseph T. Jaffe, Emily J. Sevick, Mary Ann Ruby, Christine M. Aspinall, Sherrie L. TI Impact of a Geriatric Nursing Home Palliative Care Service on Unnecessary Medication Prescribing SO AMERICAN JOURNAL OF GERIATRIC PHARMACOTHERAPY LA English DT Article DE palliative care; unnecessary drug use; Medication Appropriateness Index; geriatrics ID ADVERSE DRUG EVENTS; OLDER-PEOPLE; HOSPICE CARE; APPROPRIATENESS; POLYPHARMACY; MANAGEMENT; QUALITY; LIFE; THERAPY; PAIN AB Background: There is a lack of studies concerning improvement of medication use in palliative care patients in nursing homes. Objective: This study was conducted to evaluate whether a geriatric palliative care team reduced unnecessary medication prescribing for elderly veterans residing in a nursing home. Methods: This was a retrospective, descriptive study of patients who died while residing in a geriatric palliative care unit between August 1, 2005, and July 31, 2007. Prescribed medications were evaluated using the Unnecessary Drug Use Measure, which contains 3 items from the Medication Appropriateness Index concerning lack of indication, lack of effectiveness, and therapeutic duplication. This measure was applied at 2 time points: on transfer/admission to the palliative care unit and at the last 30-day pharmacist medication review before death. Paired t tests and McNemar tests were used to compare medication use at these 2 points. Results: Eighty-nine patients were included in the study. The majority were male (97.8%) and white (78.7%), with a mean (SD) age of 79.7 (7.8) years. The median length of stay on the unit was 39.0 days, and the mean number of chronic medical conditions was 8.4 (4.3). At baseline, the mean number of scheduled medications was 9.7 (4.3). The number Of unnecessary medications per patient decreased from a mean of 1.7 (1.5) at admission to 0.6 (0.8) at closeout (P = 0.003). The decrease was seen in all 3 categories of the Unnecessary Drug Use Measure. Conclusions: The geriatric palliative care team was associated with a reduction in the number of unnecessary medications prescribed for older veterans in this nursing home. Future studies should evaluate the impact of decreasing unnecessary prescribing on clinical outcomes such as adverse drug reactions. (Am J Geriatr Pharmacother. 2009;7:20-25) (C) 2009 Excerpta Medica Inc. C1 [Hanlon, Joseph T.; Sevick, Mary Ann; Aspinall, Sherrie L.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA 15206 USA. [Suhrie, Erin M.] VA Pittsburgh Healthcare Syst, Dept Pharm, Pittsburgh, PA 15206 USA. [Hanlon, Joseph T.; Ruby, Christine M.; Aspinall, Sherrie L.] Univ Pittsburgh, Sch Pharm, Dept Pharm & Therapeut, Pittsburgh, PA 15261 USA. [Hanlon, Joseph T.; Jaffe, Emily J.; Sevick, Mary Ann] VA Pittsburgh Healthcare Syst, Ctr Geriatr Res Educ & Clin, Pittsburgh, PA 15206 USA. [Hanlon, Joseph T.; Jaffe, Emily J.; Ruby, Christine M.] Univ Pittsburgh, Sch Med, Dept Med, Div Geriatr & Gerontol, Pittsburgh, PA USA. [Sevick, Mary Ann] Univ Pittsburgh, Sch Med, Dept Med, Div Gen Internal Med, Pittsburgh, PA USA. [Sevick, Mary Ann] Univ Pittsburgh, Grad Sch Publ Hlth, Pittsburgh, PA USA. [Aspinall, Sherrie L.] Hines VA Med Ctr, VA Ctr Medicat Safety, Hines, IL USA. RP Aspinall, SL (reprint author), VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot 151CH, 7180 Highland Dr, Pittsburgh, PA 15206 USA. EM sherrie.aspinall@va.gov FU National Institutes of Health [P30AGO24827, ROIAGO27017]; Veterans Affairs Health Services Research and Development [IIR-06-062] FX This study was supported in part by National Institutes of Health grants P30AGO24827 and ROIAGO27017 and Veterans Affairs Health Services Research and Development grant IIR-06-062 to Dr. Hanlon. The authors thank Yazan Rournard, NIS, MBA, for statistical support. NR 21 TC 18 Z9 19 U1 1 U2 7 PU EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC PI BRIDGEWATER PA 685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA SN 1543-5946 J9 AM J GERIATR PHARMAC JI Am. J. Geriatr. Pharmacother. PD FEB PY 2009 VL 7 IS 1 BP 20 EP 25 DI 10.1016/j.amjopharm.2009.02.001 PG 6 WC Geriatrics & Gerontology; Pharmacology & Pharmacy SC Geriatrics & Gerontology; Pharmacology & Pharmacy GA 413RK UT WOS:000263810000003 PM 19281937 ER PT J AU Spira, AP Stone, K Beaudreau, SA Ancoli-Israel, S Yaffe, K AF Spira, Adam P. Stone, Katie Beaudreau, Sherry A. Ancoli-Israel, Sonia Yaffe, Kristine TI Anxiety Symptoms and Objectively Measured Sleep Quality in Older Women SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY LA English DT Article; Proceedings Paper CT 60th Annual Meeting of the Gerontological-Society-of-America CY NOV 16-20, 2007 CL San Francisco, CA SP Gerontol Soc Amer DE Anxiety; sleep; older adults; depression; actigraphy ID OUTPATIENT ELECTIVE SURGERY; COGNITIVE FUNCTION; ADULTS; POPULATION; PREVALENCE; DISORDERS; LIFE; DISTURBANCES; INFLAMMATION; DEPRESSION AB Objectives: Few studies have examined the association between anxiety symptoms and objectively measured sleep quality in older adults. The authors determined this association in a large cohort of very old community-dwelling women. Design: Cross-sectional. Setting: Participants' homes, sites of the Study of Osteoporotic Fractures. Participants: Three thousand forty women (mean age: 83.6 years) enrolled in a prospective study of aging. Measurements: Participants completed the Goldberg Anxiety Scale (ANX), the 15-item Geriatric Depression Scale (GDS), and >= 3 nights of actigraphy-a method of measuring sleep by recording wrist movement with a device called an actigraph. Elevated anxiety symptoms were defined as ANX >= 6. Elevated depressive symptoms were defined as GDS >= 6. Results: Participants' mean ANX score was 1.4 (standard deviation: 2.2); 9.2% (N = 280) had ANX >= 6. Elevated anxiety symptoms were associated with greater odds of poor sleep efficiency (odds ratio [OR]: 1.73, 95% confidence interval [CI]: 1.34, 2.23) and time awake after sleep onset (OR: 1.64, 95% CI: 1.27, 2.11). Associations remained after adjustment for GDS >= 6, antianxiety medications, and other potential confounders (sleep efficiency OR: 1.50, 95% CI: 1.15, 1.97; time awake after sleep onset OR: 1.33, 95% CI: 1.01, 1.75). Anxiety symptoms were not associated with other sleep parameters. Conclusion: Findings suggest that elevated anxiety symptoms are independently associated with poor objectively measured sleep efficiency and elevated sleep fragmentation in very old women, after accounting for significant depressive symptoms, medical comorbidities, and use of antianxiety medications. (Am J Geriatr Psychiatry 2009; 17:136-143) C1 [Spira, Adam P.] Univ Calif San Francisco, Div Geriatr, San Francisco, CA 94143 USA. [Spira, Adam P.; Yaffe, Kristine] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA. [Spira, Adam P.; Yaffe, Kristine] San Francisco VA Med Ctr, San Francisco, CA USA. [Stone, Katie] Calif Pacific Med Ctr, Res Inst, San Francisco, CA USA. [Beaudreau, Sherry A.] Stanford Univ, Sch Med, Dept Psychiat & Behav Sci, Palo Alto, CA 94304 USA. [Beaudreau, Sherry A.] Sierra Pacific Mental Illness Res Educ & Clin Ctr, Vet Affairs Palo Alto Hlth Care Syst, Palo Alto, CA USA. [Ancoli-Israel, Sonia] Univ Calif San Diego, Dept Psychiat, San Diego, CA 92103 USA. [Ancoli-Israel, Sonia] San Diego Vet Affairs Healthcare Syst, San Diego, CA USA. [Yaffe, Kristine] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA. [Yaffe, Kristine] Univ Calif San Francisco, Dept Epidemiol, San Francisco, CA 94143 USA. RP Spira, AP (reprint author), Johns Hopkins Bloomberg Sch Publ Hlth, Dept Mental Hlth, 624 N Broadway,Hampton House,Room 794, Baltimore, MD 21205 USA. EM aspira@jhsph.edu FU NIA NIH HHS [R01 AG027576-24, R01 AG005407, 2 R01 AG027574-22A1, R01 AG005407-23, 2 R01 AG005394-22A1, R01 AG005394-24, T32 AG000212-14, R01 AG027574-24, R01 AG005394, AG05407, R01 AG027574, R01 AG027576-22, L30 AG030938, R01 AG027576, L30 AG030938-01, T32 AG000212, AG05394]; NIAMS NIH HHS [AR35582, R01 AR035582, R01 AR035584-21, R01 AR035584, R01 AR035583, AR35584, AR35583] NR 41 TC 22 Z9 23 U1 1 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1064-7481 J9 AM J GERIAT PSYCHIAT JI Am. J. Geriatr. Psychiatr. PD FEB PY 2009 VL 17 IS 2 BP 136 EP 143 DI 10.1097/JGP.0b013e3181871345 PG 8 WC Geriatrics & Gerontology; Gerontology; Psychiatry SC Geriatrics & Gerontology; Psychiatry GA 548DC UT WOS:000273938800006 PM 19155746 ER PT J AU Gehrman, PR Connor, DJ Martin, JL Shochat, T Corey-Bloom, J Ancoli-Israel, S AF Gehrman, Philip R. Connor, Donald J. Martin, Jennifer L. Shochat, Tamar Corey-Bloom, Jody Ancoli-Israel, Sonia TI Melatonin Fails to Improve Sleep or Agitation in Double-Blind Randomized Placebo-Controlled Trial of Institutionalized Patients With Alzheimer Disease SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY LA English DT Article DE Alzheimer; sleep; agitation; melatonin; dementia ID CIRCADIAN-RHYTHMS; NURSING-HOME; DEMENTIA AB Objectives: Patients with Alzheimer dementia often display both agitated behavior and poor sleep. Given that the disease is often associated with low endogenous levels of melatonin, exogenous melatonin administration may lead to improvements in sleep and agitation. Design: Randomized, placebo-controlled study. Setting: Nursing homes in San Diego, CA, metropolitan area. Participants: Subjects were patients with probable Alzheimer disease. Intervention: Melatonin (8.5 mg immediate release and 1.5 mg sustained release) (N = 24) or placebo (N = 17) administered at 10: 00 P. M. for 10 consecutive nights. The protocol consisted of baseline (3 days), treatment (10 days), and posttreatment (5 days) phases. Measurements: Sleep was measured continuously using actigraphy. Agitation was rated using both the Agitated Behavior Rating Scale and the Cohen-Mansfield Agitation Inventory. Treatment effects were examined both across the 24-hr day and separately by nursing shift. Results: There were no significant effects of melatonin, compared with placebo, on sleep, circadian rhythms, or agitation. Conclusion: This study failed to find a beneficial effect of exogenous melatonin, consistent with a number of other studies. The lack of efficacy may be related to the absence of a true treatment effect or to the superphysiologic dose of melatonin used. (Am J Geriatr Psychiatry 2009; 17:166-169) C1 [Gehrman, Philip R.] Hosp Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA. [Connor, Donald J.] Cleo Roberts Ctr Clin Res, Sun Hlth Res Inst, Sun City, AZ USA. [Martin, Jennifer L.] Geriatr Res Educ & Clin Ctr, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Martin, Jennifer L.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Shochat, Tamar] Univ Haifa, Dept Nursing, IL-31999 Haifa, Israel. [Corey-Bloom, Jody; Ancoli-Israel, Sonia] Vet Affairs San Diego Healthcare Syst, San Diego, CA USA. [Corey-Bloom, Jody] Univ Calif San Diego, Dept Neurosci, San Diego, CA 92103 USA. [Ancoli-Israel, Sonia] Univ Calif San Diego, Dept Psychiat, San Diego, CA 92103 USA. RP Ancoli-Israel, S (reprint author), Univ Calif San Diego, Dept Psychiat, 9500 Gilman Dr,Mail Code 0603, La Jolla, CA 92093 USA. EM sancoliisrael@ucsd.edu FU NIA [AG08415, P50 AG05131, K23 AG028452]; Research Service of the Veterans Affairs San Diego Healthcare System FX This study was supported by NIA AG08415 (to SAI), P50 AG05131, NIA K23 AG028452 (to JLM) and the Research Service of the Veterans Affairs San Diego Healthcare System. NR 10 TC 63 Z9 67 U1 2 U2 9 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1064-7481 J9 AM J GERIAT PSYCHIAT JI Am. J. Geriatr. Psychiatr. PD FEB PY 2009 VL 17 IS 2 BP 166 EP 169 DI 10.1097/JGP.0b013e318187de18 PG 4 WC Geriatrics & Gerontology; Gerontology; Psychiatry SC Geriatrics & Gerontology; Psychiatry GA 548DC UT WOS:000273938800009 PM 19155748 ER PT J AU Ullian, ME Beck, CN Walker, LP Fitzgibbon, WR Morinelli, TA AF Ullian, Michael E. Beck, C. Nicole Walker, Linda P. Fitzgibbon, Wayne R. Morinelli, Thomas A. TI Thiol Antioxidants Regulate Angiotensin II AT1 and Arginine Vasopressin V1 Receptor Functions Differently in Vascular Smooth Muscle Cells SO AMERICAN JOURNAL OF HYPERTENSION LA English DT Article ID EPIDERMAL-GROWTH-FACTOR; PROTEIN-KINASE ACTIVATION; EXTRACELLULAR DOMAINS; DISULFIDE BRIDGES; OXIDATIVE STRESS; LIGAND-BINDING; RAT; IDENTIFICATION; RESIDUES; TRANSACTIVATION AB BACKGROUND We compared the effects of the sulfhydryl-containing (thiol) antioxidant dithiothreitol (DTT), which disrupts disulfide bonds, on cell signaling through angiotensin II (Angll) Type 1 receptors (AT1Rs) and arginine vasopressin (AVP)V1 receptors (V1Rs). The AT1R contains two extracellular disulfides bonds but its ligand contains none, whereas the V1R contains no extracellular disufides bonds but its ligand contains 1. METHODS We measured radioligand binding, intracellular calcium responses, and extracellular signal-regulated kinase phosphorylation in cultured rat aortic vascular smooth muscle cells and alterations in urine osmolality in intact rats. RESULTS Preincubation of cells with DTT, a maneuver designed to target receptor disulfides, resulted in concentration-dependent decreases in specific (125)I-Angll binding to AT1Rs and acute angiotensin-stimulated intracellular calcium mobilization but no decreases in specific (125)I-AVP binding to V1Rs or AVP-stimulated intracellular calcium mobilization. In contrast, preincubation of the ligands with DTT followed by acute exposure to the cells, a maneuver designed to target ligand disulfides, blunted calcium mobilization to AVP robustly but to Angll only minimally. In intact rats, the increase in urine osmolality caused by subcutaneous injection with the AVP analogue desmopressin was significantly diminished when the analogue was preincubated with an excess of DTT. CONCLUSION DTT inhibits cell signaling to Angll AT1Rs and AVPV1Rs, at least in part through disruption of disulfide linkages, but the pattern of response depends upon whether disulfides of ligand or receptor are targeted. C1 [Ullian, Michael E.; Beck, C. Nicole; Walker, Linda P.; Fitzgibbon, Wayne R.; Morinelli, Thomas A.] Med Univ S Carolina, Ralph H Johnson Vet Adm Hosp, Dept Med, Div Nephrol, Charleston, SC 29425 USA. RP Ullian, ME (reprint author), Med Univ S Carolina, Ralph H Johnson Vet Adm Hosp, Dept Med, Div Nephrol, Charleston, SC 29425 USA. EM ullianme@musc.edu FU Dialysis Clinic Incorporation, Nashville, TN FX These results were reported in preliminary form at the annual meetings of the American Society of Nephrology in San Diego, CA (November 2006) and in San Francisco, CA (November 2007). These studies were supported by funds from Dialysis Clinic Incorporation, Nashville, TN. NR 29 TC 3 Z9 3 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0895-7061 J9 AM J HYPERTENS JI Am. J. Hypertens. PD FEB PY 2009 VL 22 IS 2 BP 221 EP 227 DI 10.1038/ajh.2008.323 PG 7 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 395PZ UT WOS:000262537300019 PM 19039312 ER PT J AU Risa, KJ McAndrew, JM Muder, RR AF Risa, Kathleen J. McAndrew, Janet M. Muder, Robert R. TI Influenza outbreak management on a locked behavioral health unit SO AMERICAN JOURNAL OF INFECTION CONTROL LA English DT Article ID CARE WORKERS; VACCINATION; DISORDERS; SERVICES AB Background: In January 2006, 8 patients on a locked behavioral health (BH) ward were identified with influenza-like illness (ILI) based on syndrome of fever. malaise, myalgia, cough, and rhinitis. Two patients initially had rapid antigen testing positive for influenza and confirmed by polymerase chain reaction. All patients present on the ward (N = 26) had been ordered influenza immunizations 6 weeks earlier: 46% (12/26) were immunized, 42% (11/26) refused, 12% (3126) had no record of immunization. All direct care staff who worked on the unit during the outbreak had been offered immunizations in the fall: 55% (22/40) were immunized. Methods: When first symptoms were identified, provider notified infection control nurse and hospital epidemiologist, who instituted control measures: patients were confined to unit, unit was closed to admissions, nonimmunized asymptomatic patients were offered immunization, temperatures were recorded every 4 hours, and nonimmunized providers were offered immunizations and prophylaxis. Patients with ILI were either admitted to acute care and placed in Droplet/Contact Precautions until afebrile for 48 hours or managed on the unit with modified isolation. All patients remaining on the unit were instructed in hand hygiene and respiratory etiquette: asymptomatic patients were offered oseltamivir phosphate prophylaxis; and previously nonimmunized patients and staff were again offered the vaccine. Results: Twenty-six patients and 28 staff were on the unit during the outbreak. Eight patients and 8 staff members reported ILI within 5 days. Of the ill patients, 3 had been immunized, 5 had not (2 refused, 3 reason unclear presumed to have refused), and 4 were admitted to acute care and placed in Droplet/Contact Precautions until asymptomatic for 48 hours. Of 22 patients who remained on the unit. 4 were symptomatic: 18 asymptomatic patients took prophylaxis, and I refused 8 (89%) patients who had earlier refused vaccine were immunized. Of the 40 staff members, 55% (22/40) were immunized, and 20% (8/40) were symptomatic (all presumptive, encouraged to remain off duty). Fifty percent (4/8) of symptomatic staff had been immunized. After 7 days, no new cases had been identified, and the unit was reopened to admissions. No ill effects resulted from the prophylaxis. Conclusion: Prompt detection of ILI and institution of control measures effectively contained the outbreaks the relatively high immunization rates among both patients and staff helped curtail spread. Refusal of immunization is a long-standing problem among BH patients and staff. Our study shows importance of immunization in preventing outbreaks in inpatient BH settings. Recommendations included development of more aggressive immunization campaign for patients and staff who historically refuse and continued high priority for provider vigilance in immunization campaign and surveillance for symptoms. (Am J Infect Control 2009;37:76-8.) C1 [Muder, Robert R.] VA Pittsburgh Healthcare Syst, Infect Dis Sect, Pittsburgh, PA 15240 USA. RP Muder, RR (reprint author), VA Pittsburgh Healthcare Syst, Infect Dis Sect, Univ Dr C, Pittsburgh, PA 15240 USA. EM Robert.Muder@va.gov NR 13 TC 1 Z9 1 U1 0 U2 1 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0196-6553 J9 AM J INFECT CONTROL JI Am. J. Infect. Control PD FEB PY 2009 VL 37 IS 1 BP 76 EP 78 DI 10.1016/j.ajic.2008.05.008 PG 3 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 409BI UT WOS:000263480800013 PM 18945518 ER PT J AU Khurana, SR Bamer, AM Turner, AP Wadhwani, RV Bowen, JD Leipertz, SL Haselkorn, JK AF Khurana, Seema R. Bamer, Alyssa M. Turner, Aaron P. Wadhwani, Rohini V. Bowen, James D. Leipertz, Steve L. Haselkorn, Jodie K. TI The Prevalence of Overweight and Obesity in Veterans with Multiple Sclerosis SO AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION LA English DT Article DE Multiple Sclerosis; Body Mass Index; Obesity; Overweight; Health Status ID BODY-MASS INDEX; SELF-REPORTED HEIGHT; UNITED-STATES; GENDER-DIFFERENCES; DISEASE; EXERCISE; WEIGHT; ADULTS; RISK; POPULATION AB Objectives: To estimate the prevalence and factors associated with overweight and obesity in veterans with multiple sclerosis (MS) enrolled in the Veterans Health Administration (VA) and to compare the prevalence in this group with gender-specific published rates for the general population of veterans receiving outpatient care at VA medical facilities. Design: Cross-sectional cohort study linking electronic medical record information to mailed survey from 1999 to 2004. A total of 4703 veterans with MS enrolled in VA who returned questionnaires as part of two cross-sectional studies. Main outcome measures included body mass index, demographic information, Veteran RAND 36-item Health Survey, frequency of physical exercise, and other health conditions. Results: Overall, 28% of female and 42.8% of male veterans with MS were overweight. Another 25% of women and 21.2% of male veterans met the criteria for obesity. Compared with a historical cohort of veterans enrolled in the VA, veterans with MS had a slightly higher adjusted prevalence of overweight than did veterans in general (42.3% vs. 39.6%, respectively) but a lower adjusted prevalence of obesity (20.1% vs. 33.1%). In adjusted logistic regression, age, smoking, and lower levels of pain were associated with a lower likelihood of overweight or obesity. Being male, married, employed and having arthritis and diabetes were associated with a greater likelihood of overweight or obesity. Conclusions: Overweight and obesity are a problem for more than 60% of veterans with MS in the VA. Screening for overweight and obesity should be done routinely. Interventions to prevent and manage excessive weight in individuals with MS should be developed and evaluated. C1 [Turner, Aaron P.] VA Puget Sound Hlth Care Syst, Rehabil Care Serv, Seattle, WA 98108 USA. [Khurana, Seema R.] Univ Miami, Dept Rehabil Med, Coral Gables, FL 33124 USA. [Bamer, Alyssa M.; Turner, Aaron P.; Wadhwani, Rohini V.; Haselkorn, Jodie K.] Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA. [Turner, Aaron P.; Leipertz, Steve L.; Haselkorn, Jodie K.] VA MS Ctr Excellence W, Seattle, WA USA. [Bowen, James D.] Evergreen Hosp, Multiple Sclerosis Ctr, Washington, DC USA. RP Turner, AP (reprint author), VA Puget Sound Hlth Care Syst, Rehabil Care Serv, S-117,1660 S Columbian Way, Seattle, WA 98108 USA. OI Turner, Aaron/0000-0001-6897-8003 FU Department of Veterans Affairs Rehabilitation Research and Development Service Career Development Award [B4927W]; VA Center of Excellence in Substance Abuse Treatment and Education; VA MS Center of Excellence West; VA Office of Quality and Performance; National Institute on Disability and Rehabilitation Research, Department of Education [H13313031129] FX This research was supported by Department of Veterans Affairs Rehabilitation Research and Development Service Career Development Award (B4927W) to Aaron Turner, Phl). Additional support was provided by the VA Center of Excellence in Substance Abuse Treatment and Education, the VA MS Center of Excellence West, and the VA Office of Quality and Performance. Additional support was also provided by a grant from the National Institute on Disability and Rehabilitation Research, Department of Education (Grant #H13313031129). NR 35 TC 32 Z9 32 U1 0 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0894-9115 J9 AM J PHYS MED REHAB JI Am. J. Phys. Med. Rehabil. PD FEB PY 2009 VL 88 IS 2 BP 83 EP 91 DI 10.1097/PHM.0b013e318194f8b5 PG 9 WC Rehabilitation; Sport Sciences SC Rehabilitation; Sport Sciences GA 398NX UT WOS:000262739900001 PM 19169174 ER PT J AU Kurahashi, K Sawa, T Ota, M Kajikawa, O Hong, K Martin, TR Wiener-Kronish, JP AF Kurahashi, Kiyoyasu Sawa, Teiji Ota, Maria Kajikawa, Osamu Hong, Keelung Martin, Thomas R. Wiener-Kronish, Jeanine P. TI Depletion of phagocytes in the reticuloendothelial system causes increased inflammation and mortality in rabbits with Pseudomonas aeruginosa pneumonia SO AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY LA English DT Article DE counterregulatory response; bacterial clearance; macrophages ID TUMOR-NECROSIS-FACTOR; RETICULO-ENDOTHELIAL SYSTEM; CONTINUOUS MECHANICAL VENTILATION; ALVEOLAR EPITHELIAL INJURY; NOSOCOMIAL PNEUMONIA; FACTOR-ALPHA; HOST-DEFENSE; NITRIC-OXIDE; IN-VITRO; UNANESTHETIZED SHEEP AB Kurahashi K, Sawa T, Ota M, Kajikawa O, Hong K, Martin TR, Wiener-Kronish JP. Depletion of phagocytes in the reticuloendothelial system causes increased inflammation and mortality in rabbits with Pseudomonas aeruginosa pneumonia. Am J Physiol Lung Cell Mol Physiol 296: L198-L209, 2009. First published November 21, 2008; doi:10.1152/ajplung.90472.2008.-Phagocytes of the reticuloendothelial system are important in clearing systemic infection; however, the role of the reticuloendothelial system in the response to localized infection is not well-documented. The major goals of this study were to investigate the roles of phagocytes in the reticuloendothelial system in terms of bacterial clearance and inflammatory modulation in sepsis caused by Pseudomonas pneumonia. Macrophages in liver and spleen were depleted by administering liposome encapsulated dichloromethylene diphosphonate (clodronate) intravenously 36 h before the instillation of Pseudomonas aeruginosa into the lungs of anesthetized rabbits. Blood samples were analyzed for bacteria and cytokine concentrations. Lung injury was assessed by the bidirectional flux of albumin and by wet-to-dry weight ratios. Blood pressure and cardiac outputs decreased more rapidly and bacteremia occurred earlier in the clodronate-treated rabbits compared with the nondepleted rabbits. Plasma TNF-alpha (1.08 +/- 0.54 vs. 0.08 +/- 0.02 ng/ml) and IL-8 (6.8 +/- 1.5 vs. 0.0 +/- 0.0 ng/ml) were higher in the depleted rabbits. The concentration of IL-10 in liver of the macrophage-depleted rabbits was significantly lower than in normal rabbits at 5 h. Treatment of macrophage-depleted rabbits with intravenous IL-10 reduced plasma proinflammatory cytokine concentrations and reduced the decline in blood pressure and cardiac output. These results show that macrophages in the reticuloendothelial system have critical roles in controlling systemic bacteremia and reducing systemic inflammation, thereby limiting the systemic effects of a severe pulmonary bacterial infection. C1 [Kurahashi, Kiyoyasu] Yokohama City Univ, Grad Sch Med, Dept Anesthesiol & Crit Care Med, Kanazawa Ku, Yokohama, Kanagawa 2360004, Japan. [Kurahashi, Kiyoyasu; Sawa, Teiji; Ota, Maria] Univ Calif San Francisco, Dept Anesthesia, San Francisco, CA 94143 USA. [Kurahashi, Kiyoyasu; Kajikawa, Osamu; Martin, Thomas R.] Univ Washington, Sch Med, Med Res Serv, Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA. [Kurahashi, Kiyoyasu; Kajikawa, Osamu; Martin, Thomas R.] Univ Washington, Sch Med, Dept Med, Div Pulm & Crit Care Med, Seattle, WA 98195 USA. [Hong, Keelung] Univ Calif San Francisco, Dept Biopharmaceut Sci, San Francisco, CA 94143 USA. [Wiener-Kronish, Jeanine P.] Univ Calif San Francisco, Dept Med, Dept Anesthesia & Perioperat Care, San Francisco, CA 94143 USA. [Wiener-Kronish, Jeanine P.] Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94143 USA. RP Kurahashi, K (reprint author), Yokohama City Univ, Grad Sch Med, Dept Anesthesiol & Crit Care Med, Kanazawa Ku, 3-9 Fukuura, Yokohama, Kanagawa 2360004, Japan. EM kiyok@med.yokohama-cu.ac.jp FU National Institutes of Health (NIH) [HL-49810, HL-55980, HL-30542, AI-29103, GM-37696, HL-073996]; Yokohama Foundation for Advancement of Medical Science; Yokohama Academic Foundation FX This study was supported, in part, by the National Institutes of Health (NIH) Grants HL-49810 and HL-55980 (to J.P. Wiener-Kronish), the NIH Grants HL-30542, AI-29103, GM-37696, and HL-073996 (to T. R. Martin), the Yokohama Foundation for Advancement of Medical Science (to K. Kurahashi), and the Yokohama Academic Foundation (to K. Kurahashi). NR 69 TC 10 Z9 10 U1 0 U2 0 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 1040-0605 J9 AM J PHYSIOL-LUNG C JI Am. J. Physiol.-Lung Cell. Mol. Physiol. PD FEB PY 2009 VL 296 IS 2 BP L198 EP L209 DI 10.1152/ajplung.90472.2008 PG 12 WC Physiology; Respiratory System SC Physiology; Respiratory System GA 399CP UT WOS:000262778300007 PM 19028978 ER PT J AU Ricono, JM Wagner, B Gorin, Y Arar, M Kazlauskas, A Choudhury, GG Abboud, HE AF Ricono, Jill M. Wagner, Brent Gorin, Yves Arar, Mazen Kazlauskas, Andrius Choudhury, Goutam Ghosh Abboud, Hanna E. TI PDGF receptor-beta modulates metanephric mesenchyme chemotaxis induced by PDGF AA SO AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY LA English DT Article DE reactive oxygen species; calcium ID CARDIAC SARCOPLASMIC-RETICULUM; SMOOTH-MUSCLE-CELLS; PROTEASE-ACTIVATED LIGAND; GROWTH-FACTOR RECEPTORS; AKT/PROTEIN KINASE-B; SIGNAL-TRANSDUCTION; MESANGIAL CELLS; ALPHA-RECEPTOR; HYDROGEN-PEROXIDE; OXYGEN RADICALS AB Ricono JM, Wagner B, Gorin Y, Arar M, Kazlauskas A, Choudhury GG, Abboud HE. PDGF receptor-beta modulates metanephric mesenchyme chemotaxis induced by PDGF AA. Am J Physiol Renal Physiol 296: F406-F417, 2009. First published November 19, 2008; doi:10.1152/ajprenal.90368.2008.-PDGF B chain or PDGF receptor (PDGFR)-beta-deficient (-/-) mice lack mesangial cells. To study responses of alpha- and beta-receptor activation to PDGF ligands, metanephric mesenchymal cells (MMCs) were established from embryonic day E11.5 wild-type (+/+) and -/- mouse embryos. PDGF BB stimulated cell migration in +/+ cells, whereas PDGF AA did not. Conversely, PDGF AA was chemotactic for -/- MMCs. The mechanism by which PDGFR-beta inhibited AA-induced migration was investigated. PDGF BB, but not PDGF AA, increased intracellular Ca(2+) and the production of reactive oxygen species (ROS) in +/+ cells. Transfection of -/- MMCs with the wild-type beta-receptor restored cell migration and ROS generation in response to PDGF BB and inhibited AA-induced migration. Inhibition of Ca(2+) signaling facilitated PDGF AA-induced chemotaxis in the wild-type cells. The antioxidant N-acetyl-L-cysteine (NAC) or the NADPH oxidase inhibitor diphenyleneiodonium (DPI) abolished the BB-induced increase in intracellular Ca(2+) concentration, suggesting that ROS act as upstream mediators of Ca(2+) in suppressing PDGF AA-induced migration. These data indicate that ROS and Ca(2+) generated by active PDGFR-beta play an essential role in suppressing PDGF AA-induced migration in +/+ MMCs. During kidney development, PDGFR beta-mediated ROS generation and Ca(2+) influx suppress PDGF AA-induced chemotaxis in metanephric mesenchyme. C1 [Wagner, Brent] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Div Nephrol, San Antonio, TX 78229 USA. [Ricono, Jill M.] Univ Texas Hlth Sci Ctr San Antonio, Inst Biotechnol, Dept Mol Med, San Antonio, TX 78229 USA. [Arar, Mazen] Univ Texas Hlth Sci Ctr San Antonio, Dept Pediat, San Antonio, TX 78229 USA. [Wagner, Brent; Choudhury, Goutam Ghosh; Abboud, Hanna E.] S Texas Vet Hlth Care Syst, Audie L Murphy Mem Hosp Div, San Antonio, TX USA. [Kazlauskas, Andrius] Harvard Univ, Sch Med, Schepens Eye Inst, Boston, MA USA. RP Wagner, B (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Div Nephrol, MC 7882,7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM wagnerb@uthscsa.edu OI Gorin, Yves/0000-0003-4048-6925 FU National Institute of Diabetes and Digestive and Kidney Diseases [DK-33665, DK-50190, DK-55815]; National American Heart Association; Juvenile Diabetes Research Foundation Regular Research Grant; National Kidney Foundation Young Investigator Award; National Kidney Foundation of South and Central Texas; Department of Veterans Affairs Merit Review grant; Department of Veterans Affairs Research Career Scientist Award; National Institutes of Health Loan Repayment Program; American Heart Association Fellow-to-Faculty Transition Award. FX These studies were supported by National Institute of Diabetes and Digestive and Kidney Diseases Grants DK-33665 (H. E. Abboud), DK-50190, and DK-55815 (G. G. Choudhury). Y. Gorin is supported through a Scientist Development Grant from the National American Heart Association, a Juvenile Diabetes Research Foundation Regular Research Grant, a National Kidney Foundation Young Investigator Award, and a National Kidney Foundation of South and Central Texas, Research Program Award. G. G. Choudbury is supported by a Department of Veterans Affairs Merit Review grant, Regular Research Grant from the Juvenile Diabetes Research Foundation, and by a Department of Veterans Affairs Research Career Scientist Award. B. Wagner is the recipient of the National Institutes of Health Loan Repayment Program, National Kidney Foundation Research Fellowship, National Kidney Foundation Jack C. Kent Third Year Research Fellowship, and an American Heart Association Fellow-to-Faculty Transition Award. NR 64 TC 9 Z9 9 U1 0 U2 2 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 1931-857X J9 AM J PHYSIOL-RENAL JI Am. J. Physiol.-Renal Physiol. PD FEB PY 2009 VL 296 IS 2 BP F406 EP F417 DI 10.1152/ajprenal.90368.2008 PG 12 WC Physiology; Urology & Nephrology SC Physiology; Urology & Nephrology GA 399EH UT WOS:000262782700022 PM 19019919 ER PT J AU Karlawish, J Rubright, J Casarett, D Cary, M Ten Have, T Sankar, P AF Karlawish, Jason Rubright, Jonathan Casarett, David Cary, Mark Ten Have, Thomas Sankar, Pamela TI Older Adults' Attitudes Toward Enrollment of Non-competent Subjects Participating in Alzheimer's Research SO AMERICAN JOURNAL OF PSYCHIATRY LA English DT Article ID INFORMED CONSENT; DISEASE PATIENTS; CLINICAL-TRIAL; PROXY CONSENT; DECISION; CAPACITY; ETHICS; HEALTH; VIEWS; RISK AB Objective: Research that seeks to enroll noncompetent patients with Alzheimer's disease without presenting any potential benefit to participants is the source of substantial ethical controversy. The authors used hypothetical Alzheimer's disease studies that included either a blood draw or a blood draw and lumbar puncture to explore older persons' attitudes on this question. Method: Face-to-face interviews were conducted with 538 persons age 65 and older. Questions explored participants' understanding of research concepts, their views on enrolling persons with Alzheimer's disease in research, and their preferences regarding having a proxy decision maker, granting advance consent, and granting their proxy leeway to override the participant's decision. Additional questions assessed altruism, trust, value for research, and perceptions of Alzheimer's disease. Results: The majority (83%) were willing to grant advance consent to a blood draw study, and nearly half (48%) to a blood draw plus lumbar puncture study. Most (96%) were willing to identify a proxy for research decision making, and most were willing to grant their proxy leeway over their advance consent: 81% for the blood draw study and 70% for the blood draw plus lumbar puncture study. Combining the preferences for advance consent and leeway, the proportion who would permit being enrolled in the blood draw and lumbar puncture studies, respectively, were 92% and 75%. Multivariate models showed that willingness to be enrolled in research was most strongly associated with a favorable attitude toward biomedical research. Conclusions: Older adults generally support enrolling noncompetent persons with Alzheimer's disease into research that does not present a benefit to subjects. Willingness to grant their proxy leeway over advance consent and a favorable attitude about biomedical research substantially explain this willingness. C1 [Karlawish, Jason] Univ Penn, Inst Aging, Philadelphia, PA 19104 USA. Univ Penn, Div Geriatr, Leonard Davis Inst Hlth Econ, Ctr Bioeth,Ctr Clin Epidemiol & Biostat,Alzheimer, Philadelphia, PA 19104 USA. Philadelphia VA Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA. RP Karlawish, J (reprint author), Univ Penn, Inst Aging, 3615 Chestnut St, Philadelphia, PA 19104 USA. EM jason.karlawish@uphs.upenn.edu FU NIMH [R01 MH-071643] FX Supported by NIMH grant R01 MH-071643, a Greenwall Faculty Scholars Award in Bioethics to Dr. Karlawish, and the Marian S. Ware Alzheimer Program. The authors thank James Beaver, Paige Brookstein, Maysa DeSousa, Lauren Fisher, Kristin Harkins, Margaret Rice, Samantha Schwartz, and Elizabeth Taylor for their assistance in data collection. NR 28 TC 32 Z9 32 U1 0 U2 7 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 0002-953X J9 AM J PSYCHIAT JI Am. J. Psychiat. PD FEB PY 2009 VL 166 IS 2 BP 182 EP 188 DI 10.1176/appi.ajp.2008.08050645 PG 7 WC Psychiatry SC Psychiatry GA 402RT UT WOS:000263031500011 PM 18923066 ER PT J AU Choi, JE Lee, SS Sunde, DA Huizar, I Haugk, KL Thannickal, VJ Vittal, R Plymate, SR Schnapp, LM AF Choi, Jung-Eun Lee, Sung-soon Sunde, Donald A. Huizar, Isham Haugk, Kathy L. Thannickal, Victor J. Vittal, Ragini Plymate, Stephen R. Schnapp, Lynn M. TI Insulin-like Growth Factor-I Receptor Blockade Improves Outcome in Mouse Model of Lung Injury SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Article DE insulin-like growth factor; lung injury; lung fibrosis ID RESPIRATORY-DISTRESS-SYNDROME; BRONCHOALVEOLAR LAVAGE FLUID; IGF-I; PULMONARY-FIBROSIS; SIGNALING PATHWAYS; MULTIPLE-MYELOMA; CROSS-TALK; CELLS; EXPRESSION; MICE AB Rationale: The insulin-like growth factor-I (IGF-I) pathway is an important determinant of survival and proliferation in many cells. However, little is known about the role of the IGF-I pathway in lung injury. We previously showed elevated levels of IGF-I in bronchoalveolar lavage fluid from patients with acute respiratory distress syndrome. Furthermore, immunodepletion of IGF from acute respiratory distress syndrome bronchoalveolar lavage increased fibroblast apoptosis. Objectives: We examined the effect of blockade of type 1 IGF tyrosine kinase receptor (IGF-IR) in a murine model of bleomycin-induced lung injury and fibrosis. Methods: Mice were treated with a monoclonal antibody against the IGF-I receptor (A12) or vehicle after intratracheal bleomycin instillation. Measurements and Main Results: Mice treated with All 2 antibody had significantly improved survival after bleomycin injury compared with control mice. Both groups of mice had a similar degree of fibrosis on days 7 and 14, but by Day 28 the A12-treated group had significantly less fibrosis. Delayed treatment with All 2 also resulted in decreased fibrosis. A12-treated mice had significantly decreased apoptotic cells on Day 28 compared with control mice. We confirmed that A12 treatment induced mouse lung fibroblast apoptosis in vitro. In addition, IGF-I increased lung fibroblast migration. The primary pathway activated by IGF-I in lung fibroblasts was the insulin receptor substrate-2/phosphatidylinositol 3-kinase/Akt axis. Conclusions: IGF-I regulated survival and migration of fibrogenic cells in the lung. Blockade of the IGF pathway increased fibroblast apoptosis and subsequent resolution of pulmonary fibrosis. Thus, IGF-IR may be a potential target for treatment of lung injury and fibrosis. C1 [Choi, Jung-Eun; Lee, Sung-soon; Sunde, Donald A.; Huizar, Isham; Schnapp, Lynn M.] Univ Washington, Harborview Med Ctr, Dept Med, Div Pulm & Crit Care Med, Seattle, WA 98104 USA. [Haugk, Kathy L.; Plymate, Stephen R.] Vet Affairs Puget Sound Hlth Care Syst, Ctr Geriatr Res Educ & Clin, Seattle, WA USA. [Thannickal, Victor J.; Vittal, Ragini] Univ Michigan, Med Ctr, Dept Med, Div Pulm Med, Ann Arbor, MI 48109 USA. RP Schnapp, LM (reprint author), Box 358052,815 Mercer St, Seattle, WA 98109 USA. EM lschnapp@u.washington.edu NR 36 TC 30 Z9 32 U1 0 U2 0 PU AMER THORACIC SOC PI NEW YORK PA 1740 BROADWAY, NEW YORK, NY 10019-4374 USA SN 1073-449X J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PD FEB 1 PY 2009 VL 179 IS 3 BP 212 EP 219 DI 10.1164/rccm.200802-228OC PG 8 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA 398ML UT WOS:000262736100006 PM 19011156 ER PT J AU McEvoy, MD Sabbagh, MJ Taylor, AG Zavadzkas, JA Koval, CN Stroud, RE Ford, RL McLean, JE Reeves, ST Mukherjee, R Spinale, FG AF McEvoy, Matthew D. Sabbagh, Michel J. Taylor, Anna Greta Zavadzkas, Juozas A. Koval, Christine N. Stroud, Robert E. Ford, Rachael L. McLean, Julie E. Reeves, Scott T. Mukherjee, Rupak Spinale, Francis G. TI Aprotinin Modifies Left Ventricular Contractility and Cytokine Release After Ischemia-Reperfusion in a Dose-Dependent Manner in a Murine Model SO ANESTHESIA AND ANALGESIA LA English DT Article ID TUMOR-NECROSIS-FACTOR; CARDIAC-SURGERY; CARDIOPULMONARY BYPASS; MYOCARDIAL-INFARCTION; INJURY; HEART; RISK; METAANALYSIS; INHIBITION; NEUTROPHIL AB BACKGROUND: Periods of ischemia-reperfusion (I/R) during cardiac surgery are associated with transient left ventricular (LV) dysfunction and an inflammatory response. In this study, we examined the potential dose-dependent effects of aprotinin (APRO) on LV contractility and cytokine release in the setting of I/R. METHODS: An index of LV contractility, LV maximal elastance (E(max)), was measured at baseline, 30 min of ischemia, and 60 min of reperfusion by microtransducer volumetry. Mice were randomized as follows: (a) APRO 20,000 kallikrein-inhibiting units (KIU)/kg (n = 11); (b) APRO 4 x 10(4) KIU/kg (n = 10); (c) APRO 8 x 10(4) KIU/kg (n = 10); and (d) vehicle (saline; n = 10). APRO doses were calculated to reflect half, full, and twice the clinical Hammersmith closing schedule. After I/R, plasma was collected for cytokine measurements. RESULTS: After I/R, E(max) decreased from the baseline value by more than 40% in the vehicle group as well as in the APRO 4 x 10(4) KIU/kg and APRO 8 x 10(4) KIU/kg groups (P < 0.05). However, E(max) returned to near baseline values in the APRO 2 x 10(4) KIU/kg group. Tumor necrosis factor (TNF) increased 10-fold after I/R, but it was reduced with higher APRO doses. CONCLUSIONS: This study demonstrated that a low dose of APRO provided protective effects on LV contractility, whereas higher doses suppressed TNF release. These unique findings suggest that there are distinct and independent mechanisms of action of APRO in the context of I/R. C1 [Spinale, Francis G.] Med Univ S Carolina, Div Cardiothorac Surg, Dept Cardiothorac Surg, Charleston, SC 29403 USA. [McEvoy, Matthew D.; Sabbagh, Michel J.; Taylor, Anna Greta; Reeves, Scott T.] Med Univ S Carolina, Dept Anesthesiol & Perioperat Med, Charleston, SC 29403 USA. [Spinale, Francis G.] Ralph H Johnson Dept Vet Affairs Med Ctr, Charleston, SC USA. RP Spinale, FG (reprint author), Med Univ S Carolina, Div Cardiothorac Surg, Dept Cardiothorac Surg, 114 Doughty St,Rm 625, Charleston, SC 29403 USA. EM wilburnm@musc.edu FU National Heart, Lung, and Blood Institute [PO1-HL-48788, RO1-HL-59165]; Research Service of the Department of Veterans Affairs; Bayer Pharmaceuticals; Foundation for Anesthesia Education and Research FX Supported by National Heart, Lung, and Blood Institute Grants PO1-HL-48788, RO1-HL-59165, Research Service of the Department of Veterans Affairs, Research Fellowships from Bayer Pharmaceuticals, and the Foundation for Anesthesia Education and Research. NR 27 TC 6 Z9 8 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0003-2999 J9 ANESTH ANALG JI Anesth. Analg. PD FEB PY 2009 VL 108 IS 2 BP 399 EP 406 DI 10.1213/ane.0b013e31818cdb13 PG 8 WC Anesthesiology SC Anesthesiology GA 396KG UT WOS:000262590000003 PM 19151263 ER PT J AU Sonnen, JA Larson, EB Gray, SL Wilson, A Kohama, SG Crane, PK Breitner, JCS Montine, TJ AF Sonnen, Joshua A. Larson, Eric B. Gray, Shelly L. Wilson, Angela Kohama, Steven G. Crane, Paul K. Breitner, John C. S. Montine, Thomas J. TI Free Radical Damage to Cerebral Cortex in Alzheimer's Disease, Microvascular Brain Injury, and Smoking SO ANNALS OF NEUROLOGY LA English DT Article ID ALPHA-TOCOPHEROL; VITAMIN-E; DEMENTIA; F-2-ISOPROSTANES; SUPPRESSION; SUPPLEMENTS; INCREASE; TRIAL; RISK AB Evidence supports a pathogenic role for free radical injury to brain in Alzheimer's disease; however, clinical trial results are only mildly encouraging. Examining brains from The Adult Changes in Thought study offers a unique perspective. Selectively increased free radical damage to cerebral cortex was associated with Alzheimer's disease, microvascular brain injury, and current smoking, but not with antioxidant supplement usage. Our results support suppression of free radical injury to brain as a therapeutic target for Alzheimer's disease and microvascular brain injury; however, future clinical trials should consider other antioxidants or doses than those identified in our study. C1 [Sonnen, Joshua A.; Wilson, Angela; Montine, Thomas J.] Univ Washington, Dept Pathol, Seattle, WA 98195 USA. [Gray, Shelly L.] Univ Washington, Dept Pharm, Seattle, WA 98195 USA. [Kohama, Steven G.] Oregon Natl Primate Res Ctr, Beaverton, OR USA. [Crane, Paul K.] Univ Washington, Dept Med, Seattle, WA 98195 USA. [Breitner, John C. S.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Breitner, John C. S.] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA. RP Sonnen, JA (reprint author), 11838 22nd Ave SW, Seattle, WA 98146 USA. EM jsonnen@u.washington.edu RI Crane, Paul/C-8623-2014; Sonnen, 37382016/H-3738-2016 OI Sonnen, 37382016/0000-0001-9267-8705; Crane, Paul/0000-0003-4278-7465 FU NIH [AG23801, AG05136, AG006781, AG 000258]; Nancy and Buster Alvord Endowment FX This work was Supported by NIH AG23801, (T.J.M.) NIH AG05136, NIH AG006781, (E.B.L.) NIH AG 000258, and the Nancy and Buster Alvord Endowment (T.J.M.). NR 15 TC 32 Z9 32 U1 1 U2 3 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0364-5134 J9 ANN NEUROL JI Ann. Neurol. PD FEB PY 2009 VL 65 IS 2 BP 226 EP 229 DI 10.1002/ana.21508 PG 4 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 415KM UT WOS:000263932700017 PM 19259965 ER PT J AU Baldwin, SW Heinze, EM Chan, G Hansen, J Clements, J Nishimura, R Reeves, M Weisbart, R AF Baldwin, S. W. Heinze, E. M. Chan, G. Hansen, J. Clements, J. Nishimura, R. Reeves, M. Weisbart, R. TI Antibody-Mediated FoxP3 Protein Therapy Induces Apoptosis in Cancer Cells In Vitro and Inhibits Metastasis In Vivo SO ANNALS OF SURGICAL ONCOLOGY LA English DT Meeting Abstract C1 [Baldwin, S. W.; Reeves, M.] Loma Linda VAMC, Loma Linda, CA 91342 USA. [Heinze, E. M.; Chan, G.; Hansen, J.; Clements, J.; Weisbart, R.] Vet Affairs Greater Los Angeles Hlth Care Syst, Sepulveda, CA USA. [Nishimura, R.] Olive View Univ Calif Los Angeles Med Ctr, Sylmar, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1068-9265 J9 ANN SURG ONCOL JI Ann. Surg. Oncol. PD FEB PY 2009 VL 16 SU 1 BP 37 EP 38 PG 2 WC Oncology; Surgery SC Oncology; Surgery GA V16GF UT WOS:000207857400116 ER PT J AU Lohavanichbutr, P Houck, J Fan, WH Yueh, B Mendez, E Futran, N Doody, DR Upton, MP Farwell, DG Schwartz, SM Zhao, LP Chen, C AF Lohavanichbutr, Pawadee Houck, John Fan, Wenhong Yueh, Bevan Mendez, Eduardo Futran, Neal Doody, David R. Upton, Melissa P. Farwell, D. Gregory Schwartz, Stephen M. Zhao, Lue Ping Chen, Chu TI Genomewide Gene Expression Profiles of HPV-Positive and HPV-Negative Oropharyngeal Cancer Potential Implications for Treatment Choices SO ARCHIVES OF OTOLARYNGOLOGY-HEAD & NECK SURGERY LA English DT Article ID HUMAN-PAPILLOMAVIRUS INFECTION; SQUAMOUS-CELL CARCINOMAS; HUMAN BREAST-CANCER; PROGNOSTIC-FACTOR; NECK-CANCER; HEAD; SENSITIVITY; RISK; STATHMIN; E6 AB Objective: To study the difference in gene expression between human papillomavirus (HPV)-positive and HPV-negative oral cavity and oropharyngeal squamous cell carcinoma (OSCC). Design: We used Affymetrix U133 plus 2.0 arrays to examine gene expression profiles of OSCC and normal oral tissue. The HPV DNA was detected using polymerase chain reaction followed by the Roche LINEAR ARRAY HPV Genotyping Test, and the differentially expressed genes were analyzed to examine their potential biological roles using the Ingenuity Pathway Analysis Software, version 5.0. Setting: Three medical centers affiliated with the University of Washington. Patients: A total of 119 patients with primary OSCC and 35 patients without cancer, all of whom were treated at the setting institutions, provided tissues samples for the study. Results: Human papillomavirus DNA was found in 41 of 119 tumors (34.5%) and 2 of 35 normal tissue samples (5.7%); 39 of the 43 HPV specimens were HPV-16. A higher prevalence of HPV DNA was found in oropharyngeal cancer (23 of 31) than in oral cavity cancer (18 of 88). We found no significant difference in gene expression between HPV-positive and HPV-negative oral cavity cancer but found 446 probe sets (347 known genes) differentially expressed in HPV-positive oropharyngeal cancer than in HPV-negative oropharyngeal cancer. The most prominent functions of these genes are DNA replication, DNA repair, and cell cycling. Some genes differentially expressed between HPV-positive and HPV-negative oropharyngeal cancer (eg, TYMS, STMN1, CCND1, and RBBP4) are involved in chemotherapy or radiation sensitivity. Conclusion: These results suggest that differences in the biology of HPV-positive and HPV-negative oropharyngeal cancer may have implications for the management of patients with these different tumors. C1 [Lohavanichbutr, Pawadee; Houck, John; Mendez, Eduardo; Doody, David R.; Schwartz, Stephen M.; Zhao, Lue Ping; Chen, Chu] Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, Program Epidemiol, Seattle, WA 98109 USA. [Fan, Wenhong; Zhao, Lue Ping] Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, Program Biostat & Biomath, Seattle, WA 98109 USA. [Yueh, Bevan] Univ Minnesota, Dept Otolaryngol Head & Neck Surg, Minneapolis, MN USA. [Mendez, Eduardo] Vet Affairs Puget Sound Hlth Care Syst, Surg & Perioperat Care Serv, Seattle, WA USA. [Farwell, D. Gregory] Univ Calif Davis, Dept Otolaryngol Head & Neck Surg, Davis, CA 95616 USA. [Mendez, Eduardo; Futran, Neal; Chen, Chu] Univ Washington, Dept Otolaryngol Head & Neck Surg, Seattle, WA 98195 USA. [Upton, Melissa P.] Univ Washington, Dept Pathol, Seattle, WA 98195 USA. [Schwartz, Stephen M.; Chen, Chu] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. RP Chen, C (reprint author), Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, Program Epidemiol, Mail Stop M5-C800,1100 Fairview Ave N, Seattle, WA 98109 USA. EM cchen@fhcrc.org OI Yueh, Bevan/0000-0003-1380-1053 FU National Cancer Institute [R01CA095419] FX This study was supported by grant R01CA095419 from the National Cancer Institute (Dr Chen). NR 24 TC 60 Z9 61 U1 0 U2 6 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA SN 0886-4470 J9 ARCH OTOLARYNGOL JI Arch. Otolaryngol. Head Neck Surg. PD FEB PY 2009 VL 135 IS 2 BP 180 EP 188 PG 9 WC Otorhinolaryngology; Surgery SC Otorhinolaryngology; Surgery GA 407QQ UT WOS:000263379800012 PM 19221247 ER PT J AU Cohen, AN Veena, MS Srivatsan, ES Wang, MB AF Cohen, Alen N. Veena, Mysore S. Srivatsan, Eri S. Wang, Marilene B. TI Suppression of Interleukin 6 and 8 Production in Head and Neck Cancer Cells With Curcumin via Inhibition of I kappa beta Kinase SO ARCHIVES OF OTOLARYNGOLOGY-HEAD & NECK SURGERY LA English DT Article ID B KINASE; TRANSCRIPTION FACTOR; CYTOKINE EXPRESSION; TUMOR-GROWTH; CARCINOMA; SURVIVAL; ACTIVATION; PROLIFERATION; ANGIOGENESIS; DIFERULOYLMETHANE AB Objectives: To evaluate the effect of curcumin on production of interleukin 6 (IL-6) and 8 (IL-8) in head and neck squamous cell carcinoma (HNSCC) cell lines and to determine the mechanism by which these effects are modulated. Curcumin suppression of HNSCC is believed to be partly due to inhibition of the transcription factor nuclear factor-kappa beta (NF-kappa beta). Interleukin 6 and IL-8 are cytokines induced by NF-kappa beta activation with elevated levels in the serum of patients with HNSCC. Design: We treated HNSCC cell lines CCL23, CAL27, UM-SCC1, and UM-SCC14A with increasing doses of curcumin and measured IL-6 and IL-8 levels using an enzyme-linked immunosorbent assay. Setting: Levels of NF-omicron beta, I kappa beta kinase (IKK), and phosphorylated I kappa beta were analyzed bymeans of Western blot. The IKK activity was measured in UM-SCC14A cells using an IKK-specific I kappa beta alpha substrate after treatment with curcumin. Main Outcome Measures: Reverse transcription polymerase chain reaction was performed to determine the effect of curcumin on the expression of IL-6 and IL-8. Results: Curcumin treatment resulted in dose-dependent inhibition of IL-6 and IL-8 in all cell lines. All cell lines had similar NF-kappa beta levels; however, UM-SCC1 and UM-SCC14A had significantly higher I kappa beta kinase levels and required considerably higher doses of curcumin before inhibition of IL-6 and IL-8 occurred. Curcumin treatment resulted in inhibition of IKK activity and inhibition of IL-6 and IL-8 expression. Conclusions: Curcumin significantly reduces IL-6 and IL-8 levels in HNSCC cell lines. This mechanism appears to be mediated via inhibition of I kappa beta-kinase activity in the NF-kappa beta pathway. Interleukins 6 and 8 have potential use as biomarkers to measure the efficacy of treatment with curcumin. C1 [Wang, Marilene B.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg, Div Head & Neck Surg, Los Angeles, CA 90095 USA. [Veena, Mysore S.; Srivatsan, Eri S.; Wang, Marilene B.] Vet Affairs Greater Los Angeles Healthcare Syst, Dept Surg, Los Angeles, CA USA. RP Wang, MB (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg, Div Head & Neck Surg, Room CHS 62-132,10833 Le Conte Ave, Los Angeles, CA 90095 USA. EM mbwang@ucla.edu FU University of California, Los Angeles, Academic Senate; Veterans Affairs Merit; National Cancer Institute [CA116826] FX This study was supported by a grant from the University of California, Los Angeles, Academic Senate (Dr Wang), a Veterans Affairs Merit Grant (Dr Srivatsan), and grant CA116826 from the National Cancer Institute(Dr Wang). NR 34 TC 27 Z9 28 U1 0 U2 1 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA SN 0886-4470 J9 ARCH OTOLARYNGOL JI Arch. Otolaryngol. Head Neck Surg. PD FEB PY 2009 VL 135 IS 2 BP 190 EP 197 PG 8 WC Otorhinolaryngology; Surgery SC Otorhinolaryngology; Surgery GA 407QQ UT WOS:000263379800013 PM 19221248 ER PT J AU Saha, S AF Saha, Somnath TI Rectifying Institutional Bias in Medical Research SO ARCHIVES OF PEDIATRICS & ADOLESCENT MEDICINE LA English DT Editorial Material ID CANCER CLINICAL-TRIALS; CONSPIRACY BELIEFS; AFRICAN-AMERICANS; RACE; AGE C1 Portland VA Med Ctr, Gen Internal Med Sect, Portland, OR 97239 USA. RP Saha, S (reprint author), Portland VA Med Ctr, Gen Internal Med Sect, 3710 SW US Vet Hosp Rd P3HSRD, Portland, OR 97239 USA. EM sahas@ohsu.edu NR 14 TC 2 Z9 2 U1 0 U2 1 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA SN 1072-4710 J9 ARCH PEDIAT ADOL MED JI Arch. Pediatr. Adolesc. Med. PD FEB PY 2009 VL 163 IS 2 BP 181 EP 182 PG 2 WC Pediatrics SC Pediatrics GA 402CM UT WOS:000262991800013 PM 19188652 ER PT J AU Silber, JH Rosenbaum, PR Romano, PS Rosen, AK Wang, YL Teng, Y Halenar, MJ Even-Shoshan, O Volpp, KG AF Silber, Jeffrey H. Rosenbaum, Paul R. Romano, Patrick S. Rosen, Amy K. Wang, Yanli Teng, Yun Halenar, Michael J. Even-Shoshan, Orit Volpp, Kevin G. TI Hospital Teaching Intensity, Patient Race, and Surgical Outcomes SO ARCHIVES OF SURGERY LA English DT Article ID QUALITY-OF-CARE; ACUTE MYOCARDIAL-INFARCTION; CLINICAL COMORBIDITY INDEX; ICD-9-CM ADMINISTRATIVE DATA; DUTY HOUR REFORM; HEALTH-CARE; MEDICARE BENEFICIARIES; NONTEACHING HOSPITALS; ADVERSE EVENTS; BLACK PATIENTS AB Objectives: To determine if the lower mortality often observed in teaching-intensive hospitals is because of lower complication rates or lower death rates after complications (failure to rescue) and whether the benefits at these hospitals accrue equally to white and black patients, since black patients receive a disproportionate share of their care at teaching-intensive hospitals. Design: A retrospective study of patient outcomes and teaching intensity using logistic regression models, with and without adjusting for hospital fixed and random effects. Setting: Three thousand two hundred seventy acute care hospitals in the United States. Patients: Medicare claims on general, orthopedic, and vascular surgery admissions in the United States for 20002005 (N = 4 658 954 unique patients). Main Outcome Measures: Thirty-day mortality, in-hospital complications, and failure to rescue (the probability of death following complications). Results: Combining all surgeries, compared with non-teaching hospitals, patients at very major teaching hospitals demonstrated a 15% lower odds of death (P < .001), no difference in complications, and a 15% lower odds of death after complications (failure to rescue) (P < .001). These relative benefits associated with higher resident-to-bed ratio were not experienced by black patients, for whom the odds of mortality and failure to rescue were similar at teaching and non-teaching hospitals, a pattern that is significantly different from that of white patients (P < .001). Conclusions: Survival after surgery is higher at hospitals with higher teaching intensity. Improved survival is because of lower mortality after complications (better failure to rescue) and generally not because of fewer complications. However, this better survival and failure to rescue at teaching-intensive hospitals is seen for white patients, not for black patients. C1 [Silber, Jeffrey H.; Wang, Yanli; Teng, Yun; Even-Shoshan, Orit] Childrens Hosp Philadelphia, Ctr Outcomes Res, Philadelphia, PA 19104 USA. [Silber, Jeffrey H.] Univ Penn, Dept Pediat, Philadelphia, PA 19104 USA. [Silber, Jeffrey H.] Univ Penn, Dept Anesthesiol, Philadelphia, PA 19104 USA. [Silber, Jeffrey H.] Univ Penn, Dept Crit Care, Philadelphia, PA 19104 USA. [Halenar, Michael J.; Volpp, Kevin G.] Univ Penn, Dept Med, Philadelphia, PA 19104 USA. [Silber, Jeffrey H.] Univ Penn, Sch Med, Dept Hlth Care Syst, Philadelphia, PA 19104 USA. [Rosenbaum, Paul R.] Univ Penn, Wharton Sch, Dept Stat, Philadelphia, PA 19104 USA. [Silber, Jeffrey H.; Even-Shoshan, Orit; Volpp, Kevin G.] Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA. [Halenar, Michael J.; Volpp, Kevin G.] Vet Adm Hosp, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA. [Romano, Patrick S.] Univ Calif Davis, Sch Med, Div Gen Med, Sacramento, CA 95817 USA. [Romano, Patrick S.] Univ Calif Davis, Sch Med, Ctr Healthcare Policy & Res, Sacramento, CA 95817 USA. [Rosen, Amy K.] Boston Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA USA. [Rosen, Amy K.] Vet Adm Hosp, Ctr Hlth Qual Outcomes & Econ Res, Bedford, MA USA. RP Silber, JH (reprint author), Childrens Hosp Philadelphia, Ctr Outcomes Res, 3535 Market St,Ste 1029, Philadelphia, PA 19104 USA. EM silberj@wharton.upenn.edu RI Rosenbaum, Paul/H-8687-2012; Romano, Patrick/N-4225-2014 OI Romano, Patrick/0000-0001-6749-3979; Halenar, Michael/0000-0002-8703-3811 FU National Heart, Lung, and Blood Institute [R01 HL082637]; Department of Veterans Affairs [IIR 04-202]; National Science Foundation [SES 0646002] FX This work was funded through National Heart, Lung, and Blood Institute grant R01 HL082637, Department of Veterans Affairs grant IIR 04-202, and National Science Foundation grant SES 0646002. NR 52 TC 74 Z9 74 U1 0 U2 2 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA SN 0004-0010 J9 ARCH SURG-CHICAGO JI Arch. Surg. PD FEB PY 2009 VL 144 IS 2 BP 113 EP 120 PG 8 WC Surgery SC Surgery GA 407QP UT WOS:000263379700004 PM 19221321 ER PT J AU Sugimoto, M Yamaoka, Y AF Sugimoto, Mitsushige Yamaoka, Yoshio TI Virulence factor genotypes of Helicobacter pylori affect cure rates of eradication therapy SO ARCHIVUM IMMUNOLOGIAE ET THERAPIAE EXPERIMENTALIS LA English DT Review DE Helicobacter pylori; eradication therapy; virulence factor; cagA; vacA; tailored regimen ID GASTRIC-ACID-SECRETION; PROTON PUMP INHIBITOR; ANTIBIOTIC-RESISTANCE PATTERNS; RANDOMIZED CONTROLLED-TRIAL; CAG PATHOGENICITY ISLAND; ADULT DYSPEPTIC PATIENTS; OUTER-MEMBRANE PROTEINS; TRIPLE THERAPY; VACUOLATING CYTOTOXIN; NONULCER DYSPEPSIA AB The cure rates of Helicobacter pylori infection by using a combination of a proton pump inhibitor (PPI) and antimicrobial agents are mainly influenced by bacterial susceptibility to antimicrobial agents and the magnitude of acid inhibition during the treatment. Currently used empirical triple therapies do not reliably produce a a parts per thousand yen80% cure rate on an intention-to-treat basis. Therefore, tailored regimens based on relevant microbiological findings and pharmacogenomics are recommended for attaining an acceptable a parts per thousand yen95% cure rate. Recently, virulence factors of H. pylori, such as cagA and vacA, are reported to be major factors determining the cure rates. Individuals infected with strains with cagA-negative and vacA s2 genotypes have significantly increased risk of eradication failure of H. pylori infection. These virulence factors enhance gastric mucosal inflammation and are associated with the development of peptic ulcer and gastric cancer. H. pylori virulence factors induce proinflammatory cytokines, such as interleukin (IL)-1, IL-8, and tumor necrosis factor (TNF)- which influence mucosal inflammation and/or gastric acid secretion. When physicians select an H. pylori eradication regimen with an acceptable cure rate, they might need to consider H. pylori virulence factors, especially cagA and vacA. C1 [Yamaoka, Yoshio] Michael E DeBakey Vet Affairs Med Ctr, Dept Med, Houston, TX 77030 USA. Baylor Coll Med, Houston, TX 77030 USA. RP Yamaoka, Y (reprint author), Michael E DeBakey Vet Affairs Med Ctr, Dept Med, 2002 Holcombe Blvd,111D Rm 3A-320, Houston, TX 77030 USA. EM yyamaoka@bcm.tmc.edu FU National Institutes of Health (NIH) [R01 DK62813] FX The project described was supported by Grant No. R01 DK62813 from the National Institutes of Health (NIH). Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the NIH. NR 105 TC 29 Z9 34 U1 1 U2 2 PU BIRKHAUSER VERLAG AG PI BASEL PA VIADUKSTRASSE 40-44, PO BOX 133, CH-4010 BASEL, SWITZERLAND SN 0004-069X J9 ARCH IMMUNOL THER EX JI Arch. Immunol. Ther. Exp. PD FEB PY 2009 VL 57 IS 1 BP 45 EP 56 DI 10.1007/s00005-009-0007-z PG 12 WC Immunology SC Immunology GA 409NI UT WOS:000263512000006 PM 19219527 ER PT J AU Nareika, A Sundararaj, KP Im, YB Game, BA Lopes-Virella, MF Huang, Y AF Nareika, Alena Sundararaj, Kamala P. Im, Yeong-Bin Game, Bryan A. Lopes-Virella, Maria F. Huang, Yan TI High glucose and interferon gamma synergistically stimulate MMP-1 expression in U937 macrophages by increasing transcription factor STAT1 activity SO ATHEROSCLEROSIS LA English DT Article DE Diabetes mellitus; Glucose; Atherosclerosis; Interferon gamma; Inflammation; Matrix metalloproteinase ID MATRIX METALLOPROTEINASE-1 EXPRESSION; CARDIOVASCULAR-DISEASE; DIABETES-MELLITUS; PLAQUE RUPTURE; HISTIOCYTES; LIPOPOLYSACCHARIDE; ATHEROSCLEROSIS; MECHANISMS AB Recent diabetes control and complications trial and epidemiology of diabetes interventions and complications (DCCT/EDIC) and other clinical studies have reported that glucose control in patients with diabetes leads to a significant reduction of cardiovascular events and atherosclerosis, indicating that hyperglycemia plays an essential role in cardiovascular disease in diabetic patients. Although several mechanisms by which hyperglycemia promotes atherosclerosis have been proposed, it remains unclear how hyperglycemia promotes atherosclerosis by interaction with inflammatory cytokines. To test our hypothesis that hyperglycemia interplays with interferon gamma (IFN gamma), a key factor involved in atherosclerosis, to up-regulate the expression of genes such as matrix metalloproteinases (MMPs) and cytokines that are involved in plaque destabilization, U937 macrophages cultured in medium containing either normal or high glucose were challenged with IFN gamma and the expression of MMPs and cytokines were then quantified by real-time polymerase chain reaction (PCR) and enzyme-linked immunosorbent assay (ELISA). Results showed that high glucose and IFN gamma had a synergistic effect on the expression of MMP-1, MMP-9 and IL-1 beta. High glucose also enhanced IFN gamma-induced priming effect on lipopolysaccharide (LPS)-stimulated MMP-1 secretion. Furthermore, high glucose and IFN gamma exert the synergistic effect on MMP-1 expression by enhancing STAT1 phosphorylation and STAT1 transcriptional activity. In summary, this study revealed a novel mechanism potentially involved in diabetes-promoted cardiovascular disease. Published by Elsevier Ireland Ltd. C1 [Game, Bryan A.; Lopes-Virella, Maria F.; Huang, Yan] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC 29403 USA. [Nareika, Alena; Sundararaj, Kamala P.; Im, Yeong-Bin; Lopes-Virella, Maria F.; Huang, Yan] Med Univ S Carolina, Dept Med, Div Endocrinol Diabet & Med Genet, Charleston, SC 29425 USA. RP Huang, Y (reprint author), Ralph H Johnson Vet Affairs Med Ctr, 114 Doughty St, Charleston, SC 29403 USA. EM huangyan@musc.edu FU Department of Veterans Affairs; NIH [DE 16353] FX This work was supported by a Merit Review Grant from Department of Veterans Affairs and NIH grant DE 16353 (to Y.H.). NR 22 TC 15 Z9 16 U1 0 U2 1 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0021-9150 J9 ATHEROSCLEROSIS JI Atherosclerosis PD FEB PY 2009 VL 202 IS 2 BP 363 EP 371 DI 10.1016/j.atherosclerosis.2008.05.043 PG 9 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 408HY UT WOS:000263427300007 PM 18586252 ER PT J AU Hammad, SM Twal, WO Barth, JL Smith, KJ Saad, AF Virella, G Argraves, WS Lopes-Virella, MF AF Hammad, Samar M. Twal, Waleed O. Barth, Jeremy L. Smith, Kent J. Saad, Antonio F. Virella, Gabriel Argraves, W. Scott Lopes-Virella, Maria F. TI Oxidized LDL immune complexes and oxidized LDL differentially affect the expression of genes involved with inflammation and survival in human U937 monocytic cells SO ATHEROSCLEROSIS LA English DT Article DE DNA microarray; Atherosclerosis; Oxidized LDL; Oxidized LDL immune complexes; Fc gamma receptors ID LOW-DENSITY-LIPOPROTEIN; THP-1 CELLS; INDUCED APOPTOSIS; HUMAN MACROPHAGES; HEME OXYGENASE-1; ANTIBODIES; RECEPTOR; ATHEROSCLEROSIS; ACTIVATION; PROTEIN AB Objective: To compare the global effects of oxidized LDL (oxLDL) and oxLDL-containing immune complexes (oxLDL-IC) on gene expression in human monocytic cells and to identify differentially expressed genes involved with inflammation and survival. Methods and results: U937 cells were treated with oxLDL-IC, oxLDL, Keyhole limpet hemocyanin immune complexes (KLH-IC), or vehicle for 4 h. Transcriptome profiling was performed using DNA microarrays. oxLDL-IC uniquely affected the expression of genes involved with pro-survival (RAD548, RUFY3, SNRPB2, and ZBTB24). oxLDL-IC also regulated many genes in a manner similar to KLH-IC. categorization of these genes revealed that 39% are involved with stress responses, including the unfolded protein response which impacts cell survival, 19% with regulation of transcription, 10% with endocytosis and intracellular transport of protein and lipid, and 16% with inflammatory responses including regulation of I-kappa B /NF-kappa B cascade and cytokine activity. One gene in particular, HSPA6, greatly up-regulated by oxLDL-IC, was found to be required for the process by which oxLDL-IC augments IL1-beta secretion. The study also revealed genes uniquely up-regulated by oxLDL, including genes involved with growth inhibition (OKL38, NEK3, and FTH1), oxidoreductase activity (SPXN1 and HMOX1), and transport of amino acids and fatty acids (SLC7A11 and ADFP). Conclusions: These findings highlight early transcriptional responses elicited by oxLDL-IC that may underlie its cytoprotective and proinflammatory effects. Cross-linking of Fc gamma receptors appears to be the trigger for most of the transcriptional responses to oxLDL-IC. The findings further strengthen the hypothesis that oxLDL and oxLDL-IC elicit disparate inflammatory responses and play distinct roles in the process of atherosclerosis. Published by Elsevier Ireland Ltd. C1 [Hammad, Samar M.; Twal, Waleed O.; Barth, Jeremy L.; Smith, Kent J.; Argraves, W. Scott] Med Univ S Carolina, Dept Cell Biol & Anat, Charleston, SC 29425 USA. [Saad, Antonio F.; Lopes-Virella, Maria F.] Med Univ S Carolina, Div Endocrinol, Dept Med, Charleston, SC 29425 USA. [Virella, Gabriel] Med Univ S Carolina, Dept Microbiol & Immunol, Charleston, SC 29425 USA. [Lopes-Virella, Maria F.] Ralph H Johnson Vet Affairs Med Ctr, Dept Vet Affairs, Charleston, SC 29401 USA. RP Hammad, SM (reprint author), Med Univ S Carolina, Dept Cell Biol & Anat, 114 Doughty St,630B POB 250776, Charleston, SC 29425 USA. EM hammadsm@musc.edu FU NIH [HL079274, POI-HL55782, HL061873]; South Carolina COBRE in Lipidomics and Pathobiology [RR17677]; American Heart Association Scientist Development [0435259N]; University Research Committee of the Medical University of South Carolina; Department of Veterans Affairs FX This work was supported by the following NIH grants: HL079274 (SMH), POI-HL55782 (MIN), HL061873 (WSA), and the South Carolina COBRE in Lipidomics and Pathobiology (P20 RR17677 from NCRR). The work was also supported by an American Heart Association Scientist Development Grant (0435259N) and a grant from the University Research Committee of the Medical University of South Carolina to SMH, and funding from the Department of Veterans Affairs to MLV We acknowledge the technical assistance of Alena Nareika and the MUSC Proteogenomics Facility (supported by RR016434, RR16461, and MUSC URRF) and their personnel, including Saurin Jani and Victor Fresco. We thank Charlyne Chassereau for assistance with lipoprotein isolation. NR 54 TC 29 Z9 30 U1 0 U2 2 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0021-9150 J9 ATHEROSCLEROSIS JI Atherosclerosis PD FEB PY 2009 VL 202 IS 2 BP 394 EP 404 DI 10.1016/j.atherosclerosis.2008.05.032 PG 11 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 408HY UT WOS:000263427300010 PM 18597759 ER PT J AU Craske, MG Waters, AM Nazarian, M Mineka, S Zinbarg, RE Griffith, JW Naliboff, B Ornitz, EM AF Craske, Michelle G. Waters, Allison M. Nazarian, Maria Mineka, Susan Zinbarg, Richard E. Griffith, James W. Naliboff, Bruce Ornitz, Edward M. TI Does Neuroticism in Adolescents Moderate Contextual and Explicit Threat Cue Modulation of the Startle Reflex? SO BIOLOGICAL PSYCHIATRY LA English DT Article DE Adolescents; context; explicit threat; risk for anxiety and depression; startle reflexes ID FEAR-POTENTIATED STARTLE; POSTTRAUMATIC-STRESS-DISORDER; ANXIETY DISORDERS; ACOUSTIC STARTLE; PERSONALITY; DEPRESSION; RESPONSES; TEMPERAMENT; PREVALENCE; VETERANS AB Background: This study evaluated the relationship between neuroticism (N), a probable risk factor for emotional disorders, and modulation of startle reflexes (SRs). Methods: One hundred thirty-two adolescents with varying levels of N but without anxiety or depressive disorders were evaluated in contextual cue and explicit threat cue paradigms. Results: Within the explicit threat cue paradigm, N potentiated SRs more in conditions that were intermediately associated with threat of an aversive biceps contraction than conditions that were the furthest from and conditions that were the closest to the same threat. Also, N potentiated SRs across the entire experiment, regardless of experimental conditions, in male and not in female subjects. Conclusions: These results suggest that adolescents with high levels of N show greater sensitivity to contexts intermediately associated with threat. Results are discussed in comparison with other studies of groups at risk for anxiety and depressive disorders. C1 [Craske, Michelle G.; Nazarian, Maria] Univ Calif Los Angeles, Dept Psychol, Los Angeles, CA 90095 USA. [Naliboff, Bruce; Ornitz, Edward M.] Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA. [Ornitz, Edward M.] Univ Calif Los Angeles, Brain Res Inst, Los Angeles, CA 90095 USA. [Naliboff, Bruce] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Waters, Allison M.] Griffith Univ, Sch Psychol, Mt Gravatt, Qld 4122, Australia. [Mineka, Susan; Zinbarg, Richard E.; Griffith, James W.] Northwestern Univ, Dept Psychol, Evanston, IL USA. [Zinbarg, Richard E.] Northwestern Univ, Family Inst, Evanston, IL USA. RP Craske, MG (reprint author), Univ Calif Los Angeles, Dept Psychol, 405 Hilgard Ave, Los Angeles, CA 90095 USA. EM craske@psych.ucla.edu RI Griffith, James/O-2551-2016 OI Griffith, James/0000-0002-4840-8692; Waters, Allison/0000-0003-2453-793X FU National Institutes of Health [MH065651, MH065652]; Virginia Friedhofer Charitable Trust FX Supplementary material cited in this article is available online. NR 33 TC 16 Z9 16 U1 2 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD FEB 1 PY 2009 VL 65 IS 3 BP 220 EP 226 DI 10.1016/j.biopsych.2008.07.020 PG 7 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 395QK UT WOS:000262538400006 PM 18789433 ER PT J AU Sorror, ML Storer, B Sandmaier, BM Chauncey, T Storb, RF Maloney, DG AF Sorror, M. L. Storer, B. Sandmaier, B. M. Chauncey, T. Storb, R. F. Maloney, D. G. TI TANDEM AUTOLOGOUS AND NONMYELOABLATIVE ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT) FROM HLA-MATCHED RELATED OR UNRELATED DONORS FOR ADVANCED LYMPHOMA OR CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION LA English DT Meeting Abstract CT Tandem Meeting on Biology of Blood and Marrow Transplantation CY FEB 11-15, 2009 CL Tampa, FL SP Amer Soc Blood & Marrow Transplantat C1 [Sorror, M. L.; Storer, B.; Sandmaier, B. M.; Chauncey, T.; Storb, R. F.; Maloney, D. G.] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA. [Sorror, M. L.; Storer, B.; Sandmaier, B. M.; Chauncey, T.; Storb, R. F.; Maloney, D. G.] Univ Washington, Seattle, WA 98195 USA. [Chauncey, T.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. NR 0 TC 2 Z9 2 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1083-8791 J9 BIOL BLOOD MARROW TR JI Biol. Blood Marrow Transplant. PD FEB PY 2009 VL 15 IS 2 MA 178 BP 66 EP 66 PG 1 WC Hematology; Immunology; Transplantation SC Hematology; Immunology; Transplantation GA 402MC UT WOS:000263016800179 ER PT J AU Xu, GF Mclaren, DG Ries, ML Fitzgerald, ME Bendlin, BB Rowley, HA Sager, MA Atwood, C Asthana, S Johnson, SC AF Xu, Guofan Mclaren, Donald G. Ries, Michele L. Fitzgerald, Michele E. Bendlin, Barbara B. Rowley, Howard A. Sager, Mark A. Atwood, Craig Asthana, Sanjay Johnson, Sterling C. TI The influence of parental history of Alzheimers disease and apolipoprotein E 4 on the BOLD signal during recognition memory SO BRAIN LA English DT Article DE Alzheimers disease; risk factors; BOLD; event-related fMRI; d-prime ID MILD COGNITIVE IMPAIRMENT; GENETIC RISK; BRAIN ACTIVATION; HIPPOCAMPAL ACTIVATION; EPISODIC MEMORY; DEFAULT-MODE; FMRI; DEMENTIA; APOE; AGE AB First-degree family history (FH) of sporadic Alzheimers disease and the apolipoprotein E 4 allele (APOE4) are risk factors for Alzheimers disease that may affect brain function prior to onset of clinical symptoms. In this functional MRI (fMRI) study, we used an episodic recognition task that required discrimination of previously viewed (PV) and novel (NV) faces to examine differences in blood oxygen level dependent (BOLD) signal due to risk factors in 74 middle-aged cognitively normal individuals. The group effects on this recognition task were tested with a 2 2 ANCOVA factorial design (FH/FH and APOE4/APOE4). There were significant APOE4 and FH effects in the left dorsal posterior cingulate cortex and precuneus, where decreased risk resulted in greater activity during recollection. Recognition performance was positively correlated with BOLD signal in the left posterior hippocampus, parahippocampalretrosplenial gyrus and left superior frontal cortex regardless of risk factors. To examine condition-specific group effects, both the PV and NV faces were tested further in separate 2 2 ANCOVAs. Both models revealed an APOE effect, with the APOE4 group showing stronger signal than the APOE4 group in anterior cingulate cortices, while a FH effect was found in the dorsal cuneus and medial frontal cortices with the FH group showing stronger signal than the FH group. Finally, interactions between APOE4 and FH effects were found bilaterally in the fusiform gyrus. These results suggest that risk factors and cognitive performance each influence brain activity during recognition. The findings lend further support to the idea that functional brain changes may begin far in advance of symptomatic Alzheimers disease. C1 [Xu, Guofan; Mclaren, Donald G.; Ries, Michele L.; Fitzgerald, Michele E.; Bendlin, Barbara B.; Atwood, Craig; Asthana, Sanjay; Johnson, Sterling C.] William S Middleton Mem Vet Adm Med Ctr, GRECC, Madison, WI 53705 USA. [Xu, Guofan; Mclaren, Donald G.; Ries, Michele L.; Fitzgerald, Michele E.; Bendlin, Barbara B.; Rowley, Howard A.; Sager, Mark A.; Atwood, Craig; Asthana, Sanjay; Johnson, Sterling C.] Univ Wisconsin, Dept Med, Madison, WI USA. [Xu, Guofan; Rowley, Howard A.] Univ Wisconsin, Dept Radiol, Madison, WI USA. RP Johnson, SC (reprint author), William S Middleton Mem Vet Adm Med Ctr, GRECC, 2500 Overlook Terrace 11G, Madison, WI 53705 USA. EM scj@medicine.wisc.edu RI McLaren, Donald/G-9906-2011 FU Department of Veterans Affairs Merit Review [AG21155, AG20013, AG27161] FX Department of Veterans Affairs Merit Review Grant (to S.C.J.); AG21155, AG20013 and AG27161. NR 54 TC 56 Z9 56 U1 3 U2 11 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0006-8950 J9 BRAIN JI Brain PD FEB PY 2009 VL 132 BP 383 EP 391 DI 10.1093/brain/awn254 PG 9 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 408BI UT WOS:000263407700012 PM 18829694 ER PT J AU Faroqi-Shah, Y Dickey, MW AF Faroqi-Shah, Yasmeen Dickey, Michael Walsh TI On-line processing of tense and temporality in agrammatic aphasia SO BRAIN AND LANGUAGE LA English DT Article DE Morphology; Agrammatism; Verbs; Reaction time; Tense; Adverb; Syntax; Anomaly; Aphasia; Comprehension ID FUNCTIONAL CATEGORIES; BROCAS APHASIA; GRAMMATICAL MORPHOLOGY; VERB INFLECTIONS; QUANTITATIVE-ANALYSIS; GERMAN AGRAMMATISM; GREEK APHASIA; PAST-TENSE; COMPREHENSION; DEFICITS AB Agrammatic aphasic individuals exhibit marked production deficits for tense morphology. This paper presents three experiments examining whether a group of English-speaking agrammatic individuals (n=10) exhibit parallel deficits in their comprehension of tense. Results from two comprehension experiments (on-line grammaticality judgment studies) suggest that these individuals are impaired for tense comprehension, and furthermore that their deficit is more pronounced for morphosemantic rather than morphosyntactic aspects of tense processing. Results from a third experiment (an elicited production study) indicate that these individuals exhibit parallel production and comprehension impairments for tense. Across the three experiments, the consistent pattern was that of a significant difficulty in associating verb forms with a pre-specified temporal context when compared to all other processes. Implications for current models of agrammatic tense and morphological deficits are discussed. (C) Published by Elsevier Inc. C1 [Faroqi-Shah, Yasmeen] Univ Maryland, Dept Hearing & Speech Sci, College Pk, MD 20742 USA. [Dickey, Michael Walsh] Univ Pittsburgh, Dept Commun Sci & Disorders, Pittsburgh, PA USA. [Dickey, Michael Walsh] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. RP Faroqi-Shah, Y (reprint author), Univ Maryland, Dept Hearing & Speech Sci, 0100 Lefrak Hall, College Pk, MD 20742 USA. EM yshah@hesp.umd.edu OI Dickey, Michael Walsh/0000-0002-9068-3313 FU University of Maryland, College Park FX This research was supported by a General Research Board award from the University of Maryland, College Park to Y. Faroqi-Shah. We thank Heather McIntosh for helping with timing of verbs. Monica Sampson and Kristin Grunwald helped with data analysis. Sarah Camponeshi and Isabelle Dunn helped with transcription and coding of narratives. The authors are grateful to the aphasic participants and their families for their participation in this research. NR 72 TC 26 Z9 26 U1 2 U2 6 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0093-934X J9 BRAIN LANG JI Brain Lang. PD FEB PY 2009 VL 108 IS 2 BP 97 EP 111 DI 10.1016/j.bandl.2008.10.003 PG 15 WC Audiology & Speech-Language Pathology; Linguistics; Neurosciences; Psychology, Experimental SC Audiology & Speech-Language Pathology; Linguistics; Neurosciences & Neurology; Psychology GA 406GT UT WOS:000263283700004 PM 19081129 ER PT J AU Fishman, J O'Dwyer, P Lu, HL Henderson, H Asch, DA Casarett, DJ AF Fishman, Jessica O'Dwyer, Peter Lu, Hien L. Henderson, Hope Asch, David A. Casarett, David J. TI Race, Treatment Preferences, and Hospice Enrollment: Eligibility Criteria May Exclude Patients With the Greatest Needs for Care SO CANCER LA English DT Article DE treatment preferences; conjoint analysis; utilities; interview; Medicare Hospice Benefit; services; palliative care; African American; race; economic; finances ID OF-LIFE CARE; RANDOMIZED CONTROLLED-TRIAL; CONJOINT-ANALYSIS; CANCER-PATIENTS; NURSING-HOMES; PALLIATIVE CARE; HEALTH RESEARCH; MANAGEMENT; END; COMMUNITY AB BACKGROUND: The requirement that patients give up curative treatment makes hospice enrollment unappealing for some patients and may particularly limit use among African-American patients. The current study was conducted to determine whether African-American patients with cancer are more likely than white patients to have preferences for cancer treatment that exclude them from hospice and whether they are less likely to want specific hospice services. METHODS: Two hundred eighty-three patients who were receiving treatment for cancer at 6 oncology clinics within the University of Pennsylvania Cancer Network completed conjoint interviews measuring their perceived need for 5 hospice services and their preferences for continuing cancer treatment. Patients were followed for 6 months or until death. RESULTS: African-American patients had stronger preferences for continuing their cancer treatments on a 7-point scale even after adjusting for age, sex, finances, education, Eastern Cooperative Oncology Group performance status, quality of life, and physical and psychologic symptom burden (adjusted mean score, 4.75 vs 3.96; beta coefficient, 0.82; 95% confidence interval, 0.22-1.41 [P=.007]). African-American patients also had greater perceived needs for hospice services after adjusting for these characteristics (adjusted mean score, 2.31 vs 1.83; beta coefficient, 0.51; 95% confidence interval, 0.11-0.92 [P=.01]). However, this effect disappeared after adjusting for household finances. CONCLUSIONS: Hospice eligibility criteria may exclude African-American patients disproportionately despite greater perceived needs for hospice services in this population. The mechanisms driving this health disparity likely include both cultural differences and economic characteristics, and consideration should be given to redesigning hospice eligibility criteria. Cancer 2009;115:689-97. (C) 2008 American Cancer Society. C1 [Fishman, Jessica; O'Dwyer, Peter; Lu, Hien L.; Asch, David A.; Casarett, David J.] Univ Penn, Sch Med, Philadelphia, PA 19104 USA. [Fishman, Jessica] Univ Penn, Annenberg Sch Commun, Philadelphia, PA 19104 USA. [Fishman, Jessica] Univ Penn, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA. [Henderson, Hope; Asch, David A.; Casarett, David J.] Vet Affairs Ctr Hlth Equ Res & Promot, Philadelphia, PA USA. [Asch, David A.; Casarett, David J.] Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA. RP Casarett, DJ (reprint author), Univ Penn, Sch Med, 3615 Chestnut St, Philadelphia, PA 19104 USA. EM casarett@mail.med.upenn.edu OI Asch, David/0000-0002-7970-286X FU American Cancer Society Mentored Scholar Research [MRSGT-08-013-01-CPPB]; University of Pennsylvania's National Institutes of Health [R01CA109540]; Veterans Administration Advanced Research Career Development Award; Presidential Early Career Award for Scientists and Engineers; Abramson Cancer Center; Center for Clinical Epidemiology and Biostatistics; Center For Health Equity Research and Promotion FX Supported by American Cancer Society Mentored Scholar Research grant MRSGT-08-013-01-CPPB (to J.F.), the University of Pennsylvania's National Institutes of Health-funded Center of Excellence for Cancer Communication Research grant (to J.F.), grant R01CA109540 (to D.J.C.), a Veterans Administration Advanced Research Career Development Award, a Presidential Early Career Award for Scientists and Engineers (to D.J.C.), and by grants from the Abramson Cancer Center (to P.O.), the Center for Clinical Epidemiology and Biostatistics (to J.F.), and the Center For Health Equity Research and Promotion (to D.J.C. and J.F.). NR 68 TC 37 Z9 37 U1 2 U2 7 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0008-543X J9 CANCER JI Cancer PD FEB 1 PY 2009 VL 115 IS 3 BP 689 EP 697 DI 10.1002/cncr.24046 PG 9 WC Oncology SC Oncology GA 402GY UT WOS:000263003400028 PM 19107761 ER PT J AU Raitt, MH AF Raitt, Meritt H. TI Are n-3 Polyunsaturated Fatty Acids Antiarrhythmic in the Absence of Ischemia? SO CARDIOVASCULAR DRUGS AND THERAPY LA English DT Editorial Material ID IMPLANTABLE CARDIOVERTER-DEFIBRILLATORS; FISH-OIL SUPPLEMENTATION; SUDDEN CARDIAC DEATH; VENTRICULAR-FIBRILLATION; RISK; TRIAL; OMEGA-3-FATTY-ACIDS; MODULATION; PREVENTION; CHANNELS C1 Portland VA Med Ctr, Portland, OR USA. [Raitt, Meritt H.] P 3 CARD, Portland, OR 97239 USA. RP Raitt, MH (reprint author), Portland VA Med Ctr, Portland, OR USA. EM merritt.raitt@va.gov NR 18 TC 3 Z9 3 U1 0 U2 0 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0920-3206 J9 CARDIOVASC DRUG THER JI Cardiovasc. Drugs Ther. PD FEB PY 2009 VL 23 IS 1 BP 1 EP 3 DI 10.1007/s10557-008-6151-6 PG 3 WC Cardiac & Cardiovascular Systems; Pharmacology & Pharmacy SC Cardiovascular System & Cardiology; Pharmacology & Pharmacy GA 396JJ UT WOS:000262587700001 PM 19005746 ER PT J AU Singh, M Peterson, ED Roe, MT Ou, FS Spertus, JA Rumsfeld, JS Anderson, HV Klein, LW Ho, KKL Holmes, DR AF Singh, Mandeep Peterson, Eric D. Roe, Matthew T. Ou, Fang-Shu Spertus, John A. Rumsfeld, John S. Anderson, H. Vernon Klein, Lloyd W. Ho, Kalon K. L. Holmes, David R. TI Trends in the Association Between Age and In-Hospital Mortality After Percutaneous Coronary Intervention National Cardiovascular Data Registry Experience SO CIRCULATION-CARDIOVASCULAR INTERVENTIONS LA English DT Article DE age; percutaneous coronary interventions; mortality; temporal trends ID ACUTE MYOCARDIAL-INFARCTION; HEALTH-CARE PROFESSIONALS; SCIENTIFIC STATEMENT; GERIATRIC-CARDIOLOGY; CLINICAL CARDIOLOGY; AMERICAN-COLLEGE; HEART-DISEASE; RISK SCORE; ANGIOPLASTY; COLLABORATION AB Background-Temporal trends and contemporary data characterizing the impact of patient age on in-hospital outcomes of percutaneous coronary interventions are lacking. We sought to determine the importance of age by assessing the in-hospital mortality of stratified age groups in the National Cardiovascular Data Registry. Methods and Results-In-hospital mortality after percutaneous coronary intervention on 1 410 069 patients was age stratified into 4 groups-group 1 (age <40, n=25 679), group 2 (40 to 59, n=496 204), group 3 (60 to 79, n=732 574), and group 4 (>= 80, n=155 612)-admitted from January 1, 2001, to December 31, 2006. Overall in-hospital mortality was 1.22%; in-hospital mortality was 0.60%, 0.59%, 1.26%, and 3.16% in groups 1 to 4, respectively, P<0.0001. Overall temporal improvement per calendar year in the adjusted in-hospital mortality after percutaneous coronary intervention was noted in most groups; however, this finding was significant only in the 2 older age groups, group 3 (odds ratio, 0.94; 95% CI, 0.92 to 0.96) and group 4 (odds ratio, 0.95; 95% CI, 0.92 to 0.97). The absolute mortality reduction was greatest in the most elderly group, those over the age of 80 years. Conclusions-In-hospital mortality after percutaneous coronary intervention has fallen for all age groups over the past 6 years. However, the largest absolute reduction was seen among patients 80 years of age or older. (Circ Cardiovasc Intervent. 2009;2:20-26.) C1 [Singh, Mandeep; Holmes, David R.] Mayo Clin, Div Cardiovasc Dis, Rochester, MN 55905 USA. [Peterson, Eric D.; Roe, Matthew T.; Ou, Fang-Shu] Duke Clin Res Inst, Durham, NC USA. [Spertus, John A.] UMKC, Mid Amer Heart Inst, Kansas City, MO USA. [Rumsfeld, John S.] Denver VA Med Ctr, Denver, CO USA. [Anderson, H. Vernon] Univ Texas Hlth Sci Ctr Houston, Houston, TX USA. [Klein, Lloyd W.] Rush Univ, Med Ctr, Chicago, IL 60612 USA. [Ho, Kalon K. L.] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. RP Singh, M (reprint author), Mayo Clin, Div Cardiovasc Dis, 200 1st St SW, Rochester, MN 55905 USA. EM singh.mandeep@mayo.edu NR 27 TC 36 Z9 36 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1941-7640 J9 CIRC-CARDIOVASC INTE JI Circ.-Cardiovasc. Interv. PD FEB PY 2009 VL 2 IS 1 BP 20 EP 26 DI 10.1161/CIRCINTERVENTIONS.108.826172 PG 7 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 575EC UT WOS:000276048500005 PM 20031689 ER PT J AU Handrakis, JP DeMeersman, RE Rosado-Rivera, D LaFountaine, MF Spungen, AM Bauman, WA Wecht, JM AF Handrakis, John P. DeMeersman, Ronald E. Rosado-Rivera, Dwindally LaFountaine, Michael F. Spungen, Ann M. Bauman, William A. Wecht, Jill M. TI Effect of hypotensive challenge on systemic hemodynamics and cerebral blood flow in persons with tetraplegia SO CLINICAL AUTONOMIC RESEARCH LA English DT Article DE spinal cord injury; autonomic nervous system disorder; orthostatic hypotension; angiotensin-converting enzyme inhibitor; tilt-table test ID SPINAL-CORD-INJURY; POWER SPECTRAL-ANALYSIS; HEAD-UP TILT; ORTHOSTATIC HYPOTENSION; TRANSCRANIAL DOPPLER; PRESSURE VARIABILITY; HUMANS; AUTOREGULATION; INDIVIDUALS; OXYGENATION AB Individuals with tetraplegia have impaired central control of sympathetic vascular modulation and blood pressure (BP); how this impairment affects cerebral blood flow (CBF) is unclear. To determine if persons with tetraplegia maintain CBF similarly to able-bodied controls after a hypotensive challenge. Seven individuals with chronic tetraplegia and seven age-matched, non-SCI control subjects underwent a hypotensive challenge consisting of angiotensin-converting enzyme (ACE) inhibition (1.25 mg enalaprilat) and 45A degrees head-up tilt (HUT). Heart rate (HR), low frequency systolic BP variability (LFsbp), brachial mean arterial pressure (MAP) and middle cerebral artery CBF were measured before and after the challenge. Group differences for the baseline (BL) to post-challenge response were determined by repeated measures ANOVA. HR did not differ between the groups in response to the hypotensive challenge. LFsbp response was significantly reduced in the tetra compared to the control group (-38 +/- A 51 vs. 72 +/- A 93%, respectively). MAP did not differ between the groups at BL but was significantly lower in the tetra compared to the control group post-challenge (55 +/- A 13 vs. 71 +/- A 9 mmHg, respectively); the percent change in MAP was significantly greater in the tetra than in the control group (-29 +/- A 14.1 vs. -13 +/- A 9%, respectively). However, CBF did not differ between the groups at baseline or post-challenge; the percent change in CBF post-challenge was not different between the tetra and control groups (-29 +/- A 13.2 vs. -23 +/- A 10.3%, respectively). Despite impaired sympathetic vasomotor and BP control, CBF in persons with tetraplegia was comparable to that of control subjects during a hypotensive challenge. C1 [Handrakis, John P.; DeMeersman, Ronald E.; LaFountaine, Michael F.; Spungen, Ann M.; Bauman, William A.; Wecht, Jill M.] James J Peters VA Med Ctr, Ctr Excellence Med Consequences Spinal Cord Injur, Bronx, NY 10468 USA. [Handrakis, John P.] Sch Hlth Profess Behav & Life Sci, NYIT, Old Westbury, NY USA. [DeMeersman, Ronald E.] Columbia Univ, Teachers Coll, New York, NY 10027 USA. [Spungen, Ann M.; Bauman, William A.; Wecht, Jill M.] Mt Sinai Sch Med, Dept Med & Rehabil Med, New York, NY USA. RP Handrakis, JP (reprint author), James J Peters VA Med Ctr, Ctr Excellence Med Consequences Spinal Cord Injur, Rm 1E-02,130 W Kingsbridge Rd, Bronx, NY 10468 USA. EM john.handrakis@va.gov FU Veteran Affairs Rehabilitation Research and Development Service; Center of Excellence for the Medical Consequences of SCI [B4162C]; Vidda Foundation FX Veteran Affairs Rehabilitation Research and Development Service, Center of Excellence for the Medical Consequences of SCI (B4162C), James J. Peters VAMC, the Vidda Foundation. NR 28 TC 11 Z9 11 U1 2 U2 3 PU DR DIETRICH STEINKOPFF VERLAG PI HEIDELBERG PA TIERGARTENSTRASSE 17, 69121 HEIDELBERG, GERMANY SN 0959-9851 J9 CLIN AUTON RES JI Clin. Auton. Res. PD FEB PY 2009 VL 19 IS 1 BP 39 EP 45 DI 10.1007/s10286-008-0496-6 PG 7 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 409NA UT WOS:000263511200007 PM 18850311 ER PT J AU Akhtar, S Meeran, SM Katiyar, N Katiyar, SK AF Akhtar, Suhail Meeran, Syed M. Katiyar, Nandan Katiyar, Santosh K. TI Grape Seed Proanthocyanidins Inhibit the Growth of Human Non-Small Cell Lung Cancer Xenografts by Targeting Insulin-Like Growth Factor Binding Protein-3, Tumor Cell Proliferation, and Angiogenic Factors SO CLINICAL CANCER RESEARCH LA English DT Article ID BREAST-CARCINOMA CELLS; SKH-1 HAIRLESS MICE; IN-VIVO; THERAPY; MECHANISMS; ACTIVATION; APOPTOSIS; RECEPTOR; ANTIBODY; MITOGEN AB Purpose: Lung cancer is a leading cause of cancer-related deaths worldwide. Here, we assessed the chemotherapeutic effect of grape seed proanthocyanidins (GSPs) on human non-small Cell lung cancer (NSCLC) cells in vitro and in vivo using a tumor xenograft model. Experimental Design: The effects of GSPs on human NSCLC cell lines in terms of cellular proliferation were determined. The chemotherapeutic effects of a GSP-supplemented AIN76A control diet fed to nude mice bearing tumor xenografts (A549 and H1299) were evaluated in terms of biomarkers of cell proliferation and angiogenesis and on insulin-like growth factor binding protein-3 using immunohistochemical detection, ELISA, and Western blotting. Results: In vitro treatment of NSCLC cells with GSPs resulted in inhibition of cellular proliferation. Administration of GSPs (0.1%, 0.2%, and 0.5%, w/w) as a supplement of an AIN76A control diet resulted in a dose-dependent inhibition of the growth of NSCLC (A549 and H1299) tumor xenografts in athymic nude mice (25-76%; P < 0.05-0.001). The growth-inhibitory effect of GSPs on the NSCLC xenograft tumors was associated with the enhancement of the levels of insulin-like growth factor binding protein-3 in the tumor microenvironment and plasma and antiproliferative, antiangiogenic, and proapoptotic effects. Conclusions: This preclinical Study reveals for the first time that dietary GSPs have the ability to inhibit the growth of human NSCLC tumor xenografts grown in vivo in athymic nude mice. More studies are needed to develop GSPs as a pharmacologically safe agent for the prevention of lung cancer in humans. C1 [Akhtar, Suhail; Meeran, Syed M.; Katiyar, Nandan; Katiyar, Santosh K.] Univ Alabama, Dept Dermatol, Birmingham, AL 35294 USA. [Katiyar, Santosh K.] Univ Alabama, Clin Nutr Res Ctr, Birmingham, AL 35294 USA. [Katiyar, Santosh K.] Univ Alabama, Ctr Comprehens Canc, Birmingham, AL 35294 USA. [Katiyar, Santosh K.] Birmingham VA Med Ctr, Birmingham, AL USA. RP Katiyar, SK (reprint author), Univ Alabama, Dept Dermatol, 1670 Univ Blvd,Volker Hall 557, Birmingham, AL 35294 USA. EM skatiyar@uab.edu NR 35 TC 43 Z9 45 U1 0 U2 2 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1078-0432 J9 CLIN CANCER RES JI Clin. Cancer Res. PD FEB 1 PY 2009 VL 15 IS 3 BP 821 EP 831 DI 10.1158/1078-0432.CCR-08-1901 PG 11 WC Oncology SC Oncology GA 405HK UT WOS:000263213600011 PM 19188152 ER PT J AU Lee, CC You, NCY Song, YQ Hsu, YH Manson, J Nathan, L Tinker, L Liu, SM AF Lee, Cathy C. You, Nai-chieh Yuko Song, Yiqing Hsu, Yi-Hsiang Manson, JoAnn Nathan, Lauren Tinker, Lesley Liu, Simin TI Relation of Genetic Variation in the Gene Coding for C-Reactive Protein with Its Plasma Protein Concentrations: Findings from the Women's Health Initiative Observational Cohort SO CLINICAL CHEMISTRY LA English DT Article ID TYPE-2 DIABETES-MELLITUS; CORONARY-HEART-DISEASE; SINGLE-NUCLEOTIDE POLYMORPHISMS; CRP LEVELS; POPULATION STRATIFICATION; CARDIOVASCULAR-DISEASE; INFLAMMATORY MARKERS; HUMAN GENOME; RISK; ASSOCIATION AB BACKGROUND: Although common genetic variants of the CRP gene (C-reactive protein, pentraxin related) have been associated with plasma concentrations of high-sensitivity CRP (hsCRP) in several cohorts of European Americans, relatively few studies have comprehensively assessed this association in well-characterized multiethnic populations. METHODS: In a case-control study of diabetes nested in the Women's Health initiative Observational Cohort, we comprehensively evaluated the association of genetic variation in CRP with plasma hsCRP concentrations. Thirteen haplotype-tagging single-nucleotide polymorphisms (tSNPs) were identified and subsequently genotyped in 3782 postmenopausal women. RESULTS: The allele frequencies for these tSNPs and the haplotype blocks defined by these tSNPs varied significantly by ethnic group (P < 0.0001). Consistent with prior studies of whites, rs3093068, rs1130864, and rs1417938 were significantly associated with higher hsCRP concentrations (geometric-mean increase per minor-allele change, 1.20-1.25 mg/L), and rs1205 and rs1800947 were significantly associated with lower hsCRP values (decrease of 1.28-1.48 mg/L). The associations with rs3093068 and rs1205 appeared to be stronger in Asians/Pacific Islanders than in whites (geometric-mean increase, 1.65 mg/L vs 1.25 mg/L, respectively). Minor alleles at rs3093075 and rs3093039 were associated with substantially increased hsCRP concentrations, whereas rs1800947 was associated with lower hsCRP values. All haplotype-based association results tended to be consistent with the associations seen with single CRP SNPs. CONCLUSIONS: Our large multiethnic case-control study of postmenopausal women provides evidence that common genetic variants in the CRP gene are substantially associated with plasma hsCRP concentrations in this case-control subcohort. The data also suggest ethnic variations in these associations. (C) 2008 American Association for Clinical Chemistry C1 [You, Nai-chieh Yuko; Liu, Simin] Univ Calif Los Angeles, Sch Publ Hlth, Dept Epidemiol, Los Angeles, CA 90095 USA. [Lee, Cathy C.; Liu, Simin] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA. [Lee, Cathy C.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Song, Yiqing; Manson, JoAnn] Brigham & Womens Hosp, Dept Med, Div Prevent Med, Boston, MA 02115 USA. [Song, Yiqing; Manson, JoAnn] Harvard Univ, Sch Med, Boston, MA USA. [Hsu, Yi-Hsiang] Harvard Univ, Sch Publ Hlth, Mol & Integrat Physiol Sci Program, Dept Environm Hlth, Boston, MA 02115 USA. [Nathan, Lauren] Univ Calif Los Angeles, David Geffen Sch Med, Dept OB GYN, Los Angeles, CA 90095 USA. [Tinker, Lesley] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA. [Liu, Simin] Univ Calif Los Angeles, David Geffen Sch Med, Johnson Comprehens Canc Ctr, Los Angeles, CA 90095 USA. RP Liu, SM (reprint author), Univ Calif Los Angeles, Sch Publ Hlth, Dept Epidemiol, Box 951772,650 Charles E Young Dr S, Los Angeles, CA 90095 USA. EM siminliu@ucla.edu RI Liu, Simin/I-3689-2014 OI Liu, Simin/0000-0003-2098-3844 FU National Heart, Lung, and Blood Institute; US Department of Health and Human Services; National Institutes of Health [R01DK062290] FX The Women's Health Initiative is funded by the National Heart, Lung, and Blood Institute, and the US Department of Health and Human Services. This study was supported by the National Institute of Diabetes and Digestive and Kidney Diseases R01DK062290 from the National Institutes of Health. NR 35 TC 23 Z9 24 U1 0 U2 1 PU AMER ASSOC CLINICAL CHEMISTRY PI WASHINGTON PA 2101 L STREET NW, SUITE 202, WASHINGTON, DC 20037-1526 USA SN 0009-9147 J9 CLIN CHEM JI Clin. Chem. PD FEB PY 2009 VL 55 IS 2 BP 351 EP 360 DI 10.1373/clinchem.2008.117176 PG 10 WC Medical Laboratory Technology SC Medical Laboratory Technology GA 401ED UT WOS:000262921300019 PM 19095725 ER PT J AU Lu, Y Chen, QY Corey, E Xie, W Fan, J Mizokami, A Zhang, J AF Lu, Yi Chen, Qiuyan Corey, Eva Xie, Wen Fan, Jie Mizokami, Atsushi Zhang, Jian TI Activation of MCP-1/CCR2 axis promotes prostate cancer growth in bone SO CLINICAL & EXPERIMENTAL METASTASIS LA English DT Article DE MCP-1; CCR2; Cell invasion; Osteoclast; Prostate cancer ID MONOCYTE CHEMOATTRACTANT PROTEIN-1; CHEMOKINE RECEPTOR EXPRESSION; ENDOTHELIAL-CELLS; TUMOR PROGRESSION; SOLUBLE RECEPTOR; METASTASIS; CARCINOMA; MIGRATION; MECHANISMS; INVASION AB Prostate cancer (PCa) frequently metastasizes to bone resulting in a mixture of osteolytic and osteoblastic lesions. We have previously reported that monocyte chemotactic protein-1 (MCP-1) is chemotactic for PCa cells, and its receptor, CCR2 expression, correlates with pathological stages. However, the role of MCP-1/CCR2 axis on PCa progression in bone remains unclear. We first evaluated the serum levels of MCP-1 in patients with bone metastases or localized PCa by enzyme-linked immunosorbent assay. We found that MCP-1 levels were elevated in patients with bone metastases compared to localized PCa. We further determined the effects of knockdown CCR2 or MCP-1 on PCa cell invasion and the tumor cell-induced osteoclast activity in vitro, respectively. PCa C4-2B and PC3 cells were transfected stably with either CCR2 short hairpin RNA (shRNA) or a scrambled RNA. CCR2 knockdown significantly diminished the MCP-1-induced PCa cell invasion. In addition, the MCP-1 production was knocked down by MCP-1 shRNA in C4-2B and PC3 cells. Conditioned media (CM) was collected and determined for the CM-induced osteoclast formation in vitro. MCP-1 knockdown significantly decreased the PCa CM-induced osteoclast formation. Finally, MCP-1 knockdown PC3 cells were implanted into the tibia of SCID mice for 4 weeks. Tumor volume was determined by histopathology and bone histomorphometry. MCP-1 knockdown diminished PC3 tumor growth in bone. We concluded that activation of MCP-1/CCR2 axis promotes PCa growth in bone. This study suggests that MCP-1 may be a target for PCa progression. C1 [Lu, Yi; Chen, Qiuyan; Fan, Jie; Zhang, Jian] Univ Pittsburgh, Dept Med, Pittsburgh, PA 15240 USA. [Chen, Qiuyan] Sun Yat Sen Univ, Ctr Canc, Dept Nasopharyngeal Carcinoma, Guangzhou 510275, Guangdong, Peoples R China. [Corey, Eva] Univ Washington, Dept Urol, Seattle, WA 98195 USA. [Xie, Wen] Univ Pittsburgh, Ctr Pharmacogenet, Pittsburgh, PA 15261 USA. [Xie, Wen] Univ Pittsburgh, Dept Pharmaceut Sci, Pittsburgh, PA 15261 USA. [Fan, Jie] VA Pittsburgh Healthcare Syst, Dept Surg, Pittsburgh, PA 15240 USA. [Mizokami, Atsushi] Kanazawa Univ, Grad Sch Med Sci, Dept Urol, Kanazawa, Ishikawa, Japan. RP Lu, Y (reprint author), Univ Pittsburgh, Dept Med, Pittsburgh, PA 15240 USA. EM luy3@upmc.edu; zhangj2@upmc.edu RI Xie, Wen/M-1768-2016 FU Department of Defense [PC061231]; University of Pittsburgh Cancer Institute CCSG FX The authors thank Dr. G. David Roodman for his helpful discussion, Dr. Zhong Cai for his technical help, and Mrs. Donna Gaspich for her editing. This study was supported by Department of Defense PC061231 and University of Pittsburgh Cancer Institute CCSG (J. Zhang). NR 37 TC 48 Z9 53 U1 0 U2 7 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0262-0898 J9 CLIN EXP METASTAS JI Clin. Exp. Metastasis PD FEB PY 2009 VL 26 IS 2 BP 161 EP 169 DI 10.1007/s10585-008-9226-7 PG 9 WC Oncology SC Oncology GA 407JK UT WOS:000263359200009 PM 19002595 ER PT J AU Graham, DY AF Graham, David Y. TI Efficient Identification and Evaluation of Effective Helicobacter pylori Therapies SO CLINICAL GASTROENTEROLOGY AND HEPATOLOGY LA English DT Article ID II CLINICAL-TRIALS; SEQUENTIAL THERAPY; TRIPLE THERAPY; IRON-DEFICIENCY; INFECTION; ERADICATION; METAANALYSIS; REGIMEN; EFFICACY; DESIGNS AB Annually hundreds if not thousands of patients fail empiric H pylori eradication therapy. Failure occurs in part because routine post treatment testing, which provides an early warning of increasing antibiotic resistance, is not universally done and physicians are generally unaware that cure rates with legacy triple therapy (a proton-pump inhibitor, amoxicillin, and clarithromycin) in most places has fallen below 80%. We propose first, institution of routine post eradication testing and second, abandonment of the "better than another therapy" approach to separating acceptable from unacceptable therapies. Instead, we propose using results-based outcomes (ie, >95% cure rates). H pylori should be evaluated as other infectious diseases (ie, few would compare a new antibiotic for pneumonia with the previous best choice whose effectiveness was now impaired because of resistance). Randomized comparisons should be restricted to studies designed to improve (eg, simplify or reduce costs) high cure rate therapies while maintaining efficacy. We also discuss potential ethical issues such as those including known or suspected low cure rate therapies. Legacy therapies cannot be identified as "approved" or "recommended" even if both statements were true. Instead patients and ethics boards must receive "full disclosures" both before and during studies that include all that might affect a patient's decision to enter or to continue. Finally, we provides advice regarding trial design using "best shot" pilot studies to efficiently identify tentative effective regimens which are then confirmed in randomized trials all the while minimizing patient risks and drug exposure. C1 [Graham, David Y.] Michael E DeBakey Vet Affairs Med Ctr, Dept Med, Houston, TX 77030 USA. [Graham, David Y.] Baylor Coll Med, Houston, TX 77030 USA. RP Graham, DY (reprint author), Michael E DeBakey Vet Affairs Med Ctr, Dept Med, RM 3A-320 1111D,2002 Holcombe Blvd, Houston, TX 77030 USA. EM dgraham@bcm.tmc.edu FU NIDDK NIH HHS [DK56338, P30 DK056338, P30 DK056338-07] NR 26 TC 56 Z9 57 U1 0 U2 5 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1542-3565 J9 CLIN GASTROENTEROL H JI Clin. Gastroenterol. Hepatol. PD FEB PY 2009 VL 7 IS 2 BP 145 EP 148 DI 10.1016/j.cgh.2008.10.024 PG 4 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 410QE UT WOS:000263592100007 PM 19026766 ER PT J AU Spiegel, BMR Ho, W Esrailian, E Targan, S Higgins, PDR Siegel, CA Dubinsky, M Melmed, GY AF Spiegel, Brennan M. R. Ho, Wayne Esrailian, Eric Targan, Stephan Higgins, Peter D. R. Siegel, Corey A. Dubinsky, Marla Melmed, Gil Y. TI Controversies in Ulcerative Colitis: A Survey Comparing Decision Making of Experts Versus Community Gastroenterologists SO CLINICAL GASTROENTEROLOGY AND HEPATOLOGY LA English DT Article ID INFLAMMATORY-BOWEL-DISEASE; QUALITY-OF-LIFE; COLORECTAL-CANCER; CROHNS-DISEASE; SURVEILLANCE; GUIDELINES; CYCLOSPORINE; MANAGEMENT; VIGNETTES; PROVIDERS AB Background & Aims: Despite the development of consensus guidelines in ulcerative colitis (UC), there remain several areas of uncertainty in the everyday management of this incompletely understood disease. We performed a national vignette survey to measure variations in decision-making in areas of controversy. Methods: We constructed a survey with 3 vignettes to measure decision-making in 4 areas of controversy in UC: (1) dysplasia management, (2) mesalamine dosing, (3) diagnostic testing for underlying Crohn's disease, and (4) treatment of steroid-refractory inpatient UC. We compared responses between a group of community gastroenterologists and UC experts. Results: We received 192 responses (36% response). Compared with community gastroenterologists, UC experts were more likely to endorse colectomy for both unifocal and multifocal low-grade dysplasia, use narrow band imaging and chromoendoscopy for surveillance colonoscopy, use high-dose mesalamine for inducing remission, use long-term mesalamine for cancer chemoprevention, order computed tomography enterography to evaluate for Crohn's disease, and to have a lower threshold to call for surgery consultation in steroid-refractory UC. There was little agreement regarding the optimal frequency of surveillance colonoscopy, even among experts. Most respondents favored using infliximab over cyclosporine in steroid-refractory UC. Conclusions: Community gastroenterologists and UC experts vary dramatically in their approach to many areas of uncertainty in UC. The only area of consensus between groups is the use of infliximab over cyclosporine in steroid-refractory UC, itself a controversial decision. These data suggest that current practice patterns are highly disparate and focus attention on specific areas of disconnect that should be further investigated. C1 [Spiegel, Brennan M. R.; Ho, Wayne] Vet Adm Greater Angeles Healthcare Syst, Los Angeles, CA USA. [Spiegel, Brennan M. R.; Esrailian, Eric] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Spiegel, Brennan M. R.] Univ Calif Los Angeles, Sch Publ Hlth, Los Angeles, CA 90024 USA. [Spiegel, Brennan M. R.] CURE Digest Dis Res Ctr, Los Angeles, CA USA. [Targan, Stephan; Dubinsky, Marla; Melmed, Gil Y.] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA. [Higgins, Peter D. R.] Univ Michigan, Sch Med, Ann Arbor, MI USA. [Siegel, Corey A.] Dartmouth Hitchcock Med Ctr, Lebanon, NH 03766 USA. [Spiegel, Brennan M. R.; Esrailian, Eric] Univ Calif Los Angeles, VA Ctr Outcomes Res & Educ, Los Angeles, CA USA. RP Spiegel, BMR (reprint author), 11301 Wilshire Blvd,Bldg 115,Room 215, Los Angeles, CA 90073 USA. EM bspiegel@mednet.ulca.edu RI Higgins, Peter/A-3511-2009 OI Higgins, Peter/0000-0003-1602-4341 FU Veteran's Affairs Health Services Research and Development (HSR&D) Career Development Transition Award [RCD 03-179-2]; Crohn's and Colitis Foundation Career Development Award; NIH [IK23DK078678-01A1, 2P30 DK 041301-17]; Procter Gamble FX The authors disclose the following: Dr Spiegel is supported by a Veteran's Affairs Health Services Research and Development (HSR&D) Career Development Transition Award (RCD 03-179-2) and the CURE Digestive Disease Research Center (NIH 2P30 DK 041301-17). Dr Corey Siegel is supported by a Crohn's and Colitis Foundation Career Development Award and NIH IK23DK078678-01A1. This study was supported by an investigator-initiated research grant by Procter & Gamble. NR 31 TC 24 Z9 25 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1542-3565 J9 CLIN GASTROENTEROL H JI Clin. Gastroenterol. Hepatol. PD FEB PY 2009 VL 7 IS 2 BP 168 EP 174 DI 10.1016/j.cgh.2008.08.029 PG 7 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 410QE UT WOS:000263592100011 PM 18952199 ER PT J AU Roodman, GD Hiruma, Y Kurihara, N AF Roodman, G. David Hiruma, Yuko Kurihara, Noriyoshi TI p62: A Potential Target for Blocking Microenvironmental Support of Myeloma SO CLINICAL LYMPHOMA & MYELOMA LA English DT Meeting Abstract ID MULTIPLE-MYELOMA; BONE MICROENVIRONMENT; OSTEOCLASTOGENESIS; DISEASE; PATHOPHYSIOLOGY; INCREASES; MUTATION; ALPHA C1 [Roodman, G. David; Hiruma, Yuko; Kurihara, Noriyoshi] Univ Pittsburgh, Pittsburgh, PA USA. [Roodman, G. David] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. NR 10 TC 0 Z9 0 U1 0 U2 1 PU CIG MEDIA GROUP, LP PI DALLAS PA 3500 MAPLE AVENUE, STE 750, DALLAS, TX 75219-3931 USA SN 1557-9190 J9 CLIN LYMPHOMA MYELOM JI Clin. Lymphoma Myeloma PD FEB PY 2009 VL 9 BP S25 EP S26 PG 2 WC Oncology SC Oncology GA 472EE UT WOS:000268111400019 ER PT J AU Beales, JL Edes, T AF Beales, Julie Leftwich Edes, Thomas TI Veteran's Affairs Home Based Primary Care SO CLINICS IN GERIATRIC MEDICINE LA English DT Article DE Home care; Chronic disease; Non-institutional long-term care; Interdisciplinary team; Home based primary care AB In response to the anticipated growth of the veteran population with chronic disabling diseases, the Department of Veterans Affairs (VA) established Home Based Primary Care (HBPC). This article focuses on that program, a home care program that specifically targets individuals with complex chronic disabling disease, with the goal of maximizing the independence of the patient and reducing preventable emergency room visits and hospitalizations. HBPC programs provide comprehensive longitudinal primary care by an interdisciplinary team in the homes of veterans with complex chronic disease, who are not effectively managed by routine clinic-based care. HBPC is very different from and complementary to standard skilled home care services, in population, processes and outcomes. HBPC targets persons with advanced chronic disease, rather than remediable conditions. HBPC provides comprehensive care of multiple co-morbidities, rather than problem-focused care. HBPC is delivered by an interdisciplinary team, rather than one or two independent providers. Currently operating in three-fourths of VA facilities, HBPC expansion continues to be driven by clinical success and the highest satisfaction of all VA services. VA HBPC is a model to emulate for the care of persons with complex, chronic disabling conditions, improving quality without added cost, and maximizing their independence through comprehensive longitudinal interdisciplinary care delivered in their homes. C1 [Beales, Julie Leftwich] VAMC, Richmond, VA 23249 USA. [Edes, Thomas] US Dept Vet Affairs, Home & Community Based Care, Washington, DC 20420 USA. RP Beales, JL (reprint author), VAMC, 1201 Broad Rock Blvd, Richmond, VA 23249 USA. EM julie.beales@va.gov NR 9 TC 47 Z9 48 U1 0 U2 2 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0749-0690 J9 CLIN GERIATR MED JI Clin. Geriatr. Med. PD FEB PY 2009 VL 25 IS 1 BP 149 EP + DI 10.1016/j.cger.2008.11.002 PG 8 WC Geriatrics & Gerontology SC Geriatrics & Gerontology GA 421ZM UT WOS:000264396800012 PM 19217499 ER PT J AU Dong, ZM Aplin, AC Nicosia, RF AF Dong, Zhao Ming (David) Aplin, Alfred C. Nicosia, Roberto F. TI Regulation of Angiogenesis by Macrophages, Dendritic Cells, and Circulating Myelomonocytic Cells SO CURRENT PHARMACEUTICAL DESIGN LA English DT Review DE Macrophages; dendritic cells; myeloid cells; neovascularization; arteriogenesis ID ENDOTHELIAL GROWTH-FACTOR; TUMOR-ASSOCIATED MACROPHAGES; ADENOSINE A(2A) RECEPTORS; COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM-CELLS; HUMAN PERIPHERAL-BLOOD; NECROSIS-FACTOR-ALPHA; ADIPOSE-TISSUE; MYELOID CELLS; BREAST-CANCER AB Angiogenesis during reactive and pathologic processes is characteristically associated with inflammation. Macrophages and dendritic cells present in the inflammatory infiltrate contribute to the angiogenic process by multiple mechanisms. Macrophages produce a broad array of angiogenic growth factors and cytokines, generate conduits for blood flow through proteolytic mechanisms, and promote the remodeling of arterioles into arteries. They can also inhibit angiogenesis and cause reabsorption of neovessels by inducing endothelial cell death. Dendritic cells can stimulate or inhibit angiogenesis depending on their activation status and subset specificity. Dendritic cells stimulate angiogenesis by secreting angiogenic factors and cytokines, promoting the proangiogenic activity of T lymphocytes, and trans-differentiating into endothelial cells. Inflammatory infiltrates associated with angiogenesis also contain Tie2+, VEGFR2+, and GR1+ myelomonocytic cells which actively regulate the angiogenic process through paracrine mechanisms. In this paper we review our current knowledge of this field and discuss how recent advances have provided the rationale for novel therapeutic approaches against cancer. C1 [Nicosia, Roberto F.] VA Puget Sound Hlth Care Syst, Div Pathol & Lab Med, Lab S 113, Pathol & Lab Med Serv, Seattle, WA 98108 USA. [Aplin, Alfred C.; Nicosia, Roberto F.] Univ Washington, Dept Pathol, Seattle, WA 98195 USA. RP Nicosia, RF (reprint author), VA Puget Sound Hlth Care Syst, Div Pathol & Lab Med, Lab S 113, Pathol & Lab Med Serv, 1660 S Columbian Way, Seattle, WA 98108 USA. EM roberto.nicosia@va.gov NR 171 TC 32 Z9 32 U1 0 U2 2 PU BENTHAM SCIENCE PUBL LTD PI SHARJAH PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB EMIRATES SN 1381-6128 J9 CURR PHARM DESIGN JI Curr. Pharm. Design PD FEB PY 2009 VL 15 IS 4 BP 365 EP 379 PG 15 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 415VF UT WOS:000263963500004 ER PT J AU McFarland, BR Klein, DN AF McFarland, Brian R. Klein, Daniel N. TI EMOTIONAL REACTIVITY IN DEPRESSION: DIMINISHED RESPONSIVENESS TO ANTICIPATED REWARD BUT NOT TO ANTICIPATED PUNISHMENT OR TO NONREWARD OR AVOIDANCE SO DEPRESSION AND ANXIETY LA English DT Article DE depression; reward; punishment; appetitive; approach; withdrawal; behavioral activation; behavioral inhibition ID BEHAVIORAL ACTIVATION; MAJOR DEPRESSION; AFFECTIVE-DISORDERS; TRIPARTITE MODEL; ANXIETY; SYSTEMS; PSYCHOPATHOLOGY; INHIBITION; DIMENSIONS; THERAPY AB Objectives: This study compared depressed and nondepressed participants' emotional reactivity to anticipated reward, anticipated punishment, failure to obtain a reward, and successful avoidance of punishment. Experimental design: This study compared residualized change scores on target emotions for currently depressed (n = 19), previously depressed (n = 19), and never-depressed (n = 43) participants during four experimental conditions: anticipated reward (cash), anticipated punishment (cold pressor), nonreward (failure to earn cash), and avoidance (successful avoidance of a cold pressor). Principal observations: Currently depressed participants' reactivity in response to anticipated reward was significantly diminished compared with never depressed participants', and marginally diminished compared with previously depressed participants'. Currently depressed, previously depressed, and never-depressed participants did not differ significantly in their emotional reactivity to anticipated punishment or to nonreward or avoidance. Conclusions: These results suggest that depressed individuals' diminished emotional reactivity may be mainly it state effect and may be limited to anticipated reward. Depression and Anxiety 26:117-122, 2009. (C) 2008 Wiley-Liss, Inc. C1 [McFarland, Brian R.; Klein, Daniel N.] SUNY Stony Brook, Dept Psychol, Stony Brook, NY 11794 USA. RP McFarland, BR (reprint author), Birmingham VAMC, 700 S 19th St, Birmingham, AL 35233 USA. EM brian.macfarland@va.gov NR 37 TC 36 Z9 36 U1 2 U2 12 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1091-4269 EI 1520-6394 J9 DEPRESS ANXIETY JI Depress. Anxiety PD FEB PY 2009 VL 26 IS 2 BP 117 EP 122 DI 10.1002/da.20513 PG 6 WC Psychology, Clinical; Psychiatry; Psychology SC Psychology; Psychiatry GA 406PN UT WOS:000263307500003 PM 18972567 ER PT J AU Utzschneider, KM Prigeon, RL Faulenbach, MV Tong, J Carr, DB Boyko, EJ Leonetti, DL McNeely, MJ Fujimoto, WY Kahn, SE AF Utzschneider, Kristina M. Prigeon, Ronald L. Faulenbach, Mirjam V. Tong, Jenny Carr, Darcy B. Boyko, Edward J. Leonetti, Donna L. McNeely, Marguerite J. Fujimoto, Wilfred Y. Kahn, Steven E. TI Oral Disposition Index Predicts the Development of Future Diabetes Above and Beyond Fasting and 2-h Glucose Levels SO DIABETES CARE LA English DT Article ID BETA-CELL FUNCTION; HEPATIC INSULIN EXTRACTION; HIGH-RISK; 1ST-DEGREE RELATIVES; PREVENTION PROGRAM; TOLERANCE TEST; SENSITIVITY; RESISTANCE; SECRETION; MELLITUS AB OBJECTIVE - We sought to determine whether an oral disposition index (DI(O)) predicts the development of diabetes over a 10-year period. First, we assessed the validity of the DI(O) by demonstrating that a hyperbolic relationship exists between oral indexes of insulin sensitivity and beta-cell function. RESEARCH DESIGN AND METHODS - A total of 613 Japanese-American subjects (322 men and 291 women) underwent a 75-g Oral glucose tolerance test (OGTT) at baseline, 5 years, and 1.0 years. Insulin sensitivity was estimated as 1/fasting insulin or homeostasis model assessment of insulin sensitivity (HOMA-S). Insulin response Was estimated as the change in insulin divided by change in glucose from 0 to 30 min (Delta l(0-30)/Delta G(0-30)). RESULTS - Delta l(0-30)/Delta G(0-30) demonstrated a curvilinear relationship with 1/fasting insulin and HOMA-S With a left and downward shift as glucose tolerance deteriorated. The confidence limits for the slope of the log(e)-transformed estimates included -1 for Delta l(0-30)/Delta G(0-30) versus 1/fasting insulin for all glucose tolerance groups, consistent with a hyperbolic relationship. When HOMA-S was used as the insulin Sensitivity measure, the confidence limits for the slope included - I only for Subjects With normal glucose tolerance (NCT) or impaired fasting glucose (IFG/impaired glucose tolerance (IGT) but not diabetes. On the basis of this hyperbolic relationship, the product of Delta l(0-30)/Delta G(0-30) and 1/fasting insulin was calculated (DI(O)) and decreased fron NGT to IFG/IGT to diabetes (P < 0.001). Among nondiabetic subjects at baseline, baseline DI(O) predicted cumulative diabetes at 10 years (P<0.001) independent of age, sex, BMI, family history of diabetes, and baseline fasting and 2-h glucose concentrations. CONCLUSIONS- The DI(O) provides a measure of beta-cell function adjusted for insulin sensitivity and is predictive of development of diabetes over 10 years. C1 [Utzschneider, Kristina M.; Faulenbach, Mirjam V.; Tong, Jenny; Kahn, Steven E.] Vet Affairs Puget Sound Hlth Care Syst, Dept Med, Div Metab Endocrinol & Nutr, Seattle, WA USA. [Utzschneider, Kristina M.; Faulenbach, Mirjam V.; Tong, Jenny; McNeely, Marguerite J.; Fujimoto, Wilfred Y.; Kahn, Steven E.] Univ Washington, Dept Med, Seattle, WA USA. [Prigeon, Ronald L.] Baltimore Vet Affairs Med Ctr, Ctr Geriatr Res Educ & Clin, Baltimore, MD USA. [Prigeon, Ronald L.] Univ Maryland, Sch Med, Div Gerontol, Baltimore, MD 21201 USA. [Carr, Darcy B.] Univ Washington, Dept Obstet & Gynecol, Div Maternal Fetal Med, Seattle, WA 98195 USA. [Boyko, Edward J.] Vet Affairs Puget Sound Hlth Care Syst, Epidemiol Res & Informat Ctr, Seattle, WA USA. [Leonetti, Donna L.] Univ Washington, Dept Anthropol, Seattle, WA 98195 USA. RP Utzschneider, KM (reprint author), Vet Affairs Puget Sound Hlth Care Syst, Dept Med, Div Metab Endocrinol & Nutr, Seattle, WA USA. EM kutzschn@u.washington.edu OI Kahn, Steven/0000-0001-7307-9002; Boyko, Edward/0000-0002-3695-192X FU Department of Veteran Affairs; Veteran Affairs Geriatrics Research, Education, and Clinical Center; National Institutes of Health [DK-02654, DK-31170, HL-49293, RR-00037, DK-35816, P30 DK-17047] FX This work was supported by the Department of Veteran Affairs and the Veteran Affairs Geriatrics Research, Education, and Clinical Center, National Institutes of Health grants DK-02654, DK-31170, HL-49293, RR-00037, DK-35816, and P30 DK-17047. NR 25 TC 185 Z9 190 U1 0 U2 4 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0149-5992 J9 DIABETES CARE JI Diabetes Care PD FEB PY 2009 VL 32 IS 2 BP 335 EP 341 DI 10.2337/dc08-1478 PG 7 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 402MV UT WOS:000263018700024 PM 18957530 ER PT J AU Metra, M Dei Cas, L Massie, BM AF Metra, Marco Dei Cas, Livio Massie, Barry M. TI Treatment of heart failure in the elderly: never say it's too late SO EUROPEAN HEART JOURNAL LA English DT Editorial Material ID EJECTION FRACTION; MORTALITY; TRIAL; MANAGEMENT; MORBIDITY; DIGOXIN C1 [Metra, Marco; Dei Cas, Livio] Univ Brescia, Dept Expt & Appl Med, Sect Cardiovasc Dis, I-25100 Brescia, Italy. [Massie, Barry M.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Massie, Barry M.] San Francisco VA Med Ctr, San Francisco, CA USA. RP Metra, M (reprint author), Univ Brescia, Dept Expt & Appl Med, Sect Cardiovasc Dis, I-25100 Brescia, Italy. EM metramarco@libero.it OI Metra, Marco/0000-0001-6691-8568 NR 15 TC 10 Z9 10 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0195-668X J9 EUR HEART J JI Eur. Heart J. PD FEB PY 2009 VL 30 IS 4 BP 391 EP 393 DI 10.1093/eurheartj/ehp024 PG 3 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 410UN UT WOS:000263603900003 PM 19181708 ER PT J AU Nyholt, DR Yu, CE Visscher, PM AF Nyholt, Dale R. Yu, Chang-En Visscher, Peter M. TI On Jim Watson's APOE status: genetic information is hard to hide SO EUROPEAN JOURNAL OF HUMAN GENETICS LA English DT Letter ID ONSET ALZHEIMERS-DISEASE; ASSOCIATION; GENOME; GENOTYPE; RISK C1 [Nyholt, Dale R.; Visscher, Peter M.] Queensland Inst Med Res, Genet Epidemiol & Queensland Stat Genet Labs, Brisbane, Qld 4006, Australia. [Yu, Chang-En] Univ Washington, Sch Med, Dept Med,Vet Affairs Puget Sound Hlth Care Syst, Div Gerontol & Geriatr Med,Geriat Res Educ & Clin, Seattle, WA 98195 USA. RP Nyholt, DR (reprint author), Queensland Inst Med Res, Genet Epidemiol & Queensland Stat Genet Labs, Brisbane, Qld 4006, Australia. EM daleN@qimr.edu.au RI Nyholt, Dale/C-8384-2013 OI Visscher, Peter/0000-0002-2143-8760 NR 13 TC 33 Z9 34 U1 1 U2 1 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 1018-4813 J9 EUR J HUM GENET JI Eur. J. Hum. Genet. PD FEB PY 2009 VL 17 IS 2 BP 147 EP 149 DI 10.1038/ejhg.2008.198 PG 3 WC Biochemistry & Molecular Biology; Genetics & Heredity SC Biochemistry & Molecular Biology; Genetics & Heredity GA 395CJ UT WOS:000262499600003 PM 18941475 ER PT J AU Tsai, TT Trimarchi, S Nienaber, CA AF Tsai, T. T. Trimarchi, S. Nienaber, C. A. TI Acute Aortic Dissection: Perspectives from the International Registry of Acute Aortic Dissection (IRAD) SO EUROPEAN JOURNAL OF VASCULAR AND ENDOVASCULAR SURGERY LA English DT Article DE aorta; aortic dissection; mortality; follow-up studies ID TRUE-LUMEN COLLAPSE; INTRAMURAL HEMATOMA; COMPUTED-TOMOGRAPHY; TRANSESOPHAGEAL ECHOCARDIOGRAPHY; VASCULAR COMPLICATIONS; PULSATILE FLOW; FALSE LUMEN; PART II; COCAINE; MANAGEMENT AB Acute aortic dissection is a rare but deadly disease first described over 200 years ago by the physician to the late King George II on necropsy. Over the ensuing 2 centuries, the understanding of the pathophysiology, presentation, diagnosis, treatment and follow-up has matured. In an effort to understand the contemporary treatment of this disease, the International Registry of Acute Aortic Dissection (IRAD) has enrolled over 2000 patients over the past 12 years. In this article we summarize the key lessons learned from this multi-national registry of patients presenting with acute aortic dissection. Published by Elsevier Ltd on behalf of European Society for Vascular Surgery. C1 [Tsai, T. T.] Univ Colorado, Div Cardiovasc Med, Dept Internal Med, Denver, CO 80202 USA. [Tsai, T. T.] Denver Vet Affairs Med Ctr, Hlth Serv Res & Dev Ctr, Denver, CO 80220 USA. [Trimarchi, S.] Policlin S Donato IRCCS, Cardiovasc Ctr E Malan, San Donato Milanese, Italy. [Nienaber, C. A.] Univ Rostock, Rostock, Germany. RP Tsai, TT (reprint author), Univ Colorado, Div Cardiovasc Med, Dept Internal Med, Denver, CO 80202 USA. EM thomas.tsai@ucdenver.edu RI Trimarchi, Santi/J-7361-2016 OI Trimarchi, Santi/0000-0001-5996-3264 NR 58 TC 134 Z9 164 U1 3 U2 8 PU W B SAUNDERS CO LTD PI LONDON PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND SN 1078-5884 J9 EUR J VASC ENDOVASC JI Eur. J. Vasc. Endovasc. Surg. PD FEB PY 2009 VL 37 IS 2 BP 149 EP 159 DI 10.1016/j.ejvs.2008.11.032 PG 11 WC Surgery; Peripheral Vascular Disease SC Surgery; Cardiovascular System & Cardiology GA 407HX UT WOS:000263355300005 PM 19097813 ER PT J AU Jacobs, JV Nutt, JG Carlson-Kuhta, P Stephens, M Horak, FB AF Jacobs, Jesse V. Nutt, John G. Carlson-Kuhta, Patricia Stephens, Marilee Horak, Fay B. TI Knee trembling during freezing of gait represents multiple anticipatory postural adjustments SO EXPERIMENTAL NEUROLOGY LA English DT Article DE Freezing of gait; FoG; Parkinson's disease; Balance; Anticipatory postural adjustment; Gait initiation ID PARKINSONS-DISEASE; STEP INITIATION; MUSCLE TONE; MOVEMENT; LEVODOPA; COORDINATION; ONSET; CAT AB Freezing of gait (FoG) is an episodic, brief inability to step that delays gait initiation or interrupts ongoing gait. FoG is often associated with an alternating shaking of the knees, clinically referred to as knee trembling or trembling in place. The pathophysiology of FoG and of the concomitant trembling knees is unknown; impaired postural adjustment in preparation for stepping is one hypothesis. We examined anticipatory postural adjustments (APAs) prior to protective steps induced by a forward loss of balance in 10 Parkinson's disease (PD) subjects with marked FoG and in 10 control subjects. The amplitude and timing of the APAs were determined from changes in the vertical ground-reaction forces recorded by a force plate under each foot and were confirmed by electromyographic recordings of bilateral medial gastrocnemius, tibialis anterior and tensor fascia latae muscles. Protective steps were accomplished with a single APA followed by a step for control subjects, whereas PD subjects frequently exhibited multiple, alternating APAs coexistent with the knee trembling commonly observed during FoG as well as delayed, inadequate or no stepping. These Multiple APAs were not delayed in onset and were of similar or larger amplitude than the single APAs exhibited by the control subjects. These observations suggest that multiple APAs produce the knee trembling commonly associated with FoG and that FoG associated with a forward loss of balance is caused by an inability to couple a normal APA to the stepping motor pattern. Published by Elsevier Inc. C1 [Jacobs, Jesse V.; Nutt, John G.; Carlson-Kuhta, Patricia; Stephens, Marilee; Horak, Fay B.] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97239 USA. [Nutt, John G.; Horak, Fay B.] Oregon Hlth & Sci Univ, Dept Physiol & Pharmacol, Portland, OR 97239 USA. [Nutt, John G.] Portland VA Med Ctr, Parkinsons Dis Res Educ & Clin Ctr, Portland, OR USA. RP Nutt, JG (reprint author), Oregon Hlth & Sci Univ, Dept Neurol, OP-32,3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA. EM nuttj@ohsu.edu FU National Institutes of Health [AG06457] FX We thank the subjects who participated in the protocol. We are grateful for the help with data analysis from Edward King, Michael Amos, and Christine Ryciewcz, and for the technical assistance from Dr. Charles Russell and Edward King. This study was funded by the National Institutes of Health, grant AG06457. NR 35 TC 93 Z9 95 U1 0 U2 4 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0014-4886 J9 EXP NEUROL JI Exp. Neurol. PD FEB PY 2009 VL 215 IS 2 BP 334 EP 341 DI 10.1016/j.expneurol.2008.10.019 PG 8 WC Neurosciences SC Neurosciences & Neurology GA 400TG UT WOS:000262890900016 PM 19061889 ER PT J AU Sun, DX Martinez, CO Ochoa, O Ruiz-Willhite, L Bonilla, JR Centonze, VE Waite, LL Michalek, JE McManus, LM Shireman, PK AF Sun, Dongxu Martinez, Carlo O. Ochoa, Oscar Ruiz-Willhite, Lourdes Bonilla, Jose R. Centonze, Victoria E. Waite, Lindsay L. Michalek, Joel E. McManus, Linda M. Shireman, Paula K. TI Bone marrow-derived cell regulation of skeletal muscle regeneration SO FASEB JOURNAL LA English DT Article DE CC chemokine receptor 2; CCR2; chimera; inflammation; monocyte/macrophage; myogenic progenitor cell ID HEMATOPOIETIC STEM-CELLS; MONOCYTE CHEMOATTRACTANT PROTEIN-1; CC-CHEMOKINE RECEPTOR-2; SATELLITE CELLS; IN-VIVO; PROGENITOR CELLS; CCR2-/-MICE; ALTERED INFLAMMATION; TUMOR ANGIOGENESIS; ENDOTHELIAL-CELLS AB Limb regeneration requires the coordination of multiple stem cell populations to recapitulate the process of tissue formation. Therefore, bone marrow (BM) -derived cell regulation of skeletal muscle regeneration was examined in mice lacking the CC chemokine receptor 2 (CCR2). Myofiber size, numbers of myogenic progenitor cells (MPCs), and recruitment of BM-derived cells and macrophages were assessed after cardiotoxin-induced injury of chimeric mice produced by transplanting BM from wild-type (WT) or CCR2(-/-) mice into irradiated WT or CCR2(-/-) host mice. Regardless of the host genotype, muscle regeneration and recruitment of BM-derived cells and macrophages were similar in mice replenished with WT BM, whereas BM-derived cells and macrophage accumulation were decreased and muscle regeneration was impaired in all animals receiving CCR2(-/-) BM. Furthermore, numbers of MPCs (CD34(+)/Sca-1(-)/CD45(-) cells) were significantly increased in mice receiving CCR2(-/-) BM despite the decreased size of regenerated myofibers. Thus, the expression of CCR2 on BM-derived cells regulated macrophage recruitment into injured muscle, numbers of MPC, and the extent of regenerated myofiber size, all of which were independent of CCR2 expression on host-derived cells. Future studies in regenerative medicine must include consideration of the role of BM-derived cells, possibly macrophages, in CCR2-dependent events that regulate effective skeletal muscle regeneration. - Sun, D., Martinez, C. O., Ochoa, O., Ruiz-Willhite, L., Bonilla, J. R., Centonze, V. E., Waite, L. L., Michalek, J. E., McManus, L. M., Shireman, P. K. Bone marrow-derived cell regulation of skeletal muscle regeneration. FASEB J. 23, 382-395 (2009) C1 [Sun, Dongxu; Martinez, Carlo O.; Ochoa, Oscar; Ruiz-Willhite, Lourdes; Bonilla, Jose R.; Shireman, Paula K.] Univ Texas Hlth Sci Ctr San Antonio, Dept Surg, San Antonio, TX 78229 USA. [Centonze, Victoria E.] Univ Texas Hlth Sci Ctr San Antonio, Dept Cell & Struct Biol, San Antonio, TX 78229 USA. [Waite, Lindsay L.; Michalek, Joel E.] Univ Texas Hlth Sci Ctr San Antonio, Dept Epidemiol & Biostat, San Antonio, TX 78229 USA. [McManus, Linda M.] Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, San Antonio, TX 78229 USA. [McManus, Linda M.] Univ Texas Hlth Sci Ctr San Antonio, Dept Periodont, San Antonio, TX 78229 USA. [McManus, Linda M.; Shireman, Paula K.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA. [Shireman, Paula K.] Univ Texas Hlth Sci Ctr San Antonio, Sam & Ann Barshop Inst Longev & Aging Studies, San Antonio, TX 78229 USA. [Shireman, Paula K.] Audie L Murphy Mem Vet Adm Med Ctr, San Antonio, TX 78284 USA. RP Shireman, PK (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Surg, 7703 Floyd Curl Dr,MC 7741, San Antonio, TX 78229 USA. EM shireman@uthscsa.edu FU UTHSCSA; San Antonio Cancer Institute [CA54174]; Nathan Shock Center [AG013319]; Veterans Administration Merit Review; San Antonio Area Foundation [Sun-UTHSCSA-060104]; National Institutes of Health, National Heart, Lung, and Blood Institute [R01HL074236, F32HL090196]; [AG19316] FX We acknowledge the expert technical assistance of Michael D. Wetzel and Jimmy Wewer in these studies. A portion of the statistical analyses was expertly performed by Lee Ann Zarzabal. The flow cytometry portion of this work was performed at the Institutional Flow Cytometry Core of the University of Texas Health Science Center, San Antonio (UTHSCSA). Images were generated in the UTHSCSA Core Optical Imaging Facility, which is supported by UTHSCSA, CA54174 (San Antonio Cancer Institute), AG013319 (Nathan Shock Center), and AG19316. These studies were supported, in part, by a Veterans Administration Merit Review grant, the San Antonio Area Foundation (Sun-UTHSCSA-060104), and the National Institutes of Health (R01HL074236 and F32HL090196) from the National Heart, Lung, and Blood Institute. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. The authors have no relationships that pose a conflict of interest for these studies. NR 71 TC 53 Z9 53 U1 1 U2 7 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD FEB PY 2009 VL 23 IS 2 BP 382 EP 395 DI 10.1096/fj.07-095901 PG 14 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA 400TZ UT WOS:000262892900010 PM 18827026 ER PT J AU Sun, W Hu, W Xu, RJ Jin, JF Szulc, ZM Zhang, GF Galadari, SH Obeid, LM Mao, CG AF Sun, Wei Hu, Wei Xu, Ruijuan Jin, Junfei Szulc, Zdzislaw M. Zhang, Guofeng Galadari, Sehamuddin H. Obeid, Lina M. Mao, Cungui TI Alkaline ceramidase 2 regulates beta 1 integrin maturation and cell adhesion SO FASEB JOURNAL LA English DT Article DE retinoic acid; protein kinase C; Golgi; sphingolipid ID INTEGRIN RECEPTORS; ALPHA-5-BETA-1 INTEGRIN; MOLECULAR-CLONING; CARCINOMA-CELLS; SPHINGOID BASES; DOWN-REGULATION; RETINOIC ACID; GLYCOSYLATION; APOPTOSIS; EXPRESSION AB The polypeptide core of the integrin beta 1 subunit (beta 1) is glycosylated sequentially in the endoplasmic reticulum and the Golgi complex to form beta 1 precursor and mature beta 1, respectively. The beta 1 precursor to mature beta 1 conversion, termed beta 1 maturation, regulates the cell surface levels and function of beta 1-containing integrins, beta 1 integrins. Here we demonstrate that the human alkaline ceramidase 2 (ACER2), a Golgi enzyme, regulates beta 1 maturation by controlling the generation of sphingosine. ACER2 overexpression inhibited beta 1 maturation, thus leading to a decrease in the levels of mature beta-1 in T-REx HeLa cells, whereas RNA interference-mediated knockdown of ACER2 enhanced beta 1 maturation in MCF-7 cells. ACER2 overexpression decreased the cell surface levels of beta 1 integrins, thus inhibiting cell adhesion to fibronectin or collagen, whereas ACER2 knockdown has the opposite effects. Treatment with all-trans retinoic acid (ATRA) increased both the expression of ACER2 and the generation of sphingosine in HeLa cells and inhibited beta 1 maturation. ACER2 knockdown attenuated the inhibitory effects of ATRA on both beta 1 maturation and cell adhesion. In contrast, treatment with phorbol myristate acetate (PMA), a protein kinase C activator, decreased the expression of ACER2 and sphingosine in T-REx HeLa cells, thus enhancing beta 1 maturation. ACER2 overexpression inhibited the stimulatory effects of PMA on both beta 1 maturation and cell adhesion. These results suggest that the ACER2/sphingosine pathway plays an important role in regulating beta 1 maturation and cell adhesion mediated by beta 1 integrins. Sun, W., Hu, W., Xu, R., Jin, J., Szulc, Z. M., Zhang, G., Galadari, S. H., Obeid, L. M, Mao, C. Alkaline ceramidase 2 regulates beta 1 integrin maturation and cell adhesion. FASEB J. 23, 656-666 (2009) C1 [Sun, Wei; Xu, Ruijuan; Obeid, Lina M.; Mao, Cungui] Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA. [Hu, Wei; Jin, Junfei; Szulc, Zdzislaw M.; Obeid, Lina M.; Mao, Cungui] Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA. [Zhang, Guofeng] NIH, Div Bioengn & Phys Sci, Bethesda, MD 20892 USA. [Galadari, Sehamuddin H.] United Arab Emirates Univ, Fac Med & Hlth Sci, Dept Biochem, Al Ain, U Arab Emirates. [Obeid, Lina M.] Ralph H Johnson Vet Adm Hosp, Charleston, SC USA. RP Mao, CG (reprint author), Div Gen Internal Med, 114 Doughty St,Rm 605 STB,POB 250779, Charleston, SC 29425 USA. EM maoc@musc.edu OI obeid, lina/0000-0002-0734-0847 FU National Institutes of Health [R01CA104834]; Veterans Affairs Merit award FX This work is supported by the National Institutes of Health grant R01CA104834 (to C.M.) and a Veterans Affairs Merit award (to L.M.O.). NR 40 TC 21 Z9 24 U1 0 U2 1 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD FEB PY 2009 VL 23 IS 2 BP 656 EP 666 DI 10.1096/fj.08-115634 PG 11 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA 400TZ UT WOS:000262892900036 PM 18945876 ER PT J AU Baddley, JW AF Baddley, John W. TI Pinpointing prognostic indicators of fungal infections in transplant patients SO FUTURE MICROBIOLOGY LA English DT Review DE Aspergillus; Candida; mortality; prognostic factors; transplant ID SOLID-ORGAN TRANSPLANTATION; BONE-MARROW-TRANSPLANTATION; STEM-CELL TRANSPLANTS; INVASIVE ASPERGILLOSIS; RISK-FACTORS; IMMUNOCOMPROMISED PATIENTS; FLUCONAZOLE PROPHYLAXIS; ATTRIBUTABLE MORTALITY; CONTROLLED TRIAL; RECIPIENTS AB A number of advances have been made in the prevention and treatment of invasive fungal Infections (IFIs) in transplant recipients. However, despite best clinical efforts, patient outcomes are often disappointing. The study of prognostic indicators of IFI for transplant patients may aid in the development of improved prevention measures, or determine more aggressive treatment pathways. Owing to the rarity of IFI, appropriately powered studies are often difficult to achieve; moreover, a lack of standardized outcome definitions make study comparisons difficult. Herein, prognostic indicators for mortality in transplant patients with IFI are reviewed, with a focus on invasive aspergillosis and invasive candidiasis C1 [Baddley, John W.] Univ Alabama, Birmingham, AL 35294 USA. [Baddley, John W.] Birmingham VA Med Ctr, Birmingham, AL USA. RP Baddley, JW (reprint author), Univ Alabama, Birmingham, AL 35294 USA. EM jbaddley@uab.ed NR 40 TC 1 Z9 1 U1 1 U2 1 PU FUTURE MEDICINE LTD PI LONDON PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3 1QB, ENGLAND SN 1746-0913 J9 FUTURE MICROBIOL JI Future Microbiol. PD FEB PY 2009 VL 4 IS 1 BP 77 EP 84 DI 10.2217/17460913.4.1.77 PG 8 WC Microbiology SC Microbiology GA 412VO UT WOS:000263752500011 PM 19207101 ER PT J AU Artifon, ELA Kumar, A Eloubeidi, MA Chu, A Halwan, B Sakai, P Bhutani, MS AF Artifon, Everson L. A. Kumar, Atul Eloubeidi, Mohamad A. Chu, Adrienne Halwan, Bhawna Sakai, Paulo Bhutani, Manoop S. TI Prospective randomized trial of EUS versus ERCP-guided common bile duct stone removal: an interim report (with video) SO GASTROINTESTINAL ENDOSCOPY LA English DT Article; Proceedings Paper CT Digestive Disease Week Meeting/108th Annual Meeting of the American-Gastroenterological-Association CY MAY 19-24, 2007 CL Washington, DC SP Amer Gastroenterol Assoc, Amer Assoc Study Liver Dis, Amer Soc Gastrointestinal Endoscopy, Soc Surg Alimentary Tract ID MAGNETIC-RESONANCE CHOLANGIOPANCREATOGRAPHY; ENDOSCOPIC ULTRASOUND; MANAGEMENT AB Background: EUS is being increasingly utilized for the diagnosis of choledocholithiasis and microlithiasis, especially in patients with biliary colic. Simultaneously, there is also a rising interest in the use of EUS for therapeutic interventions. Objectives: Our goal was to assess the effectiveness of EUS-directed common bile duct (CBD) stone removal to compare its safety and effectiveness with ERCP-directed intervention. Design: interim results of a prospective, randomized, single-center blinded clinical trial. Setting: A single tertiary care referral center. Patients: Fifty-two patients with uncomplicated CBD stones were prospectively randomized to CBD cannulation and stone removal under EUS or ERCP guidance. Main Outcome Measurements and Interventions: Primary outcome measure was the rate of successful cannulation of the CBD. Secondary Outcome measures included Successful removal of stones and overall complication rates. Results: CBD cannulation followed by stone extraction was successful in 23 of 26 patients (88.5%) in the EUS group (1) versus 25 of 26 patients (96.2%) in the ERCP group (11) (95% CI, -27.65%, 9.88%). Overall, there were 3 complications in the EUS group and 4 complications in the ERCP group. Limitation: The current study is an interim report from a single center report and performed by a single operator. Conclusions: Our preliminary analysis indicates that Outcomes following EUS-guided CBD stone retrieval are equivalent to those following ERCP EUS-related adverse events are similar to those following ERCP. ERCP and EUS-guided stone retrieval appears to be equally effective for therapeutic interventions of the bile duct. Additional studies are required to validate these preliminary results and to determine predictors of success of EUS-guided stone removal. (Gastrointest Endosc 2009;69:238-43.) C1 [Kumar, Atul] SUNY Stony Brook, US Dept Vet Affairs, Stony Brook, NY 11794 USA. [Artifon, Everson L. A.; Sakai, Paulo] Univ Sao Paulo, Sch Med, Sao Paulo, Brazil. [Halwan, Bhawna] Suny Downstate Univ, Med Ctr, Brooklyn, NY USA. [Eloubeidi, Mohamad A.] Univ Alabama, Birmingham, AL USA. [Bhutani, Manoop S.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. RP Kumar, A (reprint author), SUNY Stony Brook, US Dept Vet Affairs, Stony Brook, NY 11794 USA. EM atul.kumar2@va.gov NR 9 TC 15 Z9 16 U1 0 U2 1 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0016-5107 J9 GASTROINTEST ENDOSC JI Gastrointest. Endosc. PD FEB PY 2009 VL 69 IS 2 BP 238 EP 243 DI 10.1016/j.gie.2008.05.020 PG 6 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 402JF UT WOS:000263009300008 PM 19185687 ER PT J AU Shub, D Darvishi, R Kunik, ME AF Shub, Denis Darvishi, Roham Kunik, Mark E. TI Non-pharmacologic treatment of insomnia in persons with dementia SO GERIATRICS LA English DT Article DE aging; circadian rhythm; dementia; insomnia; light therapy; sleep hygiene ID ALZHEIMERS-DISEASE; CONTROLLED-TRIAL; OLDER-ADULTS; SLEEP; DISTURBANCES; MANAGEMENT; EXERCISE; PROJECT AB The prevalence of insomnia increases with age and affects up to 35% of community-dwelling adults with dementia. Sleep disturbances and associated cognitive and behavioral symptoms in this patient population can be a significant contributor to morbidity, mortality, and caregiver burden. Despite the frequency with which sleep disorders are encountered in primary care, few evidence-based guidelines are available to guide physician treatment plans. Sedative-hypnotic medications are commonly prescribed but are associated with significant adverse effects and have limited efficacy data. Non-pharmacologic treatments can be safe and effective adjuncts or alternatives to medications but are often underused in clinical practice. This article reviews practical applications of modalities such as light therapy, exercise, and sleep-hygiene modification in treating insomnia In persons with dementia. C1 [Shub, Denis; Kunik, Mark E.] Baylor Coll Med, Menninger Dept Psychiat & Behav Sci, Houston, TX 77030 USA. [Darvishi, Roham] Baylor Coll Med, Dept Med, Houston, TX 77030 USA. [Darvishi, Roham] Michael E DeBakey Vet Affairs Med Ctr, Houston, TX USA. [Kunik, Mark E.] Houston Ctr Qual Care & Utilizat Studies, Houston, TX USA. RP Shub, D (reprint author), Baylor Coll Med, Menninger Dept Psychiat & Behav Sci, Houston, TX 77030 USA. NR 16 TC 20 Z9 20 U1 4 U2 11 PU ADVANSTAR COMMUNICATIONS INC PI WOODLAND HILLS PA 6200 CANOGA AVE, 2ND FLR, WOODLAND HILLS, CA 91367 USA SN 0016-867X J9 GERIATRICS JI Geriatrics PD FEB PY 2009 VL 64 IS 2 BP 22 EP 26 PG 5 WC Geriatrics & Gerontology SC Geriatrics & Gerontology GA 409UN UT WOS:000263531400004 PM 19256583 ER PT J AU Liu, CF Rubenstein, LV Kirchner, JE Fortney, JC Perkins, MW Ober, SK Pyne, JM Chaney, EF AF Liu, Chuan-Fen Rubenstein, Lisa V. Kirchner, JoAnn E. Fortney, John C. Perkins, Mark W. Ober, Scott K. Pyne, Jeffrey M. Chaney, Edmund F. TI Organizational Cost of Quality Improvement for Depression Care SO HEALTH SERVICES RESEARCH LA English DT Article DE Quality improvement; depression; primary care ID RANDOMIZED CONTROLLED-TRIAL; CHRONIC ILLNESS CARE; TRANSLATING EVIDENCE; COLLABORATIVE CARE; HEALTH-CARE; MANAGEMENT; IMPLEMENTATION; IMPACT; INTERVENTIONS; INNOVATIONS AB We documented organizational costs for depression care quality improvement (QI) to develop an evidence-based, Veterans Health Administration (VA) adapted depression care model for primary care practices that performed well for patients, was sustained over time, and could be spread nationally in VA. Project records and surveys from three multistate VA administrative regions and seven of their primary care practices. Descriptive analysis. We documented project time commitments and expenses for 86 clinical QI and 42 technical expert support team participants for 4 years from initial contact through care model design, Plan-Do-Study-Act cycles, and achievement of stable workloads in which models functioned as routine care. We assessed time, salary costs, and costs for conference calls, meetings, e-mails, and other activities. Over an average of 27 months, all clinics began referring patients to care managers. Clinical participants spent 1,086 hours at a cost of $84,438. Technical experts spent 2,147 hours costing $197,787. Eighty-five percent of costs derived from initial regional engagement activities and care model design. Organizational costs of the QI process for depression care in a large health care system were significant, and should be accounted for when planning for implementation of evidence-based depression care. C1 [Liu, Chuan-Fen; Kirchner, JoAnn E.; Fortney, John C.; Pyne, Jeffrey M.] VA Puget Sound Healthcare Syst, NW Ctr Outcomes Res Older Adults, Seattle, WA 98101 USA. [Rubenstein, Lisa V.] VA Greater Los Angeles Healthcare Syst, Ctr Excellence Study Healthcare Provider Behav, Sepulveda, CA USA. [Rubenstein, Lisa V.] RAND Hlth Program, Santa Monica, CA USA. [Rubenstein, Lisa V.] Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA. [Kirchner, JoAnn E.; Fortney, John C.; Pyne, Jeffrey M.] S Cent Mental Hlth Illness Res & Educ & Clin Ctr, N Little Rock, AR USA. [Kirchner, JoAnn E.; Fortney, John C.; Pyne, Jeffrey M.] Cent Arkansas Vet Healthcare Syst, Ctr Mental Healthcare & Outcomes Res, N Little Rock, AR USA. [Kirchner, JoAnn E.; Fortney, John C.; Pyne, Jeffrey M.] Univ Arkansas Med Sci, Div Hlth Serv Res, Dept Psychiat & Behav Sci, Little Rock, AR 72205 USA. [Ober, Scott K.] Case Western Reserve Univ, Dept Med, Cleveland, OH 44106 USA. [Ober, Scott K.] Cleveland VA Med Ctr, Cleveland, OH USA. [Chaney, Edmund F.] Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Liu, Chuan-Fen] Univ Washington, Sch Publ Hlth & Community Med, Dept Hlth Serv, Seattle, WA 98195 USA. RP Liu, CF (reprint author), VA Puget Sound Healthcare Syst, NW Ctr Outcomes Res Older Adults, 1100 Olive Way,Suite 1400, Seattle, WA 98101 USA. EM chuan-fen.liu@va.gov FU Health Services Research and Development, Department of Veterans Affairs [MNT-02-209, MNT-01-027]; TIDES/WAVES/COVES FX Joint Acknowledgement/Disclosure Statement: Funding provided by Health Services Research and Development, Department of Veterans Affairs (grant numbers MNT-02-209 and MNT-01-027).; We would like to acknowledge the support and assistance from TIDES/WAVES/COVES project research staff in submitting detailed project records and contributing their comments to this paper. In addition, we would like to acknowledge the participation and support from our three VISN partners (VISNs 10, 16, and 23).; There are no contractual rights to review the manuscript before submission, but there is a requirement that Health Services Research and Development, Department of Veterans Affairs, be given a copy of the accepted manuscript before publication. The views expressed herein are those of the authors and do not necessarily represent the views of the Department of Veterans Affairs and other affiliated Institutions. NR 42 TC 25 Z9 26 U1 1 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0017-9124 EI 1475-6773 J9 HEALTH SERV RES JI Health Serv. Res. PD FEB PY 2009 VL 44 IS 1 BP 225 EP 244 DI 10.1111/j.1475-6773.2008.00911.x PG 20 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA 394TM UT WOS:000262470800014 PM 19146566 ER PT J AU Rosendorff, C AF Rosendorff, Clive TI The Chicken and the Egg Sympathetic Nervous System Activity and Left Ventricular Diastolic Dysfunction SO HYPERTENSION LA English DT Editorial Material ID MYOCARDIAL-INFARCTION; RATS C1 [Rosendorff, Clive] James J Peters Vet Affairs Med Ctr, Bronx, NY 10468 USA. [Rosendorff, Clive] Mt Sinai Sch Med, Dept Med, New York, NY USA. RP Rosendorff, C (reprint author), James J Peters Vet Affairs Med Ctr, 130 W Kingsbridge Rd, Bronx, NY 10468 USA. EM clive.rosendorff@va.gov NR 8 TC 2 Z9 2 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0194-911X J9 HYPERTENSION JI Hypertension PD FEB PY 2009 VL 53 IS 2 BP 108 EP 109 DI 10.1161/HYPERTENSIONAHA.108.126177 PG 2 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 396XM UT WOS:000262625400002 PM 19124677 ER PT J AU Du, YH Chen, AF AF Du, Yan-Hua Chen, Alex F. TI A New Role for Caveolin-1 Regulation of Guanosine Triphosphate Cyclohydrolase I and Tetrahydrobiopterin in Endothelial Cells SO HYPERTENSION LA English DT Editorial Material ID SIGNAL-TRANSDUCTION; VASCULAR-DISEASE; ACTIVATION C1 [Du, Yan-Hua; Chen, Alex F.] Univ Pittsburgh, Sch Med, Dept Surg, Pittsburgh, PA 15240 USA. [Chen, Alex F.] Vet Affairs Pittsburgh Healthcare Syst, Vasc Surg Res, Pittsburgh, PA USA. RP Chen, AF (reprint author), Univ Pittsburgh, Sch Med, Dept Surg, 2W109 151L-U,VAPHS,Univ Dr, Pittsburgh, PA 15240 USA. EM chena5@upmc.edu FU NIGMS NIH HHS [R01 GM077352, R01 GM077352-02, R01 GM077352-03, R01 GM077352-01] NR 10 TC 3 Z9 4 U1 0 U2 5 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0194-911X J9 HYPERTENSION JI Hypertension PD FEB PY 2009 VL 53 IS 2 BP 115 EP 117 DI 10.1161/HYPERTENSIONAHA.108.123356 PG 3 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 396XM UT WOS:000262625400005 PM 19104002 ER PT J AU Hernandez, MD Mansouri, MD Aslam, S Zeluff, B Darouiche, RO AF Hernandez, Maria D. Mansouri, Mohammad D. Aslam, Saima Zeluff, Barry Darouiche, Rabih O. TI Efficacy of Combination of N-acetylcysteine, Gentamicin, and Amphotericin B for Prevention of Microbial Colonization of Ventricular Assist Devices SO INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY LA English DT Article ID STAPHYLOCOCCUS-AUREUS INFECTION; CENTRAL VENOUS CATHETERS; BACTERIA; BIOFILM AB We assessed the in vitro antimicrobial activity and the in vivo efficacy of dipping ventricular assist devices in a combination of N-acetylcysteine, gentamicin, and amphotericin B (NAC/G/A). Ventricular assist devices dipped in NAC/G/A exhibited broad-spectrum antimicrobial activity in vitro and were less likely than undipped devices to become colonized with Staphylococcus aureus in a rabbit model. C1 [Mansouri, Mohammad D.; Darouiche, Rabih O.] Baylor Coll Med, Ctr Prostheses Infect, Houston, TX 77030 USA. [Mansouri, Mohammad D.; Aslam, Saima; Darouiche, Rabih O.] Michael E DeBakey Vet Affairs Med Ctr, Houston, TX USA. [Aslam, Saima; Zeluff, Barry] St Lukes Episcopal Hosp, Houston, TX 77030 USA. [Hernandez, Maria D.; Aslam, Saima; Darouiche, Rabih O.] Baylor Coll Med, Infect Dis Sect, Houston, TX 77030 USA. RP Darouiche, RO (reprint author), Baylor Coll Med, Ctr Prostheses Infect, 1333 Moursund Ave,Suite A221, Houston, TX 77030 USA. EM rdarouiche@aol.com NR 10 TC 13 Z9 13 U1 0 U2 2 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 0899-823X J9 INFECT CONT HOSP EP JI Infect. Control Hosp. Epidemiol. PD FEB PY 2009 VL 30 IS 2 BP 190 EP 192 DI 10.1086/593205 PG 3 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 394YV UT WOS:000262490000013 PM 19090771 ER PT J AU Sonnenberg, A AF Sonnenberg, Amnon TI Date of Birth in the Occurrence of Inflammatory Bowel Disease SO INFLAMMATORY BOWEL DISEASES LA English DT Article DE birth date; cyclic pattern; environmental risk factors; epidemiology of inflammatory bowel disease; hospital statistics; seasonality of births; time trends ID CROHNS-DISEASE; ULCERATIVE-COLITIS; RECORD LINKAGE; TIME TRENDS; CHILDHOOD; MORTALITY; RISK AB Background: It has been Speculated that prenatal or perinatal exposure to infections affects the risk for developing inflammatory bowel disease (11313). The aims of the study were to investigate the seasonal and monthly variations of birth dates among patients with Crohn's disease (CD) and ulcerative colitis (UC). Methods: The Hospital Episode Statistics (HES) comprises data of all patients admitted to hospitals in England. The data between April 1997 and March 2006 served to analyze birth dates of subjects with CD and UD, using the entirety of patients in the HES as controls. Results: Monthly birth dates were aggregated for the same months across Consecutive birth years from January 1920 to December 1989 to determine whether a seasonal birth pattern existed among patients with CD and UC, No different seasonal birth patterns were observed between IBD patients and controls. A second analysis of individual months of birth, year after year, found that rates of births among 11313 patients fluctuated from month to month. These fluctuations were different for CD and UC, with an overall weak correlation of r = 0.078, P = 0.018. There was a slight trend for stronger correlations to occur during more recent decades of birth, with r = 0.237 (P = 0.009) and r = 0.168 (P = 0.067) for the last 2 decades 1970-1979 and 1980-1989, respectively. Conclusions: The patterns of birth dates among IBD patients do not support the contention that seasonally or monthly varying environmental factors during early childhood shape the Subsequent risk of developing IBD. C1 [Sonnenberg, Amnon] Portland VA Med Ctr, Portland, OR 97239 USA. [Sonnenberg, Amnon] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. RP Sonnenberg, A (reprint author), Portland VA Med Ctr, P3 GI,3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM sonnenbe@ohsu.edu NR 20 TC 10 Z9 12 U1 0 U2 0 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 1078-0998 J9 INFLAMM BOWEL DIS JI Inflamm. Bowel Dis. PD FEB PY 2009 VL 15 IS 2 BP 206 EP 211 DI 10.1002/ibd.20730 PG 6 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 402TU UT WOS:000263036800008 PM 18831526 ER PT J AU Weamer, EA Emanuel, JE Varon, D Miyahara, S Wilkosz, PA Lopez, OL DeKosky, ST Sweet, RA AF Weamer, Elise A. Emanuel, James E. Varon, Daniel Miyahara, Sachiko Wilkosz, Patricia A. Lopez, Oscar L. DeKosky, Steven T. Sweet, Robert A. TI The relationship of excess cognitive impairment in MCI and early Alzheimer's disease to the subsequent emergence of psychosis SO INTERNATIONAL PSYCHOGERIATRICS LA English DT Article DE Alzheimer's disease; MCI (mild cognitive impairment); psychosis; cognitive neuropsychology in dementia; assessment of cognitive disorders/dementia ID INCREASED FAMILIAL RISK; LAST 2 DECADES; RATING-SCALE; MOUSE MODELS; SYMPTOMS; DELUSIONS; DIAGNOSIS; DEMENTIA; SCHIZOPHRENIA; HALLUCINATIONS AB Background: Psychotic symptoms in Alzheimer disease (AD + P) identify a heritable phenotype associated with greater cognitive impairment. Knowing when the cognitive course of AD + P subjects diverges from that of subjects without psychosis would enhance understanding of how genetic variation results in AD + P and its associated cognitive burden. This study seeks to determine whether the degree of cognitive impairment and cognitive decline in early AD predicts subsequent AD + P onset. Methods: 361 subjects with possible or probable AD or mild cognitive impairment (MCI) without psychosis were evaluated every 6 months until psychosis onset. Results: Severity of cognitive dysfunction was a strong predictor of AD + P up to two years prior to psychosis onset. Cognition did not decline more rapidly prior to onset of AD + P. Conclusions: Individuals who will develop AD + P already demonstrate excess cognitive impairment during the mild stages of disease. Genetic variation and brain pathophysiology may lead to a cognitive risk phenotype which is present prior to dementia onset. C1 [Weamer, Elise A.; Emanuel, James E.; Varon, Daniel; Wilkosz, Patricia A.; Lopez, Oscar L.; DeKosky, Steven T.; Sweet, Robert A.] Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA USA. [Weamer, Elise A.; Lopez, Oscar L.; Sweet, Robert A.] Univ Pittsburgh, Dept Neurol, Pittsburgh, PA USA. [Miyahara, Sachiko] Univ Pittsburgh, Dept Epidemiol, Pittsburgh, PA USA. [Sweet, Robert A.] VA Pittsburgh Healthcare Syst, VISN Mental Illness Res Educ & Clin Ctr 4, Pittsburgh, PA USA. RP Sweet, RA (reprint author), Biomed Sci Tower,Rm W-1645,3811 OHara St, Pittsburgh, PA 15213 USA. EM sweetra@upmc.edu FU National Institute of Aging [AG05133, AG027224] FX This study was supported in part by USPHS grant AG05133 and AG027224 from the National Institute of Aging. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of Aging or the National Institutes of Health. NR 46 TC 22 Z9 22 U1 1 U2 4 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 1041-6102 J9 INT PSYCHOGERIATR JI Int. Psychogeriatr. PD FEB PY 2009 VL 21 IS 1 BP 78 EP 85 DI 10.1017/S1041610208007734 PG 8 WC Psychology, Clinical; Geriatrics & Gerontology; Gerontology; Psychiatry; Psychology SC Psychology; Geriatrics & Gerontology; Psychiatry GA 408NI UT WOS:000263441300010 PM 18814807 ER PT J AU Kim, MS Casserly, IP Garcia, JA Klein, AJ Salcedo, EE Carroll, JD AF Kim, Michael S. Casserly, Ivan P. Garcia, Joel A. Klein, Andrew J. Salcedo, Ernesto E. Carroll, John D. TI Percutaneous Transcatheter Closure of Prosthetic Mitral Paravalvular Leaks Are We There Yet? SO JACC-CARDIOVASCULAR INTERVENTIONS LA English DT Article DE paravalvular leak; perivalvular leak; mitral valve; prosthetic valve; 3-dimensional echocardiography; percutaneous transcatheter closure; rapid prototyping ID AMPLATZER DUCT OCCLUDER; VALVE-REPLACEMENT; HEART-DISEASE; REGURGITATION; HEMOLYSIS; ECHOCARDIOGRAPHY; COMPLICATION; MANAGEMENT; OCCLUSION AB A potential complication of mitral valve replacement surgery is the development of a paravalvular leak (PVL). Percutaneous transcatheter closures of PVLs using a wide array of devices have been reported in the literature, although the procedural success rate of this approach remains variable. One major challenge of transcatheter mitral PVL closure lies in the ability to adequately visualize the area of interest to facilitate defect crossing and equipment selection. Furthermore, the current spectrum of devices available for off-label use in the closure of these unique defects remains limited. This review examines the current state of transcatheter. prosthetic mitral PVL closure, describes our institution's experience using advanced imaging modalities for procedural guidance, and illustrates some of the limitations associated with using existing devices in transcatheter PVL closure. (J Am Coll Cardiol Intv 2009;2: 81-90) (C) 2009 by the American College of Cardiology Foundation C1 [Kim, Michael S.; Casserly, Ivan P.; Garcia, Joel A.; Klein, Andrew J.; Salcedo, Ernesto E.; Carroll, John D.] Univ Colorado Denver, Aurora, CO 80045 USA. [Casserly, Ivan P.] Denver Vet Affairs Med Ctr, Denver, CO USA. [Garcia, Joel A.] Denver Hlth Med Ctr, Denver, CO USA. RP Carroll, JD (reprint author), Univ Colorado Denver, Anschutz Med Campus,Leprino Off Bldg,Room 524,124, Aurora, CO 80045 USA. EM John.Carroll@ucdenver.edu NR 27 TC 67 Z9 71 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1936-8798 J9 JACC-CARDIOVASC INTE JI JACC-Cardiovasc. Interv. PD FEB PY 2009 VL 2 IS 2 BP 81 EP 90 DI 10.1016/j.jcin.2008.10.012 PG 10 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 613HP UT WOS:000278970300001 PM 19463407 ER PT J AU Morasco, BJ Rifai, MA Loftis, JM Indest, DW Moles, JK Hauser, P AF Morasco, Benjamin J. Rifai, Muhamad Aly Loftis, Jennifer M. Indest, David W. Moles, James Kelly Hauser, Peter TI A randomized trial of paroxetine to prevent interferon-alpha-induced depression in patients with hepatitis C (vol 103, pg 83, 2007) SO JOURNAL OF AFFECTIVE DISORDERS LA English DT Correction C1 [Morasco, Benjamin J.; Rifai, Muhamad Aly; Loftis, Jennifer M.; Indest, David W.; Hauser, Peter] Portland VA Med Ctr, Behav Hlth & Clin Neurosci Div, Portland, OR USA. [Rifai, Muhamad Aly; Moles, James Kelly] Salem VA Med Ctr, Salem, VA USA. [Morasco, Benjamin J.; Rifai, Muhamad Aly; Loftis, Jennifer M.; Indest, David W.; Hauser, Peter] Portland VA Med Ctr, NW Hepatitis C Resource Ctr, Portland, OR USA. [Rifai, Muhamad Aly; Moles, James Kelly] Univ Virginia, Sch Med, Roanoke Salem, VA USA. [Morasco, Benjamin J.; Rifai, Muhamad Aly; Loftis, Jennifer M.; Indest, David W.; Hauser, Peter] Oregon Hlth & Sci Univ, Dept Psychiat, Portland, OR 97201 USA. [Loftis, Jennifer M.; Hauser, Peter] Portland VA Med Ctr, JENS Lab, Portland, OR USA. [Hauser, Peter] Oregon Hlth & Sci Univ, Dept Internal Med, Portland, OR 97201 USA. RP Hauser, P (reprint author), Portland VA Med Ctr, Behav Hlth & Clin Neurosci Div, 3710 SW US Vet Hosp Rd, Portland, OR USA. EM peter.hauser@med.va.gov NR 1 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0165-0327 J9 J AFFECT DISORDERS JI J. Affect. Disord. PD FEB PY 2009 VL 113 IS 1-2 BP 201 EP 201 DI 10.1016/j.jad.2008.10.001 PG 1 WC Clinical Neurology; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 402IN UT WOS:000263007500024 ER PT J AU Hedrick, SC Guihan, M Chapko, MK Sullivan, J Zhou, XH Manheim, LM Forsberg, CW Mambourg, FJ AF Hedrick, Susan C. Guihan, Marylou Chapko, Michael K. Sullivan, Jean Zhou, Xiao-Hua Manheim, Larry M. Forsberg, Christopher W. Mambourg, Floss J. TI Assisted Living Pilot Program Health Outcomes SO JOURNAL OF AGING AND HEALTH LA English DT Article DE assisted living; residential care facilities; long-term care; outcomes; longitudinal design ID RESIDENTIAL CARE; FACILITIES AB Objectives: Assisted living programs demonstrate variation in structure and services. The Department of Veterans Affairs funded this care for the first time in the Assisted Living Pilot Program (ALPP). This article presents resident health outcomes and the relationship between facility characteristics and outcomes. Method: This article presents results on 393 ALPP residents followed for 12 months after admission to 95 facilities. Results: A total of 19.8% residents died, and the average activities of daily living impairment did not change significantly. Half of the residents remained in an ALPP facility, with the average resident spending 315 days in the community during the 12-month follow-up period. This article found a limited number of characteristics of structure and staffing to be significantly associated with outcomes. Discussion: If differences among facility characteristics are not clearly related to differences in outcomes, then choices among type of setting can be based on the match of needs to available services, location, or preferences. C1 [Hedrick, Susan C.] VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, Seattle, WA 98101 USA. [Hedrick, Susan C.; Chapko, Michael K.; Zhou, Xiao-Hua] Univ Washington, Seattle, WA 98195 USA. [Guihan, Marylou; Manheim, Larry M.] Northwestern Univ, Evanston, IL 60208 USA. [Mambourg, Floss J.] Oregon Hlth & Sci Univ, Portland VA Med Ctr, Portland, OR 97201 USA. RP Hedrick, SC (reprint author), VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, 1100 Olive Way,Suite 1400, Seattle, WA 98101 USA. EM susan.hedrick@va.gov NR 19 TC 4 Z9 4 U1 2 U2 5 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0898-2643 J9 J AGING HEALTH JI J. Aging Health PD FEB PY 2009 VL 21 IS 1 BP 190 EP 207 DI 10.1177/0898264308328929 PG 18 WC Gerontology; Health Policy & Services SC Geriatrics & Gerontology; Health Care Sciences & Services GA 399QL UT WOS:000262814300009 PM 19074647 ER PT J AU Chapko, MK Manheim, LM Guihan, M Sullivan, JH Zhou, XHA Wang, L Mambourg, FJ Hedrick, SC AF Chapko, Michael K. Manheim, Larry M. Guihan, Marylou Sullivan, Jean H. Zhou, Xiao-Hua Andrew Wang, Li Mambourg, Floss J. Hedrick, Susan C. TI Assisted Living Pilot Program Utilization and Cost Findings SO JOURNAL OF AGING AND HEALTH LA English DT Article DE assisted living; residential care facilities; long-term care; cost ID HEALTH-CARE; FACILITIES; HOMES AB Objective: The Department of Veterans Affairs funded assisted living, adult family home, and adult residential care for the first time in the Assisted Living Pilot Program (ALPP) This article compares the use and cost for individuals that entered ALPP and a comparison group. Method: This was a nonrandomized study. The comparison group consisted of VA patients who were eligible but did not enter an ALPP facility. The ALPP (n = 393) and comparison (n = 259) groups were followed for 12 months to assess ALPP facility, case management, and health care costs. Results: ALPP facility and ALPP case management costs were respectively $5,560 and $2,830 per individual. Total health care costs, including ALPP costs, were $11,533 higher for the ALPP group compared to the comparison group after adjusting for baseline differences. Discussion: Although ALPP successfully helped individuals transition to longer term care in these facilities, it was more costly than the comparison group. C1 [Chapko, Michael K.] VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, Seattle, WA 98101 USA. [Chapko, Michael K.; Zhou, Xiao-Hua Andrew; Hedrick, Susan C.] Univ Washington, Seattle, WA 98195 USA. [Manheim, Larry M.; Guihan, Marylou] Edward Hines Jr VA Hosp, Hines, IL 60141 USA. [Manheim, Larry M.; Guihan, Marylou] Northwestern Univ, Evanston, IL 60208 USA. [Mambourg, Floss J.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. RP Chapko, MK (reprint author), VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, 1100 Olive Way,Suite 1400, Seattle, WA 98101 USA. EM chapko@u.washington.edu NR 30 TC 1 Z9 1 U1 1 U2 2 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0898-2643 J9 J AGING HEALTH JI J. Aging Health PD FEB PY 2009 VL 21 IS 1 BP 208 EP 225 DI 10.1177/0898264308328930 PG 18 WC Gerontology; Health Policy & Services SC Geriatrics & Gerontology; Health Care Sciences & Services GA 399QL UT WOS:000262814300010 PM 19144975 ER PT J AU Springston, EE Gupta, RS Kim, JS Smith, B Pongracic, JA Wang, X Holl, JL AF Springston, E. E. Gupta, R. S. Kim, J. S. Smith, B. Pongracic, J. A. Wang, X. Holl, J. L. TI Food Allergy Knowledge, Attitudes, and Beliefs in the United States SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY LA English DT Meeting Abstract CT 65th Annual Meeting of the American-Academy-of-Allergy-Asthma-and-Immunology CY MAR 13-17, 2009 CL Washington, DC SP Amer Acad Allergy, Asthma & Immunol C1 [Springston, E. E.; Gupta, R. S.; Kim, J. S.; Pongracic, J. A.; Wang, X.; Holl, J. L.] Childrens Mem Hosp, Chicago, IL 60614 USA. [Gupta, R. S.; Smith, B.; Holl, J. L.] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA. [Smith, B.] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Hines, IL 60141 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0091-6749 J9 J ALLERGY CLIN IMMUN JI J. Allergy Clin. Immunol. PD FEB PY 2009 VL 123 IS 2 MA 688 BP S180 EP S180 DI 10.1016/j.jaci.2008.12.679 PG 1 WC Allergy; Immunology SC Allergy; Immunology GA 410RR UT WOS:000263596301161 ER PT J AU Yong, PL Werner, RM AF Yong, P. L. Werner, R. M. TI The Impact of Geographic Variation on Racial Disparities in Asthma: Controller Medication Use among Medicaid Asthmatics in Four Large States SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY LA English DT Meeting Abstract CT 65th Annual Meeting of the American-Academy-of-Allergy-Asthma-and-Immunology CY MAR 13-17, 2009 CL Washington, DC SP Amer Acad Allergy, Asthma & Immunol C1 [Yong, P. L.; Werner, R. M.] Univ Penn, Sch Med, Philadelphia, PA 19104 USA. [Yong, P. L.; Werner, R. M.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. NR 0 TC 1 Z9 1 U1 0 U2 1 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0091-6749 J9 J ALLERGY CLIN IMMUN JI J. Allergy Clin. Immunol. PD FEB PY 2009 VL 123 IS 2 MA 581 BP S152 EP S152 DI 10.1016/j.jaci.2008.12.569 PG 1 WC Allergy; Immunology SC Allergy; Immunology GA 410RR UT WOS:000263596301054 ER PT J AU Nakano, T Inoue, I Satoh, K Yamazaki, M Awata, T Kurihara, S Goto, S Shinoda, Y Komoda, T Katayama, S AF Nakano, Takanari Inoue, Ikuo Satoh, Kentaro Yamazaki, Mochihito Awata, Takuya Kurihara, Susumu Goto, Sei-ichi Shinoda, Yu-ichi Komoda, Tsugikazu Katayama, Shigehiro TI Treatment with Glimepiride, but not Mitiglinide and Short-Acting Insulin, Resists Body Weight and Abdominal Fat Reduction Under Dietary Energy Restriction SO JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS LA English DT Letter DE Obesity; Lifestyle intervention; Oral hypoglycemic agents; Type 2 diabetes mellitus; Syndrome of inappropriate insulin secretion (SIIS) ID TYPE-2 DIABETES-MELLITUS; SECRETION; SULFONYLUREAS; KAD-1229 C1 [Nakano, Takanari; Shinoda, Yu-ichi; Komoda, Tsugikazu] Saitama Med Univ, Fac Med, Dept Biochem, Saitama, Japan. [Yamazaki, Mochihito] Kumagaya Surg Hosp, Saitama, Japan. [Goto, Sei-ichi] Meikai Univ, Sch Dent, Dept Comprehens Med Sci, Div Internal Med, Saitama, Japan. [Inoue, Ikuo] Univ Calif Los Angeles, Sch Med, Dept Med, Los Angeles, CA 90024 USA. RP Nakano, T (reprint author), W Los Angeles VA Med Ctr, Bldg 114,Suite 217,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM nk.takanari@gmail.com NR 13 TC 3 Z9 3 U1 0 U2 0 PU JAPAN ATHEROSCLEROSIS SOC PI TOKYO PA NICHINAI-KAIKAN B1, 3-28-8 HONGO BUNKYO-KU, TOKYO, 113-0033, JAPAN SN 1340-3478 EI 1880-3873 J9 J ATHEROSCLER THROMB JI J. Atheroscler. Thromb. PD FEB PY 2009 VL 16 IS 1 BP 63 EP 66 PG 4 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 413PK UT WOS:000263804800009 PM 19261996 ER PT J AU Goebel, JR Doering, LV Evangelista, LS Nyamathi, AM Maliski, SL Asch, SM Sherbourne, CD Shugarman, LR Lanto, AB Cohen, A Lorenz, KA AF Goebel, Joy R. Doering, Lynn V. Evangelista, Lorraine S. Nyamathi, Adeline M. Maliski, Sally L. Asch, Steven M. Sherbourne, Cathy D. Shugarman, Lisa R. Lanto, Andy B. Cohen, Angela Lorenz, Karl A. TI A Comparative Study of Pain in Heart Failure and Non-Heart Failure Veterans SO JOURNAL OF CARDIAC FAILURE LA English DT Article DE Palliative care; non-malignant pain; chronic pain; symptoms ID QUALITY-OF-LIFE; PALLIATIVE CARE; CARDIAC-FAILURE; HEALTH; COMMUNITY; SYMPTOMS; DEPRESSION; MANAGEMENT; DISEASE; ASSOCIATION AB Background: Progress has been made in addressing pain in specific diseases such as cancer, but less attention has focused on understanding pain in nonmalignant states, including heart failure (HF). Methods and Results: From March 2006 to June 2007, 672 veterans were surveyed and scores for the Brief Pain Inventory, pain distress, clinically significant pain levels (moderate to severe pain), and pain locations were compared using univariate and multivariate models. Fifteen percent of the final sample had HF (95/634). In our study, the HF patients were older (P < .000), reported lower levels of general health (P = .018), had more co-morbidities (P < .000), were more likely to have a history of cancer (P = .035), and suffered more chest pain and fewer headaches (P = .026, P = .03, respectively) than their non-HF cohorts. When controlling for age, co-morbidity and cancer disorders, HF and non-HF patients did not differ in pain severity, interference, distress or locations. Of the patients Currently experiencing pain, 67.3% of HF patients and 68.4% of non-HF patients rated their pain as moderate or severe (pain >= 4 on a 0 to 10 scale). Conclusions: Although HF has not been identified as a painful condition, this study suggests the burden of pain is significant for both HF and non-HF ambulatory care patients. (J Cardiac Fail 2009:15:24-30) C1 [Goebel, Joy R.] Calif State Univ Long Beach, Dept Nursing, Long Beach, CA 90840 USA. [Doering, Lynn V.; Evangelista, Lorraine S.; Nyamathi, Adeline M.; Maliski, Sally L.] Univ Calif Los Angeles, Sch Nursing, Los Angeles, CA 90024 USA. [Asch, Steven M.; Sherbourne, Cathy D.; Shugarman, Lisa R.; Lorenz, Karl A.] RAND Corp, Santa Monica, CA USA. [Asch, Steven M.; Lorenz, Karl A.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Asch, Steven M.; Lanto, Andy B.; Cohen, Angela; Lorenz, Karl A.] Vet Adm Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. RP Goebel, JR (reprint author), Calif State Univ Long Beach, Dept Nursing, 1250 Bellflower Blvd, Long Beach, CA 90840 USA. OI Cohen, Angela B./0000-0002-0620-1909 FU Veterans Administration Health Services Research and Development [IIR03-150]; VA HSR&D Career Development Award FX Supported by a grant (IIR03-150) from the Veterans Administration Health Services Research and Development. Dr. Karl Lorenz was supported by a VA HSR&D Career Development Award. NR 64 TC 10 Z9 10 U1 2 U2 3 PU CHURCHILL LIVINGSTONE INC MEDICAL PUBLISHERS PI PHILADELPHIA PA CURTIS CENTER, INDEPENDENCE SQUARE WEST, PHILADELPHIA, PA 19106-3399 USA SN 1071-9164 J9 J CARD FAIL JI J. Card. Fail. PD FEB PY 2009 VL 15 IS 1 BP 24 EP 30 DI 10.1016/j.cardfail.2008.09.002 PG 7 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 408NJ UT WOS:000263441400004 PM 19181290 ER PT J AU Voruganti, VS Nath, SD Cole, SA Thameem, F Jowett, JB Bauer, R MacCluer, JW Blangero, J Comuzzie, AG Abboud, HE Arar, NH AF Voruganti, V. Saroja Nath, Subrata D. Cole, Shelley A. Thameem, Farook Jowett, Jeremy B. Bauer, Richard MacCluer, Jean W. Blangero, John Comuzzie, Anthony G. Abboud, Hanna E. Arar, Nedal H. TI Genetics of Variation in Serum Uric Acid and Cardiovascular Risk Factors in Mexican Americans SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM LA English DT Article ID QUANTITATIVE-TRAIT LOCUS; METABOLIC SYNDROME; BLOOD-PRESSURE; LINKAGE ANALYSIS; ATHEROSCLEROSIS RISK; CHEMOKINE RECEPTOR; RENAL-DISEASE; FAMILY; HEART; HYPERURICEMIA AB Background: Elevated serum uric acid is associated with several cardiovascular disease (CVD) risk factors such as hypertension, inflammation, endothelial dysfunction, insulin resistance, dyslipidemia, and obesity. However, the role of uric acid as an independent risk factor for CVD is not yet clear. Objective: The aim of the study was to localize quantitative trait loci regulating variation in serum uric acid and also establish the relationship between serum uric acid and other CVD risk factors in Mexican Americans (n = 848; men = 310, women = 538) participating in the San Antonio Family Heart Study. Methods: Quantitative genetic analysis was conducted using variance components decomposition method, implemented in the software program SOLAR. Results: Mean +/- SD of serum uric acid was 5.35 +/- 1.38 mg/dl. Univariate genetic analysis showed serum uric acid and other CVD risk markers to be significantly heritable (P < 0.005). Bivariate analysis showed significant correlation of serum uric acid with body mass index, waist circumference, waist/hip ratio, total body fat, plasma insulin, serum triglycerides, high-density lipoprotein cholesterol, C-reactive protein, and granulocyte macrophage-colony stimulating factor (P < 0.05). A genome-wide scan for detecting quantitative trait loci regulating serum uric acid variation showed a significant logarithm of odds (LOD) score of 4.72 (empirical LOD score = 4.62; P < 0.00001) on chromosome 3p26. One LOD support interval contains 25 genes, of which an interesting candidate gene is chemokine receptor 2. Summary: There is a significant genetic component in the variation in serum uric acid and evidence of pleiotropy between serum uric acid and other cardiovascular risk factors. (J Clin Endocrinol Metab 94: 632-638, 2009) C1 [Voruganti, V. Saroja; Cole, Shelley A.; MacCluer, Jean W.; Blangero, John; Comuzzie, Anthony G.] SW Fdn Biomed Res, Dept Genet, San Antonio, TX 78227 USA. [Nath, Subrata D.; Thameem, Farook; Bauer, Richard; Abboud, Hanna E.; Arar, Nedal H.] Univ Texas Hlth Sci Ctr San Antonio, George OBrien Kidney Res Ctr, Div Nephrol, San Antonio, TX 78229 USA. [Nath, Subrata D.; Thameem, Farook; Bauer, Richard; Abboud, Hanna E.; Arar, Nedal H.] Univ Texas Hlth Sci Ctr San Antonio, S Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA. [Jowett, Jeremy B.] Int Diabet Inst, Caulfield, Vic 3162, Australia. RP Voruganti, VS (reprint author), SW Fdn Biomed Res, Dept Genet, POB 760549, San Antonio, TX 78245 USA. EM svorugan@sfbrgenetics.org RI Jowett, Jeremy/A-3809-2009 FU San Antonio Family Heart Study; Fredric C. Bartter General Clinical Research Center; University of Texas Health Science Center at San Antonio, San Antonio, Texas [M01-RR01346] FX We thank all participants of the San Antonio Family Heart Study for their cooperation and generous participation. We also acknowledge the Fredric C. Bartter General Clinical Research Center, University of Texas Health Science Center at San Antonio, San Antonio, Texas (supported by M01-RR01346), for providing clinical support for this project. NR 48 TC 21 Z9 23 U1 0 U2 0 PU ENDOCRINE SOC PI CHEVY CHASE PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA SN 0021-972X J9 J CLIN ENDOCR METAB JI J. Clin. Endocrinol. Metab. PD FEB PY 2009 VL 94 IS 2 BP 632 EP 638 DI 10.1210/jc.2008-0682 PG 7 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 403HC UT WOS:000263072700046 PM 19001525 ER PT J AU Sayers, SL Farrow, VA Ross, J Oslin, DW AF Sayers, Steven L. Farrow, Victoria A. Ross, Jennifer Oslin, David W. TI Family Problems Among Recently Returned Military Veterans Referred for a Mental Health Evaluation SO JOURNAL OF CLINICAL PSYCHIATRY LA English DT Article ID CONFIRMATORY FACTOR-ANALYSIS; MEMORY-CONCENTRATION TEST; US ARMY SOLDIERS; PRIMARY-CARE; DOMESTIC VIOLENCE; SYMPTOM STRUCTURE; DSM-IV; DEPRESSION; RELIABILITY; DEPLOYMENT AB Context: Existing evidence suggests, that military veterans with mental health disorders have poorer Family functioning, although little research has focused on this topic. Objective: To test whether psychiatric symptoms are associated with family reintegration problems in recently returned military veterans. Design: Cross-sectional survey of a clinical population. Respondents who were referred to behavioral health evaluation from April 2006 through August 2007 were considered for the survey. Setting: Philadelphia Veterans Affairs Medical Center, Pa. Participants: 199 military veterans who served in Iraq or Afghanistan after 2001 and were referred for behavioral health evaluation from primary care (mean age = 32.7 years, SD = 9.1). Main Outcome Measures: Measures included the Mini-International Neuropsychiatric Interview for psychiatric diagnoses, the 9-item Patient Health Questionnaire for depression diagnosis and severity, and screening measures of alcohol abuse and illicit substance use. A measure of military family readjustment problems and a screening measure of domestic abuse were developed for this study. Results: Three fourths of the married/cohabiting veterans reported some type of family problem in the past week, such as feeling like a guest in their household (40.7%), reporting their children acting afraid or not being warm toward them (25.0%), or being unsure about their family role (37.2%). Among veterans with current or recently separated partners, 53.7% reported conflicts involving "shouting, pushing, or shoving," and 27.6% reported that this partner was "afraid " of them." Depression and posttraumatic stress disorder symptoms were both associated with higher rates of family reintegration problems. Conclusions: Mental health problems may complicate veterans' readjustment and reintegration into family life. The findings suggest an opportunity to improve the treatment of psychiatric disorders by addressing family problems. C1 [Sayers, Steven L.; Farrow, Victoria A.; Ross, Jennifer; Oslin, David W.] Philadelphia VA Med Ctr, VISN 4, MIRECC 116, Philadelphia, PA 19104 USA. [Sayers, Steven L.; Ross, Jennifer; Oslin, David W.] Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA. RP Sayers, SL (reprint author), Philadelphia VA Med Ctr, VISN 4, MIRECC 116, 3900 Woodland Ave, Philadelphia, PA 19104 USA. EM Steven.sayers@va.gov NR 38 TC 158 Z9 161 U1 9 U2 24 PU PHYSICIANS POSTGRADUATE PRESS PI MEMPHIS PA P O BOX 240008, MEMPHIS, TN 38124 USA SN 0160-6689 J9 J CLIN PSYCHIAT JI J. Clin. Psychiatry PD FEB PY 2009 VL 70 IS 2 BP 163 EP 170 PG 8 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA 411DD UT WOS:000263627300002 PM 19210950 ER PT J AU Bartlett, BL Tyring, SK Fife, K Gnann, JW Hadala, JT Kianifard, F Berberd, E AF Bartlett, Brenda L. Tyring, Stephen K. Fife, Kenneth Gnann, John W., Jr. Hadala, Joseph T. Kianifard, Farid Berberd, Erhan TI Famciclovir treatment options for patients with frequent outbreaks of recurrent genital herpes: The RELIEF trial (vol 43, pg 190, 2008) SO JOURNAL OF CLINICAL VIROLOGY LA English DT Correction C1 [Bartlett, Brenda L.; Tyring, Stephen K.] Univ Texas Houston, Hlth Sci Ctr, Houston, TX 77030 USA. [Fife, Kenneth] Indiana Univ, Sch Med, Indianapolis, IN USA. [Gnann, John W., Jr.] Univ Alabama, Birmingham, AL USA. [Gnann, John W., Jr.] Birmingham VA Med Ctr, Birmingham, AL USA. [Hadala, Joseph T.; Kianifard, Farid; Berberd, Erhan] Novartis Pharmaceut, E Hanover, NJ 07936 USA. RP Tyring, SK (reprint author), Univ Texas Houston, Hlth Sci Ctr, 6655 Travis, Houston, TX 77030 USA. EM bbartlett@ccstexas.com; styring@ccstexas.com; kfife@iupui.edu; jgnann@uab.edu; joseph.hadala@novartis.com; farid.kianifard@novartis.com; erhan.berber@novartis.com NR 1 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 1386-6532 J9 J CLIN VIROL JI J. Clin. Virol. PD FEB PY 2009 VL 44 IS 2 BP 183 EP 183 DI 10.1016/j.jcv.2008.11.012 PG 1 WC Virology SC Virology GA 416DU UT WOS:000263986400024 ER PT J AU Lauer, AM Dooling, RJ Leek, MR AF Lauer, Amanda M. Dooling, Robert J. Leek, Marjorie R. TI Psychophysical evidence of damaged active processing mechanisms in Belgian Waterslager Canaries SO JOURNAL OF COMPARATIVE PHYSIOLOGY A-NEUROETHOLOGY SENSORY NEURAL AND BEHAVIORAL PHYSIOLOGY LA English DT Article DE Psychophysical tuning curve; Harmonic complex; Active processing; Masking; Bird hearing ID PARAKEET MELOPSITTACUS-UNDULATUS; HEARING-IMPAIRED LISTENERS; AUDITORY HAIR-CELLS; TUNING CURVES; SERINUS-CANARIUS; FREQUENCY-SELECTIVITY; HARMONIC COMPLEXES; BASILAR-MEMBRANE; MASKING; THRESHOLDS AB Belgian Waterslager canaries (BWC), bred for a distinct low-pitched song, have an inherited high-frequency hearing loss associated with hair cell abnormalities. Hair cells near the abneural edge of the papilla, which receive primarily efferent innervation in normal birds, are among the most severely affected. These cells are thought to support nonlinear active processing in the avian ear, though the mechanisms are poorly understood. Here we present psychophysical evidence that suggests degraded active processing in BWC compared to normal-hearing non-BWC. Critical ratios, psychophysical masking patterns and phase effects on masking by harmonic complexes were measured in BWC and non-BWC using operant conditioning procedures. Critical ratios were much larger in BWC than in non-BWC at high frequencies. Psychophysical tuning curves derived from the masking patterns for BWC were broadened at high frequencies. BWC also showed severely reduced phase effects on masking by harmonic complexes compared to non-BWC. As has been hypothesized previously for hearing-impaired humans, these results are consistent with a loss of active processing mechanisms in BWC. C1 [Lauer, Amanda M.; Dooling, Robert J.] Univ Maryland, Dept Psychol, College Pk, MD 20742 USA. [Leek, Marjorie R.] Portland VA Med Ctr, Natl Ctr Rehabil Auditory Res, Portland, OR 97207 USA. RP Lauer, AM (reprint author), Johns Hopkins Univ, Dept Otolaryngol, 720 Rutland Ave,521 Traylor Res Bldg, Baltimore, MD 21205 USA. EM alauer2@jhmi.edu OI Lauer, Amanda/0000-0003-4184-7374 FU NIH [DC01372, DC-005450, DC-00626, DC-04664]; National Institutes of Health; Animal Welfare Act of the USA FX This work was supported by NIH Grants DC01372 to RJD, DC-005450 to AML, DC-00626 to MRL, and DC-04664 ( Core Center grant) to the University of Maryland. These experiments comply with the "Principles of care,'' publication No. 86-23, revised 1985 of the National Institutes of Health and with the Animal Welfare Act of the USA. NR 60 TC 6 Z9 6 U1 1 U2 4 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0340-7594 J9 J COMP PHYSIOL A JI J. Comp. Physiol. A -Neuroethol. Sens. Neural Behav. Physiol. PD FEB PY 2009 VL 195 IS 2 BP 193 EP 202 DI 10.1007/s00359-008-0398-z PG 10 WC Behavioral Sciences; Neurosciences; Physiology; Zoology SC Behavioral Sciences; Neurosciences & Neurology; Physiology; Zoology GA 402AS UT WOS:000262987200008 PM 19082827 ER PT J AU Song, D Wang, Z Marmarelis, VZ Berger, TW AF Song, Dong Wang, Zhuo Marmarelis, Vasilis Z. Berger, Theodore W. TI Parametric and non-parametric modeling of short-term synaptic plasticity. Part II: Experimental study SO JOURNAL OF COMPUTATIONAL NEUROSCIENCE LA English DT Article DE Nonlinear modeling; Facilitation. Depression; Poisson stimulus; Volterra kernels ID PAIRED-PULSE DEPRESSION; GLUTAMATE-RECEPTOR DESENSITIZATION; NONLINEAR-SYSTEMS ANALYSIS; PATH-DENTATE PROJECTION; PURKINJE-CELL SYNAPSES; NEUROMUSCULAR-JUNCTION; PRESYNAPTIC TERMINALS; RELEASE PROBABILITY; FACILITATION; RAT AB This paper presents a synergistic parametric and non-parametric modeling study of short-term plasticity (STP) in the Schaffer collateral to hippocampal CA1 pyramidal neuron (SC) synapse. Parametric models in the form of sets of differential and algebraic equations have been proposed on the basis of the current understanding of biological mechanisms active within the system. Non-parametric Poisson-Volterra models are obtained herein from broadband experimental input-output data. The non-parametric model is shown to provide better prediction of the experimental output than a parametric model with a single set of facilitation/depression (FD) process. The parametric model is then validated in terms of its input-output transformational properties using the non-parametric model since the latter constitutes a canonical and more complete representation of the synaptic nonlinear dynamics. Furthermore, discrepancies between the experimentally-derived non-parametric model and the equivalent non-parametric model of the parametric model suggest the presence of multiple FD processes in the SC synapses. Inclusion of an additional set of FD process in the parametric model makes it replicate better the characteristics of the experimentally-derived non-parametric model. This improved parametric model in turn provides the requisite biological interpretability that the non-parametric model lacks. C1 [Song, Dong; Marmarelis, Vasilis Z.; Berger, Theodore W.] Univ So Calif, Dept Biomed Engn, Los Angeles, CA 90089 USA. [Berger, Theodore W.] Univ So Calif, Program Neurosci, Los Angeles, CA 90089 USA. [Song, Dong; Marmarelis, Vasilis Z.; Berger, Theodore W.] Univ So Calif, Ctr Neural Engn, Los Angeles, CA 90089 USA. [Wang, Zhuo] VA Greater Angeles Healthcare Syst, Ctr Neurovisceral Sci & Womens Hlth, Los Angeles, CA USA. RP Song, D (reprint author), Univ So Calif, Dept Biomed Engn, 403 Hedco Neurosci Bldg, Los Angeles, CA 90089 USA. EM dsong@usc.edu RI Song, Dong/A-8314-2010 FU NSF ERC; DARPA; ONR, NSF; NIH/NIBIB FX This research was supported by the NSF ERC (BMES), DARPA ( HAND),ONR, NSF ( BITS), and NIH/NIBIB (BMSR). We thank the two anonymous reviewers for their insightful comments on this manuscript. NR 39 TC 15 Z9 15 U1 0 U2 1 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0929-5313 J9 J COMPUT NEUROSCI JI J. Comput. Neurosci. PD FEB PY 2009 VL 26 IS 1 BP 21 EP 37 DI 10.1007/s10827-008-0098-2 PG 17 WC Mathematical & Computational Biology; Neurosciences SC Mathematical & Computational Biology; Neurosciences & Neurology GA 407QI UT WOS:000263379000002 PM 18504530 ER PT J AU Finan, KR Renton, D Vick, CC Hawn, MT AF Finan, Kelly R. Renton, David Vick, Catherine C. Hawn, Mary T. TI Prevention of Post-operative Leak Following Laparoscopic Heller Myotomy SO JOURNAL OF GASTROINTESTINAL SURGERY LA English DT Article CT Annual Meeting of the Society-of-American-Gastrointestinal-and-Endoscopic-Surgeons CY APR 16-22, 2007 CL Las Vegas, NV SP Soc Amer Gastrointestinal & Endoscop Surg DE Esophageal achalasia; Laparoscopic surgery; Post-operative complication; Intra-operative procedures; Heller myotomy ID PREVIOUS ENDOSCOPIC TREATMENT; BOTULINUM TOXIN INJECTION; LONG-TERM EFFICACY; ESOPHAGEAL ACHALASIA; TOUPET FUNDOPLICATION; FORCEFUL DILATATION; DOR FUNDOPLICATION; ESOPHAGOMYOTOMY; DILATION; OUTCOMES AB Laparoscopic Heller myotomy is the preferred treatment for achalasia. Post-operative leaks cause significant morbidity and impair functional outcome. This study assesses the efficacy of intra-operative leak testing on post-operative leak rate. A retrospective analysis of 106 consecutive patients undergoing laparoscopic Heller myotomy by a single surgeon between November 2001 and August 2006 was undertaken. Intra-operative leak testing was performed in all patients. Variables associated with intra-operative mucosotomy were assessed by univariate analysis and logistic regression modeling. Intra-operative mucosotomy occurred in 25% of patients. All mucosotomies were repaired primarily and tested with methylene-blue-stained saline. Dor fundoplication was performed in 74% of the patients. There were no post-operative leaks and patients were started on diet day of surgery. Mean LOS was 1.4(+/- 0.7) days. Logistic regression modeling demonstrated that prior myotomy was associated with a statistically significant increase in the rate of mucosotomy (p = 0.033), while previous botox injection (p = 0.193), pneumatic dilation (p = 0.599) or concomitant hiatal hernia (p = 0.874) were not significantly associated with mucosotomy. Laparoscopic Heller myotomy for the treatment of achalasia is a safe procedure. Intra-operative leak testing minimizes the risk of post-operative leaks and expedites post-operative management. Prior endoscopic treatment does not impair operative results. C1 [Finan, Kelly R.; Renton, David; Vick, Catherine C.; Hawn, Mary T.] Univ Alabama, Dept Surg, Sect Gastrointestinal Surg, Birmingham, AL 35294 USA. [Vick, Catherine C.; Hawn, Mary T.] Birmingham Vet Affairs Med Ctr, Deep S Ctr Effectiveness Res, Birmingham, AL USA. RP Hawn, MT (reprint author), Univ Alabama, Dept Surg, Sect Gastrointestinal Surg, KB 417 1530 3rd Ave S, Birmingham, AL 35294 USA. EM mhawn@uab.edu NR 42 TC 6 Z9 7 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1091-255X J9 J GASTROINTEST SURG JI J. Gastrointest. Surg. PD FEB PY 2009 VL 13 IS 2 BP 200 EP 205 DI 10.1007/s11605-008-0687-4 PG 6 WC Gastroenterology & Hepatology; Surgery SC Gastroenterology & Hepatology; Surgery GA 402AU UT WOS:000262987400004 PM 18781365 ER PT J AU Starrels, JL Barg, FK Metlay, JP AF Starrels, Joanna L. Barg, Frances K. Metlay, Joshua P. TI Patterns and Determinants of Inappropriate Antibiotic Use in Injection Drug Users SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE antibiotics; adherence; injection drug use; self-medication ID RESISTANT STAPHYLOCOCCUS-AUREUS; METHICILLIN-RESISTANT; ANTIRETROVIRAL THERAPY; SAN-FRANCISCO; COMMUNITY; INFECTIONS; ADHERENCE; ABSCESSES; METAANALYSIS; PREVALENCE AB Inappropriate antibiotic use contributes to the emergence and spread of drug resistant infections. Though injection drug users are at increased risk for drug resistant infections, few studies have examined antibiotic use in this population. To understand patterns and determinants of antibiotic use among injection drug users. Five focus groups were conducted with 28 current injection drug users recruited from a syringe exchange program in Philadelphia and analyzed using the constant comparative method to identify emergent themes. Twenty-six participants also completed a written survey instrument. Injection drug users reported frequent antibiotic exposure, with 12 of 26 participants reporting use of antibiotic medications at least once in the previous 30 days. Participants reported several patterns of antibiotic use that were potentially harmful, including delays in seeking medical care, failing to fill prescriptions, obtaining antibiotics from non-provider sources, and poor adherence to prescribed regimens. The major determinants of inappropriate antibiotic use were delayed recognition of severity of illness, reluctance to wait to be seen, previous mistreatment by providers, lack of insurance, prioritizing purchasing drugs of abuse over antibiotics, forgetting to take antibiotics because of distractions that accompany drug use, concerns about interactions between antibiotics and other substances, and an irregular diet. Additionally, injection drug users commonly misunderstood the concept of antibiotic resistance and equated it with tolerance. Injection drug users reported potentially dangerous antibiotic use behaviors and described determinants of these behaviors. Outreach and educational interventions to improve antibiotic use should target high-risk populations, such as injection drug users, and consider their distinct antibiotic use behaviors and determinants. C1 [Starrels, Joanna L.; Metlay, Joshua P.] Univ Penn, Sch Med, Robert Wood Johnson Clin Scholars Program, Philadelphia, PA 19104 USA. [Starrels, Joanna L.; Metlay, Joshua P.] Vet Affairs Med Ctr, Philadelphia, PA USA. [Starrels, Joanna L.; Metlay, Joshua P.] Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA. [Metlay, Joshua P.] Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA. [Barg, Frances K.] Univ Penn, Dept Anthropol, Philadelphia, PA 19104 USA. [Barg, Frances K.] Univ Penn, Sch Med, Dept Family Med & Community Hlth, Philadelphia, PA 19104 USA. [Starrels, Joanna L.] Albert Einstein Coll Med, Div Gen Internal Med, Bronx, NY 10467 USA. [Starrels, Joanna L.] Montefiore Med Ctr, Bronx, NY 10467 USA. RP Starrels, JL (reprint author), Albert Einstein Coll Med, Div Gen Internal Med, 111 E 210th St, Bronx, NY 10467 USA. EM jostarre@montefiore.org FU NIDA NIH HHS [K23 DA027719] NR 44 TC 1 Z9 2 U1 0 U2 4 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD FEB PY 2009 VL 24 IS 2 BP 263 EP 269 DI 10.1007/s11606-008-0859-7 PG 7 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 397GO UT WOS:000262651100018 PM 19082860 ER PT J AU Piccini, JP Hernandez, AF Dibernardo, LR Rogers, JG Dhallwal, G AF Piccini, Jonathan P. Hernandez, Adrian F. Dibernardo, Louis R. Rogers, Joseph G. Dhallwal, Gurpreet TI A Change of Heart SO JOURNAL OF HOSPITAL MEDICINE LA English DT Article ID RIGHT-VENTRICULAR DYSPLASIA; DYSPLASIA/CARDIOMYOPATHY C1 [Piccini, Jonathan P.; Hernandez, Adrian F.; Rogers, Joseph G.] Duke Univ, Duke Clin Res Inst, Div Cardiovasc Med, Med Ctr, Durham, NC 27710 USA. [Dibernardo, Louis R.] Duke Univ, Med Ctr, Dept Pathol, Durham, NC 27710 USA. [Dhallwal, Gurpreet] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Dhallwal, Gurpreet] San Francisco VA Med Ctr, San Francisco, CA USA. RP Piccini, JP (reprint author), Duke Univ, Duke Clin Res Inst, Div Cardiol, Med Ctr, DUMC 3115, Durham, NC 27710 USA. EM jonathan.piccini@duke.edu RI Hernandez, Adrian F./A-7818-2016 OI Hernandez, Adrian F./0000-0003-3387-9616 NR 11 TC 0 Z9 0 U1 0 U2 0 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 1553-5592 J9 J HOSP MED JI J. Hosp. Med. PD FEB PY 2009 VL 4 IS 2 BP 131 EP 136 DI 10.1002/jhm.426 PG 6 WC Medicine, General & Internal SC General & Internal Medicine GA 413QK UT WOS:000263807400008 PM 19219930 ER PT J AU Goldstein, NB Johannes, WU Gadeliya, AV Green, MR Fujita, M Norris, DA Shellman, YG AF Goldstein, Nathaniel B. Johannes, Widya U. Gadeliya, Agnessa V. Green, Matthew R. Fujita, Mayumi Norris, David A. Shellman, Yiqun G. TI Active N-Ras and B-Raf Inhibit Anoikis by Downregulating Bim Expression in Melanocytic Cells SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Article ID EPIDERMAL-GROWTH-FACTOR; EPITHELIAL-CELLS; BH3-ONLY PROTEIN; APOPTOSIS; MELANOMA; SUPPRESSION; PATHWAY; CANCER; DEGRADATION; ACTIVATION AB B-Raf and N-Ras proteins are often activated in melanoma, yet their roles in producing inherent survival signals are not fully understood. In this study, we investigated how N-RAS(Q61K) and B-RAF(V600E) contribute to melanoma's resistance to apoptosis induced by detachment from the extracellular matrix (anoikis). We found that expression of constitutively active N-RAS(Q61K) and B-RAF(V600E) downregulated the proapoptotic Bim protein in an immortalized melanocyte cell line. Bim is one of the main proapoptotic mediators of anoikis. Western blot analysis showed that detachment increased Bim expression in melanocytes, and Annexin V staining indicated that detachment induced cell death significantly in melanocytes. Blocking Bim expression by using RNAi vectors or by expressing N-RAS(Q61K) significantly inhibited anoikis in melanocytes. In summary, this report indicates that N-RAS(Q61K) and B-RAF(V600E) contribute to melanoma's resistance to apoptosis in part by downregulating Bim expression, suggesting that Bim is a possible treatment target for overriding melanoma's inherent defenses against cell death. C1 [Goldstein, Nathaniel B.; Johannes, Widya U.; Gadeliya, Agnessa V.; Green, Matthew R.; Fujita, Mayumi; Norris, David A.; Shellman, Yiqun G.] Univ Colorado Denver, Sch Med, Dept Dermatol, Aurora, CO 80010 USA. [Norris, David A.] US Dept Vet Affairs, Med Ctr, Dermatol Sect, Denver, CO USA. RP Shellman, YG (reprint author), Univ Colorado Denver, Sch Med, Dept Dermatol, Mail Stop 8127,POB 6511, Aurora, CO 80010 USA. EM Yiqun.Shellman@uchsc.edu FU Dermatology Foundation Career Award; NIAMS [R01AR26427-18]; Veterans Administrations merit grant [PN: 0012] FX This work was supported in part by Dermatology Foundation Career Award (YGS), NIAMS grant R01AR26427-18 (DAN), and Veterans Administrations merit grant PN: 0012 (DAN). We thank Anne Brauweiler for her critique of the paper. NR 28 TC 13 Z9 13 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0022-202X J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD FEB PY 2009 VL 129 IS 2 BP 432 EP 437 DI 10.1038/jid.2008.227 PG 6 WC Dermatology SC Dermatology GA 397IH UT WOS:000262655600024 PM 18668139 ER PT J AU Li, XL Lu, L Bush, DJ Zhang, XW Zheng, L Suswam, EA King, PH AF Li, Xuelin Lu, Liang Bush, Donald J. Zhang, Xiaowen Zheng, Lei Suswam, Esther A. King, Peter H. TI Mutant copper-zinc superoxide dismutase associated with amyotrophic lateral sclerosis binds to adenine/uridine-rich stability elements in the vascular endothelial growth factor 3'-untranslated region SO JOURNAL OF NEUROCHEMISTRY LA English DT Article DE RNA stability; HuR; RNA-binding proteins; electrophoresis mobility shift assay ID MESSENGER-RNA STABILITY; MALIGNANT GLIOMA-CELLS; CENTRAL-NERVOUS-SYSTEM; ANGIOGENIC FACTOR; PROTEIN HUR; CU,ZN-SUPEROXIDE DISMUTASE; GENE-EXPRESSION; IN-VITRO; ELAV; MUTATIONS AB Vascular endothelial growth factor (VEGF) is a neurotrophic factor essential for maintenance of motor neurons. Loss of this factor produces a phenotype similar to amyotrophic lateral sclerosis (ALS). We recently showed that ALS-producing mutations of Cu/Zn-superoxide dismutase (SOD1) disrupt post-transcriptional regulation of VEGF mRNA, leading to significant loss of expression [Lu et al., J. Neurosci.27 (2007), 7929]. Mutant SOD1 was present in the ribonucleoprotein complex associated with adenine/uridine-rich elements (ARE) of the VEGF 3'-untranslated region (UTR). Here, we show by electrophoretic mobility shift assay that mutant SOD1 bound directly to the VEGF 3'-UTR with a predilection for AREs similar to the RNA stabilizer HuR. SOD1 mutants A4V and G37R showed higher affinity for the ARE than L38V or G93A. Wild-type SOD1 bound very weakly with an apparent K(d) 11- to 72-fold higher than mutant forms. Mutant SOD1 showed an additional lower shift with VEGF ARE that was accentuated in the metal-free state. A similar pattern of binding was observed with AREs of tumor necrosis factor-alpha and interleukin-8, except only a single shift predominated. Using an ELISA-based assay, we demonstrated that mutant SOD1 competes with HuR and neuronal HuC for VEGF 3'-UTR binding. To define potential RNA-binding domains, we truncated G37R, G93A and wild-type SOD1 and found that peptides from the N-terminal portion of the protein that included amino acids 32-49 could recapitulate the binding pattern of full-length protein. Thus, the strong RNA-binding affinity conferred by ALS-associated mutations of SOD1 may contribute to the post-transcriptional dysregulation of VEGF mRNA. C1 [Li, Xuelin; Lu, Liang; Bush, Donald J.; Zhang, Xiaowen; Zheng, Lei; Suswam, Esther A.; King, Peter H.] Univ Alabama, Dept Neurol, Birmingham, AL 35294 USA. [Li, Xuelin; Lu, Liang; Zheng, Lei; King, Peter H.] Birmingham VA Med Ctr, Birmingham, AL USA. [King, Peter H.] Univ Alabama, Dept Genet, Birmingham, AL 35233 USA. [King, Peter H.] Univ Alabama, Dept Physiol & Biophys, Birmingham, AL 35233 USA. RP King, PH (reprint author), Suite 260 Sparks Ctr,1720 7th Ave S, Birmingham, AL 35233 USA. EM pking@uab.edu FU NIH/NINDS [NS058538]; Department of Veterans Affairs FX This study was supported by NIH/NINDS NS058538 (PHK) and a Merit Review Award from Department of Veterans Affairs (PHK). NR 76 TC 19 Z9 19 U1 0 U2 0 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0022-3042 J9 J NEUROCHEM JI J. Neurochem. PD FEB PY 2009 VL 108 IS 4 BP 1032 EP 1044 DI 10.1111/j.1471-4159.2008.05856.x PG 13 WC Biochemistry & Molecular Biology; Neurosciences SC Biochemistry & Molecular Biology; Neurosciences & Neurology GA 395IF UT WOS:000262517100017 PM 19196430 ER PT J AU Christine, CW Langston, JW Turner, RS Starr, PA AF Christine, Chadwick W. Langston, J. William Turner, Robert S. Starr, Philip A. TI The neurophysiology and effect of deep brain stimulation in a patient with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism SO JOURNAL OF NEUROSURGERY LA English DT Article; Proceedings Paper CT 9th International Congress of Parkinsons Disease and Movement Disorders CY MAR 05-08, 2005 CL New Orleans, LA DE deep brain stimulation; Parkinson disease; physiology; subthalamic nucleus; toxin ID MPTP-TREATED PRIMATE; SUBTHALAMIC NUCLEUS; NEURONAL-ACTIVITY; DISEASE; MODEL; LEVODOPA; LESIONS AB Parkinsonism caused by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) exposure was first identified in intravenous drug users. This neurotoxicant has since been used extensively in nonhuman primates to induce an experimental model of Parkinson disease (PD). In this study, the authors examined the intraoperative physiological characteristics and efficacy of subthalamic nucleus deep brain stimulation (DBS) in 1 of only 4 known living patients with MPTP-induced parkinsonism. The physiological recordings were consistent with recordings from MPTP-treated primates and humans with PD, thus providing further validation for the MPTP model in the study of the neurophysiology of the nigrostriatal dopaminergic deficit in PD. Furthermore, DBS produced a significant clinical improvement in this patient similar to the improvement seen after DBS in patients with idiopathic PD. This unique case has important implications for translational research that employs the MPTP-primate model for symptomatic therapy in PD. (DOI: 10.3171/2008.8.JNS08882) C1 [Christine, Chadwick W.; Starr, Philip A.] Univ Calif San Francisco, Sch Med, Dept Neurol, San Francisco, CA 94143 USA. [Christine, Chadwick W.] Univ Calif San Francisco, Dept Neurosurg, San Francisco, CA 94143 USA. [Langston, J. William] Parkinsons Inst, Sunnyvale, CA USA. [Turner, Robert S.] Univ Pittsburgh, Dept Neurobiol, Pittsburgh, PA USA. [Starr, Philip A.] San Francisco VA Med Ctr, Parkinson Dis Res Educ & Clin Ctr, San Francisco, CA USA. RP Christine, CW (reprint author), Univ Calif San Francisco, Sch Med, Dept Neurol, 400 Parnassus Ave,Room A838, San Francisco, CA 94143 USA. EM chad.christine@ucsf.edu FU NINDS NIH HHS [R01 NS044551-06, R01 NS044551, R21 NS055197, R21 NS055197-01A2] NR 15 TC 3 Z9 3 U1 0 U2 1 PU AMER ASSOC NEUROLOGICAL SURGEONS PI ROLLING MEADOWS PA 5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA SN 0022-3085 J9 J NEUROSURG JI J. Neurosurg. PD FEB PY 2009 VL 110 IS 2 BP 234 EP 238 DI 10.3171/2008.8.JNS08882 PG 5 WC Clinical Neurology; Surgery SC Neurosciences & Neurology; Surgery GA 399GI UT WOS:000262788000005 PM 19099380 ER PT J AU O'Neill, SM Ettner, SL Lorenz, KA AF O'Neill, Sean M. Ettner, Susan L. Lorenz, Karl A. TI Are Rural Hospices at a Financial Disadvantage? Evidence from California SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Article CT Annual Meeting of the American-Academy-of-Hospice-and-Palliative-Medicine CY FEB 08-11, 2006 CL Nashville, TN SP Amer Acad Hospice & Palliat Med DE Hospice; palliative care; rural health care; economics ID ACCESS; CARE AB Concerns have been voiced about financial pressures faced by rural hospices, because of possible implications for hospice access in rural areas. To assess whether financial performance differs between existing urban and rural hospices, we used the 2003 California Office of Statewide Health Planning and Development survey to compare revenues, costs, and profitability (with and without charitable donations). We adjusted for factors related to financial performance, including agency size, years in operation, profit status, whether hospices were freestanding or chain-, home-health or hospital-based, and the proportion of patients by insurance type and referral source, race/ethnicity, and diagnosis. One hundred forty-four (91%) hospices were urban, and 14 (9%) were rural. Mean values per patient for total revenue, total cost, and post-tax profil were $7203, $7440 and -$256, respectively, for urban hospices and $6726, $6274 and $452, respectively, for-rural hospices. Compared with urban hospices, rural hospices were at least as profitable per patient-day (+$33, P = 0.15). They were significantly more profitable (+$47, P = 0.05) when charitable donations were excluded. In summary, we found that in California, rural hospices fared no worse financially than urban hospices. These counterintuitive findings underscore the need to examine urban-rural hospice financial differences using a national sample. J Pain Symptom Manage 2009;37:189-195. (c) 2009 U.S. Cancer Pain Relief Committee. Published by Elsevier Inc. All rights reserved. C1 [O'Neill, Sean M.] Pardee RAND Grad Sch, Santa Monica, CA 90407 USA. [Ettner, Susan L.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Lorenz, Karl A.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. RP O'Neill, SM (reprint author), Pardee RAND Grad Sch, 1776 Main St,POB 2138, Santa Monica, CA 90407 USA. EM soneill@prgs.edu OI O'Neill, Sean/0000-0001-7759-8942 NR 12 TC 2 Z9 2 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2009 VL 37 IS 2 BP 189 EP 195 DI 10.1016/j.jpainsymman.2008.01.008 PG 7 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA 412BO UT WOS:000263698400006 PM 18599260 ER PT J AU Bates-Jensen, BM Guihan, M Garber, SL Chin, AS Burns, SP AF Bates-Jensen, Barbara M. Guihan, Marylou Garber, Susan L. Chin, Amy S. Burns, Stephen P. TI Characteristics of Recurrent Pressure Ulcers in Veterans With Spinal Cord Injury SO JOURNAL OF SPINAL CORD MEDICINE LA English DT Article DE Pressure ulcers, recurrent; Spinal cord injuries; Paraplegia; Closure, mucocutaneous flap; Wound healing; Veterans; Bates-Jensen Wound Assessment Tool; Salzburg Pressure Ulcer Risk Score ID SURGICAL-TREATMENT; RISK-FACTORS; SORES; PREVALENCE; PREVENTION; COVERAGE; EXPERIENCE; PEOPLE AB Background/Objective: To describe characteristics of recurrent pressure ulcers (PrUs) in veterans with spinal cord injury (SCI). Design: Descriptive, cohort study. Settings and Participants: Twenty-four veterans with SCI from 6 SCI centers in the Department of Veterans Affairs. Methods: Data from a prospective study evaluating PrUs were analyzed for 24 veterans with 29 recurrent PrUs during 9 months. Additional retrospective medical record data were analyzed for 15 veterans who received inpatient treatment. Results: Participants were male, 50% non-Hispanic white, with paraplegia (63%), complete SCI (83%), a mean age of 56 years, and mean time since SCI of 21 years. Most PrUs recurred (63%, n = 15 patients) in the same location as the most recent ulcer and at the ischial tuberosities (63%). Mean time to recurrence was 16.6 weeks. PrUs were stage III (28%, n = 8) or IV (45%, n = 13) with undermining (48%), necrotic slough (50%), and minimal exudate. One third were (n = 9) larger than 16 cm(2). Mean Bates-Jensen Wound Assessment Tool Score was 33.63. Inpatient medical record data (n = 15) showed 73% with documentation indicating infection treated with antibiotics (53%, n = 8 patients), osteomyelitis (47%, n = 7), and/or cellulitis (13%, n = 2) noted. Plastic surgery consultation was obtained for 67% with surgery as an option for 73% (1 without consultation). Scheduled repositioning was documented for 21%. Conclusions: Most PrUs were severe, located at the same anatomic site, and recurred within 4 months, suggesting that the recurrent ulcers were more likely incomplete healing of the initial PrUs. This sample of veterans with SCI provides early data on recurrent PrU characteristics. C1 [Bates-Jensen, Barbara M.] Univ Calif Los Angeles, Sch Nursing, Los Angeles, CA 90095 USA. [Bates-Jensen, Barbara M.] VA Greater Angeles Healthcare Syst, Ctr Clin, Los Angeles, CA USA. [Bates-Jensen, Barbara M.] Univ Calif Los Angeles, David Geffen Sch Med, Div Geriatr, Los Angeles, CA 90095 USA. [Guihan, Marylou; Chin, Amy S.] Edward Hines Jr VA Hosp, Ctr Management Complex Chron Care, Hines, IL USA. [Guihan, Marylou] Northwestern Univ, Inst Healthcare Studies, Chicago, IL 60611 USA. [Garber, Susan L.] Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX 77030 USA. [Burns, Stephen P.] VA Puget Sound Hlth Care Syst, SCI Serv, Seattle, WA USA. [Burns, Stephen P.] Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA. RP Bates-Jensen, BM (reprint author), Univ Calif Los Angeles, Sch Nursing, 5-954 Factor Bldg,700 Tiverton Ave, Los Angeles, CA 90095 USA. EM bbatesjensen@sonnet.ucla.edu NR 36 TC 29 Z9 30 U1 2 U2 2 PU AMER PARAPLEGIA SOC PI JACKSON HWIGHTS PA 75-20 ASTORIA BLVD, JACKSON HWIGHTS, NY 11370-1177 USA SN 1079-0268 J9 J SPINAL CORD MED JI J. Spinal Cord. Med. PD FEB PY 2009 VL 32 IS 1 BP 34 EP 42 PG 9 WC Clinical Neurology SC Neurosciences & Neurology GA 413ME UT WOS:000263796400005 PM 19264047 ER PT J AU Friedlander, AH Yoshikawa, TT Chang, DS Feliciano, Z Scully, C AF Friedlander, Arthur H. Yoshikawa, Thomas T. Chang, Donald S. Feliciano, Zenaida Scully, Crispian TI Atrial fibrillation Pathogenesis, medical-surgical management and dental implications SO JOURNAL OF THE AMERICAN DENTAL ASSOCIATION LA English DT Review DE Cardiovascular diseases; stroke; anticoagulation therapy ID ORAL ANTICOAGULANT-THERAPY; INTERNATIONAL NORMALIZED RATIO; DRUG-INTERACTIONS; ANTITHROMBOTIC THERAPY; VITAMIN-K; CARDIOVERTER-DEFIBRILLATORS; CARDIOVASCULAR HEALTH; ISCHEMIC-STROKE; RHYTHM CONTROL; RISK-FACTORS AB Background. Atrial fibrillation (AF) is a cardiac rhythm disturbance arising from disorganized electrical activity in the atria, and it is accompanied by an irregular and often rapid ventricular response. It is the most common clinically significant dysrhythmia in the general and older population. Types of Studies Reviewed. The authors conducted a MEDLINE search using the key terms "atrial fibrillation," "epidemiology," "pathophysiology," "treatment" and "dentistry." They selected contemporaneous articles published in peer-reviewed journals and gave preference to articles reporting randomized controlled trials. Clinical Implications. The anticoagulant warfarin frequently is prescribed to prevent stroke caused by cardiogenic thromboemboli arising from stagnant blood in poorly contracting atria. Most dental procedures and a limited number of surgical procedures can be performed without altering warfarin dosage if the international normalized ratio value is within the therapeutic range of 2.0 to 3.0. Certain analgesic agents, antibiotic agents, antifungal agents and sedative hypnotics, however, should not be prescribed without consultation with the patient's physician because these medications may alter the patient's risk of hemorrhage and stroke. Conclusions. AF affects nearly 2.5 million Americans, most of who are older than 60 years. Consultation with the patient's physician to discuss the planned dental treatment often is appropriate, especially for people, who frequently have comorbid diseases such as coronary artery disease, congestive heart failure, diabetes and thyrotoxicosis, which are treated with multiple drug regimens. C1 [Friedlander, Arthur H.; Yoshikawa, Thomas T.] VA Greater Angeles Healthcare Syst, Geriatr Res Educ & Clin Ctr, Los Angeles, CA 90073 USA. [Friedlander, Arthur H.] Univ Calif Los Angeles, Med Ctr, Hosp Dent Serv, Los Angeles, CA 90024 USA. [Friedlander, Arthur H.] Univ Calif Los Angeles, Sch Dent, Los Angeles, CA 90024 USA. [Yoshikawa, Thomas T.; Chang, Donald S.; Feliciano, Zenaida] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Chang, Donald S.] UCLA VA, VA Greater Los Angeles, San Fernando Valley Program, Los Angeles, CA USA. [Scully, Crispian] UCL, Eastman Dent Inst, WHO Collaborating Ctr Res Educ & Serv Oral Hlth D, London WC1E 6BT, England. RP Friedlander, AH (reprint author), VA Greater Angeles Healthcare Syst, Geriatr Res Educ & Clin Ctr, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM arthur.friedlander@med.va.gov NR 91 TC 2 Z9 2 U1 0 U2 3 PU AMER DENTAL ASSOC PI CHICAGO PA 211 E CHICAGO AVE, CHICAGO, IL 60611 USA SN 0002-8177 J9 J AM DENT ASSOC JI J. Am. Dent. Assoc. PD FEB PY 2009 VL 140 IS 2 BP 167 EP 177 PG 11 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA 406EL UT WOS:000263277700019 PM 19188413 ER PT J AU Arnold, SV Alexander, KP Masoudi, FA Ho, PM Xiao, L Spertus, JA AF Arnold, Suzanne V. Alexander, Karen P. Masoudi, Frederick A. Ho, P. Michael Xiao, Lan Spertus, John A. TI The Effect of Age on Functional and Mortality Outcomes After Acute Myocardial Infarction SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE aging; functional status; quality of life; myocardial infarction ID QUALITY-OF-LIFE; CORONARY-ARTERY-BYPASS; TIMI RISK SCORE; ACTIVITY QUESTIONNAIRE; INTERNATIONAL TRIAL; GLOBAL REGISTRY; HEART-DISEASE; EVENTS GRACE; HEALTH; CAPACITY AB To determine the prevalence of post-myocardial infarction (MI) functional decline and to describe its association with chronological age in survivors of MI. Prospective observational registry. Nineteen U.S. hospitals. Two thousand four hundred eighty-one patients with acute MI. Baseline and 1-year interviews identified subjects with functional decline, defined as a more than 5-point decline in Medical Outcomes Study 12-item Short Form Questionnaire (SF-12) Physical Component score or being "too ill" to provide a follow-up interview at 1 year. The relationship between age and functional decline was evaluated using logistic regression models adjusted for baseline SF-12 score, comorbidities, sociodemographics, and treatment characteristics. One-year mortality and a combined endpoint of death or decline were also compared across age. Of 2,009 patients who survived to 1 year, 582 (29%) experienced a functional decline. In survivors, age was not associated with functional decline in unadjusted (odds ratio (OR)=0.95/decade, 95% confidence interval (CI)=0.88-1.03) or multivariable (OR=0.94, 95% CI=0.85-1.05) models. Although age was strongly associated with 1-year mortality (adjusted hazard ratio=1.42, 95% CI=1.21-1.66), there was no association between age and the combined endpoint of death or functional decline (adjusted OR=1.02, 95% CI=0.92-1.12). More than one in four survivors of MI experiences a significant decline in physical function by 1 year. Although age is strongly associated with mortality, it had no association with functional decline. Because older patients have the same potential for favorable functional outcomes after an MI, age alone should not preclude aggressive treatment after an MI. C1 [Arnold, Suzanne V.; Xiao, Lan; Spertus, John A.] St Lukes Mid Amer Heart Inst, Kansas City, MO 64111 USA. [Alexander, Karen P.] Duke Univ, Med Ctr, Duke Clin Res Inst, Durham, NC USA. [Masoudi, Frederick A.; Ho, P. Michael] Univ Colorado, Hlth Sci Ctr, Dept Med, Denver, CO 80262 USA. [Masoudi, Frederick A.] Denver Hlth Med Ctr, Dept Med, Denver, CO USA. [Ho, P. Michael] Denver Vet Affairs Med Ctr, Denver, CO USA. [Spertus, John A.] Univ Missouri, Dept Med, Div Cardiol, Kansas City, MO 64110 USA. RP Spertus, JA (reprint author), St Lukes Mid Amer Heart Inst, 4401 Wornall Rd, Kansas City, MO 64111 USA. EM spertusj@umkc.edu FU Cardiovascular Therapeutics, Inc.; Cardiovascular Outcomes, Inc., Kansas City FX Sponsor's Role: The sponsors did not play a role in the design or conduct of the study; in the collection, management, analysis, or interpretation of the data; or in the preparation, review, or approval of the manuscript. NR 43 TC 14 Z9 14 U1 0 U2 2 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD FEB PY 2009 VL 57 IS 2 BP 209 EP 217 DI 10.1111/j.1532-5415.2008.02106.x PG 9 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 399WE UT WOS:000262829200003 PM 19170779 ER PT J AU Little, DM Crooks, VC Petitti, DB Chiu, V Schellenberg, GD Slezak, JM Jacobsen, SJ AF Little, Deborah M. Crooks, Valerie C. Petitti, Diana B. Chiu, Vicki Schellenberg, Gerard D. Slezak, Jeff M. Jacobsen, Steven J. TI Mortality, Dementia, and Apolipoprotein E Genotype in Elderly White Women in the United States SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE dementia; APOE; genotype ID E EPSILON-4 ALLELE; CORONARY-HEART-DISEASE; ALZHEIMERS-DISEASE; APOE GENOTYPE; CEREBROVASCULAR-DISEASE; COGNITIVE IMPAIRMENT; POPULATION-SAMPLE; CACHE COUNTY; E PHENOTYPES; OLDEST-OLD AB To assess the risk of death in relation to apolipoprotein E (APOE) genotype and to evaluate how APOE genotype interacts with dementia and with other major medical conditions to affect survival. A 6-year prospective cohort study of dementia, APOE genotype and survival. Health maintenance organization in southern California. One thousand eight hundred forty-two white women aged 75 and older. Dementia was determined using a multistage assessment procedure, medical record, and death certificate review. With women with the APOE 3/3 genotype as the referent, age-adjusted hazard ratios (HRs) for death according to genotype were 1.25 (95% confidence interval (CI)=1.00-1.56) for APOE 2/4, 3/4, or 4/4 and 0.83 (95% CI=0.62-1.13) for APOE 2/3 or 2/2. Survival was associated with APOE genotype (log rank test P=.02). Women with the APOE 2/4, 3/4, or 4/4 genotype died at an earlier age, and those with APOE 2/2 or 2/3 died later than those with the APOE 3/3 genotype. After adjustment for age, education, and hormone use, HRs for death were significantly higher in women with the APOE 2/4, 3/4, or 4/4 genotype who developed dementia (HR=3.74; 95% CI=2.81-4.99) and the APOE 2/3 genotype (HR=3.23; 95%=CI=1.97-5.28) than in women without dementia and the APOE 3/3 genotype. The HRs for death were greater with other medical conditions, but no interaction with any APOE genotype was found. In this population of elderly women, although having at least one epsilon 4 allele increased the chances of an earlier death, having dementia increased the risk of death regardless of APOE genotype. C1 [Little, Deborah M.] Kaiser Permanente So Calif, Dept Res & Evaluat, Pasadena, CA 91101 USA. [Schellenberg, Gerard D.] Univ Washington, Vet Affairs Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA 98195 USA. RP Crooks, VC (reprint author), Kaiser Permanente So Calif, Dept Res & Evaluat, 100 S Robles,2nd Floor, Pasadena, CA 91101 USA. EM valerie.c.crooks@kp.org OI Jacobsen, Steven/0000-0002-8174-8533 FU National Institute on Aging [AG14745] FX Sponsor's Role: The funding organization (NIA) did not have any role in the design or conduct of the study; collection, management, analysis, or interpretation of the data; or preparation, review, or approval of the manuscript. NR 42 TC 16 Z9 16 U1 0 U2 2 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD FEB PY 2009 VL 57 IS 2 BP 231 EP 236 DI 10.1111/j.1532-5415.2008.02113.x PG 6 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 399WE UT WOS:000262829200006 PM 19207139 ER PT J AU Pugh, MJV Knoefel, JE Mortensen, EM Amuan, ME Berlowitz, DR Van Cott, AC AF Pugh, Mary Jo V. Knoefel, Janice E. Mortensen, Eric M. Amuan, Megan E. Berlowitz, Dan R. Van Cott, Anne C. TI New-Onset Epilepsy Risk Factors in Older Veterans SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE epilepsy; risk factors; cohort study; race; aged ID UNPROVOKED SEIZURES; ELDERLY PATIENTS; DISORDERS; DISEASE; HYPERTENSION; PREVENTION; DEMENTIA; STROKE AB To identify risk factors for new-onset geriatric epilepsy that may trigger clinicians to consider a differential diagnosis of epilepsy at symptom onset. Retrospective cohort study. National Veterans Affairs (VA) databases. Veterans aged 66 and older in fiscal year 2000 (FY00) who received VA care in FY99 and FY00. Individuals with new-onset epilepsy based on a validated algorithm constituted the epilepsy cohort (n=1,843), and individuals without epilepsy constituted the geriatric cohort (n=1,023,376). Age, sex, and race were derived from VA databases. Clinical conditions associated with new-onset geriatric epilepsy (e.g., cerebrovascular disease, dementia, brain tumor) and stroke risk-factors (e.g., hypertension, diabetes mellitus, cardiovascular disease) were identified using validated International Classification of Diseases, Ninth Revision, Clinical Modification, codes before epilepsy onset (epilepsy cohort) and in FY00 (geriatric cohort). Multivariable logistic regression analysis indicated that patients with cerebrovascular disease (odds ratio (OR)=3.50, 95% confidence interval (CI)=3.13-3.91), cerebrovascular disease and dementia (OR=4.14, 95% CI=3.46-4.96), brain tumor (OR=2.14, 95% CI=1.46-3.13), head injury (OR=2.11, 95% CI=1.41-3.14), and other central nervous system (CNS) conditions (OR=1.57, 95% CI=1.32-1.88) were more likely to experience new-onset epilepsy. Statin prescription (OR=0.64, 95% CI=0.56-0.73), older age (>= 85 vs 66-74, OR=0.66, 95% CI=0.50-0.87), obesity (OR=0.74, 95% CI=0.62-0.87), and hypercholesterolemia (OR=0.87, 95% CI=0.76-0.98) were associated with a lower likelihood of epilepsy. These data suggest greater epilepsy risk for older individuals with CNS insult and an additive effect of cerebrovascular disease and dementia. The statin finding requires further exploration but points to a possible target for prevention of geriatric epilepsy. C1 [Pugh, Mary Jo V.; Mortensen, Eric M.] S Texas Vet Hlth Care Syst, Vet Evidence Based Res Disseminat Implementat Res, Hlth Serv Res & Dev Serv, Dept Vet Affairs, San Antonio, TX USA. [Pugh, Mary Jo V.; Mortensen, Eric M.] Univ Texas Hlth Sci Ctr San Antonio, Div Internal Med, San Antonio, TX 78229 USA. [Knoefel, Janice E.] New Mexico Vet Hlth Care Syst, Albuquerque, NM USA. [Amuan, Megan E.; Berlowitz, Dan R.] Bedford Vet Affairs Hosp, Ctr Hlth Qual Outcomes & Econ Res, Bedford, MA USA. [Berlowitz, Dan R.; Van Cott, Anne C.] Boston Univ, Sch Publ Hlth, Boston, MA USA. [Van Cott, Anne C.] Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Van Cott, Anne C.] Univ Pittsburgh, Dept Neurol, Pittsburgh, PA 15260 USA. RP Pugh, MJV (reprint author), S Texas Vet Hlth Care Syst VERDICT, Audie L Murphy Div 11C6, 7400 Merton Minter Blvd, San Antonio, TX 78229 USA. EM PughM@uthscsa.edu OI Pugh, Mary Jo/0000-0003-4196-7763; Mortensen, Eric/0000-0002-3880-5563 FU VA Health Services Research and Development Service [IIR 02-274]; GlaxoSmithKline FX Sponsor's Role: The funding source did not have a role in the study design, methods, subject recruitment, data collections, or analysis and preparation of the manuscript. NR 34 TC 34 Z9 34 U1 0 U2 4 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD FEB PY 2009 VL 57 IS 2 BP 237 EP 242 DI 10.1111/j.1532-5415.2008.02124.x PG 6 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 399WE UT WOS:000262829200007 PM 19207140 ER PT J AU Wright, RM Roumani, YF Boudreau, R Newman, AB Ruby, CM Studenski, SA Shorr, RI Bauer, DC Simonsick, EM Hilmer, SN Hanlon, JT AF Wright, Rollin M. Roumani, Yazan F. Boudreau, Robert Newman, Anne B. Ruby, Christine M. Studenski, Stephanie A. Shorr, Ronald I. Bauer, Douglas C. Simonsick, Eleanor M. Hilmer, Sarah N. Hanlon, Joseph T. CA Hlth Aging & Body Composition Stud TI Effect of Central Nervous System Medication Use on Decline in Cognition in Community-Dwelling Older Adults: Findings from the Health, Aging and Body Composition Study SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE cognition; aged; medications ID BENZODIAZEPINE USE; ELDERLY PERSONS; INFLAMMATORY MARKERS; FUNCTIONAL DECLINE; PREDICTIVE MODEL; RISK-FACTORS; DRUG-USE; DELIRIUM; IMPAIRMENT; PERFORMANCE AB To evaluate whether combined use of multiple central nervous system (CNS) medications over time is associated with cognitive change. Longitudinal cohort study. Pittsburgh, Pennsylvania, and Memphis, Tennessee. Two thousand seven hundred thirty-seven healthy adults (aged >= 65) enrolled in the Health, Aging and Body Composition study without baseline cognitive impairment (modified Mini-Mental State Examination (3MS) score >= 80). CNS medication (benzodiazepine- and opioid-receptor agonists, antipsychotics, antidepressants) use, duration, and dose were determined at baseline (Year 1) and Years 3 and 5. Cognitive function was measured using the 3MS at baseline and Years 3 and 5. The outcome variables were incident cognitive impairment (3MS score < 80) and cognitive decline (>= 5-point decline on 3MS). Multivariable interval-censored survival analyses were conducted. By Year 5, 7.7% of subjects had incident cognitive impairment; 25.2% demonstrated cognitive decline. CNS medication use increased from 13.9% at baseline to 15.3% and 17.1% at Years 3 and 5, respectively. It was not associated with incident cognitive impairment (adjusted hazard ratio (adj HR)=1.11, 95% confidence interval (CI)=0.73-1.69) but was associated with cognitive decline (adj HR 1.37, 95% CI=1.11-1.70). Longer duration (adj HR=1.39, CI=1.08-1.79) and higher doses (> 3 standardized daily doses) (adj HR=1.87, 95% CI=1.25-2.79) of CNS medications suggested greater risk of cognitive decline than with nonuse. Combined use of CNS medications, especially at higher doses, appears to be associated with cognitive decline in older adults. Future studies must explore the effect of combined CNS medication use on vulnerable older adults. C1 [Wright, Rollin M.; Roumani, Yazan F.; Newman, Anne B.; Studenski, Stephanie A.; Hanlon, Joseph T.] Univ Pittsburgh, Sch Med, Dept Med, Div Geriatr, Pittsburgh, PA 15213 USA. [Boudreau, Robert; Newman, Anne B.] Univ Pittsburgh, Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA 15213 USA. [Ruby, Christine M.; Hanlon, Joseph T.] Univ Pittsburgh, Sch Pharm, Dept Pharm & Therapeut, Pittsburgh, PA 15213 USA. [Studenski, Stephanie A.; Hanlon, Joseph T.] Vet Affairs Pittsburgh Healthcare Syst, Ctr Hlth Equ Res, Pittsburgh, PA USA. [Studenski, Stephanie A.; Hanlon, Joseph T.] Vet Affairs Pittsburgh Healthcare Syst, Ctr Geriatr Res Educ & Clin, Pittsburgh, PA USA. [Shorr, Ronald I.] N Florida S Georgia Vet Hlth Syst, Ctr Geriatr Res Educ & Clin, Gainesville, FL USA. [Bauer, Douglas C.] Univ Calif San Francisco, Div Gen Internal Med, San Francisco, CA 94143 USA. [Simonsick, Eleanor M.] Johns Hopkins Univ, Inst Med, Div Geriatr Med & Gerontol, Baltimore, MD USA. [Simonsick, Eleanor M.; Hilmer, Sarah N.] NIA, Intramural Res Program, Baltimore, MD 21224 USA. [Hilmer, Sarah N.] Univ Sydney, Sydney, NSW 2006, Australia. [Hilmer, Sarah N.] Royal N Shore Hosp, Sydney, NSW, Australia. RP Wright, RM (reprint author), Univ Pittsburgh, Dept Med Geriatr, Kaufmann Med Bldg,Suite 500,3471 5th Ave, Pittsburgh, PA 15213 USA. EM rmw27@pitt.edu RI Newman, Anne/C-6408-2013 OI Newman, Anne/0000-0002-0106-1150; Hilmer, Sarah/0000-0002-5970-1501; Boudreau, Robert/0000-0003-0162-5187 FU National Institutes of Health (NIH), National Institute on Aging; NIH c [N01-AG-6-2101, N01-AG-6-2103, N01-AG-6-2106, R01AG027017]; Pittsburgh Claude D. Pepper Older Americans Independence Center [P30AG024827]; John A. Hartford Foundation Center FX Sponsors' Roles: The organizations that funded this study did not influence the interpretation of the data or the development of this manuscript. NR 53 TC 38 Z9 39 U1 2 U2 5 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD FEB PY 2009 VL 57 IS 2 BP 243 EP 250 DI 10.1111/j.1532-5415.2008.02127.x PG 8 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 399WE UT WOS:000262829200008 PM 19207141 ER PT J AU Nazem, S Siderowf, AD Duda, JE Have, TT Colcher, A Horn, SS Moberg, PJ Wilkinson, JR Hurtig, HI Stern, MB Weintraub, D AF Nazem, Sarra Siderowf, Andrew D. Duda, John E. Have, Tom Ten Colcher, Amy Horn, Stacy S. Moberg, Paul J. Wilkinson, Jayne R. Hurtig, Howard I. Stern, Matthew B. Weintraub, Daniel TI Montreal Cognitive Assessment Performance in Patients with Parkinson's Disease with "Normal" Global Cognition According to Mini-Mental State Examination Score SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE cognitive impairment; Parkinson's disease; Mini-Mental State Examination; Montreal Cognitive Assessment; neuropsychology ID COMMUNITY POPULATION; DIAGNOSTIC-CRITERIA; ELDERLY-PEOPLE; SCREENING TOOL; IMPAIRMENT; DEMENTIA; DYSFUNCTION; PROFILE; COHORT AB To examine Montreal Cognitive Assessment (MoCA) performance in patients with Parkinson's disease (PD) with "normal" global cognition according to Mini-Mental State Examination (MMSE) score. A cross-sectional comparison of the MoCA and the MMSE. Two movement disorders centers at the University of Pennsylvania and the Philadelphia Veterans Affairs Medical Center. A convenience sample of 131 patients with idiopathic PD who were screened for cognitive and psychiatric complications. Subjects were administered the MoCA and MMSE, and only subjects defined as having a normal age- and education-adjusted MMSE score were included in the analyses (N=100). As previously recommended in patients without PD, a MoCA score less than 26 was used to indicate the presence of at least mild cognitive impairment (MCI). Mean MMSE and MoCA scores +/- standard deviation were 28.8 +/- 1.1 and 24.9 +/- 3.1, respectively. More than half (52.0%) of subjects with normal MMSE scores had cognitive impairment according to their MoCA score. Impairments were seen in numerous cognitive domains, including memory, visuospatial and executive abilities, attention, and language. Predictors of cognitive impairment on the MoCA using univariate analyses were male sex, older age, lower educational level, and greater disease severity; older age was the only predictor in a multivariate model. Approximately half of patients with PD with a normal MMSE score have cognitive impairment based on the recommended MoCA cutoff score. These results suggest that MCI is common in PD and that the MoCA is a more sensitive instrument than the MMSE for its detection. C1 [Nazem, Sarra; Moberg, Paul J.; Weintraub, Daniel] Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA. [Siderowf, Andrew D.; Duda, John E.; Colcher, Amy; Horn, Stacy S.; Moberg, Paul J.; Hurtig, Howard I.; Stern, Matthew B.; Weintraub, Daniel] Univ Penn, Dept Neurol, Philadelphia, PA 19104 USA. [Have, Tom Ten] Univ Penn, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA. [Weintraub, Daniel] Philadelphia Vet Affairs Med Ctr, Mental Illness Res Educ & Clin Ctr, Philadelphia, PA USA. RP Weintraub, D (reprint author), 3615 Chestnut St,Room 330, Philadelphia, PA 19104 USA. EM weintrau@mail.med.upenn.edu FU National Institutes of Mental Health [067894] FX Sponsor's Role: NA. NR 31 TC 142 Z9 159 U1 4 U2 33 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD FEB PY 2009 VL 57 IS 2 BP 304 EP 308 DI 10.1111/j.1532-5415.2008.02096.x PG 5 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 399WE UT WOS:000262829200017 PM 19170786 ER PT J AU Hanlon, JT Aspinall, SL Semla, TP Weisbord, SD Fried, LF Good, CB Fine, MJ Stone, RA Pugh, MJV Rossi, MI Handler, SM AF Hanlon, Joseph T. Aspinall, Sherrie L. Semla, Todd P. Weisbord, Steven D. Fried, Linda F. Good, C. Bernie Fine, Michael J. Stone, Roslyn A. Pugh, Mary Jo V. Rossi, Michelle I. Handler, Steven M. TI Consensus Guidelines for Oral Dosing of Primarily Renally Cleared Medications in Older Adults SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE aged; chronic kidney disease; suboptimal prescribing ID PHARMACOKINETICS; EFFICACY; CARE; INSUFFICIENCY; TRIAL; ALLOPURINOL; INFORMATION; LORATADINE; FAILURE; DISEASE AB To establish consensus oral dosing guidelines for primarily renally cleared medications prescribed for older adults. Literature search followed by a two-round modified Delphi survey. A nationally representative survey of experts in geriatric clinical pharmacy. Eleven geriatric clinical pharmacists. After a comprehensive literature search and review by an investigative group of six physicians (2 general internal medicine, 2 nephrology, 2 geriatrics), 43 dosing recommendations for 30 medications at various levels of renal function were created. The expert panel rated its agreement with each of these 43 dosing recommendations using a 5-point Likert scale (1=strongly disagree to 5=strongly agree). Recommendation-specific means and 95% confidence intervals were estimated. Consensus was defined as a lower 95% confidence limit of greater than 4.0 for the recommendation-specific mean score. The response rate was 81.8% (9/11) for the first round. All respondents who completed the first round also completed the second round. The expert panel reached consensus on 26 recommendations involving 18 (60%) medications. For 10 medications (chlorpropamide, colchicine, cotrimoxazole, glyburide, meperidine, nitrofurantoin, probenecid, propoxyphene, spironolactone, and triamterene), the consensus recommendation was not to use the medication in older adults below a specified level of renal function (e.g., creatinine clearance < 30 mL/min). For the remaining eight medications (acyclovir, amantadine, ciprofloxacin, gabapentin, memantine, ranitidine, rimantadine, and valacyclovir), specific recommendations for dose reduction or interval extension were made. An expert panel of geriatric clinical pharmacists was able to reach consensus agreement on a number of oral medications that are primarily renally cleared. C1 [Hanlon, Joseph T.] Univ Pittsburgh, Dept Geriatr Med, Div Geriatr Med, Pittsburgh, PA 15213 USA. [Weisbord, Steven D.; Fried, Linda F.] Univ Pittsburgh, Div Renal Electrolyte, Pittsburgh, PA 15213 USA. [Good, C. Bernie; Fine, Michael J.] Univ Pittsburgh, Div Gen Internal Med, Dept Med, Pittsburgh, PA 15213 USA. [Handler, Steven M.] Univ Pittsburgh, Sch Med, Dept Biomed Informat, Pittsburgh, PA 15213 USA. [Hanlon, Joseph T.; Aspinall, Sherrie L.] Univ Pittsburgh, Sch Pharm, Dept Pharm & Therapeut, Pittsburgh, PA 15213 USA. [Stone, Roslyn A.; Rossi, Michelle I.] Univ Pittsburgh, Grad Sch Publ Hlth, Pittsburgh, PA 15213 USA. [Hanlon, Joseph T.; Rossi, Michelle I.; Handler, Steven M.] Vet Affairs Pittsburgh Healthcare Syst, Ctr Geriatr Res Educ & Clin, Pittsburgh, PA USA. [Hanlon, Joseph T.; Aspinall, Sherrie L.; Weisbord, Steven D.; Fried, Linda F.; Good, C. Bernie; Fine, Michael J.; Stone, Roslyn A.] Vet Affairs Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. [Aspinall, Sherrie L.; Semla, Todd P.; Good, C. Bernie] Vet Affairs Ctr Medicat Safety, Hines, IL USA. [Pugh, Mary Jo V.] S Texas Vet Hlth Care Syst, San Antonio, TX USA. [Pugh, Mary Jo V.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. RP Hanlon, JT (reprint author), Univ Pittsburgh, Dept Geriatr Med, Div Geriatr Med, Kaufman Med Bldg,Suite 500,3471 5th Ave, Pittsburgh, PA 15213 USA. EM jth14@pitt.edu OI Handler, Steven/0000-0002-3940-3224; Pugh, Mary Jo/0000-0003-4196-7763 FU National Institutes of Health (NIH) [1 KL2 RR024154-01, 5T32AG021885, P30AG024827, R01AG027017]; Education and Clinical Center Pilot; Pittsburgh Veterans Affairs (VA) Geriatric Research [IIR-06-062] FX Sponsor's Role: None. NR 37 TC 40 Z9 40 U1 1 U2 2 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD FEB PY 2009 VL 57 IS 2 BP 335 EP 340 DI 10.1111/j.1532-5415.2008.02098.x PG 6 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 399WE UT WOS:000262829200022 PM 19170784 ER PT J AU Gupta, E Hartronft, S Prange, M AF Gupta, Elena Hartronft, Scotte Prange, Mark TI COCA-COLA: A NEW THERAPY FOR REFLUX SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Letter ID ESOPHAGECTOMY C1 [Gupta, Elena; Hartronft, Scotte; Prange, Mark] Univ Texas Hlth Sci Ctr San Antonio, S Texas Vet Hlth Care Syst, Dept Med, Div Geriatr Gerontol & Palliat Care, San Antonio, TX 78249 USA. RP Gupta, E (reprint author), Univ Texas Hlth Sci Ctr San Antonio, S Texas Vet Hlth Care Syst, Dept Med, Div Geriatr Gerontol & Palliat Care, San Antonio, TX 78249 USA. NR 10 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD FEB PY 2009 VL 57 IS 2 BP 364 EP 365 DI 10.1111/j.1532-5415.2009.02076.x PG 2 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 399WE UT WOS:000262829200033 PM 19207159 ER PT J AU Wiggins, KL Smith, NL Glazer, NL Rosendaal, FR Heckbert, SR Psaty, BM Rice, KM Lumley, T AF Wiggins, K. L. Smith, N. L. Glazer, N. L. Rosendaal, F. R. Heckbert, S. R. Psaty, B. M. Rice, K. M. Lumley, T. TI ABO genotype and risk of thrombotic events and hemorrhagic stroke SO JOURNAL OF THROMBOSIS AND HAEMOSTASIS LA English DT Article DE ABO genotype; genetic polymorphism; hemorrhagic stroke; ischemic stroke; myocardial infarction; venous thrombosis ID VON-WILLEBRAND-FACTOR; BLOOD-GROUP GENOTYPE; VENOUS THROMBOEMBOLIC DISEASE; FACTOR-VIII LEVELS; MYOCARDIAL-INFARCTION; HAPLOTYPE RECONSTRUCTION; POSTMENOPAUSAL WOMEN; CEREBRAL-HEMORRHAGE; HEART-DISEASE; PLASMA-LEVELS AB Background: The non-O alleles of the ABO genotype have been associated with an increased risk of thrombosis. Risk associated with the specific A(1), A(2) or B alleles is not well defined. Objectives: To examine the association of the ABO genotype with myocardial infarction (MI), ischemic stroke, hemorrhagic stroke, and venous thrombosis (VT). Patients and methods: We used data from two ongoing population-based case-control studies of MI, stroke, and VT. Cases included hypertensive adults and postmenopausal women with incident non-fatal MI (n = 1063), ischemic stroke (n = 469), and hemorrhagic stroke (n = 91), and postmenopausal women with incident non-fatal VT (n = 504). Controls were frequency matched to cases on age, sex, hypertension status, and year of identification. ABO genotypes were determined using single-nucleotide polymorphisms, and subjects were grouped by diplotype according to the presence of O(1), O(2), A(11), A(2) and B alleles. Logistic regression was used to test the association of diplotypes with risk of each outcome. Results: As compared with the O(1)O(1) group, the A(11) allele was associated with an increased risk of VT [odds ratio (OR) 1.79; 95% confidence interval (CI) 1.41-2.26] and MI (OR 1.23; 95% CI 1.05-1.44). The B allele was associated with an increased risk of VT (OR 1.82; 95% CI 1.29-2.57) and ischemic stroke (OR 1.59; 95% CI 1.17-2.17). The AB diplotype category was associated with a 2.7-fold risk of VT (OR 2.70; 95% CI 1.73-4.21). No other associations reached significance. Conclusions: The VT and MI findings are confirmatory, and the ischemic stroke finding with the B allele is a novel finding and needs replication. C1 [Wiggins, K. L.; Glazer, N. L.; Psaty, B. M.] Univ Washington, Dept Med, Cardiovasc Hlth Res Unit, Seattle, WA 98101 USA. [Smith, N. L.; Heckbert, S. R.; Psaty, B. M.] Univ Washington, Dept Epidemiol, Seattle, WA 98101 USA. [Smith, N. L.] Seattle Epidemiol Res & Informat Ctr, VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Rosendaal, F. R.] Leiden Univ, Med Ctr, Dept Clin Epidemiol, Leiden, Netherlands. [Rosendaal, F. R.] Leiden Univ, Med Ctr, Dept Haematol, Leiden, Netherlands. [Psaty, B. M.] Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA. [Rice, K. M.; Lumley, T.] Univ Washington, Dept Biostat, Seattle, WA 98195 USA. RP Wiggins, KL (reprint author), Univ Washington, Dept Med, Cardiovasc Hlth Res Unit, 1730 Minor Ave,Suite 1360, Seattle, WA 98101 USA. EM kwiggins@u.washington.edu RI Rice, Kenneth/A-4150-2013 OI Rice, Kenneth/0000-0001-5779-4495 FU National Heart, Lung, and Blood Institute [HL073410, HL068639, HL043201, HL060739, HL074745, HL068986]; National Institutes of Health [AG00956] FX This study was supported by grants HL073410, HL068639, HL043201, HL060739, HL074745 and HL068986 from the National Heart, Lung, and Blood Institute, AG00956 from the National Institutes of Health, and The Leducq Foundation, Paris, France, for the development of Transatlantic Networks of Excellence in Cardiovascular Research. NR 42 TC 46 Z9 47 U1 1 U2 7 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1538-7933 J9 J THROMB HAEMOST JI J. Thromb. Haemost. PD FEB PY 2009 VL 7 IS 2 BP 263 EP 269 DI 10.1111/j.1538-7836.2008.03243.x PG 7 WC Hematology; Peripheral Vascular Disease SC Hematology; Cardiovascular System & Cardiology GA 399ED UT WOS:000262782300004 PM 19036074 ER PT J AU Van Remmen, H Jones, DP AF Van Remmen, Holly Jones, Dean P. TI Current Thoughts on the Role of Mitochondria and Free Radicals in the Biology of Aging SO JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES LA English DT Editorial Material C1 [Van Remmen, Holly] Univ Texas Hlth Sci Ctr San Antonio, Barshop Inst Longev & Aging Studies, San Antonio, TX 78245 USA. [Van Remmen, Holly] Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, San Antonio, TX 78245 USA. [Van Remmen, Holly] S Texas Vet Hlth Care Syst, San Antonio, TX USA. [Jones, Dean P.] Emory Univ, Dept Med, Atlanta, GA 30322 USA. RP Van Remmen, H (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Barshop Inst Longev & Aging Studies, 15355 Lambda Dr, San Antonio, TX 78245 USA. EM vanremmen@uthscsa.edu NR 6 TC 31 Z9 31 U1 0 U2 5 PU GERONTOLOGICAL SOC AMER PI WASHINGTON PA 1030 15TH ST NW, STE 250, WASHINGTON, DC 20005202-842 USA SN 1079-5006 J9 J GERONTOL A-BIOL JI J. Gerontol. Ser. A-Biol. Sci. Med. Sci. PD FEB PY 2009 VL 64 IS 2 BP 171 EP 174 DI 10.1093/gerona/gln058 PG 4 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 419AB UT WOS:000264190400006 PM 19181714 ER PT J AU Schunemann, HJ Woodhead, M Anzueto, A Buist, S MacNee, W Rabe, KF Heffner, J AF Schuenemann, Holger J. Woodhead, Mark Anzueto, Antonio Buist, Sonia MacNee, William Rabe, Klaus F. Heffner, John TI A vision statement on guideline development for respiratory disease: the example of COPD SO LANCET LA English DT Editorial Material ID RECOMMENDATIONS; STRENGTH; QUALITY C1 [Schuenemann, Holger J.] McMaster Univ, Dept Clin Epidemiol & Biostat, Med Ctr 2C9, CLARITY Res Grp, Hamilton, ON L8N 3Z5, Canada. [Schuenemann, Holger J.] SUNY Buffalo, Dept Med, Buffalo, NY USA. [Woodhead, Mark] Manchester Royal Infirm, Manchester M13 9WL, Lancs, England. [Woodhead, Mark] Univ Manchester, Manchester, Lancs, England. [Anzueto, Antonio] Univ Texas Hlth Sci Ctr San Antonio, S Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA. [Buist, Sonia; Heffner, John] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [MacNee, William] Queens Med Res Inst, ELEGI Colt Res Labs, UoE MRC, Ctr Inflammat Res, Edinburgh, Midlothian, Scotland. [Rabe, Klaus F.] Leiden Univ, Med Ctr, Dept Pulmonol, Leiden, Netherlands. RP Schunemann, HJ (reprint author), McMaster Univ, Dept Clin Epidemiol & Biostat, Med Ctr 2C9, CLARITY Res Grp, 1200 Main St W, Hamilton, ON L8N 3Z5, Canada. EM schuneh@mcmaster.ca OI MacNee, William/0000-0002-3692-1448 FU NHLBI NIH HHS [1R13HL 90485-01] NR 11 TC 31 Z9 35 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0140-6736 J9 LANCET JI Lancet PD FEB-MAR PY 2009 VL 373 IS 9665 BP 774 EP 779 DI 10.1016/S0140-6736(08)61347-1 PG 6 WC Medicine, General & Internal SC General & Internal Medicine GA 412LD UT WOS:000263725400037 PM 18835641 ER PT J AU Paige, NM Nagami, GT AF Paige, Neil M. Nagami, Glenn T. TI The Top 10 Things Nephrologists Wish Every Primary Care Physician Knew SO MAYO CLINIC PROCEEDINGS LA English DT Review ID CHRONIC KIDNEY-DISEASE; CHRONIC-RENAL-FAILURE; BOWEL PREPARATION; METABOLIC EVALUATION; COMBINATION THERAPY; ALUMINUM ABSORPTION; URINE SAMPLES; PROTEINURIA; HEMOGLOBIN; HYPERPHOSPHATEMIA AB Renal disease is commonly encountered by primary care physicians during their day-to-day visits with patients. Common renal disorders include hypertension, proteinuria, kidney stones, and chronic kidney disease. Despite their prevalence, many physicians may be unfamiliar with the diagnosis and Initial treatment of these common renal disorders. Early recognition and intervention are Important In slowing the progression of chronic kidney disease and preventing Its complications. The evidence-based pearls In this article will help primary care physicians avoid common pitfalls In the recognition and treatment of such disorders and guide their decision to refer their patients to a specialist. C1 [Paige, Neil M.] Univ Calif Los Angeles, David Geffen Sch Med, VA Greater Los Angeles Healthcare Syst, Dept Med,Div Gen Internal Med, Los Angeles, CA 90073 USA. [Nagami, Glenn T.] Univ Calif Los Angeles, David Geffen Sch Med, Nephrol Sect, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. RP Paige, NM (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, VA Greater Los Angeles Healthcare Syst, Dept Med,Div Gen Internal Med, 11301 Wilshire Blvd 111A, Los Angeles, CA 90073 USA. EM neil.paige@va.gov NR 43 TC 10 Z9 11 U1 0 U2 1 PU MAYO CLINIC PROCEEDINGS PI ROCHESTER PA 660 SIEBENS BLDG MAYO CLINIC, ROCHESTER, MN 55905 USA SN 0025-6196 J9 MAYO CLIN PROC JI Mayo Clin. Proc. PD FEB PY 2009 VL 84 IS 2 BP 180 EP 186 PG 7 WC Medicine, General & Internal SC General & Internal Medicine GA 402CT UT WOS:000262992500012 PM 19181652 ER PT J AU Pickard, AS Lin, HW Knight, SL Sharifi, R Wu, ZG Hung, SY Witt, WP Chang, CH Bennett, CL AF Pickard, A. Simon Lin, Hsiang-Wen Knight, Sara L. Sharifi, Roohollah Wu, Zhigang Hung, Shih-Ying Witt, Whitney P. Chang, Chih-Hung Bennett, Charles L. TI Proxy Assessment of Health-Related Quality of Life in African American and White Respondents With Prostate Cancer Perspective Matters SO MEDICAL CARE LA English DT Article DE quality of life; proxy; prostate cancer; Veterans ID UROLOGIC RESEARCH ENDEAVOR; RADICAL PROSTATECTOMY; SYMPTOM EXPERIENCES; SIGNIFICANT OTHERS; FUNCTIONAL STATUS; MEDICARE SURVEY; PATIENT HEALTH; MEN; CAREGIVERS; OUTCOMES AB Objectives: An emerging issue in the proxy literature is whether specifying different proxy viewpoints contributes to different health-related quality of life (HRQL) assessments, and if so, how might each perspective be informative in medical decision making. The aims of this study were to determine if informal caregiver assessments of patients with prostate cancer differed when prompted from both the patient perspective (proxy-patient) and their own viewpoint (proxy-proxy), and to identify factors associated with differences in proxy perspectives (ie, the intraproxy gap). Research Design and Methods: Using a cross-sectional design, prostate cancer patients and their informal caregivers were recruited from urology clinics in the Jesse Brown Veterans Affairs Healthcare System in Chicago. Dyads assessed HRQL using the EQ-5D visual analog scale (VAS) and EORTC QLQ-C30. Results: Of 87 dyads, most caregivers were female (83%) and were spouses/partners (58%). Mean difference scores between proxy-patient and proxy-proxy perspectives were statistically significant for QLQ-C30 physical and emotional functioning, and VAS (all P < 0.05), with the proxy-patient perspective closer to patient self-report. Emotional functioning had the largest difference, mean 6.0 (SD 12.8), an effect size = 0.47. Factors weakly correlated with the intraproxy gap included relationship (spouse) and proxy gender for role functioning, and health literacy (limited/functional) for physical functioning (all P < 0.05, 0.20 < r < 0.35). Conclusions: Meaningful differences between proxy-patient and proxy-proxy perspectives on mental health were consistent with a conceptual framework for understanding proxy perspectives. Prompting different proxy viewpoints on patient health could help clinicians identify patients who may benefit from clinical intervention. C1 [Pickard, A. Simon; Lin, Hsiang-Wen; Hung, Shih-Ying] Univ Illinois, Coll Pharm, Ctr Pharmacoecon Res, Dept Pharm Practice & Pharm Adm, Chicago, IL 60612 USA. [Pickard, A. Simon; Hung, Shih-Ying; Bennett, Charles L.] Hines VA Hosp, Midwest Ctr Hlth Serv & Policy Res, Hines, IL USA. [Knight, Sara L.] Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, San Francisco, CA 94143 USA. [Knight, Sara L.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA. [Knight, Sara L.] Univ Calif San Francisco, Dept Urol, San Francisco, CA 94143 USA. [Sharifi, Roohollah; Wu, Zhigang] Univ Illinois, Coll Pharm, Dept Urol, Chicago, IL 60612 USA. [Sharifi, Roohollah; Wu, Zhigang; Bennett, Charles L.] Jesse Brown Vet Affairs Hlth Syst, Chicago, IL USA. Univ Wisconsin, Dept Social & Adm Pharm, Madison, WI USA. [Witt, Whitney P.] Univ Wisconsin, Dept Hlth Sci Res, Sch Publ Hlth, Madison, WI USA. [Chang, Chih-Hung] Northwestern Univ, Buehler Ctr Aging Hlth & Soc, Chicago, IL 60611 USA. [Bennett, Charles L.] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA. RP Pickard, AS (reprint author), Univ Illinois, Coll Pharm, Ctr Pharmacoecon Res, Dept Pharm Practice & Pharm Adm, 833 S Wood St,Rm 164,MC 886, Chicago, IL 60612 USA. EM pickard1@uic.edu FU National Cancer Institute/ National Institutes of Health [R03 CA 108395] FX Supported by grant R03 CA 108395 from the National Cancer Institute/ National Institutes of Health. NR 51 TC 12 Z9 12 U1 1 U2 6 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0025-7079 J9 MED CARE JI Med. Care PD FEB PY 2009 VL 47 IS 2 BP 176 EP 183 PG 8 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA 401BN UT WOS:000262913200007 PM 19169118 ER PT J AU Dhaliwal, G AF Dhaliwal, Gurpreet TI Medical expertise: begin with the end in mind SO MEDICAL EDUCATION LA English DT Editorial Material ID DELIBERATE PRACTICE; EDUCATION C1 Univ Calif San Francisco Med, San Francisco VA Med Ctr, San Francisco, CA 94121 USA. RP Dhaliwal, G (reprint author), Univ Calif San Francisco Med, San Francisco VA Med Ctr, 4150 Clement St 111, San Francisco, CA 94121 USA. EM gurpreet.dhaliwal@va.gov NR 11 TC 1 Z9 1 U1 0 U2 0 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0308-0110 J9 MED EDUC JI Med. Educ. PD FEB PY 2009 VL 43 IS 2 BP 105 EP 107 DI 10.1111/j.1365-2923.2008.03262.x PG 3 WC Education, Scientific Disciplines; Health Care Sciences & Services SC Education & Educational Research; Health Care Sciences & Services GA 397EJ UT WOS:000262644900003 PM 19161478 ER PT J AU Klein, AJ Casserly, IP Messenger, JC Carroll, JD Chen, SYJ AF Klein, Andrew J. Casserly, Ivan P. Messenger, John C. Carroll, John D. Chen, S. -Y. James TI In vivo 3D modeling of the femoropopliteal artery in human subjects based on x-ray angiography: Methodology and validation SO MEDICAL PHYSICS LA English DT Article DE biomechanics; blood vessels; diagnostic radiography; diseases ID SUPERFICIAL FEMORAL-ARTERY; QUANTITATIVE-ANALYSIS; 3-D RECONSTRUCTION; CORONARY-ARTERIES; TREE; STENTS AB Endovascular revascularization of the femoropopliteal (FP) artery has been limited by high rates of restenosis and stent fracture. The unique physical forces that are applied to the FP artery during leg movement have been implicated in these phenomena. The foundation for measuring the effects of physical forces on the FP artery in a clinically relevant environment is based on the ability to develop 3D models of this vessel in different leg positions in vivo in patients with peripheral arterial disease (PAD). By acquiring paired angiographic images of the FP artery, and using angiography-based 3D modeling algorithms previously validated in the coronary arteries, the authors generated 3D models of ten FP arteries in nine patients with PAD with the lower extremity in straight leg (SL) and crossed leg (CL) positions. Due to the length of the FP artery, overlapping paired angiographic images of the entire FP artery were required to image the entire vessel, which necessitated the development of a novel fusion process in order to generate a 3D model of the entire FP artery. The methodology of angiographic acquisition and 3D model generation of the FP artery is described. In a subset of patients, a third angiographic view (i.e., validation view) was acquired in addition to the standard paired views for the purpose of validating the 3D modeling process. The mean root-mean-square (rms) error of the point-to-point distances between the centerline of the main FP artery from the 2D validation view and the centerline from the 3D model placed in the validation view for the SL and CL positions were 0.93 +/- 0.19 mm and 1.12 +/- 0.25 mm, respectively. Similarly, the mean rms error of the same comparison for the main FP artery and sidebranches for the SL and CL positions were 1.09 +/- 0.38 mm and 1.21 +/- 0.25 mm, respectively. A separate validation of the novel fusion process was performed by comparing the 3D model of the FP artery derived from fusion of 3D models of adjacent FP segments with the 2D validation view incorporating the region of fusion. The mean rms error of vessel centerline points of the main FP artery, the main FP artery plus directly connected sidebranches, and the mean rms error of upstream, downstream, and sidebranch directional vectors at bifurcation points in the overlap region were 1.41 +/- 0.79 mm, 2.13 +/- 1.12 mm, 3.16 +/- 3.72 degrees, 3.60 +/- 5.39 degrees, and 8.68 +/- 8.42 degrees in the SL position, respectively, and 1.29 +/- 0.35 mm, 1.61 +/- 0.78 mm, 4.68 +/- 4.08 degrees, 3.41 +/- 2.23 degrees, and 5.52 +/- 4.41 degrees in the CL position, respectively. Inter- and intraobserver variability in the generation of 3D models of individual FP segments and the fusion of overlapping FP segments were assessed. The mean rms errors between the centerlines of nine 3D models of individual FP segments generated by two independent observers, and repeated measurement by the same observer were 2.78 +/- 1.26 mm and 3.50 +/- 1.15 mm, respectively. The mean rms errors between the centerline of four 3D models of fused overlapping FP segments generated by two independent observers, and repeated measurement by the same observer were 4.99 +/- 0.99 mm and 5.98 +/- 1.22 mm, respectively. This study documents the ability to generate 3D models of the entire FP artery in vivo in patients with PAD in both SL and CL positions using routine angiography, and validates the methodologies used. C1 [Klein, Andrew J.; Casserly, Ivan P.; Messenger, John C.; Carroll, John D.; Chen, S. -Y. James] Univ Colorado Denver, Aurora, CO 80045 USA. [Casserly, Ivan P.] Denver VA Med Ctr, Denver, CO 80220 USA. RP Klein, AJ (reprint author), Univ Colorado Denver, Aurora, CO 80045 USA. FU Boston Scientific Corporation FX The authors would like to acknowledge Adam Hansgen for assistance with graphics, the cardiac catheterization laboratory staff at the Denver VA Medical Center for assistance during acquisition of angiographic data (Sarah Doran, Mary Hall, Marsha Hallahan, Lori Harvey, Mary Ann Olson, Tracy Rankin), Philip Li and Yu- Li Liang for their efforts in reconstructing the FP arteries, and Kathy Kioussopoulos for her assistance in preparing the clinical protocol for institutional review board approval. This study was supported and funded by the research grant from Boston Scientific Corporation. NR 20 TC 5 Z9 5 U1 0 U2 2 PU AMER ASSOC PHYSICISTS MEDICINE AMER INST PHYSICS PI MELVILLE PA STE 1 NO 1, 2 HUNTINGTON QUADRANGLE, MELVILLE, NY 11747-4502 USA SN 0094-2405 J9 MED PHYS JI Med. Phys. PD FEB PY 2009 VL 36 IS 2 BP 289 EP 310 DI 10.1118/1.3006195 PG 22 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 400FE UT WOS:000262852600003 PM 19291969 ER PT J AU Cornford, E Hyman, S Cornford, M Suzuki, T Yamagata, T Yamakawa, K Rhee, J Delgado-Escueta, A AF Cornford, Eain Hyman, Shigeyo Cornford, Marcia Suzuki, Toshimitsu Yamagata, Tetsushi Yamakawa, Kazuhiro Rhee, Jennifer Delgado-Escueta, Antonio TI Immunoliposome-based, non-viral gene delivery in a knock-out mouse model of Lafora inclusion body disease SO MOLECULAR GENETICS AND METABOLISM LA English DT Meeting Abstract CT 4th Annual World Symposium of the Lysosomal-Disease-Network CY FEB 13-15, 2009 CL Las Vegas, NV SP Lysosomal Dis Network C1 [Cornford, Eain; Rhee, Jennifer; Delgado-Escueta, Antonio] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Hyman, Shigeyo; Delgado-Escueta, Antonio] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Cornford, Marcia] Harbor UCLA Med Ctr, Los Angeles, CA USA. [Suzuki, Toshimitsu; Yamagata, Tetsushi; Yamakawa, Kazuhiro] RIKEN Brain Sci Inst, Saitama, Japan. RI Yamakawa, Kazuhiro/N-5050-2015 NR 0 TC 0 Z9 0 U1 0 U2 0 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1096-7192 J9 MOL GENET METAB JI Mol. Genet. Metab. PD FEB PY 2009 VL 96 IS 2 MA 30 BP S19 EP S19 DI 10.1016/j.ymgme.2008.11.031 PG 1 WC Endocrinology & Metabolism; Genetics & Heredity; Medicine, Research & Experimental SC Endocrinology & Metabolism; Genetics & Heredity; Research & Experimental Medicine GA 399QG UT WOS:000262813800038 ER PT J AU Saxena, S Gorbis, E O'Neill, J Baker, SK Mandelkern, MA Maidment, KM Chang, S Salamon, N Brody, AL Schwartz, JM London, ED AF Saxena, S. Gorbis, E. O'Neill, J. Baker, S. K. Mandelkern, M. A. Maidment, K. M. Chang, S. Salamon, N. Brody, A. L. Schwartz, J. M. London, E. D. TI Rapid effects of brief intensive cognitive-behavioral therapy on brain glucose metabolism in obsessive-compulsive disorder SO MOLECULAR PSYCHIATRY LA English DT Article DE obsessive-compulsive disorder; cognitive-behavioral therapy; intensive treatment; functional neuroimaging; positron emission tomography; anterior cingulate ID CEREBRAL-BLOOD-FLOW; ANTERIOR CINGULATE CORTEX; POSITRON-EMISSION-TOMOGRAPHY; SEROTONIN REUPTAKE INHIBITORS; MAJOR DEPRESSION; SYMPTOM PROVOCATION; UNMEDICATED PATIENTS; RESPONSE PREVENTION; CONTROLLED TRIAL; FDG-PET AB Brief intensive cognitive-behavioral therapy (CBT) using exposure and response prevention significantly improves obsessive-compulsive disorder (OCD) symptoms in as little as 4 weeks. However, it has been thought that much longer treatment was needed to produce the changes in brain function seen in neuroimaging studies of OCD. We sought to elucidate the brain mediation of response to brief intensive CBT for OCD and determine whether this treatment could induce functional brain changes previously seen after longer trials of pharmacotherapy or standard CBT. [(18)F]-fluorodeoxyglucose positron emission tomography brain scans were obtained on 10 OCD patients before and after 4 weeks of intensive individual CBT. Twelve normal controls were scanned twice, several weeks apart, without treatment. Regional glucose metabolic changes were compared between groups. OCD symptoms, depression, anxiety and overall functioning improved robustly with treatment. Significant changes in normalized regional glucose metabolism were seen after brief intensive CBT (P = 0.04). Compared to controls, OCD patients showed significant bilateral decreases in normalized thalamic metabolism with intensive CBT but had a significant increase in right dorsal anterior cingulate cortex activity that correlated strongly with the degree of improvement in OCD symptoms (P = 0.02). The rapid response of OCD to intensive CBT is mediated by a distinct pattern of changes in regional brain function. Reduction of thalamic activity may be a final common pathway for improvement in OCD, but response to intensive CBT may require activation of dorsal anterior cingulate cortex, a region involved in reappraisal and suppression of negative emotions. C1 [Saxena, S.] Univ Calif San Diego, Sch Med, Dept Psychiat, La Jolla, CA 92093 USA. [Gorbis, E.; O'Neill, J.; Baker, S. K.; Maidment, K. M.; Chang, S.; Brody, A. L.; Schwartz, J. M.; London, E. D.] Univ Calif Los Angeles, David Geffen Sch Med, Semel Inst Neurosci & Human Behav, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA. [Mandelkern, M. A.; Brody, A. L.] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Salamon, N.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Radiol, Los Angeles, CA 90095 USA. RP Saxena, S (reprint author), Univ Calif San Diego, Obsess Compuls Disorders Program, Dept Psychiat, VA San Diego Healthcare Syst, 3350 La Jolla Village Dr, San Diego, CA 92161 USA. EM ssaxena@ucsd.edu FU NIMH [R01 MH069433]; Brain Mapping Medical Research Organization; Brain Mapping Support Foundation; Pierson-Lovelace Foundation; Ahmanson Foundation; Tamkin Foundation; Jennifer Jones-Simon Foundation; Capital Group Companies Charitable Foundation; Northern Piedmont Community Foundation; National Center for Research Resources [RR12169, RR13642, RR08655] FX This work was supported by an NIMH grant (R01 MH069433) to Dr Saxena and by donations to the Westwood Institute for Anxiety Disorders (Dr Gorbis). For generous support, we thank the Brain Mapping Medical Research Organization, Brain Mapping Support Foundation, Pierson- Lovelace Foundation, Ahmanson Foundation, Tamkin Foundation, Jennifer Jones-Simon Foundation, Capital Group Companies Charitable Foundation, Robson Family, William M and Linda R Dietel Philanthropic Fund at the Northern Piedmont Community Foundation, Northstar Fund and the National Center for Research Resources grants RR12169, RR13642 and RR08655. This work was presented in part at the American College of Neuropsychopharmacology 43rd Annual Meeting (San Juan, Puerto Rico, 15 December 2004). NR 70 TC 64 Z9 66 U1 4 U2 25 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 1359-4184 J9 MOL PSYCHIATR JI Mol. Psychiatr. PD FEB PY 2009 VL 14 IS 2 BP 197 EP 205 DI 10.1038/sj.mp.4002134 PG 9 WC Biochemistry & Molecular Biology; Neurosciences; Psychiatry SC Biochemistry & Molecular Biology; Neurosciences & Neurology; Psychiatry GA 395VD UT WOS:000262550700009 PM 18180761 ER PT J AU Tyler, KL AF Tyler, Kenneth L. TI Prednisolone-but not antiviral drugs-improves outcome in patients with Bell's palsy SO NATURE CLINICAL PRACTICE NEUROLOGY LA English DT Editorial Material DE acyclovir; Bell's palsy; peripheral facial palsy; prednisolone; valacyclovir ID HERPES-SIMPLEX-VIRUS; DOUBLE-BLIND; VALACYCLOVIR; REACTIVATION; MULTICENTER; ACYCLOVIR; TYPE-1; TRIAL AB Randomized, double-blind, placebo-controlled trials have provided compelling evidence that treatment with prednisolone improves outcome in patients with acute idiopathic peripheral facial ( Bell's) palsy. The low rate of adverse effects, the small number needed to treat, and the modest cost of therapy indicate that prednisolone should be used in all patients with facial palsy of <72 h duration who do not have contraindications to steroid therapy. By contrast, the best-designed recent clinical trials have failed to suggest any significant beneficial effect on Bell's palsy of treatment with acyclovir or valacyclovir, either as single agents or in combination with prednisolone. Antiviral therapy should not, therefore, be routinely used in the treatment of Bell's palsy. C1 [Tyler, Kenneth L.] Univ Colorado, Denver Hlth Sci Ctr, Denver, CO 80202 USA. [Tyler, Kenneth L.] Denver Vet Affairs Med Ctr, Neurol Serv, Denver, CO USA. RP Tyler, KL (reprint author), Univ Colorado, Denver Hlth Sci Ctr, Dept Neurol, B-182,RC-2,12700 E 19th Ave, Aurora, CO 80045 USA. EM ken.tyler@uchsc.edu OI Tyler, Kenneth/0000-0003-3294-5888 NR 10 TC 6 Z9 6 U1 0 U2 4 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1745-834X J9 NAT CLIN PRACT NEURO JI Nat. Clin. Pract. Neurol. PD FEB PY 2009 VL 5 IS 2 BP 74 EP 75 DI 10.1038/ncpneuro1002 PG 2 WC Clinical Neurology SC Neurosciences & Neurology GA 403OB UT WOS:000263090800005 PM 19139743 ER PT J AU Webster, CM Kelly, S Koike, MA Chock, VY Giffard, RG Yenari, MA AF Webster, Carla M. Kelly, Stephen Koike, Maya A. Chock, Valerie Y. Giffard, Rona G. Yenari, Midori A. TI Inflammation and NF kappa B activation is decreased by hypothermia following global cerebral ischemia SO NEUROBIOLOGY OF DISEASE LA English DT Article DE Global cerebral ischemia; Hypothermia; Inflammation; Nuclear factor-kappa B; Microglia ID LEUKOCYTE-ENDOTHELIUM INTERACTION; TRANSIENT FOCAL ISCHEMIA; CENTRAL-NERVOUS-SYSTEM; NITRIC-OXIDE SYNTHASE; MILD HYPOTHERMIA; EXPERIMENTAL STROKE; THERAPEUTIC HYPOTHERMIA; POSTISCHEMIC HYPOTHERMIA; ARTERY OCCLUSION; MICROGLIAL ACTIVATION AB We previously showed that hypothermia attenuates inflammation in focal cerebral ischemia (FCI) by suppressing activating kinases of nuclear factor-kappa B (NF kappa B). Here we characterize the inflammatory response in global cerebral ischemia (GCI), and the influence of mild hypothermia. Rodents were subjected to GCI by bilateral carotid artery occlusion. The inflammatory response was accompanied by microglial activation, but not neutrophil infiltration, or blood brain barrier disruption. Mild hypothermia reduced CA1 damage, decreased microglial activation and decreased nuclear NF kappa B translocation and activation. Similar anti-inflammatory effects of hypothermia were observed in a model of pure brain inflammation that does not cause brain cell death. Primary microglial cultures subjected to oxygen glucose deprivation (OGD) or stimulated with LPS under hypothermic conditions also experienced less activation and less NF kappa B translocation. However, NF kappa B regulatory proteins were not affected by hypothermia. The inflammatory response following GCI and hypothermia's anti-inflammatory mechanism is different from that observed in FCI. Published by Elsevier Inc. C1 [Webster, Carla M.; Koike, Maya A.; Yenari, Midori A.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94121 USA. [Webster, Carla M.; Koike, Maya A.; Yenari, Midori A.] San Francisco VA Med Ctr, San Francisco, CA 94121 USA. [Webster, Carla M.; Koike, Maya A.; Chock, Valerie Y.; Giffard, Rona G.] Stanford Univ, Sch Med, Dept Anesthesia, Stanford, CA 94305 USA. [Kelly, Stephen] Univ Bristol, Bristol BS1 3NY, Avon, England. RP Yenari, MA (reprint author), Univ Calif San Francisco, Dept Neurol, 4150 Clement St, San Francisco, CA 94121 USA. EM yenari@alum.mit.edu RI Kelly, Stephen/A-8307-2010 FU NIH [RO1 NS40516, P50 NS14543, P01 NS37520, R01 NS53898]; AHA [EIA0540066N] FX This work was made possible by the following institutions and grants: NIH RO1 NS40516 (MAY), AHA EIA0540066N (MAY), NIH P50 NS14543 and P01 NS37520 (RGG, MAY), NIH R01 NS53898 (RGG). NR 61 TC 58 Z9 68 U1 0 U2 4 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0969-9961 J9 NEUROBIOL DIS JI Neurobiol. Dis. PD FEB PY 2009 VL 33 IS 2 BP 301 EP 312 DI 10.1016/j.nbd.2008.11.001 PG 12 WC Neurosciences SC Neurosciences & Neurology GA 403ZM UT WOS:000263120500018 PM 19063968 ER PT J AU Humbert, IA Fitzgerald, ME McLaren, DG Johnson, S Porcaro, E Kosmatka, K Hind, J Robbins, J AF Humbert, Ianessa A. Fitzgerald, Michelle E. McLaren, Donald G. Johnson, Sterling Porcaro, Eva Kosmatka, Kris Hind, Jacqueline Robbins, JoAnne TI Neurophysiology of swallowing: Effects of age and bolus type SO NEUROIMAGE LA English DT Article ID CEREBRAL CORTICAL REPRESENTATION; PENETRATION-ASPIRATION SCALE; HEMISPHERIC ASYMMETRIES; SUSTAINED ATTENTION; NORMAL ADULTS; CORTEX; MOTOR; FMRI; INDIVIDUALS; DEGLUTITION AB This study examined age-related changes in swallowing from an integrated biomechanical and functional imaging perspective in order to more comprehensively characterize changes in swallowing associated with age. We examined swallowing-related fMRI brain activity and videoflouroscopic biomechanics of three bolus types (saliva, water and barium) in 12 young and 11 older adults. We found that age-related neurophysiological changes in swallowing are evident. The group of older adults recruited more cortical regions than young adults, including the pericentral gyri and inferior frontal gyrus pars opercularis and pars triangularis (primarily right-sided). Saliva swallows elicited significantly higher BOLD responses in regions important for swallowing compared to water and barium. In separate videofluoroscopy sessions, we obtained durational measures of supine swallowing. The older cohort had significantly longer delays before the onset of the pharyngeal swallow response and increased residue of ingested material in the pharynx. These findings suggest that older adults without neurological insult elicit more cortical involvement to complete the same swallowing tasks as younger adults. (C) 2008 Elsevier Inc. All rights reserved. C1 William S Middleton Mem Vet Adm Med Ctr, Ctr Geriatr Res Educ & Clin, Madison, WI USA. Univ Wisconsin, Madison, WI 53706 USA. RP Humbert, IA (reprint author), 98 N Broadway,Suite 413, Baltimore, MD 21231 USA. EM ihumber1@jhmi.edu RI McLaren, Donald/G-9906-2011 OI Johnson, Sterling/0000-0002-8501-545X FU National Institutes of Health (NIH); NCRR; The Training and Education to Advance MultidisciplinaryClinical- Research (TEAM) Program [8K12RR023268-02]; National Institutes of Health and National Institute [T32 AG20013]; William S. Middleton Memorial VA Hospital Geriatric Research Education and Clinical Center (GRECC) [2008-16] FX This is GRECC manuscript # 2008-16. NR 55 TC 44 Z9 49 U1 0 U2 4 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1053-8119 J9 NEUROIMAGE JI Neuroimage PD FEB 1 PY 2009 VL 44 IS 3 BP 982 EP 991 DI 10.1016/j.neuroimage.2008.10.012 PG 10 WC Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging SC Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging GA 392KL UT WOS:000262301500037 PM 19010424 ER PT J AU Benmansour, S Piotrowski, JP Altamirano, AV Frazer, A AF Benmansour, Saloua Piotrowski, Jonathan P. Altamirano, Alfonso V. Frazer, Alan TI Impact of Ovarian Hormones on the Modulation of the Serotonin Transporter by Fluvoxamine SO NEUROPSYCHOPHARMACOLOGY LA English DT Article DE serotonin transporter; estradiol; progesterone; fluvoxamine; chronoamperometry; hippocampus ID APPLIED UPTAKE INHIBITORS; ESTROGEN-RECEPTOR BETA; CLEARANCE IN-VIVO; ASTERISK-D REPORT; MESSENGER-RNA; RAT-BRAIN; GENDER-DIFFERENCES; PROTEIN-KINASE; FEMALE RATS; PROGESTERONE-RECEPTOR AB Most preclinical studies examining the mechanism(s) of action of antidepressants are carried out using male animals. Blockade of serotonin transporter (SERT) function by selective serotonin reuptake inhibitors (SSRIs) is the initial event that triggers a not completely understood process that results in clinical improvement in depression. To investigate whether there are differences in the ability of SSRIs to inhibit the SERT between male and female rats at different phases of the estrous cycle, clearance of locally applied serotonin (5-HT) was measured by in vivo chronoamperometry. Local application of the SSRI, fluvoxamine, directly into the CA3 area of hippocampus increased significantly 5-HT clearance time parameters in male rats and female rats in estrus or diestrus, but not in proestrus. The contribution of ovarian steroids to this result was investigated in ovariectomized (OVX) rats treated with estradiol benzoate (EB) and/or progesterone (P). In OVX-control rats, fluvoxamine increased clearance time parameters, whereas EB and/or P treatment blocked this effect, consistent with what was seen in female rats in proestrus. This effect was gender-specific, since treatment of castrated rats with EB/P had no effect on the ability of fluvoxamine to slow 5-HT clearance. The time course of hormonal effects showed that 1-60 min after local application of 17-beta-estradiol (E-2) into the CA3 region of OVX rats, fluvoxamine had no effect on clearance time of 5-HT. E-2-BSA mimicked E-2's effects at 10 min but not at 60 min. Pretreatment with estrogen receptor antagonists blocked the effects of E-2. The finding that acutely both estradiol and progesterone can inhibit the ability of an SSRI to slow the clearance of 5-HT, may have important implications for the use of SSRIs in women. C1 [Benmansour, Saloua; Piotrowski, Jonathan P.; Altamirano, Alfonso V.; Frazer, Alan] Univ Texas Hlth Sci Ctr San Antonio, Dept Pharmacol, San Antonio, TX 78229 USA. [Frazer, Alan] S Texas Vet Hlth Care Syst, San Antonio, TX USA. RP Benmansour, S (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Pharmacol MC 7764, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM benmansour@uthscsa.edu FU NARSAD; Department of Veterans Affairs; Forest Research Institute; Eli Lilly and Company; Wyeth Pharmaceuticals FX This work was supported by funds from NARSAD and the Department of Veterans Affairs. We thank Dr Andrea Gore for help with analysis of hormones levels and Kelly Sharp and Dr Georgianna Gould for technical assistance.; Dr Benmansour, Mr Piotrowski, and Mr Altamirano report no biomedical financial interests or potential conflicts of interest. Dr Frazer reports that he has been on advisory boards for Cyberonics Inc. and H Lundbeck A/S and that he has consulted and/or received research support for preclinical studies from Forest Research Institute, Eli Lilly and Company, and Wyeth Pharmaceuticals, but no support for this study was received by any pharmaceutical company. NR 66 TC 27 Z9 27 U1 0 U2 5 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0893-133X EI 1740-634X J9 NEUROPSYCHOPHARMACOL JI Neuropsychopharmacology PD FEB PY 2009 VL 34 IS 3 BP 555 EP 564 DI 10.1038/npp.2008.23 PG 10 WC Neurosciences; Pharmacology & Pharmacy; Psychiatry SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry GA 393MA UT WOS:000262376200004 PM 18322468 ER PT J AU Franklin, TR Lohoff, FW Wang, Z Sciortino, N Harper, D Li, Y Jens, W Cruz, J Kampman, K Ehrman, R Berrettini, W Detre, JA O'Brien, CP Childress, AR AF Franklin, Teresa R. Lohoff, Falk W. Wang, Ze Sciortino, Nathan Harper, Derek Li, Yin Jens, Will Cruz, Jeffrey Kampman, Kyle Ehrman, Ron Berrettini, Wade Detre, John A. O'Brien, Charles P. Childress, Anna Rose TI DAT Genotype Modulates Brain and Behavioral Responses Elicited by Cigarette Cues SO NEUROPSYCHOPHARMACOLOGY LA English DT Article DE fMRI; dopamine transporter; gene; smoking; reward; cue ID DOPAMINE TRANSPORTER GENE; DRD4 VNTR POLYMORPHISM; NUCLEUS-ACCUMBENS; SMOKING CUES; LIMBIC ACTIVATION; RECEPTOR GENE; CONDITIONED INCREASES; NICOTINE DEPENDENCE; INTRAVENOUS COCAINE; STRESS-DISORDER AB We previously demonstrated differential activation of the mesocorticolimbic reward circuitry in response to cigarette cues independent of withdrawal. Despite robust effects, we noted considerable individual variability in brain and subjective responses. As dopamine (DA) is critical for reward and its predictive signals, genetically driven variation in DA transmission may account for the observed differences. Evidence suggests that a variable number of tandem repeats (VNTRs) polymorphism in the DA transporter (DAT) SLC6A3 gene may influence DA transport. Brain and behavioral responses may be enhanced in probands carrying the 9-repeat allele. To test this hypothesis, perfusion fMR images were acquired during cue exposure in 19 smokers genotyped for the 40 bp VNTR polymorphism in the SLC6A3 gene. Contrasts between groups revealed that 9-repeat (9-repeats) had a greater response to smoking (vs nonsmoking) cues than smokers homozygous for the 10-repeat allele (10/10-repeats) bilaterally in the interconnected ventral striatal/pallidal/orbitofrontal cortex regions (VS/VP/OFC). Activity was increased in 9-repeats and decreased in 10/10-repeats in the VS/VP/OFC (p<0.001 for all analyses). Brain activity and craving was strongly correlated in 10/10-repeats in these regions and others (anterior cingulate, parahippocampal gyrus, and insula; r(2) = 0.79-0.86, p<0.001 in all regions). Alternatively, there were no significant correlations between brain and behavior in 9-repeats. There were no differences in cigarette dependence, demographics, or resting baseline neural activity between groups. These results provide evidence that genetic variation in the DAT gene contributes to the neural and behavioral responses elicited by smoking cues. C1 [Franklin, Teresa R.; Lohoff, Falk W.; Wang, Ze; Sciortino, Nathan; Harper, Derek; Li, Yin; Jens, Will; Cruz, Jeffrey; Kampman, Kyle; Ehrman, Ron; Berrettini, Wade; O'Brien, Charles P.; Childress, Anna Rose] Univ Penn, Dept Psychiat, Addict Treatment Res Ctr, Philadelphia, PA 19104 USA. [Kampman, Kyle; Ehrman, Ron; O'Brien, Charles P.; Childress, Anna Rose] Dept Vet Affairs Med Ctr, Philadelphia, PA 19104 USA. [Kampman, Kyle; Ehrman, Ron; O'Brien, Charles P.; Childress, Anna Rose] VA VISN 4 MIRECC, Philadelphia, PA USA. [Detre, John A.] Univ Penn, Dept Radiol, Philadelphia, PA 19104 USA. [Detre, John A.] Univ Penn, Dept Neurol, Philadelphia, PA 19104 USA. RP Franklin, TR (reprint author), Univ Penn, Dept Psychiat, Addict Treatment Res Ctr, 3900 Chestnut St, Philadelphia, PA 19104 USA. EM franklin_t@mail.trc.upenn.edu RI Wang, Ze/A-1043-2007; Lohoff, Falk/M-7951-2016 OI Jens, William/0000-0001-5201-1412 FU NIH [DA015149, K01 DA 015426-011A1, 5-P60-DA-005186-18, NS045839, BCS-0224007, RR02305, 1K08MH080372-01A1 VA VISN 4 MIRECC]; GCRC of the University of Pennsylvania FX This work was supported by NIH grants DA015149, K01 DA 015426-011A1, 5-P60-DA-005186-18, and NS045839, BCS-0224007, RR02305, 1K08MH080372-01A1 VA VISN 4 MIRECC, and the GCRC of the University of Pennsylvania. We acknowledge the nursing staff at the University of Pennsylvania Addiction Treatment Research for conducting physical evaluations. We also thank our clinicians Anita Hole PhD, Jesse Suh, PsyD, and Marta MacDougal, PsyD for conducting the psychological evaluations. And third, we take this opportunity to thank the MRI technicians at the Hospital of the University of Pennsylvania for conducting the scanning sessions. NR 80 TC 64 Z9 67 U1 6 U2 11 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0893-133X J9 NEUROPSYCHOPHARMACOL JI Neuropsychopharmacology PD FEB PY 2009 VL 34 IS 3 BP 717 EP 728 DI 10.1038/npp.2008.124 PG 12 WC Neurosciences; Pharmacology & Pharmacy; Psychiatry SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry GA 393MA UT WOS:000262376200019 PM 18704100 ER PT J AU Samaha, FF Chou, CM AF Samaha, Frederick F. Chou, Carol M. TI Blockade of the Endocannabinoid System for the Reduction of Cardiometabolic Risk Factors SO OBESITY LA English DT Review ID CANNABINOID-1 RECEPTOR BLOCKER; RANDOMIZED CONTROLLED-TRIAL; AMERICAN-HEART-ASSOCIATION; DIET-INDUCED OBESITY; ADIPOSE-TISSUE; ENERGY-BALANCE; CARDIOVASCULAR-DISEASE; CB1 RECEPTORS; SCIENTIFIC STATEMENT; ANTAGONIST SR141716 C1 [Chou, Carol M.] Univ Penn, Dept Med, Div Gen Internal Med, Philadelphia, PA 19104 USA. [Samaha, Frederick F.] Philadelphia Vet Affairs Med Ctr, Cardiovasc Sect, Philadelphia, PA USA. [Samaha, Frederick F.] Univ Penn, Dept Med, Div Cardiovasc Med, Philadelphia, PA 19104 USA. RP Chou, CM (reprint author), Univ Penn, Dept Med, Div Gen Internal Med, Philadelphia, PA 19104 USA. EM cchou@mail.med.upenn.edu NR 41 TC 1 Z9 1 U1 0 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1930-7381 J9 OBESITY JI Obesity PD FEB PY 2009 VL 17 IS 2 BP 220 EP 225 DI 10.1038/oby.2008.476 PG 6 WC Endocrinology & Metabolism; Nutrition & Dietetics SC Endocrinology & Metabolism; Nutrition & Dietetics GA 400VJ UT WOS:000262897200004 PM 19039319 ER PT J AU White-Gilbertson, S Mullen, T Senkal, C Lu, P Ogretmen, B Obeid, L Voelkel-Johnson, C AF White-Gilbertson, S. Mullen, T. Senkal, C. Lu, P. Ogretmen, B. Obeid, L. Voelkel-Johnson, C. TI Ceramide synthase 6 modulates TRAIL sensitivity and nuclear translocation of active caspase-3 in colon cancer cells SO ONCOGENE LA English DT Article DE TRAIL; ceramide; apoptosis; ceramide synthase; longevity assurance homologue ID LONGEVITY ASSURANCE GENE-1; INDUCED APOPTOSIS; FAMILY-MEMBERS; HUMAN HEAD; RESISTANCE; DEATH; METASTASIS; ACTIVATION; GROWTH; IDENTIFICATION AB We have previously shown that the death receptor ligand TRAIL (tumor necrosis factor-related apoptosis-inducing ligand) induces an increase of intracellular C(16)-ceramide in sensitive SW480 but not in resistant SW620 cells. Resistance in SW620 cells was overcome by exogenous ceramide, leading us to propose that defective ceramide signaling contributes to TRAIL resistance. In this study we found that the increase in C16-ceramide in SW480 cells was inhibited by fumonisin B1, an inhibitor of ceramide synthases (CerS). Protein analysis revealed that TRAIL-resistant SW620 cells expressed lower levels of ceramide synthase 6 (CerS6, also known as longevity assurance homologue 6), which prompted us to investigate the effect of CerS6 modulation on TRAIL phenotype. RNAi against CerS6 resulted in a specific and significant decrease of the C(16)-ceramide species, which was sufficient to inhibit TRAIL-induced apoptosis. In cells with decreased levels of CerS6, caspase-3 was activated but failed to translocate into the nucleus. CerS6 localized primarily to the perinuclear region, suggesting this enzyme may be important in regulation of nuclear permeability. Moderate elevation in CerS6 expression was sufficient to reverse TRAIL resistance in SW620 cells. These results suggest that modulation of CerS6 expression may constitute a new therapeutic strategy to alter apoptotic susceptibility. C1 [White-Gilbertson, S.; Lu, P.; Voelkel-Johnson, C.] Med Univ S Carolina, Dept Microbiol & Immunol, Charleston, SC 29403 USA. [Mullen, T.; Obeid, L.] Med Univ S Carolina, Dept Med, Charleston, SC 29403 USA. [Senkal, C.; Ogretmen, B.] Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29403 USA. [Obeid, L.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA. RP Voelkel-Johnson, C (reprint author), Med Univ S Carolina, Dept Microbiol & Immunol, POB 250504,173 Ashley Ave, Charleston, SC 29403 USA. EM johnsocv@musc.edu OI obeid, lina/0000-0002-0734-0847 FU NCI NIH HHS [CA-097132, CA-088932, P01 CA097132, P01 CA097132-060004, P01CA097132, R01 CA088932, R01 CA088932-07]; NCRR NIH HHS [1P20-RR17698, C06 RR018823, P20 RR017698, P20 RR017698-01, P20 RR017698-02, P20 RR017698-03]; NIA NIH HHS [AG016583, R01 AG016583]; NIDCR NIH HHS [DE016572, R01 DE016572, R01 DE016572-04]; NIEHS NIH HHS [1T32ES012878, T32 ES012878] NR 50 TC 65 Z9 68 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0950-9232 J9 ONCOGENE JI Oncogene PD FEB PY 2009 VL 28 IS 8 BP 1132 EP 1141 DI 10.1038/onc.2008.468 PG 10 WC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity SC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity GA 412KE UT WOS:000263722900008 PM 19137010 ER PT J AU Kulbersh, JS Day, TA Gillespie, MB Young, MRI AF Kulbersh, Jonathan S. Day, Terry A. Gillespie, M. Boyd Young, M. Rita I. TI 1 alpha,25-Dihydroxyvitamin D-3 to skew intratumoral levels of immune inhibitory CD34(+) progenitor cells into dendritic cells SO OTOLARYNGOLOGY-HEAD AND NECK SURGERY LA English DT Article ID NECK-CANCER PATIENTS; PERIPHERAL-BLOOD; HEAD; TUMOR; DIFFERENTIATION; SUPPRESSION; CARCINOMAS; MELANOMA AB OBJECTIVES: Prior studies showed that immune inhibitory CD34(+) progenitor cells, whose numbers are increased in head and neck squamous cell carcinoma (HNSCC) patients, can be differentiated into immune stimulatory dendritic cells by culture with 1 alpha,25-dihydroxyvitamin D-3 (1,25[OH](2)D-3'). This was extended to a pilot study to diminish intratumoral levels of CD34(+) progenitor cells by inducing their maturation into dendritic cells with 1,25(OH)(2)D-3. STUDY DESIGN: Newly diagnosed HNSCC patients were untreated for 3 weeks or received 3 weeks of 1,25(OH)(2)D-3 treatment befoer surgical treatment. SUBJECTS AND METHODS: HNSCC tissue was collected by biopsy from six patients who had no prior 1,25(OH)(2)D-3 treatment and at the time of surgical treatment from six untreated patients and 11 patients who completed 1,25(OH)(2)D-3 treatment. Tissues were analyzed by immunohistochemistry for levels of CD34(+) cells and dendritic cells. RESULTS: After 1,25(OH)(2)D-3 treatment, intratumoral levels of CD34(+) cells and levels of immature dendritic cells declined. However, levels of intratumoral mature dendritic cells increased. Clinical effects of 1,25(OH)(2)D-3 treatment are premature to analyze. CONCLUSIONS: Treatment of HNSCC patients with 1,25(OH)(2)D-3 reduced levels of immune inhibitory CD34(+) cells while increasing maturation of dendritic cells. This supports added studies to determine the effect of 1,25(OH)(2)D-3 on intratumoral immune competence. C1 [Young, M. Rita I.] Ralph H Johnson Vet Affairs Med Ctr, Res Serv, Charleston, SC USA. [Kulbersh, Jonathan S.; Day, Terry A.; Gillespie, M. Boyd; Young, M. Rita I.] Med Univ S Carolina, Dept Otolaryngol Head & Neck Surg, Charleston, SC 29425 USA. RP Young, MRI (reprint author), Ralph H Johnson VA Med Ctr, Res Serv 151, Charleston, SC 29401 USA. EM rita.young@va.gov FU Research Service of the Department of Veterans Affairs; National Institutes of Health [R01CA85266, R01CA97813] FX Supported by the Research Service of the Department of Veterans Affairs and by grants R01CA85266 and R01CA97813 from the National Institutes of Health to MRIY. NR 18 TC 16 Z9 17 U1 0 U2 1 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 0194-5998 J9 OTOLARYNG HEAD NECK JI Otolaryngol. Head Neck Surg. PD FEB PY 2009 VL 140 IS 2 BP 235 EP 240 DI 10.1016/j.otohns.2008.11.011 PG 6 WC Otorhinolaryngology; Surgery SC Otorhinolaryngology; Surgery GA 404LL UT WOS:000263153500018 PM 19201295 ER PT J AU Parker, LE Kirchner, JE Bonner, YM Fickel, JJ Ritchie, MJ Simons, CE Yano, EM AF Parker, Louise E. Kirchner, JoAnn E. Bonner, Laura M. Fickel, Jacqueline J. Ritchie, Mona J. Simons, Carol E. Yano, Elizabeth M. TI Creating a Quality-Improvement Dialogue: Utilizing Knowledge From Frontline Staff, Managers, and Experts to Foster Health Care Quality Improvement SO QUALITATIVE HEALTH RESEARCH LA English DT Article DE health care decision making; health care professionals; health care workplace; quality improvement; research dissemination and utilization; research implementation ID DEPRESSION; PRACTITIONERS; PARTICIPATION; DECISIONS; ACADEMICS; BEHAVIOR AB There is a growing consensus that a hybrid of two common approaches to quality improvement (QI), local participatory QI and expert QI, might be the best method for achieving quality care. Achieving such a hybrid requires that content experts establish an ongoing dialogue with both frontline staff members and managers. In this study we examined frontline staff members' and managers' preferences regarding how to conduct such a dialogue, and we provide practical suggestions for implementation. The two groups shared a number of preferences (e.g., verbal face-to-face exchanges, discussions focused on quality of care). There were also some differences. For example, although managers were interested in discussions of business aspects (e.g., costs), frontline staff members were concerned with workload issues. Finally, although informants acknowledged that engaging in a QI dialogue was time consuming, they also believed it was essential if health care organizations are to improve the quality of care they provide. C1 [Parker, Louise E.; Kirchner, JoAnn E.] VA Ctr Mental Hlth Care & Outcomes Res, HSR&D Res Enhancement Award Program, N Little Rock, AR USA. [Parker, Louise E.; Ritchie, Mona J.] VA Mental Hlth Qual Enhancement Res Initiat Coord, N Little Rock, AR USA. [Kirchner, JoAnn E.] VA S Cent Mental Illness Res, Educ & Clin Ctr, N Little Rock, AR USA. [Bonner, Laura M.] VA Puget Sound Hlth Care Syst, HSR&D NW Ctr Excellence, Seattle, WA USA. [Fickel, Jacqueline J.; Yano, Elizabeth M.] VA HSR&D Ctr Excellence Study Hlth Care Provider, Sepulveda, CA USA. [Simons, Carol E.] VA Puget Sound Hlth Care Syst, HSR&D NW Ctr Excellence Outcomes Res Older Adults, Seattle, WA USA. RP Parker, LE (reprint author), VA Ctr Mental Hlth Care & Outcomes Res, HSR&D Res Enhancement Award Program, N Little Rock, AR USA. NR 39 TC 36 Z9 36 U1 1 U2 5 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1049-7323 J9 QUAL HEALTH RES JI Qual. Health Res. PD FEB PY 2009 VL 19 IS 2 BP 229 EP 242 DI 10.1177/1049732308329481 PG 14 WC Information Science & Library Science; Social Sciences, Interdisciplinary; Social Sciences, Biomedical SC Information Science & Library Science; Social Sciences - Other Topics; Biomedical Social Sciences GA 396SX UT WOS:000262612500007 PM 19092141 ER PT J AU Boockvar, KS Liu, S Goldstein, N Nebeker, J Siu, A Fried, T AF Boockvar, K. S. Liu, S. Goldstein, N. Nebeker, J. Siu, A. Fried, T. TI Prescribing discrepancies likely to cause adverse drug events after patient transfer SO QUALITY & SAFETY IN HEALTH CARE LA English DT Article ID MEDICATION RECONCILIATION; HOSPITALIZATION; SYSTEM; SAFETY; ERRORS; CARE AB Background: Medication-prescribing discrepancies are used as a quality measure for patients transferred between sites of care. The objective of this study was to quantify the rate of adverse drug events (ADEs) caused by prescribing discrepancies and the discrimination of an index of high-risk transition drug prescribing. Methods: We examined medical records of patients transferred between seven nursing homes and three hospitals between 1999 and 2005 in New York and Connecticut for transfer- associated prescribing discrepancies. ADEs caused by discrepancies were determined by two clinician raters. We calculated the fraction of medication discrepancies that caused ADEs in each of 22 drug classes by calculating positive predictive values (PPVs). We calculated the discrimination of a count of high-risk drug discrepancies, selected from published lists of high-risk medications and using observed PPVs. Results: 208 patients were hospitalised 304 times. Overall, 65 of 1350 prescribing discrepancies caused ADEs, for a PPV of 0.048 (95% CI 0.037 to 0.061). PPVs by drug class ranged from 0 to 0.28. Drug classes with the highest PPVs were opioid analgesics, metronidazole, and non-opioid analgesics. Patients with 0, 1-2 and >= 3 high-risk discrepancies had a 13%, 23% and 47% chance of experiencing a discrepancy-related ADE, respectively. Conclusions: Discrepancies in certain drug classes more often caused ADEs than other types of discrepancies in hospitalised nursing-home patients. Information about ADEs caused by medication discrepancies can be used to enhance measurement of care quality, identify high-risk patients and inform the development of decision-support tools at the time of patient transfer. C1 [Boockvar, K. S.; Goldstein, N.; Siu, A.] James J Peters Vet Affairs Med Ctr, Geriatr Res Educ & Clin Ctr, Bronx, NY USA. [Boockvar, K. S.; Goldstein, N.; Siu, A.] Mt Sinai Sch Med, Dept Geriatr, New York, NY USA. [Boockvar, K. S.; Goldstein, N.; Siu, A.] Mt Sinai Sch Med, Dept Med, New York, NY USA. [Boockvar, K. S.] Jewish Home & Hosp, New York, NY USA. [Liu, S.; Fried, T.] Yale Univ, Sch Med, New Haven, CT USA. [Nebeker, J.] VA Geriatr Res Educ & Clin Ctr, Salt Lake City, UT USA. [Fried, T.] VA Connecticut Healthcare Syst, Clin Epidemiol Res Ctr, West Haven, CT USA. RP Boockvar, KS (reprint author), VA Med Ctr, 130 W Kingsbridge Rd, Bronx, NY 10468 USA. EM kenneth.boockvar@mssm.edu OI Boockvar, Kenneth/0000-0003-1165-5558 FU VA Health Services Research and Development Service; New York State Department of Health; Doris Duke Clinical Research Fellowship FX Financial support was provided by the VA Health Services Research and Development Service and the New York State Department of Health. SL is the recipient of a Doris Duke Clinical Research Fellowship. NR 29 TC 47 Z9 47 U1 1 U2 5 PU B M J PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1475-3898 J9 QUAL SAF HEALTH CARE JI Qual. Saf. Health Care PD FEB PY 2009 VL 18 IS 1 BP 32 EP 36 DI 10.1136/qshc.2007.025957 PG 5 WC Health Care Sciences & Services SC Health Care Sciences & Services GA 404UJ UT WOS:000263178200007 PM 19204129 ER PT J AU Turner, AP Williams, RM Sloan, AP Haselkorn, JK AF Turner, Aaron P. Williams, Rhonda M. Sloan, Alicia P. Haselkorn, Jodie K. TI Injection Anxiety Remains a Long-term Barrier to Medication Adherence in Multiple Sclerosis SO REHABILITATION PSYCHOLOGY LA English DT Article DE multiple sclerosis; medication adherence; anxiety; health behavior ID DISEASE-MODIFYING THERAPIES; QUALITY-OF-LIFE; SELF-INJECT; PATIENT COMPLIANCE; CLINICAL-PRACTICE; IMPAIRMENT; DISABILITY; MS; DYSFUNCTION; VETERANS AB Objective: To evaluate the contribution injection anxiety to disease modifying therapy (DMT) adherence among individuals with multiple sclerosis (MS). Injection anxiety has been associated with medication discontinuation early in the course of treatment, but little is known about the relationship between injection anxiety and sustained DMT adherence over time. Method. Eighty-nine outpatients receiving care at a Veterans Administration MS clinic completed a telephone survey at baseline and monthly telephone follow-up for 6 months. Results: Participants were established DMT users (M = 3.43 years, SD = 3.29), with relatively high adherence overall (over 80% achieved 80% adherence or greater). Using logistic regression and controlling for demographics, MS disability, type of DMT, and time on DMT, the authors found that baseline injection anxiety predicted lower levels of adherence at 4 months and 6 months, with a similar trend at 2 months. Conclusion: Sustained adherence to DMT remains a challenge for a subset of individuals with MS well beyond the initial period of acclimation. Injection anxiety is an important and promising target of psychological intervention during all periods of medication use. C1 [Turner, Aaron P.] VA Puget Sound Hlth Care Syst, Rehabil Care Serv, VA Multiple Sclerosis Ctr Excellence W, VA Ctr Excellence Substance Abuse Treatment & Edu, Seattle, WA 98108 USA. [Haselkorn, Jodie K.] Univ Washington, Dept Rehabil Med, VA Puget Sound Hlth Care Syst, VA Multiple Sclerosis Ctr Excellence W, Seattle, WA 98195 USA. [Haselkorn, Jodie K.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. RP Turner, AP (reprint author), VA Puget Sound Hlth Care Syst, Rehabil Care Serv, VA Multiple Sclerosis Ctr Excellence W, VA Ctr Excellence Substance Abuse Treatment & Edu, S-117-RCS,1660 S Columbian Way, Seattle, WA 98108 USA. EM Aaron.Turner@va.gov OI sloan, alicia/0000-0003-4891-3266; Turner, Aaron/0000-0001-6897-8003 NR 39 TC 42 Z9 42 U1 2 U2 5 PU EDUCATIONAL PUBLISHING FOUNDATION PI WASHINGTON PA 750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA SN 0090-5550 J9 REHABIL PSYCHOL JI Rehabil. Psychol. PD FEB PY 2009 VL 54 IS 1 BP 116 EP 121 DI 10.1037/a0014460 PG 6 WC Psychology, Clinical; Rehabilitation SC Psychology; Rehabilitation GA 410WJ UT WOS:000263608700014 PM 19618711 ER PT J AU Fraunfelder, FW Winthrop, K Suhler, E Choi, D Fraunfelder, FT AF Fraunfelder, Frederick W. Winthrop, Kevin Suhler, Eric Choi, Dongseok Fraunfelder, Frederick T. TI Untitled SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES LA English DT Letter ID BISPHOSPHONATES; SCLERITIS C1 [Fraunfelder, Frederick W.; Winthrop, Kevin; Suhler, Eric; Choi, Dongseok; Fraunfelder, Frederick T.] Oregon Hlth & Sci Univ, Casey Eye Inst, Portland, OR 97201 USA. [Winthrop, Kevin] Oregon Hlth & Sci Univ, Dept Internal Med, Portland, OR 97201 USA. [Winthrop, Kevin; Choi, Dongseok] Oregon Hlth & Sci Univ, Dept Publ Hlth & Prevent Med, Portland, OR 97201 USA. [Suhler, Eric] Portland VA Med Ctr, Portland, OR USA. RP Fraunfelder, FW (reprint author), Oregon Hlth & Sci Univ, Casey Eye Inst, Portland, OR 97201 USA. NR 5 TC 3 Z9 3 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0275-004X J9 RETINA-J RET VIT DIS JI Retin.-J. Retin. Vitr. Dis. PD FEB PY 2009 VL 29 IS 2 BP 285 EP 286 PG 2 WC Ophthalmology SC Ophthalmology GA 407BR UT WOS:000263339100029 PM 19202428 ER PT J AU Batki, SL Meszaros, ZS Strutynski, K Dimmock, JA Leontieva, L Ploutz-Snyder, R Canfield, K Drayer, RA AF Batki, Steven L. Meszaros, Zsuzsa S. Strutynski, Katherine Dimmock, Jacqueline A. Leontieva, Luba Ploutz-Snyder, Robert Canfield, Kelly Drayer, Rebecca A. TI Medical comorbidity in patients with schizophrenia and alcohol dependence SO SCHIZOPHRENIA RESEARCH LA English DT Article DE Schizophrenia; Alcohol; Medical illness; Substance abuse; Comorbidity ID ILLNESS RATING-SCALE; SUBSTANCE-ABUSE; MENTAL-ILLNESS; CO-MORBIDITY; SEVERITY; HEALTH; VALIDATION; DISORDERS; MORTALITY; PEOPLE AB Background: Schizophrenia and alcohol dependence are major risk factors for a variety of medical problems, yet there has been little research on the medical status of patients in whom both conditions coexist. Methods: We assessed the prevalence and severity of medical illness in 80 patients with schizophrenia or schizoaffective disorder and comorbid alcohol use disorders who entered a controlled trial of monitored naltrexone treatment, and analyzed the relationship between medical illness burden and demographic variables, alcohol and other substance use, and psychosis. Participants underwent physical examination, laboratory tests, medical record review and standardized assessments of medical illness burden, alcohol and other substance use, and psychosis. Nested block multiple regression analyses were used to assess the contribution to illness burden made by demographic variables, alcohol and substance use, and psychosis severity. Results: 83% of participants had at least one chronic medical illness, hypertension being the most common (43%). Medical comorbidity in this cohort was more severe than for schizophrenia patients in the CATIE trial (Chwastiak, L. Rosenheck, R., McEvoy, J.P., Keefe, R.S., Swartz, M.S., Lieberman,J.A., 2006. Interrelationships of Psychiatric Symptom Severity, Medical Comorbidity, and Functioning in Schizophrenia. Psychiatr. Serv., 57(8), 1102-1109.); the prevalence of hypertension, chronic obstructive pulmonary disease, and coronary artery disease, was more than twice greater. Medical illness burden correlated with alcohol use severity, but appeared to be independent of other substance use or psychosis severity. Conclusions: Patients with co-occurring alcohol use disorder may have significantly more medical illness burden than patients with schizophrenia or schizoaffective disorder alone. Interventions to reduce alcohol use may be necessary to lessen medical morbidity. Published by Elsevier B.V. C1 [Batki, Steven L.] Univ Calif San Francisco, Dept Psychiat, San Francisco VA Med Ctr 116P, Addict Psychiat Res Program, San Francisco, CA 94121 USA. [Batki, Steven L.] Univ Calif San Francisco, San Francisco VA Med Ctr, San Francisco, CA 94121 USA. [Batki, Steven L.; Meszaros, Zsuzsa S.; Strutynski, Katherine; Dimmock, Jacqueline A.; Leontieva, Luba; Canfield, Kelly] SUNY Upstate Med Univ, Dept Psychiat, New York, NY USA. [Batki, Steven L.; Drayer, Rebecca A.] VA Ctr Integrated Healthcare Syracuse, New York, NY USA. [Ploutz-Snyder, Robert] NASA, Houston, TX USA. [Drayer, Rebecca A.] Univ Rochester, Sch Med & Dent, Dept Med, Rochester, NY 14642 USA. RP Batki, SL (reprint author), Univ Calif San Francisco, Dept Psychiat, San Francisco VA Med Ctr 116P, Addict Psychiat Res Program, 4150 Clement St, San Francisco, CA 94121 USA. EM steven.batki@ucsf.edu FU National Institutes of Health/the National Institute on Alcoholism and Alcohol Abuse (NIH/NIAAA) [RO1 AA013655] FX The sponsor, the National Institutes of Health/the National Institute on Alcoholism and Alcohol Abuse (NIH/NIAAA) had no role in the study design, in the collection, analysis and interpretation of data, in the writing of the report, or in the decision to Submit the paper for publication.; This research was supported by NIH/NIAAA grant "Naltrexone Treatment of Alcohol Abuse in Schizophrenia" number: RO1 AA013655 to Dr. Batki. The assistance of Michelle Cavallerano, Sara DeRycke, and Lisa Gallinger is gratefully acknowledged. NR 30 TC 25 Z9 28 U1 1 U2 7 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0920-9964 EI 1573-2509 J9 SCHIZOPHR RES JI Schizophr. Res. PD FEB PY 2009 VL 107 IS 2-3 BP 139 EP 146 DI 10.1016/j.schres.2008.10.016 PG 8 WC Psychiatry SC Psychiatry GA 407XM UT WOS:000263397600005 PM 19022627 ER PT J AU Kleinman, L Lieberman, J Dube, S Mohs, R Zhao, Y Kinon, B Carpenter, W Harvey, PD Green, MF Keefe, RSE Frank, L Bowman, L Revicki, DA AF Kleinman, Leah Lieberman, Jeffrey Dube, Sanjay Mohs, Richard Zhao, Yang Kinon, Bruce Carpenter, William Harvey, Philip D. Green, Michael F. Keefe, Richard S. E. Frank, Lori Bowman, Lee Revicki, Dennis A. TI Development and psychometric performance of the schizophrenia objective functioning instrument: An interviewer administered measure of function SO SCHIZOPHRENIA RESEARCH LA English DT Article DE Functioning; Outcomes assessment; Schizophrenia; Cognitive impairment; Reliability; Validity ID QUALITY-OF-LIFE; NEUROCOGNITIVE DEFICITS; COGNITIVE IMPAIRMENT; SOCIAL-ADJUSTMENT; OLDER OUTPATIENTS; WORK PERFORMANCE; SCALE; VALIDITY; REHABILITATION; CONSEQUENCES AB Existing measures for functional assessment do not adequately address the relationship between cognitive impairment and function. The Schizophrenia Outcomes Functioning Interview (SOFI) was developed to measure community functioning related to cognitive impairment and psychopathology. Following review of existing measures and discussion with experts, caregivers, and patients, content was generated for four domains: 1) living situation; 2) IADLs; 3) productive activities; and 4) social functioning. The final SOFI was constructed with items informing domain scores, and an interviewer-completed global rating for each domain. Psychometric characteristics of the SOFI were evaluated in a sample of 104 community residing patients with schizophrenia and their informants. Test-retest reliability was evaluated in a subsample of patient-informant dyads using ICC; all values were >0.70 for both patient-interviews (SOFI-P) and informant-interviews (SOFI-I). Inter-rater reliability ICCs ranged from 0.50 to 0.79 on a different sub-sample. The SOFI demonstrated adequate construct validity based on correlations with the PSP (range 0.58 to 0.76; p < 0.0001) and the QLS (p < 0.001). Some correlations between SOFI and PETiT scores were low to moderate (p < 0.05). Discriminant validity was supported based on SOFI score comparisons for patient groups based on PANSS and BACS scores (p < 0.05); SOFI scores differed between borderline and moderately ill patients as measured by the CGI-S (p < 0.05). The SOFI expands on existing measures and more comprehensively captures functioning of patients in the real world than other performance-based (proxy) measures. The SOFI has good evidence supporting reliability and construct validity, and may be a useful measure of functional outcomes in schizophrenia. (C) 2008 Elsevier B.V. All rights reserved. C1 [Kleinman, Leah] United BioSource Corp, Seattle, WA USA. [Lieberman, Jeffrey] Columbia Univ, New York, NY USA. [Dube, Sanjay; Mohs, Richard; Zhao, Yang; Kinon, Bruce; Bowman, Lee] Eli Lilly & Co, Indianapolis, IN 46285 USA. [Carpenter, William] Univ Maryland, Sch Med, Maryland Psychiat Res Ctr, Baltimore, MD 21201 USA. [Carpenter, William] VISN 5 MIRECC, Baltimore, MD USA. [Harvey, Philip D.] Mt Sinai Sch Med, New York, NY USA. [Green, Michael F.] Univ Calif Los Angeles, Semel Inst Neurosci & Human Behav, Los Angeles, CA USA. [Green, Michael F.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Keefe, Richard S. E.] Duke Univ, Med Ctr, Durham, NC USA. [Frank, Lori; Revicki, Dennis A.] United BioSource Corp, Bethesda, MD USA. RP Kleinman, L (reprint author), United BioSource Corp, Seattle, WA USA. EM leah.kleinman@unitedbiosource.com NR 45 TC 21 Z9 21 U1 7 U2 11 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0920-9964 J9 SCHIZOPHR RES JI Schizophr. Res. PD FEB PY 2009 VL 107 IS 2-3 BP 275 EP 285 DI 10.1016/j.schres.2008.10.002 PG 11 WC Psychiatry SC Psychiatry GA 407XM UT WOS:000263397600026 PM 19013769 ER PT J AU Kern, RS Green, MF Nuechterlein, KH Keefe, RSE AF Kern, Robert S. Green, Michael F. Nuechterlein, Keith H. Keefe, Richard S. E. TI Commentary on O'Halloran et al SO SCHIZOPHRENIA RESEARCH LA English DT Letter ID CONSENSUS COGNITIVE BATTERY; SCHIZOPHRENIA; TRIALS C1 [Kern, Robert S.; Green, Michael F.; Nuechterlein, Keith H.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA. [Kern, Robert S.; Green, Michael F.] Mental Illness Res Educ & Clin Ctr, Dept Vet Affairs, VISN 22, Los Angeles, CA USA. [Nuechterlein, Keith H.] Univ Calif Los Angeles, Dept Psychol, Los Angeles, CA 90024 USA. [Keefe, Richard S. E.] Duke Univ, Dept Psychiat & Behav Sci, Durham, NC USA. RP Kern, RS (reprint author), VA Greater Los Angeles Healthcare Syst, MIRECC 210 A, Bldg 210,Room 116,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM rkern@ucla.edu NR 6 TC 2 Z9 2 U1 1 U2 1 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0920-9964 J9 SCHIZOPHR RES JI Schizophr. Res. PD FEB PY 2009 VL 107 IS 2-3 BP 327 EP 329 DI 10.1016/j.schres.2008.10.015 PG 3 WC Psychiatry SC Psychiatry GA 407XM UT WOS:000263397600034 PM 19013770 ER PT J AU Restrepo, MI Anzueto, A AF Restrepo, Marcos I. Anzueto, Antonio TI The Role of Gram-Negative Bacteria in Healthcare-Associated Pneumonia SO SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Review DE Pneumonia; healthcare-associated; outcomes ID HOME-ACQUIRED PNEUMONIA; STAPHYLOCOCCUS-AUREUS INFECTION; LONG-TERM-CARE; RISK-FACTORS; MANAGEMENT; EPIDEMIOLOGY; OUTCOMES; DEFINITION; PREVENTION; GUIDELINES AB Healthcare-associated pneumonia (HCAP) is a unique entity that differs from community-acquired pneumonia in both bacteriology and outcomes and has similarities to hospital-acquired pneumonia and ventilator-associated pneumonia. HCAP patients are at higher risk of potential multidrug-resistant pathogens, including resistant grain-negative organisms, especially Pseudomonas aeruginosa and Acinetobacter spp., but also extended-spectrum beta-lactamases (ESBLs). This manuscript reviews the epidemiology, etiology, and clinical outcomes of hospitalized HCAP patients due to gram-negative bacteria. We win focus our attention on the potential multidrug-resistant pathogens to suggest a new treatment approach for these patients. C1 [Restrepo, Marcos I.] Audie L Murphy Div San Antonio, S Texas Vet Hlth Care Syst, VERDICT 11C6, Div Pulm & Crit Care Med, San Antonio, TX 78284 USA. [Restrepo, Marcos I.; Anzueto, Antonio] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA. RP Restrepo, MI (reprint author), Audie L Murphy Div San Antonio, S Texas Vet Hlth Care Syst, VERDICT 11C6, Div Pulm & Crit Care Med, 7400 Merton Minter Blvd, San Antonio, TX 78284 USA. EM restrepom@uthscsa.edu RI Restrepo, Marcos/H-4442-2014 NR 30 TC 18 Z9 20 U1 0 U2 1 PU THIEME MEDICAL PUBL INC PI NEW YORK PA 333 SEVENTH AVE, NEW YORK, NY 10001 USA SN 1069-3424 J9 SEMIN RESP CRIT CARE JI Semin. Respir. Crit. Care Med. PD FEB PY 2009 VL 30 IS 1 BP 61 EP 66 DI 10.1055/s-0028-1119810 PG 6 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA 427SF UT WOS:000264798700009 PM 19199188 ER PT J AU O'Hearn, DJ Gold, AR Gold, MS Diggs, P Scharf, SM AF O'Hearn, Daniel J. Gold, Avram R. Gold, Morris S. Diggs, Paul Scharf, Steven M. TI Lower extremity edema and pulmonary hypertension in morbidly obese patients with obstructive sleep apnea SO SLEEP AND BREATHING LA English DT Article DE Edema; Pulmonary hypertension; Morbid obesity; Obstructive sleep apnea ID LEFT-VENTRICULAR HYPERTROPHY; POSITIVE AIRWAY PRESSURE; CARDIAC-OUTPUT; COR-PULMONALE; HEART-FAILURE; LUNG-DISEASE; CLINICAL FEATURES; CYSTIC-FIBROSIS; HEMODYNAMICS; DYSFUNCTION AB In 70 consecutive male patients with obstructive sleep apnea (OSA) diagnosed at the Northport VA Medical Center Sleep Disorders Center, we have characterized the association between obesity, OSA, and pulmonary hypertension (PH). By including anthropometric, pulmonary function, and sleep study parameters in a multivariate logistic regression model, we found that a BMI of > 40 kg/m(2) and the minimum oxygen saturation in non-rapid eye movement (NREM) sleep predicted the presence of pretibial edema in this sleep apnea population. We then characterized the hemodynamics of those OSA patients that had lower extremity edema. Twenty-nine of the 70 consecutive patients with sleep apnea (41%) had pretibial edema, and right heart catheterization data was obtained for 28 (97%) of these patients. Ninety-three percent (26/28) of the patients had right heart failure (mean RAP > 5 mm Hg; RAP range = 0-32 mmHg) and PH (PA mean a parts per thousand yenaEuro parts per thousand 20 mm Hg) was present in 86% (24/28.) The OSA patients with lower extremity edema had an increased cardiac output (7.0 + 1.4 l/min) with a normal cardiac index (2.9 + 0.5 l/min/m(2)) in the setting of an elevated pulmonary capillary wedge pressure (PCWP 17 +/- 7 mmHg) and a normal pulmonary vascular resistance (122 + 70 dynes s cm(-5)). While PCWP, FEV(1)% predicted, and the minimum oxygen saturation in NREM sleep all independently predicted PH, PCWP was the most important predictor of PH. We conclude that pulmonary hypertension is commonly seen in patients with OSA with pretibial edema and that pretibial edema is a highly specific sign of PH in OSA patients. Pulmonary hypertension appears to result from an elevated back pressure and diastolic dysfunction with contributions from lung function and nocturnal oxygen saturation. C1 Oregon Hlth & Sci Univ, Dept Med, Portland VA Med Ctr, Portland, OR 97239 USA. [Gold, Avram R.; Diggs, Paul] Northport VA Med Ctr NY, Dept Med, Northport, NY USA. [Gold, Avram R.; Diggs, Paul] SUNY Stony Brook, Sch Med, Stony Brook, NY 11794 USA. [Gold, Morris S.] Novartis Consumer Hlth, Summit, NJ USA. [Scharf, Steven M.] Univ Maryland, Sch Med, Baltimore, MD 21201 USA. RP O'Hearn, DJ (reprint author), Oregon Hlth & Sci Univ, Dept Med, Portland VA Med Ctr, P3-PULM,POB 1034, Portland, OR 97239 USA. EM ohearnd@ohsu.edu FU Novartis Consumer Health FX The authors wish to acknowledge Dr. John P. Dervan and the many attending physicians and fellows of the Cardiology Division of SUNY-Stony Brook School of Medicine who diligently obtained the catheterization data that made this study possible. The authors have no conflicts of interest to report. The work performed by Morris Gold was not connected to his position at Novartis Consumer Health. NR 69 TC 9 Z9 9 U1 0 U2 2 PU SPRINGER HEIDELBERG PI HEIDELBERG PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY SN 1520-9512 J9 SLEEP BREATH JI Sleep Breath. PD FEB PY 2009 VL 13 IS 1 BP 25 EP 34 DI 10.1007/s11325-008-0200-z PG 10 WC Clinical Neurology; Respiratory System SC Neurosciences & Neurology; Respiratory System GA 387NU UT WOS:000261959700005 PM 18615260 ER PT J AU Brausch, AM Gutierrez, PM AF Brausch, Amy M. Gutierrez, Peter M. TI The Role of Body Image and Disordered Eating as Risk Factors for Depression and Suicidal Ideation in Adolescents SO SUICIDE AND LIFE-THREATENING BEHAVIOR LA English DT Article ID ATTITUDES TEST; FEMALE ADOLESCENTS; GENDER DIFFERENCES; BULIMIA-NERVOSA; SOCIAL SUPPORT; SELF-ESTEEM; WEIGHT; DISSATISFACTION; HOPELESSNESS; BEHAVIORS AB There is much empirical literature on factors for adolescent suicide risk, but body image and disordered eating are rarely included in these models. In the current study, disordered eating and body image were examined as risk factors for suicide ideation since these factors are prevalent in adolescence, particularly for females. It was hypothesized that disordered eating and body image, in addition to depressive symptoms, would contribute to suicide ideation. It was also hypothesized that these relationships would be stronger for females than for males. Structural equation modeling was used to test a model of risk for suicide ideation incorporating the above factors in a sample of 392 high school students. Results indicated that disordered eating contributed to both suicide ideation and depressive symptoms, while body image only contributed to depressive symptoms. Depressive symptoms contributed to suicide ideation. The model was found to be cross-validated with males and females, and no gender differences emerged. Implications of these findings and their importance in constructing future models of adolescent suicide risk are discussed. C1 [Brausch, Amy M.] Eastern Illinois Univ, Dept Psychol, Charleston, IL 61920 USA. [Gutierrez, Peter M.] Mental Illness Res Educ & Clin Ctr, Denver VA Med Ctr, Denver, CO USA. RP Brausch, AM (reprint author), Eastern Illinois Univ, Dept Psychol, 600 Lincoln Ave, Charleston, IL 61920 USA. EM abrausch@eiu.edu OI Gutierrez, Peter/0000-0001-8981-8404 NR 37 TC 38 Z9 40 U1 2 U2 15 PU GUILFORD PUBLICATIONS INC PI NEW YORK PA 72 SPRING STREET, NEW YORK, NY 10012 USA SN 0363-0234 J9 SUICIDE LIFE-THREAT JI Suicide Life-Threat. Behav. PD FEB PY 2009 VL 39 IS 1 BP 58 EP 71 PG 14 WC Psychiatry; Psychology, Multidisciplinary SC Psychiatry; Psychology GA 417PR UT WOS:000264089100007 PM 19298151 ER PT J AU Walker, RH Koch, RJ Moore, C Meshul, CK AF Walker, Ruth H. Koch, Rick J. Moore, Cynthia Meshul, Charles K. TI Subthalamic Nucleus Stimulation and Lesioning Have Distinct State-Dependent Effects Upon Striatal Dopamine Metabolism SO SYNAPSE LA English DT Article DE deep brain stimulation; microdialysis; Parkinson's disease; rat; 6-hydroxydopamine ID HIGH-FREQUENCY STIMULATION; DEEP BRAIN-STIMULATION; NIGRA PARS RETICULATA; RAT SUBSTANTIA-NIGRA; INDUCED CELLULAR DEFECTS; MEDIAL FRONTAL-CORTEX; IN-VIVO MICRODIALYSIS; PARKINSONS-DISEASE; 6-HYDROXYDOPAMINE-LESIONED RATS; BASAL GANGLIA AB The mechanism by which deep brain stimulation (DBS) of the subthalamic nucleus (STN) achieves its effects in Parkinson's disease (PD) is not known. In animal models of PD, stimulation and lesioning of the STN have some effects which are the same, but others which differ, in reversing cellular and behavioral changes induced by dopamine depletion. We compared the effects of short-term STN stimulation and lesions upon extracellular levels of dopamine and metabolites using in vivo microdialysis of the dorsal striatum of awake, intact and unilateral 6-hydroxydopamine (60HDA)-lesioned rats. STN stimulation in control rats decreased striatal dopamine levels and caused a relative increase in dopamine metabolism, as expressed by HVA/dopamine and DOPAC/dopamine ratios. This suggests an increase in both vesicular dopamine release (metabolized to HVA), and release from the cytoplasmic dopamine pool (metabolized to DOPAC). STN lesions in control rats increased the HVA/dopamine ratio, also suggesting a relative increase in vesicular dopamine release. These results indicate that STN stimulation and lesioning can affect striatal dopamine metabolism in the intact system. In 60HDA-lesioned rats at baseline, metabolic ratios were markedly decreased as compared with controls. STN lesions of 60HDA-lesioned rats did not affect relative metabolic ratios as compared with baseline levels. In 6-OHDA-lesioned rats, STN stimulation decreased extracellular levels of dopamine, and, to a greater extent, metabolites, resulting in a decrease in metabolic ratios. This further decrease in dopamine turnover with STN stimulation would serve to maintain dopamine levels in the dopamine-depleted striatum, and may account for the therapeutic benefit of DBS in Parkinson's disease. Synapse 63:136-146, 2009. Published 2008 Wiley-Liss, Inc. C1 [Walker, Ruth H.; Koch, Rick J.] James J Peters Vet Affairs Med Ctr, Dept Neurol, Bronx, NY 10468 USA. [Walker, Ruth H.] Mt Sinai Sch Med, Dept Neurol, New York, NY USA. [Moore, Cynthia; Meshul, Charles K.] Oregon Hlth & Sci Univ, Vet Affairs Med Ctr, Neurocytol Lab, Res Serv, Portland, OR 97201 USA. [Meshul, Charles K.] Oregon Hlth & Sci Univ, Dept Behav Neurosci, Portland, OR 97201 USA. RP Walker, RH (reprint author), James J Peters Vet Affairs Med Ctr, Dept Neurol 127, Bronx, NY 10468 USA. EM ruth.walker@mssm.edu FU Parkinson's Disease Foundation International Research; Department of Veterans Affairs Merit awards FX Parkinson's Disease Foundation International Research Grant, Department of Veterans Affairs Merit awards. NR 70 TC 13 Z9 13 U1 1 U2 2 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0887-4476 J9 SYNAPSE JI Synapse PD FEB PY 2009 VL 63 IS 2 BP 136 EP 146 DI 10.1002/syn.20592 PG 11 WC Neurosciences SC Neurosciences & Neurology GA 389EK UT WOS:000262073500006 PM 19021215 ER PT J AU Gore, JL Litwin, MS AF Gore, John L. Litwin, Mark S. CA Urologic Dis Amer Project TI Quality of care in bladder cancer: trends in urinary diversion following radical cystectomy SO WORLD JOURNAL OF UROLOGY LA English DT Article DE Bladder cancer; Quality of care; Urinary diversion ID ILEAL CONDUIT; ORTHOTOPIC NEOBLADDER; LIFE; RECONSTRUCTION; SUBSTITUTION; GUIDELINES; SPECIMENS; OUTCOMES; WOMEN AB Quality-of-care indicators have not yet been defined for patients with bladder cancer. Nonetheless, certain aspects of bladder cancer care can be evaluated to quantify the quality of care delivered. We sought to determine trends in continent urinary diversion to evaluate the adoption of this more optimal reconstruction. Subjects who underwent radical cystectomy for a primary diagnosis of bladder cancer were identified from the Healthcare Cost and Utilization Project Nationwide Inpatient Sample. We identified covariates independently associated with utilization of continent urinary diversion after radical cystectomy using multivariate logistic regression modeling. We then examined trends in diversion type based on patient and hospital characteristics and examined the impact of hospital volume on use of continent reconstruction. Our weighted sample included 5,075 subjects (14.3%) who underwent continent urinary diversion and 30,295 subjects (85.7%) who underwent an ileal conduit. Independent correlates of continent diversion included younger age, male gender, having private insurance, and undergoing surgery at an urban teaching hospital. Hospitals performing continent diversions on more than 40% of their cystectomies had a yearly cystectomy volume of 0.8 surgeries. Subjects treated at high-volume hospitals trended toward lower rates of comorbid conditions. We identified substantial disparities in continent diversion which, based on yearly trends, are unlikely to improve in the near future. Continent reconstructions are not the exclusive domain of high-volume cystectomy centers. Yet efforts to increase rates of this complex reconstruction must concentrate on technique dissemination and better definition of the quality-of-life detriments incurred by cystectomy patients. C1 [Gore, John L.; Litwin, Mark S.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Urol, Los Angeles, CA 90095 USA. [Gore, John L.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Gore, John L.] Univ Calif Los Angeles, Robert Wood Johnson Clin Scholars Program, Los Angeles, CA 90095 USA. [Litwin, Mark S.] Univ Calif Los Angeles, Dept Hlth Serv, Sch Publ Hlth, Los Angeles, CA 90095 USA. [Litwin, Mark S.] Univ Calif Los Angeles, David Geffen Sch Med, Johnson Comprehens Canc Ctr, Los Angeles, CA 90095 USA. [Litwin, Mark S.] RAND Corp, Santa Monica, CA USA. RP Gore, JL (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Urol, Box 951738, Los Angeles, CA 90095 USA. EM jgore@mednet.ucla.edu OI Gore, John/0000-0002-2847-5062 FU NIDDK NIH HHS [N01 DK012460] NR 21 TC 33 Z9 33 U1 0 U2 2 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0724-4983 J9 WORLD J UROL JI World J. Urol. PD FEB PY 2009 VL 27 IS 1 BP 45 EP 50 DI 10.1007/s00345-008-0348-y PG 6 WC Urology & Nephrology SC Urology & Nephrology GA 398AS UT WOS:000262704200008 PM 19020881 ER PT J AU Subak, LL Wing, R West, DS Franklin, F Vittinghoff, E Creasman, JM Richter, HE Myers, D Burgio, KL Gorin, AA Macer, J Kusek, JW Grady, D AF Subak, Leslee L. Wing, Rena West, Delia Smith Franklin, Frank Vittinghoff, Eric Creasman, Jennifer M. Richter, Holly E. Myers, Deborah Burgio, Kathryn L. Gorin, Amy A. Macer, Judith Kusek, John W. Grady, Deborah CA PRIDE Investigators TI Weight Loss to Treat Urinary Incontinence in Overweight and Obese Women. SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Article ID QUALITY-OF-LIFE; RANDOMIZED CONTROLLED-TRIAL; MIDDLE-AGED WOMEN; CARDIOVASCULAR-DISEASE; STRESS-INCONTINENCE; STYLE INTERVENTION; RISK-FACTORS; FOLLOW-UP; SURGERY; HEALTH AB Background: Obesity is an established and modifiable risk factor for urinary incontinence, but conclusive evidence for a beneficial effect of weight loss on urinary incontinence is lacking. Methods: We randomly assigned 338 overweight and obese women with at least 10 urinary-incontinence episodes per week to an intensive 6-month weight-loss program that included diet, exercise, and behavior modification (226 patients) or to a structured education program (112 patients). Results: The mean (+/-SD) age of the participants was 53+/-11 years. The body-mass index (BMI) (the weight in kilograms divided by the square of the height in meters) and the weekly number of incontinence episodes as recorded in a 7-day diary of voiding were similar in the intervention group and the control group at baseline (BMI, 36+/-6 and 36+/-5, respectively; incontinence episodes, 24+/-18 and 24+/-16, respectively). The women in the intervention group had a mean weight loss of 8.0% (7.8 kg), as compared with 1.6% (1.5 kg) in the control group (P<0.001). After 6 months, the mean weekly number of incontinence episodes decreased by 47% in the intervention group, as compared with 28% in the control group (P=0.01). As compared with the control group, the intervention group had a greater decrease in the frequency of stress-incontinence episodes (P=0.02), but not of urge-incontinence episodes (P=0.14). A higher proportion of the intervention group than of the control group had a clinically relevant reduction of 70% or more in the frequency of all incontinence episodes (P<0.001), stress-incontinence episodes (P=0.009), and urge-incontinence episodes (P=0.04). Conclusions: A 6-month behavioral intervention targeting weight loss reduced the frequency of self-reported urinary-incontinence episodes among overweight and obese women as compared with a control group. A decrease in urinary incontinence may be another benefit among the extensive health improvements associated with moderate weight reduction. (ClinicalTrials.gov number, NCT00091988.) N Engl J Med 2009;360:481-90. C1 [Subak, Leslee L.; Vittinghoff, Eric; Creasman, Jennifer M.; Macer, Judith; Grady, Deborah] Univ Calif San Francisco, Womens Hlth Clin Res Ctr, San Francisco, CA 94115 USA. [Wing, Rena] Miriam Hosp, Providence, RI 02906 USA. [Wing, Rena; Myers, Deborah] Brown Univ, Warren Alpert Med Sch, Providence, RI 02912 USA. [West, Delia Smith] Univ Arkansas Med Sci, Coll Publ Hlth, Little Rock, AR 72205 USA. [Franklin, Frank; Richter, Holly E.; Burgio, Kathryn L.] Univ Alabama Birmingham, Birmingham, AL USA. [Burgio, Kathryn L.] Dept Vet Affairs, Ctr Geriatr Res Educ & Clin, Birmingham, AL USA. [Gorin, Amy A.] Univ Connecticut, Storrs, CT USA. [Kusek, John W.] NIDDKD, Bethesda, MD 20892 USA. [Grady, Deborah] San Francisco VA Med Ctr, San Francisco, CA USA. RP Subak, LL (reprint author), Univ Calif San Francisco, Womens Hlth Clin Res Ctr, 1635 Divisadero St,Suite 600, San Francisco, CA 94115 USA. EM subakl@obgyn.ucsf.edu FU National Institute of Diabetes and Digestive and Kidney Diseases [U01 DK067860, U01 DK067861, U01 DK067862]; Office of Research on Women's Health; Pfizer; Bionovo; Astellas; GlaxoSmithKline FX Supported by grants from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (U01 DK067860, U01 DK067861, and U01 DK067862) and from the Office of Research on Women's Health.; Dr. Subak reports serving on an advisory board for Pfizer and receiving grant support from Pfizer; Dr. Grady, receiving grant support from Bionovo; Dr. Kusek, owning stock in Eli Lilly, Pfizer, and deCODE Genetics; and Dr. Burgio, serving on an advisory board for Pfizer, receiving grant support from Pfizer, and receiving advisory-board fees from Astellas and GlaxoSmithKline. No other potential conflict of interest relevant to this article was reported.; The views expressed are those of the authors and do not necessarily represent the official views of the NIDDK or the National Institutes of Health. NR 36 TC 202 Z9 208 U1 1 U2 11 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 EI 1533-4406 J9 NEW ENGL J MED JI N. Engl. J. Med. PD JAN 29 PY 2009 VL 360 IS 5 BP 481 EP 490 DI 10.1056/NEJMoa0806375 PG 10 WC Medicine, General & Internal SC General & Internal Medicine GA 399PS UT WOS:000262812400007 PM 19179316 ER PT J AU Lanoy, E Dores, GM Madeleine, MM Toro, JR Fraumeni, JF Engels, EA AF Lanoy, Emilie Dores, Graca M. Madeleine, Margaret M. Toro, Jorge R. Fraumeni, Joseph F., Jr. Engels, Eric A. TI Epidemiology of nonkeratinocytic skin cancers among persons with AIDS in the United States SO AIDS LA English DT Article DE AIDS; appendageal carcinoma; epidemiology; melanoma; Merkel cell carcinoma; sebaceous carcinoma; skin cancer ID HUMAN-IMMUNODEFICIENCY-VIRUS; MUIR-TORRE-SYNDROME; SQUAMOUS-CELL CARCINOMA; CUTANEOUS HUMAN PAPILLOMAVIRUSES; ORGAN TRANSPLANT RECIPIENTS; SEBACEOUS GLAND CARCINOMA; SUN-EXPOSED SKIN; MICROSATELLITE INSTABILITY; HIV-INFECTION; RISK-FACTORS AB Objective: Immunosuppression may increase risk for some skin cancers. We evaluated skin cancer epidemiology among persons with AIDS. Design: We linked data from population-based US AIDS and cancer registries to evaluate risk of nonkeratinocytic skin cancers (melanoma, Merkel cell carcinoma, and appendageal carcinomas, including sebaceous carcinoma) in 497 142 persons with AIDS. Methods: Standardized incidence ratios (SIRs) were calculated to relate skin cancer risk to that in the general population. We used logistic regression to compare risk according to demographic factors, CD4 cell count, and a geographic index of ultraviolet radiation exposure. Results: From 60 months before to 60 months after AIDS onset, persons with AIDS had elevated risks of melanoma (SIR=1.3, 95% confidence interval 1.1-1.4, n=292 cases) and, more strongly, of Merkel cell carcinoma (SIR=11, 95% confidence interval 6.3-17, n=17) and sebaceous carcinoma (SIR=8.1, 95% confidence interval 3.2-17, n=7). Risk for appendageal carcinomas increased with progressive time relative to AIDS onset (P trend 0.03). Risk of these skin cancers was higher in non-Hispanic whites than other racial/ethnic groups, and melanoma risk was highest among men who have sex with men. Melanoma risk was unrelated to CD4 cell count at AIDS onset (P=0.32). Risks for melanoma and appendageal carcinomas rose with increasing ultraviolet radiation exposure (P trend <10 (4) and P trend -10 (3), respectively). Conclusion: Among persons with AIDS, there is a modest excess risk of melanoma, which is not strongly related to immunosuppression and may relate to ultraviolet radiation exposure. In contrast, the greatly increased risks for Merkel cell and sebaceous carcinoma suggest an etiologic role for immunosuppression. (c) 2009 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins C1 [Lanoy, Emilie; Dores, Graca M.; Toro, Jorge R.; Fraumeni, Joseph F., Jr.; Engels, Eric A.] NCI, Div Canc Epidemiol & Genet, Rockville, MD 20892 USA. [Lanoy, Emilie] Univ Paris 06, INSERM, U720, Paris, France. [Lanoy, Emilie] Univ Paris 06, UPMC, UMR S720, Paris, France. [Dores, Graca M.] US Dept Vet Affairs, Med Ctr, Med Serv, Oklahoma City, OK USA. [Madeleine, Margaret M.] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA. RP Engels, EA (reprint author), NCI, Div Canc Epidemiol & Genet, 6120 Execut Blvd,Room 7076, Rockville, MD 20892 USA. EM engelse@exchange.nih.gov RI Lanoy, Emilie/A-8541-2011 OI Lanoy, Emilie/0000-0002-4789-7770 FU Intramural Research Program of the National Cancer Institute FX We are grateful for the contributions of many staff members at the HIV/AIDS and cancer registries who collected the data, prepared data files for the mathces, and facilitated the record linkages.; E.L. and E.A.E. designed the study and conducted the statistical analyses. G.M.D., J.R.T, and J.F.F contributed expertise regarding, skin cancer. All authors contributed expertise regarding epidemiology methods and participated in the interpretation of the data. M.M.M. and E.A.E. provided data for the study. E.L. and E.A.E. drafted the article, and all authors contributed to critical revision of the article.; The study was supported by the Intramural Research Program of the National Cancer Institute. NR 42 TC 39 Z9 39 U1 0 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0269-9370 J9 AIDS JI Aids PD JAN 28 PY 2009 VL 23 IS 3 BP 385 EP 393 DI 10.1097/QAD.0b013e3283213046 PG 9 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA 406WH UT WOS:000263325100013 PM 19114864 ER PT J AU N'Diaye, EN Branda, CS Branda, SS Nevarez, L Colonna, M Lowell, C Hamerman, JA Seaman, WE AF N'Diaye, Elsa-Noah Branda, Catherine S. Branda, Steven S. Nevarez, Lisette Colonna, Marco Lowell, Clifford Hamerman, Jessica A. Seaman, William E. TI TREM-2 (triggering receptor expressed on myeloid cells 2) is a phagocytic receptor for bacteria SO JOURNAL OF CELL BIOLOGY LA English DT Article ID TYROSINE KINASE; CUTTING EDGE; RHO-GTPASES; MACROPHAGES; SYK; MECHANISMS; DAP12; ACTIVATION; PROTEIN; FAMILY AB Phagocytosis, which is essential for the immune response to pathogens, is initiated by specific interactions between pathogens and cell surface receptors expressed by phagocytes. This study identifies triggering receptor expressed on myeloid cells 2 (TREM-2) and its signaling counterpart DAP12 as a molecular complex that promotes phagocytosis of bacteria. Expression of TREM-2-DAP12 enables nonphagocytic Chinese hamster ovary cells to internalize bacteria. This function depends on actin cytoskeleton dynamics and the activity of the small guanosine triphosphatases Rac and Cdc42. Internalization also requires src kinase activity and tyrosine phosphorylation. In bone marrow-derived macrophages, phagocytosis is decreased in the absence of DAP12 and can be restored by expression of TREM-2-DAP12. Depletion of TREM-2 inhibits both binding and uptake of bacteria. Finally, TREM-2-dependent phagocytosis is impaired in Syk-deficient macrophages. This study highlights a novel role for TREM-2-DAP12 in the immune response to bacterial pathogens. C1 [N'Diaye, Elsa-Noah; Nevarez, Lisette; Seaman, William E.] San Francisco VA Med Ctr, Macrophage Biol Lab, San Francisco, CA 94121 USA. [Branda, Catherine S.; Branda, Steven S.] Sandia Natl Labs, Livermore, CA 94550 USA. [Colonna, Marco] Washington Univ, Sch Med, St Louis, MO 63110 USA. [Lowell, Clifford] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Hamerman, Jessica A.] Benaroya Res Inst, Seattle, WA 98101 USA. RP Seaman, WE (reprint author), San Francisco VA Med Ctr, Macrophage Biol Lab, San Francisco, CA 94121 USA. EM bseaman@medicine.ucsf.edu OI Colonna, Marco/0000-0001-5222-4987 FU Laboratory Directed Research and Development program at Sandia National Laboratories; Lockheed Martin Company [DE-AC04-94AL85000]; National Institutes of Health [RO1 CA87922, GM062114] FX This work was supported by the Laboratory Directed Research and Development program at Sandia National Laboratories. Sandia is a multiprogram laboratory operated by Sandia Corporation, a Lockheed Martin Company, for the U. S. Department of Energy's National Nuclear Security Administration under contract DE-AC04-94AL85000. Additional support was provided by National Institutes of Health grant RO1 CA87922 (to W. E. Seaman), by National Institutes of Health grant GM062114 to the Alliance for Cellular Signaling, and by the Veterans Administration. NR 36 TC 79 Z9 80 U1 2 U2 8 PU ROCKEFELLER UNIV PRESS PI NEW YORK PA 1114 FIRST AVE, 4TH FL, NEW YORK, NY 10021 USA SN 0021-9525 J9 J CELL BIOL JI J. Cell Biol. PD JAN 28 PY 2009 VL 184 IS 2 BP 215 EP 223 DI 10.1083/jcb.200808080 PG 9 WC Cell Biology SC Cell Biology GA 404LO UT WOS:000263153900017 PM 19171755 ER PT J AU Doshi, JA Zhu, JS Lee, BY Kimmel, SE Volpp, KG AF Doshi, Jalpa A. Zhu, Jingsan Lee, Bruce Y. Kimmel, Stephen E. Volpp, Kevin G. TI Impact of a Prescription Copayment Increase on Lipid-Lowering Medication Adherence in Veterans SO CIRCULATION LA English DT Article DE coronary disease; medication adherence; fees, pharmaceutical; statins; veterans ID ACUTE MYOCARDIAL-INFARCTION; PHARMACY BENEFITS; STATIN THERAPY; PERSISTENCE; COST; CHOLESTEROL; DATABASES; PROGRAM; DRUGS; CARE AB Background-In February 2002, the Department of Veterans Affairs (VA) increased copayments from $2 to $7 per 30-day drug supply of each medication for many veterans. We examined the impact of the copayment increase on lipid-lowering medication adherence. Methods and Results-This quasiexperimental study used electronic records of 5604 veterans receiving care at the Philadelphia VA Medical Center from November 1999 to April 2004. The all copayment group included veterans subject to copayments for all drugs with no annual cap. Veterans subject to copayments for drugs only if indicated for a non-service-connected condition with an annual cap of $840 for out-of-pocket costs made up the some copayment group. Veterans who remained copayment exempt formed a natural control group (no copayment group). Patients were identified as adherent if the proportion of days covered with lipid-lowering medications was >= 80%. Patients were identified as having a continuous gap if they had at least 1 continuous episode with no lipid-lowering medications for >= 90 days. A difference-in-difference approach compared changes in lipid-lowering medication adherence during the 24 months before and after copayment increase among veterans subject to the copayment change with those who were not. Adherence declined in all 3 groups after the copayment increase. However, the percentage of patients who were adherent (proportion of days covered >= 80%) declined significantly more in the all copayment (- 19.2%) and some copayment (- 19.3%) groups relative to the exempt group (- 11.9%). The incidence of a continuous gap increased significantly at twice the rate in both copayment groups (all copayment group, 24.6%; some copayment group, 24.1%) as the exempt group (11.7%). Compared with the exempt group, the odds of having a continuous gap in the after relative to the before period were significantly higher in both the all copayment group (odds ratio, 3.04; 95% confidence interval, 2.29 to 4.03) and the some copayment group (odds ratio, 1.85; 95% confidence interval, 1.43 to 2.40). Similar results were seen in subgroups of patients at high risk for coronary heart disease, high medication users, and elderly veterans. Conclusion-The copayment increase adversely affected lipid-lowering medication adherence among veterans, including those at high coronary heart disease risk. (Circulation. 2009; 119: 390-397.) C1 [Doshi, Jalpa A.; Zhu, Jingsan; Volpp, Kevin G.] Philadelphia Vet Affairs Med Ctr, Ctr Hlth Res & Promot, Philadelphia, PA USA. [Doshi, Jalpa A.; Zhu, Jingsan; Kimmel, Stephen E.; Volpp, Kevin G.] Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA. [Kimmel, Stephen E.] Univ Penn, Sch Med, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA. [Kimmel, Stephen E.] Univ Penn, Sch Med, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA. [Doshi, Jalpa A.; Volpp, Kevin G.] Univ Penn, Leonard Davis Inst Hlth Econ, Ctr Hlth Incent, Philadelphia, PA 19104 USA. [Volpp, Kevin G.] Univ Penn, Wharton Sch, Dept Hlth Care Syst, Philadelphia, PA 19104 USA. [Lee, Bruce Y.] Univ Pittsburgh, Sch Med, Dept Med, Pittsburgh, PA USA. [Lee, Bruce Y.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA USA. RP Doshi, JA (reprint author), 1222 Blockley Hall, Philadelphia, PA 19104 USA. EM jdoshi@mail.med.upenn.edu FU VA Center for Health Equity Research and Promotion; American Heart Association Pharmaceutical Roundtable Award [0675066N]; Commonwealth of Pennsylvania [540625]; National Institute of Aging [R01 AG024451-01]; Penn Institute on Aging FX We are grateful for funding support from the VA Center for Health Equity Research and Promotion; the American Heart Association Pharmaceutical Roundtable Award (grant 0675066N); the Commonwealth of Pennsylvania (grant 540625); the National Institute of Aging (R01 AG024451-01); and the Penn Institute on Aging. The funding organizations or sponsors played no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript. NR 24 TC 95 Z9 98 U1 0 U2 7 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD JAN 27 PY 2009 VL 119 IS 3 BP 390 EP U53 DI 10.1161/CIRCULATIONAHA.108.783944 PG 9 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 399EX UT WOS:000262784300007 PM 19139387 ER PT J AU Schuh, LA Adair, JC Drogan, O Kissela, BM Morgenlander, JC Corboy, JR AF Schuh, L. A. Adair, J. C. Drogan, O. Kissela, B. M. Morgenlander, J. C. Corboy, J. R. TI Education Research: Neurology residency training in the new millennium SO NEUROLOGY LA English DT Editorial Material AB Objective: To survey adult neurology program directors (ANPD) to identify their most pressing needs at a time of dramatic change in neurology resident education. Methods: All US ANPD were surveyed in 2007 using an instrument adjusted from a 1999 survey instrument. The goal was to characterize current program content, the institution and evaluation of the core competencies, program director characteristics, program director support, the institution of work duty hour requirements, resident support, and the curriculum needs of program directors and programs. Results: A response rate of 82.9% was obtained. There is a significant disconnect between administration time spent by ANPD and departmental/institutional support of this, with ANPD spending approximately 35% of a 50-hour week on administration with only 16.7% salary support. Rearrangement of rotations or services has been the most common mode for ANPD to deal with work duty hour requirements, with few programs employing mid level providers. Most ANPD do not feel work duty hour reform has improved resident education. More residents are entering fellowships following graduation than documented in the past. Curriculum deficiencies still exist for ANPD to meet all Neurology Program Requirements, especially for nontraditional neurology topics outside the conventional bounds of clinical neurology (e. g., practice management). Nearly one quarter of neurology residency programs do not have a meeting or book fund for every resident in the program. Conclusions: Adult neurology program directors (ANPDs) face multiple important financial and organizational hurdles. At a time of increasing complexity in medical education, ANPDs need more institutional support. Neurology (R) 2009; 72: e15-e20 C1 [Schuh, L. A.] Henry Ford Hosp, Dept Neurol, Detroit, MI 48202 USA. [Adair, J. C.] Univ New Mexico, Sch Med, Dept Neurol, Albuquerque, NM 87131 USA. [Drogan, O.] Amer Acad Neurol Staff, St Paul, MN USA. [Kissela, B. M.] Univ Cincinnati, Dept Neurol, Cincinnati, OH 45221 USA. [Morgenlander, J. C.] Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA. [Corboy, J. R.] Univ Colorado, Hlth Sci Ctr, Denver Vet Affairs Med Ctr, Denver, CO USA. [Corboy, J. R.] Univ Colorado, Hlth Sci Ctr, Dept Neurol, Denver, CO USA. RP Schuh, LA (reprint author), Henry Ford Hosp, Dept Neurol, 2799 W Grand Blvd, Detroit, MI 48202 USA. EM lschuh@neuro.hfh.edu OI Kissela, Brett/0000-0002-9773-4013 NR 4 TC 15 Z9 15 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0028-3878 J9 NEUROLOGY JI Neurology PD JAN 27 PY 2009 VL 72 IS 4 BP E15 EP E20 DI 10.1212/01.wnl.0000342389.60811.ca PG 6 WC Clinical Neurology SC Neurosciences & Neurology GA 399CK UT WOS:000262777800029 PM 19171823 ER PT J AU Martin, TM Bye, L Modi, N Stanford, MR Vaughan, R Smith, JR Wade, NK Mackensen, F Suhler, EB Rosenbaum, JT Wallace, GR AF Martin, Tammy M. Bye, Louise Modi, Neil Stanford, Miles R. Vaughan, Robert Smith, Justine R. Wade, N. Kevin Mackensen, Friederike Suhler, Eric B. Rosenbaum, James T. Wallace, Graham R. TI Genotype analysis of polymorphisms in autoimmune susceptibility genes, CTLA-4 and PTPN22, in an acute anterior uveitis cohort SO MOLECULAR VISION LA English DT Article ID LYMPHOID TYROSINE PHOSPHATASE; ANKYLOSING-SPONDYLITIS; INFLAMMATORY DISEASE; GRAVES-DISEASE; SPONDYLOARTHROPATHIES; ASSOCIATION; MANIFESTATION; INFLIXIMAB; HLA-B27; VARIANT AB Purpose: Acute anterior uveitis (AAU) is the most common form of uveitis and is thought to be autoimmune in nature. Recent studies have described genes that act as master controllers of autoimmunity. Protein tyrosine phosphatase type 22 (PTPN22) and Cytotoxic T lymphocyte antigen-4 (CTLA-4) are two of these genes, and single nucleotide polymorphisms (SNPs) in the genes encoding these molecules have been associated with several autoimmune diseases. In this study we have analyzed SNPs in PTPN22 and CTLA-4 in patients with AAU. Methods: The functional protein tyrosine phosphatase type 22 (PTPN22) SNP (R620W rs2476601, 1858C/T), and two CTLA-4 SNPs (rs5742909, -318C/T and rs231775, 49A/G) were analyzed in 140 patients with AAU and 92 healthy controls by sequence-specific primer-polymerase chain reaction (SSP-PCR). Data was analyzed by chi(2) analysis and Fisher's exact test. Results: There was no significant association between PTPN22 620W, CTLA-4 -318C/T, or CTLA-4 49A/G and AAU. Similarly, there was no association with the three SNPs when patients were classified by race or gender. Finally, there was no association with the presence of ankylosing spondylitis in the patient cohort. Conclusions: The data do not support an association between SNPs in PTPN22 and CTLA-4, genes regarded as genetic master switches of autoimmunity. This raises the issue of the etiology of AAU and the possibility that it should be regarded as an autoinflammatory rather than an autoimmune condition. C1 [Wallace, Graham R.] Univ Birmingham, Birmingham & Midland Eye Ctr, City Hosp, Acad Unit Ophthalmol, Birmingham B18 7QU, W Midlands, England. [Martin, Tammy M.; Smith, Justine R.; Suhler, Eric B.; Rosenbaum, James T.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Bye, Louise; Modi, Neil; Stanford, Miles R.; Vaughan, Robert] Kings Coll London, London WC2R 2LS, England. [Wade, N. Kevin] Kerrisdale Profess Ctr, Vancouver, BC, Canada. [Mackensen, Friederike] Heidelberg Univ, Heidelberg, Germany. [Suhler, Eric B.] Portland VA Med Ctr, Portland, OR USA. RP Wallace, GR (reprint author), Univ Birmingham, Birmingham & Midland Eye Ctr, City Hosp, Acad Unit Ophthalmol, Dudley Rd, Birmingham B18 7QU, W Midlands, England. EM g.r.wallace@bham.ac.uk FU Research to Prevent Blindness; National Institutes of Health [R01-EY-013139]; Birmingham Eye Foundation FX Supported by Research to Prevent Blindness awards to the Casey Eye Institute, and Drs. Martin, Smith and Rosenbaum; and National Institutes of Health R01-EY-013139. The Birmingham Eye Foundation (G. R. Wallace). The authors wish to thank the individuals with uveitis, referring physicians, and the Spondylitis Association of America for their cooperation. We appreciate the expert assistance of Carrie Austin, Trudy Doyle, Kelley Goodwin and Elli Kondeatis in subject enrollment and technical help. NR 28 TC 16 Z9 17 U1 0 U2 2 PU MOLECULAR VISION PI ATLANTA PA C/O JEFF BOATRIGHT, LAB B, 5500 EMORY EYE CENTER, 1327 CLIFTON RD, N E, ATLANTA, GA 30322 USA SN 1090-0535 J9 MOL VIS JI Mol. Vis. PD JAN 26 PY 2009 VL 15 IS 20-23 BP 208 EP 212 PG 5 WC Biochemistry & Molecular Biology; Ophthalmology SC Biochemistry & Molecular Biology; Ophthalmology GA 421NC UT WOS:000264364600001 PM 19180256 ER PT J AU Kiln, T Leitner, JW Adochio, R Draznin, B AF Kiln, Toni Leitner, J. Wayne Adochio, Rebecca Draznin, Boris TI Knockdown of JNK rescues 3T3-L1 adipocytes from insulin resistance induced by mitochondrial dysfunction SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS LA English DT Article DE Insulin resistance; Mitochondrial dysfunction; JNK; 3T3-L1 adipocytes ID PHOSPHATIDYLINOSITOL 3-KINASE ACTIVITY; TYPE-2 DIABETIC PARENTS; PROTEIN-KINASE-C; SKELETAL-MUSCLE; SERINE PHOSPHORYLATION; LIPID-CONTENT; FATTY-ACIDS; TRIGLYCERIDE; IRS-1; SPECTROSCOPY AB Mitochondrial dysfunction has been linked to etiology of insulin resistance, however the mechanism remains unknown. In this study we investigated whether mitochondrial dysfunction induced by cyanide p-trifluoromethoxyphenyl-hydrazone (FCCP) alters insulin sensitivity in 3T3-L1 adipocytes and which cellular signaling molecules might be involved. Fully differentiated 3T3-L1 adipocytes were treated with 10 mu M FCCP for 1 h, resulting in increased serine-307 phosphorylation of IRS-1 and decreased insulin-stimulated tyrosine phosphorylation, association of p85 alpha subunit of phosphatidylinositol 3-kinase (PI 3-kinase) with IRS-1, decreased insulin-stimulated PI 3-kinase activity and H-3-2-deoxyglucose (2DOG) uptake. A partial (46%) knockdown of JNK1 blocked FCCP-induced serine phosphorylation of IRS-1 and restored insulin-stimulated tyrosine phosphorylation of IRS-1, association of p85 alpha subunit of PI 3-kinase with IRS-1. activation of PI 3-kinase, and stimulation of 2DOG uptake. Thus, FCCP-induced mitochondrial dysfunction may cause insulin resistance that is ameliorated by reduction of JNK1 expression. (C) 2008 Elsevier Inc. All rights reserved. C1 [Adochio, Rebecca; Draznin, Boris] Univ Colorado, Denver Sch Med, Dept Med, Aurora, CO 80045 USA. [Leitner, J. Wayne; Draznin, Boris] Univ Colorado, Denver Sch Med, Denver VA Med Ctr, Res Serv, Aurora, CO 80045 USA. [Kiln, Toni] Univ Colorado, Denver Sch Med, Dept Pediat, Aurora, CO 80045 USA. RP Draznin, B (reprint author), Univ Colorado, Denver Sch Med, Dept Med, Mail Stop 8106,12631 E 17th Pl, Aurora, CO 80045 USA. EM Boris.Draznin@ucdenven.edu FU Research Service of the Department of Veterans Affairs FX This work was supported by the Research Service of the Department of Veterans Affairs. NR 32 TC 0 Z9 0 U1 0 U2 0 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0006-291X EI 1090-2104 J9 BIOCHEM BIOPH RES CO JI Biochem. Biophys. Res. Commun. PD JAN 23 PY 2009 VL 378 IS 4 BP 772 EP 776 DI 10.1016/j.bbrc.2008.11.121 PG 5 WC Biochemistry & Molecular Biology; Biophysics SC Biochemistry & Molecular Biology; Biophysics GA 394LE UT WOS:000262447400017 ER PT J AU Vetter, ML Cardillo, S Rickels, MR Iqbal, N AF Vetter, Marion L. Cardillo, Serena Rickels, Michael R. Iqbal, Nayyar TI Narrative Review: Effect of Bariatric Surgery on Type 2 Diabetes Mellitus SO ANNALS OF INTERNAL MEDICINE LA English DT Review ID GASTRIC BYPASS-SURGERY; GLUCAGON-LIKE PEPTIDE-1; MORBIDLY OBESE SUBJECTS; BETA-CELL FUNCTION; INDUCED WEIGHT-LOSS; PLASMA GHRELIN; INHIBITORY POLYPEPTIDE; GLUCOSE-METABOLISM; GUT HORMONE; FOOD-INTAKE AB Bariatric surgery leads to substantial and durable weight reduction. Nearly 30% of patients who undergo bariatric surgery have type 2 diabetes, and for many of them, diabetes resolves after surgery (84% to 98% for bypass procedures and 48% to 68% for restrictive procedures). Glycemic control improves in part because of caloric restriction but also because gut peptide secretion changes. Gut peptides, which mediate the enteroinsular axis, include the incretins glucagon-like peptide-1 and glucose-dependent insulinotropic peptide, as well as ghrelin and peptide YY. Bariatric surgery (particularly bypass procedures) alters secretion of these gut hormones, which results in enhanced insulin secretion and sensitivity. This review discusses the various bariatric procedures and how they alter the enteroinsular axis. Familiarity with these effects can help physicians decide among the different surgical procedures and avoid postoperative hypoglycemia. C1 [Vetter, Marion L.] Hosp Univ Penn, Dept Med, Div Endocrinol Diabet & Metab, Philadelphia, PA 19104 USA. Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. RP Vetter, ML (reprint author), Hosp Univ Penn, Dept Med, Div Endocrinol Diabet & Metab, 1 Maloney Bldg,3400 Spruce St, Philadelphia, PA 19104 USA. EM marion.vetter@uphs.upenn.edu NR 94 TC 97 Z9 104 U1 0 U2 2 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 J9 ANN INTERN MED JI Ann. Intern. Med. PD JAN 20 PY 2009 VL 150 IS 2 BP 94 EP U54 PG 11 WC Medicine, General & Internal SC General & Internal Medicine GA 397ID UT WOS:000262655200004 PM 19153412 ER PT J AU Qaseem, A Snow, V Shekelle, P Hopkins, R Owens, DK AF Qaseem, Amir Snow, Vincenza Shekelle, Paul Hopkins, Robert, Jr. Owens, Douglas K. CA Clinical Efficacy Assessment Subco TI Screening for HIV in Health Care Settings: A Guidance Statement From the American College of Physicians and HIV Medicine Association SO ANNALS OF INTERNAL MEDICINE LA English DT Article ID HUMAN-IMMUNODEFICIENCY-VIRUS; UNITED-STATES; COST-EFFECTIVENESS; EMERGENCY-DEPARTMENT; RECOMMENDATIONS; TRANSMISSION; INFECTION; TESTS AB Description: The American College of Physicians (ACP) developed this guidance statement to present the available evidence on screening for HIV in health care settings. Methods: This guidance statement is derived from an appraisal of available guidelines on screening for HIV. Authors searched the National Guideline Clearinghouse to identify guidelines on screening for HIV in the United States and used the AGREE ( Appraisal of Guidelines Research and Evaluation) instrument to evaluate guidelines from the U. S. Preventive Services Task Force and the Centers for Disease Control and Prevention. Guidance Statement 1: ACP recommends that clinicians adopt routine screening for HIV and encourage patients to be tested. Guidance Statement 2: ACP recommends that clinicians determine the need for repeat screening on an individual basis. C1 [Qaseem, Amir] Amer Coll Physicians, Philadelphia, PA 19106 USA. Vet Affairs Greater Los Angeles Healthcare Syst, Santa Monica, CA USA. RAND Corp, Santa Monica, CA USA. Univ Arkansas, Little Rock, AR 72204 USA. Vet Affairs Palo Alto Hlth Care Syst, Stanford, CA USA. Stanford Univ, Stanford, CA 94305 USA. RP Qaseem, A (reprint author), Amer Coll Physicians, 190 N Independence Mall W, Philadelphia, PA 19106 USA. EM aqaseem@acponline.org FU ACP operating budget FX Financial support for the development of this guideline comes exclusively from the ACP operating budget. NR 42 TC 91 Z9 91 U1 0 U2 1 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 J9 ANN INTERN MED JI Ann. Intern. Med. PD JAN 20 PY 2009 VL 150 IS 2 BP 125 EP U86 PG 8 WC Medicine, General & Internal SC General & Internal Medicine GA 397ID UT WOS:000262655200007 PM 19047022 ER PT J AU Zhao, WD Qin, WP Pan, JP Wu, Y Bauman, WA Cardozo, C AF Zhao, Weidong Qin, Weiping Pan, Jiangping Wu, Yong Bauman, William A. Cardozo, Christopher TI Dependence of dexamethasone-induced Akt/FOXO1 signaling, upregulation of MAFbx, and protein catabolism upon the glucocorticoid receptor SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS LA English DT Article DE Glucocorticoids; Muscle atrophy; MAFbx; Atrogin-1; MuRF1; FOXO1; Akt; Glucocorticoiod receptor ID SKELETAL-MUSCLE ATROPHY; FOXO TRANSCRIPTION FACTORS; GROWTH-FACTOR-I; UBIQUITIN LIGASES; GENE-EXPRESSION; PATHWAY; DEGRADATION; MURF1; IDENTIFICATION; MECHANISMS AB The muscle ubiquitin ligases MAFbx and MuRF1 are upregulated in and promote muscle atrophy. Upregulation of MAFbx and MuRF1 by glucocorticoids has been linked to activation of FOXO1 and FOXO3A resulting from reduced Akt activity. We determined the requirements for the glucocorticoid receptor (GR) in these biological responses in C2C12 cells in which GR expression was knocked down by stable expression of an shRNA. Loss of GR prevented dexamethasone-induced increases in protein catabolism. Loss of GR. or inhibition of ligand binding to GR with RU486, prevented upregulation of MAFbx and MuRF1 by dexamethasone. Loss of GR also prevented dexamethasone-induced decreases in Akt phosphorylation, and increases in the fraction of FOXO1 that was unphosphorylated. The findings establish a requirement for the GR in activating molecular signals that promote muscle protein catabolism. Published by Elsevier Inc. C1 [Zhao, Weidong; Qin, Weiping; Pan, Jiangping; Wu, Yong; Bauman, William A.; Cardozo, Christopher] James J Peters VA Med Ctr, Ctr Excellence Med Consequences SCI, Bronx, NY 10468 USA. [Qin, Weiping; Bauman, William A.; Cardozo, Christopher] Mt Sinai Sch Med, Dept Med, New York, NY 10029 USA. RP Cardozo, C (reprint author), James J Peters VA Med Ctr, Ctr Excellence Med Consequences SCI, Room 1E-02,130 W Kingsbridge Rd, Bronx, NY 10468 USA. EM Chris.Cardozo@mssm.edu FU Veterans Health Administration, Rehabilitation Research and Development Service [134162C, 133347K, 133522R] FX The research reported here was Supported by the Veterans Health Administration, Rehabilitation Research and Development Service (134162C, 133347K, 133522R). NR 24 TC 27 Z9 28 U1 0 U2 1 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0006-291X J9 BIOCHEM BIOPH RES CO JI Biochem. Biophys. Res. Commun. PD JAN 16 PY 2009 VL 378 IS 3 BP 668 EP 672 DI 10.1016/j.bbrc.2008.11.123 PG 5 WC Biochemistry & Molecular Biology; Biophysics SC Biochemistry & Molecular Biology; Biophysics GA 393AL UT WOS:000262343200066 PM 19059383 ER PT J AU Nakayama, M Hisatsune, J Yamasaki, E Isomoto, H Kurazono, H Hatakeyama, M Azuma, T Yamaoka, Y Yahiro, K Moss, J Hirayama, T AF Nakayama, Masaaki Hisatsune, Junzo Yamasaki, Eiki Isomoto, Hajime Kurazono, Hisao Hatakeyama, Masanori Azuma, Takeshi Yamaoka, Yoshio Yahiro, Kinnosuke Moss, Joel Hirayama, Toshiya TI Helicobacter pylori VacA-induced Inhibition of GSK3 through the PI3K/Akt Signaling Pathway SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article ID NF-KAPPA-B; GASTRIC EPITHELIAL-CELLS; BETA-CATENIN SIGNAL; AZ-521 CELLS; VACUOLATING TOXIN; WNT PATHWAY; ACTIVATION; PROTEIN; INDUCTION; CYTOTOXIN AB Helicobacter pylori VacA toxin contributes to the pathogenesis and severity of gastric injury. We found that incubation of AZ-521 cells with VacA resulted in phosphorylation of protein kinase B (Akt) and glycogen synthase kinase-3 beta (GSK3 beta) through a PI3K-dependent pathway. Following phosphorylation and inhibition of GSK3 beta,beta-catenin was released from a GSK3 beta/beta-catenin complex, with subsequent nuclear translocation. Methyl-beta-cyclodextrin (MCD) and phosphatidylinositol-specific phospholipase C (PIPLC), but not 5-nitro-2-(3-phenylpropylamino)-benzoic acid (NPPB) and bafilomycin A1, inhibited VacA-induced phosphorylation of Akt, indicating that it does not require VacA internalization and is independent of vacuolation. VacA treatment of AZ-521 cells transfected with TOPtkLuciferase reporter plasmid or control FOPtkLucifease reporter plasmid resulted in activation of TOPtkLuciferase, but not FOPtkLucifease. In addition, VacA transactivated the beta-catenin-dependent cyclin D1 promoter in a luciferase reporter assay. Infection of AZ-521 cells by a vacA mutant strain of H. pylori failed to induce phosphorylation of Akt and GSK3 beta, or release of beta-catenin from a GSK3 beta/beta-catenin complex. Taken together, these results support the conclusion that VacA activates the PI3K/Akt signaling pathway, resulting in phosphorylation and inhibition of GSK3 beta, and subsequent translocation of beta-catenin to the nucleus, consistent with effects of VacA on beta-catenin-regulated transcriptional activity. These data introduce the possibility that Wnt-dependent signaling might play a role in the pathogenesis of H. pylori infection, including the development of gastric cancer. C1 [Nakayama, Masaaki; Hisatsune, Junzo; Hirayama, Toshiya] Nagasaki Univ, Dept Bacteriol, Inst Trop Med, Nagasaki 8528523, Japan. [Yamasaki, Eiki; Kurazono, Hisao] Obihiro Univ Agr & Vet Med, Dept Appl Vet Med & Publ Hlth, Obihiro, Hokkaido 0808555, Japan. [Isomoto, Hajime] Nagasaki Univ, Dept Endoscopy, Sch Med, Nagasaki 8528523, Japan. [Hatakeyama, Masanori] Hokkaido Univ, Div Mol Oncol, Inst Med Genet, Sapporo, Hokkaido 0600815, Japan. [Azuma, Takeshi] Kobe Univ, Sch Med, Dept Gastroenterol, Kobe, Hyogo 6500017, Japan. [Yamaoka, Yoshio] Michael E DeBakey Vet Affairs Med Ctr, Dept Med Gastroenterol, Houston, TX 77030 USA. [Yamaoka, Yoshio] Baylor Coll Med, Houston, TX 77030 USA. [Yahiro, Kinnosuke; Moss, Joel] NHLBI, Translat Med Branch, NIH, Bethesda, MD 20892 USA. RP Hirayama, T (reprint author), Nagasaki Univ, Dept Bacteriol, Inst Trop Med, Nagasaki 8528523, Japan. EM hirayama@net.nagasaki-u.ac.jp FU Intramural Research Program of the NHLBI; National Institutes of Health; Ministry of Education, Culture, Sports, Science and Technology of Japan FX This work was supported, in whole or in part, by the Intramural Research Program of the NHLBI, National Institutes of Health (to J. M.). This work was also supported by Grants-in-aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology of Japan. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U. S. C. Section 1734 solely to indicate this fact. NR 36 TC 56 Z9 59 U1 0 U2 1 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 J9 J BIOL CHEM JI J. Biol. Chem. PD JAN 16 PY 2009 VL 284 IS 3 BP 1612 EP 1619 DI 10.1074/jbc.M806981200 PG 8 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 392VK UT WOS:000262330100029 PM 18996844 ER PT J AU Aqel, RA Hage, FG Ellipeddi, P Blackmon, L McElderry, HT Kay, GN Plumb, V Iskandrian, AE AF Aqel, Raed A. Hage, Fadi G. Ellipeddi, Pavani Blackmon, Linda McElderry, Hugh T. Kay, G. Neal Plumb, Vance Iskandrian, Ami E. TI Usefulness of Three Posterior Chest Leads for the Detection of Posterior Wall Acute Myocardial Infarction SO AMERICAN JOURNAL OF CARDIOLOGY LA English DT Article ID ST-SEGMENT ELEVATION; PERCUTANEOUS CORONARY INTERVENTION; 12-LEAD ELECTROCARDIOGRAM; STANDARD; ECG; FIBRINOLYSIS; ANGIOPLASTY; DIAGNOSIS; REGISTRY; THERAPY AB A significant proportion of patients with myocardial infarction are missed upon initial presentation to the emergency department. The 12-lead electrocardiogram (ECG) has a low sensitivity for the detection of acute myocardial infarction, especially if the culprit lesion is in the left circumflex artery (LCA). This study was designed to evaluate the benefit of adding 3 posterior chest leads on top of the 12-lead ECG to detect ischemia resulting from LC disease, using a model of temporary balloon occlusion to produce ischemia. We studied 53 consecutive patients who underwent clinically indicated coronary interventions. At the time of coronary angiography, the balloon was inflated to produce complete occlusion of the proximal LCA. We recorded and analyzed the changes noted on the 15-lead ECG, which included 3 posterior leads in addition to the standard 12 leads. In response to acute occlusion of the LCA, the posterior chest leads showed more ST elevation than the other leads, and more patients had ST elevation in the posterior leads than in any other lead. The 15-lead ECG was able to detect >= 0.5 mm (74% vs 38%, p<0.0001) and >= 1 mm (62% vs 34%, p<0.0001) ST elevation in any 2 contiguous leads more frequently than the 12-lead ECG. In conclusion, the 15-lead ECG identified more patients with posterior myocardial wall ischemia because of temporary balloon occlusion of the LC than the 12-lead ECG. This information may enhance the detection of posterior MI in the emergency department and potentially facilitate early institution of reperfusion therapy. (C) 2009 Elsevier Inc. (Am J Cardiol 2009;103:159-164) C1 [Aqel, Raed A.] Birmingham Vet Affairs Med Ctr, Div Cardiol, Birmingham, AL USA. Univ Alabama, Dept Med, Div Cardiovasc Dis, Birmingham, AL 35294 USA. RP Aqel, RA (reprint author), Birmingham Vet Affairs Med Ctr, Div Cardiol, Birmingham, AL USA. EM raed.aqel@med.va.gov OI Hage, Fadi/0000-0002-1397-4942 NR 26 TC 10 Z9 11 U1 0 U2 3 PU EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC PI BRIDGEWATER PA 685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA SN 0002-9149 J9 AM J CARDIOL JI Am. J. Cardiol. PD JAN 15 PY 2009 VL 103 IS 2 BP 159 EP 164 DI 10.1016/j.amjcard.2008.09.008 PG 6 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 396AJ UT WOS:000262564300003 PM 19121429 ER PT J AU Kramarenko, II Bunni, MA Morinelli, TA Raymond, JR Garnovskaya, MN AF Kramarenko, Inga I. Bunni, Marlene A. Morinelli, Thomas A. Raymond, John R. Garnovskaya, Maria N. TI Identification of functional bradykinin B-2 receptors endogenously expressed in HEK293 cells SO BIOCHEMICAL PHARMACOLOGY LA English DT Article DE G protein-coupled receptors; Signal transduction; Intracellular Ca2(+); Na+/H+ exchange; Extracellular signal-regulated protein kinase 1 and 2 ID ARACHIDONIC-ACID RELEASE; EPITHELIAL-CELLS; MESANGIAL CELLS; NA+/H+ EXCHANGE; SMOOTH-MUSCLE; NUCLEAR-LOCALIZATION; SIGNAL-TRANSDUCTION; PROTEIN-KINASE; MIMCD-3 CELLS; MAP KINASE AB The human embryonic kidney (HEK) 293 cell line is widely used in cell biology research. Although HEK293 cells have been meticulously studied, our knowledge about endogenous G protein-coupled receptors (GPCR) in these cells is incomplete. While studying the effects of bradykinin (BK), a potent growth factor for renal cells, we unexpectedly discovered that BK activates extracellular signal-regulated protein kinase 1 and 2 (ERK) in HEK293 cells. Thus, we hypothesized that HEK293 cells possess endogenous BK receptors. RT-PCR demonstrated the presence of mRNAs for BK B-1 and BK B-2 receptors in HEK293 cells. Western blotting with BK B-1 and BK B-2 receptor antibodies confirmed this result at the protein level. To establish that BK receptors are functional, we employed fluorescent measurements of intracellular Ca2+, measured changes in extracellular acidification rate (ECAR) as a reflection of the Na+/H+ exchange (NHE) with a Cytosensor (TM) microphysiometer, and assessed ERK activation by Western blotting with a phospho-specific ERK antibody. Exposure of HEK293 cells to BK produced a concentration-dependent rise in intracellular Ca2+, (EC50 = 36.5 +/- 8.0 x 10 (9) M), a rapid increase in tyrosine phosphorylation of ERK (EC50 = 9.8 +/- 0.4 x 10 (9) M), and elevation in ECAR by similar to 20%. All of these signals were blocked by HOE-140 (B-2 receptor antagonist) but not by des-Arg(10)-HOE-140 (B-1 receptor antagonist). We conclude that HEK293 cells express endogenous functional BK B-2 receptors, which couple to the mobilization of intracellular Ca2+, increases in ECAR and increases in ERK phosphorylation. Published by Elsevier Inc. C1 [Kramarenko, Inga I.; Bunni, Marlene A.; Morinelli, Thomas A.; Raymond, John R.; Garnovskaya, Maria N.] Med Univ S Carolina, Dept Med, Div Nephrol, Charleston, SC 29425 USA. [Kramarenko, Inga I.; Bunni, Marlene A.; Morinelli, Thomas A.; Raymond, John R.; Garnovskaya, Maria N.] Ralph H Johnson Vet Affairs Med Ctr, Med & Res Serv, Charleston, SC 29401 USA. RP Garnovskaya, MN (reprint author), Med Univ S Carolina, Dept Med Nephrol, 96 Jonathan Lucas St,MSC 629, Charleston, SC 29425 USA. EM garnovsk@musc.edu FU Department of Veterans Affairs; AHA [GIA 0655445U]; National Institutes of Health [DK52448, GM63909]; M.U.S.C. Division of Nephrology and Dialysis Clinics, Incorporated FX This work was supported by grants from the Department of Veterans Affairs (Merit Awards and a REAP Award to MNG and JRR), AHA (GIA 0655445U to MNG), the National Institutes of Health (DK52448 and GM63909 to JRR), and a laboratory endowment jointly supported by the M.U.S.C. Division of Nephrology and Dialysis Clinics, Incorporated (JRR). NR 33 TC 12 Z9 12 U1 1 U2 3 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0006-2952 J9 BIOCHEM PHARMACOL JI Biochem. Pharmacol. PD JAN 15 PY 2009 VL 77 IS 2 BP 269 EP 276 DI 10.1016/j.bcp.2008.09.027 PG 8 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 394ZW UT WOS:000262492700014 PM 18938142 ER PT J AU Chen, Y Craigen, WJ Riley, DJ AF Chen, Yumay Craigen, William J. Riley, Daniel J. TI Nek1 regulates cell death and mitochondrial membrane permeability through phosphorylation of VDAC1 SO CELL CYCLE LA English DT Article DE cytochrome c; polycystic kidney disease; kat mouse; Nek1; VDAC1; apoptosis; DNA damage ID DEPENDENT ANION CHANNEL; POLYCYSTIC KIDNEY-DISEASE; DNA-DAMAGE RESPONSE; PROTEIN-KINASE; TRANSITION PORE; CYCLOPHILIN-D; CYTOCHROME-C; ASPERGILLUS-NIDULANS; HEXOKINASE-I; APOPTOSIS AB The mammalian NIMA-related protein kinase 1 (Nek1) is important for keeping cells alive after DNA damage, but the mechanism by which injured cells die without functional Nek1 has not yet been demonstrated. Here we show that Nek1 regulates the pathway to mitochondrial cell death through phosphorylation of voltage dependent anion channel 1 (VDAC1) on serine 193. Nek1 associates with VDAC1 in a yeast two-hybrid system, as well as by GST pull-down assays and by reciprocal immunoprecipitation. A portion of Nek1 in cells also localizes at mitochondria. Ectopic expression of a kinase-dead Nek1 mutant results in cell death, which is immediately preceded by loss of the Nek1-dependent VDAC1-S193 phosphorylation. UV irradiation of Nek1-deficient cells or silencing of endogenous Nek1 expression similarly results in loss of the specific S193 phosphorylation before cells die. Nek1-deficient cells are characterized by exaggerated mitochondrial membrane permeability (MMP) and accelerated cell death. Ectopic expression of a VDAC1-Ser193Ala mutant, which cannot be phosphorylated by Nek1, also results in cell death. A VDAC1-Ser193Glu mutant, designed to mimic constitutive phosphorylation by Nek1, rescues exaggerated MMP and keeps cells alive after DNA damaging injury, but only transiently. The direct interaction between Nek1 and VDAC1 provides a mechanism to explain how Nek1 prevents excessive cell death, as well as the first direct evidence that a specific kinase regulates VDAC1 activity. C1 [Chen, Yumay; Riley, Daniel J.] Univ Texas Hlth Sci Ctr San Antonio, Div Nephrol, Dept Med, San Antonio, TX 78229 USA. [Riley, Daniel J.] Univ Texas Hlth Sci Ctr San Antonio, Transplant Ctr, Dept Surg, San Antonio, TX 78229 USA. [Craigen, William J.] Baylor Coll Med, Dept Mol & Human Genet, San Antonio, TX USA. [Riley, Daniel J.] S Texas Vet Hlth Care Syst, Audie L Murphy Div, Renal Res Div, San Antonio, TX USA. RP Chen, Y (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Div Nephrol, Dept Med, MC 7882,7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM cheny@uthscsa.edu FU PKD Foundation; American Society of Nephrology; National Kidney Foundation; NIH [RO1-DK067339, P50-DK061597, RO1-DK61626] FX This work was supported by grants from the PKD Foundation, the American Society of Nephrology, the National Kidney Foundation, and the NIH (RO1-DK067339) to Y. C.; a George M. O'Brien Kidney Research Center grant from the NIH to Y. C. (P50-DK061597, Hanna E. Abboud, Program Director); and a grant from the NIH to D. J. R. (RO1-DK61626). We thank Rosaria Polci, Patricia Litchfield, and Sergio Garcia for assistance with early stages of the project and with technical matters; and a Veterans Administration Renal Research Excellence Award Program to the South Texas Veterans Health Care System, Audie L. Murphy Division for core facility support. NR 54 TC 27 Z9 27 U1 2 U2 4 PU LANDES BIOSCIENCE PI AUSTIN PA 1002 WEST AVENUE, 2ND FLOOR, AUSTIN, TX 78701 USA SN 1538-4101 J9 CELL CYCLE JI Cell Cycle PD JAN 15 PY 2009 VL 8 IS 2 BP 257 EP 267 DI 10.4161/cc.8.2.7551 PG 11 WC Cell Biology SC Cell Biology GA 396WT UT WOS:000262622800016 PM 19158487 ER PT J AU Wu, JD Atteridge, CL Wang, XJ Seya, T Plymate, SR AF Wu, Jennifer D. Atteridge, Catherine L. Wang, Xuanjun Seya, Tsukasa Plymate, Stephen R. TI Obstructing Shedding of the Immunostimulatory MHC Class I Chain-Related Gene B Prevents Tumor Formation SO CLINICAL CANCER RESEARCH LA English DT Article ID ACTIVATING IMMUNORECEPTOR NKG2D; CELL-MEDIATED REJECTION; NK CELLS; RETINOIC-ACID; DOWN-REGULATION; CUTTING EDGE; LIGANDS; EXPRESSION; RECEPTOR; MICA AB Purpose: Clinical observations have suggested that shedding of the MHC class I chain - related molecule (MIC) may be one of the mechanisms by which tumors evade host immunosurveillance and progress. However, this hypothesis has never been proven. In this study, we tested this hypothesis using a prostate tumor model and investigated the effect of shedding of MIC on tumor development. Experimental Design: We generated a shedding-resistant noncleavable form of MICB (MICB.A2). We overexpressed MICB.A2, the wild-type MICB, and the recombinant soluble MICB (rsMICB) in mouse prostate tumor TRAMP-C2 (TC2) cells and implanted these cells into severe combined immunodeficient mice. Results: No tumors were developed in animals that were implanted with TC2-MICB.A2 cells, whereas all the animals that were implanted with TC2, TC2-MICB, or TC2-rsMICB cells developed tumors. When a NKG2D-specific antibody CX5 or purified rsMICB was administered to animals before tumor implantation, all animals that were implanted with TC2-MICB.A2 cells developed tumors. In vitro cytotoxicity assay revealed the loss of NKG2D-mediated natural killer cell function in these prechallenged animals, suggesting that persistent levels of soluble MICB in the serum can impair natural killer cell function and thus allow tumor growth. Conclusions: These data suggest that MIC shedding may contribute significantly to tumor formation by transformed cells and that inhibition of MIC shedding to sustain the NKG2D receptor-MIC ligand recognition may have potential clinical implication in targeted cancer treatment. C1 [Wu, Jennifer D.; Atteridge, Catherine L.; Wang, Xuanjun; Plymate, Stephen R.] Univ Washington, Dept Med, Seattle, WA 98104 USA. [Plymate, Stephen R.] Vet Affairs Puget Sound Hlth Care Syst, Ctr Geriatr Res Educ & Clin, Seattle, WA USA. [Seya, Tsukasa] Hokkaido Univ, Dept Microbiol & Immunol, Grad Sch Med, Sapporo, Hokkaido, Japan. RP Wu, JD (reprint author), Univ Washington, Dept Med, 325 9th Ave,Box 359625, Seattle, WA 98104 USA. EM wuj@u.washington.edu RI Seya, Tsukasa/A-4336-2012 OI wang, xuanjun/0000-0003-1211-506X FU DOD-USMRC New Investigators [W81XWH-04-1-0577]; IDEA Development [W81XWH-06-1-0014]; W Prostate SPORE Program; NIH [1K01CA116002] FX Grant support: DOD-USMRC New Investigators Grant W81XWH-04-1-0577 and IDEA Development Award W81XWH-06-1-0014, NW Prostate SPORE Program, and NIH Temin Award 1K01CA116002 (J.D.Wu). NR 41 TC 30 Z9 30 U1 0 U2 1 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1078-0432 J9 CLIN CANCER RES JI Clin. Cancer Res. PD JAN 15 PY 2009 VL 15 IS 2 BP 632 EP 640 DI 10.1158/1078-0432.CCR-08-1305 PG 9 WC Oncology SC Oncology GA 397VD UT WOS:000262689300026 PM 19147769 ER PT J AU Lo Re, V Amorosa, VK Localio, AR O'Flynn, R Teal, V Dorey-Stein, Z Kostman, JR Gross, R AF Lo Re, Vincent, III Amorosa, Valerianna K. Localio, A. Russell O'Flynn, Rose Teal, Valerie Dorey-Stein, Zachariah Kostman, Jay R. Gross, Robert TI Adherence to Hepatitis C Virus Therapy and Early Virologic Outcomes SO CLINICAL INFECTIOUS DISEASES LA English DT Article; Proceedings Paper CT 24th International Conference on Pharmacoepidemiology and Therapeutic Risk Management CY AUG 17-20, 2008 CL Copenhagen, DENMARK ID INTERFERON-ALPHA-2B PLUS RIBAVIRIN; PEGINTERFERON ALPHA-2A; ANTIRETROVIRAL THERAPY; COMBINATION THERAPY; SUSTAINED RESPONSE; PHARMACY RECORDS; VIRAL LOAD; MANAGEMENT; INFECTION; IMPACT AB Background. Suboptimal drug exposure attributable to physician-directed dosage reductions of pegylated interferon and/or ribavirin are associated with decreased sustained virologic response rates. However, data are limited with regard to suboptimal drug exposure that is attributable to missed doses by patients with chronic hepatitis C virus (HCV) infection. We examined the relationship between adherence to pegylated interferon and ribavirin therapy, measured by pharmacy refill, and HCV suppression during the initial 12 weeks of therapy. Methods. We conducted a cohort study involving 188 patients with chronic HCV infection who were treated with pegylated interferon plus ribavirin. Adherence was calculated using pharmacy refill data and could exceed 100%. The primary outcome was decrease in HCV load at 12 weeks; early virologic response was a secondary outcome. Mixed-effects regression models estimated the association between adherence and HCV suppression during the initial 12 weeks. Subanalyses were performed among patients who received optimal weight-based dosages. Results. The mean decrease in HCV load at 12 weeks was 0.66 log IU/mL greater for patients with >= 85% adherence than for those with < 85% adherence (3.23 vs. 2.57 log IU/mL;). When patients who received Pp. 04 a suboptimal ribavirin dosage were excluded, the decrease in viral load was 1.00 log IU/mL greater for persons with >= 85% adherence (3.32 vs. 2.32 log IU/mL;). Early virologic response was more common among Pp. 01 patients with >= 85% adherence than it was among those with < 85% adherence to treatment with pegylated interferon (73% vs. 29%; P=.02) and ribavirin (73% vs. 55%; P=.08 Conclusions. Adherence of >= 85% to pegylated interferon and ribavirin treatment was associated with increased HCV suppression. Decreases in HCV load became greater when patients with >= 85% adherence to their regimen continued to receive their recommended weight-based ribavirin dosage. C1 [Lo Re, Vincent, III; Localio, A. Russell; Teal, Valerie; Gross, Robert] Univ Penn, Sch Med, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA. [Lo Re, Vincent, III; Amorosa, Valerianna K.; Dorey-Stein, Zachariah; Kostman, Jay R.; Gross, Robert] Univ Penn, Sch Med, Div Infect Dis, Dept Med, Philadelphia, PA 19104 USA. [Lo Re, Vincent, III; Localio, A. Russell; Teal, Valerie; Gross, Robert] Univ Penn, Sch Med, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA. [Lo Re, Vincent, III; Localio, A. Russell; Gross, Robert] Univ Penn, Sch Med, Ctr Educ & Res Therapeut, Philadelphia, PA 19104 USA. [Lo Re, Vincent, III; Amorosa, Valerianna K.; O'Flynn, Rose; Gross, Robert] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. RP Lo Re, V (reprint author), Univ Penn, Sch Med, Ctr Clin Epidemiol & Biostat, 809 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA. EM vincentl@mail.med.upenn.edu RI Lo Re, Vincent/N-7817-2015 OI Teal, Valerie/0000-0001-7116-5353 FU AHRQ HHS [HS 10399, U18 HS010399]; NIAID NIH HHS [K01 AI070001-02, K01 AI 070001, K01 AI070001] NR 17 TC 29 Z9 31 U1 0 U2 1 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD JAN 15 PY 2009 VL 48 IS 2 BP 186 EP 193 DI 10.1086/595685 PG 8 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 389JJ UT WOS:000262088400009 PM 19086908 ER PT J AU Riley, DE Krieger, JN AF Riley, Donald E. Krieger, John N. TI Embryonic nervous system genes predominate in searches for dinucleotide simple sequence repeats flanked by conserved sequences SO GENE LA English DT Article DE Highly conserved elements; HCEs; Simple sequence repeats; SSRs; Dinucleotide simple sequence repeats; diSSRs; Microsatellites; Nervous system; Development ID BINDING PROTEIN; ULTRACONSERVED ELEMENTS; SYNAPTIC VESICLES; MESSENGER-RNAS; HUMAN GENOME; EXPRESSION; EVOLUTION; BRAIN; MOUSE; REGIONS AB To study evolution of dinucleotide simple sequence repeats (diSSRs) we searched recently available mammalian genomes for UTR-localized diSSRs with conserved upstream flanking sequences (CFS). There were 252 reported Homo sapiens genes containing the repeats (AC)n, (GT)n, (AG)n or (CT)n in their UTRs including 22 (8.7%) with diSSR-upstream flanking sequences conserved comparing divergent mammalian lineages represented by Homo sapiens and the marsupial, Monodelphis domestica. Of these 22 genes, 19 had known functions including 18 (95%) that proved critical for mammalian nervous systems (Fishers exact test, P<0.0001). The remaining gene, Cd2ap, proved critical for development of kidney podocytes, cells that have multiple similarities to neurons. Gene functions included voltage and chloride channels, synapse-associated proteins, neurotransmitter receptors, axon and dendrite pathfinders, a NeuroD potentiator and other neuronal activities. Repeat length polymorphism was confirmed for 68% of CFS diSSRs even though these repeats were nestled among highly conserved sequences. This finding supports a hypothesis that SSR polymorphism has functional implications. A parallel study was performed on the self-complementary diSSRs (AT)n and (GC)n. When flanked by conserved sequences, the self-complementary diSSR (AT)n was also associated with genes expressed in the developing nervous system. Our findings implicate functional roles for diSSRs in nervous system development. Published by Elsevier B.V. C1 [Riley, Donald E.; Krieger, John N.] Univ Washington, Dept Urol, Seattle, WA 98195 USA. [Riley, Donald E.; Krieger, John N.] VA Puget Sound Hlth Care Syst, Dept Res, Seattle, WA 98012 USA. RP Riley, DE (reprint author), Puget Sound Hlth Care Syst VA, Room 517,Bldg 1,1660 S Columbian Way, Seattle, WA 98108 USA. FU NIDDK NIH HHS [R01 DK038955-15] NR 57 TC 13 Z9 15 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0378-1119 J9 GENE JI Gene PD JAN 15 PY 2009 VL 429 IS 1-2 BP 74 EP 79 DI 10.1016/j.gene.2008.09.025 PG 6 WC Genetics & Heredity SC Genetics & Heredity GA 399CL UT WOS:000262777900011 PM 18952158 ER PT J AU Riley, DE Krieger, JN AF Riley, Donald E. Krieger, John N. TI UTR dinucleotide simple sequence repeat evolution exhibits recurring patterns including regulatory sequence motif replacements SO GENE LA English DT Article DE SSR, simple sequence repeat; HCE, highly conserved element; STR, short tandem repeats; Microsatellites; Nervous system; Development; Post-transcriptional regulation; ARE, AU-rich elements ID MESSENGER-RNA TRAFFICKING; 3'-UNTRANSLATED REGION; ELEMENTS; MULTIPLE; PROTEINS; HUR; MICROSATELLITES; STABILIZATION; EXPRESSION; ALIGNMENT AB New genome sequence information was used to study evolution of 22 dinucleotide simple sequence repeat (diSSR) sites whose upstream flanking sequences were shown to be conserved comparing Homo sapiens with the marsupial, Monodelphis domestica. Among mammals, most of these diSSR sites were conserved both upstream and downstream of the diSSR. However, individual diSSRs were frequently replaced by alternative repeats. Conserved among mammals examined, the Vsnl1 gene's 3' UTR-localized (AC)n repeat replaced an A-rich tract in non-mammalian vertebrates examined. The Sema6D gene's (GT)n was also well conserved among mammals examined. Such conservation provides evidence of a functional role. The UTR-localized diSSRs of other genes evolved by replacing alternative diSSRs, by replacing mononucleotide-rich tracts and, in fewer cases, by expansion from short repeating sequences. Extension of the study to less conserved diSSR sites revealed that some diSSRs replaced post-transcriptional regulatory motifs, such as AU-rich elements (AREs) and C-rich tracts. The Mtap2 gene's UTR-localized (AC)n was located within a known dendritic targeting element. These evolutionary replacements suggest that some diSSRs belong to a broader group of weak-folding repetitive sequences with potential regulatory roles. Published by Elsevier B.V. C1 Univ Washington, Dept Urol, Seattle, WA 98195 USA. VA Puget Sound Hlth Care Syst, Dept Res, Seattle, WA 98012 USA. RP Riley, DE (reprint author), Sound Hlth Care Syst VA, Room 517,Bldg 1,1660 S Columbian Way, Seattle, WA 98108 USA. EM dri@u.washington.edu FU NIDDK NIH HHS [R01 DK038955-15] NR 28 TC 17 Z9 19 U1 0 U2 2 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0378-1119 J9 GENE JI Gene PD JAN 15 PY 2009 VL 429 IS 1-2 BP 80 EP 86 DI 10.1016/j.gene.2008.09.030 PG 7 WC Genetics & Heredity SC Genetics & Heredity GA 399CL UT WOS:000262777900012 PM 18955121 ER PT J AU Paintlia, AS Paintlia, MK Singh, I Skoff, RB Singh, AK AF Paintlia, Ajaib S. Paintlia, Manjeet K. Singh, Inderjit Skoff, Robert B. Singh, Avtar K. TI Combination Therapy of Lovastatin and Rolipram Provides Neuroprotection and Promotes Neurorepair in Inflammatory Demyelination Model of Multiple Sclerosis SO GLIA LA English DT Article DE combination therapy; EAE/MS; demyelination; inflammation ID EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; COA REDUCTASE INHIBITOR; TRAUMATIC BRAIN-INJURY; GLATIRAMER ACETATE; SPINAL-CORD; PHOSPHODIESTERASE INHIBITOR; AXONAL REGENERATION; NEUROTROPHIC FACTOR; NEURITE OUTGROWTH AB Drug combination therapies for central nervous system (CNS) demyelinating diseases including multiple sclerosis (MS) are gaining momentum over monotherapy. Over the past decade, both in vitro and in vivo studies established that statins (HMG-CoA reductase inhibitors) and rolipram (phosphodiesterase-4 inhibitor; blocks the degradation of intracellular cyclic AMP) can prevent the progression of MS in affected individuals via different mechanisms of action. In this study, we evaluated the effectiveness of lovastatin (LOV) and rolipram (RLP) in combination therapy to promote neurorepair in an inflammatory CNS demyelination model of MS, experimental autoimmune encephalomyelitis (EAE). Combination treatment with suboptimal doses of these drugs in an established case of EAE (clinical disease score >= 2.0) significantly attenuated the infiltration of inflammatory cells and protected myelin sheath and axonal integrity in the CNS. It was accompanied with elevated level of cyclic AMP and activation of its associated protein kinase A. Interestingly, combination treatment with these drugs impeded neurodegeneration and promoted neurorepair in established EAE animals (clinical disease score >= 3.5) as verified by quantitative real-time polymerase chain reaction, immunohistochemistry and electron microscopic analyses. These effects of combination therapy were minimal and/or absent with either drug alone in these settings. Together, these data suggest that combination therapy with LOV and RLP has the potential to provide neuroprotection and promote neurorepair in MS, and may have uses in other related CNS demyelinating diseases. (C) 2008 Wiley-Liss, Inc. C1 [Paintlia, Ajaib S.; Paintlia, Manjeet K.; Singh, Inderjit; Singh, Avtar K.] Med Univ S Carolina, Dept Pediat, Charleston, SC 29425 USA. [Skoff, Robert B.] Wayne State Univ, Sch Med, Dept Anat & Cell Biol, Detroit, MI 48201 USA. [Singh, Avtar K.] Med Univ S Carolina, Dept Pathol & Lab Med, Charleston, SC 29425 USA. [Singh, Avtar K.] Ralph H Johnson VA Med Ctr, Charleston, SC 29425 USA. RP Singh, AK (reprint author), Med Univ S Carolina, Dept Pediat, 173 Ashley Ave, Charleston, SC 29425 USA. EM paintlia@musc.edu; singhi@musc.edu OI Paintlia, Ajaib/0000-0003-4525-5333 FU NIH [NS-22576, NS-34741, NS-37766, NS-40144, NS-038236, C06-RR015455, C06-RR018823]; Merck Company FX NIH; Grant number: NS-22576, NS-34741, NS-37766, NS-40144, NS-038236, C06-RR015455, C06-RR018823; Grant sponsor; Merck & Company. NR 65 TC 36 Z9 37 U1 0 U2 2 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0894-1491 J9 GLIA JI Glia PD JAN 15 PY 2009 VL 57 IS 2 BP 182 EP 193 DI 10.1002/glia.20745 PG 12 WC Neurosciences SC Neurosciences & Neurology GA 383OA UT WOS:000261681700005 PM 18720408 ER PT J AU Wen, Y Feng, J Scott, DR Marcus, EA Sachs, G AF Wen, Yi Feng, Jing Scott, David R. Marcus, Elizabeth A. Sachs, George TI The pH-Responsive Regulon of HP0244 (FlgS), the Cytoplasmic Histidine Kinase of Helicobacter pylori SO JOURNAL OF BACTERIOLOGY LA English DT Article ID HP0165-HP0166 2-COMPONENT SYSTEM; ALPHA-CARBONIC ANHYDRASE; SIGNAL-TRANSDUCTION; RALSTONIA-EUTROPHA; ACID ACCLIMATION; GENE-EXPRESSION; RESISTANCE DETERMINANT; ALCALIGENES-EUTROPHUS; NUCLEOTIDE-SEQUENCE; H-2 SENSOR AB Helicobacter pylori colonizes the acidic gastric environment, in contrast to all other neutralophiles, whose acid resistance and tolerance responses allow only gastric transit. This acid adaptation is dependent on regulation of gene expression in response to pH changes in the periplasm and cytoplasm. The cytoplasmic histidine kinase, HP0244, which until now was thought only to regulate flagellar gene expression via its cognate response regulator, HP0703, was found to generate a response to declining medium pH. Although not required for survival at pH 4.5, HP0244 is required for survival at pH 2.5 with 10 mM urea after 30 min. Transcriptional profiling of a HP0244 deletion mutant grown at pH 7.4 confirmed the contribution of HP0244 to sigma(54) activation via HP0703 to coordinate flagellar biosynthesis by a pH-independent regulon that includes 14 flagellar genes. Microarray analysis of cells grown at pH 4.5 without urea revealed an additional 22 genes, including 4 acid acclimation genes (ureA, ureB, ureI, and amiE) that are positively regulated by HP0244. Additionally, 86 differentially expressed genes, including 3 acid acclimation genes (ureF, rocF [arginase], and ansB [asparaginase]), were found in cells grown at pH 2.5 with 30 mM urea. Hence, HP0244 has, in addition to the pH-independent flagellar regulon, a pH-dependent regulon, which allows adaptation to a wider range of environmental acid conditions. An acid survival study using an HP0703 mutant and an electrophoretic mobility shift assay with in vitro-phosphorylated HP0703 showed that HP0703 does not contribute to acid survival and does not bind to the promoter regions of several genes in the HP0244 pH-dependent regulon, suggesting that there is a pathway outside the HP0703 regulon which transduces the acid-responsive signal sensed by HP0244. C1 Univ Calif Los Angeles, David Geffen Sch Med, Dept Physiol, Membrane Biol Lab, Los Angeles, CA 90073 USA. VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. RP Wen, Y (reprint author), 11301 Wilshire Blvd,Bldg 113,Rm 324, Los Angeles, CA 90073 USA. EM ywen@ucla.edu FU U.S. Veterans Administration; NIH [DK46917, 53462, 58333]; The CURE Digestive Diseases Research Center at UCLA FX This work was supported by U.S. Veterans Administration and NIH grants DK46917, 53462, and 58333 and by a pilot and feasibility grant from The CURE Digestive Diseases Research Center at UCLA. NR 52 TC 25 Z9 27 U1 0 U2 6 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0021-9193 J9 J BACTERIOL JI J. Bacteriol. PD JAN 15 PY 2009 VL 191 IS 2 BP 449 EP 460 DI 10.1128/JB.01219-08 PG 12 WC Microbiology SC Microbiology GA 389TP UT WOS:000262117700001 PM 18978046 ER PT J AU Lipe, H Bird, T AF Lipe, Hillary Bird, Thomas TI Late onset Huntington Disease: Clinical and genetic characteristics of 34 cases SO JOURNAL OF THE NEUROLOGICAL SCIENCES LA English DT Article DE Huntington Disease; Late onset; Neurogenetics; CAG repeat expansion ID AGE; PROGRESSION; DURATION; REPEAT AB We performed a retrospective observational study of thirty-four persons with late onset of Huntington Disease (HD) (onset range 60-79 years). CAG trinucleotide expansion size ranged from 38-44 repeats. Even at this late age a significant negative correlation (r = -0.421, p < 0.05) was found between the length of repeat and age of onset. important characteristics of these older subjects were: (1) Most (68%) were the first in the family to have a diagnosis of HD, (2) Motor problems were the initial symptoms at onset, (3) Disability increased and varied from mild to severe (4) Disease duration was somewhat shorter (12 years) than that reported for mid life onset, (5) Death was often related to diseases of old age, Such as cancer and cerebrovascular disease, (6) Serious falls were a major risk and (7) Global dementia may be associated with coincident Alzheimer disease. Recognizing these characteristics will help physicians and other health care providers better identify and follow the late onset presentation of this disease. Published by Elsevier B.V. C1 [Lipe, Hillary; Bird, Thomas] VA Puget Sound Hlth Care Syst, Geriat Res & Clin Ctr, Seattle, WA 98109 USA. [Bird, Thomas] Univ Washington, Dept Neurol, Seattle, WA 98195 USA. [Bird, Thomas] Univ Washington, Dept Med, Seattle, WA 98195 USA. RP Bird, T (reprint author), VA Puget Sound Hlth Care Syst, Geriat Res & Clin Ctr, 1660 S Columbian Way,S-182 GRECC, Seattle, WA 98109 USA. EM tomnroz@u.washington.edu FU Department of Veterans Affairs research funds; Huntington's Disease Society of America FX Supported by the Department of Veterans Affairs research funds and the Huntington's Disease Society of America. Our appreciation to Our colleagues and the staff of the Medical Genetics clinic at the University of Washington for identifying late onset cases. Thanks to DG Cook and S Elmore for assistance with the figures. NR 17 TC 22 Z9 22 U1 1 U2 4 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0022-510X J9 J NEUROL SCI JI J. Neurol. Sci. PD JAN 15 PY 2009 VL 276 IS 1-2 BP 159 EP 162 DI 10.1016/j.jns.2008.09.029 PG 4 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 404BH UT WOS:000263125200035 PM 18977004 ER PT J AU Szumski, NR Cheng, EM AF Szumski, Nicholas R. Cheng, Eric M. TI Optimizing Algorithms to Identify Parkinson's Disease Cases Within an Administrative Database SO MOVEMENT DISORDERS LA English DT Article DE Parkinson's disease; ICD-9-CM codes; administrative data; predictive value; sensitivity; specificity ID INTERNATIONAL CLASSIFICATION; ACCURACY; CODES; DIAGNOSIS; ICD-9-CM AB Patients assigned file diagnostic ICD-9-CM code for Parkinson's disease (PD) in an administrative database may not truly carry that diagnosis because Of the Various error sources. Improved ability to identify PD cases within databases may facilitate specific research goals. Experienced chart reviewers abstracted the working diagnosis of all 577 patients assigned diagnostic code 332.0 (PD) during 1 year at it VA Healthcare System. We then tested the ability of various algorithms making use of PD and non-PD diagnostic codes, specialty of clinics visited, and medication prescription data to predict the abstracted working diagnosis. Chart review determined 436 (75.6%) patients to be PD or Possibly PD, and 141 (24.4%) to lie Not PD. Our tiered consensus algorithm preferentially used data from specialists over nonspecialists improved PPV to 83.2% (P = 0.003 vs. baseline). When presence of a PD prescription was an additional criterion, PPV increased further to 88.2% (P = 0.04 vs. without medication criterion), but sensitivity decreased from 87.4 to 77.1% (P = 0.0001). We demonstrate that algorithms provide better identification of PD cases than using a single Occurrence of the diagnostic code for PD, and modifications of such algorithms can be tuned to maximize parameters that best meet the goals of a particular database query. 0 2008 Movement Disorder Society C1 [Szumski, Nicholas R.; Cheng, Eric M.] Univ Calif Los Angeles, Dept Neurol, Los Angeles, CA 90095 USA. [Szumski, Nicholas R.; Cheng, Eric M.] SW Parkinsons Dis Res Educ & Clin Ctr PADRECC, Los Angeles, CA USA. [Szumski, Nicholas R.; Cheng, Eric M.] VA Greater Los Angeles Healthcare Syst, Dept Neurol, Los Angeles, CA USA. RP Szumski, NR (reprint author), Univ Calif Los Angeles, Dept Neurol, 710 Westwood Plaza,RNRC A-153, Los Angeles, CA 90095 USA. EM nszumski@mednet.ucla.edu FU Southwest Parkinson's Disease Research, Education, and Clinical Center [PADRECC]; NINDS career development award [K23NS058571] FX Research supported by the Southwest Parkinson's Disease Research, Education, and Clinical Center (PADRECC). Dr. Cheng is supported by an NINDS career development award (K23NS058571). We thank Stefanie D. Vassar for her help in compiling data and performing statistical analyses. NR 15 TC 17 Z9 18 U1 2 U2 5 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0885-3185 J9 MOVEMENT DISORD JI Mov. Disord. PD JAN 15 PY 2009 VL 24 IS 1 BP 51 EP 56 DI 10.1002/mds.22283 PG 6 WC Clinical Neurology SC Neurosciences & Neurology GA 402CW UT WOS:000262992800006 PM 18816696 ER PT J AU Qin, W Ho, L Wang, J Peskind, E Pasinetti, GM AF Qin, Weiping Ho, Lap Wang, Jun Peskind, Elaine Pasinetti, Giulio Maria TI S100A7, a Novel Alzheimer's Disease Biomarker with Non-Amyloidogenic alpha-Secretase Activity Acts via Selective Promotion of ADAM-10 SO PLOS ONE LA English DT Article AB Alzheimer's disease (AD) is the most common cause of dementia among older people. At present, there is no cure for the disease and as of now there are no early diagnostic tests for AD. There is an urgency to develop a novel promising biomarker for early diagnosis of AD. Using surface-enhanced laser desorption ionization-mass spectrometry SELDI-(MS) proteomic technology, we identified and purified a novel 11.7-kDa metal-binding protein biomarker whose content is increased in the cerebrospinal fluid (CSF) and in the brain of AD dementia subjects as a function of clinical dementia. Following purification and protein-sequence analysis, we identified and classified this biomarker as S100A7, a protein known to be involved in immune responses. Using an adenoviral- S100A7 expression system, we continued to examine the potential role of S100A7 in AD amyloid neuropathology in in vitro model of AD. We found that the expression of exogenous S100A7 in primary cortico-hippocampal neuron cultures derived from Tg2576 transgenic embryos inhibits the generation of beta-amyloid (A beta)(1-42) and A beta(1-40) peptides, coincidental with a selective promotion of "non- amyloidogenic'' alpha-secretase activity via promotion of ADAM (a disintegrin and metalloproteinase)-10. Finally, a selective expression of human S100A7 in the brain of transgenic mice results in significant promotion of alpha-secretase activity. Our study for the first time suggests that S100A7 may be a novel biomarker of AD dementia and supports the hypothesis that promotion of S100A7 expression in the brain may selectively promote alpha-secretase activity in the brain of AD precluding the generation of amyloidogenic peptides. If in the future we find that S1000A7 protein content in CSF is sensitive to drug intervention experimentally and eventually in the clinical setting, S100A7 might be developed as novel surrogate index (biomarker) of therapeutic efficacy in the characterization of novel drug agents for the treatment of AD. C1 [Qin, Weiping; Ho, Lap; Wang, Jun; Pasinetti, Giulio Maria] Mt Sinai Sch Med, Dept Psychiat, New York, NY USA. [Pasinetti, Giulio Maria] Mt Sinai Sch Med, Dept Neurosci, New York, NY USA. [Ho, Lap; Wang, Jun; Pasinetti, Giulio Maria] James J Peters Vet Affairs Med Ctr, GCRC, Bronx, NY USA. [Peskind, Elaine] Univ Washington, Sch Med, Seattle, WA 98195 USA. RP Qin, WP (reprint author), Mt Sinai Sch Med, Dept Psychiat, New York, NY USA. EM giulio.pasinetti@mssm.edu FU James J. Peters VA GRECC Program; NIA [AG02219] FX These studies were supported by James J. Peters VA GRECC Program and NIA AG02219 to GMP. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 41 TC 34 Z9 35 U1 1 U2 8 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD JAN 13 PY 2009 VL 4 IS 1 AR e4183 DI 10.1371/journal.pone.0004183 PG 13 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 437IE UT WOS:000265479600002 PM 19159013 ER PT J AU Yu, J Kindy, MS Gattoni-Celli, S AF Yu, Jin Kindy, Mark S. Gattoni-Celli, Sebastiano TI Semi-allogeneic vaccines and tumor-induced immune tolerance SO JOURNAL OF TRANSLATIONAL MEDICINE LA English DT Article ID REGULATORY T-CELLS; HYBRIDS; CANCER; IMMUNOTHERAPY; EXPRESSION AB Experimental results from studies with inbred mice and their syngeneic tumors indicated that the inoculation of semi-allogeneic cell hybrids (derived from the fusion between syngeneic tumor cells and an allogeneic cell line) protects the animal host from a subsequent lethal challenge with unmodified syngeneic tumor cells. Semi-allogeneic somatic cell hybrids were generated by the fusion of EL-4 T lymphoma cells (H-2(b)) and BALB/c-derived renal adenocarcinoma RAG cells (H-2(d)). Cell hybrids were injected intra-peritoneally (i.p.) in C57BL/6 mice (H-2(b)) before challenging the mice with a tumorigenic dose of EL-4 cells. Semi-allogeneic tumor cell hybrids could not form a tumor in the animal host because they expressed allogeneic determinants (H-2(d)) and were rejected as a transplant. However, they conferred protection against a tumorigenic challenge of EL-4 cells compared to control mice that were mock-vaccinated with i.p.-injected phosphate-buffered saline (PBS) and in which EL-4 lymphomas grew rapidly to a large size in the peritoneal cavity. Screening of spleen-derived RNA by means of focused microarray technology showed up-regulation of genes involved in the Th-1-type immune response and in the activation of dendritic antigen-presenting cells (APC). The results of our studies confirm the role of APC in mediating the immune protection induced by semi-allogeneic vaccines by activating a Th-1 response; these studies also reveal that semi-allogeneic vaccines are able to interfere with or even block the tumor-mediated induction of immune tolerance, a key mechanism underlying the suppression of antitumor immunity in the immune competent host. C1 [Yu, Jin; Kindy, Mark S.] Med Univ S Carolina, Dept Neurosci, Charleston, SC 29425 USA. [Gattoni-Celli, Sebastiano] Med Univ S Carolina, Dept Radiat Oncol, Charleston, SC 29425 USA. [Kindy, Mark S.; Gattoni-Celli, Sebastiano] Ralph H Johnson VA Med Ctr, Charleston, SC 29401 USA. [Kindy, Mark S.; Gattoni-Celli, Sebastiano] SemiAlloGen Inc, Mt Pleasant, SC 29466 USA. RP Gattoni-Celli, S (reprint author), Med Univ S Carolina, Dept Neurosci, Charleston, SC 29425 USA. EM yujin@musc.edu; kindyms@musc.edu; gattonis@musc.edu FU National Science Foundation [EPS-0132573, EPS-0447660]; Veterans Administration Merit Review; SCLaunch FX The authors wish to acknowledge support by the National Science Foundation EPSCoR grants (MSK, EPS-0132573 and EPS-0447660), Veterans Administration Merit Review (MSK) and support from SCLaunch to Semi-AlloGen. NR 16 TC 1 Z9 1 U1 0 U2 0 PU BIOMED CENTRAL LTD PI LONDON PA CURRENT SCIENCE GROUP, MIDDLESEX HOUSE, 34-42 CLEVELAND ST, LONDON W1T 4LB, ENGLAND SN 1479-5876 J9 J TRANSL MED JI J. Transl. Med. PD JAN 8 PY 2009 VL 7 AR 3 DI 10.1186/1479-5876-7-3 PG 6 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA 409WZ UT WOS:000263537800001 PM 19133135 ER PT J AU Segar, TM Kasckow, JW Welge, JA Herman, JP AF Segar, Tracy M. Kasckow, John W. Welge, Jeffrey A. Herman, James P. TI Heterogeneity of neuroendocrine stress responses in aging rat strains SO PHYSIOLOGY & BEHAVIOR LA English DT Article DE Aging; Stress; HPA; ACTH; Corticosterone; Homoscedasticity ID PITUITARY-ADRENAL AXIS; INDIVIDUAL-DIFFERENCES; BROWN-NORWAY; AGE; BRAIN; CORTICOSTERONE; MEMORY; IMPAIRMENT; RESPONSIVENESS; HIPPOCAMPUS AB Hyperactivity of the hypothalamo-pituitary-adrenocortical (HPA) axis is linked with age-related decrements in cognition and neuronal survival. However. the nature and extent of age-related HPA axis deficits vary considerably across and indeed, within strains. The current study was designed to assess variance in HPA axis function using two rodent models commonly used in aging Studies: Fischer 344 (F344) and F344/Brown-Norway F1 hybrid rats (F344/BN). We examined both basal and stress-induced ACTH and corticosterone (CORT) release in two stress contexts thought to differ in intensity: novel environment ('mild') and restraint ('intense'). Variability of the data was tested with a modification of the Brown-Forsythe test of homoscedasticity. The results indicated that F344 rats exhibit greater peak HPA responses. Furthermore, in most cases variability was increased in aged rats relative to young and middle-aged rats of the same strain, indicative of the emergence of individual differences in stress responsivity amongst older rats. The results suggest that these older rat strains may be useful models to further assess individual differences in neuroendocrine aging. Published by Elsevier Inc. C1 VA Pittsburgh Hlth Care Syst, Pittsburgh, PA 15206 USA. [Segar, Tracy M.; Welge, Jeffrey A.; Herman, James P.] Univ Cincinnati, Dept Psychiat, Cincinnati, OH 45237 USA. [Kasckow, John W.] Univ Pittsburgh, Dept Psychiat, Western Psychiat Inst & Clin, Pittsburgh, PA 15213 USA. RP Kasckow, JW (reprint author), VA Pittsburgh Hlth Care Syst, Behav Hlth 116A,7180 Highland Dr, Pittsburgh, PA 15206 USA. EM kasckowjw@upmc.edu RI Herman, James/D-4960-2015 OI Herman, James/0000-0003-3571-2406 FU VA Pittsburgh VISN 4 MIRECC [AG12962, AG10836] FX This research was supported by AG12962 and AG10836 (JPH) as well as the VA Pittsburgh VISN 4 MIRECC site (JWK). We Would also like to thank Ben Packard, Amy Bruestle, Amy Furay, Michelle Ostrander, Yve Ulrich-Lai, Helmer Figueiredo, Nancy Mueller, Nate Evanson and Ingrid Thomas for their expertise and assistance. NR 43 TC 17 Z9 19 U1 1 U2 3 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0031-9384 J9 PHYSIOL BEHAV JI Physiol. Behav. PD JAN 8 PY 2009 VL 96 IS 1 BP 6 EP 11 DI 10.1016/j.physbeh.2008.07.024 PG 6 WC Psychology, Biological; Behavioral Sciences SC Psychology; Behavioral Sciences GA 402LA UT WOS:000263014000002 PM 18722394 ER PT J AU Weaver, FM Follett, K Stern, M Hur, K Harris, C Marks, WJ Rothlind, J Sagher, O Reda, D Moy, CS Pahwa, R Burchiel, K Hogarth, P Lai, EC Duda, JE Holloway, K Samii, A Horn, S Bronstein, J Stoner, G Heemskerk, J Huang, GD AF Weaver, Frances M. Follett, Kenneth Stern, Matthew Hur, Kwan Harris, Crystal Marks, William J., Jr. Rothlind, Johannes Sagher, Oren Reda, Domenic Moy, Claudia S. Pahwa, Rajesh Burchiel, Kim Hogarth, Penelope Lai, Eugene C. Duda, John E. Holloway, Kathryn Samii, Ali Horn, Stacy Bronstein, Jeff Stoner, Gatana Heemskerk, Jill Huang, Grant D. CA CSP 468 Study Grp TI Bilateral Deep Brain Stimulation vs Best Medical Therapy for Patients With Advanced Parkinson Disease A Randomized Controlled Trial SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Article ID QUALITY-OF-LIFE; SUBTHALAMIC STIMULATION; MOTOR FLUCTUATIONS; ADVERSE EVENTS; FOLLOW-UP; MULTICENTER; NUCLEUS; METAANALYSIS; VALIDATION AB Context Deep brain stimulation is an accepted treatment for advanced Parkinson disease ( PD), although there are few randomized trials comparing treatments, and most studies exclude older patients. Objective To compare 6- month outcomes for patients with PD who received deep brain stimulation or best medical therapy. Design, Setting, and Patients Randomized controlled trial of patients who received either deep brain stimulation or best medical therapy, stratified by study site and patient age ( < 70 years vs >= 70 years) at 7 Veterans Affairs and 6 university hospitals between May 2002 and October 2005. A total of 255 patients with PD ( Hoehn and Yahr stage >= 2 while not taking medications) were enrolled; 25% were aged 70 years or older. The final 6- month follow- up visit occurred in May 2006. Intervention Bilateral deep brain stimulation of the subthalamic nucleus ( n= 60) or globus pallidus ( n= 61). Patients receiving best medical therapy ( n= 134) were actively managed by movement disorder neurologists. Main Outcome Measures The primary outcome was time spent in the "on" state ( good motor control with unimpeded motor function) without troubling dyskinesia, using motor diaries. Other outcomes included motor function, quality of life, neurocognitive function, and adverse events. Results Patients who received deep brain stimulation gained a mean of 4.6 h/ d of on time without troubling dyskinesia compared with 0 h/ d for patients who received best medical therapy ( between group mean difference, 4.5 h/ d [ 95% CI, 3.7- 5.4 h/ d]; P <. 001). Motor function improved significantly ( P <. 001) with deep brain stimulation vs best medical therapy, such that 71% of deep brain stimulation patients and 32% of best medical therapy patients experienced clinically meaningful motor function improvements ( >= 5 points). Compared with the best medical therapy group, the deep brain stimulation group experienced significant improvements in the summary measure of quality of life and on 7 of 8 PD quality- of- life scores ( P <. 001). Neurocognitive testing revealed small decrements in some areas of information processing for patients receiving deep brain stimulation vs best medical therapy. At least 1 serious adverse event occurred in 49 deep brain stimulation patients and 15 best medical therapy patients ( P <. 001), including 39 adverse events related to the surgical procedure and 1 death secondary to cerebral hemorrhage. Conclusion In this randomized controlled trial of patients with advanced PD, deep brain stimulation was more effective than best medical therapy in improving on time without troubling dyskinesias, motor function, and quality of life at 6 months, but was associated with an increased risk of serious adverse events. Trial Registration clinicaltrials. gov Identifier: NCT00056563. C1 [Weaver, Frances M.] Edward Hines Jr VA Hosp, Ctr Management Complex Chron Care, Hines, IL 60141 USA. [Hur, Kwan; Reda, Domenic] Edward Hines Jr VA Hosp, Cooperat Studies Coordinating Ctr, Hines, IL 60141 USA. [Weaver, Frances M.] Northwestern Univ, Dept Neurol, Chicago, IL 60611 USA. [Follett, Kenneth] Univ Nebraska, Dept Neurosurg, Omaha, NE 68182 USA. [Stern, Matthew; Duda, John E.; Horn, Stacy] Univ Penn Hlth Syst, Dept Neurol, Philadelphia, PA USA. [Stern, Matthew; Duda, John E.] Philadelphia VA Med Ctr, Philadelphia, PA USA. [Harris, Crystal] Clin Res Pharm, VA Cooperat Studies Program, Albuquerque, NM USA. [Marks, William J., Jr.; Rothlind, Johannes] San Francisco VA Med Ctr, San Francisco, CA USA. [Marks, William J., Jr.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA. [Rothlind, Johannes] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA. [Sagher, Oren] Univ Michigan, Med Ctr, Dept Neurosurg, Ann Arbor, MI 48109 USA. [Moy, Claudia S.; Heemskerk, Jill] NINDS, Rockville, MD USA. [Pahwa, Rajesh] Univ Kansas, Med Ctr, Dept Neurol, Kansas City, KS 66103 USA. [Burchiel, Kim; Hogarth, Penelope] Portland VA Med Ctr, Portland, OR USA. [Burchiel, Kim] Oregon Hlth & Sci Univ, Dept Neurosurg, Portland, OR 97201 USA. [Hogarth, Penelope] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97201 USA. [Lai, Eugene C.] Michael E DeBakey VA Med Ctr, Houston, TX USA. [Lai, Eugene C.] Baylor Coll Med, Dept Neurol, Houston, TX 77030 USA. [Holloway, Kathryn] Richmond VA Med Ctr, Richmond, VA USA. [Holloway, Kathryn] Virginia Commonwealth Univ, Dept Neurosurg, Richmond, VA USA. [Samii, Ali] Puget Sound Hlth Care Syst, Seattle, WA USA. [Bronstein, Jeff] W Los Angeles VA Med Ctr, Los Angeles, CA USA. [Stoner, Gatana] Univ Iowa Health Care, Dept Neurosurg, Iowa City, IA USA. [Huang, Grant D.] VA Off Res & Dev, Dept Vet Affairs, Cooperat Studies Program Cent Off, Washington, DC USA. RP Weaver, FM (reprint author), Edward Hines Jr VA Hosp, Ctr Management Complex Chron Care, 5000 S 5th Ave 151H, Hines, IL 60141 USA. EM Frances.Weaver@va.gov FU The Cooperative Studies Program of the Department of Veterans Affairs Office of Research and Development; National Institute of Neurological Disorders and Stroke; Medtronic Neuromodulation FX The Cooperative Studies Program of the Department of Veterans Affairs Office of Research and Development, the National Institute of Neurological Disorders and Stroke, and Medtronic Neuromodulation provided financial support for this study. NR 31 TC 546 Z9 561 U1 7 U2 52 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA SN 0098-7484 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD JAN 7 PY 2009 VL 301 IS 1 BP 63 EP 73 PG 11 WC Medicine, General & Internal SC General & Internal Medicine GA 391FY UT WOS:000262220400021 PM 19126811 ER PT J AU Carabello, BA AF Carabello, Blase A. TI Role of Mitral Valve Surgery for Secondary Mitral Regurgitation in Heart Failure Reply SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY LA English DT Letter ID TRIAL C1 Vet Affairs Med Ctr, Houston Vet Affairs Med Ctr, Houston, TX 77030 USA. RP Carabello, BA (reprint author), Vet Affairs Med Ctr, Houston Vet Affairs Med Ctr, Bldg 100,Room 4C211,2002 Holcombe, Houston, TX 77030 USA. EM blaseanthony.carabello@med.va.gov NR 7 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0735-1097 J9 J AM COLL CARDIOL JI J. Am. Coll. Cardiol. PD JAN 6 PY 2009 VL 53 IS 1 BP 75 EP 75 DI 10.1016/j.jacc.2008.09.021 PG 1 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 389IF UT WOS:000262085400014 ER PT J AU Bird, TD AF Bird, Thomas D. TI A new disease mimicking Refsum syndrome SO NEUROLOGY LA English DT Editorial Material C1 Univ Washington, VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. RP Bird, TD (reprint author), Univ Washington, VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. EM tomnroz@u.washington.edu NR 4 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0028-3878 J9 NEUROLOGY JI Neurology PD JAN 6 PY 2009 VL 72 IS 1 BP 13 EP 13 DI 10.1212/01.wnl.0000334358.71615.fd PG 1 WC Clinical Neurology SC Neurosciences & Neurology GA 390KL UT WOS:000262162600003 PM 19005173 ER PT J AU Mocroft, A Wyatt, C Szczech, L Neuhaus, J El-Sadr, W Tracy, R Kuller, L Shlipak, M Angus, B Klinker, H Ross, M AF Mocroft, Amanda Wyatt, Christina Szczech, Lynda Neuhaus, Jacquie El-Sadr, Wafaa Tracy, Russell Kuller, Lewis Shlipak, Michael Angus, Brian Klinker, Harting Ross, Michael CA Insight Smart Study Grp TI Interruption of antiretroviral therapy is associated with increased plasma cystatin C SO AIDS LA English DT Article DE cystatin C; randomized trial; treatment interruption ID GLOMERULAR-FILTRATION-RATE; CHRONIC KIDNEY-DISEASE; IMMUNODEFICIENCY-VIRUS-INFECTION; TUBULAR EPITHELIAL-CELLS; CARDIOVASCULAR-DISEASE; SERUM CREATININE; RENAL-FUNCTION; HIV-1-ASSOCIATED NEPHROPATHY; REFERENCE RANGES; HIV-1 INFECTION AB Background: Cystatin C has been proposed as an alternative marker of renal function. We sought to determine whether participants randomized to episodic use of antiretroviral therapy guided by CD4(+) cell count (drug conservation) had altered cystatin C levels compared with those randomized to Continuous antiretroviral therapy (viral suppression) in the Strategies for Management of Antiretroviral Therapy trial, and to identify factors associated with increased cystatin C. Methods: Cystatin C was measured in plasma collected at randomization, 1, 2, 4, 8 and 12 months after randomization in a random sample of 249 and 250 participants in the drug conservation and viral suppression groups, respectively. Logistic regression was used to model the odds of at least 0.15 mg/dl increase in cystatin C (1 SD) in the first month after randomization, adjusting for demographic and clinical characteristics. Results: At randomization, mean (SD) cystatin C level was 0.99 (0.26 mg/dl) and 1.01 (0.28 mg/dl) in the drug conservation and viral Suppression arms, respectively (P = 0.29). In the first month after randomization, 21.8 and 10.6% had at least 0.15 mg/dl increase in cystatin C in the drug conservation and viral suppression arms, respectively (P=0.0008). The difference in cystatin C between the treatment arms was maintained through 1 year after randomization. After adjustment, participants in the viral suppression arm had significantly reduced odds of at least 0.15 mg/dl increase in cystatin C in the first month (odds ratio 0.42; 95% confidence interval 0.23-0.74, P = 0.0023). Conclusion: These results demonstrate that interruption of antiretroviral therapy is associated with an increase in cystatin C, which may reflect worsened renal function. (C) 2009 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins C1 [Mocroft, Amanda] UCL, Sch Med, Res Dept Infect & Populat Hlth, London NW3 2PF, England. [Wyatt, Christina; Ross, Michael] Mt Sinai Sch Med, New York, NY USA. [Szczech, Lynda] Duke Univ, Med Ctr, Durham, NC 27706 USA. [Neuhaus, Jacquie] Univ Minnesota, Sch Publ Hlth, Minneapolis, MN USA. [El-Sadr, Wafaa] Columbia Univ Coll Phys & Surg, Harlem Hosp Ctr, New York, NY 10032 USA. [El-Sadr, Wafaa] Columbia Univ, New York, NY USA. [Tracy, Russell] Univ Vermont, Coll Med, Burlington, VT 05405 USA. [Kuller, Lewis] Univ Pittsburgh, Pittsburgh, PA USA. [Shlipak, Michael] San Francisco VA Med Ctr, San Francisco, CA USA. [Shlipak, Michael] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Angus, Brian] Univ Oxford, Nuffield Dept Med, Oxford OX1 2JD, England. [Angus, Brian] MRC, HIV Clin Trials Unit, London, England. [Klinker, Harting] Klinikum Univ Wurzburg, Wurzburg, Germany. RP Mocroft, A (reprint author), UCL, Sch Med, Res Dept Infect & Populat Hlth, Royal Free Campus,Rowland Hill St, London NW3 2PF, England. EM a.mocroft@pcps.ucl.ac.uk RI Mocroft, Amanda/C-1527-2008; Mocroft, Amanda/G-8748-2011; SHCS, int. coll. B/G-4090-2011; SHCS, all/G-4072-2011; Pulido, Federico/B-8417-2009; Brites, Carlos/D-1353-2013 OI Pulido, Federico/0000-0002-7414-8812; Koirala, Janak/0000-0002-3608-474X; Brites, Carlos/0000-0002-4673-6991; Gayet-Ageron, Angele/0000-0002-6164-9693; Magenta, Lorenzo/0000-0002-7644-3647; Okhuysen, Pablo/0000-0002-1596-3411; Angus, Brian/0000-0003-3598-7784 FU NIAID; NIH [U01AI042170, U01A1068641, U01A146362] FX This study was supported by NIAID, NIH grants U01AI042170, U01A1068641 and U01A146362 Clinical Trials.gov identifier: NCT00027352. NR 44 TC 36 Z9 38 U1 1 U2 6 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0269-9370 J9 AIDS JI Aids PD JAN 2 PY 2009 VL 23 IS 1 BP 71 EP 82 DI 10.1097/QAD.0b013e32831cc129 PG 12 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA 390XS UT WOS:000262197600010 PM 19050388 ER PT J AU Bhattacharya, A Muller, FL Liu, YH Sabia, M Liang, HY Song, W Jang, YC Ran, QT Van Remmen, H AF Bhattacharya, Arunabh Muller, Florian L. Liu, Yuhong Sabia, Marian Liang, Hanyu Song, Wook Jang, Youngmok C. Ran, Qitao Van Remmen, Holly TI Denervation Induces Cytosolic Phospholipase A(2)-mediated Fatty Acid Hydroperoxide Generation by Muscle Mitochondria SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article ID AMYOTROPHIC-LATERAL-SCLEROSIS; AGING SKELETAL-MUSCLE; GLUTATHIONE-PEROXIDASE; OXIDATIVE STRESS; SELENOORGANIC COMPOUND; SUPEROXIDE-DISMUTASE; LIPID-PEROXIDATION; BIOLOGICAL-SYSTEMS; INDUCED APOPTOSIS; MICE DEFICIENT AB Previously, we demonstrated that mitochondria from denervated muscle exhibited dramatically higher Amplex Red dependent fluorescence (thought to be highly specific for hydrogen peroxide) compared with control muscle mitochondria. We now demonstrate that catalase only partially inhibits the Amplex Red signal in mitochondria from denervated muscle. In contrast, ebselen (a glutathione peroxidase mimetic and inhibitor of fatty acid hydroperoxides) significantly inhibits the Amplex Red signal. This suggests that the majority of the Amplex Red signal in mitochondria from denervated muscle is not derived from hydrogen peroxide. Because Amplex Red cannot react with substrates in the lipid environment, we hypothesize that lipid hydroperoxides formed within the mitochondrial lipid bilayer are released as fatty acid hydroperoxides and react with the Amplex Red probe. We also suggest that the release of fatty acid hydroperoxides from denervated muscle mitochondria may be an important determinant of muscle atrophy. In support of this, muscle atrophy and the Amplex Red signal are inhibited in caloric restricted mice and in transgenic mice that overexpress the lipid hydroperoxide-detoxifying enzyme glutathione peroxidase 4. Finally, we propose that cytosolic phospholipase A(2) may be a potential source of these hydroperoxides. C1 [Bhattacharya, Arunabh; Liu, Yuhong; Liang, Hanyu; Song, Wook; Ran, Qitao; Van Remmen, Holly] Univ Texas Hlth Sci Ctr San Antonio, Barshop Inst Longev & Aging Studies, San Antonio, TX 78229 USA. [Bhattacharya, Arunabh; Muller, Florian L.; Liu, Yuhong; Liang, Hanyu; Jang, Youngmok C.; Ran, Qitao; Van Remmen, Holly] Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA. [Sabia, Marian; Ran, Qitao; Van Remmen, Holly] S Texas Vet Hlth Care Syst, San Antonio, TX 78284 USA. RP Van Remmen, H (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Barshop Inst Longev & Aging Studies, Texas Res Pk Campus,15355 Lambda Dr, San Antonio, TX 78245 USA. EM vanremmen@uthscsa.edu RI Liang, Hanyu/A-1066-2010 FU National Institutes of Health [AG20591]; Muscular Dystrophy Association [MDA 3879]; Veterans Affairs merit grant FX This work was supported, in whole or in part, by National Institutes of Health Grant AG20591 (to H. V. R.). This work was also supported by Muscular Dystrophy Association Grant MDA 3879 (to H. V. R.) and a Veterans Affairs merit grant (to H. V. R.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U. S. C. Section 1734 solely to indicate this fact. NR 54 TC 30 Z9 30 U1 1 U2 4 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 J9 J BIOL CHEM JI J. Biol. Chem. PD JAN 2 PY 2009 VL 284 IS 1 BP 46 EP 55 DI 10.1074/jbc.M806311200 PG 10 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 387TP UT WOS:000261974800006 PM 19001413 ER PT B AU Sundara-Rajan, K Rowe, GI Simon, AJ Klute, GK Ledoux, WR Mamishev, AV AF Sundara-Rajan, Kishore Rowe, Gabriel I. Simon, Anthony J. Klute, Glenn K. Ledoux, William R. Mamishev, Alexander V. BE Evans, BM TI Shear Sensor for Lower Limb Prosthetic Applications SO 2009 FIRST ANNUAL ORNL BIOMEDICAL SCIENCE & ENGINEERING CONFERENCE: EXPLORING THE INTERSECTIONS OF INTERDISCIPLINARY BIOMEDICAL RESEARCH LA English DT Proceedings Paper CT 1st Annual ORNL Biomedical Science and Engineering Conference CY MAR 18-19, 2009 CL Oak Ridge, TN SP Oak Ridge Natl Lab AB Lower limb amputees using a prosthetic device often suffer from mechanically-induced skin injuries. Shear stresses are believed to play a significant role in the formation of these skin injuries. The work presented in this paper is aimed at creating a new class of adaptive prosthetic and orthotic interfaces involving a capacitive shear stress sensor. The sensor design and transfer function are discussed. A few preliminary test results demonstrating the functionality of the sensor are also presented. C1 [Sundara-Rajan, Kishore; Rowe, Gabriel I.; Simon, Anthony J.; Mamishev, Alexander V.] Univ Washington, Dept Elect Engn, Sensors Energy & Automat Lab, Seattle, WA 98195 USA. [Klute, Glenn K.; Ledoux, William R.] VA Puget Sound Hlth Care Syst, Ctr Excellence Limb Loss Prevent & Prosthet Engn, Seattle, WA USA. [Klute, Glenn K.; Ledoux, William R.] Univ Washington, Dept Engn Mech, Seattle, WA USA. RP Sundara-Rajan, K (reprint author), Univ Washington, Dept Elect Engn, Sensors Energy & Automat Lab, Seattle, WA 98195 USA. EM kishore@u.washington.edu FU U.S. National Institute of Health under Grant [R21HD052109-02]; Department of Veterans Affairs Grant [A4843C] FX This work was supported in part by the U.S. National Institute of Health under Grant R21HD052109-02 and the Department of Veterans Affairs Grant A4843C. NR 11 TC 0 Z9 0 U1 0 U2 0 PU IEEE PI NEW YORK PA 345 E 47TH ST, NEW YORK, NY 10017 USA BN 978-1-4244-3837-2 PY 2009 BP 61 EP + PG 2 WC Engineering, Biomedical SC Engineering GA BMB15 UT WOS:000271720900011 ER PT J AU Bader, B Velayos-Baeza, A Walker, RH Danek, A AF Bader, Benedikt Velayos-Baeza, Antonio Walker, Ruth H. Danek, Adrian TI Dominant transmission of chorea-acanthocytosis with VPS13A mutations remains speculative SO ACTA NEUROPATHOLOGICA LA English DT Letter ID CHAC GENE C1 [Bader, Benedikt; Danek, Adrian] Univ Munich, Neurol Klin & Poliklin, Munich, Germany. [Velayos-Baeza, Antonio] Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford, England. [Walker, Ruth H.] James J Peters Vet Affairs Med Ctr, Dept Neurol, Bronx, NY USA. [Walker, Ruth H.] Mt Sinai Sch Med, New York, NY USA. RP Bader, B (reprint author), Univ Munich, Neurol Klin & Poliklin, Munich, Germany. EM benedikt.bader@med.uni-muenchen.de RI Danek, Adrian/G-7339-2011 OI Danek, Adrian/0000-0001-8857-5383 NR 10 TC 8 Z9 8 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0001-6322 J9 ACTA NEUROPATHOL JI Acta Neuropathol. PD JAN PY 2009 VL 117 IS 1 BP 95 EP 96 DI 10.1007/s00401-008-0418-7 PG 2 WC Clinical Neurology; Neurosciences; Pathology SC Neurosciences & Neurology; Pathology GA 376LN UT WOS:000261185200011 PM 18661137 ER PT J AU Yehuda, R Schmeidler, J Labinsky, E Bell, A Morris, A Zemelman, S Grossman, RA AF Yehuda, R. Schmeidler, R. Labinsky, E. Bell, A. Morris, A. Zemelman, S. Grossman, R. A. TI Ten-year follow-up study of PTSD diagnosis, symptom severity and psychosocial indices in aging holocaust survivors SO ACTA PSYCHIATRICA SCANDINAVICA LA English DT Article DE holocaust survivors; longitudinal course; post-traumatic stress disorder; morale; traumatic loss ID POSTTRAUMATIC-STRESS-DISORDER; WORLD-WAR-II; FORMER PRISONERS; LONGITUDINAL ASSESSMENT; LIFETIME TRAUMA; COMBAT VETERANS; IMPACT; SCALE AB Objective: We performed a longitudinal study of holocaust survivors with and without post-traumatic stress disorder ( PTSD) by assessing symptoms and other measures at two intervals, approximately 10 years apart. Method: The original cohort consisted of 63 community-dwelling subjects, of whom 40 were available for follow-up. Results: There was a general diminution in PTSD symptom severity over time. However, in 10% of the subjects (n = 4), new instances of delayed onset PTSD developed between time 1 and time 2. Self-report ratings at both assessments revealed a worsening of trauma-related symptoms over time in persons without PTSD at time 1, but an improvement in those with PTSD at time 1. Conclusion: The findings suggest that a nuanced characterization of PTSD trajectory over time is more reflective of PTSD symptomatology than simple diagnostic status at one time. The possibility of delayed onset trajectory complicates any simplistic overall trajectory summarizing the longitudinal course of PTSD. C1 [Yehuda, R.; Schmeidler, R.; Labinsky, E.; Bell, A.; Morris, A.; Zemelman, S.; Grossman, R. A.] Mt Sinai Sch Med, Dept Psychiat, Div Traumat Stress Studies, New York, NY USA. [Yehuda, R.; Schmeidler, R.; Labinsky, E.; Bell, A.; Morris, A.; Zemelman, S.; Grossman, R. A.] James J Peters Vet Affairs Med Ctr, Bronx, NY USA. RP Yehuda, R (reprint author), Bronx Vet Affairs Med Ctr, 130 W Kingsbridge Rd, Bronx, NY 10468 USA. EM rachel.yehuda@va.gov FU NIMH [R01 MH 64675-01, 5 M01 RR00071]; National Institute of Health FX This work was supported by NIMH R01 MH 64675-01 entitled 'Biology of Risk and PTD in Holocaust Survivor spring' and in part by a grant (5 M01 RR00071) for the Mount Sinai General Clinical Research Center from the National Institute of Health. The authors acknowledge Ms Shira Kaufman and Mr William Blair for research coordination, and Drs Lisa Tischler and Alicia Hirsch for diagnostic evaluations and consensus conferencing. The authors report no financial or other relationship relevant to the subject of this article. NR 30 TC 26 Z9 26 U1 0 U2 6 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0001-690X J9 ACTA PSYCHIAT SCAND JI Acta Psychiatr. Scand. PD JAN PY 2009 VL 119 IS 1 BP 25 EP 34 DI 10.1111/j.1600-0447.2008.01248.x PG 10 WC Psychiatry SC Psychiatry GA 394LX UT WOS:000262449300004 PM 18785948 ER PT S AU Matute-Bello, G Martin, TR AF Matute-Bello, Gustavo Martin, Thomas R. BE Choi, AMK TI Apoptosis in the Pathogenesis and Resolution of Acute Lung Injury SO Acute Respiratory Distress Syndrome, 2nd Edition SE Lung Biology in Health and Disease LA English DT Article; Book Chapter ID RESPIRATORY-DISTRESS-SYNDROME; ENDOTHELIAL-CELL APOPTOSIS; ALVEOLAR EPITHELIAL-CELLS; COLONY-STIMULATING FACTOR; FAS-INDUCED APOPTOSIS; NEUTROPHIL APOPTOSIS; IN-VIVO; PULMONARY INFLAMMATION; FIBROBLAST APOPTOSIS; CASPASE INHIBITOR C1 [Matute-Bello, Gustavo; Martin, Thomas R.] Univ Washington, Sch Med, Dept Med, Div Pulm & Crit Care Med, Seattle, WA 98195 USA. [Martin, Thomas R.] Univ Washington, Sch Med, Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA. RP Matute-Bello, G (reprint author), Univ Washington, Sch Med, Dept Med, Div Pulm & Crit Care Med, Seattle, WA 98195 USA. NR 80 TC 0 Z9 0 U1 0 U2 0 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL ST, LONDON, EC2A 4LQ, ENGLAND SN 0362-3181 BN 978-1-4200-8841-0; 978-1-4200-8840-3 J9 LUNG BIOL HEALTH DIS PY 2009 VL 233 BP 93 EP 108 PG 16 WC Respiratory System SC Respiratory System GA BD6KI UT WOS:000362321700010 ER PT S AU Anzueto, A Gattinoni, L AF Anzueto, Antonio Gattinoni, Luciano BE Choi, AMK TI Prone Position in ARDS SO Acute Respiratory Distress Syndrome, 2nd Edition SE Lung Biology in Health and Disease LA English DT Article; Book Chapter ID RESPIRATORY-DISTRESS-SYNDROME; ACUTE LUNG INJURY; INHALED NITRIC-OXIDE; END-EXPIRATORY PRESSURE; PULMONARY BLOOD-FLOW; MECHANICAL VENTILATION; REGIONAL DISTRIBUTION; VERTICAL-DISTRIBUTION; AIRWAY PRESSURE; INSPIRED GAS C1 [Anzueto, Antonio] South Texas Vet Hlth Care Syst, Audie L Murphy Div, San Antonio, TX USA. [Anzueto, Antonio] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Gattinoni, Luciano] Osped Maggiore Policlin, Milan, Italy. RP Anzueto, A (reprint author), South Texas Vet Hlth Care Syst, Audie L Murphy Div, San Antonio, TX USA. NR 80 TC 0 Z9 0 U1 0 U2 0 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL ST, LONDON, EC2A 4LQ, ENGLAND SN 0362-3181 BN 978-1-4200-8841-0; 978-1-4200-8840-3 J9 LUNG BIOL HEALTH DIS PY 2009 VL 233 BP 313 EP 334 PG 22 WC Respiratory System SC Respiratory System GA BD6KI UT WOS:000362321700020 ER PT J AU Gleason, CE Carlsson, CM Barnet, JH Meade, SA Setchell, KDR Atwood, CS Johnson, SC Ries, ML Asthana, S AF Gleason, Carey E. Carlsson, Cynthia M. Barnet, Jodi H. Meade, Sarah A. Setchell, Kenneth D. R. Atwood, Craig S. Johnson, Sterling C. Ries, Michele L. Asthana, Sanjay TI A preliminary study of the safety, feasibility and cognitive efficacy of soy isoflavone supplements in older men and women SO AGE AND AGEING LA English DT Article ID RANDOMIZED CONTROLLED-TRIAL; HEALTH INITIATIVE MEMORY; POSTMENOPAUSAL WOMEN; PHARMACOKINETICS; CONSUMPTION; FREQUENCY; LIPIDS; SERUM; EQUOL AB Background: a small number of reports exist on the cognitive effects of soy isoflavones, the findings from which are mixed. Isoflavone efficacy is dependent upon conversion of glycosides contained in soy foods and supplements to the biologically active aglycons. Of particular interest is the production of the metabolite, equol, which is dependent upon intestinal microflora and an integrous digestive system, both being altered by age and age-associated conditions. Unfortunately, few studies enrolled adults over the age of 70, and none included older men. Objective: we examined safety, feasibility and cognitive efficacy of soy isoflavone administration in older nondemented men and women (age 62-89 years). Design and Methods: in this randomised, placebo-controlled, double-blind pilot study, subjects ingested either 100 mg/day soy isoflavones (glycoside weight) or matching placebo tablets for 6 months. Results: active and placebo-treated subjects exhibited a comparable side-effect profile. Plasma levels of genistein and daidzein (P < 0.001), but not equol, increased with isoflavone administration. While similar at baseline, the two groups differed across 6 months of treatment on 8 of 11 cognitive tests administered. Isoflavone-treated subjects improved on tests of visual-spatial memory (P < 0.01) and construction (P = 0.01), verbal fluency (P < 0.01) and speeded dexterity (P = 0.04). Placebo-treated participants were faster than isoflavone-treated subjects on two tests of executive function (P < 0.05). Conclusions: these data suggest that administration of 100 mg/day of isoflavones was well tolerated. Plasma genistein and daidzein levels, but not equol, increased with isoflavone administration. Finally, data support the potential cognitive effects of soy isoflavones in older adults. C1 [Gleason, Carey E.; Carlsson, Cynthia M.; Meade, Sarah A.; Atwood, Craig S.; Johnson, Sterling C.; Ries, Michele L.; Asthana, Sanjay] Univ Wisconsin, Dept Med, Madison VA GRECC 11G, Sect Geriatr & Gerontol, Madison, WI 53705 USA. [Gleason, Carey E.; Carlsson, Cynthia M.; Atwood, Craig S.; Johnson, Sterling C.; Asthana, Sanjay] William S Middleton Mem Vet Adm Med Ctr, GRECC, Madison, WI 53705 USA. [Barnet, Jodi H.] Univ Wisconsin, Dept Biostat & Med Informat, Madison, WI 53792 USA. [Meade, Sarah A.] Univ Wisconsin, Wisconsin Alzheimers Inst, Madison, WI 53719 USA. [Setchell, Kenneth D. R.] Univ Cincinnati, Coll Med, Dept Pediat, Cincinnati, OH 45267 USA. [Setchell, Kenneth D. R.] Cincinnati Childrens Hosp, Med Ctr, Dept Pathol & Lab Med, Cincinnati, OH 45267 USA. RP Gleason, CE (reprint author), Univ Wisconsin, Dept Med, Madison VA GRECC 11G, Sect Geriatr & Gerontol, 2500 Overlook Terrace, Madison, WI 53705 USA. EM ceg@medicine.wisc.edu FU UW General Clinical Research Center from the National Center for Research Resources, National Institutes of Health [M01 RR03186]; NIH/NIA [K23 AG024302] FX Work was supported by grants: M01 RR03186 awarded to The UW General Clinical Research Center from the National Center for Research Resources, National Institutes of Health and K23 AG024302 NIH/NIA (C.E.G.). Archer Daniels Midland provided Novasoy brand isoflavones tablets and matching placebo. Sponsors of the project played no role in the design, execution, analysis or interpretation of the data or writing of the study. NR 32 TC 30 Z9 31 U1 1 U2 4 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0002-0729 J9 AGE AGEING JI Age Ageing PD JAN PY 2009 VL 38 IS 1 BP 86 EP 93 DI 10.1093/ageing/afn227 PG 8 WC Geriatrics & Gerontology SC Geriatrics & Gerontology GA 395IP UT WOS:000262518100017 PM 19054783 ER PT J AU Paukert, AL LeMaire, A Cully, JA AF Paukert, Amber Lynn LeMaire, Ashley Cully, Jeffrey A. TI Predictors of depressive symptoms in older veterans with heart failure SO AGING & MENTAL HEALTH LA English DT Article DE depression; locus of control; illness intrusiveness; anxiety; geriatric ID PERCEIVED SOCIAL SUPPORT; QUALITY-OF-LIFE; PSYCHOMETRIC PROPERTIES; MULTIDIMENSIONAL SCALE; ILLNESS INTRUSIVENESS; ELDERLY-PATIENTS; HEALTH-STATUS; PREVALENCE; VALIDATION; DISEASE AB Objectives: This study collected data on demographic factors, heart failure physical limitations, perception of heart failure intrusiveness, coping mechanisms, locus of control, self-efficacy and social support for 104 older veterans with heart failure (HF) to determine the factors' relative importance in predicting depressive symptoms. Method: Participants were veterans at least 60 years of age with HF who were screened for depression and anxiety with the Geriatric Depression Scale and Geriatric Anxiety Inventory, respectively, so that the final sample consisted of equal numbers with and without significant levels of anxiety and depression. Other measures included the Kansas City Cardiomyopathy Questionnaire, Heart Failure Illness Intrusiveness Rating Scale, Brief-COPE, Multidimensional Health Locus of Control Scale, Chronic Disease Self-Efficacy and Multidimensional Scale of Perceived Social Support. Results: Correlational analyses indicated that depressive symptoms were significantly associated with physical limitations from HF, HF perceptions of intrusiveness, maladaptive coping, attributing locus of control to chance and HF self-efficacy. Including these variables in one regression equation predicting depressive symptoms indicated that perceptions of intrusiveness from HF and attributing locus of control to chance were the only variables to predict depressive symptoms independent of the influence of other significant bivariate predictors. Conclusion: Even if physical limitations, maladaptive coping and self-efficacy are held constant, decreasing perceptions of HF intrusiveness and locus of control to chance reduce depressive symptoms. These two cognitive/perceptual factors may play a salient role in treatment of depression among older HF patients. C1 [Paukert, Amber Lynn] Affairs Puget Sound Hlth Care Syst, Seattle, WA USA. [Paukert, Amber Lynn; LeMaire, Ashley; Cully, Jeffrey A.] Michael E DeBakey Vet Affairs Med Ctr, Houston Ctr Qual Care & Utilizat Studies, Houston, TX USA. [Paukert, Amber Lynn; Cully, Jeffrey A.] Baylor Coll Med, Menninger Dept Psychiat & Behav Sci, Houston, TX 77030 USA. [Cully, Jeffrey A.] Vet Affairs S Cent Mental Illness Res Educ & Clin, Houston, TX USA. RP Paukert, AL (reprint author), Affairs Puget Sound Hlth Care Syst, Seattle, WA USA. EM Amber.Paukert@VA.gov NR 65 TC 25 Z9 25 U1 4 U2 7 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 1360-7863 J9 AGING MENT HEALTH JI Aging Ment. Health PY 2009 VL 13 IS 4 BP 601 EP 610 AR PII 913279815 DI 10.1080/13607860802459823 PG 10 WC Geriatrics & Gerontology; Gerontology; Psychiatry SC Geriatrics & Gerontology; Psychiatry GA 474JP UT WOS:000268279900013 PM 19629786 ER PT J AU Pinkerton, SD Bogart, LM Howerton, D Snyder, S Becker, K Asch, SM AF Pinkerton, Steven D. Bogart, Laura M. Howerton, Devery Snyder, Susan Becker, Kirsten Asch, Steven M. TI Cost of OraQuick oral fluid rapid HIV testing at 35 community clinics and community-based organizations in the USA SO AIDS CARE-PSYCHOLOGICAL AND SOCIO-MEDICAL ASPECTS OF AIDS/HIV LA English DT Article DE HIV; rapid testing; cost; community-based organizations ID UNITED-STATES; PREVENTION; INFECTION; VIRUS AB The US Centers for Disease Control and Prevention recommends the expanded use of rapid HIV antibody tests in community settings to increase the proportion of persons who are aware of their HIV status. The cost of providing rapid testing services in these settings is not known. We conducted a cost survey of non-profit community clinics and community-based organizations (CBOs). The final study sample for the cost analyses included 28 community clinics and seven CBOs that offered rapid HIV testing, all of which used OraSure's OraQuick oral fluid assay. Overall, the mean per-client rapid testing cost was $36.68 for HIV-negative clients (2006 dollars, provider perspective) and $44.22 for preliminary-positive clients. Personnel costs accounted for 55.6% of overall testing costs for negative clients and 63.2% for preliminary-positive clients. This study contributes unique empirical data about the costs of OralQuick rapid testing that can be used by clinic and CBO directors to assess the economic impact of implementing rapid testing at their sites. The findings also could be used to inform discussions regarding national and local HIV testing policies. C1 [Pinkerton, Steven D.] Med Coll Wisconsin, Dept Psychiat & Behav Med, Ctr AIDS Intervent Res, Milwaukee, WI 53226 USA. [Bogart, Laura M.; Becker, Kirsten; Asch, Steven M.] RAND Corp, Hlth Program, Santa Monica, CA USA. [Bogart, Laura M.] Harvard Univ, Sch Med, Childrens Hosp Boston, Cambridge, MA 02138 USA. [Howerton, Devery; Snyder, Susan] Ctr Dis Control & Prevent, Div Lab Syst, Lab Practice Evaluat & Genom Branch, Atlanta, GA USA. [Asch, Steven M.] VA Greater Los Angeles Healthcare Network, Los Angeles, CA USA. [Asch, Steven M.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. RP Pinkerton, SD (reprint author), Med Coll Wisconsin, Dept Psychiat & Behav Med, Ctr AIDS Intervent Res, Milwaukee, WI 53226 USA. EM pinkrton@mcw.edu FU NIMH NIH HHS [P30-MH52776]; PHS HHS [U65/CCU924523-01] NR 20 TC 7 Z9 7 U1 1 U2 1 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 0954-0121 J9 AIDS CARE JI Aids Care-Psychol. Socio-Med. Asp. Aids-Hiv PY 2009 VL 21 IS 9 BP 1157 EP 1162 DI 10.1080/09540120902729940 PG 6 WC Health Policy & Services; Public, Environmental & Occupational Health; Psychology, Multidisciplinary; Respiratory System; Social Sciences, Biomedical SC Health Care Sciences & Services; Public, Environmental & Occupational Health; Psychology; Respiratory System; Biomedical Social Sciences GA 515MX UT WOS:000271477000010 PM 20024775 ER PT J AU Savas, LS White, DL Wieman, M Daci, K Fitzgerald, S Smith, SL Tan, G Graham, DP Cully, JA El-Serag, HB AF Savas, L. S. White, D. L. Wieman, M. Daci, K. Fitzgerald, S. Smith, S. Laday Tan, G. Graham, D. P. Cully, J. A. El-Serag, H. B. TI Irritable bowel syndrome and dyspepsia among women veterans: prevalence and association with psychological distress SO ALIMENTARY PHARMACOLOGY & THERAPEUTICS LA English DT Article ID POSTTRAUMATIC-STRESS-DISORDER; FUNCTIONAL GASTROINTESTINAL DISORDERS; DEPRESSION INVENTORY-II; PSYCHOSOCIAL-ASPECTS; ABDOMINAL-PAIN; HEALTH-STATUS; RISK-FACTORS; POPULATION; SYMPTOMS; DISEASE AB Background The burden of functional GI disorders and their associations with psychological distress in women veterans is unclear. Aim To examine 1-year prevalence of irritable bowel syndrome (IBS) and dyspepsia symptoms and their associations with anxiety, depression and post-traumatic stress disorder (PTSD) among women veterans receiving primary care at a Veteran Affairs Medical Center Women's Clinic. Methods Irritable bowel syndrome, dyspepsia and psychological distress were assessed using the validated self-administered Bowel Disorder Questionnaire, the Beck Depression and Anxiety Inventories, as well as the Mississippi Scale for Combat-Related Post-Traumatic Stress Disorder Questionnaire. Results We enrolled 248 women (84% participation rate). Ninety-three (38%) reported IBS and 51 (21%) dyspepsia symptoms. Women with IBS and dyspepsia reported higher mean scores of anxiety (IBS: 24 vs. 12, P < 0.0005 and dyspepsia: 26 vs. 12, P < 0.0005), depression (IBS: 22 vs. 11, P = 0.0005 and dyspepsia: 23 vs. 11, P < 0.0005) and PTSD (IBS: 87 vs. 69, P < 0.001 and dyspepsia: 86 vs. 69, P < 0.0005). Age-and ethnicity-adjusted logistic regression analyses showed a 3-to 46-fold increase in odds of IBS and dyspepsia among women with anxiety, depression or PTSD. Conclusion Women veterans have high prevalence of IBS and dyspepsia symptoms, both of which are highly associated with presence of depression, anxiety and PTSD. C1 [Savas, L. S.; White, D. L.; Wieman, M.; Fitzgerald, S.; Cully, J. A.; El-Serag, H. B.] Baylor Coll Med, Sect Hlth Serv Res, Houston, TX 77030 USA. [Savas, L. S.] Baylor Coll Med, Dept Family & Community Med, Houston, TX 77030 USA. [White, D. L.; Wieman, M.; Graham, D. P.; Cully, J. A.; El-Serag, H. B.] Michael E DeBakey Dept Vet Affairs Med Ctr, Houston Ctr Qual Care & Utilizat Studies, Hlth Serv Res & Dev Serv, Houston, TX USA. [White, D. L.; Daci, K.; El-Serag, H. B.] Baylor Coll Med, Gastroenterol Sect, Houston, TX 77030 USA. [White, D. L.; Daci, K.; El-Serag, H. B.] Michael E DeBakey Dept Vet Affairs Med Ctr, Gastroenterol Sect, Houston, TX USA. [Smith, S. Laday] Michael E DeBakey Dept Vet Affairs Med Ctr, Omen Vet Program, Houston, TX USA. [Smith, S. Laday] Baylor Coll Med, Dept Anesthesiol & Phys Med & Rehabil, Houston, TX 77030 USA. [Graham, D. P.; Cully, J. A.] Baylor Coll Med, Menninger Dept Psychiat & Behav Sci, Houston, TX 77030 USA. [Cully, J. A.] Vet Affairs S Cent Mental Illness Res Educ & Clin, Houston, TX USA. RP El-Serag, HB (reprint author), Houston VA Med Ctr, Houston Ctr Qual Care & Utilizat Studies, 152, Houston, TX 77030 USA. EM hasheme@bcm.tmc.edu RI Graham, David /J-1158-2014 FU Novartis pharmaceuticals; National Institute of Health [K-24 DK07815403]; Health Resources and Services [5 T32 HP10031-09]; Veterans Health Administration, HSR D Service [CDA-2; 05-288] FX Declaration of personal interests: Hashim El-Serag has served as a consultant and an advisory board member for Novartis Pharmaceuticals. None of the authors is an employee, owns stocks or shares, or has patents that constitute a conflict of interest. Hashem B. El-Serag was responsible for the study design. Hashem B. El-Serag, Donna L. White and Lara S. Savas were responsible for the interpretation of results and manuscript. Data analysis was done by Lara S. Savas. All authors reviewed and revised the manuscript of the paper and approved its final version. All analyses and writing was conducted solely by the listed authors. There are no conflicts of interest. Declaration of funding interests: This material is based upon work supported in part by Health Services Research and Development (HSR& D) Service, Office of Research and Development, Department of Veterans Affairs. This study is partly funded by a grant from Novartis pharmaceuticals to Dr El-Serag. Dr El-Serag is supported by National Institute of Health grant K-24 DK07815403. Dr Savas is supported by the National Research Service Award 5 T32 HP10031-09 funded by the Health Resources and Services. Dr Cully is supported by a Career Development Award (CDA-2; 05-288) from the Veterans Health Administration, HSR& D Service. NR 58 TC 32 Z9 33 U1 2 U2 4 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0269-2813 J9 ALIMENT PHARM THER JI Aliment. Pharmacol. Ther. PD JAN 1 PY 2009 VL 29 IS 1 BP 115 EP 125 DI 10.1111/j.1365-2036.2008.03847.x PG 11 WC Gastroenterology & Hepatology; Pharmacology & Pharmacy SC Gastroenterology & Hepatology; Pharmacology & Pharmacy GA 384ZB UT WOS:000261781600013 PM 18785989 ER PT J AU Reifel, N Bayhylle, R Harada, N Villa, V AF Reifel, Nancy Bayhylle, Ruth Harada, Nancy Villa, Valentine TI American Indian Veterans' Views about Their Choices in Health Care: VA, IHS, and Medicare SO AMERICAN INDIAN CULTURE AND RESEARCH JOURNAL LA English DT Article ID SYSTEM; SERVICES; HISTORY C1 [Bayhylle, Ruth] Univ Calif Los Angeles, Dept Informat Studies, Los Angeles, CA 90024 USA. [Bayhylle, Ruth] Native Amer Vet Grp, Los Angeles, CA USA. [Harada, Nancy] Vet Adm Greater Los Angeles Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Hlth Serv Res, Los Angeles, CA USA. [Villa, Valentine] Calif State Coll, Los Angeles, CA USA. [Villa, Valentine] Univ Calif Los Angeles, Sch Publ Hlth, Los Angeles, CA 90024 USA. NR 22 TC 0 Z9 0 U1 1 U2 2 PU U C L A, AMER INDIAN STUDIES CENTER PI LOS ANGELES PA 3220 CAMPBELL HALL, BOX 951548, LOS ANGELES, CA 90095-1548 USA SN 0161-6463 J9 AM INDIAN CULT RES J JI Am. Indian Cult. Res. J. PY 2009 VL 33 IS 3 BP 23 EP 33 PG 11 WC History SC History GA 502NB UT WOS:000270466000003 ER PT J AU Naik, A Dyer, C Kunik, M McCullough, L AF Naik, Aanand D. Dyer, Carmel B. Kunik, Mark E. McCullough, Laurence B. TI Patient Autonomy for the Management of Chronic Conditions: A Two-Component Re-Conceptualization SO AMERICAN JOURNAL OF BIOETHICS LA English DT Article DE autonomy; decision-making; capacity; executive control functions; older adults; functional assessment ID EXECUTIVE CONTROL FUNCTIONS; INFORMED CONSENT; DECISION-MAKING; ELDERLY PERSONS; CARE; IMPAIRMENT; COMPETENCE; INSTRUMENT; LITERACY; CAPACITY AB The clinical application of the concept of patient autonomy has centered on the ability to deliberate and make treatment decisions (decisional autonomy) to the virtual exclusion of the capacity to execute the treatment plan (executive autonomy). However, the one-component concept of autonomy is problematic in the context of multiple chronic conditions. Adherence to complex treatments commonly breaks down when patients have functional, educational, and cognitive barriers that impair their capacity to plan, sequence, and carry out tasks associated with chronic care. The purpose of this article is to call for a two-component re-conceptualization of autonomy and to argue that the clinical assessment of capacity for patients with chronic conditions should be expanded to include both autonomous decision-making and autonomous execution of the agreed-upon treatment plan. We explain how the concept of autonomy should be expanded to include both decisional and executive autonomy, describe the biopsychosocial correlates of the two-component concept of autonomy, and recommend diagnostic and treatment strategies to support patients with deficits in executive autonomy. C1 [Naik, Aanand D.; Kunik, Mark E.] Houston Ctr Qual Care Utilizat Studies, Baylor Coll Med, Michael DeBakey VA Med Ctr, Houston, TX USA. [McCullough, Laurence B.] Baylor Coll Med, Ctr Med Eth & Hlth Policy, Houston, TX 77030 USA. [Dyer, Carmel B.] Univ Texas Houston, Sch Med, Houston, TX USA. RP Naik, A (reprint author), Michael E DeBakey VA Med Ctr 152, Houston Ctr Qual Care & Utilizat Studies, 2002 Holcombe Blvd, Houston, TX 77030 USA. EM anaik@bcm.tmc.edu FU Houston Center for Quality of Care & Utilization Studies; Michael E. DeBakey Veterans Affairs Medical Center; Consortium for Research in Elder Self-Neglect of Texas (NIH) [P20-RR020626]; Greenwall Foundation; National Institute of Aging [K23AG027144]; [FP90-020] FX This article is the result of work supported with resources and the use of facilities at the Houston Center for Quality of Care & Utilization Studies (FP90-020), Michael E. DeBakey Veterans Affairs Medical Center, the Consortium for Research in Elder Self-Neglect of Texas (NIH P20-RR020626), and a bioethics grant from the Greenwall Foundation. Dr. Naik is also supported by the National Institute of Aging (K23AG027144). The authors would like to thank Sonora Hudson for her careful review of a prior version of the manuscript. NR 47 TC 34 Z9 34 U1 1 U2 6 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 1526-5161 J9 AM J BIOETHICS JI Am. J. Bioeth. PY 2009 VL 9 IS 2 BP 23 EP 30 AR PII 908346820 DI 10.1080/15265160802654111 PG 8 WC Ethics; Medical Ethics; Social Issues; Social Sciences, Biomedical SC Social Sciences - Other Topics; Medical Ethics; Social Issues; Biomedical Social Sciences GA 400ZG UT WOS:000262907300011 PM 19180389 ER PT J AU Naik, AD Dyer, CB Kunik, ME McCullough, LB AF Naik, Aanand D. Dyer, Carmel B. Kunik, Mark E. McCullough, Laurence B. TI Response to Commentaries on Patient Autonomy for the Management of Chronic Conditions: A Two-Component Re-Conceptualization SO AMERICAN JOURNAL OF BIOETHICS LA English DT Letter C1 [McCullough, Laurence B.] Baylor Coll Med, Ctr Med Eth & Hlth Policy, Houston, TX 77030 USA. [Dyer, Carmel B.] Univ Texas Houston, Sch Med, Houston, TX USA. RP Naik, A (reprint author), Houston Ctr Qual Care & Utilizat Studies, Michael E DeBakey VA Med Ctr 152, 2002 Holcombe Blvd, Houston, TX 77030 USA. EM anaik@bcm.tmc.edu FU NIA NIH HHS [K23 AG027144] NR 11 TC 4 Z9 4 U1 2 U2 2 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 1526-5161 J9 AM J BIOETHICS JI Am. J. Bioeth. PY 2009 VL 9 IS 2 BP W3 EP W5 AR PII 908347610 DI 10.1080/15265160802670984 PG 3 WC Ethics; Medical Ethics; Social Issues; Social Sciences, Biomedical SC Social Sciences - Other Topics; Medical Ethics; Social Issues; Biomedical Social Sciences GA 400ZG UT WOS:000262907300026 PM 19180379 ER PT J AU Stoelb, BL Jensen, MP Tackett, MJ AF Stoelb, Brenda L. Jensen, Mark P. Tackett, M. Jan TI Hypnotic Analgesia for Combat-Related Spinal Cord Injury Pain: A Case Study SO AMERICAN JOURNAL OF CLINICAL HYPNOSIS LA English DT Article DE Spinal cord injury; pain; chronic pain; hypnosis; self-hypnosis training ID VETERANS; HYPNOTHERAPY; NONVETERANS; PREVALENCE; DISABILITY; HYPNOSIS; SAMPLE; MEN AB A U.S. Army soldier stationed in Iraq developed myriad pain problems after sustaining a high-level spinal cord injury (SCI) from a gunshot wound. These problems were negatively impacting his ability to participate fully in his physical rehabilitation and care. Ten sessions of self-hypnosis training were administered to the patient over a 5-week period to help him address these problems. Both the patient and his occupational therapist reported a substantial reduction in pain over the course of treatment, which allowed the patient to actively engage in his therapies. Six months post treatment, the patient reported continued use of the hypnosis strategies taught, which effectively reduced his experience of pain. This case study demonstrates the efficacy of hypnotic analgesia treatment for U.S. military veterans who are experiencing pain problems due to traumatic or combat-related SCIs. C1 [Stoelb, Brenda L.; Jensen, Mark P.] Univ Washington, Dept Rehabil Med, Sch Med, Seattle, WA 98195 USA. [Tackett, M. Jan] VA Puget Sound Hlth Care Syst, Seattle, WA USA. RP Stoelb, BL (reprint author), Univ Washington, Dept Rehabil Med, Sch Med, 1959 NE Pacific St,Box 356490, Seattle, WA 98195 USA. EM bstoelb@u.washington.edu NR 25 TC 1 Z9 1 U1 0 U2 7 PU AMER SOC CLINICAL HYPNOSIS PI BLOOMINGDALE PA 140 N BLOOMINGDALE RD, BLOOMINGDALE, IL 60108-1017 USA SN 0002-9157 J9 AM J CLIN HYPN JI Am. J. Clin. Hypn. PD JAN PY 2009 VL 51 IS 3 BP 273 EP 280 PG 8 WC Psychology, Clinical SC Psychology GA 397SB UT WOS:000262681300005 PM 19216212 ER PT J AU Al-Ghananeem, AM Herman, BH Abbassi, M Yu, E Miotto, K O'Brien, CP Ling, W Montgomery, A Walsh, R AF Al-Ghananeem, Abeer M. Herman, Barbara H. Abbassi, Maggie Yu, Elmer Miotto, Karen O'Brien, Charles P. Ling, Walter Montgomery, Ann Walsh, Robert TI Urine and Plasma Pharmacokinetics of Lofexidine after Oral Delivery in Opiate-Dependent Patients SO AMERICAN JOURNAL OF DRUG AND ALCOHOL ABUSE LA English DT Article DE Clinical trial; lofexidine; oral delivery; pharmacokinetics; urine AB Objectives: The objective of this study was to investigate lofexidine urine and plasma pharmacokinetics using three different dosing regimens in opioid dependent subjects. To date, there have been no published studies on lofexidine appearance and excretion in urine of opioid dependent subjects. Methods: Subjects were stabilized with 100 mg morphine sulphate on days 3-8 of the study. The dosing regimens of lofexidine hydrochloride were .8 mg twice a day (BID), 1.2 mg BID, or .8 mg three times a day (TID) on days 9 through 16 of the study. Plasma and urine samples were collected at appropriate time points. Area under the concentration-time curve (AUC), maximum concentration in plasma (C(max)), time when maximum concentration was reached (T(max)) and fraction excreted unchanged in urine (Fe) were calculated. Results: The average half-life obtained from all profiles was 12.1 +/- 6.3 hr. Steady-state (SS) was reached by study day 15. The plasma pharmacokinetic parameters for 1.2 mg BID and .8 mg TID dosing regimens did not seem to be different at steady state (day 15). T(max) was not statistically significantly different across dosing regimens. Fe values ranged between .01% and 34% with high variability within the same dosing regimen. For the total dose of 2.4 mg/day the two dosing regimens that were evaluated, namely 1.2 mg BID and .8 mg TID, did not show a significant statistical difference in plasma and urine pharmacokinetic parameters. Conclusion: Although preliminary due to the limited number of subjects, these findings are the first to document lofexidine urine pharmacokinetics in opiate addicts using a highly sensitive liquid chromatography tandem mass spectrometric analysis. C1 [Al-Ghananeem, Abeer M.; Abbassi, Maggie] Univ Kentucky, Coll Pharm, Dept Pharmaceut Sci, Lexington, KY 40536 USA. [Herman, Barbara H.; Montgomery, Ann; Walsh, Robert] Natl Inst Drug Abuse, DPMCDA, NIH, Bethesda, MD USA. [Yu, Elmer; O'Brien, Charles P.] Univ Penn, Philadelphia, PA 19104 USA. [Yu, Elmer; O'Brien, Charles P.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. [Miotto, Karen; Ling, Walter] Univ Calif Los Angeles, David Geffen Sch Med, Long Beach Vet Affairs Med Ctr, Los Angeles, CA 90095 USA. RP Al-Ghananeem, AM (reprint author), Univ Kentucky, Coll Pharm, Dept Pharmaceut Sci, 927 Rose St, Lexington, KY 40536 USA. EM amalg0@email.uky.edu NR 17 TC 0 Z9 0 U1 1 U2 3 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 0095-2990 J9 AM J DRUG ALCOHOL AB JI Am. J. Drug Alcohol Abuse PY 2009 VL 35 IS 5 BP 311 EP 315 DI 10.1080/00952990903060135 PG 5 WC Psychology, Clinical; Substance Abuse SC Psychology; Substance Abuse GA 562EG UT WOS:000275031700009 PM 19637105 ER PT J AU Karlamangla, AS Sarkisian, CA Kado, DM Dedes, H Liao, DH Kim, S Reuben, DB Greendale, GA Moore, AA AF Karlamangla, Arun S. Sarkisian, Catherine A. Kado, Deborah M. Dedes, Howard Liao, Diana H. Kim, Sungjin Reuben, David B. Greendale, Gail A. Moore, Alison A. TI Light to Moderate Alcohol Consumption and Disability: Variable Benefits by Health Status SO AMERICAN JOURNAL OF EPIDEMIOLOGY LA English DT Article ID CORONARY-HEART-DISEASE; BODY-MASS INDEX; UNITED-STATES; OLDER PERSONS; FOLLOW-UP; LATE-LIFE; AGED 65; DRINKING; WOMEN; RISK AB In adults, light to moderate alcohol consumption is associated with lower risks for heart disease, diabetes, and mortality. This study examined whether light to moderate alcohol use is also associated with lower risk of incident physical disability over two 5-year periods in 4,276 noninstitutionalized adults in the United States, aged 50 years or older, by using data from 3 waves of the National Health and Nutrition Examination Survey Epidemiologic Follow-up Study surveys from 1982 to 1992. Light/moderate drinking (< 15 drinks per week and < 5 per drinking day or 4 per drinking day for women) was associated with reduced risk for incident disability or death over 5 years, compared with abstention (adjusted odds ratio = 0.77; P = 0.008). Among survivors, light/moderate drinking was associated with lower risk for incident disability, compared with abstention (adjusted odds ratio = 0.75; P = 0.009). In stratified analyses, disability risk decreased with light/moderate drinking in a dose-dependent fashion in men and women with good or better self-reported health but not in men or women with fair or worse self-reported health. Alcohol consumption in moderation might reduce the risk of developing physical disability in older adults in good health but not in those in poor health. C1 [Karlamangla, Arun S.; Kado, Deborah M.; Dedes, Howard; Liao, Diana H.; Kim, Sungjin; Reuben, David B.; Greendale, Gail A.; Moore, Alison A.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA. [Sarkisian, Catherine A.] VA Greater Los Angeles Healthcare Syst, Geriatr Res Educ & Clin Ctr, Los Angeles, CA USA. RP Moore, AA (reprint author), Div Geriatr, 10945 Le Conte Ave,Suite 2339, Los Angeles, CA 90095 USA. EM aamoore@mednet.ucla.edu FU John A. Hartford Foundation/American Federation for Aging Research Medical Student Geriatric Scholars Program; National Institute on Alcohol Abuse and Alcoholism [R01-AA-013937, R01-AA-013990, R01-DA-020944]; Claude D. Pepper Older Americans Independence Center; National Institute on Aging [5P30 AG028748] FX This work was supported by the John A. Hartford Foundation/American Federation for Aging Research Medical Student Geriatric Scholars Program (to H. D.); the National Institute on Alcohol Abuse and Alcoholism (grants R01-AA-013937, R01-AA-013990, and R01-DA-020944 to A. A. M.); and the Claude D. Pepper Older Americans Independence Center, National Institute on Aging (grant 5P30 AG028748 to A. S. K.). NR 45 TC 24 Z9 24 U1 0 U2 4 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0002-9262 J9 AM J EPIDEMIOL JI Am. J. Epidemiol. PD JAN 1 PY 2009 VL 169 IS 1 BP 96 EP 104 DI 10.1093/aje/kwn294 PG 9 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 390GL UT WOS:000262152200012 PM 19022829 ER PT J AU Muddana, V Whitcomb, DC Khalid, A Slivka, A Papachristou, GI AF Muddana, Venkata Whitcomb, David C. Khalid, Asif Slivka, Adam Papachristou, Georgios I. TI Elevated Serum Creatinine as a Marker of Pancreatic Necrosis in Acute Pancreatitis SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Article ID INTRAVENOUS CONTRAST-MEDIUM; NECROTIZING PANCREATITIS; COMPUTED-TOMOGRAPHY; RISK-FACTOR; HEMOCONCENTRATION; SEVERITY; MICROCIRCULATION; ANTIPROTEASES; IMPAIRMENT; FAILURE AB OBJECTIVES: Pancreatic necrosis is a serious complication of acute pancreatitis. The identification of simple laboratory tests to detect subjects at risk of pancreatic necrosis may direct management and improve outcome. This study focuses on the association between routine laboratory tests and the development of pancreatic necrosis in patients with acute pancreatitis. METHODS: In a cohort of 185 patients with acute pancreatitis prospectively enrolled in the Severity of Acute Pancreatitis Study, patients with contrast-enhanced computerized tomography performed were selected (n = 129). Serum hematocrit, creatinine, and urea nitrogen on admission and peak values within 48 h of admission were analyzed. The volume of intravenous fluid resuscitation was calculated for each patient. RESULTS: Of 129 patients, 35 (27%) had evidence of pancreatic necrosis. Receiver operating characteristic curves for pancreatic necrosis revealed an area under the curve of 0.79 for admission hematocrit, 0.77 for peak creatinine, and 0.72 for peak urea nitrogen. Binary logistic regression yielded that all three tests were significantly associated with pancreatic necrosis (P < 0.0001), with the highest odds ratio, 34.5, for peak creatinine. The volume of intravenous fluid resuscitation was similar in patients with and without necrosis. Low admission hematocrit (= 44.8%) yielded a negative predictive value of 89%; elevated peak creatinine (> 1.8 mg/dl) within 48 h yielded a positive predictive value of 93%. CONCLUSIONS: We confirm that a low admission hematocrit indicates a low risk of pancreatic necrosis (PNec) in patients with acute pancreatitis. In contrast, an increase in creatinine within the first 48 h is strongly associated with the development of PNec. This finding may have important clinical implications and warrants further investigation. C1 [Muddana, Venkata; Whitcomb, David C.; Khalid, Asif; Slivka, Adam; Papachristou, Georgios I.] Univ Pittsburgh, Sch Med, Dept Med, UPMC Presbyterian Hosp,Div Gastroenterol Hepatol, Pittsburgh, PA 15213 USA. [Whitcomb, David C.] Univ Pittsburgh, Sch Med, Dept Human Genet, Pittsburgh, PA 15213 USA. [Khalid, Asif; Papachristou, Georgios I.] Vet Affairs Pittsburgh Hlth Syst, Div Gastroenterol, Dept Med, Pittsburgh, PA USA. RP Papachristou, GI (reprint author), Univ Pittsburgh, Sch Med, Dept Med, UPMC Presbyterian Hosp,Div Gastroenterol Hepatol, Mezzanine Level 2,C Wing,200 Lothrop St, Pittsburgh, PA 15213 USA. EM papachristoug@dom.pitt.edu FU VA Stars and Stripes Healthcare Network 2007 Competitive Pilot Project Fund (GIP); NIH [R01 DK61451] FX This work was supported by the VA Stars and Stripes Healthcare Network 2007 Competitive Pilot Project Fund (GIP) and NIH R01 DK61451 (DCW). NR 32 TC 47 Z9 53 U1 0 U2 3 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0002-9270 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD JAN PY 2009 VL 104 IS 1 BP 164 EP 170 DI 10.1038/ajg.2008.66 PG 7 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 391WV UT WOS:000262265800027 PM 19098865 ER PT J AU Brandt, LJ Chey, WD Foxx-Orenstein, AE Quigley, EMM Schiller, LR Schoenfeld, PS Spiegel, BM Talley, NJ Moayyedi, P AF Brandt, Lawrence J. Chey, William D. Foxx-Orenstein, Amy E. Quigley, Eamonn M. M. Schiller, Lawrence R. Schoenfeld, Philip S. Spiegel, Brennan M. Talley, Nicholas J. Moayyedi, Paul TI An Evidence-Based Position Statement on the Management of Irritable Bowel Syndrome SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Review ID RANDOMIZED-CONTROLLED-TRIAL; QUALITY-OF-LIFE; PLACEBO-CONTROLLED TRIAL; INTESTINAL BACTERIAL OVERGROWTH; DOUBLE-BLIND TRIAL; 5-HT3 RECEPTOR ANTAGONIST; PREDOMINANCE IBS-D; CORTICOTROPIN-RELEASING HORMONE; CHRONIC IDIOPATHIC CONSTIPATION; COST-EFFECTIVENESS ANALYSIS C1 [Brandt, Lawrence J.; Moayyedi, Paul] Montefiore Med Ctr, Div Gastroenterol, Bronx, NY 10467 USA. [Chey, William D.] Univ Michigan Hlth Syst, Div Gastroenterol, Ann Arbor, MI USA. [Foxx-Orenstein, Amy E.] Mayo Clin, Dept Internal Med, Div Gastroenterol & Hepatol, Rochester, MN USA. [Quigley, Eamonn M. M.] Cork Univ Hosp, Dept Med, Cork, Ireland. [Schiller, Lawrence R.] Baylor Univ, Med Ctr, Digest Hlth Associates Texas, Dallas, TX USA. [Schoenfeld, Philip S.] Vet Affairs Ann Arbor Healthcare Syst, Div Gastroenterol, Ann Arbor, MI USA. [Spiegel, Brennan M.] Univ Calif Los Angeles, David Geffen Sch Med, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90095 USA. [Talley, Nicholas J.] Mayo Clin, Dept Med, Jacksonville, FL 32224 USA. [Moayyedi, Paul] McMaster Univ, Med Ctr, Div Gastroenterol, Dept Med, Hamilton, ON, Canada. RP Brandt, LJ (reprint author), Montefiore Med Ctr, Div Gastroenterol, 111 E 210 St, Bronx, NY 10467 USA. RI Talley, nicholas/D-5399-2013 OI Talley, nicholas/0000-0003-2537-3092 NR 320 TC 301 Z9 316 U1 7 U2 25 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0002-9270 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD JAN PY 2009 VL 104 SU 1 BP S1 EP S36 DI 10.1038/ajg.2008.122 PG 36 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 391XB UT WOS:000262266400001 ER PT J AU Frick, KD Burton, LC Clark, R Mader, SI Naughton, WB Burl, JB Greenough, WB Steinwachs, DM Leff, B AF Frick, Kevin D. Burton, Lynda C. Clark, Rebecca Mader, Scott I. Naughton, W. Bruce Burl, Jeffrey B. Greenough, William B., III Steinwachs, Donald M. Leff, Bruce TI Substitutive Hospital at Home for Older Persons: Effects on Costs SO AMERICAN JOURNAL OF MANAGED CARE LA English DT Article ID RANDOMIZED CONTROLLED-TRIAL; MINIMIZATION ANALYSIS; EARLY DISCHARGE; INPATIENT INTERVENTIONS; CARE; HEALTH; PROGRAM AB Objective:To compare the cost of substitutive Hospital at Home care versus traditional inpatient care for older patients with community-acquired pneumonia, exacerbation of chronic obstructive pulmonary disease, exacerbation of congestive heart failure, or cellulitis. Study Design: Prospective nonrandomized clinical trial involving 455 community-dwelling older patients in 3 Medicare managed care health systems and at a Department of Veterans Affairs medical center. Methods: Costs were analyzed across all patients, within each of the separate health systems, and by condition. Generalized linear models controlling for confounders and using a log link and gamma family specification were used to make inferences about the statistical significance of cost differences. tTests were used to make inferences regarding differences in follow-up utilization. Results: The costs of the Hospital at Home intervention were significantly lower than those of usual acute hospital care (mean [SD], $5081 [$4427] vs $7480 [$8113]; P<.001). Laboratory and procedure expenditures were lower across all study sites and at each site individually. There were minimal significant differences in health service utilization between the study groups during the 8 weeks after the index hospitalization. As-treated analysis results were consistent with Hospital at Home costs being lower. Conclusions: Total costs seem to be lower when substitutive Hospital at Home care is available for patients with congestive heart failure or chronic obstructive pulmonary disease. This result may be related to the study-based requirement for continuous nursing input. Savings may be possible, particularly for care of conditions that typically use substantial laboratory tests and procedures in traditional acute settings. C1 [Frick, Kevin D.; Burton, Lynda C.; Clark, Rebecca; Naughton, W. Bruce; Steinwachs, Donald M.; Leff, Bruce] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD 21205 USA. [Mader, Scott I.] Portland VA Med Ctr, Portland, OR USA. [Mader, Scott I.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Naughton, W. Bruce] SUNY Buffalo, Buffalo, NY 14260 USA. [Burl, Jeffrey B.] Fallon Clin Inc, Worcester, MA USA. [Naughton, W. Bruce; Leff, Bruce] Johns Hopkins Sch Med, Baltimore, MD USA. RP Frick, KD (reprint author), Johns Hopkins Bloomberg Sch Publ Hlth, 624 N Broadway,Rm 606, Baltimore, MD 21205 USA. EM kfrick@jhsph.edu FU John A. Hartford Foundation of New York [98309-G]; Department of Veterans Affairs New Clinical Initiative [99-027a] FX This study was supported by grant 98309-G from the John A. Hartford Foundation of New York and was supplemented at Portland Veterans Affairs Medical Center by Department of Veterans Affairs New Clinical Initiative Program grant 99-027a. NR 32 TC 9 Z9 9 U1 1 U2 1 PU MANAGED CARE & HEALTHCARE COMMUNICATIONS LLC PI PLAINSBORO PA 666 PLAINSBORO RD, STE 300, PLAINSBORO, NJ 08536 USA SN 1088-0224 J9 AM J MANAG CARE JI Am. J. Manag. Care PD JAN PY 2009 VL 15 IS 1 BP 49 EP 56 PG 8 WC Health Care Sciences & Services; Health Policy & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 400HA UT WOS:000262857400005 PM 19146364 ER PT J AU Smith, MEB Desai, SS Allen, ES Saha, S Hunter, AJ AF Smith, M. E. Beth Desai, Sima S. Allen, Elizabeth S. Saha, Somnath Hunter, Alan J. TI Impact of Shorter Inpatient Faculty Rotations on Resident Learning Experience SO AMERICAN JOURNAL OF MEDICINE LA English DT Article; Proceedings Paper CT National Meeting of the Alliance-for-Academic-Internal-Medicine CY OCT, 2006 CL New Orleans, LA SP Alliance Acad Internal Med ID MEDICAL-EDUCATION; FACTORIAL VALIDATION; PHYSICIAN BURNOUT; INTERNAL-MEDICINE; CARE; STRATEGIES; FRAMEWORK; PROGRAM; NIH C1 [Smith, M. E. Beth] Oregon Hlth & Sci Univ, Div Gen Med & Geriatr, Portland, OR 97239 USA. [Desai, Sima S.; Hunter, Alan J.] Oregon Hlth & Sci Univ, Div Hosp Med, Dept Med, Portland, OR 97239 USA. [Allen, Elizabeth S.; Saha, Somnath] Portland VA Med Ctr, Div Gen Med & Geriatr, Portland, OR USA. RP Smith, MEB (reprint author), Oregon Hlth & Sci Univ, Div Gen Med & Geriatr, 3181 SW Sam Jackson Pk Rd,Mail Code CH9G, Portland, OR 97239 USA. EM smithbet@ohsu.edu NR 21 TC 2 Z9 2 U1 1 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-9343 J9 AM J MED JI Am. J. Med. PD JAN PY 2009 VL 122 IS 1 BP 96 EP 100 DI 10.1016/j.amjmed.2008.09.031 PG 5 WC Medicine, General & Internal SC General & Internal Medicine GA 387XZ UT WOS:000261986200018 PM 19114177 ER PT J AU Shlipak, MG Katz, R Kestenbaum, B Fried, LF Newman, AB Siscovick, DS Stevens, L Sarnak, MJ AF Shlipak, Michael G. Katz, Ronit Kestenbaum, Bryan Fried, Linda F. Newman, Anne B. Siscovick, David S. Stevens, Lesley Sarnak, Mark J. TI Rate of Kidney Function Decline in Older Adults: A Comparison Using Creatinine and Cystatin C SO AMERICAN JOURNAL OF NEPHROLOGY LA English DT Article DE Glomerular filtration rate; Creatinine; Cystatin C; Chronic kidney disease ID GLOMERULAR-FILTRATION-RATE; CORONARY-HEART-DISEASE; STAGE RENAL-DISEASE; CARDIOVASCULAR EVENTS; MORTALITY RISK; SERUM CREATININE; PROGRESSION; GFR; FAILURE; DEATH AB Background/Aims: The aim of this study was to determine the decline in the estimated glomerular filtration rate (eGFR) in elderly persons and to compare estimates based on creatinine and cystatin C. Methods: In the Cardiovascular Health Study, GFR changes in an elderly cohort were estimated from serum creatinine and cystatin C measured at baseline, year 3 and year 7 in 4,380 participants (age 72 +/- 5 years at entry). Outcomes were mean eGFR decline, incident chronic kidney disease (CKD) and rapid decline in eGFR (annual loss >3 ml/min/1.73 m(2)). Results: Mean annual eGFR loss as estimated from creatinine was 0.4 +/- 3.6 ml/min/1.73 m(2), with 16% of the participants experiencing a rapid decline. Mean eGFR loss as estimated from cystatin C was 1.8 +/- 2.6, with 25% of the participants experiencing a rapid decline (p<0.001 for both). Among participants without baseline CKD, incident CKD was detected at year 7 in 10% (n=263) using creatinine and 19% (n=544) using cystatin C (p<0.001). Increasing age was the strongest predictor of rapid decline; adjusted odds ratios were 1.38 (1.16-1.65), 1.62 (1.31-1.99) and 2.96 (2.28-3.84) for participants aged 70-74, 75-79 and 80+ at baseline, compared with those aged 65-69. Conclusion: In elderly persons, cystatin C estimated substantially larger declines in kidney function than creatinine did. Defining the optimal measurement of kidney function in elderly persons should be a high priority for future research. Copyright (C) 2009 S. Karger AG, Basel C1 [Shlipak, Michael G.] Univ Calif San Francisco, Gen Internal Med Sect, San Francisco VA Med Ctr, San Francisco, CA 94143 USA. [Shlipak, Michael G.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Shlipak, Michael G.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. [Katz, Ronit] Univ Washington, Collaborat Hlth Studies Coordinating Ctr, Dept Biostat, Seattle, WA 98195 USA. [Kestenbaum, Bryan] Univ Washington, Sch Med, Div Nephrol, Seattle, WA USA. [Fried, Linda F.] Univ Pittsburgh, Grad Sch Publ Hlth, Renal Sect, Med Serv,VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Newman, Anne B.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA USA. [Newman, Anne B.] Univ Pittsburgh, Sch Med, Div Geriatr Med, Pittsburgh, PA USA. [Siscovick, David S.] Univ Washington, Dept Med, Seattle, WA USA. [Siscovick, David S.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. [Stevens, Lesley; Sarnak, Mark J.] Tufts Med Ctr, Div Nephrol, Dept Med, Boston, MA USA. RP Shlipak, MG (reprint author), VA Med Ctr 111A1, Gen Internal Med Sect, 4150 Clement St, San Francisco, CA 94121 USA. EM michael.shlipak@ucsf.edu RI Newman, Anne/C-6408-2013 OI Newman, Anne/0000-0002-0106-1150 FU National Heart, Lung and Blood Institute (NHLBI) [R01 HL073208-01, R01 DK066488]; National Institute of Diabetes and Digestive and Kidney Diseases; National Institutes of Health [R01AG027002, K24DK078204-01]; NHLBI [N01-HC-85079, N01-HC-85086, N01-HC-35129, N01 HC-15103] FX This work was supported by contracts R01 HL073208-01 and R01 DK066488 from the National Heart, Lung and Blood Institute (NHLBI) and the National Institute of Diabetes and Digestive and Kidney Diseases, respectively. In addition, this work was supported by the American Federation for Aging Research by a Paul Beeson Scholars Program award and R01AG027002 and K24DK078204-01 from the National Institutes of Health. The CHS is supported by contracts N01-HC-85079 through N01-HC-85086, N01-HC-35129, and N01 HC-15103 from the NHLBI. This study was funded through contracts with the NHLBI and included substantial NHLBI involvement in data collection, analysis and interpretation, as well as manuscript preparation. A full list of participating CHS investigators and institutions can be found at http://www.chs-nhlbi.org. NR 27 TC 60 Z9 63 U1 1 U2 4 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 0250-8095 J9 AM J NEPHROL JI Am. J. Nephrol. PY 2009 VL 30 IS 3 BP 171 EP 178 DI 10.1159/000212381 PG 8 WC Urology & Nephrology SC Urology & Nephrology GA 485PN UT WOS:000269136000001 PM 19349699 ER PT J AU Fried, LF Katz, R Cushman, M Sarnak, M Shlipak, MG Kuller, L Newman, AB AF Fried, Linda F. Katz, Ronit Cushman, Mary Sarnak, Mark Shlipak, Michael G. Kuller, Lewis Newman, Anne B. TI Change in Cardiovascular Risk Factors with Progression of Kidney Disease SO AMERICAN JOURNAL OF NEPHROLOGY LA English DT Article; Proceedings Paper CT 46th Annual Conference on Cardiovascular Disease Epidemiology and Prevention CY MAR 02-05, 2006 CL Phoenix, AZ SP Amer Heart Assoc, Natl Heart, Lung & Blood Inst DE Cardiovascular risk factors; Chronic kidney disease; Disease progression; Inflammation; Lipids ID C-REACTIVE PROTEIN; RENAL-INSUFFICIENCY; VENOUS THROMBOEMBOLISM; ELDERLY PERSONS; CYSTATIN-C; MORTALITY; HEALTH; ATHEROSCLEROSIS; INFLAMMATION; CLEARANCE AB Background: Prior studies evaluating the relationship of kidney disease with cardiovascular risk factors have been limited by their cross-sectional design. We evaluated the change in lipids, inflammatory and procoagulant biomarkers with decline in kidney function in a nested case-cohort study in the Cardiovascular Health Study, a community-based study of adults aged >65 years. Methods: Individuals with an increase in serum creatinine >= 0.3 mg/dl (baseline to 3 years later, n = 207) were matched to controls of similar age, race, gender, diabetes and baseline serum creatinine, but whose change in creatinine was <0.3 mg/dl. Baseline and change in risk factors were analyzed with conditional logistic regression. Results: Changes in C-reactive protein were similar. In contrast, cases had larger increases in fibrinogen (OR 1.38 per standard deviation, 95% confidence interval 1.08-1.76) and factor VIII [1.38 (1.10-1.72)] and larger decreases in HDL [OR 0.80 (0.64, 1.00)]. Change in interleukin-6 was greater in cases than controls, but this did not persist after multivariate adjustment. However, in linear regression, change in interleukin-6 was correlated with change in creatinine. Conclusion: Cardiovascular risk factors and kidney function may change concurrently. This could lead to an increased risk of cardiovascular disease as kidney function worsens. Copyright (C) 2008 S. Karger AG, Basel C1 [Fried, Linda F.] VA Pittsburgh Healthcare Syst, Renal Sect, Univ Dr Div, Pittsburgh, PA 15240 USA. [Fried, Linda F.; Newman, Anne B.] Univ Pittsburgh, Sch Med, Dept Med, Pittsburgh, PA USA. [Fried, Linda F.; Kuller, Lewis; Newman, Anne B.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA USA. [Katz, Ronit] Univ Washington, Coordinating Ctr, Seattle, WA 98195 USA. [Cushman, Mary] Univ Vermont, Dept Med, Thrombosis & Hemostasis Program, Burlington, VT 05401 USA. [Sarnak, Mark] Tufts Med Ctr, Dept Med, Div Nephrol, Boston, MA USA. [Shlipak, Michael G.] Univ Calif San Francisco, Gen Internal Med Sect, San Francisco Vet Affairs Med Ctr, San Francisco, CA 94143 USA. [Shlipak, Michael G.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA. [Shlipak, Michael G.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. RP Fried, LF (reprint author), VA Pittsburgh Healthcare Syst, Renal Sect, Univ Dr Div, Mailstop 111F-U, Pittsburgh, PA 15240 USA. EM linda.fried@va.gov RI Newman, Anne/C-6408-2013 OI Newman, Anne/0000-0002-0106-1150 FU NHLBI NIH HHS [N01 HC015103, N01 HC-55222, N01 HC035129, N01 HC045133, N01-HC-75150, N01-HC-85079, N01-HC-85080, N01-HC-85081, N01-HC-85082, N01-HC-85083, N01-HC-85084, N01-HC-85085, N01-HC-85086, N01HC55222, N01HC75150, N01HC85079, N01HC85086, U01 HL080295]; NIA NIH HHS [R01 AG027002] NR 31 TC 7 Z9 8 U1 1 U2 3 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 0250-8095 J9 AM J NEPHROL JI Am. J. Nephrol. PY 2009 VL 29 IS 4 BP 334 EP 341 DI 10.1159/000166598 PG 8 WC Urology & Nephrology SC Urology & Nephrology GA 375RX UT WOS:000261132100007 PM 18948687 ER PT J AU Jolly, SE Li, S Chen, SC Narva, AS Jurkovitz, CT Norris, KC Shlipak, MG AF Jolly, Stacey E. Li, Suying Chen, Shu-Cheng Narva, Andrew S. Jurkovitz, Claudine T. Norris, Keith C. Shlipak, Michael G. TI Risk Factors for Chronic Kidney Disease among American Indians and Alaska Natives - Findings from the Kidney Early Evaluation Program SO AMERICAN JOURNAL OF NEPHROLOGY LA English DT Article DE Chronic kidney disease; Risk factors; American Indians; Alaska Natives ID GLOMERULAR-FILTRATION-RATE; TYPE-2 DIABETES-MELLITUS; SERUM CREATININE VALUES; STAGE RENAL-DISEASE; UNITED-STATES; COLLABORATIVE APPROACH; NATIONAL-HEALTH; HEART-FAILURE; PIMA-INDIANS; FOLLOW-UP AB Background: American Indians and Alaska Natives (AIAN) have a high incidence of end-stage renal disease. Less is known about chronic kidney disease (CKD) among AIAN and whether risk factors differ for low estimated glomerular filtration rate (eGFR) versus albuminuria with a normal eGFR. Methods: Cross-sectional study examining the associations of age, sex, smoking, obesity, diabetes, hypertension, family history, and geographic region with CKD among a screened population of AIAN participants in the Kidney Early Evaluation Program from 2000 to 2006. CKD was defined by the presence of either a low eGFR, < 60 ml/min/1.73 m(2), or albuminuria, a urine albumin/creatinine ratio >= 30 mg/g. Results: The prevalence of any CKD was 29%, of low eGFR was 17%, and of albuminuria with a normal eGFR was 12%. Older age was the strongest predictor of low eGFR (61+ years OR 8.42, 95% Cl 5.92-11.98), followed by hypertension (OR 2.38, 95% Cl 1.74-3.26). In contrast, diabetes (OR 2.04, 95% Cl 1.57-2.64) and hypertension (OR 2.63, 95% Cl 1.93-3.59) were the only predictors of albuminuria among persons with a normal eGFR. Conclusion: The burden of CKD was high among this screened population of AIAN, and different risk factor patterns were associated with low eGFR and albuminuria. Innovative programs and longitudinal research are needed to address CKD among AIAN. Copyright (c) 2008 S. Karger AG, Basel C1 [Jolly, Stacey E.; Shlipak, Michael G.] Univ Calif San Francisco, Div Gen Internal Med, San Francisco, CA 94143 USA. [Li, Suying; Chen, Shu-Cheng] Minneapolis Med Res Fdn Inc, Chron Dis Res Grp, Minneapolis, MN USA. [Narva, Andrew S.] NIDDK, Bethesda, MD USA. [Jurkovitz, Claudine T.] Christiana Care Hlth Syst, Ctr Outcomes Res, Newark, DE USA. [Norris, Keith C.] Charles R Drew Univ, Dept Internal Med, Los Angeles, CA USA. [Shlipak, Michael G.] San Francisco VA Med Ctr, San Francisco, CA USA. RP Jolly, SE (reprint author), Univ Calif San Francisco, San Francisco Gen Hosp, Div Gen Internal Med, Campus Mailbox 1364, San Francisco, CA 94143 USA. EM stacey.jolly@ucsf.edu FU Health Resources and Services Administration Faculty Development [D55HP05165]; American Heart Association's Established Investigator; [R01-DK066488]; [R01-AG027002] FX Dr. Jolly was supported by Health Resources and Services Administration Faculty Development in Primary Care Grant D55HP05165 for this study. Dr. Shlipak's effort on this paper was supported by R01-DK066488, R01-AG027002, and the American Heart Association's Established Investigator Award. NR 32 TC 9 Z9 9 U1 0 U2 0 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 0250-8095 J9 AM J NEPHROL JI Am. J. Nephrol. PY 2009 VL 29 IS 5 DI 10.1159/000174857 PG 7 WC Urology & Nephrology SC Urology & Nephrology GA 428SO UT WOS:000264870200014 PM 19011277 ER PT J AU Slack, D Nelson, L Patterson, D Burns, S Hakimi, K Robinson, L AF Slack, David Nelson, Lonnie Patterson, David Burns, Stephen Hakimi, Kevin Robinson, Lawrence TI The Feasibility of Hypnotic Analgesia in Ameliorating Pain and Anxiety Among Adults Undergoing Needle Electromyography SO AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION LA English DT Article DE Electromyography (EMG); Hypnosis; Hypnotic Analgesia ID HYPNOSIS; PERCEPTION; ABSORPTION; DISTRESS; OPENNESS; CANCER AB Objective: Our hypothesis was that hypnotic analgesia reduces pain and anxiety during electromyography (EMG). Design: We performed a prospective randomized, controlled clinical trial at outpatient electrodiagnostic clinics in teaching hospitals. Just before EMG, 26 subjects were randomized to one of three 20-min audio programs: education about EMG (EDU) (n = 8); hypnotic induction without analgesic suggestion (n = 10); or hypnotic induction with analgesic suggestion (n = 8). The blinded electromyographer provided a posthypnotic suggestion at the start of EMG. After EMG, subjects rated worst and average pain and anxiety using visual analog scales. Results: Mean values for the EDU, hypnotic induction without analgesic suggestion, and hypnotic induction with analgesic suggestion groups were not significantly different (mean +/- SD): worst pain 67 +/- 25, 42 +/- 18, and 49 +/- 30; average pain 35 +/- 26, 27 +/- 14, and 25 +/- 22; and anxiety 44 +/- 41, 42 +/- 23, and 22 +/- 24. When hypnosis groups were merged (n = 18) and compared with the EDU condition (n = 8), average and worst pain and anxiety were less for the hypnosis group than EDU, but this was statistically significant only for worst pain (hypnosis, 46 +/- 24 vs. EDU, 67 +/- 35; P = 0.049) with a 31% average reduction. Conclusions: A short hypnotic induction seems to reduce worst pain during electromyography. C1 [Nelson, Lonnie; Patterson, David; Burns, Stephen; Hakimi, Kevin; Robinson, Lawrence] Univ Washington, Harborview Med Ctr, Sch Med,Dept Rehabil Med, Electrodiagnost Clin, Seattle, WA 98195 USA. [Slack, David] Vet Affairs Puget Sound Hlth Care Syst, Rehabil Care Serv, Electrodiagnost Clin, Seattle, WA USA. RP Robinson, L (reprint author), Univ Washington, Harborview Med Ctr, Sch Med,Dept Rehabil Med, Electrodiagnost Clin, Box 356380, Seattle, WA 98195 USA. FU National Institutes of Health [R01 GM42725-09A1] FX This study was supported in part by grant R01 GM42725-09A1 from the National Institutes of Health. NR 24 TC 10 Z9 10 U1 2 U2 6 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0894-9115 J9 AM J PHYS MED REHAB JI Am. J. Phys. Med. Rehabil. PD JAN PY 2009 VL 88 IS 1 BP 21 EP 29 DI 10.1097/PHM.0b013e31818e00bd PG 9 WC Rehabilitation; Sport Sciences SC Rehabilitation; Sport Sciences GA 388NS UT WOS:000262027100004 PM 18971768 ER PT J AU Quinn, LS Anderson, BG Strait-Bodey, L Stroud, AM Argiles, JM AF Quinn, LeBris S. Anderson, Barbara G. Strait-Bodey, Lena Stroud, Ashley M. Argiles, Josep M. TI Oversecretion of interleukin-15 from skeletal muscle reduces adiposity SO AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM LA English DT Article DE adipose tissue; obesity; cytokines; adipokines; myokines; bone; skeletal muscle; interleukin-15; body composition ID MECHANISMS LINKING OBESITY; TUMOR-BEARING RATS; INSULIN-RESISTANCE; BODY-COMPOSITION; TRANSGENIC MICE; NATURAL-KILLER; ENERGY-BALANCE; CRUCIAL ROLE; FAT; IL-15 AB Quinn LS, Anderson BG, Strait-Bodey L, Stroud AM, Argiles JM. Oversecretion of interleukin-15 from skeletal muscle reduces adiposity. Am J Physiol Endocrinol Metab 296: E191-E202, 2009. First published November 11, 2008; doi: 10.1152/ajpendo.90506.2008.-Obesity is a risk factor for development of insulin resistance, type 2 diabetes, cardiovascular disease, osteoarthritis, and some forms of cancer. Many of the adverse health consequences of excess fat deposition are caused by increased secretion of proinflammatory adipokines by adipose tissue. Reciprocal muscle-to-fat signaling factors, or myokines, are starting to be identified. Interleukin-15 (IL-15) is a cytokine that is highly expressed in muscle tissue and that, on the basis of cell culture experiments, has been proposed to act as a circulating myokine that inhibits adipose tissue deposition. To test this hypothesis in vivo, two lines of transgenic mice that overexpressed IL-15 mRNA and protein in skeletal muscle tissue were constructed. By substitution of the inefficient native IL-15 signal peptide with a more efficient signal peptide, one of the transgenic mouse lines also exhibited elevated secretion of IL-15 in the circulation. Overexpression of IL-15 in muscle tissue without secretion in the bloodstream resulted in no differences in body composition. Elevated circulating levels of IL-15 resulted in significant reductions in body fat and increased bone mineral content, without appreciably affecting lean body mass or levels of other cytokines. Elevated circulating levels of IL-15 also inhibited adiposity induced by consumption of a high-fat/high-energy diet in male, but not female, transgenic mice. Female mice with elevated serum IL-15 exhibited increased deposition of lean body mass on a low-fat/low-energy diet and a high-fat/high-energy diet. These findings indicate that muscle-derived circulating IL-15 can modulate adipose tissue deposition and support addition of IL-15 to the growing list of potential myokines that are increasingly being implicated in regulation of body composition. C1 [Quinn, LeBris S.] VA Puget Sound Hlth Care Syst, Amer Lake Div 151, Ctr Geriatr Res Educ & Clin, Tacoma, WA 98493 USA. [Strait-Bodey, Lena; Stroud, Ashley M.] VA Puget Sound Hlth Care Syst, Res Serv, Tacoma, WA 98493 USA. [Quinn, LeBris S.; Anderson, Barbara G.] Univ Washington, Dept Med, Div Gerontol & Geriatr Med, Seattle, WA USA. [Quinn, LeBris S.; Stroud, Ashley M.] Seattle Inst Biomed & Clin Res, Seattle, WA USA. [Argiles, Josep M.] Univ Barcelona, Fac Biol, Dept Biochem & Mol Biol, Barcelona, Spain. RP Quinn, LS (reprint author), VA Puget Sound Hlth Care Syst, Amer Lake Div 151, Ctr Geriatr Res Educ & Clin, Tacoma, WA 98493 USA. EM quinnL@u.washington.edu FU United States Department of Agriculture Cooperative State Research, Education [2005-35206-15264]; National Institute on Aging (NIA) [RO1AG-024136, 5P30AG-013280]; National Institute of Diabetes and Digestive and Kidney Diseases [5P30DK-17047] FX This work was supported by National Research Initiative Competitive Grant no. 2005-35206-15264 from the United States Department of Agriculture Cooperative State Research, Education, and Extension Service Animal Growth and Nutrient Utilization Program to L. S. Quinn, National Institute on Aging (NIA) Grant RO1AG-024136 ( L. S. Quinn), the Transgenic Resource Core of the University of Washington Nathan Shock Center of Excellence in the Basic Biology of Aging (NIA Grant 5P30AG-013280), the Molecular Genetics Core of the University of Washington Diabetes Endocrinology Research Center ( National Institute of Diabetes and Digestive and Kidney Diseases Grant 5P30DK-17047), and by use of resources and facilities at the Veterans Affairs Puget Sound Health Care System, Seattle/Tacoma, WA. NR 74 TC 73 Z9 79 U1 0 U2 12 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0193-1849 J9 AM J PHYSIOL-ENDOC M JI Am. J. Physiol.-Endocrinol. Metab. PD JAN PY 2009 VL 296 IS 1 BP E191 EP E202 DI 10.1152/ajpendo.90506.2008 PG 12 WC Endocrinology & Metabolism; Physiology SC Endocrinology & Metabolism; Physiology GA 388XU UT WOS:000262054400022 PM 19001550 ER PT J AU Bem, RA van Woensel, JBM Bos, AP Koski, A Farnand, AW Domachowske, JB Rosenberg, HF Martin, TR Matute-Bello, G AF Bem, Reinout A. van Woensel, Job B. M. Bos, Albert P. Koski, Amy Farnand, Alex W. Domachowske, Joseph B. Rosenberg, Helene F. Martin, Thomas R. Matute-Bello, Gustavo TI Mechanical ventilation enhances lung inflammation and caspase activity in a model of mouse pneumovirus infection SO AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY LA English DT Article DE respiratory syncytial virus; acute lung injury ID RESPIRATORY SYNCYTIAL VIRUS; EPITHELIAL-CELL APOPTOSIS; TIDAL VOLUME VENTILATION; DISTRESS-SYNDROME; PNEUMONIA VIRUS; ORGAN DYSFUNCTION; VIRAL BRONCHIOLITIS; CYTOKINE RESPONSE; FAS LIGAND; RAT LUNGS AB Bem RA, van Woensel JB, Bos AP, Koski A, Farnand AW, Domachowske JB, Rosenberg HF, Martin TR, Matute-Bello G. Mechanical ventilation enhances lung inflammation and caspase activity in a model of mouse pneumovirus infection. Am J Physiol Lung Cell Mol Physiol 296: L46-L56, 2009. First published November 7, 2008; doi:10.1152/ajplung.00467.2007.-Severe infection with respiratory syncytial virus (RSV) in children can progress to respiratory distress and acute lung injury (ALI). Accumulating evidence suggests that mechanical ventilation (MV) is an important cofactor in the development of ALI by modulating the host immune responses to bacteria. This study investigates whether MV enhances the host response to pneumonia virus of mice (PVM), a mouse pneumovirus that has been used as a model for RSV infection in humans. BALB/c mice were inoculated intranasally with diluted clarified lung homogenates from mice infected with PVM strain J3666 or uninfected controls. Four days after inoculation, the mice were subjected to 4 h of MV (tidal volume, 10 ml/kg) or allowed to breathe spontaneously. When compared with that of mice inoculated with PVM only, the administration of MV to PVM-infected mice resulted in increased bronchoalveolar lavage fluid concentrations of the cytokines macrophage inflammatory protein (MIP)-2, MIP-1 alpha (CCL3), and IL-6; increased alveolar-capillary permeability to high molecular weight proteins; and increased caspase-3 activity in lung homogenates. We conclude that MV enhances the activation of inflammatory and caspase cell death pathways in response to pneumovirus infection. We speculate that MV potentially contributes to the development of lung injury in patients with RSV infection. C1 [Bem, Reinout A.; van Woensel, Job B. M.; Bos, Albert P.] Univ Amsterdam, Acad Med Ctr, Pediat Intens Care Unit, Emma Childrens Hosp, NL-1105 AZ Amsterdam, Netherlands. [Koski, Amy; Martin, Thomas R.] Univ Washington, Sch Med, Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA. [Farnand, Alex W.; Matute-Bello, Gustavo] Univ Washington, Sch Med, Dept Med, Ctr Lung Biol,Div Pulm & Crit Care Med, Seattle, WA 98195 USA. [Domachowske, Joseph B.] SUNY Upstate Med Univ, Syracuse, NY USA. [Rosenberg, Helene F.] NIAID, Lab Allerg Dis, NIH, Bethesda, MD 20892 USA. RP Matute-Bello, G (reprint author), Univ Washington Med, S Lake Union Campus,815 Mercer St,Box 358052, Seattle, WA 98109 USA. FU National Heart, Lung, and Blood Institute [HL-083044, HL-073996]; American Lung Association FX This work was supported in part by National Heart, Lung, and Blood Institute Grants HL-083044 and HL-073996 and by the American Lung Association. NR 57 TC 21 Z9 22 U1 0 U2 0 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 1040-0605 J9 AM J PHYSIOL-LUNG C JI Am. J. Physiol.-Lung Cell. Mol. Physiol. PD JAN PY 2009 VL 296 IS 1 BP L46 EP L56 DI 10.1152/ajplung.00467.2007 PG 11 WC Physiology; Respiratory System SC Physiology; Respiratory System GA 388YR UT WOS:000262056900007 PM 18996903 ER PT J AU Figlewicz, DP Benoit, SC AF Figlewicz, Dianne P. Benoit, Stephen C. TI Insulin, leptin, and food reward: update 2008 SO AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY LA English DT Review DE motivation; food intake; dopamine ID CENTRAL-NERVOUS-SYSTEM; BLOOD-BRAIN-BARRIER; MELANIN-CONCENTRATING HORMONE; HYPOTHALAMIC NEUROPEPTIDE-Y; VENTRAL TEGMENTAL AREA; OBESE ZUCKER RATS; CONDITIONED PLACE PREFERENCE; RECEPTOR MESSENGER-RNA; AGOUTI-RELATED PEPTIDE; MODERATE-FAT DIET AB Figlewicz DP, Benoit SC. Insulin, leptin, and food reward: update 2008. Am J Physiol Regul Integr Comp Physiol 296: R9-R19, 2009. First published October 22, 2008; doi:10.1152/ajpregu.90725.2008.- The hormones insulin and leptin have been demonstrated to act in the central nervous system (CNS) as regulators of energy homeostasis at medial hypothalamic sites. In a previous review, we described new research demonstrating that, in addition to these direct homeostatic actions at the hypothalamus, CNS circuitry that subserves reward and motivation is also a direct and an indirect target for insulin and leptin action. Specifically, insulin and leptin can decrease food reward behaviors and modulate the function of neurotransmitter systems and neural circuitry that mediate food reward, i.e., midbrain dopamine and opioidergic pathways. Here we summarize new behavioral, systems, and cellular evidence in support of this hypothesis and in the context of research into the homeostatic roles of both hormones in the CNS. We discuss some current issues in the field that should provide additional insight into this hypothetical model. The understanding of neuroendocrine modulation of food reward, as well as food reward modulation by diet and obesity, may point to new directions for therapeutic approaches to overeating or eating disorders. C1 [Figlewicz, Dianne P.] VA Puget Sound Hlth Care Syst, Seattle Div, Seattle, WA 98108 USA. [Figlewicz, Dianne P.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Benoit, Stephen C.] Univ Cincinnati, Dept Psychiat, Cincinnati, OH USA. RP Figlewicz, DP (reprint author), VA Puget Sound Hlth Care Syst, Seattle Div, 1660 So Columbian Way, Seattle, WA 98108 USA. EM latte@u.washington.edu FU Department of Veterans Affairs; National Institute of Diabetes and Digestive and Kidney Diseases [DK-40963, DK-066223] FX This work is supported by a Career Scientist Award from the Department of Veterans Affairs and National Institute of Diabetes and Digestive and Kidney Diseases Grants DK-40963 (D. P. Figlewicz, Lattemann) and DK-066223 (S. C. Benoit). NR 198 TC 102 Z9 104 U1 5 U2 10 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0363-6119 EI 1522-1490 J9 AM J PHYSIOL-REG I JI Am. J. Physiol.-Regul. Integr. Comp. Physiol. PD JAN PY 2009 VL 296 IS 1 BP R9 EP R19 DI 10.1152/ajpregu.90725.2008 PG 11 WC Physiology SC Physiology GA 388YM UT WOS:000262056300002 PM 18945945 ER PT J AU Nazeer, K Janech, MG Lin, JJC Ryan, KJ Arthur, JM Budisavljevic, MN AF Nazeer, Khurram Janech, Michael G. Lin, Jim J. -C. Ryan, Kevin J. Arthur, John M. Budisavljevic, Milos N. TI Changes in protein profiles during course of experimental glomerulonephritis SO AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY LA English DT Article DE two-dimensional electrophoresis; mass spectrometry; anti-Thy-1 glomerulonephritis; tropomyosin ID MESANGIAL PROLIFERATIVE GLOMERULONEPHRITIS; SMOOTH MUSCLE ACTIN; TROPOMYOSIN ISOFORMS; EXPRESSION; CELLS; CYTOSKELETON; PROGRESSION; MICROARRAY; NEPHRITIS; INJURY AB Nazeer K, Janech MG, Lin JJ, Ryan KJ, Arthur JM, Budisavljevic MN. Changes in protein profiles during course of experimental glomerulonephritis. Am J Physiol Renal Physiol 296: F186-F193, 2009. First published November 5, 2008; doi: 10.1152/ajprenal.90222.2008. Better characterization of the molecular mechanisms underlying glomerular cell proliferation may improve our understanding of the pathogenesis of glomerulonephritis and yield disease-specific markers. We used two-dimensional gel electrophoresis (2DE) and mass spectrometry (MS) to generate expression profiles of glomerular proteins in the course of anti-Thy-1 nephritis. Glomeruli were isolated from Wistar rats by sieving, and proteins were separated by 2DE. In preliminary studies using normal rats, we identified known glomerular proteins from microfilaments [tropomyosin (Tm)] and intermediate filaments (vimentin and lamin A), proteins involved in assembly (alpha-actinin-4, F-actin capping protein) and membrane cytoskeletal linking (ezrin), as well as several enzymes (protein disulfide isomerase, ATP synthase, and aldehyde dehydrogenase). Comparison of glomerular protein abundance between normal rats and rats in the early phase of anti-Thy-1 nephritis yielded 28 differentially expressed protein spots. MS analysis identified 16 differentially expressed proteins including Tm. Altered Tm abundance in the course of anti-Thy-1 nephritis was confirmed, and specific isoforms were characterized by Western blotting. We demonstrated a complex change in Tm isoform abundance in the course of anti-Thy-1 nephritis. The early mesangiolytic phase of the disease was characterized by decreased abundance of low-molecular-weight isoforms Tm5a/5b and increased abundance of high-molecular-weight isoforms Tm6, Tm1, Tm2, and Tm3. The late proliferative phase of the disease was associated with increased abundance of isoforms Tm5a/5b, Tm6, and Tm1 and decreased abundance of Tm3. Isoforms Tm4 and Tm5 remained unchanged in the course of this model of experimental glomerulonephritis. Characterization of Tm isoform abundance in the course of clinical glomerulonephritis may identify disease-specific markers. C1 [Janech, Michael G.; Ryan, Kevin J.; Arthur, John M.; Budisavljevic, Milos N.] Med Univ S Carolina, Div Nephrol, Dept Med, Charleston, SC 29425 USA. [Nazeer, Khurram] Univ Louisville, Dept Med, Louisville, KY 40292 USA. [Lin, Jim J. -C.] Univ Iowa, Dept Biol Sci, Iowa City, IA USA. [Janech, Michael G.; Arthur, John M.; Budisavljevic, Milos N.] Ralph H Johnson Dept Vet Affairs Med Ctr, Dept Med, Charleston, SC USA. RP Budisavljevic, MN (reprint author), Med Univ S Carolina, Div Nephrol, Dept Med, 96 Jonathan Lucas St,POB 250623, Charleston, SC 29425 USA. EM budisamn@musc.edu OI Janech, Michael/0000-0002-3202-4811 FU Department of Veterans Affairs; Dialysis Clinics, Inc [DCI 2340] FX Support for this project came from the Department of Veterans Affairs and Grant DCI 2340 from Dialysis Clinics, Inc. NR 20 TC 8 Z9 10 U1 1 U2 1 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 1931-857X J9 AM J PHYSIOL-RENAL JI Am. J. Physiol.-Renal Physiol. PD JAN PY 2009 VL 296 IS 1 BP F186 EP F193 DI 10.1152/ajprenal.90222.2008 PG 8 WC Physiology; Urology & Nephrology SC Physiology; Urology & Nephrology GA 389NU UT WOS:000262101200021 PM 18987115 ER PT J AU Eisenman, DP Glik, D Ong, M Zhou, Q Tseng, CH Long, A Fielding, J Asch, S AF Eisenman, David P. Glik, Deborah Ong, Michael Zhou, Qiong Tseng, Chi-Hong Long, Anna Fielding, Jonathan Asch, Steven TI Terrorism-Related Fear and Avoidance Behavior in a Multiethnic Urban Population SO AMERICAN JOURNAL OF PUBLIC HEALTH LA English DT Article ID SEPTEMBER 11; ATTACKS; BIOTERRORISM; PREPAREDNESS; STRESS; HEALTH; EXPERIENCES; RISK AB Objectives. We sought to determine whether groups traditionally most vulnerable to disasters would be more likely than would be others to perceive population level risk as high (as measured by the estimated color-coded alert level) would worry more about terrorism, and would avoid activities because of terrorism concerns. Methods. We conducted a random digit dial survey of the Los Angeles County population October 2004 through January 2005 in 6 languages. We asked respondents what color alert level the country was under, how often they worry about terrorist attacks, and how often they avoid activities because of terrorism. Multivariate regression modeled correlates of worry and avoidance, including mental illness, disability, demographic factors, and estimated color-coded alert level. Results. Persons who are mentally ill, those who are disabled, African Americans, Latinos, Chinese Americans, Korean Americans, and non-US citizens were more likely to perceive population-level risk as high, as measured by the estimated color-coded alert level. These groups also reported more worry and avoidance behaviors because of concerns about terrorism. Conclusions. Vulnerable populations experience a disproportionate burden of the psychosocial impact of terrorism threats and our national response. Further studies should investigate the specific behaviors affected and further elucidate disparities in the disaster burden associated with terrorism and terrorism policies. (Am J Public Health. 2009;99:168-174. doi:10.2105/AJPH. 2007.124206) C1 [Eisenman, David P.] Univ Calif Los Angeles, David Geffen Sch Med, Div Gen Internal Med, Los Angeles, CA 90095 USA. [Eisenman, David P.; Asch, Steven] RAND Corp, Santa Monica, CA USA. [Glik, Deborah; Fielding, Jonathan] Univ Calif Los Angeles, Sch Publ Hlth, Los Angeles, CA 90024 USA. [Asch, Steven] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Asch, Steven] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA. [Long, Anna; Fielding, Jonathan] Los Angeles Cty Dept Publ Hlth, Los Angeles, CA USA. RP Eisenman, DP (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Div Gen Internal Med, 911 Broxton Plaza, Los Angeles, CA 90095 USA. EM deisenman@mednet.ucla.edu RI Ong, Michael/F-7397-2013 FU Centers for Disease Control and Prevention [UB90/CCU917012-06, K01-CD000049-02] FX Funding for this study was provided to D. P. Eisenman through a grant to the Los Angeles County Department of Public Health from the Centers for Disease Control and Prevention (UB90/CCU917012-06) and from another award to D. P. Eisenman from the Centers for Disease Control and Prevention (K01-CD000049-02). NR 45 TC 20 Z9 21 U1 2 U2 9 PU AMER PUBLIC HEALTH ASSOC INC PI WASHINGTON PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA SN 0090-0036 J9 AM J PUBLIC HEALTH JI Am. J. Public Health PD JAN PY 2009 VL 99 IS 1 BP 168 EP 174 DI 10.2105/AJPH.2007.124206 PG 7 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 391OA UT WOS:000262241400027 PM 19008521 ER PT J AU Badesch, DB Feldman, J Keogh, A Mathier, MA Oudiz, RJ Shapiro, S Farber, H McGoon, M Frost, A Rubin, LJ AF Badesch, D. B. Feldman, J. Keogh, A. Mathier, M. A. Oudiz, R. J. Shapiro, S. Farber, H. McGoon, M. Frost, A. Rubin, L. J. CA ARIES-3 Study Grp TI ARIES-3: Ambrisentan Therapy in a Diverse Population of Patients with Pulmonary Hypertension SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Meeting Abstract C1 [Badesch, D. B.] Univ Colorado, Denver, CO 80202 USA. [Feldman, J.] Arizona Pulm Specialists Ltd, Phoenix, AZ USA. [Keogh, A.] St Vincents Hosp, Sydney, NSW 2010, Australia. [Mathier, M. A.] Univ Pittsburgh, Pittsburgh, PA USA. [Oudiz, R. J.] Harbor UCLA, LA Biomed Res Inst, Torrance, CA USA. [Shapiro, S.] VA Greater LA Healthcare Syst, Los Angeles, CA USA. [Shapiro, S.] David Geffen UCLA Sch Med, Los Angeles, CA USA. [Farber, H.] Boston Univ, Sch Med, Boston, MA 02118 USA. [McGoon, M.] Mayo Clin, Rochester, MN USA. [Frost, A.] Baylor Coll Med, Houston, TX 77030 USA. [Rubin, L. J.] UCSD, La Jolla, CA USA. NR 0 TC 4 Z9 4 U1 0 U2 0 PU AMER THORACIC SOC PI NEW YORK PA 61 BROADWAY, FL 4, NEW YORK, NY 10006 USA SN 1073-449X J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PY 2009 VL 179 MA A3357 PG 1 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA V29FA UT WOS:000208733102592 ER PT J AU Chandrasena, AR Ho, G Araujo, L Mao, Y Pan, J Frank, JA AF Chandrasena, A. R. Ho, G. Araujo, L. Mao, Y. Pan, J. Frank, J. A. TI Regulation of Paracellular Transport by Differential Claudin Expression in Alveolar Epithelial Cells. SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Meeting Abstract C1 [Chandrasena, A. R.; Ho, G.; Araujo, L.; Pan, J.; Frank, J. A.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Chandrasena, A. R.; Frank, J. A.] San Francisco VA Med Ctr, San Francisco, CA USA. [Mao, Y.; Frank, J. A.] NCIRE VHRI, San Francisco, CA USA. EM anita.chandrasena@ucsf.edu NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER THORACIC SOC PI NEW YORK PA 61 BROADWAY, FL 4, NEW YORK, NY 10006 USA SN 1073-449X J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PY 2009 VL 179 MA A3560 PG 2 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA V29FA UT WOS:000208733102794 ER PT J AU Conhaim, RL Watson, KE Dovi, WF Harms, BA AF Conhaim, R. L. Watson, K. E. Dovi, W. F. Harms, B. A. TI Microthrombus Formation Continues in Rat Lungs for up to 24 Hours Following Acute Hemorrhage SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Meeting Abstract C1 [Conhaim, R. L.; Watson, K. E.; Harms, B. A.] Univ Wisconsin, Sch Med, Madison, WI USA. [Dovi, W. F.] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER THORACIC SOC PI NEW YORK PA 61 BROADWAY, FL 4, NEW YORK, NY 10006 USA SN 1073-449X J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PY 2009 VL 179 MA A3870 PG 1 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA V29FA UT WOS:000208733103223 ER PT J AU Coppersmith, JC Gylys-Colwell, IM Dougherty, CM Schneider, C Hunziker, J Short, V Sablinsky, M Steele, BG AF Coppersmith, J. C. Gylys-Colwell, I. M. Dougherty, C. M. Schneider, C. Hunziker, J. Short, V. Sablinsky, M. Steele, B. G. TI Combined Rehabilitation Program for Chronic Obstructive Pulmonary Disease (COPD) and Heart Failure (HF). SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Meeting Abstract C1 [Coppersmith, J. C.; Gylys-Colwell, I. M.; Schneider, C.; Hunziker, J.; Short, V.; Sablinsky, M.; Steele, B. G.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Dougherty, C. M.] Univ Washington, Sch Nursing, Seattle, WA 98195 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER THORACIC SOC PI NEW YORK PA 61 BROADWAY, FL 4, NEW YORK, NY 10006 USA SN 1073-449X J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PY 2009 VL 179 MA A2370 PG 1 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA V29FA UT WOS:000208733101489 ER PT J AU de Molina, RMM Mortensen, EM Copeland, LA Pugh, MJV Anzueto, A Restrepo, MI AF de Molina, R. M. Malo Mortensen, E. M. Copeland, L. A. Pugh, M. J. V. Anzueto, A. Restrepo, M. I. TI Outpatient Inhaled Corticosteroid (ICS) Therapy Decreases Mortality in Patients with Chronic Obstructive Pulmonary Disease (COPD) and Pneumonia SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Meeting Abstract C1 [de Molina, R. M. Malo; Anzueto, A.; Restrepo, M. I.] Univ Texas Hlth Care Syst, San Antonio, TX USA. [de Molina, R. M. Malo; Mortensen, E. M.; Copeland, L. A.; Pugh, M. J. V.; Restrepo, M. I.] S Texas Vet Hlth Care Syst VERDICT, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER THORACIC SOC PI NEW YORK PA 61 BROADWAY, FL 4, NEW YORK, NY 10006 USA SN 1073-449X J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PY 2009 VL 179 MA A6115 PG 1 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA V29FA UT WOS:000208733105706 ER PT J AU Fan, VS Udris, EM Au, DH AF Fan, V. S. Udris, E. M. Au, D. H. TI Factors Associated with Self-Efficacy in COPD SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Meeting Abstract C1 [Fan, V. S.; Udris, E. M.; Au, D. H.] VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, Seattle, WA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER THORACIC SOC PI NEW YORK PA 61 BROADWAY, FL 4, NEW YORK, NY 10006 USA SN 1073-449X J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PY 2009 VL 179 MA A1077 PG 1 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA V29FA UT WOS:000208733100078 ER PT J AU Herrero, R Kajikawa, O Matute-Bello, G Fu, X Wong, VA Martin, TR AF Herrero, R. Kajikawa, O. Matute-Bello, G. Fu, X. Wong, V. A. Martin, T. R. TI The N-Terminal Sequence of Soluble FasL Determines Its Bioactivity SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Meeting Abstract C1 [Herrero, R.; Kajikawa, O.; Matute-Bello, G.; Wong, V. A.] VA Puget Sound, Seattle, WA USA. [Herrero, R.; Kajikawa, O.; Matute-Bello, G.; Fu, X.; Wong, V. A.] U Washington, Seattle, WA USA. EM rherrero@u.washington.edu NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER THORACIC SOC PI NEW YORK PA 61 BROADWAY, FL 4, NEW YORK, NY 10006 USA SN 1073-449X J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PY 2009 VL 179 MA A2496 PG 1 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA V29FA UT WOS:000208733101615 ER PT J AU Ho, G Mao, Y Chandrasena, A Lam, D Frank, JA AF Ho, G. Mao, Y. Chandrasena, A. Lam, D. Frank, J. A. TI The Contribution of Claudin 4 to In Vitro Alveolar Epithelial Barrier Repair SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Meeting Abstract C1 [Ho, G.; Chandrasena, A.; Frank, J. A.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Lam, D.; Frank, J. A.] San Francisco VA Med Ctr, San Francisco, CA USA. [Mao, Y.; Frank, J. A.] NCIRE VHRI, San Francisco, CA USA. EM gwendolyn.ho@ucsf.edu NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER THORACIC SOC PI NEW YORK PA 61 BROADWAY, FL 4, NEW YORK, NY 10006 USA SN 1073-449X J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PY 2009 VL 179 MA A2395 PG 2 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA V29FA UT WOS:000208733101514 ER PT J AU Koff, PB Min, S Freitag, TJ James, SS Keith, RL Kveton, C Carwin, S Stelzner, TJ Brand, DW Ritzwoller, DP Beck, AL Voelkel, NF Vandivier, RW AF Koff, P. B. Min, S. Freitag, T. J. James, S. S. Keith, R. L. Kveton, C. Carwin, S. Stelzner, T. J. Brand, D. W. Ritzwoller, D. P. Beck, A. L. Voelkel, N. F. Vandivier, R. W. TI Proactive Integrated Care Reduces Critical Care & Improves Quality-of-Life in COPD SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Meeting Abstract C1 [Koff, P. B.; Freitag, T. J.; James, S. S.] Univ CO Hosp, Aurora, CO USA. [Min, S.; Keith, R. L.; Vandivier, R. W.] Univ CO Hlth Sci Ctr, Dept Med, Aurora, CO USA. [Keith, R. L.] Denver Vet Affairs Med Ctr, Dept Med, Denver, CO USA. [Kveton, C.; Carwin, S.; Stelzner, T. J.; Brand, D. W.; Ritzwoller, D. P.; Beck, A. L.] Kaiser Permanente, Inst Hlth Res, Denver, CO USA. [Voelkel, N. F.] VA Commonwealth Univ, Dept Med, Richmond, VA USA. EM patricia.koff@uch.edu NR 0 TC 1 Z9 1 U1 0 U2 0 PU AMER THORACIC SOC PI NEW YORK PA 61 BROADWAY, FL 4, NEW YORK, NY 10006 USA SN 1073-449X J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PY 2009 VL 179 MA A3100 PG 1 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA V29FA UT WOS:000208733102335 ER PT J AU Kurahashi, K Kajikawa, O Matute-Bello, G Martin, TR AF Kurahashi, K. Kajikawa, O. Matute-Bello, G. Martin, T. R. TI FasL and LPS Have Synergistic Effects on Inflammation of Epithelial Cells. SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Meeting Abstract C1 [Kurahashi, K.; Kajikawa, O.; Matute-Bello, G.; Martin, T. R.] VA Puget Sound Hlth Care Syst, Med Res Serv, Seattle, WA USA. [Kurahashi, K.; Kajikawa, O.; Matute-Bello, G.; Martin, T. R.] Univ Washington, Sch Med, Dept Med, Div Pulm & Crit Care Med, Seattle, WA 98195 USA. [Kurahashi, K.] Yokohama City Univ, Grad Sch Med, Dept Anesthesiol & Crit Care Med, Yokohama, Kanagawa 232, Japan. EM yasuk@u.washington.edu NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER THORACIC SOC PI NEW YORK PA 61 BROADWAY, FL 4, NEW YORK, NY 10006 USA SN 1073-449X J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PY 2009 VL 179 MA A5642 PG 1 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA V29FA UT WOS:000208733105233 ER PT J AU Lipke, AB Wong, VA Matute-Bello, G Martin, TR AF Lipke, A. B. Wong, V. A. Matute-Bello, G. Martin, T. R. TI Mechanisms of Enhanced Lung Injury in Febrile Hyperthermia: Role of Alveolar Epithelial Apoptosis SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Meeting Abstract C1 [Lipke, A. B.; Wong, V. A.; Martin, T. R.] VA Puget Sound, Seattle, WA USA. [Matute-Bello, G.] Ctr Lung Biol, Seattle, WA USA. EM ablipke@u.washington.edu NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER THORACIC SOC PI NEW YORK PA 61 BROADWAY, FL 4, NEW YORK, NY 10006 USA SN 1073-449X J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PY 2009 VL 179 MA A3862 PG 1 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA V29FA UT WOS:000208733103215 ER PT J AU Mao, Y Chandrasena, A Araujo, L Ho, G Frank, JA AF Mao, Y. Chandrasena, A. Araujo, L. Ho, G. Frank, J. A. TI Claudin 4 Is Induced in the Alveolar Epithelium by a JNK-Dependent Mechanism SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Meeting Abstract C1 [Chandrasena, A.; Araujo, L.; Ho, G.; Frank, J. A.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Frank, J. A.] San Francisco VA Med Ctr, San Francisco, CA USA. [Mao, Y.; Frank, J. A.] NCIRE VHRI, San Francisco, CA USA. EM james.frank@ucsf.edu NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER THORACIC SOC PI NEW YORK PA 61 BROADWAY, FL 4, NEW YORK, NY 10006 USA SN 1073-449X J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PY 2009 VL 179 MA A5001 PG 2 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA V29FA UT WOS:000208733104465 ER PT J AU Mortensen, EM Copeland, LA Pugh, MJ de Molina, RM Restrepo, MI Anzueto, A AF Mortensen, E. M. Copeland, L. A. Pugh, M. J. de Molina, R. Malo Restrepo, M. I. Anzueto, A. TI Impact of Prior Statin and ACE Inhibitor Use on Mortality for Subjects Hospitalized with COPD Exacerbations. SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Meeting Abstract C1 [Mortensen, E. M.; Copeland, L. A.; Pugh, M. J.; de Molina, R. Malo; Restrepo, M. I.; Anzueto, A.] South Texas Vet Hlth Care Syst, San Antonio, TX USA. [Mortensen, E. M.; Copeland, L. A.; Pugh, M. J.; de Molina, R. Malo; Restrepo, M. I.; Anzueto, A.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. EM mortensene@uthscsa.edu NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER THORACIC SOC PI NEW YORK PA 61 BROADWAY, FL 4, NEW YORK, NY 10006 USA SN 1073-449X J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PY 2009 VL 179 MA A5354 PG 1 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA V29FA UT WOS:000208733104818 ER PT J AU Nyendak, M Swarbrick, G Null, M Cansler, M Frieder, M Mayanja-Kizza, H Mugerwa, RD Boom, WH Zalwango, S Rajaraman, V Sherman, D Mori, T McWeeney, S Park, B Lewinsohn, DA Lewinsohn, DM AF Nyendak, M. Swarbrick, G. Null, M. Cansler, M. Frieder, M. Mayanja-Kizza, H. Mugerwa, R. D. Boom, W. H. Zalwango, S. Rajaraman, V. Sherman, D. Mori, T. McWeeney, S. Park, B. Lewinsohn, D. A. Lewinsohn, D. M. TI The Diagnostic Potential of the CD8(+) T Cell Response: Identification of Immunodominant CD8(+) T Cell Antigens and the Potential To Differentiate Latent from Active Tuberculosis SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Meeting Abstract C1 [Nyendak, M.; Swarbrick, G.; Null, M.; Cansler, M.; Rajaraman, V.; Mori, T.; McWeeney, S.; Park, B.; Lewinsohn, D. A.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Swarbrick, G.; Null, M.; Cansler, M.; Frieder, M.; Lewinsohn, D. M.] Portland VA Med Ctr, Portland, OR USA. [Mayanja-Kizza, H.; Mugerwa, R. D.; Zalwango, S.] Makerere Univ, Kampala, Uganda. [Boom, W. H.] Case Western Reserve Univ, TB Res Unit, Cleveland, OH 44106 USA. [Sherman, D.] Univ Washington, Seattle, WA 98195 USA. EM nyendakm@ohsu.edu NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER THORACIC SOC PI NEW YORK PA 61 BROADWAY, FL 4, NEW YORK, NY 10006 USA SN 1073-449X J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PY 2009 VL 179 MA A1016 PG 1 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA V29FA UT WOS:000208733100017 ER PT J AU Slatore, CG Udris, EM Cecere, LM Moss, BR Bryson, CL Au, DH AF Slatore, C. G. Udris, E. M. Cecere, L. M. Moss, B. R. Bryson, C. L. Au, D. H. TI Provider Communication among Patients with Chronic Obstructive Pulmonary Disease: Association with Patient Reported Outcomes SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Meeting Abstract C1 [Slatore, C. G.; Udris, E. M.; Cecere, L. M.; Moss, B. R.; Bryson, C. L.; Au, D. H.] Vet Affairs Puget Sound Healthcare Syst, Hlth Serv Res & Dev, Seattle, WA USA. EM cslatore@u.washington.edu NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER THORACIC SOC PI NEW YORK PA 61 BROADWAY, FL 4, NEW YORK, NY 10006 USA SN 1073-449X J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PY 2009 VL 179 MA A5200 PG 1 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA V29FA UT WOS:000208733104664 ER PT J AU Slatore, CG Au, DH Gould, MK AF Slatore, C. G. Au, D. H. Gould, M. K. TI Insurance Status and Disparities in Outcomes of Lung Cancer Care: A Systematic Review. SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Meeting Abstract C1 [Slatore, C. G.; Au, D. H.] VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, Seattle, WA USA. [Gould, M. K.] Vet Affairs Palo Alto Hlth Care Syst, Palo Alto, CA USA. EM cslatore@u.washington.edu NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER THORACIC SOC PI NEW YORK PA 61 BROADWAY, FL 4, NEW YORK, NY 10006 USA SN 1073-449X J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PY 2009 VL 179 MA A3748 PG 1 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA V29FA UT WOS:000208733103101 ER PT J AU Minowada, G Miller, YE AF Minowada, George Miller, York E. TI Overexpression of Sprouty 2 in Mouse Lung Epithelium Inhibits Urethane-Induced Tumorigenesis SO AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY LA English DT Article DE Sprouty; lung cancer; mouse; chemoprevention; Ras ID K-RAS; MOLECULAR PATHOGENESIS; SIGNAL-TRANSDUCTION; A/J MICE; GROWTH; CANCER; PATHWAY; TUMORS; EXPRESSION; PULMONARY AB Members of the Sprouty family encode novel proteins that are thought to function primarily as intracellular antagonists of the Ras-signaling pathway. Increased Ras signaling is a critical characteristic of human lung adenocarcinoma, the most common type of non-small cell lung cancer. Sprouty 2 is expressed in the lung epithelium, the tissue layer from which lung cancers arise. We hypothesized that overexpression of Sprouty 2 in the distal lung epithelium would inhibit lung tumorigenesis. To test the hypothesis, the consequences of overexpressing Sprouty 2 in the distal lung epithelium on urethane-induced mouse lung tumorigenesis were determined. Urethane is a chemical carcinogen found in tobacco smoke that causes activating mutations in Kras and induces lung tumors in mice. Sprouty 2-overexpressor mice developed significantly fewer lung tumors compared with their littermate controls (113.2 +/- 1.1 versus 18.1 +/- 1.3, P = 0.006). Tumor diameter was also significantly smaller in Sprouty 2 overexpressors (0.85 mm +/- 0.03 versus 0.95 mm +/- 0.02, P = 0.005). Sprouty 2 overexpression did not alter Kras mutational frequencies in urethane-induced tumors, suggesting that the tumor-suppressing effect of Sprouty 2 overexpression acts at a stage after Kras mutation, perhaps by interfering with receptor tyrosine kinase-induced signaling. These results demonstrate that Sprouty 2 overexpression inhibited both tumor initiation and subsequent tumor growth. C1 [Miller, York E.] Univ Colorado, Ctr Canc, Denver Vet Affairs Med Ctr, Div Pulm Sci & Crit Care Med, Denver, CO 80220 USA. [Miller, York E.] Univ Colorado, Hlth Sci Ctr, Denver, CO 80220 USA. [Minowada, George] Louis Stokes Cleveland Vet Affairs Med Ctr, Cleveland, OH USA. [Minowada, George] Case Western Reserve Univ, Univ Hosp Cleveland, Div Pulm & Crit Care Med, Cleveland, OH 44106 USA. RP Miller, YE (reprint author), Univ Colorado, Ctr Canc, Denver Vet Affairs Med Ctr, Div Pulm Sci & Crit Care Med, Pulm 111A, Denver, CO 80220 USA. EM york.miller@uchsc.edu FU University of California, San Francisco; Skin Diseases Research Center FX The first author developed the conditional Spry2GOF transgenic line as a postdoctoral fellow in Gail Martin's laboratory at the University of California, San Francisco. The authors thank her for her support and encouragement. The authors thank the histopathology core facility in the Skin Diseases Research Center for processing, sectioning, and staining of tissue, and the sequencing core facility in the orthopedics department for sequencing. An early version of this work was presented at the 2003 Thomas L. Petty Aspen Lung Conference and reported in abstract form (31). NR 31 TC 19 Z9 19 U1 0 U2 0 PU AMER THORACIC SOC PI NEW YORK PA 1740 BROADWAY, NEW YORK, NY 10019-4374 USA SN 1044-1549 J9 AM J RESP CELL MOL JI Am. J. Respir. Cell Mol. Biol. PD JAN PY 2009 VL 40 IS 1 BP 31 EP 37 DI 10.1165/rcmb.2008-0147OC PG 7 WC Biochemistry & Molecular Biology; Cell Biology; Respiratory System SC Biochemistry & Molecular Biology; Cell Biology; Respiratory System GA 388XW UT WOS:000262054700005 PM 18635814 ER PT J AU Chennupati, SK Chiu, AG Tamashiro, E Banks, CA Cohen, MB Bleier, BS Kofonow, JM Tam, E Cohen, NA AF Chennupati, Sri Kiran Chiu, Alexander G. Tamashiro, Edwin Banks, Caroline A. Cohen, Michael B. Bleier, Benjamin S. Kofonow, Jennifer M. Tam, Eric Cohen, Noam A. TI Effects of an LL-37-derived antimicrobial peptide in an animal model of biofilm Pseudomonas sinusitis SO AMERICAN JOURNAL OF RHINOLOGY & ALLERGY LA English DT Article DE Animal model; antimicrobial peptide; biofilm; cathelicidin; LL-37; Pseudomonas; sinusitis; topical therapies ID CHRONIC RHINOSINUSITIS; BACTERIAL BIOFILMS; IN-VITRO; STAPHYLOCOCCUS-AUREUS; TOPICAL TOBRAMYCIN; LL-37; MUCOSA; INFECTIONS; SPECIMENS; SURGERY AB Background: LL-37, all innate immunity protein expressed within sinonasal mucosa, has in vitro antibacterial and antifungal properties as Well as efficacy against preformed Pseudomonas aeruginosa biofilms. We hypothesize that a 24 amino acid peptide derivative of LL-37 will show efficacy against biofilm-forming P. aeruginosa in ail established animal model of sinusitis. Methods: Five groups of six New Zealand rabbits were each infected with P. aeruginosa (PAO-1) and fitted with irrigating catheters 7 days later. Each group was instilled with either one of three different concentrations of peptide, a positive control of topical tobramycin, or the carrier solution without the peptide once a day for 10 days. Nasal diluent was collected throughout the irrigation period to assess for persistence or resolution of infection by determining colony-forming units (CFU). At study end, sinus mucosa was harvested for histological assessment of inflammation and SEM evaluation for ciliary integrity and presence Of biofilms. Results: Topical tobramycin at 400X minimum inhibitory concentration and 2.5 mg/mL of peptide were effective in significantly lowering CFUs after 10 days of irrigation. Histological evaluation showed increased signs of inflammation in a dose-dependent manner within mucosa and bone of the groups receiving the peptide. SEM analysis showed ciliary loss in a dose-dependent manner. Biofilms were present ill all groups except for the highest concentration of peptide and tobramycin. Conclusion: High concentrations of LL-37-derived peptide showed in vivo ability to eradicate Pseudomonas biofilms and decrease bacterial counts. However, increasing concentrations of peptide showed proinflammatory and ciliotoxic effects oil sinus mucosa. C1 [Chennupati, Sri Kiran; Chiu, Alexander G.; Tamashiro, Edwin; Bleier, Benjamin S.; Cohen, Noam A.] Univ Penn, Dept Otorhinolaryngol Head & Neck Surg, Philadelphia, PA 19104 USA. [Tamashiro, Edwin; Kofonow, Jennifer M.; Tam, Eric; Cohen, Noam A.] Philadelphia Vet Affairs Med Ctr, Div Otolaryngol, Philadelphia, PA USA. [Banks, Caroline A.; Cohen, Michael B.] Univ Penn, Sch Med, Philadelphia, PA 19104 USA. RP Chiu, AG (reprint author), Univ Penn, Dept Otorhinolaryngol Head & Neck Surg, 5 Silverstein,3400 Spruce St, Philadelphia, PA 19104 USA. EM alexander.chiu@uphs.upenn.edu RI Chiu, Alexander/J-1230-2014; Tamashiro, Edwin/C-5062-2012 OI Chiu, Alexander/0000-0002-7592-6575; Tamashiro, Edwin/0000-0002-3153-6292; Cohen, Noam/0000-0002-9462-3932 NR 42 TC 38 Z9 38 U1 0 U2 6 PU OCEAN SIDE PUBLICATIONS INC PI PROVIDENCE PA 95 PITMAN ST, PROVIDENCE, RI 02906 USA SN 1945-8924 J9 AMJ RHINOL ALLERGY JI Am. J. Rhinol. Allergy PD JAN-FEB PY 2009 VL 23 IS 1 BP 46 EP 51 DI 10.2500/ajra.2009.23.3261 PG 6 WC Otorhinolaryngology SC Otorhinolaryngology GA 430NN UT WOS:000264995900010 PM 19379612 ER PT J AU Ellis, C Egede, LE AF Ellis, Charles Egede, Leonard E. TI Stroke Recognition Among Individuals With Stroke Risk Factors SO AMERICAN JOURNAL OF THE MEDICAL SCIENCES LA English DT Article DE stroke; cardiovascular disease; hypertension; diabetes; smoking; survey research ID AMERICAN-HEART-ASSOCIATION; EMERGENCY-DEPARTMENT; WARNING SIGNS; HEALTH-CARE; KNOWLEDGE; AWARENESS; DELAY; SYMPTOMS; TIME; EPIDEMIOLOGY AB Background: This study examined recognition of all 5 early warning signs/symptoms of stroke and appropriate first action to call 9-1-1 across stroke risk groups, Methods: Data from 264,684 adults from the 2003 Behavioral Risk Factor Surveillance System were examined. Recognition of the 5 warning signs/symptoms of stroke and appropriate first action to call 9-1-1 was compared among 3 stroke risk groups no stroke risk factors, stroke risk factors, and prior stroke, using multiple logistic regression controlling for covariates. Results: Recognition of the 5 individual warning signs of stroke ranged from 82% to 98%. Cumulative recognition of all 5 warning signs of stroke ranged from 30.8% in individuals with prior stroke to 12.6% in those with no stroke risk factors,. Cumulative recognition of all 5 warning signs of stroke and taking appropriate action to call 9-1-1 ranged from 26.1% in individuals with prior stroke to 11.2% in those with no stroke risk factors. Adjusted odds ratios for recognition of all 5 symptoms was 3.35 for individuals with previous stroke and 1.15 for individuals with stroke risk factors, compared with the reference group (individuals without stroke risk factors). Adjusted odds ratios for recognition of all 5 symptoms and taking appropriate action to call 9-1-1 was 3.06 for individuals with previous stroke and 1.14 for individuals with stroke risk factors, Conclusions: Recognition of individual stroke warning symptoms is high in general. Cumulative recognition of stroke warning signs and taking appropriate action is very low, although higher in those with prior stroke. C1 [Egede, Leonard E.] Med Univ S Carolina, Ctr Hlth Dispar Res, Dept Med, Charleston, SC 29425 USA. [Ellis, Charles] Med Univ S Carolina, Dept Rehabil Sci, Charleston, SC 29425 USA. [Egede, Leonard E.] Ralph H Johnson VA Med Ctr, Charleston VA TREP, Charleston, SC USA. RP Egede, LE (reprint author), Med Univ S Carolina, Ctr Hlth Dispar Res, Dept Med, Charleston, SC 29425 USA. EM egedel@musc.edu NR 32 TC 15 Z9 19 U1 0 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0002-9629 J9 AM J MED SCI JI Am. J. Med. Sci. PD JAN PY 2009 VL 337 IS 1 BP 5 EP 10 PG 6 WC Medicine, General & Internal SC General & Internal Medicine GA 400MQ UT WOS:000262872700002 PM 19057378 ER PT J AU Webb, R Jeffries, M Sawalha, AH AF Webb, Ryan Jeffries, Matlock Sawalha, Amr H. TI Uric Acid Directly Promotes Human T-Cell Activation SO AMERICAN JOURNAL OF THE MEDICAL SCIENCES LA English DT Article DE Uric acid; T cells; Gout; Autoimmunity ID ENDOGENOUS ADJUVANTS; IMMUNE-SYSTEM; PATHOGENESIS AB Background: Abnormally high serum uric acid levels have been associated with several disease conditions including gout and kidney stone disease. More recently, it was shown that uric acid crystals stimulate dendritic cell maturation, activate the NALP3 inflamasome, and enhance antigen-specific immune responses. We hypothesize that uric acid can also stimulate T cells directly and in the absence of antigen presentation. Methods: Purified primary human T cells were incubated with and without uric acid at concentrations of 50, 100, 150, and 200 mu g/mL. The expression of T-cell activation markers CD25 and CD70 was assessed by flow cytometry. In other experiments, Jurkat T cells were used and the expression of the costimulatory molecule CD70 was determined at the mRNA level. Result: Uric acid directly activates primary human T cells in tire absence of antigen presentation. Furthermore, primary human T cells and Jurkat T cells treated with uric acid overexpress the costimulatory molecule CD70, which plays an important role in T cell-B cell interaction and antibody production. Conclusions: The finding that uric acid directly promotes T-cell activation in ail antigen-independent system is novel and might play a mechanistic role in the inflammatory response observed in gouty arthritis and other immune-mediated diseases. C1 [Webb, Ryan; Jeffries, Matlock; Sawalha, Amr H.] Oklahoma Med Res Fdn, Arthritis & Immunol Program, Oklahoma City, OK 73104 USA. [Jeffries, Matlock; Sawalha, Amr H.] Univ Oklahoma, Hlth Sci Ctr, Dept Med, Oklahoma City, OK USA. [Sawalha, Amr H.] US Dept Vet Affairs, Med Ctr, Oklahoma City, OK USA. RP Sawalha, AH (reprint author), 825 NE 13th St,MS 24, Oklahoma City, OK 73104 USA. EM amr-sawalha@omrf.ouhsc.edu OI Jeffries, Matlock/0000-0001-9516-4312 FU National Center for Research Resources [P20-RR015577]; University of Oklahoma College of Medicine FX This study was supported by NIH Grant number P20-RR015577 from the National Center for Research Resources and by funding from the University of Oklahoma College of Medicine. NR 14 TC 21 Z9 31 U1 0 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0002-9629 J9 AM J MED SCI JI Am. J. Med. Sci. PD JAN PY 2009 VL 337 IS 1 BP 23 EP 27 PG 5 WC Medicine, General & Internal SC General & Internal Medicine GA 400MQ UT WOS:000262872700005 PM 19057377 ER PT J AU Wharton, W Gleason, CE Lorenze, KR Markgraf, TS Ries, ML Carlsson, CM Asthana, S AF Wharton, Whitney Gleason, Carey E. Lorenze, Katelin R. Markgraf, Tamara S. Ries, Michele L. Carlsson, Cynthia M. Asthana, Sanjay TI Potential role of estrogen in the pathobiology and prevention of Alzheimer's disease SO AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH LA English DT Review DE Estrogen; estrogen therapy; hormone therapy; cognition; Alzheimer's disease; postmenopausal cognition; women's health initiative AB Over a decade of converging findings from clinical, observational and basic science research indicate that estrogen administration during the menopausal transition exerts beneficial effects on cognition and decreases a woman's risk of developing Alzheimer's disease (AD) later in life. This review article stresses the research focus of AD prevention, and introduces hormone therapy (HT) as a probable catalyst that may achieve this goal. Furthermore, this article outlines 3 mechanisms proposed to mediate estrogen's beneficial effects, discusses the controversy surrounding HT administration, and presents the most promising estrogen related research in AD prevention and treatment. Although controversial, cumulative evidence suggests that the potential of estrogen initiated during perimenopause to prevent AD needs to be systematically evaluated. C1 [Wharton, Whitney; Gleason, Carey E.; Lorenze, Katelin R.; Markgraf, Tamara S.; Ries, Michele L.; Carlsson, Cynthia M.; Asthana, Sanjay] Univ Wisconsin, Dept Med, Madison, WI 53705 USA. [Wharton, Whitney; Gleason, Carey E.; Lorenze, Katelin R.; Markgraf, Tamara S.; Ries, Michele L.; Carlsson, Cynthia M.; Asthana, Sanjay] William S Middleton Mem Vet Adm Med Ctr, Geriatr Res Educ & Clin Ctr, Madison, WI USA. RP Wharton, W (reprint author), Univ Wisconsin, Sch Med & Publ Hlth, William S Middleton VA Hosp, 2500 Overlook Terrace,GRECC 11G, Madison, WI 53705 USA. EM wlwharto@medicine.wisc.edu FU NIH [AG029624, K07AG021582, K23AG024302, K23AG026752] FX This research was conducted with the help of the Section of Geriatrics and Gerontology, Department of Medicine at the University of Wisconsin, Madison and the Geriatric Research, Education and Clinical Center (GRECC), William S. Middleton Memorial Veterans Hospital. This research was supported by NIH grants AG029624, K07AG021582, K23AG024302 and K23AG026752. VA manuscript number 2008-31. NR 172 TC 7 Z9 7 U1 2 U2 4 PU E-CENTURY PUBLISHING CORP PI MADISON PA 40 WHITE OAKS LN, MADISON, WI 53711 USA SN 1943-8141 J9 AM J TRANSL RES JI Am. J. Transl. Res. PY 2009 VL 1 IS 2 BP 131 EP 147 PG 17 WC Oncology; Medicine, Research & Experimental SC Oncology; Research & Experimental Medicine GA V28PW UT WOS:000208693700004 PM 19956426 ER PT J AU Cacciarelli, TV Wagener, M Karuman, P Wannstedt, C Akoad, M AF Cacciarelli, Thomas V. Wagener, Marilyn Karuman, Philip Wannstedt, Cheryl Akoad, Mohamed TI The Fate of "Refused" Imported and Locally Procurred Cadaver Donor Liver Allografts and Impact on Survival SO AMERICAN JOURNAL OF TRANSPLANTATION LA English DT Meeting Abstract CT 9th Joint Meeting of the American-Society-of-Transplant-Surgeon/American-Society-of-Transplantati on CY MAY 30-JUN 03, 2009 CL Boston, MA SP Amer Soc Transplant Surg, Amer Soc Transplantat C1 [Cacciarelli, Thomas V.; Karuman, Philip; Wannstedt, Cheryl] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Wagener, Marilyn] Univ Pittsburgh, Pittsburgh, PA USA. [Akoad, Mohamed] Lahey Clin Fdn, Burlington, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1600-6135 J9 AM J TRANSPLANT JI Am. J. Transplant. PY 2009 VL 9 BP 451 EP 451 PG 1 WC Surgery; Transplantation SC Surgery; Transplantation GA 431NQ UT WOS:000265068800914 ER PT J AU Ahmad, J Wagner, M Francis, FF Karuman, P Cacciarelli, TV AF Ahmad, Jawad Wagner, Marilyn Francis, Fadi F. Karuman, Phillip Cacciarelli, Thomas V. TI Impact of the MELD System on Long-Term Outcome after Liver Transplantation in United States Veterans SO AMERICAN JOURNAL OF TRANSPLANTATION LA English DT Meeting Abstract CT 9th Joint Meeting of the American-Society-of-Transplant-Surgeon/American-Society-of-Transplantati on CY MAY 30-JUN 03, 2009 CL Boston, MA SP Amer Soc Transplant Surg, Amer Soc Transplantat C1 [Ahmad, Jawad; Wagner, Marilyn; Francis, Fadi F.; Karuman, Phillip] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Ahmad, Jawad] Univ Pittsburgh, Div Gastroenterol Hepatol & Nutr, Pittsburgh, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1600-6135 J9 AM J TRANSPLANT JI Am. J. Transplant. PY 2009 VL 9 BP 455 EP 455 PG 1 WC Surgery; Transplantation SC Surgery; Transplantation GA 431NQ UT WOS:000265068800927 ER PT J AU Sun, HY Cacciarelli, TV Wagener, MM Singh, N AF Sun, Hsin-Yun Cacciarelli, Thomas V. Wagener, Marilyn M. Singh, Nina TI Impact of Pre-Transplant Infections on Clinical Outcomes in Liver Transplant Recipients. SO AMERICAN JOURNAL OF TRANSPLANTATION LA English DT Meeting Abstract CT 9th Joint Meeting of the American-Society-of-Transplant-Surgeon/American-Society-of-Transplantati on CY MAY 30-JUN 03, 2009 CL Boston, MA SP Amer Soc Transplant Surg, Amer Soc Transplantat C1 [Sun, Hsin-Yun; Cacciarelli, Thomas V.; Singh, Nina] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Sun, Hsin-Yun] Natl Taiwan Univ Hosp, Taipei, Taiwan. [Cacciarelli, Thomas V.; Wagener, Marilyn M.; Singh, Nina] Univ Pittsburgh, Pittsburgh, PA 15260 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1600-6135 J9 AM J TRANSPLANT JI Am. J. Transplant. PY 2009 VL 9 BP 637 EP 637 PG 1 WC Surgery; Transplantation SC Surgery; Transplantation GA 431NQ UT WOS:000265068801623 ER PT J AU Murray, DR Osaki, S Jewel-Ripp, P Johnson, MR Lozonschi, L Edwards, NM Kohmoto, T AF Murray, David R. Osaki, Satoru Jewel-Ripp, Polly Johnson, Maryl R. Lozonschi, Lucian Edwards, Niloo M. Kohmoto, Takushi TI Ventricular Assist Device Therapy in United States Veterans: A Single Center 5-Year Experience. SO AMERICAN JOURNAL OF TRANSPLANTATION LA English DT Meeting Abstract CT 9th Joint Meeting of the American-Society-of-Transplant-Surgeon/American-Society-of-Transplantati on CY MAY 30-JUN 03, 2009 CL Boston, MA SP Amer Soc Transplant Surg, Amer Soc Transplantat C1 [Murray, David R.; Osaki, Satoru; Jewel-Ripp, Polly; Lozonschi, Lucian; Edwards, Niloo M.; Kohmoto, Takushi] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. [Osaki, Satoru; Lozonschi, Lucian; Edwards, Niloo M.; Kohmoto, Takushi] Univ Wisconsin, Sch Med & Publ Hlth, Div Cardiothorac Surg, Madison, WI USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1600-6135 J9 AM J TRANSPLANT JI Am. J. Transplant. PY 2009 VL 9 BP 655 EP 655 PG 1 WC Surgery; Transplantation SC Surgery; Transplantation GA 431NQ UT WOS:000265068801688 ER PT J AU Becker, WC Meghani, SH Barth, KS Wiedemer, N Gallagher, RM AF Becker, William C. Meghani, Salimah H. Barth, Kelly S. Wiedemer, Nancy Gallagher, Rollin M. TI Characteristics and Outcomes of Patients Discharged from the Opioid Renewal Clinic at the Philadelphia VA Medical Center SO AMERICAN JOURNAL ON ADDICTIONS LA English DT Article ID CHRONIC PAIN PATIENTS; PRIMARY-CARE; SUBSTANCE-ABUSE; THERAPY; MANAGEMENT AB The Opioid Renewal Clinic (ORC) is a pharmacist-run program that assists primary care providers in the management of chronic pain patients with aberrant behavior or high risk of prescription opioid abuse. In this study, charts of all discharged patients over a 22-month span (n = 86) were reviewed for outcomes for two years after discharge. The most frequent reason for discharge from the program was recurrent positive urine drug screens for illicit substances (n = 40; 47%). Only 15 (17%) were seen for addiction treatment in the two-year follow-up period. Forty-one percent of patients (n = 35) were prescribed opioids within two years of discharge. There was a positive correlation between length of time in the ORC and receipt of opioids post discharge. These outcomes reveal areas of need in the management of this complex population. C1 [Becker, William C.; Wiedemer, Nancy; Gallagher, Rollin M.] Philadelphia Vet Affairs Med Ctr, VISN4 MIRECC, Philadelphia, PA USA. Univ Penn, Sch Nursing, NewCourtland Ctr Transit & Hlth, Philadelphia, PA 19104 USA. [Barth, Kelly S.] Univ Penn, Sch Med, Philadelphia, PA 19104 USA. RP Becker, WC (reprint author), VAMC 3900 Woodland Ave, Philadelphia, PA 19104 USA. EM William.Becker4@va.gov OI Becker, William/0000-0002-0788-1467 NR 13 TC 3 Z9 3 U1 1 U2 2 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1055-0496 J9 AM J ADDICTION JI Am. J. Addict. PY 2009 VL 18 IS 2 BP 135 EP 139 AR PII 909499370 DI 10.1080/10550490902772496 PG 5 WC Substance Abuse SC Substance Abuse GA 418GX UT WOS:000264137800006 PM 19283565 ER PT J AU Newton, TF La Garza, R Kalechstein, AD Tziortzis, D Jacobsen, CA AF Newton, Thomas F. De La Garza, Richard, II Kalechstein, Ari D. Tziortzis, Desey Jacobsen, Caitlin A. TI Theories of Addiction: Methamphetamine Users' Explanations for Continuing Drug Use and Relapse SO AMERICAN JOURNAL ON ADDICTIONS LA English DT Article ID INTERNATIONAL NEUROPSYCHIATRIC INTERVIEW; COCAINE-DEPENDENT PATIENTS; DSM-IV; IMPULSIVITY; REWARD; ABUSE; WITHDRAWAL; BEHAVIOR; BRAIN; DYSREGULATION AB A variety of preclinical models have been constructed to emphasize unique aspects of addiction-like behavior. These include Negative Reinforcement (Pain Avoidance), Positive Reinforcement (Pleasure Seeking), Incentive Salience (Craving), Stimulus Response Learning (Habits), and Inhibitory Control Dysfunction (Impulsivity). We used a survey to better understand why methamphetamine-dependent research volunteers (N = 73) continue to use methamphetamine, or relapse to methamphetamine use after a period of cessation of use. All participants met DSM-IV criteria for methamphetamine abuse or dependence, and did not meet criteria for other current Axis I psychiatric disorders or dependence on other drugs of abuse, other than nicotine. The questionnaire consisted of a series of face-valid questions regarding drug use, which in this case referred to methamphetamine use. Examples of questions include: Do you use drugs mostly to make bad feelings like boredom, loneliness, or apathy go away?, Do you use drugs mostly because you want to get high?, Do you use drugs mostly because of cravings?, Do you find yourself getting ready to take drugs without thinking about it?, and Do you impulsively take drugs?. The scale was anchored at 1 (not at all) and 7 (very much). For each question, the numbers of participants rating each question negatively (1 or 2), neither negatively or affirmatively (3-5), and affirmatively (6 or 7) were tabulated. The greatest number of respondents (56%) affirmed that they used drugs due to pleasure seeking. The next highest categories selected were impulsivity (27%) and habits(25%). Surprisingly, many participants reported that pain avoidance (30%) and craving (30%) were not important for their drug use. Results from this study support the contention that methamphetamine users (and probably other drug users as well) are more heterogeneous than is often appreciated, and imply that treatment development might be more successful if treatments targeted subtypes of patients, though a range of limitations to the approach used are acknowledged. C1 [Newton, Thomas F.; De La Garza, Richard, II] Baylor Coll Med, Menninger Dept Psychiatry& Behav Sci, Houston, TX 77030 USA. [Newton, Thomas F.; De La Garza, Richard, II] Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA. [Kalechstein, Ari D.; Tziortzis, Desey; Jacobsen, Caitlin A.] Univ Calif Los Angeles, Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA. RP Newton, TF (reprint author), Baylor Coll Med, Menninger Dept Psychiatry& Behav Sci, 1 Baylor Plaza,BCM350, Houston, TX 77030 USA. EM tnewton@bcm.edu RI De La Garza, Richard/B-2489-2014 OI De La Garza, Richard/0000-0003-1943-4469; newton, thomas/0000-0002-3198-5901 FU NIDA NIH HHS [K24 DA017754, R21 DA017182, R01 DA023468] NR 51 TC 23 Z9 23 U1 2 U2 15 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1055-0496 J9 AM J ADDICTION JI Am. J. Addict. PY 2009 VL 18 IS 4 BP 294 EP 300 AR PII 911211983 DI 10.1080/10550490902925920 PG 7 WC Substance Abuse SC Substance Abuse GA 446FJ UT WOS:000266105800005 PM 19444733 ER PT J AU Gordon, AJ Liberto, J Granda, S Salmon-Cox, S Andree, T McNicholas, L AF Gordon, Adam J. Liberto, Joseph Granda, Stephanie Salmon-Cox, Sara Andree, Tykia McNicholas, Laura TI Physician Training is Never a Failure SO AMERICAN JOURNAL ON ADDICTIONS LA English DT Letter ID OFFICE-BASED TREATMENT; OPIOID DEPENDENCE; ADDICTION MEDICINE; PRIMARY-CARE; BUPRENORPHINE; NALOXONE; UPDATE C1 [Gordon, Adam J.] VA Pittsburgh Healthcare Syst, Mental Illness Res Educ & Clin Ctr, VISN 4, Ctr Hlth Equ Res & Promot, Pittsburgh, PA 15206 USA. [Gordon, Adam J.] Univ Pittsburgh, Ctr Res Hlth Care, Pittsburgh, PA USA. [Gordon, Adam J.] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA. [Liberto, Joseph] VA Maryland Healthcare Syst, Baltimore, MD USA. [Liberto, Joseph] Univ Maryland, Sch Med, Baltimore, MD 21201 USA. [Granda, Stephanie] St Louis Univ, Dept Psychol, St Louis, MO 63103 USA. [McNicholas, Laura] Philadelphia VA Med Ctr, Philadelphia, PA USA. RP Gordon, AJ (reprint author), VA Pittsburgh Healthcare Syst, Mental Illness Res Educ & Clin Ctr, VISN 4, Ctr Hlth Equ Res & Promot, Mailcode 151 C-H,7180 Highland Dr, Pittsburgh, PA 15206 USA. EM adam.gordon@va.gov NR 16 TC 6 Z9 6 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1055-0496 J9 AM J ADDICTION JI Am. J. Addict. PY 2009 VL 18 IS 4 BP 337 EP 338 AR PII 911212111 DI 10.1080/10550490902931373 PG 2 WC Substance Abuse SC Substance Abuse GA 446FJ UT WOS:000266105800040 ER PT J AU Thase, ME Sloan, DM AF Thase, Michael E. Sloan, Diane M. BE Schatzberg, AF Nemeroff, CB TI Venlafaxine and Desvenlafaxine SO AMERICAN PSYCHIATRIC PUBLISHING TEXTBOOK OF PSYCHOPHARMACOLOGY, 4TH EDITION LA English DT Article; Book Chapter ID GENERALIZED ANXIETY DISORDER; MAJOR DEPRESSIVE DISORDER; RANDOMIZED CONTROLLED-TRIAL; EXTENDED-RELEASE VENLAFAXINE; SEROTONIN REUPTAKE INHIBITORS; PLACEBO-CONTROLLED TRIAL; PREMENSTRUAL DYSPHORIC DISORDER; TREATMENT-RESISTANT DEPRESSION; POSTTRAUMATIC-STRESS-DISORDER; OBSESSIVE-COMPULSIVE DISORDER C1 [Thase, Michael E.] Univ Penn, Sch Med, Dept Psychiat, Philadelphia Vet Affairs Med Ctr, Philadelphia, PA 19104 USA. [Thase, Michael E.] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA. [Sloan, Diane M.] Advogent, Wayne, NJ USA. RP Thase, ME (reprint author), Univ Penn, Sch Med, Dept Psychiat, Philadelphia Vet Affairs Med Ctr, Philadelphia, PA 19104 USA. NR 140 TC 2 Z9 2 U1 0 U2 1 PU AMER PSYCHIATRIC PRESS, INC PI WASHINGTON PA 1400 K ST NW, WASHINGTON, DC 20005 USA BN 978-1-58562-309-9 PY 2009 BP 439 EP 452 PG 14 WC Neurosciences; Pharmacology & Pharmacy; Psychiatry SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry GA BCF29 UT WOS:000310050700023 ER PT J AU Marder, SR Wirshing, DA AF Marder, Stephen R. Wirshing, Donna A. BE Schatzberg, AF Nemeroff, CB TI Clozapine SO AMERICAN PSYCHIATRIC PUBLISHING TEXTBOOK OF PSYCHOPHARMACOLOGY, 4TH EDITION LA English DT Article; Book Chapter ID DRUG-INDUCED PSYCHOSIS; INDUCED WEIGHT-GAIN; CHILDHOOD-ONSET SCHIZOPHRENIA; SENSORIMOTOR GATING DEFICITS; SERUM TRIGLYCERIDE LEVELS; COLONY-STIMULATING FACTOR; SUBSTANCE USE DISORDER; INDUCED AGRANULOCYTOSIS; DOUBLE-BLIND; TREATMENT-RESISTANT C1 [Marder, Stephen R.] Univ Calif Los Angeles, Sect Psychosis, Semel Inst Neurosci & Human Behav, Los Angeles, CA 90024 USA. [Marder, Stephen R.] W Los Angeles Vet Affairs Med Ctr, Desert Pacific Mental Illness Res Educ & Clin Ctr, Los Angeles, CA 90073 USA. [Wirshing, Donna A.] Univ Calif Los Angeles, David Geffen Sch Med, Semel Inst Neurosci & Human Behav, Los Angeles, CA 90095 USA. RP Marder, SR (reprint author), Univ Calif Los Angeles, Sect Psychosis, Semel Inst Neurosci & Human Behav, Los Angeles, CA 90024 USA. NR 149 TC 1 Z9 1 U1 3 U2 4 PU AMER PSYCHIATRIC PRESS, INC PI WASHINGTON PA 1400 K ST NW, WASHINGTON, DC 20005 USA BN 978-1-58562-309-9 PY 2009 BP 555 EP 571 PG 17 WC Neurosciences; Pharmacology & Pharmacy; Psychiatry SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry GA BCF29 UT WOS:000310050700029 ER PT J AU Ballon, JS Wirshing, DA Schulz, SC AF Ballon, Jacob S. Wirshing, Donna A. Schulz, S. Charles BE Schatzberg, AF Nemeroff, CB TI Olanzapine SO AMERICAN PSYCHIATRIC PUBLISHING TEXTBOOK OF PSYCHOPHARMACOLOGY, 4TH EDITION LA English DT Article; Book Chapter ID PLACEBO-CONTROLLED-TRIAL; OBSESSIVE-COMPULSIVE DISORDER; INDUCED WEIGHT-GAIN; BORDERLINE PERSONALITY-DISORDER; ATYPICAL ANTIPSYCHOTIC-DRUGS; PROMINENT NEGATIVE SYMPTOMS; RANDOMIZED CONTROLLED-TRIAL; D-2 RECEPTOR OCCUPANCY; METHYL-D-ASPARTATE; ORALLY DISINTEGRATING OLANZAPINE C1 [Ballon, Jacob S.] Stanford Univ, Dept Psychiat & Behav Sci, Stanford, CA 94305 USA. [Schulz, S. Charles] Univ Minnesota, Dept Psychiat, Sch Med, Riverside, CA USA. [Wirshing, Donna A.] Univ Calif Los Angeles, David Geffen Sch Med, Semel Inst Neurosci & Human Behav, Los Angeles, CA 90095 USA. [Wirshing, Donna A.] W Los Angeles Vet Affairs Med Ctr, Los Angeles, CA 90073 USA. RP Ballon, JS (reprint author), Stanford Univ, Dept Psychiat & Behav Sci, Stanford, CA 94305 USA. NR 202 TC 1 Z9 1 U1 1 U2 1 PU AMER PSYCHIATRIC PRESS, INC PI WASHINGTON PA 1400 K ST NW, WASHINGTON, DC 20005 USA BN 978-1-58562-309-9 PY 2009 BP 573 EP 598 PG 26 WC Neurosciences; Pharmacology & Pharmacy; Psychiatry SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry GA BCF29 UT WOS:000310050700030 ER PT J AU Ali, R Cusi, K AF Ali, Rafeeq Cusi, Kenneth TI New diagnostic and treatment approaches in non-alcoholic fatty liver disease (NAFLD) SO ANNALS OF MEDICINE LA English DT Review DE Fatty liver; insulin resistance; NAFLD; NASH; obesity; thiazolidinediones; type 2 diabetes mellitus ID TYPE-2 DIABETIC-PATIENTS; HEPATIC INSULIN-RESISTANCE; ACTIVATED PROTEIN-KINASE; MAGNETIC-RESONANCE-SPECTROSCOPY; PLACEBO-CONTROLLED TRIAL; SEVERELY OBESE SUBJECTS; LIFE-STYLE MODIFICATION; II RECEPTOR ANTAGONIST; GASTRIC BYPASS-SURGERY; NECROSIS-FACTOR-ALPHA AB Non-alcoholic fatty liver disease or NAFLD is a chronic liver condition characterized by hepatic steatosis and associated with insulin resistance and type 2 diabetes mellitus (T2DM). In many patients fat accumulation leads to steatohepatitis (NASH) with chronic necrosis, inflammation, and fibrosis, and eventually to the development of cirrhosis. Obese and T2DM patients are at the greatest risk for NASH and progressive disease. New diagnostic techniques, such as magnetic resonance imaging and spectroscopy (MRS), have enhanced our way to non-invasively quantify liver fat and suggest that the epidemic of NAFLD is much larger than previously believed. However, the diagnosis of NAFLD for clinicians remains difficult due to a number of factors: limited awareness, non-specific symptoms, few laboratory findings, and the need for a liver biopsy to confirm the diagnosis. Traditional treatment approaches have centered on weight loss, but data are limited on its long-term efficacy, and the overall compliance is poor. Recently, pioglitazone has been shown to be safe and effective in patients with NASH and may radically change our approach to the disease. Still, many aspects remain poorly understood. Taken together, wider use of new diagnostic methods and treatment approaches appears to signal the dawn of a new era in the management of NAFLD. C1 [Cusi, Kenneth] Univ Texas Hlth Sci Ctr San Antonio, Diabet Div, San Antonio, TX 78284 USA. [Ali, Rafeeq] Univ Texas Hlth Sci Ctr San Antonio, Div Endocrinol, San Antonio, TX 78284 USA. [Cusi, Kenneth] Audie L Murphy Mem Vet Adm Med Ctr, San Antonio, TX 78284 USA. RP Cusi, K (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Diabet Div, Room 3-380S,7703 Floyd Curl Dr, San Antonio, TX 78284 USA. EM cusi@uthscsa.edu NR 125 TC 61 Z9 78 U1 0 U2 4 PU INFORMA HEALTHCARE PI NEW YORK PA 52 VANDERBILT AVE, NEW YORK, NY 10017 USA SN 0785-3890 EI 1365-2060 J9 ANN MED JI Ann. Med. PY 2009 VL 41 IS 4 BP 265 EP 278 AR PII 907688313 DI 10.1080/07853890802552437 PG 14 WC Medicine, General & Internal SC General & Internal Medicine GA 434QY UT WOS:000265290400003 PM 19353360 ER PT J AU Garvey, WT AF Garvey, W. Timothy TI NUTRITION AND CONTROL OF DIABETES IN HOSPITALIZED PATIENTS SO ANNALS OF NUTRITION AND METABOLISM LA English DT Meeting Abstract C1 [Garvey, W. Timothy] Birmingham VAMC, Birmingham, AL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 0250-6807 J9 ANN NUTR METAB JI Ann. Nutr. Metab. PY 2009 VL 55 SU 1 BP 57 EP 57 PG 1 WC Endocrinology & Metabolism; Nutrition & Dietetics SC Endocrinology & Metabolism; Nutrition & Dietetics GA 507CF UT WOS:000270827200211 ER PT J AU Bilimoria, KY Bentrem, DJ Wayne, JD Ko, CY Bennett, CL Talamonti, MS AF Bilimoria, Karl Y. Bentrem, David J. Wayne, Jeffrey D. Ko, Clifford Y. Bennett, Chales L. Talamonti, Mark S. TI Small Bowel Cancer in the United States Changes in Epidemiology, Treatment, and Survival Over the Lost 20 Years SO ANNALS OF SURGERY LA English DT Article ID CARCINOID-TUMORS; CLINICAL CHARACTERISTICS; REGISTRY; METASTASES; RESECTION; QUALITY; LIVER AB Background: Previous Studies have shown an increasing incidence of small bowel tumors in the United States. Our objective was to assess this increase by examining changes in histology-specific incidence, treatment, and survival. Methods: Patients with small bowel malignancies were identified front the National Cancer Data Base (NCDB, 1985-2005) and the Surveillance Epidemiology and End Results (SEER, 1973-2004) database. Age-adjusted incidence rates were calculated using SEER. Treatment and survival trends over time were examined using the National Cancer Data Base. Regression models were developed to assess survival over time. Results: Sixty-seven thousand eight hundred forty-three patients were identified with small bowel malignancies: 37.4% carcinoid, 36.9% adenocarcinomas, 8.4% stromal tumors, and 17.3% lymphomas. From 1973 to 2004, the incidence of carcinoid tumors increased more than 4-fold (2.1 to 9.3 per million), whereas changes in adenocarcinomas, stromal tumors, and lymphomas were less pronounced. From 1985 to 2005, utilization of surgery increased significantly for carcinoid tumors from 78.8% to 87.4% (P < 0.0001). Adjuvant chemotherapy utilization for adenocarcinoma increased from 8.1 % in 1985 to 23.8% in 2005 (P < 0.0001). Treatment over time was generally unchanged for lymphoma and stromal tumors. Five-year survival after resection remained unchanged overtime for all histologic subtypes even after adjusting for changes in patient demographics, tumor characteristics, and treatment approaches. Conclusions: The overall incidence of small intestine malignancies has increased considerably, primarily because of carcinoid rumors which are now the most common small bowel cancer. With current treatments, Survival has remained relatively unchanged over the last 20 years. Novel therapeutic options need to be investigated. C1 [Bilimoria, Karl Y.; Ko, Clifford Y.] Northwestern Univ, Amer Coll Surg, Canc Programs, Chicago, IL 60611 USA. [Bilimoria, Karl Y.; Bentrem, David J.; Wayne, Jeffrey D.; Talamonti, Mark S.] Northwestern Univ, Dept Surg, Feinberg Sch Med, Chicago, IL 60611 USA. [Ko, Clifford Y.] Univ Calif Los Angeles, Dept Surg, Los Angeles, CA 90024 USA. [Ko, Clifford Y.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Bennett, Chales L.] Northwestern Univ, Div Hematol Oncol, Robert H Lurie Comprehens Canc Ctr, Feinberg Sch Med, Chicago, IL 60611 USA. [Talamonti, Mark S.] Evanston NW Healthcare, Dept Surg, Chicago, IL USA. RP Bilimoria, KY (reprint author), Northwestern Univ, Amer Coll Surg, Canc Programs, 633 N St Clair St,25th Floor, Chicago, IL 60611 USA. EM k-bilimoria@northwestern.edu FU American Cancer Society [IRG 93-037-12] FX The National Cancer Data Base is supported by the American College of Surgeons, the Commission on Cancer, and the American Cancer Society. Supported by the American College of Surgeons Clinical Scholars in Residence (to K.Y.B.) and a grant from the American Cancer Society (ACS IRG 93-037-12) (to D.J.13.). NR 34 TC 151 Z9 164 U1 1 U2 7 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0003-4932 J9 ANN SURG JI Ann. Surg. PD JAN PY 2009 VL 249 IS 1 BP 63 EP 71 DI 10.1097/SLA.0b013e31818c4641 PG 9 WC Surgery SC Surgery GA 391FN UT WOS:000262219300011 PM 19106677 ER PT S AU Stengel, A Tache, Y AF Stengel, Andreas Tache, Yvette TI Neuroendocrine Control of the Gut During Stress: Corticotropin-Releasing Factor Signaling Pathways in the Spotlight SO ANNUAL REVIEW OF PHYSIOLOGY SE Annual Review of Physiology LA English DT Review; Book Chapter DE motility; CRF antagonists; colon; stomach; urocortin ID IRRITABLE-BOWEL-SYNDROME; CENTRAL-NERVOUS-SYSTEM; COLONIC MOTOR FUNCTION; DORSAL VAGAL COMPLEX; FACTOR-RECEPTOR SUBTYPE-1; HORMONE TYPE-1 RECEPTOR; WATER-AVOIDANCE STRESS; FACTOR CRF ANTAGONIST; BINDING-PROTEIN; RAT-BRAIN AB Stress affects the gastrointestinal tract as part of the visceral response. Various stressors induce similar profiles Of gut motor function alterations, including inhibition of gastric emptying, stimulation of colonic propulsive motility, and hypersensitivity to colorectal distension. In recent years, substantial progress has been made in our understanding of the underlying mechanisms of stress's impact on gut function. Activation of corticotropin-releasing factor (CRF) signaling pathways mediates both the inhibition of upper gastrointestinal (GI) and the stimulation of lower GI motor function through interaction with different CRF receptor subtypes. Here, we review how various stressors affect the gut, with special emphasis on the central and peripheral CRF signaling systems. C1 [Stengel, Andreas] Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Ctr Neurobiol Stress, Cure Digest Dis Res Ctr, Los Angeles, CA 90073 USA. VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. RP Stengel, A (reprint author), Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90073 USA. EM ytache@mednet.ucla.edu FU NIAMS NIH HHS [P50 AR 049550]; NIDDK NIH HHS [DK57238, R01 DK057238-08, R01 DK-33061, R01 DK033061, P30 DK041301, R01 DK057238, DK-41301] NR 174 TC 51 Z9 59 U1 0 U2 6 PU ANNUAL REVIEWS PI PALO ALTO PA 4139 EL CAMINO WAY, PO BOX 10139, PALO ALTO, CA 94303-0139 USA SN 0066-4278 BN 978-0-8243-0371-6 J9 ANNU REV PHYSIOL JI Annu. Rev. Physiol. PY 2009 VL 71 BP 219 EP 239 DI 10.1146/annurev.physiol.010908.163221 PG 21 WC Physiology SC Physiology GA 423II UT WOS:000264489600011 PM 18928406 ER PT J AU Finegold, SM Molitoris, D Vaisanen, ML AF Finegold, S. M. Molitoris, D. Vaisanen, M.-L. TI Study of the In Vitro Activities of Rifaximin and Comparator Agents against 536 Anaerobic Intestinal Bacteria from the Perspective of Potential Utility in Pathology Involving Bowel Flora SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY LA English DT Article ID VOLUNTEERS AB Rifaximin, ampicillin-sulbactam, neomycin, nitazoxanide, teicoplanin, and vancomycin were tested against 536 strains of anaerobic bacteria. The overall MIC of rifaximin at which 50% of strains were inhibited was 0.25 mu g/ml. Ninety percent of the strains tested were inhibited by 256 mu g/ml of rifaximin or less, an activity equivalent to those of teicoplanin and vancomycin but less than those of nitazoxanide and ampicillin-sulbactam. C1 [Finegold, S. M.] VA Greater Angeles Healthcare Syst, Med Serv, Los Angeles, CA USA. [Finegold, S. M.; Molitoris, D.; Vaisanen, M.-L.] VA Greater Angeles Healthcare Syst, Res Serv, Los Angeles, CA USA. [Finegold, S. M.] Univ Calif Los Angeles, Sch Med, Dept Med, Los Angeles, CA 90024 USA. [Finegold, S. M.] Univ Calif Los Angeles, Sch Med, Dept Microbiol Immunol & Mol Genet, Los Angeles, CA 90024 USA. RP Finegold, SM (reprint author), Greater Los Angeles VAMC, 11301 Wilshire Blvd,Bldg 304,Rm E3-237, Los Angeles, CA 90073 USA. EM sidfinegol@aol.com FU Salix Pharmaceuticals, Inc., Morrisville, NC FX This study was supported in part by a grant from Salix Pharmaceuticals, Inc., Morrisville, NC. NR 12 TC 15 Z9 15 U1 0 U2 1 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0066-4804 J9 ANTIMICROB AGENTS CH JI Antimicrob. Agents Chemother. PD JAN PY 2009 VL 53 IS 1 BP 281 EP 286 DI 10.1128/AAC.00441-08 PG 6 WC Microbiology; Pharmacology & Pharmacy SC Microbiology; Pharmacology & Pharmacy GA 387JW UT WOS:000261949500040 PM 18955526 ER PT J AU Thompson, GR Wiederhold, NP Fothergill, AW Vallor, AC Wickes, BL Patterson, TF AF Thompson, George R., III Wiederhold, Nathan P. Fothergill, Annette W. Vallor, Ana C. Wickes, Brian L. Patterson, Thomas F. TI Antifungal Susceptibilities among Different Serotypes of Cryptococcus gattii and Cryptococcus neoformans SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY LA English DT Article ID IN-VITRO SUSCEPTIBILITIES; 2 VARIETIES; EPIDEMIOLOGY; INFECTION; DRUGS; HOST AB We measured antifungal activity against 128 cryptococcal isolates (86 of C. neoformans and 42 of C. gattii) to determine if differences in serotype susceptibility exist. Contrary to previous results, we found no serotype susceptibility differences. Isavuconazole, posaconazole, and voriconazole demonstrated excellent potency against each isolate and serotype, including isolates with reduced fluconazole susceptibilities. C1 [Thompson, George R., III; Wiederhold, Nathan P.; Vallor, Ana C.; Patterson, Thomas F.] Univ Texas Hlth Sci Ctr San Antonio, Dept Internal Med, Div Infect Dis, San Antonio, TX 78229 USA. [Wiederhold, Nathan P.] Univ Texas Hlth Sci Ctr San Antonio, Pharmacotherapy Educ & Res Ctr, San Antonio, TX 78229 USA. [Fothergill, Annette W.] Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, Fungus Testing Lab, San Antonio, TX 78229 USA. [Wickes, Brian L.] Univ Texas Hlth Sci Ctr San Antonio, Dept Microbiol, San Antonio, TX 78229 USA. [Wiederhold, Nathan P.] Univ Texas Austin, Coll Pharm, Austin, TX 78712 USA. [Thompson, George R., III; Wiederhold, Nathan P.; Vallor, Ana C.; Patterson, Thomas F.] S Texas Vet Hlth Care Syst, San Antonio, TX USA. RP Thompson, GR (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Internal Med, Div Infect Dis, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM thompsong2@uthscsa.edu OI Wiederhold, Nathan/0000-0002-2225-5122 FU NIH [NOI-A1-25475]; Pfizer; ScheringPlough; Merck; Nektar Therapeutics FX G. R. T., A. W. F, A. C. V., and B. L. W. report no conflicts of interest. N. P. W. has received research support from Pfizer and ScheringPlough. T. F. P. has received research support from Merck, Pfizer, ScheringPlough, and Nektar Therapeutics and has served on the speaker's bureau for Merck and Pfizer and as a consultant for Basilea, Merck, Nektar, Pfizer, and Toyama. NR 20 TC 70 Z9 71 U1 0 U2 1 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0066-4804 J9 ANTIMICROB AGENTS CH JI Antimicrob. Agents Chemother. PD JAN PY 2009 VL 53 IS 1 BP 309 EP 311 DI 10.1128/AAC.01216-08 PG 3 WC Microbiology; Pharmacology & Pharmacy SC Microbiology; Pharmacology & Pharmacy GA 387JW UT WOS:000261949500047 PM 18955539 ER PT B AU Lopez-Ribot, JL Patterson, TF AF Lopez-Ribot, Jose L. Patterson, Thomas F. BE Mayers, DL TI Fungal Drug Resistance: Azoles SO ANTIMICROBIAL DRUG RESISTANCE, VOL 1: MECHANISMS OF DRUG RESISTANCE SE Infectious Disease LA English DT Article; Book Chapter ID HUMAN-IMMUNODEFICIENCY-VIRUS; CANDIDA-ALBICANS STRAINS; YEAST MULTIDRUG-RESISTANCE; AMINO-ACID SUBSTITUTIONS; ABC TRANSPORTERS CDR1; MESSENGER-RNA LEVELS; ANTIFUNGAL AGENTS; FLUCONAZOLE RESISTANCE; OROPHARYNGEAL CANDIDIASIS; INFECTED PATIENTS C1 [Patterson, Thomas F.] Univ Texas Hlth Sci Ctr San Antonio, Div Infect Dis, San Antonio, TX 78229 USA. [Patterson, Thomas F.] S Texas Vet Healthcare Syst, San Antonio, TX USA. [Lopez-Ribot, Jose L.] Univ Texas San Antonio, Dept Biol, San Antonio, TX USA. [Lopez-Ribot, Jose L.] Univ Texas San Antonio, S Texas Ctr Emerging Infect Dis, San Antonio, TX USA. RP Patterson, TF (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Div Infect Dis, San Antonio, TX 78229 USA. EM patterson@uthscsa.edu NR 61 TC 0 Z9 0 U1 1 U2 1 PU HUMANA PRESS INC PI TOTOWA PA 999 RIVERVIEW DR, STE 208, TOTOWA, NJ 07512-1165 USA BN 978-1-60327-592-7 J9 INFECT DIS PY 2009 BP 307 EP 312 DI 10.1007/978-1-59745-180-2_26 PG 6 WC Infectious Diseases; Microbiology; Pharmacology & Pharmacy SC Infectious Diseases; Microbiology; Pharmacology & Pharmacy GA BKN91 UT WOS:000268730400026 ER PT J AU Gowen, BB Fairman, J Dow, S Troyer, R Wong, MH Jung, KH Melby, PC Morrey, JD AF Gowen, Brian B. Fairman, Jeff Dow, Steven Troyer, Ryan Wong, Min-Hui Jung, Kie-Hoon Melby, Peter C. Morrey, John D. TI Prophylaxis with cationic liposome-DNA complexes protects hamsters from phleboviral disease: Importance of liposomal delivery and CpG motifs SO ANTIVIRAL RESEARCH LA English DT Article DE Liposomes; Antiviral; CpG; Rift Valley fever; Punta Toro virus; Phlebovirus ID RIFT-VALLEY FEVER; PUNTA-TORO-VIRUS; INNATE IMMUNE-RESPONSE; BACTERIAL-DNA; TLR9-INDEPENDENT PATHWAYS; HEMORRHAGIC-FEVER; DENDRITIC CELLS; RHESUS-MONKEYS; INFECTION; PATHOGENESIS AB Cationic liposome-DNA complexes (CLDC) are cationic/neutral lipid carriers complexed with plasmid DNA that when administered systemically results in a robust T(H)1 cytokine response. CLDC have been shown to be effective in prophylaxis and therapeutic treatment of animal models of viral disease. To determine the contribution of liposomal delivery and CpG content of the plasmid DNA to the efficacy of CLDC; plasmid, CpG-free plasmid DNA, or CpG-containing oligodeoxynucleotides (ODN) with and without liposomes, as well as poly(I:C(12)U), were evaluated for their ability to elicit protection against lethal Punta Toro virus (PTV, Bunyaviridae, phlebovirus) challenge in hamsters. CLDC-containing plasmid significantly improved survival, decreased systemic and liver viral loads, and reduced liver damage due to progression of viral infection. Mouse-reactive ODNs complexed with liposomes failed to protect hamsters, whereas ODNs known to cross-react with human and mouse (CpG 2006) or non-liposomal poly(I:C(12)U) showed survival benefit but did not limit liver injury. Liposomes complexed with a non-CpG motif-containing plasmid reduced liver viral load and tissue damage, but did not protect hamsters from death. To evaluate the mechanisms of the enhanced activity of CLDC, microarray experiments examined differences in the gene expression profile. The results suggest a broad T(H)1 response elicited by liposomal delivery of a diverse sequence containing CpG and non-CpG elements may be a more effective antiviral treatment than other nucleic acid based immunotherapeutics. (C) 2008 Elsevier B.V. All rights reserved. C1 [Gowen, Brian B.; Wong, Min-Hui; Jung, Kie-Hoon; Morrey, John D.] Utah State Univ, Inst Antiviral Res, Logan, UT 84322 USA. [Gowen, Brian B.; Wong, Min-Hui; Jung, Kie-Hoon; Morrey, John D.] Utah State Univ, Dept Anim Dairy & Vet Sci, Logan, UT 84322 USA. [Fairman, Jeff] Juvaris BioTherapeut, Buringame, CA USA. [Dow, Steven; Troyer, Ryan] Colorado State Univ, Dept Microbiol Immunol & Pathol, Ft Collins, CO 80523 USA. [Melby, Peter C.] S Texas Vet Hlth Care Syst, Res Serv, San Antonio, TX USA. [Melby, Peter C.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA. RP Gowen, BB (reprint author), Utah State Univ, Inst Antiviral Res, Logan, UT 84322 USA. EM bgowen@cc.usu.edu FU Virology Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health [N01-AI-15435]; National Institute of Allergy and Infectious Diseases, National Institutes of Health [1R43AI060146-01A2] FX This work was supported by contract grant N01-AI-15435 from the Virology Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health and grant 1R43AI060146-01A2 from the National Institute of Allergy and Infectious Diseases, National Institutes of Health NR 43 TC 16 Z9 18 U1 0 U2 2 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0166-3542 J9 ANTIVIR RES JI Antiviral Res. PD JAN PY 2009 VL 81 IS 1 BP 37 EP 46 DI 10.1016/j.antiviral.2008.09.001 PG 10 WC Pharmacology & Pharmacy; Virology SC Pharmacology & Pharmacy; Virology GA 396KF UT WOS:000262589900005 PM 18840471 ER PT J AU Hula, WD Hula, SNA Doyle, PJ AF Hula, William D. Hula, Shannon N. Austermann Doyle, Patrick J. TI A preliminary evaluation of the reliability and validity of a self-reported communicative functioning item pool SO APHASIOLOGY LA English DT Article CT 38th Annual Clinical Aphasiology Conference CY MAY 27-JUN 01, 2008 CL Jackson Hole, WY DE Assessment; Aphasia; Psychometrics ID QUALITY-OF-LIFE; STROKE SURVIVORS; RASCH ANALYSIS; SCALE; RATINGS; BURDEN AB Background: Item banking, an approach to test development based in item response theory (IRT), is beginning to be applied to the measurement of communicative functioning in aphasia. This approach involves calibrating a set of test items responding to a particular latent trait to a common measurement scale. One method for validating such scales is to examine the degree to which obtained item calibration estimates agree with a priori item rankings based on theory or expert opinion. Aims: The purpose of this study was to evaluate the utility of magnitude estimation (ME) procedures for validating item banks containing self-reported functional performance items, and to make a preliminary analysis of the validity of a proposed item pool for measuring self-reported communicative functioning in aphasia. Methods Procedures: A total of 14 raters made ME ratings of physical and communicative functioning items. These ratings were evaluated for their intra and inter-observer reliability and, for subsets of the items, their correspondence with previously published IRT calibration estimates was also evaluated. Outcomes Results: Intra-rater reliability was moderate to high, and inter-rater reliability was high. Correspondence with IRT calibrations was high for physical items, and moderate for communication items. The distribution of ME ratings for the communication items was negatively skewed. Conclusions: ME procedures have utility for investigating the validity of functional performance items. The results suggest that communicative functioning may have a more complex latent structure than physical functioning, and that the proposed item pool might benefit from the inclusion of additional items at the lower end of the scale. C1 [Hula, William D.; Hula, Shannon N. Austermann; Doyle, Patrick J.] Dept Vet Affairs Med Ctr, Pittsburgh, PA USA. [Hula, William D.; Doyle, Patrick J.] Univ Pittsburgh, Pittsburgh, PA USA. RP Hula, WD (reprint author), Ctr Geriatr Res Educ & Clin, VA Pittsburgh Healthcare Syst, 7180 Highland Dr,132A-H Pittsburgh, Pittsburgh, PA 15206 USA. EM William.hula@va.gov NR 27 TC 2 Z9 2 U1 1 U2 2 PU PSYCHOLOGY PRESS PI HOVE PA 27 CHURCH RD, HOVE BN3 2FA, EAST SUSSEX, ENGLAND SN 0268-7038 J9 APHASIOLOGY JI Aphasiology PY 2009 VL 23 IS 7-8 BP 783 EP 796 AR PII 909565759 DI 10.1080/02687030802526064 PG 14 WC Clinical Neurology SC Neurosciences & Neurology GA 468QR UT WOS:000267835400002 ER PT J AU Sung, JE McNeil, MR Pratt, SR Dickey, MW Hula, WD Szuminsky, NJ Doyle, PJ AF Sung, Jee Eun McNeil, Malcolm R. Pratt, Sheila R. Dickey, Michael Walsh Hula, William D. Szuminsky, Neil J. Doyle, Patrick J. TI Verbal working memory and its relationship to sentence-level reading and listening comprehension in persons with aphasia SO APHASIOLOGY LA English DT Article CT 38th Annual Clinical Aphasiology Conference CY MAY 27-JUN 01, 2008 CL Jackson Hole, WY DE Working memory; Aphasia; Sentence comprehension; Aphasia severity ID INDIVIDUAL-DIFFERENCES; CAPACITY; ADULTS; TASK AB Background: Working memory (WM) has gained recent attention as a cognitive construct that may account for language comprehension deficits in persons with aphasia (PWA) (Caspari, Parkinson, LaPointe, Katz, 1998; Martin, Kohen, Kalinyak-Fliszar, 2008; Wright, Downey, Gravier, Love, Shapiro, 2007). However, few studies have investigated individual differences in performance on sentence comprehension tasks as a function of WM capacity in PWA when WM demands are manipulated. Aims: The purposes of the current study were: (1) to examine the relationships among verbal WM, sentence comprehension, and severity of impairment in PWA and (2) to investigate the differential performance of high versus low verbal WM groups on sentence comprehension tasks in which task demands were manipulated by the length of the sentence stimuli, complexity of syntactic structure, and by presentation method which varied the time over which the linguistic material was available for computation. Methods Procedures: A total of 20 PWA were divided into high and low WM groups based on a listening version of a WM sentence span task. Each participant completed a listening version (CRTT) and three reading versions (CRTT-R) of the Computerised Revised Token Test as the sentence comprehension tasks. Outcomes Results: The WM task significantly predicted performance on the CRTT conditions in which information was only temporarily available, thereby imposing greater WM demands on sentence comprehension. The verbal WM task was significantly correlated with aphasia severity and a principal components analysis revealed that the WM task, overall aphasia severity, and overall reading impairment level loaded on a single factor with 76% of shared variance. The low WM group's performance was significantly lower than the high WM group on the CRTT subtests with syntactically more complex structures and on the CRTT conditions with temporally restricted presentation methods. Conclusions: This verbal WM task was significantly and moderately correlated with the overall severity of aphasia as well as with both listening and reading sentence comprehension. The WM group differences emerged only in sentence comprehension tasks with greater WM demands. These results are consistent with the notion that WM effects are most evident when WM capacity is sufficiently taxed by the task demands (e.g., Caplan Waters, 1999; Just Carpenter, 1992). C1 [Sung, Jee Eun] Univ Pittsburgh, Pittsburgh, PA 15260 USA. VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. RP Sung, JE (reprint author), Univ Pittsburgh, 4033 Forbes Tower, Pittsburgh, PA 15260 USA. EM jee311@gmail.com RI Pratt, Sheila/H-7139-2013 OI Dickey, Michael Walsh/0000-0002-9068-3313 NR 25 TC 18 Z9 18 U1 2 U2 14 PU PSYCHOLOGY PRESS PI HOVE PA 27 CHURCH RD, HOVE BN3 2FA, EAST SUSSEX, ENGLAND SN 0268-7038 J9 APHASIOLOGY JI Aphasiology PY 2009 VL 23 IS 7-8 BP 1040 EP 1052 AR PII 909574662 DI 10.1080/02687030802592884 PG 13 WC Clinical Neurology SC Neurosciences & Neurology GA 468QR UT WOS:000267835400021 ER PT J AU Allen, DN Goldstein, G Caponigro, JM Donohue, B AF Allen, Daniel N. Goldstein, Gerald Caponigro, Janelle M. Donohue, Bradley TI The Effects of Alcoholism Comorbidity on Neurocognitive Function Following Traumatic Brain Injury SO APPLIED NEUROPSYCHOLOGY LA English DT Article DE alcoholism; Halstead-Reitan Neuropsychological Battery; traumatic brain injury ID YOUNG-ADULTS; ABUSE; SCHIZOPHRENIA; INTOXICATION; CONSUMPTION; DYSFUNCTION; LEVEL AB Alcoholism and traumatic brain injury (TBI) often produce neuropsychological deficits. However, the extent and manner by which these factors interact is unclear. In this study, it was hypothesized that alcoholism would have compounding cognitive effects in individuals with TBI and alcoholism. Participants were divided into three groups, including a patient comparison (PC) group and groups with TBI with or without alcoholism histories. Participants were administered the Wechsler Adult Intelligence Scale-Revised and major components of the Halstead-Reitan Neuropsychological Test Battery. Comparing the groups on test performance, the TBI groups performed significantly worse than the PC group but did not significantly differ from each other. Thus, the effects of TBI on cognitive function overshadow preexisting deficits from the alcoholism. C1 [Allen, Daniel N.; Donohue, Bradley] Univ Nevada, Dept Psychol, Las Vegas, NV 89154 USA. [Goldstein, Gerald; Caponigro, Janelle M.] VA Pittsburgh Healthcare Syst, Mental Illness Res Educ & Clin Ctr, Pittsburgh, PA USA. RP Allen, DN (reprint author), Univ Nevada, Dept Psychol, 4505 Maryland Pkwy, Las Vegas, NV 89154 USA. EM daniel.allen@unlv.edu NR 30 TC 3 Z9 3 U1 2 U2 4 PU PSYCHOLOGY PRESS PI HOVE PA 27 CHURCH RD, HOVE BN3 2FA, EAST SUSSEX, ENGLAND SN 0908-4282 J9 APPL NEUROPSYCHOL JI Appl. Neuropsychol. PY 2009 VL 16 IS 3 BP 186 EP 192 DI 10.1080/09084280903098687 PG 7 WC Clinical Neurology; Psychology SC Neurosciences & Neurology; Psychology GA 500LD UT WOS:000270301000007 PM 20183171 ER PT J AU Moghadam-Kia, S Chilek, K Gaines, E Costner, M Rose, M Okawa, J Werth, VP AF Moghadam-Kia, Siamak Chilek, Katherine Gaines, Elizabeth Costner, Melissa Rose, Mathew Okawa, Joyce Werth, Victoria P. TI A Cutaneous Lupus Erythematosus Database: Review of The First 116 Prospectively Enrolled Patients SO ARCHIVES OF DERMATOLOGICAL RESEARCH LA English DT Meeting Abstract C1 [Werth, Victoria P.] Philadelphia VA Med Ctr, Philadelphia, PA USA. [Moghadam-Kia, Siamak; Chilek, Katherine; Gaines, Elizabeth; Rose, Mathew; Okawa, Joyce; Werth, Victoria P.] Univ Penn, Sch Med, Dept Dermatol, Philadelphia, PA 19104 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0340-3696 J9 ARCH DERMATOL RES JI Arch. Dermatol. Res. PD JAN PY 2009 VL 301 IS 1 BP 45 EP 45 PG 1 WC Dermatology SC Dermatology GA 387QG UT WOS:000261966100050 ER PT J AU Kwarciak, AM Sisto, SA Yarossi, M Price, R Komaroff, E Boninger, ML AF Kwarciak, Andrew M. Sisto, Sue Ann Yarossi, Mathew Price, Robert Komaroff, Eugene Boninger, Michael L. TI Redefining the Manual Wheelchair Stroke Cycle: Identification and Impact of Nonpropulsive Pushrim Contact SO ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION LA English DT Article DE Biomechanics; Rehabilitation; Wheelchair ID SPINAL-CORD-INJURY; SHOULDER JOINT KINETICS; UPPER EXTREMITY PAIN; 2 SPEEDS; PROPULSION BIOMECHANICS; MECHANICAL EFFICIENCY; SEAT POSITION; USERS; INDIVIDUALS; PARAPLEGIA AB Objectives: To create a comprehensive definition of the manual wheelchair stroke cycle, which includes multiple periods of pushrim contact, and to show its improved clinical benefit to wheelchair propulsion analyses. Design: Cross-sectional biomechanics study. Setting: Three motion analysis laboratories. Participants: Persons (N=54) with paraplegia who use a manual wheelchair. Interventions: Not applicable. Main Outcome Measures: Pushrim forces, axle moments, and contact angles measured during wheelchair propulsion. Results: Total force on the pushrim was used to define pushrim contact and positive axle moment was used to identify the included period of propulsive contact. During most strokes, periods of nonpropulsive contact existed before and after propulsive contact. Within these periods, braking moments were applied to the pushrim, resulting in negative power output, or power loss. Including nonpropulsive data decreased mean stroke moment and power. The magnitude and the angle over which braking moments and power loss occurred increased with wheel speed. Mean braking moment and power loss within the initial contact period were significantly (P<.001) related to stroke pattern. Conclusions: The proposed definition of the stroke cycle provides a thorough and practical description of wheelchair propulsion. Researchers and clinicians should use this definition to understand and minimize the impact of nonpropulsive contact throughout the stroke. C1 [Kwarciak, Andrew M.; Sisto, Sue Ann; Yarossi, Mathew; Komaroff, Eugene] Kessler Med Rehabil Res & Educ Ctr, W Orange, NJ 07052 USA. [Sisto, Sue Ann; Komaroff, Eugene] Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Phys Med & Rehabil, Newark, NJ 07103 USA. [Sisto, Sue Ann] SUNY Stony Brook, Dept Rehabil Sci, Stony Brook, NY 11794 USA. [Price, Robert] Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA. [Boninger, Michael L.] Vet Affairs Pittsburgh Healthcare Syst, Human Engn Res Labs, Pittsburgh, PA USA. [Boninger, Michael L.] Univ Pittsburgh, Dept Bioengn & Rehabil Sci & Technol, Pittsburgh, PA USA. [Boninger, Michael L.] Univ Pittsburgh, Dept Phys Med & Rehabil, Med Ctr Hlth Syst, Pittsburgh, PA USA. RP Kwarciak, AM (reprint author), Kessler Med Rehabil Res & Educ Ctr, 1199 Pleasant Valley Way, W Orange, NJ 07052 USA. EM akwarciak@kesslerfoundation.net OI Boninger, Michael/0000-0001-6966-919X FU National Institute on Disability and Rehabilitation Research [H133A011107]; Henry H. Kessler Foundation. FX Supported by the National Institute on Disability and Rehabilitation Research (grain no. H133A011107) and by the Henry H. Kessler Foundation. NR 37 TC 20 Z9 20 U1 2 U2 4 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0003-9993 J9 ARCH PHYS MED REHAB JI Arch. Phys. Med. Rehabil. PD JAN PY 2009 VL 90 IS 1 BP 20 EP 26 DI 10.1016/j.apmr.2008.07.013 PG 7 WC Rehabilitation; Sport Sciences SC Rehabilitation; Sport Sciences GA 397IY UT WOS:000262657600004 PM 19154825 ER PT J AU Muehlenkamp, JJ Williams, KL Gutierrez, PM Claes, L AF Muehlenkamp, Jennifer J. Williams, Kirsten L. Gutierrez, Peter M. Claes, Laurence TI Rates of Non-Suicidal Self-Injury in High School Students Across Five Years SO ARCHIVES OF SUICIDE RESEARCH LA English DT Article DE adolescents; deliberate self-harm; high-school students; non-suicidal self-injury; suicide ID SUICIDE ATTEMPTS; COMMUNITY SAMPLE; RISK-FACTORS; ADOLESCENTS; HARM; BEHAVIOR; TRENDS AB It is believed that the rate of non-suicidal self-injury (NSSI) among high school students is increasing. However, no known research has examined the rates of NSSI among non-clinical, high school samples of adolescents across several years. The current study utilized archival data from five academic years [2001 to 2005 (N = 1393)] to address this limitation by examining the lifetime prevalence rates of NSSI in urban high school students within the Midwestern United States. Results indicate a significant difference in rates across years by gender. Females showed a significant increase in their rates of NSSI compared to males, who showed a significant decline, during the last 3 years of the study. Implications of these findings for school personnel and directions for future research discussed. C1 [Muehlenkamp, Jennifer J.] Univ Wisconsin, Dept Psychol, Eau Claire, WI 54702 USA. [Muehlenkamp, Jennifer J.; Williams, Kirsten L.] Univ N Dakota, Grand Forks, ND 58201 USA. [Gutierrez, Peter M.] Mental Illness Res Educ & Clin Ctr, Denver VA Med Ctr, Denver, CO USA. [Claes, Laurence] Catholic Univ Louvain, B-3000 Louvain, Belgium. RP Muehlenkamp, JJ (reprint author), Univ Wisconsin, Dept Psychol, 277 Hibbard Hall, Eau Claire, WI 54702 USA. EM muehlejj@uwec.edu OI Gutierrez, Peter/0000-0001-8981-8404 NR 25 TC 20 Z9 21 U1 2 U2 5 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 1381-1118 J9 ARCH SUICIDE RES JI Arch. Suicide Res. PY 2009 VL 13 IS 4 BP 317 EP 329 DI 10.1080/13811110903266368 PG 13 WC Psychiatry; Psychology; Psychology, Multidisciplinary SC Psychiatry; Psychology GA 579XO UT WOS:000276410900002 PM 19813109 ER PT J AU Amstadter, AB Koenen, KC Ruggiero, KJ Acierno, R Galea, S Kilpatrick, DG Gelernter, J AF Amstadter, Ananda B. Koenen, Karestan C. Ruggiero, Kenneth J. Acierno, Ron Galea, Sandro Kilpatrick, Dean G. Gelernter, Joel TI Variation in RGS2 is Associated with Suicidal Ideation in an Epidemiological Study of Adults Exposed to the 2004 Florida Hurricanes SO ARCHIVES OF SUICIDE RESEARCH LA English DT Article DE gene association; RGS2; suicidal ideation; suicide; trauma ID POPULATION GROUP ASSIGNMENT; POSTTRAUMATIC-STRESS; GENE POLYMORPHISMS; SOCIAL SUPPORT; RISK-FACTORS; BEHAVIOR; ANXIETY; MARKERS; MODULATORS; GENOTYPE AB This study examined whether rs4606, a single nucleotide polymorphism (SNP) in the translated region at the 3' end of RGS2, was related to suicidal ideation in an epidemiologic sample of adults living in areas affected by the 2004 Florida hurricanes. An epidemiologic sample of residents of Florida was recruited via random digit-dial procedures after the 2004 Florida hurricanes; participants were interviewed about suicidal ideation, hurricane exposure, and social support. Participants who returned buccal DNA samples via mail (n = 607) were included here. Rs4606 in RGS2 was associated with increased symptoms of current suicidal ideation (p < 0.01). Each "C" allele was associated with 5.59 times increased risk of having current ideation. No gene-by-environment interactions were found, perhaps due to low power. RGS2 rs4606 is related to risk of current suicidal ideation in stressor-exposed adults. C1 [Amstadter, Ananda B.] Med Univ S Carolina, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA. [Koenen, Karestan C.] Harvard Univ, Sch Publ Hlth, Dept Soc Human Dev & Hlth, Boston, MA 02115 USA. [Koenen, Karestan C.] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA. [Ruggiero, Kenneth J.; Acierno, Ron; Kilpatrick, Dean G.] Med Univ S Carolina, Dept Psychiat, Charleston, SC 29425 USA. [Ruggiero, Kenneth J.; Acierno, Ron] Ralph Johnson VA Med Ctr, Charleston, SC USA. [Galea, Sandro] Univ Michigan, Sch Publ Hlth, Dept Epidemiol, Ann Arbor, MI 48109 USA. [Gelernter, Joel] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT USA. [Gelernter, Joel] Yale Univ, Sch Med, Dept Genet, New Haven, CT 06510 USA. [Gelernter, Joel] Yale Univ, Sch Med, Dept Neurobiol, New Haven, CT USA. RP Amstadter, AB (reprint author), Med Univ S Carolina, Dept Psychiat & Behav Sci, 67 President St,2-S, Charleston, SC 29425 USA. EM amstadt@musc.edu FU NIDA NIH HHS [K24 DA015105, K24 DA15105]; NIMH NIH HHS [F32 MH083469, F32 MH083469-01, K08 MH070627, K08 MH070627-06, K08-MH070627, MH05220, MH07055, MH078928, R01 MH078928, R01 MH078928-01A1, R21 MH074469-02]; PHS HHS [083469] NR 31 TC 6 Z9 6 U1 4 U2 6 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 1381-1118 J9 ARCH SUICIDE RES JI Arch. Suicide Res. PY 2009 VL 13 IS 4 BP 349 EP 357 DI 10.1080/13811110903266541 PG 9 WC Psychiatry; Psychology; Psychology, Multidisciplinary SC Psychiatry; Psychology GA 579XO UT WOS:000276410900005 PM 19813112 ER PT J AU Gaffo, AL Edwards, NL Saag, KG AF Gaffo, Angelo L. Edwards, N. Lawrence Saag, Kenneth G. TI Hyperuricemia and cardiovascular disease: how strong is the evidence for a causal link? SO ARTHRITIS RESEARCH & THERAPY LA English DT Review ID SERUM URIC-ACID; INTIMA-MEDIA THICKNESS; ALL-CAUSE MORTALITY; GLOMERULAR HYPERTENSION; BLOOD-PRESSURE; LONG-TERM; INDEPENDENT PREDICTOR; METABOLIC SYNDROME; OXIDATIVE STRESS; KIDNEY-FUNCTION AB An association between high levels of serum urate and cardiovascular disease has been proposed for many decades. However, it was only recently that compelling basic science data, small clinical trials, and epidemiological studies have provided support to the idea of a true causal effect. In this review we present recently published data that study the association between hyperuricemia and selected cardiovascular diseases, with a final conclusion about the possibility of this association being causal. C1 [Saag, Kenneth G.] Univ Alabama, Div Clin Immunol & Rheumatol, Birmingham, AL 35294 USA. [Edwards, N. Lawrence] Univ Florida, Div Rheumatol, Gainesville, FL 32610 USA. [Gaffo, Angelo L.] Birmingham VA Med Ctr, Birmingham, AL 35233 USA. RP Saag, KG (reprint author), Univ Alabama, Div Clin Immunol & Rheumatol, FOT 820,1530 3rd Ave S, Birmingham, AL 35294 USA. EM ksaag@uab.edu FU Takeda; Savient; Merck FX Research grants were received from Takeda, Savient and Merck. NR 51 TC 30 Z9 32 U1 1 U2 3 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1478-6354 J9 ARTHRITIS RES THER JI Arthritis Res. Ther. PY 2009 VL 11 IS 4 AR 240 DI 10.1186/ar2761 PG 7 WC Rheumatology SC Rheumatology GA 508MU UT WOS:000270936400011 PM 19725932 ER PT J AU Tian, L Luo, NL Klein, RL Chung, BH Garvey, WT Fu, YC AF Tian, Ling Luo, Nanlan Klein, Richard L. Chung, B. Hong Garvey, W. Timothy Fu, Yuchang TI Adiponectin reduces lipid accumulation in macrophage foam cells SO ATHEROSCLEROSIS LA English DT Article DE Adiponectin; Lipid accumulation; Macrophage foam cells; Atherosclerosis ID LOW-DENSITY-LIPOPROTEIN; MONOCYTE-DERIVED MACROPHAGES; PLASMA-PROTEIN ADIPONECTIN; ACTIVATED RECEPTOR-GAMMA; PPAR-GAMMA; CHOLESTEROL EFFLUX; METABOLIC SYNDROME; DEFICIENT MICE; ATHEROSCLEROSIS; DIFFERENTIATION AB Adiponectin is one of several, important metabolically active cytokines secreted from adipocytes. Low circulating levels of this adipokine have been associated epidemiologically with obesity. insulin resistance, type 11 diabetes, and cardiovascular disease. To determine if adiponectin can modulate lipid metabolism in macrophages, we expressed the adiponectin gene in human THP-1 macrophage foam Cells using a lentiviral vector expression system and demonstrated that macrophages transduced with the adiponectin gene had decreased lipid accumulation compared with control macrophages transduced with the LacZ gene. Macrophages transduced with the adiponectin gene also exhibited decreased oxidized low-density lipoprotein (oxLDL) uptake and increased HDL-mediated cholesterol efflux. Additional studies Suggest two potential mechanisms for the reduced lipid accumulation in these adiponectin-transduced macrophage foam cells. The first mechanism involves the PPAR gamma and LXR signaling pathways which up-regulate the expression of ABCA1 and promote lipid efflux front these cells. The second mechanism involves decreased lipid uptake and increased lipid hydrolysis which may result front decreased SR-AI and increased SR-BI and HSL gene activities in the transformed macrophage foam cells. We also demonstrated that the expression of two proatherogenic cytokines, MCP-1 and TNF alpha. were decreased in the adiponectin-transduced macrophage foam cells. These results suggest that adiponectin may modulate Multiple pathways of lipid metabolism in macrophages. Our Studies provide new insights into potential mechanisms of adiponectin-mediated alterations in lipid metabolism and macrophage foam cell formation which may impact the development of atherosclerosis. (C) 2008 Elsevier Ireland Ltd. All rights reserved. C1 [Tian, Ling; Luo, Nanlan; Chung, B. Hong; Garvey, W. Timothy; Fu, Yuchang] Univ Alabama, Dept Nutr Sci, Birmingham, AL 35294 USA. [Garvey, W. Timothy] Birmingham VA Med Ctr, Birmingham, AL 35233 USA. [Klein, Richard L.] Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA. [Klein, Richard L.] Ralph H Johnson Dept Vet Affairs Med Ctr, Charleston, SC 29401 USA. RP Fu, YC (reprint author), Univ Alabama, Dept Nutr Sci, Shelby Bldg 1213, Birmingham, AL 35294 USA. EM yfu@uab.edu RI Tian, Ling/J-6417-2012 FU National Institutes of Health [PO1-HL55782, DK38764, P20 RR16434]; Medical Research Service of the Department of Veterans Affairs; American Diabetes Association [1-07-RA-49] FX This work was supported by grants from the National Institutes of Health (PO1-HL55782, DK38764) and the Merit Review Program of the Medical Research Service of the Department of Veterans Affairs to WTG and RLK: by grants from National Institutes of Health (P20 RR16434) and American Diabetes Association (1-07-RA-49) to YF NR 30 TC 61 Z9 67 U1 0 U2 10 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0021-9150 J9 ATHEROSCLEROSIS JI Atherosclerosis PD JAN PY 2009 VL 202 IS 1 BP 152 EP 161 DI 10.1016/j.atherosclerosis.2008.04.011 PG 10 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 398JW UT WOS:000262729400021 PM 18511057 ER PT J AU Carlson, NE Brenner, LA Wierman, ME Harrison-Felix, C Morey, C Gallagher, S Ripley, D AF Carlson, N. E. Brenner, L. A. Wierman, M. E. Harrison-Felix, C. Morey, C. Gallagher, S. Ripley, D. TI Hypogonadism on admission to acute rehabilitation is correlated with lower functional status at admission and discharge SO BRAIN INJURY LA English DT Article DE Endocrine dysfunction; physical function; testosterone; traumatic brain injury ID TRAUMATIC BRAIN-INJURY; LOW TESTOSTERONE LEVELS; SEX-HORMONES; HEAD-INJURY; NEUROENDOCRINE DYSFUNCTION; SUBARACHNOID HEMORRHAGE; COGNITIVE FUNCTION; PRACTICAL SCALE; INFECTED MEN; ELDERLY-MEN AB Primary objective: To investigate the association between hormone levels and functional status during acute TBI rehabilitation. Research design: Retrospective cohort study of 43 men with moderate-to-severe TBI admitted to an acute rehabilitation unit during a 1 year period. Methods and procedures: Labs were drawn on admission, including total and free testosterone (T), prolactin, adrenocorticotropin hormone (ACTH), cortisol, thyroid stimulating hormone (TSH), free thyroxine (fT4) and insulin-like growth factor (IGF-1). Functional Independence Measure (FIM) scores were obtained at admission and discharge. Main outcome and results: Associations between admission hormone levels and the main outcomes, admission and discharge FIM scores, were assessed using linear regression. Lower total and free T-levels at admission were associated with lower total FIM scores at admission (p 0.038) and discharge (p 0.046). Higher cortisol levels at admission were significantly associated with lower admission (p = 0.012) and discharge (p = 0.036) scores on the cognitive-FIM. Prolactin, TSH, fT4 and IGF-1 were not correlated with functional status. Conclusions: In men, lower total and free T-levels at admission to acute rehabilitation correlate with lower admission and discharge FIM scores. These data support the need for studies to investigate the impact of physiological testosterone therapy on outcomes during and post-rehabilitation. C1 [Carlson, N. E.] Univ Colorado Denver, Dept Biostat & Informat, Aurora, CO 80045 USA. [Brenner, L. A.] VA VISN 19 Mental Illness Res Educ & Clin Ctr, Denver, CO USA. [Brenner, L. A.; Harrison-Felix, C.; Morey, C.; Ripley, D.] Craig Hosp, Rocky Mt Reg Traumat Brain Injury Syst, Englewood, CO USA. [Wierman, M. E.] Univ Colorado, Dept Psychiat, Denver, CO USA. [Brenner, L. A.] Univ Colorado, Dept Neurol, Denver, CO USA. [Brenner, L. A.; Harrison-Felix, C.] Univ Colorado, Dept Phys Med & Rehabil, Denver, CO USA. [Wierman, M. E.] Univ Colorado, Sch Med, Dept Med, Denver, CO USA. [Wierman, M. E.] Denver VA Med Ctr, Res Serv, Denver, CO USA. [Gallagher, S.] Childrens Hosp, Denver, CO 80218 USA. RP Carlson, NE (reprint author), Univ Colorado Denver, Dept Biostat & Informat, 17000 E 17th PL,MS C245, Aurora, CO 80045 USA. EM nichole.carlson@ucdenver.edu NR 48 TC 15 Z9 15 U1 0 U2 0 PU TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND SN 0269-9052 J9 BRAIN INJURY JI Brain Inj. PY 2009 VL 23 IS 4 BP 336 EP 344 AR PII 909972518 DI 10.1080/02699050902788535 PG 9 WC Neurosciences; Rehabilitation SC Neurosciences & Neurology; Rehabilitation GA 425MY UT WOS:000264643000008 PM 19330595 ER PT J AU Saunders, LL Selassie, AW Hill, EG Nicholas, JS Horner, MD Corrigan, JD Lackland, DT AF Saunders, Lee L. Selassie, Anbesaw W. Hill, Elizabeth G. Nicholas, Joyce S. Horner, Michael David Corrigan, John D. Lackland, Daniel T. TI A population-based study of repetitive traumatic brain injury among persons with traumatic brain injury SO BRAIN INJURY LA English DT Article DE Brain injuries; epilepsy; seizures; epidemiology; survival analysis ID PROFESSIONAL FOOTBALL PLAYERS; RECURRENT CONCUSSION; SOCIOECONOMIC-STATUS; UNITED-STATES; HEAD TRAUMA; RATES; HOSPITALIZATION; COLLEGIATE; SEIZURES; OUTCOMES AB Primary objective: The objective was to estimate and compare the hazards of repetitive traumatic brain injury (RTBI) events as a function of the index TBI severity, in a cohort of TBI hospital discharges include in the South Carolina Traumatic Brain Injury Follow-up Registry. Research design: Retrospective cohort. Methods and procedures: There were 4357 persons with TBI who were followed from the index hospital discharge through 31 December 2005 for RTBI events through the statewide hospital discharge (HD) and emergency department (ED) records. Prentice, Williams, Peterson total time/conditional probability model (PWP-CP) for recurrent events survival analysis was used to assess RTBI as a function of index TBI severity. Main outcomes and results: Index TBI severity approached significance in its relationship with RTBI, with persons with a severe index TBI experiencing events at a higher rate than those with a mild/moderate index TBI. Among the other covariates evaluated, epilepsy/seizure disorder, race, gender, payer status, cause of injury and having a prior history of TBI were associated with RTBI. Conclusions: While TBI severity approached significance with RTBI, other variables, such as epilepsy/seizure disorder, seem to have a more significant relationship with RTBI. C1 [Saunders, Lee L.] Med Univ S Carolina, Dept Hlth Sci & Res, Charleston, SC 29425 USA. [Selassie, Anbesaw W.; Hill, Elizabeth G.; Nicholas, Joyce S.; Lackland, Daniel T.] Med Univ S Carolina, Dept Biostat Bioinformat & Epidemiol, Charleston, SC 29425 USA. [Horner, Michael David] Med Univ S Carolina, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA. [Horner, Michael David] Ralph H Johnson Dept Vet Affairs Med Ctr, Mental Hlth Serv, Charleston, SC USA. [Corrigan, John D.] Ohio State Univ, Dept Phys Med & Rehabil, Columbus, OH 43210 USA. RP Saunders, LL (reprint author), Med Univ S Carolina, Dept Hlth Sci & Res, 77 President St,Suite 117,MSC 700, Charleston, SC 29425 USA. EM saundel@musc.edu FU Division of Injury Response, National Center for Injury Prevention and Control (CIPC), Centers for Disease Control and Prevention (CDC) [U17/CCU421926] FX This study was supported by Grant No. U17/CCU421926 from the Division of Injury Response, National Center for Injury Prevention and Control (CIPC), Centers for Disease Control and Prevention (CDC) ( PI: Anbesaw W. Selassie). The study was performed pursuant to a jointly financed cooperative arrangement between the NCPIC, the National Center for Chronic Disease Prevention and Health Promotion, CDC and the Social Security Administration (SSA), Office of Disability Income and Support Programs. The opinions and conclusions expressed are solely the authors' and should not be construed as representing the opinions or policy of CDC, SSA, or any agency of the federal government. NR 33 TC 10 Z9 10 U1 5 U2 8 PU TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND SN 0269-9052 J9 BRAIN INJURY JI Brain Inj. PY 2009 VL 23 IS 11 BP 866 EP 872 AR PII 915242880 DI 10.1080/02699050903283213 PG 7 WC Neurosciences; Rehabilitation SC Neurosciences & Neurology; Rehabilitation GA 498JY UT WOS:000270137300002 PM 20100122 ER PT J AU Xiang, N Zhao, R Zhong, WX AF Xiang, Nong Zhao, Rui Zhong, Weixiong TI Sodium selenite induces apoptosis by generation of superoxide via the mitochondrial-dependent pathway in human prostate cancer cells SO CANCER CHEMOTHERAPY AND PHARMACOLOGY LA English DT Article DE Antioxidant enzymes; Apoptosis; Mitochondria; Selenium Superoxide ID OXIDATIVE STRESS; CARCINOSTATIC ACTIVITY; IONIZING-RADIATION; HEPG(2) CELLS; PREVENTION; SELENOMETHIONINE; RISK; CHEMOPREVENTION; METHIONINASE; INVOLVEMENT AB Purpose Studies have demonstrated that selenium supplementation reduces the incidence of cancer, particularly prostate cancer. Evidence from experimental studies suggests that apoptosis is a key event in cancer chemoprevention by selenium and reactive oxygen species play a role in induction of apoptosis by selenium compounds. The current study was designed to investigate the role of superoxide and mitochondria in selenite-induced apoptosis in human prostate cancer cells. Methods LNCaP cells were transduced with adenoviral constructs to overexpress four primary antioxidant enzymes: manganese superoxide dismutase (MnSOD), copper-zinc superoxide dismutase (CuZnSOD), catalase (CAT), or glutathione peroxidase 1 (GPx1). Cell viability, apoptosis, and superoxide production induced by sodium selenite were analyzed by the MTT assay, chemiluminescence, flow cytometry, western blot analysis, and Hoechst 33342 staining following overexpression of these antioxidant enzymes. Results Our study shows the following results: (1) selenite induced cancer cell death and apoptosis by producing superoxide radicals; ( 2) selenite-induced superoxide production, cell death, and apoptosis were inhibited by overexpression of MnSOD, but not by CuZnSOD, CAT, or GPx1; and (3) selenite treatment resulted in a decrease in mitochondrial membrane potential, release of cytochrome c into the cytosol, and activation of caspases 9 and 3, events that were suppressed by overexpression of MnSOD. Conclusions This study demonstrates that selenite induces cell death and apoptosis by production of superoxide in mitochondria and activation of the mitochondrial apoptotic pathway and MnSOD plays an important role in protection against prooxidant effects of superoxide from selenite. The data suggest that superoxide production in mitochondria is, at least in part, a key event in selenium-induced apoptosis in prostate cancer cells. C1 [Xiang, Nong; Zhao, Rui; Zhong, Weixiong] Univ Wisconsin, Dept Pathol & Lab Med, Sch Med & Publ Hlth, Madison, WI 53792 USA. [Zhong, Weixiong] William S Middleton Mem Vet Adm Med Ctr, Pathol & Lab Med Serv, Madison, WI 53705 USA. RP Zhong, WX (reprint author), Univ Wisconsin, Dept Pathol & Lab Med, Sch Med & Publ Hlth, Madison, WI 53792 USA. EM wzhong3@wisc.edu FU National Cancer Institute [CA114281]; Office of Research and Development, Biomedical Laboratory Research and Development Service, Department of Veterans Affairs FX We thank Dr. Jeanne Bourdeau-Heller for her technical assistance. This work was funded, in part, by grants from the National Cancer Institute (CA114281) and the Office of Research and Development, Biomedical Laboratory Research and Development Service, Department of Veterans Affairs. NR 44 TC 55 Z9 60 U1 0 U2 12 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0344-5704 J9 CANCER CHEMOTH PHARM JI Cancer Chemother. Pharmacol. PD JAN PY 2009 VL 63 IS 2 BP 351 EP 362 DI 10.1007/s00280-008-0745-3 PG 12 WC Oncology; Pharmacology & Pharmacy SC Oncology; Pharmacology & Pharmacy GA 377XX UT WOS:000261286800018 PM 18379781 ER PT J AU Latini, DM Hart, SL Coon, DW Knight, SJ AF Latini, David M. Hart, Stacely L. Coon, David W. Knight, Sara J. TI Sexual Rehabilitation After Localized Prostate Cancer Current Interventions and Future Directions SO CANCER JOURNAL LA English DT Article DE prostate cancer; symptom management; psychosocial interventions; conceptual model ID QUALITY-OF-LIFE; SELF-MANAGEMENT PROGRAM; LOW-INCOME PATIENTS; RADICAL PROSTATECTOMY; ERECTILE DYSFUNCTION; STRESS-MANAGEMENT; RANDOMIZED-TRIAL; SUPPORT GROUPS; HEALTH-STATUS; STEPPED CARE AB Many published articles have documented the impact of prostate-cancer treatment on sexual functioning in men treated for localized disease. Surprisingly, the literature on interventions to rehabilitate men's sexual functioning is much more limited. In this article, we review the sexual-rehabilitation interventions for prostate-cancer patients and identify a number of common themes across interventions. We also identify areas where further research is needed and propose a conceptual model based on psychologic and nursing theories and informed by the published research. C1 [Latini, David M.] Michael E DeBakey VA Med Ctr, Dev Ctr Excellence, Houston, TX USA. [Latini, David M.] Michael E DeBakey VA Med Ctr, Hlth Serv Res, Houston, TX USA. [Latini, David M.] Michael E DeBakey VA Med Ctr, Baylor Coll Med, Dan L Duncan Canc Ctr, Houston, TX USA. [Latini, David M.] Michael E DeBakey VA Med Ctr, Scott Dept Urol, Houston, TX USA. [Hart, Stacely L.] Ryerson Univ, Dept Psychol, Toronto, ON, Canada. [Coon, David W.] Arizona State Univ, Coll Nursing & Healthcare Innovat, Phoenix, AZ USA. [Knight, Sara J.] Univ Calif San Francisco, San Francisco Comprehens Canc Ctr, San Francisco, CA 94143 USA. [Knight, Sara J.] Genitourinary Canc Epidemiol & Populat Sci Progra, Dept Psychiat, San Francisco, CA USA. [Knight, Sara J.] Genitourinary Canc Epidemiol & Populat Sci Progra, Dept Urol, San Francisco, CA USA. [Knight, Sara J.] San Francisco VA Med Ctr, San Francisco, CA USA. RP Latini, DM (reprint author), Michael E DeBakey Vet Affairs Med Ctr 152, HSR&D Ctr Excellence, 2002 Holcombe Blvd, Houston, TX 77030 USA. EM david.latini@va.gov RI Hart, Stacey/E-4819-2011 OI Latini, David/0000-0002-6161-4861 FU National Cancer Institute [R03 CA101586, R03 CA128475]; Health Services Research & Development Center of Excellence; Michael E. DeBakey Veterans Affairs Medical Center [HFP90-020]; American Cancer Society [06-083-01-CPPB] FX Supported by National Cancer Institute grants R03 CA101586 (to D.M.L.) and R03 CA128475 (to D.W.C.), in part by Health Services Research & Development Center of Excellence, Michael E. DeBakey Veterans Affairs Medical Center grant HFP90-020, and the American Cancer Society Grant 06-083-01-CPPB (to D.M.L.). NR 60 TC 15 Z9 16 U1 1 U2 8 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1528-9117 J9 CANCER J JI Cancer J. PD JAN-FEB PY 2009 VL 15 IS 1 BP 34 EP 40 PG 7 WC Oncology SC Oncology GA 405FA UT WOS:000263207000007 PM 19197171 ER PT J AU Knight, SJ Latini, DM AF Knight, Sara J. Latini, David M. TI Sexual Side Effects and Prostate Cancer Treatment Decisions Patient Information Needs and Preferences SO CANCER JOURNAL LA English DT Article DE prostate; cancer treatment; sexual side effects ID QUALITY-OF-LIFE; TREATMENT CHOICES; HEALTH STATES; UTILITIES; MEN; AIDS; PREDICTORS; MANAGEMENT; CARCINOMA; OUTCOMES AB Prostate cancer treatment decision making requires complex trade-offs among treatment outcomes, and sexual function is a central consideration for most men. Although sexual function is included in prostate cancer decision models, survival and fear of recurrence and cancer progression weigh more heavily in these decisions for many men than concerns about treatment impact on sexuality. In this article, we discuss the importance of sexuality in men's treatment decisions for prostate cancer. We focus on men's preferences for maintaining sexual function and their needs for information about the risk of sexual side effects with prostate cancer treatment. Our review suggests that among men diagnosed with prostate cancer sexual function is less important to men than concerns about survival, but is more highly valued than other side effects and treatment characteristics. However, there is evidence that concerns about sexuality are not in proportion with the associated risk for sexual problems with prostate cancer treatment and men acknowledge unmet needs for information about sexuality in making prostate cancer treatment decisions. C1 [Knight, Sara J.] Univ Calif San Francisco, San Francisco VA Med Ctr, Program Improve Care Vet Complex Comorbid Condit, San Francisco, CA 94121 USA. [Knight, Sara J.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94121 USA. [Knight, Sara J.] Univ Calif San Francisco, Dept Urol, San Francisco, CA 94121 USA. [Latini, David M.] Baylor Coll Med, Michael E DcBakey VA Med Ctr, Hlth Serv Res & Dev Ctr Excellence, Scott Dept Urol, Houston, TX 77030 USA. [Latini, David M.] Baylor Coll Med, Dan L Duncan Canc Ctr, Houston, TX 77030 USA. RP Knight, SJ (reprint author), Univ Calif San Francisco, San Francisco VA Med Ctr, Program Improve Care Vet Complex Comorbid Condit, 4150 Clement St, San Francisco, CA 94121 USA. EM sara.knight@med.va.gov OI Latini, David/0000-0002-6161-4861 FU Veterans Administration (VA) Health Services Research and Development [IIR02-142-1]; Health Services Research & Development Center of Excellence [HFP90-020]; Mentored Research Scholar [06-083-01-CPPB]; American Cancer Society FX The contents of this work are solely the responsibility of the author and do not necessarily represent the official views of the Department of Veterans Affairs. NR 45 TC 14 Z9 15 U1 2 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1528-9117 J9 CANCER J JI Cancer J. PD JAN-FEB PY 2009 VL 15 IS 1 BP 41 EP 44 PG 4 WC Oncology SC Oncology GA 405FA UT WOS:000263207000008 PM 19197172 ER PT J AU Tabassam, FH Graham, DY Yamaoka, Y AF Tabassam, Fazal H. Graham, David Y. Yamaoka, Yoshio TI Helicobacter pylori activate epidermal growth factor receptor- and phosphatidylinositol 3-OH kinase-dependent Akt and glycogen synthase kinase 3 beta phosphorylation SO CELLULAR MICROBIOLOGY LA English DT Article ID GASTRIC EPITHELIAL-CELLS; NF-KAPPA-B; MUCOSAL INTERLEUKIN-8 PRODUCTION; PROMOTER ACTIVATION; DOWN-REGULATION; CANCER CELLS; PROTEIN; PATHWAY; OIPA; CHEMORESISTANCE AB The signalling pathways leading to the development of Helicobacter pylori-induced gastric cancer remain poorly understood. We tested the hypothesis that H. pylori infections involve the activation of Akt signalling in human gastric epithelial cancer cells. Immunoblot, immunofluorescence and kinase assays show that H. pylori infection of gastric epithelial cells induced phosphorylation of Akt at Ser 473 and Thr 308. Mutations in the H. pylori virulence factor OipA dramatically reduced phosphorylation of Ser 473, while the cag pathogenicity island mutants predominantly inhibited phosphorylation of Thr 308. As the downstream of Akt activation, H. pylori infection inactivated the inactivation of glycogen synthase kinase 3 beta at Ser 9 by its phosphorylation. As the upstream of Akt activation, H. pylori infection activated epidermal growth factor receptor (EGFR) at Tyr 992, phosphatidylinositol 3-OH kinase (PI3K) p85 subunit and PI3K-dependent kinase 1 at Ser 241. Pharmacologic inhibitors of PI3K or mitogen-activated protein kinase kinase (MEK), Akt knock-down and EGFR knock-down showed that H. pylori infection induced the activation of EGFR -> PI3K -> PI3K-dependent kinase 1 -> Akt -> extracellular signal-regulated kinase signalling pathways, the inactivation of glycogen synthase kinase 3 beta and interleukin-8 production. The combined functions of cag pathogenicity island and OipA were necessary and sufficient for full activation of signalling at each level. We propose activation of these pathways as a novel mechanism for H. pylori-mediated carcinogenesis. C1 [Yamaoka, Yoshio] Michael DeBakey Vet Affairs Med Ctr, Dept Med Gastroenterol, Houston, TX 77030 USA. Baylor Coll Med, Houston, TX 77030 USA. RP Yamaoka, Y (reprint author), Michael DeBakey Vet Affairs Med Ctr, Dept Med Gastroenterol, Houston, TX 77030 USA. EM yyamaoka@bcm.tmc.edu FU Office of Research and Development Medical Research Service Department of Veterans Affairs [DK56338]; NIH [DK 62813] FX This material is based upon work supported in part by the Office of Research and Development Medical Research Service Department of Veterans Affairs, by Public Health Service Grant DK56338 that funds the Texas Medical Center Digestive Diseases Center. The project described was also supported by Grant Number DK 62813 from NIH. Their contents are solely the responsibility of the authors and do not necessarily represent the official views of the VA or NIH. NR 49 TC 53 Z9 53 U1 0 U2 0 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1462-5814 J9 CELL MICROBIOL JI Cell Microbiol. PD JAN PY 2009 VL 11 IS 1 BP 70 EP 82 DI 10.1111/j.1462-5822.2008.01237.x PG 13 WC Cell Biology; Microbiology SC Cell Biology; Microbiology GA 390FQ UT WOS:000262150100006 PM 18782353 ER PT J AU Zimmerman, B Simaan, M Lee, MH Luttrell, LM Laporte, SA AF Zimmerman, Brandon Simaan, May Lee, Mi-Hye Luttrell, Louis M. Laporte, Stephane A. TI c-Src-mediated phosphorylation of AP-2 reveals a general mechanism for receptors internalizing through the clathrin pathway SO CELLULAR SIGNALLING LA English DT Article DE G protein-coupled receptors; AT1R; beta arrestins; c-Src; AP-2; Clathrin; EGF receptor ID PROTEIN-COUPLED RECEPTORS; INTRACELLULAR TRAFFICKING PATHWAYS; AGONIST-INDUCED INTERNALIZATION; ACTIVATING-FACTOR RECEPTOR; GROWTH-FACTOR RECEPTOR; II TYPE-1 RECEPTOR; TYROSINE PHOSPHORYLATION; BETA-ARRESTIN; ADAPTER PROTEIN-2; MU-2 SUBUNIT AB Clathrin-mediated endocytosis is a complex process regulated at many different levels. We showed previously that activation of the angiotensin type 1 receptor (AT1R), which belongs to the G protein-coupled receptor (GPCR) family, leads to c-Src-dependent tyrosine phosphorylation of beta 2-adaptin, a subunit of the clathrin adaptor AP-2. The phosphorylation of beta 2-adaptin on tyrosine residue 737 (Y737) negatively regulates its interaction with beta arrestin, another important clathrin adaptor for GPCR internalization. Here we sought to determine whether AP-2 phosphorylation represents a general mechanism for different receptors internalizing through the clathrin pathway. Using a specifically designed antibody against the phosphorylated form of Y737 on beta 2-adaptin, we demonstrate that this residue is phosphorylated by AT1R in different cell types like HEK293, COS-7 and vascular smooth muscle cells. Using RNA interference approaches, we reveal that this agonist-mediated event is both beta arrestin- and c-Src-dependent, and that it occurs at the plasma membrane in clathrin-coated vesicles (CCVs). We further show that this is not only a common event employed by other GPCRs like the beta 2-adrenergic, vasopressin V2, bradykinin type 2, platelet-activating factor and endothelin A receptors but that the epidermal growth factor receptor is capable of eliciting the phosphorylation of AP-2 in CCVs. Our results imply that tyrosine phosphorylation of Y737 on beta 2-adaptin is a common regulatory mechanism employed by different receptors undergoing clathrin-dependent endocytosis, and suggest a wider function for this event than originally anticipated. (C) 2008 Elsevier Inc. All rights reserved. C1 [Zimmerman, Brandon; Simaan, May; Laporte, Stephane A.] McGill Univ, Royal Victoria Hosp, Dept Med, Hormones & Canc Res Unit,Hlth Ctr,Res Inst, Montreal, PQ H3A 1A1, Canada. [Zimmerman, Brandon; Laporte, Stephane A.] McGill Univ, Dept Pharmacol & Therapeut, Montreal, PQ H3G 1Y6, Canada. [Lee, Mi-Hye; Luttrell, Louis M.] Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA. [Lee, Mi-Hye; Luttrell, Louis M.] Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA. [Lee, Mi-Hye; Luttrell, Louis M.] Ralph H Johnson Vet Affairs Med Ctr, Res Serv, Charleston, SC 29401 USA. RP Laporte, SA (reprint author), McGill Univ, Royal Victoria Hosp, Dept Med, Hormones & Canc Res Unit,Hlth Ctr,Res Inst, 687 Pine Ave W,Room H7-64, Montreal, PQ H3A 1A1, Canada. EM stephane.laporte@mcgill.ca RI Laporte, Stephane/F-3282-2012 FU Canadian Institutes of Health Research (CIHR); CIHR; McGill University Health Center Research Institute (MUHC-RI); Fonds de la Recherche en Sante du Quebec (FRSQ) FX We thank Drs Witold A. Neugebauer and Emanuel Escher (Universite de Sherbrooke) for peptide synthesis and the Angiotensin II analog. This work was supported by a Canadian Institutes of Health Research (CIHR) Operating Grant and a CIHR Confocal Maintenance Grant to S.A.L. B.Z. holds a CIHR studentship award. M.S. holds a Fellowship award from the McGill University Health Center Research Institute (MUHC-RI), which is a recognized Fonds de la Recherche en Sante du Quebec (FRSQ) supported Institute. SAL holds a Canada Research Chair in Molecular Endocrinology. NR 41 TC 31 Z9 33 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0898-6568 J9 CELL SIGNAL JI Cell. Signal. PD JAN PY 2009 VL 21 IS 1 BP 103 EP 110 DI 10.1016/j.cellsig.2008.09.013 PG 8 WC Cell Biology SC Cell Biology GA 389AB UT WOS:000262060900013 PM 18938240 ER PT J AU Lerner, A Bagic, A Hanakawa, T Boudreau, EA Pagan, F Mari, Z Bara-Jimenez, W Aksu, M Sato, S Murphy, DL Hallett, M AF Lerner, Alicja Bagic, Anto Hanakawa, Takashi Boudreau, Eilis A. Pagan, Fernando Mari, Zoltan Bara-Jimenez, William Aksu, Murat Sato, Susumu Murphy, Dennis L. Hallett, Mark TI Involvement of Insula and Cingulate Cortices in Control and Suppression of Natural Urges SO CEREBRAL CORTEX LA English DT Article ID EVENT-RELATED FMRI; OBSESSIVE-COMPULSIVE DISORDER; OLD-WORLD MONKEY; STOP-SIGNAL TASK; RESPONSE-INHIBITION; FUNCTIONAL MRI; PHYSIOLOGICAL CONDITION; VOLUNTARY SUPPRESSION; TOURETTE-SYNDROME; BRAIN RESPONSES AB The physiology of control and suppression of natural urges is not well understood. We used [(15)O]H(2)O positron-emission tomography imaging to identify neural circuits involved in suppression of spontaneous blinking as a model of normal urges. Suppression of blinking was associated with prominent activation of bilateral insular-claustrum regions, right more than left; activation was also found in bilateral anterior cingulate cortex (ACC), supplementary motor areas, and the face area of the primary motor cortex bilaterally. These results suggest a central role for the insula possibly together with ACC in suppression of blinking. C1 [Lerner, Alicja; Hallett, Mark] Natl Inst Neurol Disorders & Stroke, Human Motor Control Sect, NIH, Bethesda, MD 20892 USA. [Bagic, Anto] Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA 15213 USA. [Hanakawa, Takashi] Natl Ctr Neurol & Psychiat, Dept Cort Funct Disorder, Tokyo 1878502, Japan. [Boudreau, Eilis A.] Portland VA Med Ctr, Hlth Sci Res & Dev Program, Portland, OR 97239 USA. [Pagan, Fernando] Georgetown Univ Hosp, Dept Neurol, Washington, DC 20007 USA. [Mari, Zoltan] Johns Hopkins Univ, Dept Neurol, Baltimore, MD 21287 USA. [Bara-Jimenez, William] Bethesda Neurosci Clin, Bethesda, MD 20885 USA. [Aksu, Murat] Erciyes Univ, Fac Med, Dept Neurol, TR-38039 Kayseri, Turkey. [Sato, Susumu] Natl Inst Neurol Disorders & Stroke, EEG Sect, Bethesda, MD 20892 USA. [Murphy, Dennis L.] NIMH, Clin Sci Lab, NIH, Bethesda, MD 20892 USA. RP Lerner, A (reprint author), Natl Inst Neurol Disorders & Stroke, Human Motor Control Sect, NIH, 10 Ctr Dr,Bldg 10, Bethesda, MD 20892 USA. EM lernera@mail.nih.gov FU Intramural Research Programs of the National Institute of Neurological Disorders and Stroke; National Institute of Mental Health with the National Institutes of Health FX Intramural Research Programs of the National Institute of Neurological Disorders and Stroke and the National Institute of Mental Health with the National Institutes of Health. NR 69 TC 43 Z9 46 U1 4 U2 12 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1047-3211 J9 CEREB CORTEX JI Cereb. Cortex PD JAN PY 2009 VL 19 IS 1 BP 218 EP 223 DI 10.1093/cercor/bhn074 PG 6 WC Neurosciences SC Neurosciences & Neurology GA 383ND UT WOS:000261679400021 PM 18469316 ER PT J AU Pandhi, N Smith, MA Kind, AJH Frytak, JR Finch, MD AF Pandhi, Nancy Smith, Maureen A. Kind, Amy J. H. Frytak, Jennifer R. Finch, Michael D. TI The Quality of Diabetes Care following Hospitalization for Ischemic Stroke SO CEREBROVASCULAR DISEASES LA English DT Article DE Cerebrovascular accident; Diabetes mellitus; Quality of care ID HEALTH-CARE; RACIAL DISPARITIES; UNITED-STATES; RISK-FACTORS; PREVENTION; HISPANICS; AMERICAN; VETERANS; DISEASE; BLACKS AB Background: Follow-up is critically important for stroke survivors with diabetes, yet there is limited research about the quality of diabetes care that these patients receive. We investigated performance on diabetes quality of care indicators for stroke survivors overall and by race. Methods: Claims data was extracted for 1,460 Medicare beneficiaries with preexisting diabetes who survived hospitalization for acute ischemic stroke in 2000. Adjusted probabilities of receiving HbA1c, LDL and dilated eye exams were estimated using logistic regression. Results: 53% had a dilated eye exam, 60% received an LDL check, 73% percent had their HbA1c checked at least once and only 51% received two or more HbA1c checks. In the unadjusted results, blacks were significantly less likely than whites to receive these tests. Conclusions: Care of stroke survivors, particularly blacks, shows gaps according to guidelines. Copyright (C) 2009 S. Karger AG, Basel C1 [Pandhi, Nancy; Smith, Maureen A.; Kind, Amy J. H.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Populat Hlth Sci, Madison, WI USA. [Pandhi, Nancy] Univ Wisconsin, Sch Med & Publ Hlth, Dept Family Med, Madison, WI USA. [Kind, Amy J. H.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Med, Div Geriatr, Madison, WI USA. [Kind, Amy J. H.] William S Middleton Mem Vet Adm Med Ctr, US Dept Vet Affairs, Ctr Geriatr Res Educ & Clin, Madison, WI USA. [Frytak, Jennifer R.] i3 Innovus, Minneapolis, MN USA. [Finch, Michael D.] Finch & King Inc, Minneapolis, MN USA. RP Pandhi, N (reprint author), 557 WARF Off Bldg,610 Walnut St, Madison, WI 53726 USA. EM nancy.pandhi@fammed.wisc.edu FU National Institute of Aging [R01-AG19747]; Community-Academic Partnerships core of the University of Wisconsin Institute for Clinical and Translational Research (UW ICTR) funded through an NIH [1 UL1 RR025011] FX This study was supported by a grant (R01-AG19747) from the National Institute of Aging (Principal Investigator: Maureen Smith, MD, PhD). This project was also supported by the Community-Academic Partnerships core of the University of Wisconsin Institute for Clinical and Translational Research (UW ICTR) funded through an NIH Clinical and Translational Science Award (CTSA), grant No. 1 UL1 RR025011. NR 28 TC 4 Z9 4 U1 0 U2 0 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 1015-9770 J9 CEREBROVASC DIS JI Cerebrovasc. Dis. PY 2009 VL 27 IS 3 BP 235 EP 240 DI 10.1159/000196821 PG 6 WC Clinical Neurology; Peripheral Vascular Disease SC Neurosciences & Neurology; Cardiovascular System & Cardiology GA 409VN UT WOS:000263534000005 PM 19176956 ER PT J AU Kuschner, WG Gruenewald, DA Clum, N Beal, A Ezeji-Okoye, SC AF Kuschner, Ware G. Gruenewald, David A. Clum, Nancy Beal, Alice Ezeji-Okoye, Stephen C. TI Implementation of ICU Palliative Care Guidelines and Procedures A Quality Improvement Initiative Following an Investigation of Alleged Euthanasia SO CHEST LA English DT Article DE end-of-life care; guidelines; ICU; life support; palliative care ID LIFE-SUSTAINING TREATMENT; INTENSIVE-CARE; END; UNIT; WITHDRAWAL; SUPPORT; STATEMENT; DEATH AB Ethical conflicts are commonly encountered in the course of delivering end-of-life care in the ICU. Some ethical concerns have legal dimensions, including concerns about inappropriate hastening of death. Despite these concerns, many lCUs do not have explicit policies and procedures for withdrawal of life-sustaining treatments. We, describe a US Office of Inspector General (OIG) investigation of end-of-life care practices in our ICU. The investigation focused on care delivered to four critically ill patients with terminal diseases and an ICU nurse's concern that the patients had been subjected to euthanasia. The OIG investigation also assessed the validity of allegations that patient flow in and out of our ICU wits inappropriately influenced by, scheduled surgeries and that end-of-life care policies in our ICU were not clear. Although the investigation did not substantiate the allegations of euthanasia or inappropriate ICU patient flow, it did find that the policies that discuss end-of-life care issues were not clear and allowed for wide-ranging interpretations. Acting on the OIG recommendations, we developed a quality improvement initiative addressing end-of-life care in our ICU, intended to enhance communication and understanding about palliative care practices in our ICU, to prevent ethical conflicts surrounding end-of-life care, and to improve patient care. The initiative included the introduction of newly developed ICU comfort care guidelines, a physician order set, and a physician template note. Additionally, we implemented an educational program for ICU staff. Staff feedback regarding the initiative has been highly favorable, and the nurse whose concerns led to the investigation was satisfied not only with the investigation but also the policies and procedures that were subsequently introduced in our ICU. (CHEST 2009; 135:26-32) C1 [Kuschner, Ware G.] Palo Alto Hlth Care Syst, US Dept Vet Affairs, Pulm & Crit Care Med Sect, Med Serv, Palo Alto, CA 94304 USA. [Gruenewald, David A.] Puget Sound Hlth Care Syst, US Dept Vet Affairs, Geriatr & Extended Care Serv, Seattle, WA USA. [Beal, Alice] New York Harbor Hlth Care Syst, US Dept Vet Affairs, Med Serv, Brooklyn, NY USA. RP Kuschner, WG (reprint author), Palo Alto Hlth Care Syst, US Dept Vet Affairs, Pulm & Crit Care Med Sect, Med Serv, 3801 Miranda Ave,Mail Code 111P, Palo Alto, CA 94304 USA. EM ware.kuschnermd@ca.gov NR 26 TC 10 Z9 13 U1 0 U2 0 PU AMER COLL CHEST PHYSICIANS PI NORTHBROOK PA 3300 DUNDEE ROAD, NORTHBROOK, IL 60062-2348 USA SN 0012-3692 J9 CHEST JI Chest PD JAN PY 2009 VL 135 IS 1 BP 26 EP 32 DI 10.1378/chest.08-1685 PG 7 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA 392LN UT WOS:000262304300008 PM 19136403 ER PT J AU Parashar, S Rumsfeld, JS Reid, KJ Buchanan, D Dawood, N Khizer, S Lichtman, J Vaccarino, V AF Parashar, Susmita Rumsfeld, John S. Reid, Kimberly J. Buchanan, Donna Dawood, Nazeera Khizer, Saadia Lichtman, Judith Vaccarino, Viola CA PREMIER Registry Investigators TI Impact of Depression on Sex Differences in Outcome After Myocardial Infarction SO CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES LA English DT Article DE sex; depression; myocardial infarction; women ID CORONARY-ARTERY-DISEASE; HEART-DISEASE; GENDER-DIFFERENCES; PATIENT OUTCOMES; MORTALITY; EVENTS; ANGINA; CARE; ASSOCIATION; SYMPTOMS AB Background-Women have an unexplained worse outcome after myocardial infarction (MI) compared with men in many studies. Depressive symptoms predict adverse post-MI outcomes and are more prevalent among women than men. We examined whether depressive symptoms contribute to women's worse outcomes after MI. Methods and Results-In a prospective multicenter study ( PREMIER), 2411 ( 807 women) MI patients were enrolled. Depressive symptoms were assessed with the Patient Health Questionnaire. Outcomes included 1-year rehospitalization, presence of angina using the Seattle Angina Questionnaire, and 2-year mortality. Multivariable analyses were used to evaluate the association between sex and these outcomes, adjusting for clinical characteristics. The depressive symptoms score was added to the models to evaluate whether it attenuated the association between sex and outcomes. Depressive symptoms were more prevalent in women compared with men (29% versus 18.8%, P < 0.001). After adjusting for demographic factors, comorbidities, and MI severity, women had a mildly higher risk of rehospitalization ( hazard ratio, 1.20; 95% CI, 1.04 to 1.40), angina ( odds ratio, 1.32; 95% CI, 1.00 to 1.75), and mortality ( hazard ratio, 1.27; 95% CI, 0.98 to 1.64). After adding depressive symptoms to the multivariable models, the relationship further declined toward the null, particularly for rehospitalization ( hazard ratio, 1.14; 95% CI, 0.98 to 1.34) and angina (odds ratio, 1.22; 95% CI, 0.91 to 1.63), whereas there was little change in the estimate for mortality ( hazard ratio, 1.24; 95% CI, 0.95 to 1.62). Depressive symptoms were significantly associated with each of the study outcomes with a similar magnitude of effect in both women and men. Conclusions-A higher prevalence of depressive symptoms in women modestly contributes to their higher rates of rehospitalization and angina compared with men but not mortality after MI. Our results support the recent recommendations of improving recognition of depressive symptoms after MI. ( Circ Cardiovasc Qual Outcomes. 2009;2:33-40.) C1 [Parashar, Susmita] Emory Univ, Sch Med, Dept Med, Div Cardiol,EPICORE, Atlanta, GA 30307 USA. [Rumsfeld, John S.] Denver VA Med Ctr, Denver, CO USA. [Reid, Kimberly J.; Buchanan, Donna] St Lukes Hosp, Mid Amer Heart Inst, Kansas City, MO 64111 USA. [Lichtman, Judith] Yale Univ, Sch Med, Dept Epidemiol & Publ Hlth, New Haven, CT 06510 USA. RP Parashar, S (reprint author), Emory Univ, Sch Med, Dept Med, Div Cardiol,EPICORE, 1256 Briarcliff Rd,Bldg A,Suite 1 N, Atlanta, GA 30307 USA. EM susmita.parashar@emory.edu FU Emory University General Clinical Research Center [NIH MO1-RR00039]; National Institutes of Health [K12RR17643, P50 HL077113]; Mentored Clinical Scientist Development [1K23RR023171]; [K24HL077506] FX Cardiovascular Therapeutics and Cardiovascular Outcomes funded the PREMIER data collection and analysis. This study was also supported by the Emory University General Clinical Research Center ( NIH MO1-RR00039) and National Institutes of Health grant K12RR17643. Dr Parashar is supported by Mentored Clinical Scientist Development Award 1K23RR023171. Dr Vaccarino is supported by grant K24HL077506. Ms Reid is supported through National Institutes of Health grant P50 HL077113. Ms Reid had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. NR 31 TC 34 Z9 35 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1941-7713 J9 CIRC-CARDIOVASC QUAL JI Circ.-Cardiovasc. Qual. Outcomes PD JAN PY 2009 VL 2 IS 1 BP 33 EP 40 DI 10.1161/CIRCOUTCOMES.108.818500 PG 8 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 575NL UT WOS:000276073800007 PM 20031810 ER PT J AU Miyauchi, K Takaya, N Hirose, T Ikeda, F Kawamori, R Ohishi, H Yoshida, K Yamamoto, M Arai, H Urabe, T Hattori, N Suzuki, M Maehara, T Sase, K Hatsukami, TS Yuan, C Daida, H AF Miyauchi, Katsumi Takaya, Norihide Hirose, Takahisa Ikeda, Fuki Kawamori, Ryuzo Ohishi, Hidenori Yoshida, Kensaku Yamamoto, Munetaka Arai, Hajime Urabe, Takao Hattori, Nobutaka Suzuki, Michimasa Maehara, Tadayuki Sase, Kazuhiro Hatsukami, Thomas S. Yuan, Chun Daida, Hiroyuki TI Rationale and Design of the Carotid Plaque in Human for All Evaluations With Aggressive Rosuvastatin Therapy (CHALLENGER Trial) - Evaluation by Magnetic Resonance Imaging SO CIRCULATION JOURNAL LA English DT Article DE Carotid intima-media thickness; Carotid plaque; High-resolution magnetic resonance imaging; Plaque stability; Rosuvastatin ID ACUTE CORONARY SYNDROME; INTRAVASCULAR ULTRASOUND; HEART-DISEASE; ATHEROSCLEROSIS; PREVENTION; PRAVASTATIN; REPRODUCIBILITY; STABILIZATION; ATHEROMA; JAPANESE AB Background Intensive lipid-lowering therapy with statins reduces levels of low-density lipoprotein (LDL)-C cholesterol (C) and improves plaque volume and composition in patients with cardiovascular disease. Furthermore. rosuvastatin ameliorated carotid stenosis in the ASTEROID study, and altered the composition of plaques in a predominantly Caucasian study population in the ORION study. However, it is not known whether statin therapy achieves similar quantitative improvement in carotid artery plaque in other ethnic groups. Methods and Results Fifty patients with hypercholesterolemia (LDL-C >= 120 mg/dl) and a maximum carotid intima-media thickness >= 1.8 mm will be enrolled and treated with rosuvastatin at a dose of 5 mg/day for 96 weeks. The primary endpoints will be the percent change of carotid plaque volume and the change in plaque composition after 96 weeks of treatment, as evaluated by magnetic resonance imaging. Conclusions The CHALLENGER study will provide a noninvasive assessment of the changes in carotid plaque volume and composition achieved by reduction of LDL levels in Japanese patients with carotid stenosis oil long-term rosuvastatin therapy. C1 [Daida, Hiroyuki] Juntendo Univ, Sch Med, Dept Cardiovasc Med, Bunkyo Ku, Tokyo 1130033, Japan. [Hirose, Takahisa; Ikeda, Fuki; Kawamori, Ryuzo] Juntendo Univ, Sch Med, Dept Med, Tokyo 1130033, Japan. [Hirose, Takahisa; Ikeda, Fuki; Kawamori, Ryuzo] Juntendo Univ, Sch Med, Dept Endocrinol & Metab, Tokyo 1130033, Japan. [Ohishi, Hidenori; Yoshida, Kensaku; Yamamoto, Munetaka; Arai, Hajime] Juntendo Univ, Sch Med, Dept Neurosurg, Tokyo 1130033, Japan. [Urabe, Takao; Hattori, Nobutaka] Juntendo Univ, Sch Med, Dept Neurol, Tokyo 1130033, Japan. [Suzuki, Michimasa; Maehara, Tadayuki] Juntendo Univ, Sch Med, Dept Radiol, Tokyo 1130033, Japan. [Sase, Kazuhiro] Juntendo Univ, Sch Med, Dept Clin Pharmacol, Tokyo 1130033, Japan. [Hatsukami, Thomas S.] Univ Washington, Dept Surg, Seattle, WA 98195 USA. [Yuan, Chun] Univ Washington, Dept Radiol, Seattle, WA 98195 USA. [Hatsukami, Thomas S.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. RP Daida, H (reprint author), Juntendo Univ, Sch Med, Dept Cardiovasc Med, Bunkyo Ku, 3-1-3 Hongo, Tokyo 1130033, Japan. EM daida@med.juntendo.ac.jp NR 27 TC 10 Z9 10 U1 0 U2 1 PU JAPANESE CIRCULATION SOC PI KYOTO PA KINKI INVENTION CENTER, 14 YOSHIDA KAWAHARACHO, SAKYO-KU, KYOTO, 606-8305, JAPAN SN 1346-9843 J9 CIRC J JI Circ. J. PD JAN PY 2009 VL 73 IS 1 BP 111 EP 115 PG 5 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 388ZI UT WOS:000262058800019 PM 19057091 ER PT J AU Allen, RS Phillips, LL Pekmezi, D Crowther, MR Prentice-Dunn, S AF Allen, Rebecca S. Phillips, Laura L. Pekmezi, Dorothy Crowther, Martha R. Prentice-Dunn, Steven TI Living Well with Living Wills: Application of Protection Motivation Theory to Living Wills Among Older Caucasian and African American Adults SO CLINICAL GERONTOLOGIST LA English DT Article DE living wills; race/ethnicity and health; protection motivation theory; preventive health ID LIFE-SUSTAINING TREATMENTS; ADVANCE DIRECTIVES; DECISION-MAKING; INDIVIDUAL-DIFFERENCES; FAMILY CAREGIVERS; END; PREFERENCES; HEALTH; INFORMATION; RESPONSES AB Using protection motivation theory, we examined racial differences in intent to complete a living will, rational problem solving (e.g., information seeking), and maladaptive coping responses (i.e., wishful thinking) to a health crisis. Sixty healthy, older adults without living wills responded to written vignettes, including information about living wills as an effective coping mechanism to avoid a health crisis. Use of adaptive coping responses predicted intent to execute a living will. A significant race-by-threat interaction predicted use of rational problem solving, with Caucasians more likely to seek information in response to perceived threat in comparison with African Americans. A significant race-by-adaptive-coping interaction predicted maladaptive coping, indicating that Caucasians were more variable in their maladaptive responses. The effectiveness of health care messages regarding living wills for older adults may be enhanced by focusing on racial differences in response to perceived health threat and perceived adaptive coping information. C1 [Allen, Rebecca S.; Crowther, Martha R.; Prentice-Dunn, Steven] Univ Alabama, Dept Psychol, Tuscaloosa, AL 35487 USA. [Allen, Rebecca S.; Crowther, Martha R.] Ctr Mental Hlth & Aging, Tuscaloosa, AL USA. [Phillips, Laura L.] Houston Vet Affairs Med Ctr, Houston, TX USA. [Pekmezi, Dorothy] Miriam Hosp, Providence, RI 02906 USA. [Pekmezi, Dorothy] Brown Med Sch, Ctr Behav & Prevent Med, Providence, RI USA. RP Allen, RS (reprint author), Univ Alabama, Dept Psychol, Box 870348, Tuscaloosa, AL 35487 USA. EM rsallen@bama.ua.edu OI Allen, Rebecca Sue/0000-0002-2563-4996 FU National Institute on Aging [K01AG00943]; Department of Psychology at The University of Alabama FX Portions of this article were presented at the 56th annual scientific meeting of the Gerontological Society of America, San Diego, CA, November 2003. Funding from the National Institute on Aging (K01AG00943) to Rebecca S. Allen partially supported data collection for this project and preparation of this manuscript. Additionally, funding for data collection was provided by the Department of Psychology at The University of Alabama as part of Dorothy Pekmezi's undergraduate honors thesis. NR 26 TC 6 Z9 6 U1 2 U2 9 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 0731-7115 J9 CLIN GERONTOLOGIST JI Clin. Gerontol. PY 2009 VL 32 IS 1 BP 44 EP 59 DI 10.1080/07317110802474643 PG 16 WC Geriatrics & Gerontology; Gerontology; Psychiatry SC Geriatrics & Gerontology; Psychiatry GA 675UP UT WOS:000283864400004 PM 19337566 ER PT J AU Moghadam-Kia, S Klein, R Chilek, K Gaines, E Costner, M Rose, M Okawa, J Werth, V AF Moghadam-Kia, Siamak Klein, Rachel Chilek, Katherine Gaines, Elizabeth Costner, Melissa Rose, Mathew Okawa, Joyce Werth, Victoria TI Characteristics of Patients with Refractory Cutaneous Lupus Erythematosus: A Database Analysis of 152 Patients Seen at an Outpatient Dermatology Clinic SO CLINICAL IMMUNOLOGY LA English DT Meeting Abstract CT 9th Annual Meeting of the Federation-of-Clinical-Immunology-Societies CY JUN 11-14, 2009 CL San Francisco, CA SP Federat Clin Immunol Soc C1 [Moghadam-Kia, Siamak; Klein, Rachel; Chilek, Katherine; Gaines, Elizabeth; Rose, Mathew; Okawa, Joyce; Werth, Victoria] Univ Penn, Philadelphia VA Med Ctr, Philadelphia, PA 19104 USA. [Costner, Melissa] Univ Texas SW, Dallas, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1521-6616 J9 CLIN IMMUNOL JI Clin. Immunol. PY 2009 VL 131 BP S129 EP S129 DI 10.1016/j.clim.2009.03.382 PG 1 WC Immunology SC Immunology GA 449PK UT WOS:000266342300374 ER PT J AU Gist, S Tio-Matos, I Falzgraf, S Cameron, S Beebe, M AF Gist, Steve Tio-Matos, Iris Falzgraf, Sharon Cameron, Shirley Beebe, Michael TI Wound care in the geriatric client SO CLINICAL INTERVENTIONS IN AGING LA English DT Review DE wound care; pressure ulcers; vascular ulcers; diabetic ulcers; debridement; elderly AB With our aging population, chronic diseases that compromise skin integrity such as diabetes, peripheral vascular disease (venous hypertension, arterial insufficiency) are becoming increasingly common. Skin breakdown with ulcer and chronic wound formation is a frequent consequence of these diseases. Types of ulcers include pressure ulcers, vascular ulcers (arterial and venous hypertension), and neuropathic ulcers. Treatment of these ulcers involves recognizing the four stages of healing: coagulation, inflammation, proliferation, and maturation. Chronic wounds are frequently stalled in the inflammatory stage. Moving past the inflammation stage requires considering the bacterial burden, necrotic tissue, and moisture balance of the wound being treated. Bacterial overgrowth or infection needs to be treated with topical or systemic agents. In most cases, necrotic tissue needs to be debrided and moisture balance needs to be addressed by wetting dry tissue and drying wet tissue. Special dressings have been developed to accomplish these tasks. They include films, hydrocolloids, hydrogel dressings, foams, hydrofibers, composite and alginate dressings. C1 VA Puget Sound Hlth Care Syst, Geriatr Program, Amer Lake Div, Tacoma, WA USA. VA Puget Sound Hlth Care Syst, Extended Care Program, Amer Lake Div, Tacoma, WA USA. RP Beebe, M (reprint author), VA Puget Sound Hlth Care Syst, Integrated Geriatr Programs, Tacoma, WA USA. EM michael.beebe@va.gov NR 48 TC 28 Z9 28 U1 1 U2 8 PU DOVE MEDICAL PRESS LTD PI ALBANY PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND SN 1176-9092 J9 CLIN INTERV AGING JI Clin. Interv. Aging PY 2009 VL 4 BP 269 EP 287 PG 19 WC Geriatrics & Gerontology SC Geriatrics & Gerontology GA V21WZ UT WOS:000208239000030 PM 19554098 ER PT J AU Chakkera, HA Chertow, GM O'Hare, AM Amend, WJ Gonwa, TA AF Chakkera, Harini A. Chertow, Glenn M. O'Hare, Ann M. Amend, William J., Jr. Gonwa, Thomas A. TI Regional Variation in Kidney Transplant Outcomes: Trends Over Time SO CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY LA English DT Article ID UNITED-STATES; VASCULAR ACCESS; HEMODIALYSIS; VARIABILITY; MANAGEMENT; SURGERY; US AB Background and objectives: Clinical outcomes after kidney transplant have improved considerably in the United States over the past several decades. However, the degree to which this has occurred uniformly across the country is unknown. Design, setting, participants, & measurements: Regional variations in graft failure after kidney transplant during three different time periods were examined. These time periods were chosen to coincide with major shifts in immunosuppressant usage: Era 1, cyclosporine usage, 3.988 through 1989; Era 2, introduction of tacrolimus and mycophenolate mofetil, 1994 through 1995; and Era 3, widespread use of tacrolimus and mycophenolate mofetil, 1998 through 1999. Patient data were obtained from the United States Renal Data System database. For each period, regional differences in time from transplant to graft failure (organ removal, death, or return to dialysis) were examined. For each region, differences in graft failure over time were examined. Results: One-year graft survival rates ranged from 76% to 83% between regions in Era 1 (n = 13,669), from 84% to 89% in Era 2 (n = 17,456), and from 87.5%, to 92% in Era 3 (n = 20,375). Three-year graft survival ranged from 65% to 75% between regions in Era 1, from 84% to 89% in Era 2, and from 77% to 86%) in Era 3. Adjusted models for donor and recipient characteristics showed improvements in graft survival over time in all United Network for Organ Sharing regions with minimal variation across regions. Conclusions: Regional differences in graft survival after kidney transplant are minimal, particularly when compared with the dramatic improvements in graft survival that have occurred over time. C1 [Chakkera, Harini A.] Mayo Clin, Div Transplant Med, Scottsdale, AZ USA. [Chertow, Glenn M.] Stanford Univ, Sch Med, Div Nephrol, Palo Alto, CA 94304 USA. [O'Hare, Ann M.] Univ Washington, Sch Med, Div Nephrol, Seattle, WA USA. [O'Hare, Ann M.] Vet Affairs Puget Sound Healthcare Syst, Seattle, WA USA. [Amend, William J., Jr.] Univ Calif San Francisco, Div Nephrol, San Francisco, CA 94143 USA. [Gonwa, Thomas A.] Mayo Clin, Div Transplant Med, Jacksonville, FL 32224 USA. RP Chakkera, HA (reprint author), Mayo Clin Hosp, Div Transplantat, MCSB, 5777 E Mayo Blvd, Phoenix, AZ 85054 USA. EM chakkera.harini@mayo.edu FU Health Resources and Services Administration [234-2005-370011C] FX This,vas Supported in part by Health Resources and Services Administration contract 234-2005-370011C. The content is the responsibility Of the authors alone and does not necessarily reflect the view of the Department of Health and Human Services. NR 18 TC 5 Z9 6 U1 0 U2 0 PU AMER SOC NEPHROLOGY PI WASHINGTON PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA SN 1555-9041 EI 1555-905X J9 CLIN J AM SOC NEPHRO JI Clin. J. Am. Soc. Nephrol. PD JAN PY 2009 VL 4 IS 1 BP 152 EP 159 DI 10.2215/CJN.02050408 PG 8 WC Urology & Nephrology SC Urology & Nephrology GA 397SA UT WOS:000262681200024 PM 18922989 ER PT J AU Iverson, GL Langlois, JA McCrea, MA Kelly, JP AF Iverson, Grant L. Langlois, Jean A. McCrea, Michael A. Kelly, James P. TI CHALLENGES ASSOCIATED WITH POST-DEPLOYMENT SCREENING FOR MILD TRAUMATIC BRAIN INJURY IN MILITARY PERSONNEL SO CLINICAL NEUROPSYCHOLOGIST LA English DT Article DE Mild Traumatic Brain Injury; Military; Screening; Epidemiology ID POSTCONCUSSIVE SYMPTOMS; CHRONIC PAIN; CONCUSSION; IRAQ; METAANALYSIS; AFGHANISTAN; DISORDER; CARE AB There is ongoing debate regarding the epidemiology of mild traumatic brain injury (MTBI) in military personnel. Accurate and timely estimates of the incidence of brain injury and the prevalence of long-term problems associated with brain injuries among active duty service members and veterans are essential for (a) operational planning, and (b) to allocate sufficient resources for rehabilitation and ongoing services and supports. The purpose of this article is to discuss challenges associated with post-deployment screening for MTBI. Multiple screening methods have been used in military, Veterans Affairs, and independent studies, which complicate cross-study comparisons of the resulting epidemiological data. We believe that post-deployment screening is important and necessary-but no screening methodology will be flawless, and false positives and false negatives are inevitable. Additional research is necessary to refine the sequential screening methodology, with the goal of minimizing false negatives during initial post-deployment screening and minimizing false positives during follow-up evaluations. C1 [Iverson, Grant L.] Univ British Columbia, Dept Psychiat, Vancouver, BC V6T 2A1, Canada. [Iverson, Grant L.] British Columbia Mental Hlth & Addict Serv, Vancouver, BC, Canada. [Langlois, Jean A.] US Dept Vet Affairs, Off Res & Dev, Washington, DC USA. [McCrea, Michael A.] Waukesha Mem Hosp, Ctr Neurosci, Waukesha, WI USA. [McCrea, Michael A.] Med Coll Wisconsin, Dept Neurol, Milwaukee, WI 53226 USA. [Kelly, James P.] Univ Colorado, Dept Neurosurg, Denver Sch Med, Denver, CO 80202 USA. [Kelly, James P.] Univ Colorado, Dept Phys Med & Rehabil, Denver Sch Med, Denver, CO 80202 USA. [Kelly, James P.] Def Ctr Excellence Psychol Hlth, Natl Intrepid Ctr Excellence, Washington, DC USA. [Kelly, James P.] US Dept Def, TBI, Washington, DC 20305 USA. RP Iverson, GL (reprint author), Univ British Columbia, Dept Psychiat, 2255 Wesbrook Mall, Vancouver, BC V6T 2A1, Canada. EM giverson@interchange.ubc.ca NR 24 TC 53 Z9 53 U1 0 U2 4 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA SN 1385-4046 J9 CLIN NEUROPSYCHOL JI Clin. Neuropsychol. PY 2009 VL 23 IS 8 BP 1299 EP 1314 DI 10.1080/13854040903153902 PG 16 WC Psychology, Clinical; Clinical Neurology; Psychology SC Psychology; Neurosciences & Neurology GA 524KF UT WOS:000272141500005 PM 19882473 ER PT J AU Cruciani, M Lipsky, BA Mengoli, C de Lalla, F AF Cruciani, M. Lipsky, B. A. Mengoli, C. de Lalla, F. TI Granulocyte-colony stimulating factors as adjunctive therapy for diabetic foot infections SO COCHRANE DATABASE OF SYSTEMATIC REVIEWS LA English DT Review ID MONONUCLEAR-CELL IMPLANTATION; CRITICAL LIMB ISCHEMIA; MEDICAL-TREATMENT; CONTROLLED-TRIAL; AUTOLOGOUS TRANSPLANTATION; LOCAL CARE; ULCERS; IMPROVES; FILGRASTIM; METAANALYSIS AB Background G-CSF increases the release of neutrophil endothelial progenitor cells from the bone marrow, and improves neutrophil functions, which are often impaired in people with diabetes. Objectives To examine the effects of adjunctive G-CSF compared with placebo or no growth factor added to usual care on rates of infection, cure and wound healing in people with diabetes who have a foot infection. Search strategy We searched the Cochrane Wounds Group Specialised Register (Searched 16/3/09); the Cochrane Central Register of Controlled Trials (The Cochrane Library, issue 1 2009); Ovid MEDLINE (1950 to March Week 1 2009); Ovid EMBASE (1980 to 2009 Week 11); EBSCO CINAHL (1982 to March Week 2 2009); LookSmart's Find Articles (January 1990 to January 2008); conference proceedings and references lists in the included studies. Selection criteria Randomised controlled trials (RCTs) that evaluated the effect of adding G-CSF to usual care in people with a diabetic foot infection. Data collection and analysis Three review authors independently assessed trial eligibility, methodological quality and extracted data. Relative risk (RR), or for continuous outcomes, mean differences (MD), with 95% confidence intervals (CI) were reported. In the case of low or no heterogeneity studies were pooled using a fixed-effect model. Main results We identified and included five eligible trials with a total of 167 patients. The investigators administered various G-CSF preparations, at different doses and for different durations of time. Adding G-CSF did not significantly affect the likelihood of resolution of infection or wound healing, but it was associated with a significantly reduced likelihood of lower extremity surgical interventions (RR 0.37; 95 % CI 0.20 to 0.68), including amputation (RR 0.41; 95 % CI 0.18 to 0.95). Moreover, providing G-CSF reduced the duration of hospital stay ( MD, -1.40 days; 95% CI, -2.27 to -0.53 days), but did not significantly affect the duration of systemic antibiotic therapy (MD, -0.27 days; 95 % CI, -1.30 to 0.77 days). Authors' conclusions The available evidence is limited, but suggests that adjunctive G-CSF treatment in people with a diabetic foot infection, including infected ulcers, does not appear to increase the likelihood of resolution of infection or healing of the foot ulcer. However, it does appear to reduce the need for surgical interventions, especially amputations, and the duration of hospitalisation. Clinicians might consider adding G-CSF to the usual treatment of diabetic foot infections, especially in patients with a limb-threatening infection, but it is not clear which patients might benefit. C1 [Cruciani, M.] G Fracastoro Hosp, Ctr Prevent Med, I-37135 Verona, Italy. [Cruciani, M.] G Fracastoro Hosp, HIV Outpatient Clin, I-37135 Verona, Italy. [Lipsky, B. A.] Univ Washington, VA Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. [Mengoli, C.] Univ Padua, Dept Histol Microbiol & Med Biotechnol, Padua, Italy. [de Lalla, F.] Osped san Bortolo, Dept Infect Dis, Vicenza, Italy. RP Cruciani, M (reprint author), G Fracastoro Hosp, Ctr Prevent Med, Via Germania 20, I-37135 Verona, Italy. EM crucianimario@virgilio.it OI Lipsky, Benjamin A./0000-0001-9886-5114; Mengoli, Carlo/0000-0002-7422-0554 NR 66 TC 16 Z9 16 U1 1 U2 1 PU JOHN WILEY & SONS LTD PI CHICHESTER PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND SN 1469-493X J9 COCHRANE DB SYST REV JI Cochrane Database Syst Rev. PY 2009 IS 3 AR CD006810 DI 10.1002/14651858.CD006810.pub2 PG 35 WC Medicine, General & Internal SC General & Internal Medicine GA 471EE UT WOS:000268037500012 PM 19588405 ER PT J AU Kogai, T Brent, GA AF Kogai, Takahiko Brent, Gregory A. BE Preedy, VR Burrow, GN Watson, RR TI Regulation and Enhancement of Endogenous Sodium Iodide Symporter Expression: NIS Regulatory Pathways in Thyroid and Breast Cancer SO COMPREHENSIVE HANDBOOK OF IODINE: NUTRITIONAL, BIOCHEMICAL, PATHOLOGICAL AND THERAPEUTIC ASPECTS LA English DT Article; Book Chapter ID HUMAN CHORIONIC-GONADOTROPIN; CHORIOCARCINOMA CELL-LINE; SODIUM/IODIDE SYMPORTER; GENE-EXPRESSION; NA+/I-SYMPORTER; RADIOIODIDE UPTAKE; TRANSCRIPTION FACTOR; DIFFERENTIAL REGULATION; UPSTREAM ENHANCER; CARCINOMA CELLS AB The sodium iodide symporter (NIS) gene is expressed at a high level in the thyroid gland and the lactating breast. Thyroid-stimulating hormone, or thyrotropin (TSH) is the major regulator of NIS expression in the normal thyroid and also stimulates NIS in more than 80% of differentiated thyroid cancers. TSH stimulates NIS gene expression through the proximal promoter and the NIS far upstream enhancer (NUE). The NUE requires at least two transcription factors, Pax-8 and CREB, for stimulation. Reduced expression of these transcription factors may contribute to the reduction in NIS expression that is seen in some differentiated thyroid cancer. High levels of endogenous TSH, or administration of recombinant TSH, are required to enhance the iodide uptake in thyroid cancer before radioiodide therapy. NIS gene expression in lactating breast tissue is primarily regulated by oxytocin and prolactin. A modest level of NIS expression has been reported in approximately 80% of cases of breast cancers. A number of strategies have been used to enhance NIS expression and radioiodide uptake in thyroid cancer and breast cancer. These include redifferentiation agents, such as retinoic acid and other nuclear hormone receptor ligands, as well as epigenetic modifiers. The results from application of these agents to in vitro models of thyroid and breast cancer will be described. Insights into NIS regulation, as well as agents that promote endogenous NIS expression, should lead to new approaches to using radioiodine in the treatment of thyroid and breast cancers. C1 [Kogai, Takahiko; Brent, Gregory A.] Univ Calif Los Angeles, VA Greater Los Angeles Healthcare Syst, Dept Med, David Geffen Sch Med,Mol Endocrinol Lab, Los Angeles, CA 90073 USA. [Kogai, Takahiko; Brent, Gregory A.] Univ Calif Los Angeles, VA Greater Los Angeles Healthcare Syst, Dept Physiol, David Geffen Sch Med,Mol Endocrinol Lab, Los Angeles, CA 90073 USA. RP Kogai, T (reprint author), Univ Calif Los Angeles, VA Greater Los Angeles Healthcare Syst, Dept Med, David Geffen Sch Med,Mol Endocrinol Lab, Los Angeles, CA 90073 USA. NR 46 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA SARA BURGERHARTSTRAAT 25, PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS BN 978-0-08-092086-3 PY 2009 BP 221 EP 230 DI 10.1016/B978-0-12-374135-6.00023-6 PG 10 WC Biochemistry & Molecular Biology; Endocrinology & Metabolism; Nutrition & Dietetics SC Biochemistry & Molecular Biology; Endocrinology & Metabolism; Nutrition & Dietetics GA BCR55 UT WOS:000311104900024 ER PT B AU Rehman, SU Ahmed, MM Hutchison, FN AF Rehman, Shakaib U. Ahmed, Mohammed M. Hutchison, Florence N. BE Preedy, VR Burrow, GN Watson, RR TI Goiter in the Elderly: The Role of Iodine SO COMPREHENSIVE HANDBOOK OF IODINE: NUTRITIONAL, BIOCHEMICAL, PATHOLOGICAL AND THERAPEUTIC ASPECTS LA English DT Article; Book Chapter ID PERCUTANEOUS ETHANOL INJECTION; NODULAR THYROID-DISEASE; OPERATIVE MANAGEMENT; INTRATHORACIC GOITER; SURGICAL-MANAGEMENT; SUBSTERNAL GOITER; THERAPY; OBSTRUCTION; DISORDERS; HYPERTHYROIDISM AB The term goiter means thyroid enlargement, either diffuse or nodular. The incidence of goiter increases with age. The most common type of goiter in the elderly is multinodular goiter. Graves' disease is very rare in older adults. The most common cause of goiter worldwide is iodine deficiency. It is becoming less of a problem in developed countries, due to the addition of iodine to salt and bread. Goiter commonly presents as neck mass. Although most patients with goiter do not have any symptom other than neck swelling, occasionally patients complain of dysphagia, dysphonia, or pain. Many goiters do not cause any thyroidal hormonal abnormality (euthyroid status). Some can present with either excess thyroidal hormonal activity (hyperthyroidism) or deficiency of thyroid hormones (hypothyroidism). Proper work-up for elderly patients with goiter includes a thorough history, detailed clinical examination, thyroid hormone assays, e. g., TSH, T4, T3, and an ultrasound or CT scan. Most goiters are benign in nature and may not require tissue diagnosis. In some elderly patients, fine needle aspiration and biopsy may be considered to rule out malignancy. Most elderly patients with nodular goiter are treated best by surgical removal, while radioiodine therapy and/or antithyroid drugs are the most effective therapy for non-nodular goiter. C1 [Rehman, Shakaib U.; Hutchison, Florence N.] Ralph H Johnson Vet Affairs Hosp, Charleston, SC 29401 USA. [Rehman, Shakaib U.; Hutchison, Florence N.] Med Univ S Carolina, Charleston, SC 29401 USA. [Ahmed, Mohammed M.] Univ Toledo, Dept Med, Toledo, OH 43614 USA. RP Rehman, SU (reprint author), Ralph H Johnson Vet Affairs Hosp, Charleston, SC 29401 USA. NR 47 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA SARA BURGERHARTSTRAAT 25, PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS BN 978-0-08-092086-3; 978-0-12-374135-6 PY 2009 BP 323 EP 329 DI 10.1016/B978-0-12-374135-6.00034-0 PG 7 WC Biochemistry & Molecular Biology; Endocrinology & Metabolism; Nutrition & Dietetics SC Biochemistry & Molecular Biology; Endocrinology & Metabolism; Nutrition & Dietetics GA BCR55 UT WOS:000311104900035 ER PT J AU Flory, JD Yehuda, R Grossman, R New, AS Mitropoulou, V Siever, LJ AF Flory, Janine D. Yehuda, Rachel Grossman, Robert New, Antonia S. Mitropoulou, Vivian Siever, Larry J. TI Childhood trauma and basal cortisol in people with personality disorders SO COMPREHENSIVE PSYCHIATRY LA English DT Article ID POSTTRAUMATIC-STRESS-DISORDER; ABUSE; NEGLECT; DEPRESSION; BEHAVIOR AB This study examined the influence of various forms of childhood abuse on basal cortisol levels in a sample of adults with Axis II personality disorders. Participants included 63 adults (n = 19 women) who provided basal plasma cortisol samples and completed the Childhood Trauma Questionnaire. Linear regression analyses that included all 5 subscales (ie, sexual abuse, physical abuse, emotional abuse, physical neglect and emotional neglect) demonstrated that physical abuse was related to lower cortisol levels (beta = -.43 P = .007), consistent with prior literature. In contrast, physical neglect was associated with higher cortisol (beta = .36, P = .02), after controlling for other forms of abuse. Results are consistent with the view that childhood trauma has long-lasting neurobiological effects and suggest that different forms of trauma may have distinct biological effects. (C) 2009 Elsevier Inc. All rights reserved. C1 [Flory, Janine D.] CUNY Queens Coll, Dept Psychol, Flushing, NY 11367 USA. [Flory, Janine D.; Yehuda, Rachel; Grossman, Robert; New, Antonia S.; Mitropoulou, Vivian; Siever, Larry J.] Mt Sinai Sch Med, Dept Psychiat, New York, NY 10029 USA. [Yehuda, Rachel; New, Antonia S.; Siever, Larry J.] Bronx Vet Affairs Med Ctr, Dept Psychiat, Bronx, NY 10468 USA. RP Flory, JD (reprint author), CUNY Queens Coll, Dept Psychol, Flushing, NY 11367 USA. EM janine.flory@qc.cuny.edu FU Mount Sinai General Clinical Research Center [MH069979, RO1 MH056606, RO1 MH063875, RO3 MH58697, MO1 RR0071] FX This work was supported by MH069979 (JDF) RO1 MH056606 (LJS), RO1 MH063875 (LJS), RO3 MH58697 (RG), and MO1 RR0071 (Mount Sinai General Clinical Research Center). NR 21 TC 25 Z9 25 U1 1 U2 6 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0010-440X J9 COMPR PSYCHIAT JI Compr. Psychiat. PD JAN-FEB PY 2009 VL 50 IS 1 BP 34 EP 37 DI 10.1016/j.comppsych.2008.05.007 PG 4 WC Psychiatry SC Psychiatry GA 389KA UT WOS:000262090100006 PM 19059511 ER PT J AU Sonnenberg, A AF Sonnenberg, Amnon TI Transposed Markov matrix as a new decision tool of how to choose among competing investment options in academic medicine SO COMPUTATIONAL AND MATHEMATICAL METHODS IN MEDICINE LA English DT Article DE decision analysis; decision tree; Markov chain; stochastic modelling AB Medical institutions face the challenge of promoting excellence in a variety of competing focus areas, such as grants, publications, income, research, faculty, variety, patient care and teaching. A transposed Markov chain is used analyse the interactions between the various focus areas and their transition towards steady-state. In contradistinction with a regular Markov chain, in the transposed chain used for the present analysis, the sum of inputs (rather than outputs) of each individual state is 100%, whereas the outputs are left to assume any possible value. The mathematics of calculating the steady state conditions of a transposed Markov matrix are similar to those of a regular Markov matrix. The analysis shows that a focus area more dependent on other areas is also more likely to lose its investment, whereas largely self-reliant areas will generate the largest return. Full strength of all academic focus areas can be achieved only by investments in all areas. In academic systems with one or several exclusively self-reliant focus areas, only investment in these particular areas will invigorate the system, as all other investments are bound to dissipate over time. The newly developed decision tool of a transposed Markov matrix could be helpful in stochastic modelling of medical phenomena. C1 [Sonnenberg, Amnon] Portland VA Med Ctr, Portland, OR USA. [Sonnenberg, Amnon] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. RP Sonnenberg, A (reprint author), Portland VA Med Ctr, Portland, OR USA. EM sonnenbe@ohsu.edu NR 11 TC 2 Z9 2 U1 1 U2 1 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 1748-670X J9 COMPUT MATH METHOD M JI Comput. Math. Method Med. PY 2009 VL 10 IS 1 BP 1 EP 7 AR PII 789782974 DI 10.1080/17486700701865323 PG 7 WC Mathematical & Computational Biology SC Mathematical & Computational Biology GA 428LD UT WOS:000264848500001 ER PT J AU Lang, JD Matute-Bello, G AF Lang, John D. Matute-Bello, Gustavo TI Lymphocytes, apoptosis and sepsis: making the jump from mice to humans SO CRITICAL CARE LA English DT Editorial Material ID MONOCYTE DEACTIVATION; UNITED-STATES; DOUBLE-BLIND; PHASE-III; RECEPTOR; TRIAL; EPIDEMIOLOGY; DEATH AB Sepsis is an important clinical problem with a mortality rate of 20% to 30%. Lymphocyte apoptosis has been recognized as an important step in the pathogenesis of experimental sepsis, by inducing a state of 'immune paralysis' that renders the host vulnerable to invading pathogens. The importance of lymphocyte apoptosis in human disease is now confirmed by Weber and colleagues, who demonstrate extensive apoptosis in circulating lymphocytes from patients with severe sepsis. Weber and colleagues' data set the basis for further studies aimed at modulating lymphocyte apoptosis in sepsis. C1 [Matute-Bello, Gustavo] Univ Washington, Dept Med, Ctr Lung Biol, Div Pulm & Crit Care Med, Seattle, WA 98109 USA. [Lang, John D.] VA Puget Sound HealthCare Syst, Seattle, WA 98108 USA. [Lang, John D.] Univ Washington, Dept Anesthesiol, Seattle, WA 98195 USA. RP Matute-Bello, G (reprint author), Univ Washington, Dept Med, Ctr Lung Biol, Div Pulm & Crit Care Med, Seattle, WA 98109 USA. NR 14 TC 26 Z9 32 U1 0 U2 1 PU BIOMED CENTRAL LTD PI LONDON PA CURRENT SCIENCE GROUP, MIDDLESEX HOUSE, 34-42 CLEVELAND ST, LONDON W1T 4LB, ENGLAND SN 1466-609X J9 CRIT CARE JI Crit. Care PY 2009 VL 13 IS 1 AR 109 DI 10.1186/cc7144 PG 2 WC Critical Care Medicine SC General & Internal Medicine GA 421IC UT WOS:000264351600037 PM 19216722 ER PT J AU Palevsky, PM O'Connor, TZ Chertow, GM Crowley, ST Zhang, JH Kellum, JA AF Palevsky, Paul M. O'Connor, Theresa Z. Chertow, Glenn M. Crowley, Susan T. Zhang, Jane Hongyuan Kellum, John A. CA US Dept Vet Affairs Natl Inst Hlth TI Intensity of renal replacement therapy in acute kidney injury: perspective from within the Acute Renal Failure Trial Network Study SO CRITICAL CARE LA English DT Article ID CRITICALLY-ILL PATIENTS; CONTINUOUS VENOVENOUS HEMOFILTRATION; INTERMITTENT HEMODIALYSIS; RANDOMIZED-TRIAL; DIALYSIS; SUPPORT; SURVIVAL AB Determination of the optimal dose of renal replacement therapy in critically ill patients with acute kidney injury has been controversial. Questions have recently been raised regarding the design and execution of the US Department of Veterans Affairs/National Institutes of Health Acute Renal Failure Trial Network (ATN) Study, which demonstrated no improvement in 60-day all-cause mortality with more intensive management of renal replacement therapy. In the present article we present our rationale for these aspects of the design and conduct of the study, including our use of both intermittent and continuous modalities of renal support, our approach to initiation of study therapy and the volume management during study therapy. In addition, the article presents data on hypotension during therapy and recovery of kidney function in the perspective of other studies of renal support in acute kidney injury. Finally, we address the implications of the ATN Study results for clinical practice from the perspective of the study investigators. C1 [Palevsky, Paul M.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA 15240 USA. [Palevsky, Paul M.; Kellum, John A.] Univ Pittsburgh, Sch Med, Pittsburgh, PA 15261 USA. [O'Connor, Theresa Z.; Crowley, Susan T.; Zhang, Jane Hongyuan] VA Connecticut Healthcare Syst, West Haven, CT 06516 USA. [Chertow, Glenn M.] Stanford Univ, Sch Med, Stanford, CA 94305 USA. [Crowley, Susan T.] Yale Univ, Sch Med, New Haven, CT 06520 USA. RP Palevsky, PM (reprint author), VA Pittsburgh Healthcare Syst, Room 7E123 111F-U,Univ Dr, Pittsburgh, PA 15240 USA. EM Palevsky@pitt.edu OI Palevsky, Paul/0000-0002-7334-5400 FU Department of Veterans Affairs Office of Research and Development; National Institute of Diabetes and Digestive and Kidney Diseases [Y1-DK-3508-01] FX Supported by the Cooperative Studies Program of the Department of Veterans Affairs Office of Research and Development and by the National Institute of Diabetes and Digestive and Kidney Diseases (interagency agreement Y1-DK-3508-01). NR 32 TC 22 Z9 25 U1 0 U2 3 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1466-609X J9 CRIT CARE JI Crit. Care PY 2009 VL 13 IS 4 AR 310 DI 10.1186/cc7901 PG 6 WC Critical Care Medicine SC General & Internal Medicine GA 525OL UT WOS:000272225600066 PM 19678919 ER PT J AU Renaud, B Labarere, J Coma, E Santin, A Hayon, J Gurgui, M Camus, N Roupie, E Hemery, F Herve, J Salloum, M Fine, MJ Brun-Buisson, C AF Renaud, Bertrand Labarere, Jose Coma, Eva Santin, Aline Hayon, Jan Gurgui, Merce Camus, Nicolas Roupie, Eric Hemery, Francois Herve, Jerome Salloum, Mirna Fine, Michael J. Brun-Buisson, Christian TI Risk stratification of early admission to the intensive care unit of patients with no major criteria of severe community-acquired pneumonia: development of an international prediction rule SO CRITICAL CARE LA English DT Article ID SYSTEMIC INFLAMMATORY RESPONSE; SURVIVING SEPSIS CAMPAIGN; SEPTIC SHOCK; CONTROLLED-TRIAL; DECISION RULES; GUIDELINES; MANAGEMENT; OUTCOMES; ADULTS; MULTICENTER AB Introduction To identify risk factors for early (< three days) intensive care unit (ICU) admission of patients hospitalised with community-acquired pneumonia (CAP) and not requiring immediate ICU admission, and to stratify the risk of ICU admission on days 1 to 3. Methods Using the original data from four North American and European prospective multicentre cohort studies of patients with CAP, we derived and validated a prediction rule for ICU admission on days 1 to 3 of emergency department (ED) presentation, for patients presenting with no obvious reason for immediate ICU admission (not requiring immediate respiratory or circulatory support). Results A total of 6560 patients were included (4593 and 1967 in the derivation and validation cohort, respectively), 303 (4.6%) of whom were admitted to an ICU on days 1 to 3. The Risk of Early Admission to ICU index (REA-ICU index) comprised 11 criteria independently associated with ICU admission: male gender, age younger than 80 years, comorbid conditions, respiratory rate of 30 breaths/minute or higher, heart rate of 125 beats/minute or higher, multilobar infiltrate or pleural effusion, white blood cell count less than 3 or 20 G/L or above, hypoxaemia (oxygen saturation < 90% or arterial partial pressure of oxygen (PaO2) < 60 mmHg), blood urea nitrogen of 11 mmol/L or higher, pH less than 7.35 and sodium less than 130 mEq/L. The REA-ICU index stratified patients into four risk classes with a risk of ICU admission on days 1 to 3 ranging from 0.7 to 31%. The area under the curve was 0.81 (95% confidence interval (CI) = 0.78 to 0.83) in the overall population. Conclusions The REA-ICU index accurately stratifies the risk of ICU admission on days 1 to 3 for patients presenting to the ED with CAP and no obvious indication for immediate ICU admission and therefore may assist orientation decisions. C1 [Renaud, Bertrand; Santin, Aline; Camus, Nicolas; Herve, Jerome; Salloum, Mirna] Grp Hosp Henri Mondor Albert Chenevier, AP HP, Dept Emergency Med, F-94010 Creteil, France. [Labarere, Jose; Brun-Buisson, Christian] CHU Grenoble, Unite Evaluat Med, F-38043 Grenoble, France. [Coma, Eva] USAC, Inst Catala Oncol, Hosp Duran & Reynals, Serv Atencio Continuada, Barcelona 08907, Spain. [Hayon, Jan] Ctr Hosp Intercommunal Poissy St Germain, Dept Intens Care Med, F-78100 St Germain En Laye, France. [Gurgui, Merce] Hosp Santa Creu & Sant Pau, Dept Emergency Med, Barcelona, Spain. [Camus, Nicolas; Brun-Buisson, Christian] Univ Paris 12, Fac Med, F-94000 Creteil, France. [Roupie, Eric] CHU Caen, Dept Emergency Med, Hop Cote Nacre, F-14033 Caen, France. [Roupie, Eric] Univ Caen Basse Normandie, Fac Med, F-14032 Caen, France. [Hemery, Francois] Grp Hosp Henri Mondor Albert Chenevier, AP HP, Dept Informat Hosp, PMSI & Rech Clin, F-94010 Creteil, France. [Fine, Michael J.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equity Res & Promot, Pittsburgh, PA 15206 USA. [Fine, Michael J.] Univ Pittsburgh, UPMC Montefiore Hosp, Dept Med, Div Gen Internal Med, Pittsburgh, PA 15213 USA. [Brun-Buisson, Christian] Grp Hosp Henri Mondor Albert Chenevier, AP HP, F-94010 Creteil, France. RP Renaud, B (reprint author), Grp Hosp Henri Mondor Albert Chenevier, AP HP, Dept Emergency Med, F-94010 Creteil, France. EM bertrand.renaud@hmn.aphp.fr RI Labarere, Jose/N-1688-2014 OI Labarere, Jose/0000-0001-7621-6586 FU "Direction de la Recherche Clinique d'Ile de France" [AOM 89-145] FX This study was funded by the "Direction de la Recherche Clinique d'Ile de France" as part of the "Programme Hospitalier de Recherche Clinique" (Grant N degrees AOM 89-145). NR 33 TC 47 Z9 48 U1 1 U2 1 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1466-609X EI 1364-8535 J9 CRIT CARE JI Crit. Care PY 2009 VL 13 IS 2 AR R54 DI 10.1186/cc7781 PG 11 WC Critical Care Medicine SC General & Internal Medicine GA 453UN UT WOS:000266638500026 PM 19358736 ER PT J AU Moore, SA AF Moore, Sally A. TI Cognitive abnormalities in posttraumatic stress disorder SO CURRENT OPINION IN PSYCHIATRY LA English DT Article DE cognition; information processing; memory; posttraumatic stress disorder; trauma ID AUTOBIOGRAPHICAL MEMORY SPECIFICITY; FALSE MEMORIES; INTERPERSONAL TRAUMA; OVERGENERAL MEMORY; EXECUTIVE CONTROL; INVENTORY PTCI; PTSD; DEPRESSION; SYMPTOMS; VICTIMS AB Purpose of review The current review aims to describe and evaluate research on cognitive difficulties associated with posttraumatic stress disorder (PTSD) published between January 2007 and June 2008. Recent findings The reviewed studies provide additional evidence that negative appraisals and decrements on verbal and autobiographical memory tasks are exhibited by individuals with PTSD relative to controls and may represent preexisting risk factors for PTSD rather than a result or concomitant of PTSD symptoms. In addition, the reviewed findings provide further evidence for source monitoring difficulties and attentional biases toward trauma-relevant information in PTSD. Recent research also provides evidence that, although memories of traumatic events differ in PTSD relative to other types of memories and memories of depressed individuals, they are likely on the same continuum as nontraumatic memories rather than qualitatively different. Summary Individuals with PTSD experience cognitive alterations ranging from impairments in overall memory functioning to difficulties specific to trauma-related cues. These cognitive difficulties appear to be importantly related to the development and/or maintenance of the disorder. At this point, it is unclear whether common mechanisms may account for these diverse cognitive difficulties and whether cognitive impairments are attributable to comorbid depression. C1 [Moore, Sally A.] VA Puget Sound Healthcare Syst, Seattle, WA 98108 USA. [Moore, Sally A.] Univ Washington, Dept Psychol, Seattle, WA 98195 USA. RP Moore, SA (reprint author), VA Puget Sound Healthcare Syst, MH 116,1660 S Columbian Way, Seattle, WA 98108 USA. EM sally.moore2@va.gov NR 55 TC 38 Z9 39 U1 5 U2 23 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0951-7367 J9 CURR OPIN PSYCHIATR JI Curr. Opin. Psychiatr. PD JAN PY 2009 VL 22 IS 1 BP 19 EP 24 DI 10.1097/YCO.0b013e328314e3bb PG 6 WC Psychiatry SC Psychiatry GA 393UH UT WOS:000262398400005 PM 19122530 ER PT J AU Teng, E Tingus, KD Lu, PH Cummings, JL AF Teng, Edmond Tingus, Kathleen D. Lu, Po H. Cummings, Jeffrey L. TI Persistence of Neuropsychological Testing Deficits in Mild Cognitive Impairment SO DEMENTIA AND GERIATRIC COGNITIVE DISORDERS LA English DT Article DE Alzheimer disease; Memory; Cognition; Dementia; Psychometrics ID OSTERRIETH COMPLEX FIGURE; VASCULAR RISK-FACTORS; ALZHEIMERS-DISEASE; NORMATIVE DATA; CLINICAL SUBTYPES; MEMORY IMPAIRMENT; TEST-PERFORMANCE; OLDER-ADULTS; DEMENTIA; CONVERSION AB Background: The significant variability across studies of mild cognitive impairment (MCI) in rates of progression to Alzheimer's disease (AD) and reversion to normal cognition may be due to differences in specific neuropsychological tests and thresholds used to define MCI. Methods: We assessed 115 subjects with amnestic (AMN) or non-amnestic (NON) MCI on a standardized neuropsychological battery at baseline and after a mean follow-up of 16.4 months to determine the prevalence and persistence of deficits identified with specific tests. Results: The prevalence of impaired performance varied widely across tests. Deficits were more persistent in the AMN group than in the NON group. Baseline deficits in Visual Reproduction II and the California Verbal Learning Test were the best predictors of persistent memory impairment. Subjects who at baseline were impaired on multiple memory tests or had poorer overall memory performance were more likely to exhibit persistent memory deficits. Conclusions: The use of different neuropsychological tests and thresholds to diagnose MCI identified subsets of subjects with different rates of persistence of cognitive impairment. Standardization of the operational definition of cognitive impairment in MCI may result in more consistent predictions of progression to AD. Copyright (C) 2009 S. Karger AG, Basel C1 [Teng, Edmond; Tingus, Kathleen D.; Lu, Po H.; Cummings, Jeffrey L.] Univ Calif Los Angeles, Dept Neurol, Los Angeles, CA 90024 USA. [Cummings, Jeffrey L.] Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, David Geffen Sch Med, Los Angeles, CA 90024 USA. RP Teng, E (reprint author), W Los Angeles VA Healthcare Ctr, Neurobehav Unit, Bldg 500 116AF,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM eteng@ucla.edu FU National Institute on Aging [P50 AG 16570]; Alzheimer's Disease Research Centers of California; Sidell-Kag an Foundation FX This research was supported by the National Institute on Aging (P50 AG 16570), the Alzheimer's Disease Research Centers of California, and the Sidell-Kag an Foundation. We would like to thank Charmaine Lowe, Myha Ngo, Alice Yau, and Michelle Zeller for their assistance with data management. NR 77 TC 19 Z9 20 U1 1 U2 4 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 1420-8008 J9 DEMENT GERIATR COGN JI Dement. Geriatr. Cogn. Disord. PY 2009 VL 28 IS 2 BP 168 EP 178 DI 10.1159/000235732 PG 11 WC Geriatrics & Gerontology; Clinical Neurology; Psychiatry SC Geriatrics & Gerontology; Neurosciences & Neurology; Psychiatry GA 494DA UT WOS:000269788500010 PM 19707017 ER PT J AU Lesser, GT Haroutunian, V Purohit, DP Beeri, MS Schmeidler, J Honkanen, L Neufeld, R Libow, LS AF Lesser, Gerson T. Haroutunian, Vahram Purohit, Dushyant P. Beeri, Michal Schnaider Schmeidler, James Honkanen, Linda Neufeld, Richard Libow, Leslie S. TI Serum Lipids Are Related to Alzheimer's Pathology in Nursing Home Residents SO DEMENTIA AND GERIATRIC COGNITIVE DISORDERS LA English DT Article DE Lipids and dementia; Alzheimer's disease; Neuropathology of dementia; Nursing home; Cholesterol; Serum lipids ID DIFFERENT DIAGNOSTIC-CRITERIA; MILD COGNITIVE IMPAIRMENT; VASCULAR RISK-FACTORS; LATE-ONSET DEMENTIA; APOLIPOPROTEIN-E; DENSITY-LIPOPROTEIN; CHOLESTEROL LEVEL; NEURITIC PLAQUES; APOE GENOTYPE; OLDER PERSONS AB Background: Studies of associations between serum lipids and Alzheimer's disease ( AD) or other dementias in the elderly show conflicting results, perhaps due to misclassification of the various dementias. Methods: For 358 nursing home residents, serum lipids were studied at admission and diagnoses established at autopsy. We used defined neuropathological criteria to distinguish the presence of AD and to avoid errors of clinical dementia assessment. Results: Residents with any AD pathology, as compared to those without AD pathology, had higher mean serum total cholesterol (TC; 200.4 vs. 185.9 mg/dl; p = 0.02) and higher mean low-density lipoprotein cholesterol (LDL; 124.5 vs. 111.5 mg/dl; p = 0.03). Further, mean TC, LDL and high-density lipoprotein cholesterol levels all increased progressively with increasing pathological certainty of AD ( p for trend = 0.001, 0.02 and 0.02). Conclusions: TC and LDL were significantly related to pathologically defined AD. If serum lipids have a role in the pathogenesis of AD, interventions may modify the course of disease. Copyright (c) 2009 S. Karger AG, Basel C1 [Lesser, Gerson T.; Honkanen, Linda; Neufeld, Richard; Libow, Leslie S.] Jewish Home & Hosp, New York, NY 10025 USA. [Lesser, Gerson T.; Neufeld, Richard; Libow, Leslie S.] Mt Sinai Sch Med, Dept Geriatr & Adult Dev, New York, NY USA. [Haroutunian, Vahram; Beeri, Michal Schnaider; Schmeidler, James] Mt Sinai Sch Med, Dept Psychiat, New York, NY USA. [Purohit, Dushyant P.] Mt Sinai Sch Med, Dept Pathol, New York, NY USA. [Haroutunian, Vahram] Bronx Vet Affairs Med Ctr, New York, NY USA. RP Lesser, GT (reprint author), Jewish Home & Hosp, 120 W 106th St, New York, NY 10025 USA. EM glesser@jhha.org FU Dextra Baldwin McGonagle Foundation; NIA [AG02219]; NIH [M01-RR-00071] FX This work was supported by the Dextra Baldwin McGonagle Foundation, Joseph E. and Norma G. Saul Foundation, NIA grant AG02219 and NIH grant M01-RR-00071. NR 63 TC 22 Z9 23 U1 0 U2 2 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 1420-8008 J9 DEMENT GERIATR COGN JI Dement. Geriatr. Cogn. Disord. PY 2009 VL 27 IS 1 BP 42 EP 49 DI 10.1159/000189268 PG 8 WC Geriatrics & Gerontology; Clinical Neurology; Psychiatry SC Geriatrics & Gerontology; Neurosciences & Neurology; Psychiatry GA 400WD UT WOS:000262899200006 PM 19129700 ER PT J AU Carrion-Baralt, JR Melendez-Cabrero, J Beeri, MS Sano, M Silverman, JM AF Carrion-Baralt, Jose R. Melendez-Cabrero, Josefina Beeri, Michal Schnaider Sano, Mary Silverman, Jeremy M. TI The Neuropsychological Performance of Nondemented Puerto Rican Nonagenarians SO DEMENTIA AND GERIATRIC COGNITIVE DISORDERS LA English DT Article DE Successful cognitive aging; Puerto Rican nonagenarians; Oldest old population ID BOSTON NAMING TEST; AFRICAN-AMERICANS; ALZHEIMER-DISEASE; BATTERY; CERAD; NORMS; UTILITY; ELDERS; ADULTS; TRAIL AB Background/Aims: While the oldest old are the fastest growing segment of the US population, normative neuropsychological data for nondemented oldest old Spanish speakers are nonexistent. This study sought to evaluate the neuropsychological performance of nondemented nonagenarians residing in Puerto Rico and to compare their results with those of a similar English-speaking sample from New York. Methods: We studied 81 subjects who had a complete CERAD neuropsychological assessment in Spanish. We used multiple regression analysis to predict performance on the CERAD battery and ANCOVA to compare the Puerto Rico and New York samples. Results: In 10 out of the 13 neuropsychological tests administered, education was a significant predictor of performance. There were significant differences between the Puerto Rico and New York groups only in the Trail Making Tests. Conclusions: In this Puerto Rican sample, education was the strongest predictor of neuropsychological performance, which is consistent with previous studies. When education level is properly accounted for, the performance of Puerto Rican nonagenarians in the CERAD battery does not differ from the performance of US English-speaking nonagenarians. Copyright (c) 2009 S. Karger AG, Basel C1 [Carrion-Baralt, Jose R.] San Juan VA Med Ctr, Res & Dev Serv 151, San Juan, PR 00921 USA. [Carrion-Baralt, Jose R.; Melendez-Cabrero, Josefina; Beeri, Michal Schnaider; Sano, Mary; Silverman, Jeremy M.] Mt Sinai Sch Med, Dept Psychiat, New York, NY USA. [Sano, Mary; Silverman, Jeremy M.] James J Peters Bronx Veteran Affairs Med Ctr, Bronx, NY USA. RP Carrion-Baralt, JR (reprint author), San Juan VA Med Ctr, Res & Dev Serv 151, 10 Casia St, San Juan, PR 00921 USA. EM jose.carrion-baralt@mssm.edu FU NIA [1 K01 AG025203, 1 K01 AG023515, P50-AG05138, P01-AG02219]; US Alzheimer's Association grants FX This research was supported by NIA grants 1 K01 AG025203 (for J.R.C.-B.), 1 K01 AG023515 (for M. S. B.), P50-AG05138 (for M. S.), project 4 in P01-AG02219 (for J.M.S.) and two US Alzheimer's Association grants (for J.R.C.-B. and J.M.S.). NR 24 TC 5 Z9 5 U1 0 U2 2 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 1420-8008 J9 DEMENT GERIATR COGN JI Dement. Geriatr. Cogn. Disord. PY 2009 VL 27 IS 4 BP 353 EP 360 DI 10.1159/000209213 PG 8 WC Geriatrics & Gerontology; Clinical Neurology; Psychiatry SC Geriatrics & Gerontology; Neurosciences & Neurology; Psychiatry GA 428SQ UT WOS:000264870500008 PM 19293568 ER PT J AU Gleason, CE Gangnon, RE Fischer, BL Mahoney, JE AF Gleason, Carey E. Gangnon, Ronald E. Fischer, Barbara L. Mahoney, Jane E. TI Increased Risk for Falling Associated with Subtle Cognitive Impairment: Secondary Analysis of a Randomized Clinical Trial SO DEMENTIA AND GERIATRIC COGNITIVE DISORDERS LA English DT Article DE Accidental falls; Falls; Mini Mental State Exam; Cognition; Geriatrics; Older adults; Risk factors ID COMMUNITY; DEMENTIA; GAIT; SELECTION; PEOPLE; ADULTS AB Background/Aims: Having dementia increases patients' risk for accidental falls. However, it is unknown if having mild cognitive deficits also elevates a person's risk for falls. This study sought to clarify the relationship between subtle cognitive impairment, measured with a widely-used, clinic-based assessment, the Mini Mental State Exam (MMSE), and risk for falls. Methods: In a secondary analysis of the Kenosha County Falls Prevention Study, a randomized controlled trial targeting older adults at risk for falls, we examined the association between baseline MMSE and prospective rate of falls over 12 months in 172 subjects randomized to control group. Results: Using univariate analysis, the rate of falls increased with each unit decrease in MMSE score down to at least 22 (rate ratio 1.25, 95% confidence interval (CI) 1.09-1.45, p = 0.0026). Using stepwise multivariate regression, controlling for ability to perform activities of daily living, use of assistive device, current exercise, and arthritis, the association between MMSE score and falls rate persisted ( rate ratio 1.20, 95% CI 1.03-1.40, p = 0.021). Conclusion: Minimal decrements on the MMSE were associated with elevations in rate of falls, suggesting that subtle cognitive deficits reflected in MMSE scores above a cut-off consistent with a diagnosis of dementia, can influence risk for falls. Copyright (C) 2009 S. Karger AG, Basel C1 [Gleason, Carey E.; Mahoney, Jane E.] Univ Wisconsin, Dept Med, Sect Geriatr & Gerontol, Madison, WI 53705 USA. [Gangnon, Ronald E.] Univ Wisconsin, Dept Biostat, Madison, WI 53705 USA. [Gangnon, Ronald E.] Univ Wisconsin, Dept Med Informat, Madison, WI 53705 USA. [Gangnon, Ronald E.] Univ Wisconsin, Dept Populat Hlth Sci, Madison, WI 53705 USA. [Fischer, Barbara L.] William S Middleton Mem Vet Adm Med Ctr, Mental Hlth Serv, Madison, WI USA. [Gleason, Carey E.] William S Middleton Mem Vet Adm Med Ctr, GRECC, Madison, WI USA. RP Gleason, CE (reprint author), Univ Wisconsin, Dept Med, Sect Geriatr, Madison VA GRECC, Room D4211,2500 Overlook Terrace, Madison, WI 53705 USA. EM ceg@medicine.wisc.edu FU NIH-NIA [K23 AG024302]; Kenosha County Multi-Factorial Falls Prevention Program for Older Adults; Wisconsin Family Care Aging and/or Disability Resource Center Prevention; Wm. S. Middleton Memorial VA, Madison, Wisc FX This work was supported by NIH-NIA grant K23 AG024302 (PI: C.E.G.), the Kenosha County Multi-Factorial Falls Prevention Program for Older Adults; A Wisconsin Family Care Aging and/or Disability Resource Center Prevention Funding Grant (PI: J.E.M.); and the Geriatric Research, Education and Clinical Center and Mental Health Service of the Wm. S. Middleton Memorial VA, Madison, Wisc. This is GRECC Manuscript Number: 2007-015. NR 24 TC 37 Z9 39 U1 0 U2 9 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 1420-8008 EI 1421-9824 J9 DEMENT GERIATR COGN JI Dement. Geriatr. Cogn. Disord. PY 2009 VL 27 IS 6 BP 557 EP 563 DI 10.1159/000228257 PG 7 WC Geriatrics & Gerontology; Clinical Neurology; Psychiatry SC Geriatrics & Gerontology; Neurosciences & Neurology; Psychiatry GA 485XY UT WOS:000269160500010 PM 19602883 ER PT J AU Vexler, ZS Yenari, MA AF Vexler, Zinaida S. Yenari, Midori A. TI Does Inflammation after Stroke Affect the Developing Brain Differently than Adult Brain? SO DEVELOPMENTAL NEUROSCIENCE LA English DT Article; Proceedings Paper CT 6th Hershey Conference on Developmental Brain Injury CY JUN 04-07, 2008 CL Ecquevilly, FRANCE SP Natl Inst Neurolog Disorders & Stroke DE Stroke; Hypoxia-ischemia; Cytokine; Chemokine; Microglia; Neuroprotection; Neurogenesis ID FOCAL CEREBRAL-ISCHEMIA; TUMOR-NECROSIS-FACTOR; NF-KAPPA-B; MONOCYTE CHEMOATTRACTANT PROTEIN-1; NITRIC-OXIDE SYNTHASE; CENTRAL-NERVOUS-SYSTEM; INTERLEUKIN-1 RECEPTOR ANTAGONIST; SUBVENTRICULAR ZONE NEUROGENESIS; NEONATAL HYPOXIA-ISCHEMIA; LONG-TERM NEUROPROTECTION AB The immature brain is prone to hypoxic-ischemic encephalopathy and stroke. The incidence of arterial stroke in newborns is similar to that in the elderly. However, the pathogenesis of ischemic brain injury is profoundly affected by age at the time of the insult. Necrosis is a dominant type of neuronal cell death in adult brain, whereas widespread neuronal apoptosis is unique for the early postnatal synaptogenesis period. The inflammatory response, in conjunction with excitotoxic and oxidative responses, is the major contributor to ischemic injury in both the immature and adult brain, but there are several areas where these responses diverge. We discuss the contribution of various inflammatory mechanisms to injury and repair after cerebral ischemia in the context of CNS immaturity. In particular, we discuss the role of lower expression of selectins, a more limited leukocyte transmigration, undeveloped complement pathways, a more rapid microglial activation, differences in cytokine and chemokine interplay, and a different threshold to oxidative stress in the immature brain. We also discuss differences in activation of intracellular pathways, especially nuclear factor kappa B and mitogen-activated protein kinases. Finally, we discuss emerging data on both the supportive and adverse roles of inflammation in plasticity and repair after stroke. Copyright (C) 2009 S. Karger AG, Basel C1 [Vexler, Zinaida S.; Yenari, Midori A.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA. [Yenari, Midori A.] San Francisco VA Med Ctr, San Francisco, CA USA. RP Vexler, ZS (reprint author), Univ Calif San Francisco, Dept Neurol, 521 Parnassus Ave,C215, San Francisco, CA 94143 USA. EM Zena.Vexler@ucsf.edu FU NINDS NIH HHS [R01 NS040516, R01 NS044025, R01 NS40516, R01 NS44025] NR 222 TC 65 Z9 66 U1 0 U2 9 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 0378-5866 J9 DEV NEUROSCI-BASEL JI Dev. Neurosci. PY 2009 VL 31 IS 5 BP 378 EP 393 DI 10.1159/000232556 PG 16 WC Developmental Biology; Neurosciences SC Developmental Biology; Neurosciences & Neurology GA 491JH UT WOS:000269574200002 PM 19672067 ER PT J AU Sale, MM Lu, LY Spruill, IJ Fernandes, JK Lok, KH Divers, J Langefeld, CD Garvey, WT AF Sale, Michele M. Lu, Lingyi Spruill, Ida J. Fernandes, Jyotika K. Lok, Kerry H. Divers, Jasmin Langefeld, Carl D. Garvey, W. Timothy TI Genome-Wide Linkage Scan in Gullah-Speaking African American Families With Type 2 Diabetes The Sea Islands Genetic African American Registry (Project SuGAR) SO DIABETES LA English DT Article; Proceedings Paper CT 68th Annual Meeting of the American-Diabetes-Association CY JUN 06-10, 2008 CL San Francisco, CA SP Amer Diabet Assoc ID SINGLE NUCLEOTIDE POLYMORPHISMS; FACTOR-7-LIKE-2 TCF7L2 GENE; SUSCEPTIBILITY GENES; ASSOCIATION ANALYSIS; IDENTIFICATION; VARIANTS; MELLITUS; POPULATIONS; AFFINITIES; LOCUS AB OBJECTIVE-The Gullah-speaking African American population from the Sea Islands of South Carolina is characterized by a low degree of European admixture and high rates of type 2 diabetes and diabetic complications. Affected relative pairs with type 2 diabetes were recruited through the Sea Islands Genetic African American Registry (Project SuGAR). RESEARCH DESIGN AND METHODS-We conducted a genome-wide linkage scan, genotyping 5,974 single nucleotide polymorphisms in 471 affected subjects and 50 unaffected relatives from 197 pedigrees. Data were analyzed using a multipoint engine for rapid likelihood inference and ordered subsets analyses (OSAs) for age at type 2 diabetes diagnosis, waist circumference, waist-to-hip ratio, and BMI. We searched for heterogeneity and interactions using a conditional logistic regression likelihood approach. RESULTS-Linkage peaks on chromosome 14 at 123-124 cM were detected for type 2 diabetes (logarithm of odds [LOD] 2. 10) and for the subset with later age at type 2 diabetes diagnosis (maximum LOD 4.05). Two linkage peaks on chromosome 7 were detected at 44-45 cM for type 2 diabetes (LOD 1.18) and at 78 cM for type 2 diabetes (LOD 1.64) and the subset with earlier age at type 2 diabetes diagnosis (maximum LOD 3.93). The chromosome 14 locus and a peak on 7p at 29.5 cM were identified as important in the multilocus model. Other regions that provided modest evidence for linkage included chromosome 1 at 167.5 cM (LOD 1.51) and chromosome 3 at 121.0 cM (LOD 1.61). CONCLUSIONS-This study revealed a novel type 2 diabetes locus in an African American population on 14q that appears to reduce age of disease onset and confirmed two loci on chromosome 7. Diabetes 58:260-267, 2009 C1 [Sale, Michele M.] Univ Virginia, Ctr Publ Hlth Genom, Charlottesville, VA 22903 USA. [Sale, Michele M.] Univ Virginia, Dept Med, Charlottesville, VA USA. [Sale, Michele M.] Univ Virginia, Dept Biochem & Mol Genet, Charlottesville, VA USA. [Lu, Lingyi; Divers, Jasmin; Langefeld, Carl D.] Wake Forest Univ, Sch Med, Dept Biostat Sci, Winston Salem, NC 27109 USA. [Spruill, Ida J.; Fernandes, Jyotika K.] Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA. [Lok, Kerry H.; Garvey, W. Timothy] Univ Alabama, Dept Nutr Sci, Birmingham, AL 35294 USA. [Garvey, W. Timothy] Birmingham VA Med Ctr, Birmingham, AL USA. RP Sale, MM (reprint author), Univ Virginia, Ctr Publ Hlth Genom, Charlottesville, VA 22903 USA. EM msale@virginia.edu FU NCRR NIH HHS [P20 RR017696, M01-RR-1070, P20-RR-17696, M01 RR007122-150269, M01 RR007122, M01 RR001070]; NHGRI NIH HHS [N01HG65403]; NIDDK NIH HHS [R01 DK066358-01, R01 DK066358-03, DK-66358, R01 DK066358-02, P30-DK-56336, R01 DK047461, P30 DK056336, R01 DK066358] NR 36 TC 16 Z9 16 U1 2 U2 4 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0012-1797 J9 DIABETES JI Diabetes PD JAN PY 2009 VL 58 IS 1 BP 260 EP 267 DI 10.2337/db08-0198 PG 8 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 390TR UT WOS:000262187100038 PM 18835935 ER PT J AU Coletta, DK Schneider, J Hu, SL Dyer, TD Puppala, S Farook, VS Arya, R Lehman, DM Blangero, J DeFronzo, RA Duggirala, R Jenkinson, CP AF Coletta, Dawn K. Schneider, Jennifer Hu, Shirley L. Dyer, Thomas D. Puppala, Sobha Farook, Vidya S. Arya, Rector Lehman, Donna M. Blangero, John DeFronzo, Ralph A. Duggirala, Ravindranath Jenkinson, Christopher P. TI Genome-Wide Linkage Scan for Genes Influencing Plasma Triglyceride Levels in the Veterans Administration Genetic Epidemiology Study SO DIABETES LA English DT Article ID OLD ORDER AMISH; MEXICAN-AMERICANS; SUSCEPTIBILITY LOCUS; INSULIN-RESISTANCE; QUANTITATIVE TRAITS; ASSOCIATION; DISEASE; FAMILY; SEGREGATION; CHOLESTEROL AB OBJECTIVE-Elevated plasma triglyceride concentration is a component of the insulin resistance syndrome and is commonly associated with type 2 diabetes, obesity, and coronary heart disease. The goal. of our study was to perform a genome-wide linkage scan to identify genetic regions that influence variation in plasma triglyceride levels in families that are enriched with individuals with type 2 diabetes. RESEARCH DESIGN AND METHODS-We used phenotypic and genotypic data from 1,026 individuals distributed across 294 Mexican-American families, who were ascertained for type 2 diabetes, from the Veterans Administration Genetic Epidemiology Study (VAGES). Plasma triglyceride values were transformed, and a variance-components technique was used to conduct multipoint linkage analysis. RESULTS-After adjusting for the significant effects of sex and BMI, heritability for plasma triglycerides was estimated as 46 +/- 7% (P < 0.0001). Multipoint linkage analysis yielded the strongest evidence for linkage of plasma triglycerides near marker D12S391 on chromosome 12p (logarithm of odds [LOD] = 2.4). Our linkage signal on chromosome 12p provides independent replication of a similar finding in another Mexican-American sample from the San Antonio Family Diabetes Study (SAFDS). Combined multipoint linkage analysis of the VAGES and SAFDS data yielded significant evidence for linkage of plasma triglycerides to a genetic location between markers GATA49D12 and D12S391 on 12p (LOD = 3.8, empirical P value = 2.0 X 10(-5)). This region on 12p harbors the gene-encoding adiponectin receptor 2 (AdipoR2), where we previously have shown that multiple single nucleotide polymorphisms are associated with plasma triglyceride concentrations in the SAFDS. In the present study, we provided suggestive evidence in favor of association for rs929434 with triglyceride concentrations in the VAGES. CONCLUSIONS-Collectively, these results provide strong evidence for a major locus on chromosome 12p that influences plasma triglyceride levels in Mexican Americans. Diabetes 58: 279-284, 2009 C1 [Coletta, Dawn K.; Hu, Shirley L.; DeFronzo, Ralph A.; Jenkinson, Christopher P.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Div Diabet, San Antonio, TX 78229 USA. [Schneider, Jennifer; Dyer, Thomas D.; Puppala, Sobha; Farook, Vidya S.; Blangero, John; Duggirala, Ravindranath; Jenkinson, Christopher P.] SW Fdn Biomed Res, San Antonio, TX 78284 USA. [Arya, Rector; Lehman, Donna M.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Div Clin Epidemiol, San Antonio, TX 78229 USA. [DeFronzo, Ralph A.; Jenkinson, Christopher P.] S Texas Vet Hlth Care Syst, San Antonio, TX USA. RP Coletta, DK (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Div Diabet, San Antonio, TX 78229 USA. EM dawn.coletta@asu.edu RI Coletta, Dawn/G-6382-2016 OI Coletta, Dawn/0000-0001-5819-5152 FU Veterans Administration Epidemiologic; National Institutes of Health [DK42273, DK47482, DK53889, DK70746]; American Heart Association National Scientist Development FX We thank Marcel J. Fourcaudot and Lenore M. Rodriguez for excellent technical assistance. We thank our nurses (James King, John Kincaid, Rose Kaminski-Graham, and Norma Diaz) for their excellent care of the patients throughout the study. We thank the participants of VAGES and are grateful for their participation and cooperation. NR 38 TC 12 Z9 13 U1 0 U2 1 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0012-1797 J9 DIABETES JI Diabetes PD JAN PY 2009 VL 58 IS 1 BP 279 EP 284 DI 10.2337/db08-0491 PG 6 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 390TR UT WOS:000262187100041 PM 18931038 ER PT B AU Watson, GS Craft, S AF Watson, G. Stennis Craft, Suzanne BE Biessels, GJ Luchsinger, JA TI The Role of Insulin Resistance in Age-Related Cognitive Decline and Dementia SO DIABETES AND THE BRAIN SE Contemporary Diabetes LA English DT Article; Book Chapter DE Alzheimer's disease; Apolipoprotein E; Beta amyloid; Diabetes; Diet and exercise; Glucose; Inflammation; Insulin; Insulin resistance; IGF-1; Intranasal; Memory; PPAR-gamma ID CENTRAL-NERVOUS-SYSTEM; IMPAIRED GLUCOSE-TOLERANCE; APOLIPOPROTEIN-E GENOTYPE; GROWTH-FACTOR EXPRESSION; SPORADIC ALZHEIMERS-DISEASE; AMYLOID PRECURSOR PROTEIN; OXIDE SYNTHASE EXPRESSION; NECROSIS-FACTOR-ALPHA; FREE FATTY-ACIDS; PEROXISOME PROLIFERATOR AB The role of insulin in peripheral energy metabolism has been well described, and converging evidence has identified a role for insulin in central nervous system functions. Epidemiological studies support an important relationship between diabetes and other insulin-resistant conditions, and cognitive functioning. For example, diabetes increases the risk for memory loss, and treating diabetes can reverse memory loss. These studies have also identified a reciprocal relationship between insulin resistance and dementia, such that one condition increases the risk for the other. A substantial body of work has explored the role of insulin in regulating brain glucose metabolism, memory function, inflammatory responses, and amyloid concentrations. Knowledge of these relationships has suggested that increasing brain insulin activity may have a beneficial impact on memory and may serve as the basis for novel therapeutic strategies for Alzheimer's disease. Three such strategies include intranasal administration of insulin, drugs that improve insulin sensitivity, and diet and exercise C1 [Watson, G. Stennis; Craft, Suzanne] Univ Washington, Geriatr Res Educ & Clin Ctr, Vet Affairs Puget Sound, Seattle, WA 98108 USA. RP Watson, GS (reprint author), Univ Washington, Geriatr Res Educ & Clin Ctr, Vet Affairs Puget Sound, Seattle, WA 98108 USA. EM gswatson@u.washington.edu; scraft@u.washington.edu NR 107 TC 0 Z9 0 U1 1 U2 2 PU HUMANA PRESS INC PI TOTOWA PA 999 RIVERVIEW DR, STE 208, TOTOWA, NJ 07512-1165 USA BN 978-1-60327-850-8 J9 CONTEMP DIABETES PY 2009 BP 433 EP 457 DI 10.1007/978-1-60327-850-8_18 D2 10.1007/978-1-60327-850-8 PG 25 WC Endocrinology & Metabolism; Medicine, General & Internal; Neurosciences SC Endocrinology & Metabolism; General & Internal Medicine; Neurosciences & Neurology GA BLZ66 UT WOS:000271604300018 ER PT J AU Maciejewski, ML Liu, CF Fihn, SD AF Maciejewski, Matthew L. Liu, Chuan-Fen Fihn, Stephan D. TI Performance of Comorbidity, Risk Adjustment, and Functional Status Measures in Expenditure Prediction for Patients With Diabetes SO DIABETES CARE LA English DT Article ID REPORTED HEALTH-STATUS; CASE-MIX; SEVERITY INDEX; CARE; VALIDATION; QUALITY; MODEL; POPULATION; MORTALITY; SELECTION AB OBJECTIVE - To compare the ability of generic comorbidity and risk adjustment measures, a diabetes-specific measure, and a self-reported functional status measure to explain variation in health care expenditures for individuals with diabetes. RESEARCH DESIGN AND METHODS - This study included a retrospective cohort of 3,092 diabetic veterans participating in a multisite trial. Two comorbidity measures, four risk adjusters, a functional Status measure, a diabetes complication count, and baseline expenditures were constructed from administrative and survey data. Outpatient, inpatient, and total expenditure models were estimated using ordinary least squares regression. Adjusted R(2) statistics and predictive ratios were compared across measures to assess overall explanatory power and explanatory power of low- and high-cost subgroups. RESULTS - Administrative data-based risk adjusters performed better than the comorbidity, functional status, and diabetes-specific measures in all expenditure models. The diagnostic cost groups (DCGs) measure had the greatest predictive power overall and for the low- and high-cost subgroups, while the diabetes-specific measure had the lowest predictive power. A model with DCGs and the diabetes-specific measure modestly improved predictive power. CONCLUSIONS - Existing generic measures can be useful for diabetes-specific research and policy applications, but more predictive diabetes-specific measures are needed. C1 [Maciejewski, Matthew L.] Durham VA Med Ctr, Hlth Serv Res & Dev, Dept Vet Affairs, Durham, NC USA. [Maciejewski, Matthew L.] Univ N Carolina, Sch Pharm, Div Pharmaceut Outcomes & Policy, Chapel Hill, NC USA. [Liu, Chuan-Fen; Fihn, Stephan D.] Dept Vet Affairs, VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, Washington, DC USA. [Liu, Chuan-Fen; Fihn, Stephan D.] Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA. [Fihn, Stephan D.] Univ Washington, Dept Med, Seattle, WA 98195 USA. RP Maciejewski, ML (reprint author), Durham VA Med Ctr, Hlth Serv Res & Dev, Dept Vet Affairs, Durham, NC USA. EM matthew.maciejewski@va.gov FU Department of Veterans Affairs; Veterans Health Administration; Office of Research and Development; Health Services Research and Development Service (HSRD) [LIP 61-105, SDR 96-002, IIR 99-376] FX No potential conflicts of interest relevant to this article were reported. Comments from Sarah Krein, the manuscript editor, two anonymous reviewers, and Outstanding research assistance from Mark Perkins are appreciated. NR 25 TC 25 Z9 25 U1 1 U2 8 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0149-5992 J9 DIABETES CARE JI Diabetes Care PD JAN PY 2009 VL 32 IS 1 BP 75 EP 80 DI 10.2337/dc08-1099 PG 6 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 390UA UT WOS:000262188000016 PM 18945927 ER PT J AU Izumi, Y Satterfield, K Lee, S Harkless, LB Lavery, LA AF Izumi, Yuki Satterfield, Kathleen Lee, Shuko Harkless, Lawrence B. Lavery, Lawrence A. TI Mortality of first-time amputees in diabetics: A 10-year observation SO DIABETES RESEARCH AND CLINICAL PRACTICE LA English DT Article DE Diabetic foot; Mortality; Amputation ID LOWER-EXTREMITY AMPUTATION; 6.5-YEAR FOLLOW-UP; MAJOR AMPUTATION; LOWER-LIMB; FOOT PROBLEMS; SURVIVAL; POPULATION; DISEASE; REAMPUTATION; PROGNOSIS AB Aims: We analyze mortality of first-time diabetic amputees by stratifying by level of amputation, differentiating short-term and long-term mortality. Methods: We evaluated 277 diabetic patients who received their first lower extremity amputation (LEA) during 1993-97. Subjects were followed until December 2003, and categorized by level of amputation. We compared the mortality difference by level for 0-10 years, 0-10 months, and 10 months-10 years, and examined the association of comorbid conditions and death for each level. Results: We found a significant difference in mortality by amputation level for 0-10 years (p < 0.05) and < 10 months (p < 0.01) survival, but not for the one of 10 months-10 years. For major amputees deceased within 10 months, sepsis was as frequent a cause of death as cardiovascular disease. in distal. amputees, CVD, CAD and ESRD were strongly associated with death, but only CAD was associated death among major amputees. Conclusion: For diabetic patients undergoing first LEAS, the mortality of major amputees was worse than that of minor amputees due to the difference in first 10-month mortality. The history of comorbid conditions in first-time major amputees was less important than in minor amputees since sepsis was the frequent cause of death in major amputees in this early period. (C) 2008 Elsevier Ireland Ltd. All rights reserved. C1 [Izumi, Yuki] Natl Hosp Org, Kyoto Med Ctr, WHO, Collaborating Ctr Diabet, Kyoto 6128555, Japan. [Satterfield, Kathleen] Univ Texas Hlth Sci Ctr San Antonio, Dept Orthopaed, San Antonio, TX 78229 USA. [Lee, Shuko] S Texas Vet Hlth Care Syst, Audie L Murphy Div, Res & Dev Serv, San Antonio, TX USA. [Harkless, Lawrence B.] Western Univ Hlth Sci, Coll Podiatr Med, Pomona, CA 91766 USA. [Lavery, Lawrence A.] Texas A&M Univ, Coll Med, Hlth Sci Ctr, Temple, TX 76508 USA. [Lavery, Lawrence A.] Scott & White Hosp, Temple, TX USA. RP Izumi, Y (reprint author), Natl Hosp Org, Kyoto Med Ctr, WHO, Collaborating Ctr Diabet, 1-1 Mukaihata Cho Fukakusa, Kyoto 6128555, Japan. EM dfootjapan@hotmail.co.jp OI Lavery, Lawrence/0000-0002-7920-9952 NR 22 TC 27 Z9 28 U1 0 U2 1 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0168-8227 J9 DIABETES RES CLIN PR JI Diabetes Res. Clin. Pract. PD JAN PY 2009 VL 83 IS 1 BP 126 EP 131 DI 10.1016/j.diabres.2008.09.005 PG 6 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 398VC UT WOS:000262758600019 PM 19097667 ER PT J AU Bradesi, S Mayer, EA AF Bradesi, Sylvie Mayer, Emeran A. TI Experimental Models of Stress and Pain: Do They Help to Develop New Therapies? SO DIGESTIVE DISEASES LA English DT Article DE Irritable bowel syndrome; Animal models; Human experimental medicine models; Drug development; Predictive validity; Intermediate phenotypes ID IRRITABLE-BOWEL-SYNDROME; FUNCTIONAL GASTROINTESTINAL DISORDERS; BRAIN-GUT AXIS; NOXIOUS COLORECTAL DISTENSION; PSEUDO-AFFECTIVE RESPONSES; 5-HT3 RECEPTOR ANTAGONIST; KAPPA-AGONIST FEDOTOZINE; FACTOR-I RECEPTORS; COLONIC DISTENSION; ANIMAL-MODELS AB The majority of functional gastrointestinal disorders are characterised by recurrent abdominal pain, with stress playing an important role in first onset and exacerbation of existing symptoms. These disorders are currently defined by symptom criteria, while their pathophysiology remains controversial and incompletely understood. Modeling these disorders in humans and animals has been difficult. While some of the models have adequate face and construct validity, the predictive validity of most of the models has been disappointing, which has put into question the traditional modeling approach. Similar problems have been encountered in drug development for pain and psychiatric disorders. New approaches have been proposed in the form of reverse translation, which include better characterisation of biological intermediate phenotypes in human disease which can be modeled in humans and in animals. Continuation of the current approach focusing on complex clinical phenotypes is likely to be ineffective for the development of novel and effect treatments. Copyright (C) 2010 S. Karger AG, Basel C1 [Bradesi, Sylvie] Univ Calif Los Angeles, David Geffen Sch Med, Div Digest Dis, Ctr Neurobiol Stress,Dept Med, Los Angeles, CA 90095 USA. Univ Calif Los Angeles, David Geffen Sch Med, Ctr Neurobiol Stress, Dept Physiol, Los Angeles, CA 90095 USA. Univ Calif Los Angeles, David Geffen Sch Med, Ctr Neurobiol Stress, Dept Psychiat, Los Angeles, CA 90095 USA. VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. RP Bradesi, S (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Div Digest Dis, Ctr Neurobiol Stress,Dept Med, Bldg 115 CURE,11303 Wilshire Blvd, Los Angeles, CA 90095 USA. EM sbradesi@ucla.edu FU Boehringer Ingelheim International GmbH; GSK; Novartis; Avera; Danone FX S. Bradesi has received research support from Boehringer Ingelheim International GmbH. E. A. Mayer is a consultant for GSK, Novartis, Lilly, Avery, Forrest, Ironwood and Danone and has received research support from GSK, Novartis, Avera and Danone. NR 92 TC 6 Z9 6 U1 5 U2 5 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 0257-2753 J9 DIGEST DIS JI Dig. Dis. PY 2009 VL 27 SU 1 BP 55 EP 67 DI 10.1159/000268122 PG 13 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 566FM UT WOS:000275355500009 PM 20203498 ER PT J AU Kaunitz, JD AF Kaunitz, Jonathan D. TI Gastroenterology Research Group and Digestive Diseases and Sciences SO DIGESTIVE DISEASES AND SCIENCES LA English DT Editorial Material C1 Univ Calif Los Angeles, David Geffen Sch Med, Greater Los Angeles VA Hlth Care Syst, Los Angeles, CA 90095 USA. RP Kaunitz, JD (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Greater Los Angeles VA Hlth Care Syst, Los Angeles, CA 90095 USA. EM jake@ucla.edu NR 1 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0163-2116 J9 DIGEST DIS SCI JI Dig. Dis. Sci. PD JAN PY 2009 VL 54 IS 1 BP 5 EP 5 DI 10.1007/s10620-008-0625-z PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 383DD UT WOS:000261653400002 ER PT J AU Sporner, ML Fitzgerald, SG Dicianno, BE Collins, D Teodorski, E Pasquina, PF Cooper, RA AF Sporner, Michelle L. Fitzgerald, Shirley G. Dicianno, Brad E. Collins, Diane Teodorski, Emily Pasquina, Paul F. Cooper, Rory A. TI Psychosocial impact of participation in the National Veterans Wheelchair Games and Winter Sports Clinic SO DISABILITY AND REHABILITATION LA English DT Article DE Exercise; sports; wheelchairs; activities of daily living; quality of life ID SPINAL-CORD-INJURY; PHYSICAL-ACTIVITY; MENTAL-HEALTH; CONTROLLED-TRIAL; EXERCISE; PREVENTION; DEPRESSION; DEPLOYMENT; MOOD; IRAQ AB Purpose. The purpose of this study was to determine the characteristics of individuals who participate in the National Veterans Wheelchair Games (NVWG) and the Winter Sports Clinic (WSC) for veterans with disabilities. In addition, it was of interest to determine how these events had impacted their lives. Method. Participants were recruited at the 20th Winter Sports Clinic, held in Snowmass Colorado and the 26th National Veterans Wheelchair Games held in Anchorage, Alaska. Data of interest included demographic, sport participation information, community integration, self-esteem, and quality of life. A secondary data analysis was completed to determine how comparable individuals who attended the NVWG/WSC were to individuals who did not participate in these events. Results. The 132 participants were a mean age of 47.4 + 13.4 and lived with a disability for an average of 13.4 + 12.1. Participants felt that the NVWG/WSC increased their knowledge of sports equipment (92%), learning sports (89%), mobility skills (84%), and acceptance of disability (84%). The majority of participants stated that the NVWG/WSC improved their life. Of those who participated at the NVWG/WSC, they tended to be more mobile, but have increased physical and cognitive limitations as measured by the CHART when compared to the non-attendees. Conclusions. Recommending veterans participate in events such as the NVWG and WSC can provide psychosocial benefits to veterans with disabilities. C1 [Sporner, Michelle L.; Collins, Diane] VA Pittsburgh Healthcare Syst, Human Engn Res Labs, Pittsburgh, PA USA. [Fitzgerald, Shirley G.] James Haley Tampa VA, Patient Safety Ctr, Tampa, FL USA. [Dicianno, Brad E.] VA Pittsburgh Healthcare Syst, Human Engn Res Labs, Pittsburgh, PA USA. [Teodorski, Emily] VA Pittsburgh Healthcare Syst, Human Engn Res Labs, Pittsburgh, PA USA. [Pasquina, Paul F.] Dept Orthoped & Rehabil, Walter Reed Army Med Ctr, Washington, DC USA. [Cooper, Rory A.] VA Pittsburgh Healthcare Syst, Human Engn Res Labs, Pittsburgh, PA USA. [Sporner, Michelle L.; Dicianno, Brad E.; Collins, Diane; Teodorski, Emily; Cooper, Rory A.] VA Pittsburgh Healthcare Syst, Human Engn Res Labs, Pittsburgh, PA USA. [Sporner, Michelle L.; Collins, Diane; Cooper, Rory A.] Univ Pittsburgh, Sch Hlth & Rehabil Sci, Dept Rehabil Sci & Technol, Pittsburgh, PA 15260 USA. [Fitzgerald, Shirley G.] James A Haley Tampa VA, Patient Safety Ctr, Tampa, FL USA. [Dicianno, Brad E.; Cooper, Rory A.] Univ Pittsburgh, Dept Phys Med & Rehabil, Pittsburgh, PA 15260 USA. [Pasquina, Paul F.] Walter Reed Army Med Ctr, Dept Orthoped & Rehabil, Washington, DC 20307 USA. RP Fitzgerald, SG (reprint author), Patient Safety Ctr Inquiry, 11605 N Nebraska Ave, Tampa, FL 33612 USA. EM Shirley.Fitzgerald@va.gov OI Dicianno, Brad/0000-0003-0738-0192 FU VA Center of Excellence, VA Pittsburgh Healthcare System; The Telemedicine and Advanced Technology Research Center [06053001]; HSRRB [A-13839]; Center of Excellence for Wheelchairs and Associated Rehabilitation Engineering [VA B3142C] FX This project was completed solely at the VA Center of Excellence, VA Pittsburgh Healthcare System. This study was supported by The Telemedicine and Advanced Technology Research Center under Proposal Number 06053001, HSRRB Log Number A-13839 and Center of Excellence for Wheelchairs and Associated Rehabilitation Engineering (VA B3142C). NR 36 TC 19 Z9 20 U1 4 U2 30 PU TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND SN 0963-8288 J9 DISABIL REHABIL JI Disabil. Rehabil. PY 2009 VL 31 IS 5 BP 410 EP 418 AR PII 792789939 DI 10.1080/09638280802030923 PG 9 WC Rehabilitation SC Rehabilitation GA 417SM UT WOS:000264098200009 PM 18608391 ER PT J AU Bull, LM White, DL Bray, M Nurgalieva, Z El-Serag, HB AF Bull, L. M. White, D. L. Bray, M. Nurgalieva, Z. El-Serag, H. B. TI Phase I and II enzyme polymorphisms as risk factors for Barrett's esophagus and esophageal adenocarcinoma: a systematic review and meta-analysis SO DISEASES OF THE ESOPHAGUS LA English DT Review DE Barrett's esophagus; epidemiology; esophageal adenocarcinoma; genetic association; GST; single-nucleotide polymorphism (SNP) ID GLUTATHIONE-S-TRANSFERASE; MICROSOMAL EPOXIDE HYDROLASE; SQUAMOUS-CELL-CARCINOMA; ARYLAMINE N-ACETYLTRANSFERASE; LUNG-CANCER RISK; GENETIC POLYMORPHISMS; REFLUX ESOPHAGITIS; MOLECULAR-GENETICS; C609T POLYMORPHISM; ALLELIC VARIANTS AB P>Although several studies have examined the association between phase I/II enzyme polymorphisms and esophageal adenocarcinoma (EAC) and/or Barrett's esophagus (BE), their overall findings remain unclear. We performed a systematic review and meta-analysis to determine whether phase I/II polymorphisms are independent risk factors for either BE or EAC. We employed keyword searches in multiple databases to identify studies published before October 1, 2007. Single-nucleotide polymorphisms (SNPs) examined in >= 3 studies were meta-analyzed to obtain a pooled estimate of effect. Meta-analysis suggested the minor allele for GSTP1 Val105 conveys modest excess risk (odds ratio [OR](BE) = 1.50, 95% confidence interval [CI] 1.16-1.95; OR(EAC) = 1.20, 95% CI 0.94-1.54). No excess risk was observed with GSTM1 null (OR(BE) = 0.77, 95% CI: 0.56-1.08; OR(EAC) = 1.08, 95% CI: 0.79-1.48), GSTT1 null (OR(BE) = 1.35, 95% CI: 0.91-2.01; OR(EAC) = 0.84, 95% CI: 0.48-1.49), or CYP1A Val462 (OR(EAC) = 0.89, 95% CI: 0.40-1.97). Insufficient data existed to meta-analyze remaining SNPs. Our review identified GSTP1(Ile105Val) as a possible risk factor for BE and EAC in Caucasian males. No excess risk was observed for other phase I/II polymorphisms with sufficient data to meta-analyze. Additional studies are needed to determine if GSTP1 conveys excess risk in females or non-Caucasians and to evaluate other phase I/II polymorphisms. C1 [Bull, L. M.; White, D. L.; Bray, M.; Nurgalieva, Z.; El-Serag, H. B.] Baylor Coll Med, Houston, TX 77030 USA. RP El-Serag, HB (reprint author), Michael E DeBakey Vet Affairs Med Ctr, Houston Ctr Qual Care & Utilizat Studies, 2002 Holcombe Blvd MS 152, Houston, TX 77030 USA. EM hasheme@bcm.tmc.edu FU Helis Foundation FX The study is supported in part by a grant from the Helis Foundation. NR 92 TC 11 Z9 11 U1 1 U2 6 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1120-8694 J9 DIS ESOPHAGUS JI Dis. Esophagus PY 2009 VL 22 IS 7 BP 571 EP 587 DI 10.1111/j.1442-2050.2009.00947.x PG 17 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 497OX UT WOS:000270070500005 PM 19222528 ER PT J AU Montenovo, M Tatum, RP Figueredo, E Martin, AV Vu, H Quiroga, E Pellegrini, CA Oelschlager, BK AF Montenovo, M. Tatum, R. P. Figueredo, E. Martin, A. Valeria Vu, H. Quiroga, E. Pellegrini, C. A. Oelschlager, B. K. TI Does combined multichannel intraluminal esophageal impedance and manometry predict postoperative dysphagia after laparoscopic Nissen fundoplication? SO DISEASES OF THE ESOPHAGUS LA English DT Article DE dysphagia; esophageal motility; fundoplication; impedance ID GASTROESOPHAGEAL-REFLUX DISEASE; RANDOMIZED CLINICAL-TRIAL; ANTIREFLUX SURGERY; MOTILITY; THERAPY; PERISTALSIS; SYMPTOMS AB P>Laparoscopic Nissen fundoplication (LNF) is an effective treatment for gastroesophageal reflux disease; however, some patients develop dysphagia postoperatively. Manometry is used to evaluate disorders of peristalsis, but has not been proven useful to identify which patients may be at risk for postoperative dysphagia. Multichannel intraluminal impedance (MII) evaluates the effective clearance of a swallowed bolus through the esophagus. We hypothesized that MII combined with manometry may detect those patients most at risk of developing dysphagia after LNF. Between March 2003 and January 2007, 74 patients who agreed to participate in this study were prospectively enrolled. All patients completed a preoperative symptom questionnaire, MII/manometry, and 24-h pH monitoring. All patients underwent LNF. Symptom questionnaires were administered postoperatively at a median of 18 months (range: 6-46 months), and we defined dysphagia (both preoperatively and postoperatively) as occurring more than once a month with a severity >= 4 (0-10 Symptom Severity Index). Thirty-two patients (43%) reported preoperative dysphagia, but there was no significant difference in pH monitoring, lower esophageal sphincter pressure/relaxation, peristalsis, liquid or viscous bolus transit (MII), or bolus transit time (MII) between patients with and without preoperative dysphagia. In those patients reporting preoperative dysphagia, the severity of dysphagia improved significantly from 6.8 +/- 2 to 2.6 +/- 3.4 (P < 0.001) after LNF. Thirteen (17%) patients reported dysphagia postoperatively, 10 of whom (75%) reported some degree of preoperative dysphagia. The presence of postoperative dysphagia was significantly more common in patients with preoperative dysphagia (P = 0.01). Patients with postoperative dysphagia had similar lower esophageal sphincter pressure and relaxation, peristalsis, and esophageal clearance to those without dysphagia. Neither MII nor manometry predicts dysphagia in patients with gastroesophageal reflux disease or its occurrence after LNF. The presence of dysphagia preoperatively is the only predictor of dysphagia after LNF. C1 [Tatum, R. P.] Univ Washington, VA Puget Sound HCS, Dept Surg, Swallowing Ctr, Seattle, WA 98108 USA. RP Tatum, RP (reprint author), Univ Washington, VA Puget Sound HCS, Dept Surg, Swallowing Ctr, 1660 S Columbian Way S-112-Gs,Box 358280, Seattle, WA 98108 USA. EM rtatum@u.washington.edu NR 27 TC 18 Z9 21 U1 1 U2 1 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1120-8694 J9 DIS ESOPHAGUS JI Dis. Esophagus PY 2009 VL 22 IS 8 BP 656 EP 663 DI 10.1111/j.1442-2050.2009.00988.x PG 8 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 524FE UT WOS:000272128400005 PM 19515186 ER PT J AU Suh, JJ Langleben, DD Ehrman, RN Hakun, JG Wang, Z Li, Y Busch, SI O'Brien, CP Childress, AR AF Suh, Jesse J. Langleben, Daniel D. Ehrman, Ronald N. Hakun, Jonathan G. Wang, Ze Li, Yin Busch, Samantha I. O'Brien, Charles P. Childress, Anna Rose TI Low prefrontal perfusion linked to depression symptoms in methadone-maintained opiate-dependent patients SO DRUG AND ALCOHOL DEPENDENCE LA English DT Article DE Opiate dependence; Depression; Methadone-maintenance; Affect regulation; Comorbidity; Prefrontal cortex ID CEREBRAL-BLOOD-FLOW; INTERNATIONAL NEUROPSYCHIATRIC INTERVIEW; HAMILTON RATING-SCALE; MAJOR DEPRESSION; SUBSTANCE USE; COGNITIVE REGULATION; UNIPOLAR DEPRESSION; ANTERIOR CINGULATE; EXCHANGE PROGRAM; HEROIN USERS AB Background: Clinically depressed patients Without substance use disorders, compared to controls, exhibit significantly lower resting regional cerebral blood flow (rCBF) in the prefrontal cortex (PFC). In this study, we examined the link between resting rCBF in the PFC and current depressive symptoms in methadone-maintained opiate-dependent (MM) patients with or without major depression. Methods: Arterial spin labeled perfusion fMRI at 3 Tesla was used to measure resting rCBF in 21 MM patients. Per-fusion data were analyzed using SPM2. The relationship between Beck Depression Inventory (BDI) score and resting rCBF was examined in a single regression analysis. Results: The BDI scores ranged between 0 and 18 (m = 7.0, S.D. = 4.8), and 30% of the sample had mild to moderate depression symptoms according to BDI scores. A negative correlation was observed between BDI scores and relative rCBF in the bilateral ventrolateral prefrontal cortex, and middle frontal gyri. Conclusions: The inverse relationship between prefrontal paralimbic rCBF and depression Scores Suggests a link between reduced fronto-limbic activity and depressive symptoms in MM patients. A significant subgroup of opiate-dependent patients has clinical or sub-clinical depression that is often undetected; our data identify brain Substrates of depression symptoms that may also be a potential marker of relapse in this population. Treatment strategies targeting these brain regions may improve Outcomes in depressed Substance abusers. (c) 2008 Elsevier Ireland Ltd. All rights reserved. C1 [Suh, Jesse J.; Langleben, Daniel D.; Ehrman, Ronald N.; Hakun, Jonathan G.; Wang, Ze; Li, Yin; Busch, Samantha I.; O'Brien, Charles P.; Childress, Anna Rose] Univ Penn, Sch Med, Dept Psychiat, Ctr Studies Addict, Philadelphia, PA 19104 USA. [Langleben, Daniel D.; Ehrman, Ronald N.; O'Brien, Charles P.; Childress, Anna Rose] Vet Affairs Med Ctr, Philadelphia, PA 19104 USA. RP Suh, JJ (reprint author), Univ Penn, Sch Med, Dept Psychiat, Ctr Studies Addict, 3900 Chestnut St, Philadelphia, PA 19104 USA. EM Suh_J@mail.trc.upenn.edu RI Wang, Ze/A-1043-2007; Langleben, Daniel/K-7407-2014 FU National Institute of Drug Abuse [T32 DA0724 1, K23 DAO 15746, RO1 DA10241, RO1 DA15149, P60 DA05186, P50 DA12756]; Veterans Affairs Medical Center-Philadelphia [VA VISN 4 MIRECC]; Alexander Foundation FX This study is supported by grants from the National Institute of Drug Abuse (T32 DA0724 1, K23 DAO 15746; RO1 DA10241, RO1 DA15149, P60 DA05186, P50 DA12756), the Veterans Affairs Medical Center-Philadelphia (VA VISN 4 MIRECC), and Alexander Foundation. NR 65 TC 3 Z9 7 U1 5 U2 9 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0376-8716 J9 DRUG ALCOHOL DEPEN JI Drug Alcohol Depend. PD JAN 1 PY 2009 VL 99 IS 1-3 BP 11 EP 17 DI 10.1016/j.drugalcdep.2008.06.007 PG 7 WC Substance Abuse; Psychiatry SC Substance Abuse; Psychiatry GA 397ZH UT WOS:000262700500002 PM 18674871 ER PT J AU Farren, CK Scimeca, M Wu, R Malley, SO AF Farren, Conor K. Scimeca, Michael Wu, Ran Malley, Stephanie O. TI A double-blind, placebo-controlled study of sertraline with naltrexone for alcohol dependence SO DRUG AND ALCOHOL DEPENDENCE LA English DT Article DE Alcohol dependence; Sertraline; Naltrexone; Clinical trial; Alcohol typology ID COGNITIVE-BEHAVIORAL THERAPY; RANDOMIZED CONTROLLED-TRIAL; DEPRESSED ALCOHOLICS; CLINICAL-EVIDENCE; DRINKING; FLUOXETINE; SEROTONIN; ABUSE; RATS; PHARMACOTHERAPY AB Introduction: Significant preclinical evidence exists for a synergistic interaction between the opioid and the serotonin systems in determining alcohol consumption. Naltrexone, an opiate receptor antagonist, is approved for the treatment of alcohol dependence. This double-blind placebo-controlled study examined whether the efficacy of naltrexone Would be augmented by Concurrent treatment with sertraline, a selective serotonin receptor uptake inhibitor (SSRI). Methods: One hundred and thirteen participants meeting DSM IV alcohol dependence criteria, who were abstinent from alcohol between 5 and 30 days, were randomly assigned to receive one of two treatments at two sites. One group received naltrexone 12.5 mg once daily for 3 days, 25 mg once daily for 4 days, and 50 mg once daily for the next 11 weeks, together with placebo sertraline. The other group received naltrexone as outlined and simultaneously received sertraline 50 mg once daily for 2 weeks, followed by 100 mg once daily for 10 weeks. Both groups received group relapse prevention psychotherapy on a weekly basis. Results: Compliance and attendance rates were comparable and high, The groups did not differ on the two primary outcomes, time to first drink and time to relapse to heavy drinking, or oil secondary treatment outcomes. With the exception of sexual side effects which were more common in the combination group, most adverse event, were similar for the two conditions. Conclusions: As the doses are tested in combination with specialized behavioral therapy, this study does not provide sufficient evidence for the combined use of sertraline and naltrexone above naltrexone alone. (C) 2008 Elsevier Ireland Ltd. All rights reserved. C1 [Farren, Conor K.; Wu, Ran; Malley, Stephanie O.] Yale Univ, Sch Med, Dept Psychiat, Subst Abuse Treatment Unit, New Haven, CT 06419 USA. [Farren, Conor K.; Scimeca, Michael] Bronx Vet Adm Med Ctr, Mt Sinai Sch Med, Dept Psychiat, Bronx, NY 10468 USA. RP Farren, CK (reprint author), St Patricks Hosp, James St, Dublin 8, Ireland. EM cfarren@stpatsmail.com FU Mount Sinai GCRC [RO1AA11122, K05AA014715]; Pfizer Inc.; National Institutes of Health [RO1AA11122, K05AA014715]; State of Connecticut, Department of Mental Health and Addiction Services FX This study was supported by National Institutes of Health grants RO1AA11122, K05AA014715, by the Mount Sinai GCRC, and by the State of Connecticut, Department of Mental Health and Addiction Services. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute on Alcohol Abuse and Alcoholism or the National Institute of Health. NR 34 TC 11 Z9 13 U1 2 U2 5 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0376-8716 J9 DRUG ALCOHOL DEPEN JI Drug Alcohol Depend. PD JAN 1 PY 2009 VL 99 IS 1-3 BP 317 EP 321 DI 10.1016/j.drugalcdep.2008.06.006 PG 5 WC Substance Abuse; Psychiatry SC Substance Abuse; Psychiatry GA 397ZH UT WOS:000262700500034 PM 18644685 ER PT J AU Yong, PL Bigman, C Flynn, DN Mittermaier, D Long, JA AF Yong, Pierre L. Bigman, Cabral Flynn, David N. Mittermaier, Danielle Long, Judith A. TI Messages about Black-Box Warnings A Comparative Analysis of Reports from the FDA and Lay Media in the US SO DRUG SAFETY LA English DT Article ID PRESCRIPTION MEDICATIONS; NEWSPAPER COVERAGE; NEWS COVERAGE; BEHAVIOR; COMMUNICATION AB Background: The US FDA and lay media are important sources of information for the public about the risks of adverse events associated with drugs, yet the quality of FDA and US lay media reports about medication 'black-box' warnings, which highlight potentially severe adverse events from medications, is unknown. Objective: To determine and compare the content of FDA and US lay media reports about medication black-box warnings. Methods: We assessed FDA and US lay media reports about medication black-box warnings published or aired between I January 2003 and 31 December 2007 for the presence of six core message components, including (i) the affected drug's brand name; (ii) generic name; (iii) treatment indication; (iv) reason for the black-box warning; (v) clinical recommendations for patients, such as warning signs and symptoms of the adverse effect addressed by the black-box warning; and (vi) encouragement to discuss the issue with a healthcare provider, and additional characteristics. Results: FDA reports presented more core information than lay media reports (median 5 vs 3 message components; p < 0.001). FDA reports were more likely to mention generic names (84.6% vs 18.1%; p < 0.001) of affected drugs, while lay media reports less frequently detailed clinical recommendations for patients (43.9% vs 96.2%; p<0.001). Only 10.6% of lay media reports encouraged patients to seek additional information from their healthcare provider, compared with 48.1% of FDA reports (p < 0.001). Conclusions: FDA and US lay media reports about medication black-box warnings presented different information. This may reflect a difference in underlying motivation for reporting of news about risks of adverse drug events. It may also indicate a lack of agreement and understanding about the best methods to communicate risk information to the public, thus indicating areas for future research. C1 [Yong, Pierre L.] Univ Penn, Sch Med, Robert Wood Johnson Clin Scholars Program, Philadelphia, PA 19104 USA. [Yong, Pierre L.; Long, Judith A.] Philadelphia Vet Affairs Med Ctr, Dept Med, Philadelphia, PA USA. [Yong, Pierre L.; Long, Judith A.] Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA. [Yong, Pierre L.] Univ Penn, Ctr Publ Hlth Initiat, Philadelphia, PA 19104 USA. [Bigman, Cabral; Mittermaier, Danielle] Univ Penn, Annenberg Sch Commun, Philadelphia, PA 19104 USA. [Flynn, David N.; Long, Judith A.] Univ Penn, Sch Med, Div Gen Internal Med, Philadelphia, PA 19104 USA. RP Yong, PL (reprint author), Univ Penn, Sch Med, Robert Wood Johnson Clin Scholars Program, 1303A Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA. EM pyong@nas.edu OI Bigman, Cabral/0000-0002-4510-7878 NR 30 TC 4 Z9 4 U1 0 U2 3 PU ADIS INT LTD PI AUCKLAND PA 41 CENTORIAN DR, PRIVATE BAG 65901, MAIRANGI BAY, AUCKLAND 1311, NEW ZEALAND SN 0114-5916 J9 DRUG SAFETY JI Drug Saf. PY 2009 VL 32 IS 12 BP 1147 EP 1157 PG 11 WC Public, Environmental & Occupational Health; Pharmacology & Pharmacy; Toxicology SC Public, Environmental & Occupational Health; Pharmacology & Pharmacy; Toxicology GA 531MM UT WOS:000272670400006 PM 19916582 ER PT J AU Patel, M AF Patel, Mukesh TI Community-Associated Meticillin-Resistant Staphylococcus aureus Infections Epidemiology, Recognition and Management SO DRUGS LA English DT Review ID ACQUIRED METHICILLIN-RESISTANT; PANTON-VALENTINE LEUKOCIDIN; SKIN-STRUCTURE INFECTIONS; INDUCIBLE CLINDAMYCIN RESISTANCE; CHROMOSOMAL CASSETTE MEC; SOFT-TISSUE INFECTIONS; MINIMUM INHIBITORY CONCENTRATION; VENTILATOR-ASSOCIATED PNEUMONIA; PROSTHETIC JOINT INFECTIONS; CARE-ASSOCIATED INFECTIONS AB Meticillin-resistant Staphylococcus aureus (MRSA) is an important cause of infection, particularly in hospitalized patients and those with significant healthcare exposure. In recent years, epidemic community-associated MRSA (CA-MRSA) infections occurring in patients without healthcare risk factors have become more frequent. The most common manifestation of CA-MRSA infection is skin and soft tissue infection, although necrotizing pneumonia, sepsis and osteoarticular infections can occur. CA-MRSA strains have become endemic in many communities and are genetically distinct from previously identified MRSA strains. CA-MRSA may be more capable colonizers of humans and more virulent than other S. aureus strains. Specific mechanisms of pathogenicity have not been elucidated, but several factors have been proposed as responsible for the virulence of CA-MRSA, including the Panton-Valentine leukocidin, phenol-soluble modulins and type I arginine catabolic mobile element. The movement of CA-MRSA strains into the nosocomial setting limits the utility of using clinical risk factors alone to designate community- or healthcare-associated status. Identification of unique genetic characteristics and genotyping are valuable tools for MRSA epidemiological studies. Although the optimum pharmacological therapy for CA-MRSA infections has not been determined, many CA-MRSA strains remain broadly susceptible to several non-p-lactam antibacterial agents. Empirical antibacterial therapy should include an MRSA-active agent, particularly in areas where CA-MRSA is endemic. C1 [Patel, Mukesh] Univ Alabama Birmingham, Div Infect Dis, Birmingham, AL 35294 USA. [Patel, Mukesh] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. RP Patel, M (reprint author), Univ Alabama Birmingham, Div Infect Dis, THT 229,1530 3rd Ave S, Birmingham, AL 35294 USA. EM mukesh@uab.edu NR 214 TC 25 Z9 28 U1 1 U2 6 PU ADIS INT LTD PI AUCKLAND PA 41 CENTORIAN DR, PRIVATE BAG 65901, MAIRANGI BAY, AUCKLAND 1311, NEW ZEALAND SN 0012-6667 EI 1179-1950 J9 DRUGS JI Drugs PY 2009 VL 69 IS 6 BP 693 EP 716 PG 24 WC Pharmacology & Pharmacy; Toxicology SC Pharmacology & Pharmacy; Toxicology GA 455WW UT WOS:000266800200004 PM 19405550 ER PT J AU Gazdag, G Mann, SC Ungvari, GS Caroff, SN AF Gazdag, Gabor Mann, Stephan C. Ungvari, Gabor S. Caroff, Stanley N. BE Swartz, CM TI Clinical evidence for the efficacy of electroconvulsive therapy in the treatment of catatonia and psychoses SO ELECTROCONVULSIVE AND NEUROMODULATION THERAPIES LA English DT Article; Book Chapter ID LIFE-THREATENING CATATONIA; SCHIZOAFFECTIVE DISORDER; ELDERLY-PATIENTS; LETHAL CATATONIA; 1ST-EPISODE SCHIZOPHRENIA; REFRACTORY SCHIZOPHRENIA; MALIGNANT CATATONIA; CONVULSIVE THERAPY; ORGANIC CATATONIA; MANIC EPISODES C1 [Gazdag, Gabor] Jahn Ferenc Hosp, Inpatient Sect, Dept Psychiat, Budapest, Hungary. [Mann, Stephan C.] Univ Louisville, Sch Med, Dept Psychiat & Behav Sci, Louisville, KY 40292 USA. [Mann, Stephan C.] Cent Montgomery Mental Hlth & Mental Retardat Ctr, Norristown, PA USA. [Ungvari, Gabor S.] Chinese Univ Hong Kong, Dept Psychiat, Hong Kong, Hong Kong, Peoples R China. [Ungvari, Gabor S.] Shatin Hosp, Dept Psychiat, Shatin, Hong Kong, Peoples R China. [Caroff, Stanley N.] Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA. [Caroff, Stanley N.] Vet Affairs Med Ctr, Inpatient Sect, Behav Hlth Serv, Philadelphia, PA USA. RP Gazdag, G (reprint author), Jahn Ferenc Hosp, Inpatient Sect, Dept Psychiat, Budapest, Hungary. NR 122 TC 4 Z9 4 U1 1 U2 1 PU CAMBRIDGE UNIV PRESS PI CAMBRIDGE PA THE PITT BUILDING, TRUMPINGTON ST, CAMBRIDGE CB2 1RP, CAMBS, ENGLAND BN 978-0-521-88388-7 PY 2009 BP 124 EP 148 DI 10.1017/CBO9780511576393.008 D2 10.1017/CBO9780511576393 PG 25 WC Psychology, Clinical; Psychiatry; Psychology SC Psychology; Psychiatry GA BDX12 UT WOS:000315519200008 ER PT J AU Harrington, AT Castellanos, JA Ziedalski, TM Clarridge, JE Cookson, BT AF Harrington, Amanda T. Castellanos, Jaime A. Ziedalski, Tomasz M. Clarridge, Jill E., III Cookson, Brad T. TI Isolation of Bordetella avium and Novel Bordetella Strain from Patients with Respiratory Disease SO EMERGING INFECTIOUS DISEASES LA English DT Article ID BRONCHISEPTICA AB Bordetella avium is thought to be strictly an avian pathogen. However, 16S rRNA gene sequencing identified 2 isolates from 2 humans with respiratory disease as B. avium and a novel B. avium-like strain. Thus, B. avium and B. avium-like organisms are rare opportunistic human pathogens.. C1 [Harrington, Amanda T.; Clarridge, Jill E., III; Cookson, Brad T.] Univ Washington, Dept Lab Med, Seattle, WA 98195 USA. [Clarridge, Jill E., III] VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Castellanos, Jaime A.] Baylor Coll Med, Houston, TX 77030 USA. [Ziedalski, Tomasz M.] Western Washington Med Grp, Everett, WA USA. RP Cookson, BT (reprint author), Univ Washington, Dept Lab Med, Box 357110,1959 NE Pacific St, Seattle, WA 98195 USA. EM cookson@u.washington.edu NR 7 TC 17 Z9 20 U1 0 U2 2 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD JAN PY 2009 VL 15 IS 1 BP 72 EP 74 DI 10.3201/eid1501.071677 PG 3 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 393AG UT WOS:000262342700016 PM 19116056 ER PT J AU Houser, CR AF Houser, C. R. BE Schwartzkroin, PA TI Plasticity and Reorganization of GABA Neurons in Epilepsy SO ENCYCLOPEDIA OF BASIC EPILEPSY RESEARCH, VOLS 1-3 LA English DT Article; Book Chapter ID TEMPORAL-LOBE EPILEPSY; SPONTANEOUS RECURRENT SEIZURES; GABAERGIC INTERNEURONS; PILOCARPINE MODEL; MOUSE MODEL; VULNERABILITY; HIPPOCAMPUS; RECEPTORS; SYSTEM C1 [Houser, C. R.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Houser, C. R.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. RP Houser, CR (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. NR 12 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER ACADEMIC PRESS INC PI SAN DIEGO PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA BN 978-0-12-373961-2 PY 2009 BP 619 EP 625 PG 7 WC Medicine, Research & Experimental; Clinical Neurology SC Research & Experimental Medicine; Neurosciences & Neurology GA BFJ85 UT WOS:000320162800106 ER PT J AU Davies, TF Latif, R Yin, XM AF Davies, Terry F. Latif, Rauf Yin, Xiaoming TI INHERITING AUTOIMMUNE THYROID DISEASE SO ENDOCRINE PRACTICE LA English DT Editorial Material ID GENOME-WIDE ASSOCIATION; GRAVES-DISEASE; SUSCEPTIBILITY LOCI; HASHIMOTOS-THYROIDITIS; GENETIC-HETEROGENEITY; WHICKHAM SURVEY; FAMILIES; PEROXIDASE; HLA; AUTOANTIBODIES C1 [Davies, Terry F.; Latif, Rauf; Yin, Xiaoming] James J Peters VA Med Ctr, Mt Sinai Sch Med, Thyroid Res Unit, New York, NY USA. RP Davies, TF (reprint author), Mt Sinai Med Ctr, Box 1055,1 Gustave L Levy Pl, New York, NY 10029 USA. EM terry.davies@mssm.edu FU NIDDK NIH HHS [DK052464, DK069713] NR 26 TC 1 Z9 1 U1 0 U2 1 PU AMER ASSOC CLIN ENDOCRINOL PI JACKSONVILLE PA 1000 RIVERSIDE AVE, STE 205, JACKSONVILLE, FL 32204 USA SN 1530-891X J9 ENDOCR PRACT JI Endocr. Pract. PD JAN-FEB PY 2009 VL 15 IS 1 BP 63 EP 66 PG 4 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 437NO UT WOS:000265494400014 PM 19211403 ER PT J AU Bokov, AF Ko, DJ Richardson, A AF Bokov, Alex F. Ko, Daijin Richardson, Arlan TI The Effect Of Gonadectomy And Estradiol On Sensitivity To Oxidative Stress SO ENDOCRINE RESEARCH LA English DT Review DE Estradiol; Paraquat; Oxidative Stress; Mice; Gonadectomy ID RANDOMIZED CONTROLLED-TRIAL; ESTROGEN PLUS PROGESTIN; ERYTHROCYTE GLUTATHIONE-PEROXIDASE; DISMUTASE MIMETIC PROTECTS; HEALTH INITIATIVE MEMORY; CORONARY HEART-DISEASE; INDUCED LUNG INJURY; POSTMENOPAUSAL WOMEN; PARAQUAT TOXICITY; SUPEROXIDE-DISMUTASE AB The sexual dimorphism of life span and caloric restriction effects in numerous species suggest that estradiol (E2) is protective against oxidative damage. The only direct test of E2's protective effect in mice against in vivo oxidative stress to date may have been confounded by E2's direct chemical action as an antioxidant because it was administered at very high dosages. Therefore, we have identified a low yet physiologically effective dose of E2. We then administered this dose using subcutaneous time-release pellets to ovariectomized mice. Two weeks after E2 pellet implantation, sham-operated, ovariectomized, and ovariectomized E2-supplemented female mice were injected with a lethal dose of paraquat and their survival was followed. It was observed that ovariectomy exacerbates paraquat-induced mortality and is rescued by E2 supplementation. An equivalent experiment was performed on sham-operated, orchidectomized, and E2-supplemented orchidectomized male mice. The survival of male mice was improved by orchidectomy, and E2 gave no further benefit. We interpret the results to mean that E2 is protective against oxidative stress through its regulatory role and that testosterone diminishes protection against oxidative stress. C1 [Bokov, Alex F.] Univ Texas Hlth Sci Ctr San Antonio, Dept Epidemiol & Biostat, San Antonio, TX 78229 USA. [Ko, Daijin] Univ Texas San Antonio, Coll Business, Dept Management Sci & Stat, San Antonio, TX USA. [Richardson, Arlan] Univ Texas Hlth Sci Ctr San Antonio, Dept Physiol, San Antonio, TX 78229 USA. [Richardson, Arlan] Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA. [Richardson, Arlan] S Texas Vet Hlth Care Syst, Geriatr Res Educ & Clin Ctr, San Antonio, TX USA. RP Bokov, AF (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Epidemiol & Biostat, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM bokov@uthscsa.edu FU National Institutes of Health [AGO-21890, AG-19316, AG-13319, AG-23843, AG-26557]; San Antonio Nathan Shock Aging Center [1P30-AG13319]; Department of Veterans Affairs Merit Grant; Research Enhancement Award Program; Department of Veterans Affairs FX The authors gratefully acknowledge support from the National Institutes of Health: AGO-21890 (A. F. B); AG-19316, AG-13319, AG-23843, and AG-26557 (A. R.); the San Antonio Nathan Shock Aging Center (1P30-AG13319) (A. R.); Department of Veterans Affairs Merit Grant (A. R.); and a Research Enhancement Award Program from the Department of Veterans Affairs (A. R.) NR 117 TC 9 Z9 9 U1 1 U2 2 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 0743-5800 EI 1532-4206 J9 ENDOCR RES JI Endocr. Res. PY 2009 VL 34 IS 1-2 BP 43 EP 58 AR PII 910860504 DI 10.1080/07435800902913600 PG 16 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 462QO UT WOS:000267370900005 PM 19557590 ER PT S AU Frieder, M Lewinsohn, DM AF Frieder, Marisa Lewinsohn, David M. BE Reineke, U Schutkowski, M TI T-Cell Epitope Mapping in Mycobacterium tuberculosis Using PepMixes Created by Micro-Scale SPOT (TM)- Synthesis SO EPITOPE MAPPING PROTOCOLS, SECOND EDITION SE Methods in Molecular Biology LA English DT Article; Book Chapter DE Tuberculosis; CD8+T cells; Immunodominance; Antigen/epitope discovery; Elispot; Peptide library ID INFECTION; IDENTIFICATION; RESISTANCE; ANTIGEN; MICE; LYMPHOCYTES; COMPLEX; MACROPHAGES; PROTECTION; DEFICIENT AB Mycobacterium tuberculosis (Mtb) remains a major threat to human health worldwide. Although treatment of infection is an important part of tuberculosis control, an improved vaccine is essential for the elimination of this disease. Control of infection with Mtb is dependent on the cellular immune system, which in turn requires an understanding of those antigens that are capable Of stimulating CD4+ and CD8+ T-cell responses. Peptide libraries provide a high-throughput system for identifying novel T-cell epitopes. They can also be used to assess the hierarchy of immunodominance of these novel antigens and epitopes that are associated with infection with Mtb. This T-cell-driven means of antigen discovery is well adapted to vaccine development as wen as developing the tools necessary to understand the natural history of this important human pathogen. C1 [Frieder, Marisa; Lewinsohn, David M.] Portland VA Med Ctr, Pulm & CCM, R&D 11, Portland, OR USA. RP Frieder, M (reprint author), Portland VA Med Ctr, Pulm & CCM, R&D 11, Portland, OR USA. RI Lewinsohn, David/I-4936-2013 OI Lewinsohn, David/0000-0001-9906-9494 NR 28 TC 3 Z9 4 U1 0 U2 0 PU HUMANA PRESS INC PI TOTOWA PA 999 RIVERVIEW DR, STE 208, TOTOWA, NJ 07512-1165 USA SN 1064-3745 BN 978-1-934115-17-6 J9 METHODS MOL BIOL JI Methods Mol. Biol. PY 2009 VL 524 BP 369 EP 382 DI 10.1007/978-1-59745-450-6_27 D2 10.1007/978-1-59745-450-6 PG 14 WC Biochemical Research Methods SC Biochemistry & Molecular Biology GA BKJ95 UT WOS:000268335800027 PM 19377959 ER PT J AU Restrepo, MI Mortensen, EM Waterer, GW Wunderink, RG Coalson, JJ Anzueto, A AF Restrepo, M. I. Mortensen, E. M. Waterer, G. W. Wunderink, R. G. Coalson, J. J. Anzueto, A. TI Impact of macrolide therapy on mortality for patients with severe sepsis due to pneumonia SO EUROPEAN RESPIRATORY JOURNAL LA English DT Article DE Antibiotics; community-acquired pneumonia; outcomes; sepsis ID COMMUNITY-ACQUIRED PNEUMONIA; BACTEREMIC PNEUMOCOCCAL PNEUMONIA; RESPIRATORY-TRACT INFECTIONS; BETA-LACTAM; ANTIMICROBIAL THERAPY; UNITED-STATES; CLARITHROMYCIN; EPIDEMIOLOGY; GUIDELINES; MANAGEMENT AB Recent studies suggest that macrolides may have beneficial effects for patients at risk for certain infections. The current authors examined the effect of macrolide therapy on 30-and 90-day mortality for patients with severe sepsis caused by pneumonia. A retrospective cohort study was conducted at two tertiary teaching hospitals. Eligible subjects were admitted with a diagnosis of, had chest radiography consistent with, and had a discharge diagnosis of pneumonia and clinical criteria of severe sepsis. Subjects were considered to be on macrolides if they received at least one dose within 48 h of admission. Severe sepsis was present in 237 (30.1%) subjects, out of whom 104 (43.9%) received macrolides. Mortality was 20.3% at 30 days and 24.5% at 90 days. In the multivariable analysis, the use of macrolide was associated with decreased mortality at 30 days (hazard ratio (HR) 0.3, 95% confidence interval (CI) 0.2-0.7) and at 90 days (HR 0.3, 95% CI 0.2-0.6) in patients with severe sepsis and in patients with macrolide-resistant pathogens (HR 0.1, 95% CI 0.02-0.5). Macrolide use was associated with decreased mortality in patients with severe sepsis due to pneumonia and macrolide-resistant pathogens. Confirmatory studies are needed to determine whether macrolide therapy may be protective for patients with sepsis. C1 [Restrepo, M. I.; Mortensen, E. M.] Univ Texas Hlth Sci Ctr San Antonio, Audie L Murphy Vet Affairs Hosp, Vet Evidence Based Res Disseminat Implementat Ctr, San Antonio, TX 78229 USA. [Restrepo, M. I.; Anzueto, A.] Univ Texas Hlth Sci Ctr San Antonio, Div Pulm & Crit Care Med, San Antonio, TX 78229 USA. Univ Texas Hlth Sci Ctr San Antonio, S Texas Vet Hlth Care Syst Audie L Murphy Div, San Antonio, TX 78229 USA. Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA. [Coalson, J. J.] Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, Div Gen Med, San Antonio, TX 78229 USA. Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA. [Waterer, G. W.] Univ Western Australia, Sch Med & Pharmacol, Royal Perth Hosp Unit, Perth, WA 6009, Australia. RP Restrepo, MI (reprint author), S Texas Vet Hlth Care Syst Audie L Murphy Div, VERDICT 1106, 7400 Menon Minter Blvd, San Antonio, TX 78229 USA. EM restrepo@uthscsa.edu RI Restrepo, Marcos/H-4442-2014 OI Mortensen, Eric/0000-0002-3880-5563; Wunderink, Richard/0000-0002-8527-4195 FU Howard Hughes Medical Institute [00378-001] NR 30 TC 92 Z9 95 U1 0 U2 1 PU EUROPEAN RESPIRATORY SOC JOURNALS LTD PI SHEFFIELD PA 442 GLOSSOP RD, SHEFFIELD S10 2PX, ENGLAND SN 0903-1936 J9 EUR RESPIR J JI Eur. Resp. J. PD JAN PY 2009 VL 33 IS 1 BP 153 EP 159 DI 10.1183/09031936.00054108 PG 7 WC Respiratory System SC Respiratory System GA 430KM UT WOS:000264988000023 PM 18768577 ER PT J AU Caplan, L Saag, KG AF Caplan, Liron Saag, Kenneth G. TI Glucocorticoids and the risk of osteoporosis SO EXPERT OPINION ON DRUG SAFETY LA English DT Review DE adverse effects; glucocorticoids; osteoporosis ID BONE-MINERAL DENSITY; CORTICOSTEROID-INDUCED OSTEOPOROSIS; VERTEBRAL FRACTURE RISK; RHEUMATOID-ARTHRITIS PATIENTS; RANDOMIZED CONTROLLED-TRIALS; RECEPTOR GENE POLYMORPHISMS; HIGH-DOSE GLUCOCORTICOIDS; ORAL CORTICOSTEROIDS; HIP FRACTURE; POSTMENOPAUSAL WOMEN AB Background: Glucocorticoid-induced osteoporosis (GIO) refers to a clinical condition in which a class of corticosteroids increases the susceptibility of bones to fracture. Numerous recent studies have improved our understanding of the underlying biology of this condition, whereas data from randomized controlled trials have provided clinicians with more options for prevention of GIO. Objective: To review the pathophysiology and epidemiology of GIO, as well as current pharmacologic treatment and prevention modalities available. To review the state of healthcare provider concordance with GIO prevention guidelines. Methods: Representative examples of various cellular and molecular processes underlying GIO were included, with an emphasis towards more recent discoveries. The data used to describe the epidemiology of GIO were derived from both randomized controlled studies and observational studies, framed through a discussion of known osteoporosis risk factors. Results/conclusion: Progress has been made in clarifying the pathophysiologic mechanisms that result in GIO. Although the options for preventions and treatment of GIO continue to expand, provider compliance with preventive measures remains suboptimal. C1 [Caplan, Liron] Univ Colorado, Denver Vet Affairs Med Ctr, Denver, CO 80045 USA. [Saag, Kenneth G.] Univ Alabama Birmingham, Birmingham, AL USA. RP Caplan, L (reprint author), Univ Colorado, Denver Vet Affairs Med Ctr, POB 6511,B115, Denver, CO 80045 USA. EM liron.caplan@uchsc.edu NR 149 TC 19 Z9 23 U1 4 U2 10 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 1474-0338 EI 1744-764X J9 EXPERT OPIN DRUG SAF JI Expert Opin. Drug Saf. PD JAN PY 2009 VL 8 IS 1 BP 33 EP 47 DI 10.1517/14740330802648194 PG 15 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 401FW UT WOS:000262926300005 PM 19236216 ER PT J AU Kavirajan, H AF Kavirajan, Harish TI Memantine: a comprehensive review of safety and efficacy SO EXPERT OPINION ON DRUG SAFETY LA English DT Review DE age-associated memory impairment; alcohol dependence; Alzheimer's; amyotropic lateral sclerosis; attention deficit hyperactivity disorder; autism; bipolar disorder; cholinesterase inhibitor; cocaine dependence; dementia; frontotemporal dementia; glaucoma; headache; Huntington's disease; major depression; memantine; migraine; neuropathic pain; nicotine dependence; nystagmus; obsessive-compulsive disorder; opiate dependence; pervasive development disorder; phantom limb pain; pharmacology; postherpetic neuralgia; post-traumatic stress disorder; safety; schizophrenia; substance abuse; vascular dementia ID PLACEBO-CONTROLLED TRIAL; RECEPTOR ANTAGONIST MEMANTINE; OBSESSIVE-COMPULSIVE DISORDER; MODERATE ALZHEIMERS-DISEASE; MAJOR DEPRESSIVE DISORDER; OPEN-LABEL EXTENSION; PHANTOM LIMB PAIN; DOUBLE-BLIND; VASCULAR DEMENTIA; NMDA-RECEPTOR AB Background: Memantine is an uncompetitive antagonist of the N-methyl-D-aspartate glutamate receptor. It is now approved only for treatment of mode rate-to-severe Alzheimer's disease (AD). However, as a growing body of evidence indicates that disturbed glutamate neurotransmission may be central to the pathophysiology of such conditions as obesity, schizophrenia, depression, substance abuse, pain disorders and glaucoma, clinical trials have explored the role of memantine in these and other disorders. Objective: To provide a comprehensive review of the safety and efficacy of memantine across the range of clinical applications in which it has been studied. Methods: A search was done on Pubmed using keyword 'memantine' to identify clinical trials of memantine. Results/conclusion: At present, clinical trial evidence supports the use of memantine in only moderate-to-severe AD. Preliminary studies suggest benefit in frontotemporal dementia, alcohol dependence, post-traumatic stress disorder, headache and obesity, but rigorous clinical trials are needed to confirm these results. Available data indicate that across a range of clinical applications, memantine is a safe and well-tolerated drug. C1 [Kavirajan, Harish] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 92626 USA. [Kavirajan, Harish] Univ Calif Los Angeles, Dept Psychiat & Behav Sci, Los Angeles, CA 92626 USA. RP Kavirajan, H (reprint author), VA Greater Los Angeles Healthcare Syst, 950 S Coast Dr,Ste 202, Los Angeles, CA 92626 USA. EM hkaviraj@gmail.com NR 83 TC 31 Z9 35 U1 1 U2 4 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 1474-0338 J9 EXPERT OPIN DRUG SAF JI Expert Opin. Drug Saf. PD JAN PY 2009 VL 8 IS 1 BP 89 EP 109 DI 10.1517/14740330802528420 PG 21 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 401FW UT WOS:000262926300010 PM 19236221 ER PT J AU Snider, AJ Kawamori, T Bradshaw, SG Orr, KA Gilkeson, GS Hannun, YA Obeid, LM AF Snider, Ashley J. Kawamori, Toshihiko Bradshaw, Sarah G. Orr, K. Alexa Gilkeson, Gary S. Hannun, Yusuf A. Obeid, Lina M. TI A role for sphingosine kinase 1 in dextran sulfate sodium-induced colitis SO FASEB JOURNAL LA English DT Article DE sphingosine-1-phosphate; tumor necrosis factor alpha; cyclooxygenase-2; inflammation; ceramide ID INFLAMMATORY-BOWEL-DISEASE; TUMOR-NECROSIS-FACTOR; TNF-ALPHA; LYMPHOCYTE TRAFFICKING; COLON CARCINOGENESIS; ENDOTHELIAL-CELLS; COX-2 INHIBITOR; DENDRITIC CELLS; MICE; 1-PHOSPHATE AB The bioactive lipid sphingosine-1-phosphate (S1P) is emerging as an important mediator of immune and inflammatory responses. S1P formation is catalyzed by sphingosine kinase (SK), of which the SK1 isoenzyme is activated by tumor necrosis alpha (TNF-alpha). SK1 has been shown to be required for mediating TNF-alpha inflammatory responses in cells, including induction of cyclooxygenase 2 (COX-2). Because TNF-alpha and COX-2 are increased in patients with inflammatory bowel disease (IBD), we investigated the role of SK1 in a murine model of colitis. SK1(-/-) mice treated with dextran sulfate sodium (DSS) had significantly less blood loss, weight loss, colon shortening, colon histological damage, and splenomegaly than did wild-type (WT) mice. In addition, SK1(-/-) mice had no systemic inflammatory response. Moreover, WT but not SK1(-/-) mice treated with dextran sulfate sodium had significant increases in blood S1P levels, colon SK1 message and activity, and colon neutrophilic infiltrate. Unlike WT mice, SK1(-/-) mice failed to show colonic COX-2 induction despite an exaggerated TNF-alpha response; thus implicating for the first time SK1 in TNF-alpha-mediated COX-2 induction in vivo. Inhibition of SK1 may prove to be a valuable therapeutic target by inhibiting systemic and local inflammation in IBD.-Snider, A. J., Kawamori, T., Bradshaw, S. G., Orr, K. A., Gilkeson, G. S., Hannun, Y. A., Obeid, L. M. A role for sphingosine kinase 1 in dextran sulfate sodium-induced colitis. FASEB J. 23, 143-152 (2009) C1 [Snider, Ashley J.; Obeid, Lina M.] Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA. [Kawamori, Toshihiko] Med Univ S Carolina, Dept Pathol & Lab Med, Charleston, SC 29425 USA. [Orr, K. Alexa] Med Univ S Carolina, Dept Mol & Cellular Biol & Pathobiol, Charleston, SC 29425 USA. [Hannun, Yusuf A.; Obeid, Lina M.] Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA. [Bradshaw, Sarah G.; Gilkeson, Gary S.; Obeid, Lina M.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. RP Obeid, LM (reprint author), Med Univ S Carolina, Dept Med, 114 Doughty St,MSC 779, Charleston, SC 29425 USA. EM obeidl@musc.edu RI Kawamori, Toshihiko/G-7636-2012 OI obeid, lina/0000-0002-0734-0847 FU U.S. National Institutes of Health (NIH) [GM062887, C06 RR018823]; Veterans Affairs (VA) Merit Award; American College of Rheumatology Research and Education Foundation's FX This work was supported by U.S. National Institutes of Health (NIH) grant GM062887 and a Veterans Affairs (VA) Merit Award (L.M.O.) and by the American College of Rheumatology Research and Education Foundation's Within Our Reach: Finding a Cure for Arthritis campaign (G.S.G.). Lipid analysis was conducted by the Lipidomics Core at MUSC and was supported by NIH grant C06 RR018823. We thank Dr. Richard Proia (NIDDK, Bethesda, MD, USA) for supplying the SK1-/- mice; George Washington, DeAnna Baker, Samer Maalouf, and Tatsuya Kaneshiro for technical help; Margaret H. Romano and the Core Histology Laboratory for their technical assistance; Chris Clarke for careful examination of the manuscript; and Kathy Wiita-Fisk for her administrative assistance. NR 52 TC 78 Z9 82 U1 0 U2 2 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD JAN PY 2009 VL 23 IS 1 BP 143 EP 152 DI 10.1096/fj.08-118109 PG 10 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA 389LZ UT WOS:000262095500017 PM 18815359 ER PT J AU Daines, SB Rohr, ES Pace, AP Fassbind, MJ Sangeorzan, BJ Ledoux, WR AF Daines, S. Bradley Rohr, Eric S. Pace, Andrew P. Fassbind, Michael J. Sangeorzan, Bruce J. Ledoux, William R. TI Cadaveric Simulation of a Pes Cavus Foot SO FOOT & ANKLE INTERNATIONAL LA English DT Article DE Pes Cavus; Foot Deformity; Foot Structure; Cadaver; Muscle Imbalance ID OSTEOTOMY; FEET AB Background: The pes cavus deformity has been well described in the literature; relative bony positions have been determined and specific muscle imbalances have been summarized. However, we are unaware of a cadaveric model that has been used to generate this foot pathology. The purpose of this study was to create such a model for future work on surgical and conservative treatment simulation. Materials and Methods: We used a custom designed, pneumatically actuated loading frame to apply forces to otherwise normal cadaveric feet while measuring bony motion as well as force beneath the foot. The dorsal tarsometatarsal and the dorsal intercuneiform ligaments were attenuated and three muscle imbalances, each similar to imbalances believed to cause the pes cavus deformity, were applied while bony motion and plantar forces were measured. Results: Only one of the muscle imbalances (overpull of the Achilles tendon, tibialis anterior, tibialis posterior, flexor hallucis longus and flexor digitorum longus) was successful at consistently generating the changes seen in pes cavus feet. This imbalance led to statistically significant changes including hindfoot inversion, talar dorsiflexion, medial midfoot plantar flexion and inversion, forefoot plantar flexion and adduction and an increase in force on the lateral mid- and forefoot. Conclusion: We have created a cadaveric model that approximates the general changes of the pes cavus deformity compared to normal feet. These changes mirror the general patterns of deformity produced by several disease mechanisms. Clinical Relevance: Future work will entail increasing the severity of the model and exploring various pes cavus treatment strategies. C1 [Ledoux, William R.] RR&D Ctr Excellence Limb Loss Prevent & Prosthet, VA Puget Sound, Seattle, WA 98108 USA. RP Ledoux, WR (reprint author), RR&D Ctr Excellence Limb Loss Prevent & Prosthet, VA Puget Sound, MS 151,1600 S Columbian Way, Seattle, WA 98108 USA. EM wrledoux@u.washington.edu RI Ledoux, William/K-6815-2015 OI Ledoux, William/0000-0003-4982-7714 FU University of Washington School of Medicine; Department of Veterans Affairs, Rehabilitation RD Service [A2661C] FX This work was supported in part by the Medical Student Research and Training Program at the University of Washington School of Medicine, and the Department of Veterans Affairs, Rehabilitation R&D Service grant number A2661C. NR 20 TC 2 Z9 2 U1 0 U2 2 PU AMER ORTHOPAEDIC FOOT & ANKLE SOC, INC PI SEATTLE PA 2517 EASTLAKE AVE EAST, STE 200, SEATTLE, WA 98102 USA SN 1071-1007 J9 FOOT ANKLE INT JI Foot Ankle Int. PD JAN PY 2009 VL 30 IS 1 BP 44 EP 50 DI 10.3113/FAI.2009.0044 PG 7 WC Orthopedics SC Orthopedics GA 390IC UT WOS:000262156500008 PM 19176185 ER PT J AU Shan, WH Oberley, TD AF Shan, Weihua Oberley, Terry D. TI Compartmental Redox Regulation of Androgen-Induced Prostate Cancer Cell Growth and Survival SO FREE RADICAL BIOLOGY AND MEDICINE LA English DT Meeting Abstract CT 16th Annual Meeting of the Society-for-Free-Radical-Biology-and-Medicine CY NOV 18-22, 2009 CL San Francisco, CA SP Soc Free Rad Biol & Med C1 [Shan, Weihua; Oberley, Terry D.] Univ Wisconsin, Sch Med, Madison, WI 53706 USA. [Oberley, Terry D.] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0891-5849 J9 FREE RADICAL BIO MED JI Free Radic. Biol. Med. PY 2009 VL 47 BP S175 EP S175 PG 1 WC Biochemistry & Molecular Biology; Endocrinology & Metabolism SC Biochemistry & Molecular Biology; Endocrinology & Metabolism GA 522HM UT WOS:000271988500508 ER PT J AU Siedlak, SL Casadesus, G Webber, KM Pappolla, MA Atwood, CS Smith, MA Perry, G AF Siedlak, Sandra L. Casadesus, Gemma Webber, Kate M. Pappolla, Miguel A. Atwood, Craig S. Smith, Mark A. Perry, George TI Chronic antioxidant therapy reduces oxidative stress in a mouse model of Alzheimer's disease SO FREE RADICAL RESEARCH LA English DT Article DE Alzheimer's disease; amyloid-beta; antioxidant; R-alpha lipoic acid; transgenic mice ID ALPHA-LIPOIC-ACID; MILD COGNITIVE IMPAIRMENT; AMYLOID PRECURSOR PROTEIN; TRANSGENIC MICE; LIPID-PEROXIDATION; MITOCHONDRIAL DYSFUNCTION; NEURODEGENERATIVE DISEASES; NEUROFIBRILLARY PATHOLOGY; LUTEINIZING-HORMONE; PROMINENT FEATURE AB Oxidative modifications are a hallmark of oxidative imbalance in the brains of individuals with Alzheimer's, Parkinson's and prion diseases and their respective animal models. While the causes of oxidative stress are relatively well-documented, the effects of chronically reducing oxidative stress on cognition, pathology and biochemistry require further clarification. To address this, young and aged control and amyloid-beta protein precursor-over-expressing mice were fed a diet with added R-alpha lipoic acid for 10 months to determine the effect of chronic antioxidant administration on the cognition and neuropathology and biochemistry of the brain. Both wild type and transgenic mice treated with R-alpha lipoic acid displayed significant reductions in markers of oxidative modifications. On the other hand, R-alpha lipoic acid had little effect on Y-maze performance throughout the study and did not decrease end-point amyloid-beta load. These results suggest that, despite the clear role of oxidative stress in mediating amyloid pathology and cognitive decline in ageing and A beta PP-transgenic mice, long-term antioxidant therapy, at levels within tolerable nutritional guidelines and which reduce oxidative modifications, have limited benefit. C1 [Perry, George] Univ Texas San Antonio, Coll Sci, San Antonio, TX 78249 USA. [Siedlak, Sandra L.; Webber, Kate M.; Smith, Mark A.; Perry, George] Case Western Reserve Univ, Dept Pathol, Cleveland, OH 44106 USA. [Casadesus, Gemma] Case Western Reserve Univ, Dept Neurosci, Cleveland, OH 44106 USA. [Pappolla, Miguel A.] LSU Hlth Sci Ctr, Neurosci Ctr Excellence, New Orleans, LA USA. [Atwood, Craig S.] Univ Wisconsin, William S Middleton Mem Vet Adm Hosp, Educ & Clin Ctr, Dept Med & Geriatr Res, Madison, WI USA. RP Perry, G (reprint author), Univ Texas San Antonio, Coll Sci, 1 UTSA Circle, San Antonio, TX 78249 USA. EM george.perry@utsa.edu RI Smith, Mark/A-9053-2009; Perry, George/A-8611-2009 OI Perry, George/0000-0002-6547-0172 FU National Institutes of Health; Alzheimer's Association; Philip Morris USA Inc.; Philip Morris International. FX Work in the authors' laboratories is supported by the National Institutes of Health, the Alzheimer's Association and Philip Morris USA Inc. and Philip Morris International. NR 86 TC 38 Z9 38 U1 2 U2 7 PU TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND SN 1071-5762 J9 FREE RADICAL RES JI Free Radic. Res. PY 2009 VL 43 IS 2 BP 156 EP 164 DI 10.1080/10715760802644694 PG 9 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 405EB UT WOS:000263204400008 PM 19160110 ER PT J AU Radant, AD Dobie, DJ Peskind, ER Murburg, MM Petrie, EC Kanter, ED Raskind, MA Wilkinson, CW AF Radant, Allen D. Dobie, Dorcas J. Peskind, Elaine R. Murburg, M. Michele Petrie, Eric C. Kanter, Evan D. Raskind, Murray A. Wilkinson, Charles W. TI Adrenocortical responsiveness to infusions of physiological doses of ACTH is not altered in posttraumatic stress disorder SO FRONTIERS IN BEHAVIORAL NEUROSCIENCE LA English DT Article DE PTSD; HPA axis; ACTH; adrenal responsiveness; cortisol; DHEA; human ID PITUITARY-ADRENAL AXIS; AGE-RELATED-CHANGES; 1 MU-G; FEEDBACK INHIBITION; SALIVARY CORTISOL; PLASMA ADRENOCORTICOTROPIN; HEALTHY-SUBJECTS; COMBAT VETERANS; SYNACTHEN TEST; PTSD AB Early studies of posttraumatic stress disorder (PTSD) reported that abnormal function of the hypothalamic-pituitary-adrenocortical (HPA) system was associated with the disorder. However, subsequent studies attempting to identify a specific aspect of HPA dysfunction that characterizes PTSD have been marked by considerable inconsistency of results. A facet of HPA regulation that has been considered but not definitively investigated is the possibility that the responsiveness of the adrenal cortex to physiological concentrations of adrenocorticotropin (ACTH) is diminished in PTSD. Relationships between PTSD and the adrenal androgen dehydroepiandrosterone (DHEA) have also been postulated. In this study we investigated the magnitude and time course of changes in concentrations of plasma cortisol and DHEA in response to bolus infusions of physiological doses of ACTH(1-24) in PTSD patients and control subjects. We found no evidence for PTSD-related alterations in cortisol or DHEA secretion in response to stimulation by low doses of ACTH and conclude that adrenocortical responsiveness is normal in PTSD. Results from this and other studies suggest that the occurrence of defects in HPA function in PTSD may be specific responses to particular combinations of trauma type, genetic susceptibility, and individual history. C1 [Radant, Allen D.; Dobie, Dorcas J.; Peskind, Elaine R.; Petrie, Eric C.; Kanter, Evan D.; Raskind, Murray A.] VA Puget Sound Hlth Care Syst, Northwest Network, VISN Mental Illness Res Educ & Clin Ctr 20, Seattle, WA 98108 USA. [Radant, Allen D.; Dobie, Dorcas J.; Peskind, Elaine R.; Petrie, Eric C.; Kanter, Evan D.; Raskind, Murray A.; Wilkinson, Charles W.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Wilkinson, Charles W.] VA Puget Sound Hlth Care Syst, Ctr Geriatr Res Educ & Clin, Seattle, WA 98108 USA. RP Wilkinson, CW (reprint author), VA Puget Sound Hlth Care Syst, Northwest Network, VISN Mental Illness Res Educ & Clin Ctr 20, S-182 GRECC,1660 S Columbian Way, Seattle, WA 98108 USA. EM wilkinso@u.washington.edu FU Northwest Network VISN 20 Mental Illness Research; Education and Clinical Center (MIRECC); VA Puget Sound Geriatric Research; Education and Clinical Center (GRECC); Office of Research and Development Medical Research Service, Department of Veterans Affairs FX For their excellent assistance that made this study possible, we thank Jane Hammett RN, and Jennifer Acselrod RN, for nursing care of study participants, Jill Perander, Robert Beckham III, Shawna Feely, and Kristina Purganan for recruitment and study coordination, Libby Colasurdo and Carl Sikkema for hormone assays, Molly Chinn for assistance in preparing ACTH doses, and Nadia Czajkiewicz for graphic design. This material is based upon work supported by the Northwest Network VISN 20 Mental Illness Research, Education and Clinical Center (MIRECC), the VA Puget Sound Geriatric Research, Education and Clinical Center (GRECC), and the Office of Research and Development Medical Research Service, Department of Veterans Affairs. NR 65 TC 5 Z9 5 U1 1 U2 3 PU FRONTIERS RESEARCH FOUNDATION PI LAUSANNE PA PO BOX 110, LAUSANNE, 1015, SWITZERLAND SN 1662-5153 J9 FRONT BEHAV NEUROSCI JI Front. Behav. Neurosci. PY 2009 VL 3 AR 40 DI 10.3389/neuro.08.040.2009 PG 8 WC Behavioral Sciences; Neurosciences SC Behavioral Sciences; Neurosciences & Neurology GA V18VE UT WOS:000208031500039 PM 19893760 ER PT J AU Lanford, RE Evans, MJ Lohmann, V Lindenbach, B Gale, M Rehermann, B Chang, KM Lemon, SM AF Lanford, Robert E. Evans, Matthew J. Lohmann, Volker Lindenbach, Brett Gale, Michael, Jr. Rehermann, Barbara Chang, Kyong-Mi Lemon, Stanley M. TI The Accelerating Pace of HCV Research: A Summary of the 15th International Symposium on Hepatitis C Virus and Related Viruses SO GASTROENTEROLOGY LA English DT Editorial Material C1 Univ Texas Med Branch, Inst Human Infect & Immun, 6200 Galveston Natl Lab, Galveston, TX 77555 USA. Southwest Fdn Biomed Res, San Antonio, TX USA. Mt Sinai Sch Med, Dept Microbiol, New York, NY USA. Univ Heidelberg, Dept Molec Virol, Heidelberg, Germany. Yale Univ, Sch Med, Sect Microbial Pathogenesis, New Haven, CT USA. Univ Washington, Dept Immunol, Seattle, WA USA. NIDDKD, Liver Dis Branch, Immunol Sect, Bethesda, MD USA. Univ Penn, Philadelphia, PA USA. Philadelphia VA Med Ctr, Philadelphia, PA USA. RP Lemon, SM (reprint author), Univ Texas Med Branch, Inst Human Infect & Immun, 6200 Galveston Natl Lab, 301 Univ Blvd, Galveston, TX 77555 USA. EM smlemon@utmb.edu OI Lohmann, Volker/0000-0001-8719-7608; Gale, Michael/0000-0002-6332-7436; Evans, Matthew/0000-0002-4991-3877 FU Intramural NIH HHS; NCI NIH HHS [K01-CA107092, K01 CA107092]; NIAID NIH HHS [K99 AI077800, K99-AI077800, R01 AI047519, R01 AI060389, R01-AI060389, R01-AI47519, U19 AI040035, U19-AI040035]; NIDA NIH HHS [R01 DA024563] NR 0 TC 10 Z9 11 U1 0 U2 0 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0016-5085 J9 GASTROENTEROLOGY JI Gastroenterology PD JAN PY 2009 VL 136 IS 1 BP 9 EP 16 DI 10.1053/j.gastro.2008.11.019 PG 8 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 388OG UT WOS:000262028500045 PM 19026648 ER PT J AU Chung, CH Shugrue, C Nagar, A Doll, JA Cornwell, M Gattu, A Kolodecik, T Pandol, SJ Gorelick, F AF Chung, Chuhan Shugrue, Christine Nagar, Anil Doll, Jennifer A. Cornwell, Mona Gattu, Arijeet Kolodecik, Tom Pandol, Stephen J. Gorelick, Fred TI Ethanol Exposure Depletes Hepatic Pigment Epithelium-Derived Factor, a Novel Lipid Regulator SO GASTROENTEROLOGY LA English DT Article ID ALCOHOLIC LIVER-DISEASE; STELLATE CELL ACTIVATION; MATRIX METALLOPROTEINASES; SECRETED PROTEINS; FATTY LIVER; PPAR-ALPHA; IDENTIFICATION; STEATOSIS; FIBROSIS; DIFFERENTIATION AB Background & Aims: Ethanol abuse can lead to hepatic steatosis and evolve into cirrhosis and hepatocellular carcinoma. Pigment epithelium-derived factor (PEDF) is a multifunctional secreted glycoprotein. that is expressed by hepatocytes. Proteomic, experimental, and clinical studies implicate PEDF's role in lipid regulation. Because matrix metalloproteinase (MMP)-2/9 activity regulates PEDF levels, we investigated whether PEDF degradation by MMPs has a permissive role in ethanol-induced hepatic steatosis. Methods: PEDF levels were examined in liver biopsy specimens from patients with ethanol-induced steatosis. Hepatic PEDF levels and MMP activity were assessed in 2 animal models of ethanol feeding (rats on an alcohol-containing liquid diet and mice given intragastric infusion of ethanol). The consequences of PEDF depletion in the liver were examined in PEDF-null mice. Results: Liver biopsy samples from patients with ethanol-induced steatosis had reduced PEDF levels, compared with normal liver samples. Ethanol-fed animals had histologic steatosis and increased liver triglyceride content (P < .05), as well as reduced levels of hepatic PEDF and increased MMP-2/9 activity. Ethanol-exposed hepatic lysates degraded PEDF in a MMP-2/9-dependent manner, and liver sections demonstrated abundant MMP-2/9 activity in situ. Addition of recombinant PEDF to PEDF-null hepatocytes, reduced their triglyceride content. Conclusions: Ethanol exposure leads to marked loss of hepatic PEDF in human livers and in 2 animal models of ethanol feeding. Loss of PEDF contributes to the accumulation of lipids in ethanol-induced hepatic steatosis. C1 [Chung, Chuhan; Shugrue, Christine; Nagar, Anil; Gattu, Arijeet; Kolodecik, Tom; Gorelick, Fred] Yale Univ, Sch Med, Dept Med, Sect Digest Dis, New Haven, CT 06510 USA. [Chung, Chuhan; Nagar, Anil; Gorelick, Fred] VA Connecticut Healthcare Syst, West Haven, CT USA. [Doll, Jennifer A.; Cornwell, Mona] Northwestern Univ, Dept Pathol, Feinberg Sch Med, Chicago, IL 60611 USA. [Pandol, Stephen J.] VA Greater Angeles Hlth Care Syst, Los Angeles, CA USA. RP Chung, CH (reprint author), Yale Univ, Sch Med, Dept Med, Sect Digest Dis, GI Res Bldg, West Haven, CT 06516 USA. EM chuhan.chung@yale.edu FU American Liver Foundation; NIH [DK34989, P60 AA11999, DK54021]; VA Merit Award FX The authors disclose the following: Supported by an American Liver Foundation grant; NIH Liver Center Core DK34989 (to C.C.), P60 AA11999 (to S.J.P.), DK54021; and VA Merit Award (to F.S.G.). NR 35 TC 23 Z9 25 U1 1 U2 3 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0016-5085 J9 GASTROENTEROLOGY JI Gastroenterology PD JAN PY 2009 VL 136 IS 1 BP 331 EP 340 DI 10.1053/j.gastro.2008.09.065 PG 10 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 388OG UT WOS:000262028500041 PM 18996124 ER PT J AU Jou, J Radowsky, J Gangnon, R Sadowski, E Kays, S Hind, J Gaumnitz, E Taylor, A Robbins, J AF Jou, Janice Radowsky, Jason Gangnon, Ronald Sadowski, Elizabeth Kays, Stephanie Hind, Jacqueline Gaumnitz, Eric Taylor, Andrew Robbins, JoAnne TI Esophageal Clearance Patterns in Normal Older Adults as Documented with Videofluoroscopic Esophagram SO GASTROENTEROLOGY RESEARCH AND PRACTICE LA English DT Article ID HEALTHY-SUBJECTS; MANOMETRY; MOTILITY; AGE; VOLUNTEERS; IMPEDANCE; BARIUM AB Normal esophageal bolus transport in asymptomatic healthy older adults has not been well defined, potentially leading to ambiguity in differentiating esophageal swallowing patterns of dysphagic and healthy individuals. This pilot study of 24 young (4564 years) and old (65+years) men and women was designed to assess radiographic esophageal bolus movement patterns in healthy adults using videofluoroscopic recording. Healthy, asymptomatic adults underwent videofluoroscopic esophagram to evaluate for the presence of ineffective esophageal clearance, namely, intraesophageal stasis and intraesophageal reflux. Intraesophageal stasis and intraesophageal reflux were visualized radiographically in these normal subjects. Intraesophageal stasis occurred significantly more frequently with semisolid (96%) compared with liquid (16%) barium, suggesting that a variety of barium consistencies, as opposed to only the traditional fluids, would better define the spectrum of esophageal transport. Intraesophageal reflux was observed more frequently in older males than in their younger counterparts. The rates of intraesophageal stasis and intraesophageal reflux were potentially high given that successive bolus presentations were spaced 10 seconds apart. These findings suggest a need for a more comprehensive definition regarding the range of normal esophageal bolus transport to (a) prevent misdiagnosis of dysphagia and (b) to enhance generalization to functional eating, which involves solid foods in addition to liquids. Copyright (C) 2009 Janice Jou et al. C1 [Jou, Janice; Radowsky, Jason; Kays, Stephanie; Hind, Jacqueline; Gaumnitz, Eric; Robbins, JoAnne] Univ Wisconsin, Sch Med & Publ Hlth, Dept Med, Sect Gastroenterol & Hepatol, Madison, WI 53792 USA. [Radowsky, Jason; Kays, Stephanie; Hind, Jacqueline; Robbins, JoAnne] William S Middleton Mem Vet Adm Med Ctr, US Dept Vet Affairs, Ctr Geriatr Res Educ & Clin, Madison, WI 53705 USA. [Gangnon, Ronald] Univ Wisconsin, Sch Med & Publ Hlth, Dept Biostat & Med Informat, Madison, WI 53792 USA. [Sadowski, Elizabeth; Taylor, Andrew] Univ Wisconsin, Sch Med & Pulic Hlth, Dept Radiol, Madison, WI 53792 USA. RP Robbins, J (reprint author), Univ Wisconsin, Sch Med & Publ Hlth, Dept Med, Sect Gastroenterol & Hepatol, Madison, WI 53792 USA. EM jrobbin2@wisc.edu FU Geriatric Research, Education and Clinical Center (GRECC); William S. Middleton Memorial VA Hospital FX This work supported by the Geriatric Research, Education and Clinical Center (GRECC), and William S. Middleton Memorial VA Hospital. The authors would like to thank Abby Duane, BS, for manuscript preparation and also extend their appreciation to the Department of Radiology University of Wisconsin. This is GRECC manuscript 2006-12. NR 24 TC 7 Z9 7 U1 0 U2 1 PU HINDAWI PUBLISHING CORPORATION PI NEW YORK PA 410 PARK AVENUE, 15TH FLOOR, #287 PMB, NEW YORK, NY 10022 USA SN 1687-6121 J9 GASTROENT RES PRACT JI Gastroenterol. Res. Pract. PY 2009 AR 965062 DI 10.1155/2009/965062 PG 6 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 689FJ UT WOS:000284912400001 ER PT J AU Shergill, AK Asundi, KR Barr, A Shah, JN Ryan, JC McQuaid, KR Rempel, D AF Shergill, Amandeep K. Asundi, Krishna R. Barr, Alan Shah, Janak N. Ryan, James C. McQuaid, Kenneth R. Rempel, David TI Pinch force and forearm-muscle load during routine colonoscopy: a pilot study SO GASTROINTESTINAL ENDOSCOPY LA English DT Article ID CUMULATIVE TRAUMA DISORDERS; OVERUSE AB Background and Objective: Overuse injuries of the hand, wrist, forearm, and shoulder are common among endoscopists and may be from repetitive pinching and gripping forces or awkward posturing. In this pilot study, we evaluated distal upper-extremity musculoskeletal load during colonoscopy (1) to confirm the feasibility of performing ergonomic measurements in endoscopists and (2) to identify tasks that may contribute to overuse injuries. Design and Subjects: Three experienced gastroenterologists were evaluated during 3 colonoscopies each Setting: Veterans Affairs Medical Center, San Francisco, California. Main Outcome Measurement: Right-thumb pinch force using a thumb-force sensor and bilateral forearm-muscle activity using electromyography. Results: The mean duration of the 9 colonoscopies was 19.5 minutes. The highest mean (SD) right-thumb peak pinch forces occurred during left (10.4 [4.1] N) and right (10.1 [4.5] N) colon insertion, which exceeded the injury threshold of 10 N. Mean peak forearm-muscle activity was also greatest during left and right colon insertion. Activity of the left abductor pollicis longus, left extensor carpi radialis, and right extensor carpi radialis exceeded the American Conference of industrial Hygienists (ACGIH) hand activity level (HAL) action limit. The left extensor carpi radialis was at the ACGIH HAL threshold limit. Limitations: The small sample size, no force measurement for the left thumb, and all the gastroenterologists were men. Conclusion: The pinch forces and forearm-muscle loads applied during routine colonoscopy may pose a risk for overuse injuries at the elbow and wrist. C1 [Shergill, Amandeep K.] Univ Calif San Francisco, Dept Med, Div Gastroenterol, VA Med Ctr, San Francisco, CA 94121 USA. [Shergill, Amandeep K.; Shah, Janak N.; Ryan, James C.; McQuaid, Kenneth R.] San Francisco VA Med Ctr, San Francisco, CA USA. [Barr, Alan; Rempel, David] Univ Calif San Francisco, Dept Med, Div Occupat Med, San Francisco, CA 94121 USA. [Barr, Alan; Rempel, David] Univ Calif Berkeley, Dept Bioengn, Berkeley, CA 94720 USA. [Asundi, Krishna R.] Harvard Univ, Sch Med, Dept Environm Hlth, Boston, MA USA. RP Shergill, AK (reprint author), Univ Calif San Francisco, Dept Med, Div Gastroenterol, VA Med Ctr, 4150 Clement St,Bldg 203,111B1, San Francisco, CA 94121 USA. EM amandeep.shergill@ucsf.edu RI Rempel, David/E-8424-2013 NR 10 TC 23 Z9 24 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0016-5107 J9 GASTROINTEST ENDOSC JI Gastrointest. Endosc. PD JAN PY 2009 VL 69 IS 1 BP 142 EP 146 DI 10.1016/j.gie.2008.09.030 PG 5 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 391VI UT WOS:000262261900023 PM 19111694 ER PT S AU Yehuda, R AF Yehuda, Rachel BE Judd, LL Sternberg, EM TI Status of Glucocorticoid Alterations in Post-traumatic Stress Disorder SO GLUCOCORTICOIDS AND MOOD CLINICAL MANIFESTATIONS, RISK FACTORS, AND MOLECULAR MECHANISMS SE Annals of the New York Academy of Sciences LA English DT Article; Proceedings Paper CT Conference on Glucocorticoids and Mood - Clinical Manifestations, Risk Factors and Molecular Mechanisms CY JUN 20-21, 2008 CL San Diego, CA DE acth; cortisol; depression; dexamethasone; glucocorticoid receptors ID PITUITARY-ADRENAL AXIS; DEXAMETHASONE-SUPPRESSION TEST; URINARY CORTISOL-LEVELS; BORDERLINE PERSONALITY-DISORDER; CORTICOTROPIN-RELEASING-FACTOR; MAJOR DEPRESSIVE DISORDER; VEHICLE ACCIDENT VICTIMS; HORMONE STIMULATION TEST; CIVILIAN TRAUMA VICTIMS; CHILDHOOD SEXUAL ABUSE AB The current status of glucocorticoid alterations in post-traumatic stress disorder (PTSD) will be described in this chapter. Emphasis will be placed on data that suggest that at least some glucocorticoid-related observations in PTSD reflect pretraumatic glucocorticoid status. Recent observations have provided some evidence that pretraumatic glucocorticoid alterations may arise from genetic, epigenetic, and possibly other environmental influences that serve to increase the likelihood of developing PTSD following trauma exposure, as well as modulate attendant biological alterations associated with its pathophysiology. Current studies in the field of PTSD employ glucocorticoid challenge strategies to delineate effects of exogenously administered glucocorticoids on neuroendocrine, cognitive, and brain function. Results of these studies have provided an important rationale for using glucocorticoid strategies in the treatment of PTSD. C1 [Yehuda, Rachel] Mt Sinai Sch Med, Dept Psychiat, Traumat Stress Studies Program, New York, NY USA. [Yehuda, Rachel] James J Peters Vet Affairs Med Ctr, PTSD Program, Bronx, NY USA. RP Yehuda, R (reprint author), Bronx VA, OOMH, 130 W Kingsbridge Rd, Bronx, NY 10468 USA. EM Rachel.Yehuda@med.va.gov FU NIH [R01 N4H064675-02, R01 MH64104-01]; VA Merit Funds; DOD funds FX This work was Supported by NIH: R01 N4H064675-02, R01 MH64104-01. VA Merit Funds, and DOD funds. The author wishes to acknowledge Janelle Wolaltmann, Casey Sarapas, Chuck Burton, and Michelle Pelcovitz for assisting in the preparation of this manuscript. NR 140 TC 162 Z9 171 U1 5 U2 27 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN STREET, MALDEN 02148, MA USA SN 0077-8923 BN 978-1-57331-748-1 J9 ANN NY ACAD SCI JI Ann.NY Acad.Sci. PY 2009 VL 1179 BP 56 EP 69 DI 10.1111/j.1749-6632.2009.04979.x PG 14 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA BMJ24 UT WOS:000272551200004 PM 19906232 ER PT J AU Hess, CJ Feller, N Denkers, F Kelder, A Merle, PA Heinrich, MC Harlow, A Berkhof, J Ossenkoppele, GJ Waisfisz, Q Schuurhuis, GJ AF Hess, Corine J. Feller, Nicole Denkers, Fedor Kelder, Angele Merle, Pauline A. Heinrich, Michael C. Harlow, Amy Berkhof, Johannes Ossenkoppele, Gert J. Waisfisz, Quinten Schuurhuis, Gerrit J. TI Correlation of minimal residual disease cell frequency with molecular genotype in patients with acute myeloid leukemia SO Haematologica-The Hematology Journal LA English DT Article DE acute myeloid leukemia; minimal residual disease; FLT3 ID RESISTANCE PROTEIN-ACTIVITY; P-GLYCOPROTEIN; FLOW-CYTOMETRY; MUTATIONS; AML; DIAGNOSIS; THERAPY; SURVIVAL; RELAPSE AB Background About 70-80 percent of patients with acute myeloid leukemia enter complete remission, but at least half of these patients who achieve remission go on to relapse. Improved treatment is likely to come from increasing the time to relapse, especially for younger patients. With the vastly increasing number of targeted therapies there is a strong need for short-term end-points to efficiently test such therapies for further pursuance. Minimal residual disease assessment may offer such an end-point since it is a strong independent prognostic factor. As proof of principle we examined this concept for FLT3-ITD status at diagnosis. Design and Methods We determined FLT3-ITD status in bone marrow samples from 196 patients with newly diagnosed acute myeloid leukemia. The frequencies of residual leukemic cells of these 196 patients were assessed in 267 follow-up bone marrow samples using immunophenotypic assessment of minimal residual disease. Results The median frequency of residual leukemic cells after the first cycle of chemotherapy was 8.5-fold higher in patients with FLT3-ITD than in those with wild type FLT3. Such a difference translates into differences in survival, even if other potentially outcome-modulating mutations, such as NPM1, KIT, NRAS, KRAS, FLT3-exon 20 and PTPN11 are included in the analysis. Conclusions This study shows that it could be possible to study the efficacy of FLT3 inhibitors using the level of minimal residual disease as a short-term end-point. C1 [Schuurhuis, Gerrit J.] Vrije Univ Amsterdam, Med Ctr, Dept Hematol, BR248, NL-1081 HV Amsterdam, Netherlands. [Heinrich, Michael C.; Harlow, Amy] Oregon Hlth & Sci Univ, Inst Canc, Dept Pathol & Med, Portland, OR 97201 USA. [Heinrich, Michael C.; Harlow, Amy] Portland VA Med Ctr, Portland, OR USA. [Berkhof, Johannes] Vrije Univ Amsterdam, Med Ctr, Dept Clin Epidemiol & Biostat, NL-1081 HV Amsterdam, Netherlands. RP Schuurhuis, GJ (reprint author), Vrije Univ Amsterdam, Med Ctr, Dept Hematol, BR248, Boelelaan 1117, NL-1081 HV Amsterdam, Netherlands. EM gj.schuurhuis@vumc.nl FU Leukemia and Lymphoma Society; VA merit Review Grant FX Funding: this manuscript was supported in part by funding from the Leukemia and Lymphoma Society (MCH) and a VA merit Review Grant (MCH). NR 20 TC 6 Z9 6 U1 0 U2 0 PU FERRATA STORTI FOUNDATION PI PAVIA PA VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY SN 0390-6078 J9 HAEMATOL-HEMATOL J JI Haematol-Hematol. J. PD JAN PY 2009 VL 94 IS 1 BP 46 EP 53 DI 10.3324/haematol.13110 PG 8 WC Hematology SC Hematology GA 396LL UT WOS:000262593100009 PM 19042917 ER PT B AU Ritchie, CS Kvale, E AF Ritchie, Christine Seel Kvale, Elizabeth BE Bales, CW Ritchie, CS TI Nutrition at the End of Life: Ethical Issues SO HANDBOOK OF CLINICAL NUTRITION AND AGING, SECOND EDITION SE Nutrition and Health Series LA English DT Article; Book Chapter DE Nutrition support; terminal illness; palliative treatment ID PERCUTANEOUS ENDOSCOPIC GASTROSTOMY; ARTIFICIAL NUTRITION; ADVANCED DEMENTIA; HYDRATION; IMPACT; CARE AB Because of the importance of food as an integral part of life, health-care providers need to be well versed in the issues surrounding nutrition and hydration in terminal illness in order to assist patients and their families in treatment decisions. Case law in the United States considers enteral nutrition to be medical treatment and as such recognizes a patient's right to refuse artificial nutritional support. The decision about feeding should be consistent with the overall goals of care: for example, curative treatment, rehabilitative treatment or palliative treatment. C1 [Ritchie, Christine Seel] Univ Alabama, Birmingham Atlanta VA Geriatr Res Educ & Clin Ctr, Birmingham, AL 35294 USA. [Kvale, Elizabeth] Univ Alabama, Div Gerontol, Birmingham, AL USA. [Kvale, Elizabeth] Birmingham VA Med Ctr, Birmingham, AL USA. RP Ritchie, CS (reprint author), Univ Alabama, Birmingham Atlanta VA Geriatr Res Educ & Clin Ctr, Birmingham, AL 35294 USA. NR 24 TC 1 Z9 1 U1 1 U2 2 PU HUMANA PRESS INC PI TOTOWA PA 999 RIVERVIEW DR, STE 208, TOTOWA, NJ 07512-1165 USA BN 978-1-60327-384-8 J9 NUTR HEALTH SER JI Nutr. Health Ser. PY 2009 BP 235 EP 244 DI 10.1007/978-1-60327-385-5_13 PG 10 WC Geriatrics & Gerontology; Gerontology; Public, Environmental & Occupational Health; Medicine, General & Internal; Nutrition & Dietetics SC Geriatrics & Gerontology; Public, Environmental & Occupational Health; General & Internal Medicine; Nutrition & Dietetics GA BJT85 UT WOS:000267149000013 ER PT B AU Kvale, E Ritchie, CS Balducci, L AF Kvale, Elizabeth Ritchie, Christine Seel Balducci, Lodovico BE Bales, CW Ritchie, CS TI Nutrition Support in Cancer SO HANDBOOK OF CLINICAL NUTRITION AND AGING, SECOND EDITION SE Nutrition and Health Series LA English DT Article; Book Chapter DE Cancer; aging; cachexia; inflammation ID COMPREHENSIVE GERIATRIC ASSESSMENT; RESTING ENERGY-EXPENDITURE; ANOREXIA-CACHEXIA SYNDROME; LONG-TERM SURVIVAL; FISH-OIL CAPSULES; LEUKEMIA GROUP-B; QUALITY-OF-LIFE; CONTROLLED-TRIAL; NECK-CANCER; WEIGHT-LOSS AB Older cancer patients have unique qualities related to aging that place them at nutritional risk during cancer treatment. Routine assessment of nutritional risk is indicated in older cancer patients. Comprehensive geriatric assessment of older cancer patients can assist with determination of which older patients can tolerate cancer treatment with acceptable levels of morbidity and mortality. Dietary counseling and nutritional intervention (especially protein supplementation) should be incorporated into the care of nutritionally compromised older cancer patients as needed. Cancer is a frequent indication for enteral nutrition support (when there is intact gut function) or total parenteral nutrition. Management of nutritional compromise should be guided by patient-centered goals of care that incorporate the existing evidence-base into decision-making. C1 [Kvale, Elizabeth] Univ Alabama, Div Gerontol, Birmingham, AL 35294 USA. [Kvale, Elizabeth] Birmingham VA Med Ctr, Birmingham, AL USA. [Balducci, Lodovico] Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33682 USA. [Ritchie, Christine Seel] Univ Alabama, Birmingham Atlanta VA Geriatr Res Educ & Clin Ctr, Birmingham, AL USA. RP Kvale, E (reprint author), Univ Alabama, Div Gerontol, Birmingham, AL 35294 USA. NR 99 TC 0 Z9 0 U1 0 U2 0 PU HUMANA PRESS INC PI TOTOWA PA 999 RIVERVIEW DR, STE 208, TOTOWA, NJ 07512-1165 USA BN 978-1-60327-384-8 J9 NUTR HEALTH SER JI Nutr. Health Ser. PY 2009 BP 355 EP 372 DI 10.1007/978-1-60327-385-5_19 PG 18 WC Geriatrics & Gerontology; Gerontology; Public, Environmental & Occupational Health; Medicine, General & Internal; Nutrition & Dietetics SC Geriatrics & Gerontology; Public, Environmental & Occupational Health; General & Internal Medicine; Nutrition & Dietetics GA BJT85 UT WOS:000267149000019 ER PT B AU Fan, J AF Fan, Jie BE Hagg, R Kohlund, S TI Receptor Cross-Talk Mechanisms of Neutrophil Priming SO HANDBOOK OF GRANULOCYTES : CLASSIFICATION, TOXIC MATERIALS PRODUCED AND PATHOLOGY SE Human Anatomy and Physiology LA English DT Article; Book Chapter ID TOLL-LIKE RECEPTOR-4; MOBILITY GROUP BOX-1; MEDIATES HEPATIC-INJURY; MULTIPLE ORGAN FAILURE; TLR2 UP-REGULATION; FACTOR-KAPPA-B; NADPH OXIDASE; HEMORRHAGIC-SHOCK; INNATE IMMUNITY; MYD88-INDEPENDENT PATHWAY AB Severe trauma and hemorrhage renders the patient more susceptible to a second, seemingly trivial, inflammatory stimulus, the so-called "two-hit" hypothesis. The post-trauma sepsis, which involves activation of innate immunity, can lead to severe multi-organ failure (MOF) or systemic inflammatory response syndrome (SIRS), and death. Studies have suggested that inflammatory cell priming caused by a first hit is the mechanism for enhanced response of the cell to a second hit. Polymorphonuclear neutrophils (PMN) are essential effector cells of the innate immune system. The accumulation of PMN in tissue is considered a critical event in organ inflammation and injury, and has been the target of preventative strategies. PMN migration is a result of a cascade of cellular events, in which PMN, endothelial cells (EC), and macrophages (M phi) act in concert. Recent studies explored interrelated novel findings indicating that receptor cross-talk mechanisms occurring in PMN, EC, and M phi are important determinants for priming PMN migration in a sepsis setting. This chapter will focus on the detailed receptor cross-talk mechanisms underlying PMN priming. In M phi and EC, lipopolysaccharide (LPS) acts through Toll-like receptor (TLR)4 signaling to up-regulate TLR2. Oxidant signaling derived from PMN NAD(P)H oxidase enhances the TLR2 upregulation through PMN-M phi or PMN-EC interaction, resulting in an amplified release of cytokines and chemokines from the M phi and expression of adhesion molecules in the EC in response to TLR2 ligands, thereby promoting PMN migration. Furthermore, hemorrhagic shock is potent in activating PMN NAD(P)H oxidase through high-mobility group box 1 (HMGB1)-TLR4-p38 MAPK signaling, and therefore initiates the mechanisms of cell priming. On the other hand, LPS through TLR4 on PMN and phosphoinositide 3-kinase gamma (PI3K gamma) signaling down-regulates the expression of G protein-coupled receptor kinases (GRK)2 and GRK5 in response to chemokine, thereby decreases chemokine receptor desensitization and augments the PMN migration. Taken together, receptor cross-talk mechanisms are important determinants for cell priming and subsequent augmented PMN infiltration in sepsis. C1 [Fan, Jie] Univ Pittsburgh, Pittsburgh, PA 15260 USA. [Fan, Jie] Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA USA. RP Fan, J (reprint author), Univ Pittsburgh, Pittsburgh, PA 15260 USA. NR 86 TC 0 Z9 0 U1 0 U2 0 PU NOVA SCIENCE PUBLISHERS, INC PI HAUPPAUGE PA 400 OSER AVE, STE 1600, HAUPPAUGE, NY 11788-3635 USA BN 978-1-60741-582-4 J9 HUM ANAT PHYSIOL PY 2009 BP 205 EP 228 PG 24 WC Anatomy & Morphology; Physiology SC Anatomy & Morphology; Physiology GA BPC23 UT WOS:000278499700007 ER PT B AU Horan, WP Greenwood, TA Braff, DL Gur, RE Green, MF AF Horan, William P. Greenwood, Tiffany A. Braff, David L. Gur, Raquel E. Green, Michael F. BE Ritsner, MS TI The Use of Neurocognitive Endophenotypes in Large-Scale Family Genetic Studies of Schizophrenia SO HANDBOOK OF NEUROPSYCHIATRIC BIOMARKERS, ENDOPHENOTYPES AND GENES, VOL 1: NEUROPSYCHOLOGICAL ENDOPHENOTYPES AND BIOMARKERS LA English DT Article; Book Chapter DE Schizophrenia; endophenotype; neurocognition ID VERBAL WORKING-MEMORY; DORSOLATERAL PREFRONTAL CORTEX; TRAIT LINKAGE ANALYSIS; 4-MONTH FOLLOW-UP; SUSTAINED ATTENTION; NEUROPSYCHOLOGICAL DEFICITS; NONPSYCHOTIC RELATIVES; COGNITIVE NEUROSCIENCE; NAIVE PATIENTS; 1ST-DEGREE RELATIVES AB Neurocognitive deficits are core features of schizophrenia and are among the most promising candidate endophenotypes for genetic studies of this disorder. The detection of gene-endophenotype associations requires large family cohort or case-control samples that are often only possible to collect through multisite collaborations, which presents considerable challenges for the use of endophenotypes. This chapter focuses on the rationale for using neurocognitive tasks of working memory, attention, and verbal declarative memory in large-scale, collaborative efforts to apply an endophenotype approach to schizophrenia. As an example, we describe the Consortium on the Genetics of Schizophrenia (COGS), a seven-site research network that investigates the genetic architecture of these neurocognitive and other candidate endophenotypes in families with schizophrenia. After providing a brief overview of the rigorous recruitment, data acquisition, and quality assurance procedures established by the COGS, we present recent results from this project that support utility of these procedures and the validity of neurocognitive endophenotypes. We conclude with a discussion of preliminary COGS findings that point toward specific candidate genes and future directions for this and other large-scale endophenotype studies of schizophrenia. C1 [Greenwood, Tiffany A.; Braff, David L.] Univ Calif San Diego, Dept Psychiat, San Diego, CA 92103 USA. [Horan, William P.; Green, Michael F.] Univ Calif Los Angeles, Semel Inst, Los Angeles, CA 90024 USA. [Gur, Raquel E.] Univ Penn, Dept Psychiat, Med Ctr, Philadelphia, PA 19104 USA. [Green, Michael F.] VA Greater Los Angeles Healthcare Ctr, Los Angeles, CA USA. [Horan, William P.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Gur, Raquel E.] Univ Penn, Dept Neurol, Med Ctr, Philadelphia, PA 19104 USA. [Gur, Raquel E.] Univ Penn, Dept Radiol, Med Ctr, Philadelphia, PA 19104 USA. [Gur, Raquel E.] Univ Penn, Neuropsychiat Sect, Med Ctr, Philadelphia, PA 19104 USA. RP Horan, WP (reprint author), Univ Calif Los Angeles, Semel Inst, Los Angeles, CA 90024 USA. EM horan@ucla.edu; tgreenwood@ucsd.edu; DBraff@ucsd.edu; raquel@upenn.edu; mgreen@ucla.edu NR 111 TC 1 Z9 1 U1 2 U2 2 PU SPRINGER PI DORDRECHT PA PO BOX 17, 3300 AA DORDRECHT, NETHERLANDS BN 978-1-4020-9463-7 PY 2009 BP 177 EP 193 DI 10.1007/978-1-4020-9464-4_12 D2 10.1007/978-1-4020-9464-4 PG 17 WC Genetics & Heredity; Neurosciences; Psychiatry; Psychology SC Genetics & Heredity; Neurosciences & Neurology; Psychiatry; Psychology GA BKM02 UT WOS:000268464200012 ER PT B AU Chaiswing, L Oberley, TD AF Chaiswing, Luksana Oberley, Terry D. BE Meridith, AT TI Redox State and Prostate Cancer Behavior SO HANDBOOK OF PROSTATE CANCER CELL RESEARCH: GROWTH, SIGNALLING AND SURVIVAL SE Cancer Etiology Diagnosis and Treatments LA English DT Article; Book Chapter ID DAMAGE; TRANSDUCTION; PERSPECTIVE AB Cellular or tissue reduction-oxidation (redox) state is the result of the net balance of molecular reducing and oxidizing equivalents, and can be subdivided into intra-or extracellular redox state (inside or outside the cell), respectively. Under physiological conditions, redox state regulates cell metabolism, survival, and the cell cycle. Prostate cancer is the most common malignancy diagnosed in men and is the second leading cause of cancer deaths in males in the U.S.A. Many studies have documented that prostate cancer cell lines have altered levels of intracellular reactive oxygen species/reactive nitrogen species and/or antioxidant levels in relation to nonmalignant cells. This abnormal intracellular redox state may play an important role in prostate cancer cell cycle progression and cell survival through regulation of redox- modulated transcription factors. Our laboratory recently reported that prostate cancer cells in the cell cultures exhibited an increased glutathione/glutathione disulfide ratio in the media in comparison to immortalized but nonmalignant prostate epithelial cells, suggesting an alteration of extracellular redox state of prostate cancer cells. We also demonstrated that modulation of extracellular redox state by overexpression of extracellular superoxide dismutase resulted in inhibition of prostate cancer cell invasiveness through a mechanism responsive to superoxide radical and/or nitric oxide. We propose that both intra- and extracellular redox states play complementary role(s) in regulation of prostate cancer cell proliferation and/or invasion. This possible relationship between redox states may lead to the development of anti-cancer therapeutics utilizing redox-modulating compounds that are specifically designed to target prostate cancer cells and/or the prostate cancer microenviromnent. C1 [Chaiswing, Luksana] Univ Wisconsin, William S Middleton Mem Vet Hosp, Pathol & Lab Med Serv, Madison, WI 53706 USA. Univ Wisconsin, Dept Pathol & Lab Med, Sch Med & Publ Hlth, Madison, WI USA. RP Chaiswing, L (reprint author), Univ Wisconsin, William S Middleton Mem Vet Hosp, Pathol & Lab Med Serv, Madison, WI 53706 USA. NR 16 TC 0 Z9 0 U1 1 U2 2 PU NOVA SCIENCE PUBLISHERS, INC PI HAUPPAUGE PA 400 OSER AVE, STE 1600, HAUPPAUGE, NY 11788-3635 USA BN 978-1-60741-954-9 J9 CANCER ETIOL DIAGN T PY 2009 BP 489 EP 495 PG 7 WC Oncology; Cell Biology SC Oncology; Cell Biology GA BNU54 UT WOS:000275598000017 ER PT J AU El-Serag, HB Engels, EA Landgren, O Chiao, E Henderson, L Amaratunge, HC Giordano, TP AF El-Serag, Hashem B. Engels, Eric A. Landgren, Ola Chiao, Elizabeth Henderson, Louise Amaratunge, Harshinie C. Giordano, Thomas P. TI Risk of Hepatobiliary and Pancreatic Cancers After Hepatitis C Virus Infection: A Population-Based Study of US Veterans SO HEPATOLOGY LA English DT Article ID ADMINISTRATION MEDICAL SYSTEM; UNITED-STATES; INTRAHEPATIC CHOLANGIOCARCINOMA; EXTRAHEPATIC CHOLANGIOCARCINOMA; LIVER; CIRRHOSIS; ASCERTAINMENT; PREVALENCE; CARCINOMA; AFFAIRS AB Hepatitis C virus (HCV) may increase the risk of hepatopancreaticobiliary tumors other than hepatocellular carcinoma (HCC). Previous case control studies indicated a possible association between HCV and intrahepatic cholangiocarcinoma (ICC). Little is known about the association between HCV and extrahepatic cholangiocarcinoma (ECC) or pancreatic cancer. We conducted a cohort study including 146,394 HCV-infected and 572,293 HCV-uninfected patients who received care at Veterans Affairs health care facilities. Patients with two visits between 1996 and 2004 with HCV infection were included, as were up to four matched HCV-uninfected subjects for each HCV-infected subject. Risks of ICC, ECC, pancreatic cancer, and HCC were assessed using proportional hazards regression. In the 1.37 million person-years of follow-up, which began 6 months after the baseline visit, there were 75 cases of ECC, 37 cases of ICC, 617 cases of pancreatic cancer, and 1679 cases of HCC. As expected, the risk of HCC associated with HCV was very high (hazard ratio [HR], 15.09; 95% confidence interval [95% CI], 13.44, 16.94). Risk for ICC was elevated with HCV infection 2.55; 1.31, 4.95), but risk for ECC was not significantly increased (1.50; 0.60, 1.85). Adjustments for cirrhosis, diabetes, inflammatory bowel disease, hepatitis B, alcoholism, and alcoholic liver disease did not reduce the risk for ICC below twofold. The risk of pancreatic cancer was slightly elevated (1.23; 1.02, 1.49), but was attenuated after adjusting for alcohol use, pancreatitis, and other variables. Conclusions. Findings indicated that HCV infection conferred a more than twofold elevated risk of ICC. Absence of an association with ECC was consistent in adjusted and unadjusted models. A significant association with pancreatic cancer was erased by alcohol use and other variables. (HEPATOLOGY 2009;49:116-123.) C1 [El-Serag, Hashem B.; Chiao, Elizabeth; Henderson, Louise; Amaratunge, Harshinie C.; Giordano, Thomas P.] Baylor Coll Med, Dept Med, Houston, TX 77030 USA. [El-Serag, Hashem B.; Chiao, Elizabeth; Henderson, Louise; Amaratunge, Harshinie C.; Giordano, Thomas P.] Dept Vet Affairs Med Ctr, Hlth Serv Res & Dev Serv, Houston Ctr Qual Care & Utilizat Studies, Houston, TX USA. [Engels, Eric A.; Landgren, Ola] NCI, Div Canc Epidemiol & Genet, NIH, Rockville, MD USA. RP El-Serag, HB (reprint author), Houston VA Med Ctr 152, 2002 Holcombe Blvd, Houston, TX 77030 USA. EM hasheme@bcm.tmc.edu FU National Cancer Institute, National Institutes of Health; Michael E. DeBakey Veterans Affairs Medical Center; Department of Veterans Affairs, Houston; NIH [K24 DK078154-01] FX Supported by the Intramural Program of the National Cancer Institute, National Institutes of Health, and the Michael E. DeBakey Veterans Affairs Medical Center, Department of Veterans Affairs, Houston, TX. Dr. El-Sang is sup